<SEC-DOCUMENT>0001447362-22-000137.txt : 20220808
<SEC-HEADER>0001447362-22-000137.hdr.sgml : 20220808
<ACCEPTANCE-DATETIME>20220808170407
ACCESSION NUMBER:		0001447362-22-000137
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220808
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASTLE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001447362
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				770701774
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38984
		FILM NUMBER:		221145277

	BUSINESS ADDRESS:	
		STREET 1:		505 S FRIENDSWOOD DRIVE
		STREET 2:		SUITE 401
		CITY:			FRIENDSWOOD
		STATE:			TX
		ZIP:			77546
		BUSINESS PHONE:		866-788-9007

	MAIL ADDRESS:	
		STREET 1:		505 S FRIENDSWOOD DRIVE
		STREET 2:		SUITE 401
		CITY:			FRIENDSWOOD
		STATE:			TX
		ZIP:			77546
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cstl-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2c77279c-977d-402a-b1b2-5d29ed09603d,g:da8c0f38-2da3-40ff-b133-9fd71c151e0e,d:85ed73ce88b34118965f36f66c298ae1--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:cstl="http://www.castlebiosciences.com/20220630" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cstl-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8yLTEtMS0xLTk3Mjcy_c0e85284-916e-4f02-8708-db6c0bee2ec7">0001447362</ix:nonNumeric><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8zLTEtMS0xLTk3Mjcy_6af2283e-cc45-4feb-ae02-30946ed9d030">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8xMy0xLTEtMS05NzI3Mg_2b958efe-726a-44b5-95cc-e01b5eb6d614">2022</ix:nonNumeric><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8xNC0xLTEtMS05NzI3Mg_af7d814b-1635-4153-b03e-e5858bfc5578">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8xNS0xLTEtMS05NzI3Mg_c178f4e1-8978-40f6-905c-593081027b8e">false</ix:nonNumeric><ix:nonNumeric contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0wLTEtMS05NzI3Mg_042c296b-db1d-4ee0-a8b1-7a689239030a">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cstl-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b225592077a49468f91c5a7a8070c8d_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i43af39ae2b5a4502ad42c6b29becf672_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idf13288bff8d454995f61e624f289d17_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if579dae83b8c4e9985cc1382db6773cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43334b369424f43a0a7ff7c5379bfab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c2daf116a748ca9d99a88a918f8a7a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97c57848b43a4b04908a15f751f228eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55427030f29b4ec8919acde7614ce80a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05142cc79cab4fe39aed0b747ac5ab72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a028b432814c468151325be76f2288_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d79afbe3db4e63a8376b96ad2c2a19_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e07a9c7b20e45d8a34bc3494233bad0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db3849ecf344540b631208a8486e731_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aef283682a0409391f3889a859516ee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf5f2d1d61c4399a85c38536d1b5870_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d8bc5806cc42a1a590de3ddefa542e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45b15080c9a490e9b40a981b88c2ab4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a350df83e449a7bfb41c9fa0e438df_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief70ba11123c4a588f9021f36a8018f2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4716841dad0e4b91aa853fdde46b4497_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ddcfe5a62234411adef323f129a9431_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876c6b7aacd34ac085dd8fed79a56ddc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ba51b1cf454b719b762b76d13bee4f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b43ea83fdf47bdaaabf1e474427f66_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c649fe497204cb2a717f0ed7d84eb66_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb16faf4fb149658bbba1601aa0bbc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50aac6883ff6400fa2cae1a080701556_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d01d11a47442dd85ecf3c5da42e59c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie414d3b9f48f4a62b15be9a778052e3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64651995ef994fb784afda58278f15c2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d23ca5218f4f239df0df99e61be5fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff9ba1ac9bdc4a2f8c18d78ab64539ae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a71817e0bcd412b9689d66aaaede50c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519d138276e44889b2be7e9e5bda9d96_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652198504ae942f4b9eb116281a3e9fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie63ac35e1982419cab5b0e55ac7a9ec0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb246820c6d498e90a506f4b515e485_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if188768c20ab47cdb0dff4b33bd0c0ff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34f5ad41aeed41b08758233329facba3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5404bc6eaf484be4813006a731482c19_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85254eabd1f425ca0d60cbd627df78d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5cf2e6b2e24c06be4b1939e1daf492_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa26bc228544c24a0666ef5b1bd5976_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9947a18f7d40039c6b420a80007dba_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03e51765e914b8a9011d48a1ca77348_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8336c818a9d24de1b01f985248828ffd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131a7e641770456ba0f7359e16012f93_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743fbc9ec6194ca792d7d9caf96f471a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0183c80be36439e982930171a859a72_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia301a48e31e3464b850d1a0710a2fb2e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icb4d6409a095497989a2cb7fb57c9812_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05824dd7aebb44438f53e1deb76ad500_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94472029ae74477fb2fffb4ece2766a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i323f1187bec8480581a9940120e35818_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb78aa5b5c14c7cad3c10b3fed78ccd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8aeb153e06f4174a607042caec7e398_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f647f897a49453e97a9bc858216da0d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8647297e768439fa24eb3a61573953f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf616ceceff4a9789bd794cf9f29b01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i202ecb6dff6b4729b49d234fb2bef137_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ef15e282314f3d8fec2981a454d8a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id36b4a825e7f469b8fd2f597b3af8390_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfdb2a1c4c384d149ee8bca6e20af292_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1f44ce249142beac6ca7381822ec8b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc96b39f3484f47995755bc11a69ddc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0135a04774dc4b219792a238d8bafb56_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4caeb8a1e254252b6c25709ec4ec9d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3851b8892a64a6bb5ee4d6a59a6d586_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1e593f0419b463ab2feaebd198a1f36_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c32637b65384bdb811ce3fde43efe9c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0fa44c09bb549a8bab2bb18b6137f27_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae420fb56f4e41199cef237838e485c7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec43d4abf35e401b9ee6ac4b9e162d95_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id190812a859648c4aa204468be09784d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e027d558f18441ebd34443aff9c0b0e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d5c289e6d474738890e1b72e04b9576_D20210528-20210528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:MyriadMyPathLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-28</xbrli:startDate><xbrli:endDate>2021-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d6bf4b13ce4a24ae2fea8c910f9894_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140b75ca6fb545eca7808706ff716d73_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4208ab3203fb45e2b40efa980b003a60_I20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tradingday"><xbrli:measure>cstl:tradingDay</xbrli:measure></xbrli:unit><xbrli:context id="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc558f1bcfcf460c9f62c48b28e4c8cd_D20220426-20220426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-26</xbrli:startDate><xbrli:endDate>2022-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba6c475c71e34bab977bbfc04f289e75_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342fb6e319104d52a2a096369c394d0a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">cstl:IncomeTaxAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18246336ddbc4d7d82e4f43fbb8713f5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a6d97ebe2b4ac8ac03f0f597e399e8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19966e00f06e4894824f928b10bfb6ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3cbac6e564649baabb13f60dd0dd0e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5070d2dd0947412eb17de036ae48867f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id512a2f4079a4e7f8d0d10261566c191_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d1fba04ed24847a7ae1ad277983eb2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c244a39341a448791b5db69d1b41724_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64acefec6184784b9890c8d9573b5ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd539bbaa4f45da97e6726e6d501957_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2fa89ae0cb4fa7942493ffe73929b4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55d01cabd3e4dfd8fc8d7634ccc3e6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f3cc6a21d0455faa3a247ed3871fc2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i695763ce94f847ecb79699e832614ae4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5660ce4bef94584b72a1722257e6ddd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf326b10a224bb6a24085924905410c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90b080f71e6434ea6c9ba3acadadcef_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfa896825f1413cb48c6b0e5e4b5954_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f7c25b470c347d698685f93340964f3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3700a82a151f4c0a8bda6c74f43fe33d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb27d09e15f1493bafb7c9641c3f51aa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2f11e2e9a840b5a7a47d3f927f7647_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id95b5f253eb44af8b25296728af91542_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b3a400ca564d61a070f1edf776917a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901262209e794dce8a44fee61a9bfe50_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie686513e9d7f42f78dcefb7c17ec2bc3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2da820ae08bd4d858fbbc2c1c5bb1868_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4cd64260f474238bc48f5f8fbf709cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8dca6d7270d44eda30a928ed849ac36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697af5026be14ac08242de05f2632427_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1494102bc084aa0a7b78f886f46a23c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a424bc53f249fd89099cba54892a4c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e94943a8f84b59ae78cc37b86399dd_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if08210db194a470bb8c79782f96d1583_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08a4fbd714c45cdbc0c0ef66a81837b_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseFirstSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id35ad05f10784973b277cc9339184bd2_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseAfterSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9e74951a454794934048985403ea08_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>cstl:claim</xbrli:measure></xbrli:unit><xbrli:context id="ibb8ceb3988914d2f9c2a79143d8fb4b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21125ac2093648aea31470a65bc3c38d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i104f7bbc8cb7403d8a1ec5e1df30fa49_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6324a446c6ed44dcb012258eeb725d85_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide11ef39260549e8a2e5914ad0f0afcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ff935b4508458d896d72b6072dda6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fb402740817463da336bf3ad4500350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i684e2cbe0aee4089866a63e63228dd12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028a35f4072e424b80f6c2c0e7c85713_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib99692ae97b9426581ef0e9d0e18336f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b6b0adf1ed4564ab66d5e6c116b521_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02dfd58348864c25bf52e8044eb44e80_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64336bd6bad643a38e66641fec94637b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05f1698a24e4537b9b6e321a862849e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab51d3dc6bd949c99033fd013c8820dd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d374e88975f4250b70acfc62ee7b455_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683d8e181278402690a483021f8294d6_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8aa2919a654f9fb404a6244f4977b1_D20240101-20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b51146ced54358bef8f0e24c5ad59a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0ab012cf684932bc3842b6be81dc6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30a1bb97eb834ce49721240374fb0bcd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedeeba3b13c34684a6126c12757e02db_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3ed91cdcfc41dfa12bd21a3ade3077_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id49668ed558840d8a0b90ca6b883101e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4165eb4a39cb4beb89cc3cbf69e6654d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7805af27e10c4b63a1bc23dc07855219_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11a61c8eb4b741ceae0ea9615e6fd60b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6684a747cbc242f286866f7a3ae50ae7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447362</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i85ed73ce88b34118965f36f66c298ae1_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTcw_9bf14b77-32fc-4e1f-b585-73b1a90b2afe">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Mark One)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NjNhNTU5NGU5MTgwNGI2YjgxNDNlMWVmNDU4ZDA1ZTQvdGFibGVyYW5nZTo2M2E1NTk0ZTkxODA0YjZiODE0M2UxZWY0NThkMDVlNF8xLTAtMS0xLTk3Mjcy_aee8fdac-7283-472f-b350-e6289fe74c4c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xMjg_ae8aecf7-b919-4dea-bc92-d29a024e7daa">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NTZhYjIxZWIwZmMzNDY3MDkyYjdhYjkxODc0MzRlYzUvdGFibGVyYW5nZTo1NmFiMjFlYjBmYzM0NjcwOTJiN2FiOTE4NzQzNGVjNV8wLTAtMS0xLTk3Mjcy_070e346c-4263-42bd-9665-1ed7b6d7f185">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;_________&#160;to&#160;_________&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY3_bc5f93fc-86ff-4f6b-9a8f-652f8b984f3f">001-38984</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTYy_b6b4bcf8-0f54-415f-9237-57a0c4c5d79f">CASTLE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8wLTAtMS0xLTk3Mjcy_c5835997-bf6d-4bf0-9fe6-3cdf4250096e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8wLTItMS0xLTk3Mjcy_72003507-91ad-4199-babd-ee0cdcca6554">77-0701774</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfNQ_3ee413d9-38a8-486d-b6fd-a561f59a373b">505 S. Friendswood Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfOQ_15eb5ee6-2b2e-4272-9385-32fa02fa2587">Suite 401</ix:nonNumeric>, <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfMTM_a6f64b2d-e595-47ad-a4bf-50d6ccb9d9d8">Friendswood</ix:nonNumeric>, <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfMTc_297d899e-a468-4730-aa3a-fdc0747ddbd5">Texas</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTItMS0xLTk3Mjcy_d191aec4-cf71-474b-b79f-9315b0add5d5">77546</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY4_0cee9395-5c61-430a-b9e6-c65cc37a2a28">866</ix:nonNumeric>) <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTcx_511bf817-385e-48aa-bd08-e0137fb0a1cd">788-9007</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6ZTY2YTVkZjhiZDg3NDcxZDhjZGQ0MTdlMTJlMjA1YzUvdGFibGVyYW5nZTplNjZhNWRmOGJkODc0NzFkOGNkZDQxN2UxMmUyMDVjNV8xLTAtMS0xLTk3Mjcy_d78b2586-8dd7-4157-b683-20bff8ee87f9">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6ZTY2YTVkZjhiZDg3NDcxZDhjZGQ0MTdlMTJlMjA1YzUvdGFibGVyYW5nZTplNjZhNWRmOGJkODc0NzFkOGNkZDQxN2UxMmUyMDVjNV8xLTEtMS0xLTk3Mjcy_651ed6a1-b23f-49b4-9a5d-2e216ad73428">CSTL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6ZTY2YTVkZjhiZDg3NDcxZDhjZGQ0MTdlMTJlMjA1YzUvdGFibGVyYW5nZTplNjZhNWRmOGJkODc0NzFkOGNkZDQxN2UxMmUyMDVjNV8xLTItMS0xLTk3Mjcy_5e8ed6b3-a37c-45ad-8199-cd206e9dc902">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY5_0722b2ac-10b6-4951-9b1d-84acfd377ad7">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTYz_40bfd4eb-fe3f-4350-92b9-5a4e0e8f51ee">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8216;&#8216;large accelerated filer,&#8217;&#8217; &#8216;&#8216;accelerated filer,&#8217;&#8217; &#8216;&#8216;smaller reporting company,&#8217;&#8217; and &#8216;&#8216;emerging growth company&#8217;&#8217; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6MmE0MzExN2E4OTMzNGExYmE4YTM0YzQ0M2I2MmMwYTcvdGFibGVyYW5nZToyYTQzMTE3YTg5MzM0YTFiYThhMzRjNDQzYjYyYzBhN18wLTAtMS0xLTk3Mjcy_bfc73090-30b9-4e4b-aed8-01aaccbad131">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6MmE0MzExN2E4OTMzNGExYmE4YTM0YzQ0M2I2MmMwYTcvdGFibGVyYW5nZToyYTQzMTE3YTg5MzM0YTFiYThhMzRjNDQzYjYyYzBhN18xLTMtMS0xLTk3Mjcy_565d0e32-5e0a-4c3b-a7d0-2512108f008f">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6MmE0MzExN2E4OTMzNGExYmE4YTM0YzQ0M2I2MmMwYTcvdGFibGVyYW5nZToyYTQzMTE3YTg5MzM0YTFiYThhMzRjNDQzYjYyYzBhN18yLTMtMS0xLTk3Mjcy_47c5cd41-8c16-4350-b0c5-12b0ccb86073">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;padding-right:56.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange&#160;Act.&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY2_f1e95109-b2e0-46e1-a5ed-55aea02b1aef">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;1, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i5b225592077a49468f91c5a7a8070c8d_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xODgy_c4611986-412e-4349-95a8-be1946f0c755">26,296,968</ix:nonFraction> shares of common stock, $0.001 par value per share, issued and outstanding. </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_16">, 2022 (Unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">and Six Months </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22">Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22"> and Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25">Unaudited Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_67">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_136">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_136">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_139">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_139">38</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_142">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_142">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_145">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_145">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_148">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_148">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_169">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_169">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_172">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_172">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_175">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_175">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_178">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_178">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_181">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_181">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_184">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_184">81</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNC0xLTEtMS05NzI3Mg_5a9ba610-8fd0-4c38-bd4b-7a401a4f0b32">273,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNC0zLTEtMS05NzI3Mg_93e48e6f-9883-45f4-8618-d1e2b54dbcae">329,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNS0xLTEtMS05NzI3Mg_e02807cc-227e-4c95-91f0-a0406511be19">22,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNS0zLTEtMS05NzI3Mg_61b08a96-6d05-4552-afe4-18e53a380f7b">17,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNi0xLTEtMS05NzI3Mg_f2765371-3718-4105-be71-06904369fecc">3,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNi0zLTEtMS05NzI3Mg_c2c006e4-768c-4dcd-b246-672d702cd177">2,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNy0xLTEtMS05NzI3Mg_c62b7833-0ca6-4b55-b312-e1ab3ef39ad1">5,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNy0zLTEtMS05NzI3Mg_c4bf6b28-7efb-48d0-bd8e-e07e12c3d775">4,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOC0xLTEtMS05NzI3Mg_2ce1ebe6-3bf6-4b29-b952-d990e9c0ae59">304,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOC0zLTEtMS05NzI3Mg_6fc0728d-3e38-4414-9823-64b4f2c40629">353,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOS0xLTEtMS05NzI3Mg_9d89f6c3-9001-429c-901c-6c0f93b02d21">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOS0zLTEtMS05NzI3Mg_6720efeb-8979-47e7-a7cf-51f6462a014d">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTAtMS0xLTEtOTcyNzI_77e454c7-ccdf-432f-b634-2a3676b5066f">11,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTAtMy0xLTEtOTcyNzI_aa08942b-c18c-4c25-badd-eb9db4ed66f0">9,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTEtMS0xLTEtOTcyNzI_d6459cf7-e983-4264-8caf-d45cb74ded40">7,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTEtMy0xLTEtOTcyNzI_cf018f61-bf8b-4423-b1a2-f7d7381a823d">7,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and other intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTItMS0xLTEtOTcyNzI_bf657902-9152-4eb7-abc3-fb4d45bd4ff7">132,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTItMy0xLTEtOTcyNzI_7b20f49f-afcb-4d37-a9c6-5f13b6b6a0ca">88,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets &#8211; long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTMtMS0xLTEtOTcyNzI_5137221c-b335-4402-9419-3a637d240f5a">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTMtMy0xLTEtOTcyNzI_6d37f8e2-a401-4970-975c-c9708d7d6ea6">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTQtMS0xLTEtOTcyNzI_e4dd1edc-e4ba-4b04-a607-b53fba894ee3">458,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTQtMy0xLTEtOTcyNzI_1781c4d9-736e-4dd5-8206-605e86ac1b13">462,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTgtMS0xLTEtOTcyNzI_f8435c35-2dad-4c87-9c1f-086a64a74192">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTgtMy0xLTEtOTcyNzI_baec6d76-1f84-47f1-b94f-e57e573e9ac0">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTktMS0xLTEtOTcyNzI_34a6cd0a-40d4-4984-a4ae-a2dcfa28eecc">14,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTktMy0xLTEtOTcyNzI_476648f6-0115-4253-896d-56374e04e665">15,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjEtMS0xLTEtOTcyNzI_aad8f9c7-1a0d-405f-8029-3f437b786e96">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjEtMy0xLTEtOTcyNzI_ee361b75-6eaf-4a8a-8d62-65af6edc3a3a">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjItMS0xLTEtOTcyNzI_2ebcd722-83dc-42b1-8396-9280a6b29516">8,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjItMy0xLTEtOTcyNzI_89c9df84-eb8b-478b-bd5f-c9496d193175">5,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjMtMS0xLTEtOTcyNzI_ead25bba-f765-4cd8-b083-034d126edf44">27,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjMtMy0xLTEtOTcyNzI_0e4db1fe-451d-4b40-90e0-17d542a005a6">24,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjQtMS0xLTEtOTcyNzI_14e2d15d-4d74-4ec0-9c65-709c01c3113e">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjQtMy0xLTEtOTcyNzI_d0508281-e40e-4763-ab35-91ba383d1291">18,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjUtMS0xLTEtOTcyNzI_0bf418a4-b36a-449a-8da6-ddcbbfd459f6">6,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjUtMy0xLTEtOTcyNzI_034e2cb6-eba3-46d5-a5e3-a0601bb9204d">6,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjYtMS0xLTEtOTcyNzI_f2146d19-7388-493f-91cb-021bef6302ac">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjYtMy0xLTEtOTcyNzI_ee6e1f4f-2ac8-43d7-847d-68aacbf987ce">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjctMS0xLTEtOTcyNzI_246a92df-9a95-47c6-94b7-2058c8cc7c2b">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjctMy0xLTEtOTcyNzI_81d5e07c-479f-4a60-98d6-bcd457a9572a">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjgtMS0xLTEtOTcyNzI_bca5ffed-5c93-41c0-b1c7-159622c1639c">36,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjgtMy0xLTEtOTcyNzI_a0a2bf21-7ed6-4832-897b-b63ba4c3bde0">50,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjktMS0xLTEtOTcyNzI_11b6ba62-7f4e-4f6a-87ba-c11d5c6c4835"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjktMy0xLTEtOTcyNzI_8cd207af-34cd-407e-ae2f-8e33413d1c8f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN18yMQ_1a34b340-f152-43be-b3ae-2bcbe24d5006"><ix:nonFraction unitRef="usdPerShare" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN18yMQ_51e5f927-ac3e-4392-9dc7-e9290a0abc7b">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN180NQ_8e094fe9-1dd7-4f1c-aec0-d60bc5dd2169"><ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN180NQ_ef79770a-01da-46ae-a130-6009c908e6ad">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_513abd1e-909b-49a1-b570-62bb0ac7b876"><ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_532adf0c-dcb6-4e21-bb7a-8c18e617d71f"><ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_96693a7a-0ad3-4c3b-a129-c603c4690479"><ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_d0e0b7a6-c928-494b-90d0-cab65edbbb9f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMS0xLTEtOTcyNzI_b1afeb71-3c87-4669-8445-0d2b2c556a97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMy0xLTEtOTcyNzI_1cc20e3a-5d7c-4402-9811-42027b75a204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV8xOA_15576ab2-0d2f-44e7-ada0-a7620748d9dc"><ix:nonFraction unitRef="usdPerShare" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV8xOA_9dca0291-8efd-4c88-94a4-bb5c35be0632">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV80Mg_13ace84f-58df-48db-8596-c7254d244429"><ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV80Mg_fe35eedb-009b-48d1-aef3-b75eae83fb53">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84MA_61e41eb1-6f57-4446-bead-9dd1c00b7836"><ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84MA_aade4747-24be-412f-abb5-ee36356172f8">26,292,299</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84Nw_b2f6765d-d85d-45c8-bee1-234811dd9f18"><ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84Nw_b84c6020-9295-42c1-a348-398f12164f21">25,378,520</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMS0xLTEtOTcyNzI_c478d4fd-b003-44c5-974a-76e38cf79784">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMy0xLTEtOTcyNzI_63882a3c-18e1-476a-8771-b3f8a2fce092">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzMtMS0xLTEtOTcyNzI_a096fc63-de9f-493b-aa3d-f5e6e69f962c">541,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzMtMy0xLTEtOTcyNzI_bbffb025-f330-4857-8945-4014b75f3ae0">505,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzQtMS0xLTEtOTcyNzI_a4c13c75-3061-4f68-b958-fea3ca0af839">120,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzQtMy0xLTEtOTcyNzI_963819d3-1581-48a3-b6d8-a783f202fd62">93,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzUtMS0xLTEtOTcyNzI_8f746c26-5cec-490b-94dd-36884d9a1ba9">421,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzUtMy0xLTEtOTcyNzI_5d0a5889-b3b4-4576-8e1b-10c483985708">411,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzYtMS0xLTEtOTcyNzI_b8b82b22-f65e-4575-8dc1-8445fe50c603">458,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzYtMy0xLTEtOTcyNzI_5d9616de-e21d-4fb9-9aed-cbce3814022e">462,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET REVENUES</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi0xLTEtMS05NzI3Mg_4b31ec70-41bb-4edf-bfeb-195dbdc6f258">34,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi0zLTEtMS05NzI3Mg_028748cc-c257-4330-b404-54ccc57fa2fe">22,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi01LTEtMS05NzI3Mg_b25e576e-f52d-4061-9ebb-5b3ef0c567c3">61,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi03LTEtMS05NzI3Mg_1810e0c7-70c5-454d-ac2c-f7e4f60c1108">45,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING EXPENSES AND OTHER OPERATING INCOME</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC0xLTEtMS05NzI3Mg_25c1bf50-7573-416d-a0e3-2f8ad5f470d2">7,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC0zLTEtMS05NzI3Mg_0e10c08e-15d1-4a6c-84fd-1cfc4d7cfaaa">3,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC01LTEtMS05NzI3Mg_0f9014b2-ca0e-4812-adc6-7498199b2bf3">13,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC03LTEtMS05NzI3Mg_8eff2236-6027-4663-bcbe-cf19999f76ee">6,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS0xLTEtMS05NzI3Mg_d513c3f0-68ae-4f0b-9e42-612722491a69">11,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS0zLTEtMS05NzI3Mg_143041e2-9c2f-4a9a-9983-0121526d6179">6,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS01LTEtMS05NzI3Mg_9ee040a1-6973-46b0-baca-9f6fc3704ab6">22,687</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS03LTEtMS05NzI3Mg_49167a39-930c-4ebf-8c34-2844d7dbea3e">12,701</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi0xLTEtMS05NzI3Mg_9c5a3408-876e-4d81-ac79-eedf5df478b8">37,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi0zLTEtMS05NzI3Mg_c427f26c-a906-4cfb-8423-01cc09808ea2">20,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi01LTEtMS05NzI3Mg_e94f1798-41f1-4664-b14e-e8126930e66f">67,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi03LTEtMS05NzI3Mg_14dcbc54-15e5-409b-ae6f-49aba3ac2b14">38,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy0xLTEtMS05NzI3Mg_664e9b77-7ae5-41d6-a67c-655c6d33a54a">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy0zLTEtMS05NzI3Mg_e415479d-6baa-4363-b70a-eb061f19ef60">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy01LTEtMS05NzI3Mg_35137fbc-bdc4-4f98-be15-4b237a17be0f">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy03LTEtMS05NzI3Mg_7e0419e8-4500-4881-bd4b-894477a22030">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC0xLTEtMS05NzI3Mg_096cdceb-29a2-4e02-b1f4-c1b35f59d25e">20,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC0zLTEtMS05NzI3Mg_6b6f1ca3-00fa-45c6-b0cb-15676e923a5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC01LTEtMS05NzU3NQ_96bcbcc1-cb6d-4440-95b9-e0fbd17315a1">17,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC03LTEtMS05NzU3NQ_7ade91f0-9f99-4a0f-a876-230c4bff479b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="cstl:OperatingExpensesNetOfOtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtMS0xLTEtOTcyNzI_26d5de2b-233f-4c03-9c3e-c7320bc54168">38,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="cstl:OperatingExpensesNetOfOtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtMy0xLTEtOTcyNzI_4c6a694c-4516-4764-bba3-defc9f634f03">31,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="cstl:OperatingExpensesNetOfOtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtNS0xLTEtOTcyNzI_29b07c1f-b800-4a18-804f-f9b41cc42b89">90,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="cstl:OperatingExpensesNetOfOtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtNy0xLTEtOTcyNzI_c6bd860c-4515-4a7f-8f86-cf21496abf89">58,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtMS0xLTEtOTcyNzI_84a58e22-f948-4c95-9095-9c8eb4a2a0ad">3,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtMy0xLTEtOTcyNzI_67f90dc1-c7d3-4396-bfa1-bcd250f4d7f2">8,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtNS0xLTEtOTcyNzI_fe0ae596-3a7c-4ed5-bf4a-596e0da9b23b">28,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtNy0xLTEtOTcyNzI_8753ed63-1ed6-451c-a54d-0cc4bc2f9151">13,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItMS0xLTEtOTcyNzI_f85e04bb-aab6-4e2a-8d7c-fbf4493ee181">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItMy0xLTEtOTcyNzI_57c133ac-ef16-46eb-974d-e7e02c5aab0e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItNS0xLTEtOTcyNzI_8f99110e-f32b-491f-b95d-5b2bb44b4b41">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItNy0xLTEtOTcyNzI_e3ae1e92-58e4-45fd-bea9-54a2f05923fc">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtMS0xLTEtOTcyNzI_106bf60d-ff7d-4a89-931c-f5b320757ff8">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtMy0xLTEtOTcyNzI_9ea9c228-e8ea-4450-8831-9991cf0b1901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtNS0xLTEtOTcyNzI_a64294b6-6af7-4f03-a90d-f5b7cc33270e">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtNy0xLTEtOTcyNzI_e0f23689-9ca7-4796-b5d9-a9330983fa25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtMS0xLTEtOTcyNzI_21315e98-c99f-4fae-ad42-31923b4f93de">3,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtMy0xLTEtOTcyNzI_ed4227ba-b004-450a-8db8-705adf0890c7">8,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtNS0xLTEtOTcyNzI_af8b1d65-c09f-4eed-9e3d-458dac4f3607">28,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtNy0xLTEtOTcyNzI_34652534-5be6-4206-92b5-35d964b5b3dc">13,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctMS0xLTEtOTcyNzI_d12fbbfc-efb4-461c-abbf-ce71e0151354">1,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctMy0xLTEtOTcyNzI_3b993e39-0683-4645-b139-8d212512568a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctNS0xLTEtOTcyNzI_2862abae-3f8b-4490-a9ed-8a8ccfef42ca">1,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctNy0xLTEtOTcyNzI_ecd9f29b-ed41-423f-b414-4699cd64ca5a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMS0xLTEtOTcyNzI_e7b3e940-a1f9-4de0-b7c1-4a4bb4c514d5"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMS0xLTEtOTcyNzI_e9fa4b2d-c919-4d95-9303-da8b66cfd5b8">1,648</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMy0xLTEtOTcyNzI_544fc713-4277-4f49-928e-f3ef43dfed6b"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMy0xLTEtOTcyNzI_fa7a3668-2fcc-4f16-8d38-4d6cd03121b7">8,791</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNS0xLTEtOTcyNzI_0b4df884-efd3-49b9-8260-74187429688d"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNS0xLTEtOTcyNzI_a02a867e-c8b7-44d5-bf44-ed66de306644">26,271</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNy0xLTEtOTcyNzI_4e5528ad-9830-4ea5-8105-120f4a61a27a"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNy0xLTEtOTcyNzI_743f789d-cc22-4253-89b5-72653e04d48e">13,071</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMS0xLTEtOTcyNzI_75724a60-75e6-4a85-a9d5-dc899e2a9fb5"><ix:nonFraction unitRef="usdPerShare" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMS0xLTEtOTcyNzI_934df12d-3101-4444-9188-1cd0c3a5a91c">0.06</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMy0xLTEtOTcyNzI_005b3bf2-c88f-432b-a40e-9b95a6dcfa45"><ix:nonFraction unitRef="usdPerShare" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMy0xLTEtOTcyNzI_b497d8f4-e973-4380-9574-acd29b5ad046">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNS0xLTEtOTcyNzI_01c84a81-8a75-4510-a72e-381cac8849ad"><ix:nonFraction unitRef="usdPerShare" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNS0xLTEtOTcyNzI_f9a29728-d2e5-4790-96ee-f89b4d7d653f">1.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNy0xLTEtOTcyNzI_1bdd3a6e-b40a-413b-864f-e5b45dd68023"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNy0xLTEtOTcyNzI_f576ae70-5dbc-4dcd-a5ea-e335b76d11ff">0.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMS0xLTEtOTcyNzI_d60c3cd4-64e5-4b75-a937-10e7ada581f0"><ix:nonFraction unitRef="shares" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMS0xLTEtOTcyNzI_e7f2c821-3ba3-4351-ae19-f6c185e19abb">26,064</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMy0xLTEtOTcyNzI_a5205ade-0b25-476a-bf3f-b6b13d37fb56"><ix:nonFraction unitRef="shares" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMy0xLTEtOTcyNzI_e2ea7f3f-61a0-4cac-a2ad-4d9bb674dee1">25,091</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNS0xLTEtOTcyNzI_4ab02432-4c67-4a25-8d0c-19b3083db651"><ix:nonFraction unitRef="shares" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNS0xLTEtOTcyNzI_a0903c81-9cef-4801-9c0c-fc387429df19">25,746</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNy0xLTEtOTcyNzI_9dc071d1-a6a6-4552-ba1f-de60fffad1a2"><ix:nonFraction unitRef="shares" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNy0xLTEtOTcyNzI_f49e0768-d172-4583-b519-40b6793249bd">25,002</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.727%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, JANUARY 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if579dae83b8c4e9985cc1382db6773cc_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0yLTEtMS05NzI3Mg_e00b0827-8114-4128-8aaa-f54048b1f870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if579dae83b8c4e9985cc1382db6773cc_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi00LTEtMS05NzI3Mg_480c88e0-2ac3-4c4f-9429-c45918e71715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie43334b369424f43a0a7ff7c5379bfab_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi02LTEtMS05NzI3Mg_356bd882-765d-409a-b801-d4b41d30e948">24,812,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43334b369424f43a0a7ff7c5379bfab_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi04LTEtMS05NzI3Mg_20a3c5f1-5ebd-4107-a757-86a9f48dfaeb">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c2daf116a748ca9d99a88a918f8a7a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0xMC0xLTEtOTcyNzI_b2654ba6-7427-48cd-b775-023933a63cd9">478,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97c57848b43a4b04908a15f751f228eb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0xMi0xLTEtOTcyNzI_a941cafe-8331-45e5-888f-38d3747dbeae">62,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55427030f29b4ec8919acde7614ce80a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0xNC0xLTEtOTcyNzI_00ac9ae1-cf0a-4b40-a93d-4e9ac83a08b6">415,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0wLTEtMS05NzI3Mg_042c296b-db1d-4ee0-a8b1-7a689239030a">Adoption of ASU No. 2016-02</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05142cc79cab4fe39aed0b747ac5ab72_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0xMi0xLTEtOTcyNzI_e37c3b06-a5c6-4d23-8290-f62260fdb4e5">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a028b432814c468151325be76f2288_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0xNC0xLTEtOTcyNzI_0d33faa0-c0c2-4094-9afd-40b537707de1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNC0xMC0xLTEtOTcyNzI_63fe4cba-41a9-4674-aac1-bee578cc5b8f">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNC0xNC0xLTEtOTcyNzI_3260e772-1989-4da5-8500-73719ece9173">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96d79afbe3db4e63a8376b96ad2c2a19_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNS02LTEtMS05NzI3Mg_07f075e6-15e4-4c3f-98c4-7bfd8c978704">171,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNS0xMC0xLTEtOTcyNzI_629a52b9-c64c-455c-8d1e-1456ee24918c">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNS0xNC0xLTEtOTcyNzI_27c527d2-6723-4d9a-84d0-078387afb898">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under the employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96d79afbe3db4e63a8376b96ad2c2a19_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNi02LTEtMS05NzI3Mg_cdf8d869-42d8-478f-9178-c850207e5f78">70,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNi0xMC0xLTEtOTcyNzI_0f43c89c-4f80-4163-a0ad-f59058d2207c">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNi0xNC0xLTEtOTcyNzI_43e139c0-768c-45e3-a22d-b12063b0312c">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Public offering of common stock, adjustment to offering costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNy0xMC0xLTEtOTcyNzI_86fc4266-9c20-4cf7-ac17-92734a21133a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNy0xNC0xLTEtOTcyNzI_36c6f21d-7480-4a53-82b8-f0e86d8fa21d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e07a9c7b20e45d8a34bc3494233bad0_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOC0xMi0xLTEtOTcyNzI_09a8fdd9-f245-4fbf-885a-507212244d20">4,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOC0xNC0xLTEtOTcyNzI_696d0397-d3cb-4823-b356-579543155ab1">4,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, MARCH 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db3849ecf344540b631208a8486e731_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0yLTEtMS05NzI3Mg_3f048d14-ba30-4e11-966b-4451c7479306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db3849ecf344540b631208a8486e731_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS00LTEtMS05NzI3Mg_76723820-470f-49a7-abcd-913fb64199f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8aef283682a0409391f3889a859516ee_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS02LTEtMS05NzI3Mg_a4a64d56-e8c1-4e2d-a669-95340fec2e2a">25,054,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aef283682a0409391f3889a859516ee_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS04LTEtMS05NzI3Mg_119b8e6d-2145-46d6-884c-bd48c7b95f78">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf5f2d1d61c4399a85c38536d1b5870_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0xMC0xLTEtOTcyNzI_b6defd01-42c6-4314-8525-1fb83a68f84c">485,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10d8bc5806cc42a1a590de3ddefa542e_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0xMi0xLTEtOTcyNzI_7456ca07-d8ea-4c86-a968-b3a2ee25f24a">66,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45b15080c9a490e9b40a981b88c2ab4_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0xNC0xLTEtOTcyNzI_30ac6357-96d8-4e1f-88fa-2fb12a3afb17">418,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a350df83e449a7bfb41c9fa0e438df_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTAtMTAtMS0xLTk3Mjcy_c128e399-0416-4a38-9284-40acfa225461">4,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTAtMTQtMS0xLTk3Mjcy_4f02f117-0a14-49ac-a390-d620896d3d98">4,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief70ba11123c4a588f9021f36a8018f2_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTEtNi0xLTEtOTcyNzI_8919ece4-cb44-49c4-b8d5-66869d9e269e">109,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a350df83e449a7bfb41c9fa0e438df_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTEtMTAtMS0xLTk3Mjcy_d1db7c8e-1b19-4250-b7b7-70b5800f0e6a">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTEtMTQtMS0xLTk3Mjcy_01aa73fe-d20e-4f02-b190-0baf31bfe4fc">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4716841dad0e4b91aa853fdde46b4497_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTItMTItMS0xLTk3Mjcy_013f76af-ad4a-4032-a6eb-5c11b3d3a73f">8,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTItMTQtMS0xLTk3Mjcy_8a60d10e-f8f7-4275-935b-20b2ae6f44dc">8,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, JUNE 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ddcfe5a62234411adef323f129a9431_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMi0xLTEtOTcyNzI_789256f9-ef3a-4bb8-80e5-59680d52ccb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ddcfe5a62234411adef323f129a9431_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtNC0xLTEtOTcyNzI_39f0b03f-6d33-4351-9d83-52f2d7ba8239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i876c6b7aacd34ac085dd8fed79a56ddc_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtNi0xLTEtOTcyNzI_650625df-e319-4e65-8ff2-dda4f8e07814">25,164,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876c6b7aacd34ac085dd8fed79a56ddc_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtOC0xLTEtOTcyNzI_5505d753-20bb-4723-a962-476351b970ef">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ba51b1cf454b719b762b76d13bee4f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMTAtMS0xLTk3Mjcy_1d4ade1b-96dd-424a-9473-3b78b9f5a781">491,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4b43ea83fdf47bdaaabf1e474427f66_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMTItMS0xLTk3Mjcy_a5fcf826-42b8-4331-a5e3-a13663af2b98">75,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMTQtMS0xLTk3Mjcy_d54bbad3-2f76-4776-863f-5de3b0bf4bcb">415,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BALANCE, JANUARY 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcb16faf4fb149658bbba1601aa0bbc7_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMi0xLTEtOTcyNzI_07914f1c-bf60-4b02-bf5b-dbec370cf930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb16faf4fb149658bbba1601aa0bbc7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtNC0xLTEtOTcyNzI_8116cf76-1106-48ee-be50-66e9af0d888c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50aac6883ff6400fa2cae1a080701556_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtNi0xLTEtOTcyNzI_0bee92be-5c22-4938-a06b-2172a9317187">25,378,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50aac6883ff6400fa2cae1a080701556_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtOC0xLTEtOTcyNzI_f3eeb0ae-8618-4f78-abf3-aba3f3ac592b">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d01d11a47442dd85ecf3c5da42e59c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMTAtMS0xLTk3Mjcy_7f073a84-9708-4d29-b7bd-d164628a2b82">505,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie414d3b9f48f4a62b15be9a778052e3e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMTItMS0xLTk3Mjcy_f57015e4-05f4-4d0a-9756-52c8e85cf852">93,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMTQtMS0xLTk3Mjcy_73e368b8-bd01-41dc-9768-ae31fd828753">411,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjEtMTAtMS0xLTk3Mjcy_0b21c99d-b67a-4c8a-b6df-28e560552e70">8,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjEtMTQtMS0xLTk3Mjcy_07add295-7882-470b-abbe-e6af29ab5637">8,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjItNi0xLTEtOTcyNzI_4c861954-ffb6-40c1-9ae2-d96e9ea55251">62,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjItMTAtMS0xLTk3Mjcy_3d21cb06-41d4-4be8-ae23-7caafc8f35f0">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjItMTQtMS0xLTk3Mjcy_34698128-1122-4426-8dce-34f43ec01a15">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock from vested restricted stock units and payment of employees&#8217; taxes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjMtNi0xLTEtOTcyNzI_16e66d74-97b7-49b9-be4b-a2077d74f3a4">2,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjMtMTAtMS0xLTk3Mjcy_1dcd0006-2160-4417-b922-71122551cdfe">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjMtMTQtMS0xLTk3Mjcy_061575ee-cb31-4b60-838e-34b5c8b4f3d3">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under the employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjQtNi0xLTEtOTcyNzI_1f19ac4b-14f3-49a1-aa66-5aec8a8588b4">42,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjQtMTAtMS0xLTk3Mjcy_2247abd0-ddf1-4d50-98a6-3f42900a0ca5">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjQtMTQtMS0xLTk3Mjcy_50cee72d-48b2-48a7-bcbc-977990848942">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80d23ca5218f4f239df0df99e61be5fb_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjUtMTItMS0xLTk3Mjcy_50e87af4-ea9f-4fc4-98d2-3e08034f467b">24,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjUtMTQtMS0xLTk3Mjcy_af3fbde9-b162-4f63-bb95-6fe20caa7951">24,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BALANCE, MARCH 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff9ba1ac9bdc4a2f8c18d78ab64539ae_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMi0xLTEtOTcyNzI_8d6606ec-ed4f-404f-81da-84c2e6c5fe8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff9ba1ac9bdc4a2f8c18d78ab64539ae_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtNC0xLTEtOTcyNzI_ae6f01a3-c563-4857-9f8b-fd6aaf3e0ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a71817e0bcd412b9689d66aaaede50c_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtNi0xLTEtOTcyNzI_9ac70376-523a-4a1f-b063-181cbc5821d6">25,485,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a71817e0bcd412b9689d66aaaede50c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtOC0xLTEtOTcyNzI_97555af7-772d-4a21-84b0-abd3b96c77c8">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519d138276e44889b2be7e9e5bda9d96_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMTAtMS0xLTk3Mjcy_647e35aa-8bd8-4ebd-8710-c9de45c4eeff">515,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i652198504ae942f4b9eb116281a3e9fc_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMTItMS0xLTk3Mjcy_01cd3d4b-25f3-4d81-a27b-439242d0b6cd">118,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63ac35e1982419cab5b0e55ac7a9ec0_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMTQtMS0xLTk3Mjcy_7a8f1436-33f9-454c-8f2f-eb7367865701">397,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjctMTAtMS0xLTk3NjU1_74921d30-de7b-4402-a5e2-7e369eeda2fe">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjctMTQtMS0xLTk3Mjcy_b8bb2060-cf8f-4b98-a5cd-67fb0af370d4">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjgtNi0xLTEtOTc2NTU_68854356-3704-4571-8a47-2d146209fe2e">36,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjgtMTAtMS0xLTk3NjU1_b71a1a48-4e82-4880-9831-6d642c1350c7">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjgtMTQtMS0xLTk3Mjcy_d4d28267-feb4-4b12-b05f-296f1892c1c2">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock from vested restricted stock units and payment of employees&#8217; taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktNi0xLTEtOTc5MTI_4b0d3daa-26a7-4331-a80d-f87a80cb04a4">6,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTAtMS0xLTk3OTEy_3bdeffc5-f0e7-4d09-a847-28db13e4e67d">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTQtMS0xLTk3OTEy_6a54cf20-39ad-4103-8cbf-2462f68f8909">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in acquisition of business</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtNi0xLTEtMTA1NDU4_33c57653-d052-4616-a1fb-6abb60077f32">763,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtOC0xLTEtMTA1NDU4_a655673f-14f7-4d0d-956f-367d99fa68f8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTAtMS0xLTEwNTQ1OA_6f452276-245d-4c92-b5b4-690cf372bc48">17,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTQtMS0xLTEwNTQ1OA_21fbd1e7-cfda-4540-b023-d3e6e6000d6e">17,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cb246820c6d498e90a506f4b515e485_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTItMS0xLTk3NjU1_4c7cecf3-6a3f-4642-9c2a-2b85926688af">1,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTQtMS0xLTk3Mjcy_2c7a6740-d6d2-4781-8987-48dc07f9e7c4">1,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BALANCE, JUNE 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if188768c20ab47cdb0dff4b33bd0c0ff_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMi0xLTEtOTcyNzI_85c274f0-ee7f-448b-81b8-733ba83f8c75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if188768c20ab47cdb0dff4b33bd0c0ff_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtNC0xLTEtOTcyNzI_2f109050-db07-4100-a7da-2d199c5a83ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34f5ad41aeed41b08758233329facba3_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtNi0xLTEtOTcyNzI_3ad7a3ee-6937-4522-b6af-1fabae811afd">26,292,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f5ad41aeed41b08758233329facba3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtOC0xLTEtOTcyNzI_d4d26cad-3c57-4e85-9b17-9f669df285d3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5404bc6eaf484be4813006a731482c19_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTAtMS0xLTk3Mjcy_635c2b34-976e-4265-8688-932060e6307f">541,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id85254eabd1f425ca0d60cbd627df78d_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTItMS0xLTk3Mjcy_8aca9967-b8a8-4aa7-9f23-281564652b6b">120,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTQtMS0xLTk3Mjcy_ad8c5b13-b457-4c48-8d69-c9a669acaacf">421,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMy0xLTEtMS05NzI3Mg_67a7a12e-79d4-4ad3-97eb-698b2b4c37f2">26,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMy0zLTEtMS05NzI3Mg_4cb8ff34-57fc-46c1-8c12-9fa3e287c1e8">13,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNS0xLTEtMS05NzI3Mg_e2bff59f-ae74-4dd2-9938-b0fe8761b3cb">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNS0zLTEtMS05NzI3Mg_e571fcbc-ebee-46c3-afac-c2f12fd2dd31">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNi0xLTEtMS05NzI3Mg_cfe4f5d6-dd9f-42bb-a71a-c55d29e90a84">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNi0zLTEtMS05NzI3Mg_5691de0c-ea66-4a7f-8d7f-c55896a10f1d">9,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNy0xLTEtMS05NzI3Mg_9934f143-ee5a-4f24-b24a-670e7606ef74">17,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNy0zLTEtMS05NzI3Mg_5a4a08ab-6cea-4db0-82f1-ea721f467e5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOC0xLTEtMS05NzI3Mg_b65e7b41-5cc1-4491-bbce-71ed8655542a">1,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOC0zLTEtMS05NzI3Mg_4773536f-7862-4d48-b975-89af2d975fd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOS0xLTEtMS05NzI3Mg_255b6577-ab19-45f2-b3a6-0a2d5b8347f9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOS0zLTEtMS05NzI3Mg_ee360257-1927-4e10-a996-91bd2b0cd0b6">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTEtMS0xLTEtOTcyNzI_e5670441-4da8-4144-afc3-c02a2923f7f8">5,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTEtMy0xLTEtOTcyNzI_a4966459-5726-4de3-9625-e3baa8503c21">5,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTItMS0xLTEtOTcyNzI_6ef08f6d-35b5-463e-9264-5b6b5bd4dc9f">707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTItMy0xLTEtOTcyNzI_a7b627fc-ae95-478b-bfa2-a7799ae9399b">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTMtMS0xLTEtOTcyNzI_ce61e9b3-b736-410e-bf10-d85874ed78de">1,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTMtMy0xLTEtOTcyNzI_41b6960e-f544-4f40-a489-7f4d04bb1b14">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTQtMS0xLTEtOTcyNzI_d823ee5d-5375-4a2d-8875-37ed70c0023b">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTQtMy0xLTEtOTcyNzI_3170d97f-6baf-43cd-8004-c552bfa40a2f">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTUtMS0xLTEtOTcyNzI_c9986162-0583-42f5-9444-d171582c0387">504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTUtMy0xLTEtOTcyNzI_f7a71820-af60-4159-97f8-561c955075ae">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTYtMS0xLTEtOTcyNzI_02676e2b-e326-4c29-a986-66c71f56f530">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTYtMy0xLTEtOTcyNzI_7f34ebd1-9169-40d9-9ecd-f198cac3b3a6">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTctMS0xLTEtOTcyNzI_0191f0a8-909d-46e6-a326-bd5ec7efbad6">445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTctMy0xLTEtOTcyNzI_4c9a69dd-7302-4fd2-8d31-1faf71b7f586">590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTgtMS0xLTEtOTcyNzI_e5c2a3c6-5b86-4f5d-88e1-f4b7aae91306">1,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTgtMy0xLTEtOTcyNzI_96b16571-8b41-47d6-8a40-0db6f4c59ca2">523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare advance payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTktMS0xLTEtOTcyNzI_311a9584-3af8-4f0f-950a-42be23c28f93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTktMy0xLTEtOTcyNzI_ba278d07-56d7-4bfb-a58c-b08878d0357d">2,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjAtMS0xLTEtOTcyNzI_f6bb1682-6dee-41b9-b8d6-2be5b66607d4">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjAtMy0xLTEtOTcyNzI_c89d3ef9-ed85-402e-9488-53eecca9d847">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjItMS0xLTEtOTcyNzI_cdb12ef2-45d2-4ec9-beeb-97eecd28e4c1">30,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjItMy0xLTEtOTcyNzI_29d7b6a8-d9d2-43a2-9fb6-0ca268d096ca">10,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjUtMS0xLTEtOTcyNzI_d4e886b0-b279-485e-9900-9fd8c9eb2f6c">1,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjUtMy0xLTEtOTcyNzI_b0158045-9864-401b-b2ff-33737eb12cfd">1,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="cstl:ProceedsFromPreviousAssetAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjYtMS0xLTEtOTcyNzI_6153c873-5a64-4d70-ae8c-97e911807458">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjYtMy0xLTEtOTcyNzI_0e443d74-bf7f-45db-b923-2f492c5ed471">33,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of business, net of cash and cash equivalents acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMS0xLTEtMTA2MjY4_85a66587-300e-4db8-9bf0-ad6ee83d6a19">26,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMy0xLTEtMTA2MjY4_962f01cd-a691-4e47-b127-c6dc352a8456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMS0xLTEtOTcyNzI_9de5f30b-ac40-4637-abfa-a7a3f3ccf75c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMy0xLTEtOTcyNzI_3db74641-a090-42bb-8800-7bb0c0ae75dc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjktMS0xLTEtOTcyNzI_283746ef-ed99-4160-b879-81c0ee73c966">27,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjktMy0xLTEtOTcyNzI_c9fc976f-9f74-4154-96b7-6ea41416ad7a">34,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of common stock offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzItMS0xLTEtOTcyNzI_d05adcb6-fbd9-4d2e-b7d1-5474919b394d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzItMy0xLTEtOTcyNzI_d407568f-1176-4c65-a18f-e30c11b8a907">336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzMtMS0xLTEtOTcyNzI_f832cc86-686e-4214-bc9b-c718948795bb">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzMtMy0xLTEtOTcyNzI_d8d4f580-861a-4b4b-be78-5bffdbf5ece8">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of employees&#8217; taxes on vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzQtMS0xLTEtOTcyNzI_32640bcc-aa89-4ddf-a2b2-9e6e0e536e69">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzQtMy0xLTEtOTcyNzI_dadea61f-ef32-493a-ad29-0b16e093bf8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from contributions to the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzUtMS0xLTEtOTcyNzI_d291aeb1-450a-407d-bd93-4a3928f5cfaf">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzUtMy0xLTEtOTcyNzI_94a1cfaf-7143-4c71-b0da-25d5848d05f6">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of principal portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzYtMS0xLTEtOTcyNzI_6541188f-353f-4fb5-b686-7b26f3ba8672">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzYtMy0xLTEtOTcyNzI_524033cd-c515-4ad2-a2a6-59d7ef593d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzctMS0xLTEtOTcyNzI_df73183f-ffb5-4cd6-bddc-1cee85b3d86d">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzctMy0xLTEtOTcyNzI_7f14eba5-3aed-4333-bda5-ee609c242f3e">3,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET CHANGE IN CASH AND CASH EQUIVALENTS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzktMS0xLTEtOTcyNzI_66f0956e-8710-40f0-83c9-cef4772c0af5">56,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzktMy0xLTEtOTcyNzI_bec5eb88-7b36-4f47-8c92-f5c0d802d81b">41,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDAtMS0xLTEtOTcyNzI_c1c3253a-aa42-4c9d-8066-33dccc5c6335">329,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55427030f29b4ec8919acde7614ce80a_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDAtMy0xLTEtOTcyNzI_83896cf6-06a9-4296-877c-88d1df8796e1">409,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDEtMS0xLTEtOTcyNzI_1155b617-e06e-4625-85e5-6809d7ca497f">273,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDEtMy0xLTEtOTcyNzI_cfe0a41f-ab2e-41ec-8051-d8c9b125b099">368,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DISCLOSURE OF NON-CASH INVESTING AND FINANCING</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACTIVITIES:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDQtMS0xLTEtOTcyNzI_b71e153e-a56c-44d2-a826-58852d61e264">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDQtMy0xLTEtOTcyNzI_a1f9c588-ac29-4154-81f4-a05823303e8f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in acquisition of business</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDYtMS0xLTEtMTA2Mjk4_b1044b6a-9570-4539-9cfc-d7544f24f17a">17,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDYtMy0xLTEtMTA2MzAx_cc42ffa8-4ad6-4e5e-beaa-fa5044d9f36d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration in acquisition of business</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="cstl:BusinessCombinationNoncashContingentConsiderationGiven" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDctMS0xLTEtMTA2OTcw_badbb260-f81f-43e6-a75a-1b14467a0f27">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="cstl:BusinessCombinationNoncashContingentConsiderationGiven" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDctMy0xLTEtMTA2OTcw_d3408903-618b-4bc3-b9b3-cb7d26e933d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration payable in acquisition of business</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDgtMS0xLTEtMTA2OTcw_ad7d8e4d-8782-4da7-b5f9-9485ad68d0fc">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDgtMy0xLTEtMTA2OTcw_729c4583-194b-486d-8007-b93bdffc1540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED) </span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i85ed73ce88b34118965f36f66c298ae1_31"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zMS9mcmFnOjE1MGEzZmEyNmYxZjRiODQ5NWQ0YjFhZTEyMzNhYWU0L3RleHRyZWdpb246MTUwYTNmYTI2ZjFmNGI4NDk1ZDRiMWFlMTIzM2FhZTRfMTI4OA_b1460e9a-f4f4-431c-bea0-c0baf4d2f8af" continuedAt="id93d0506fd274817bb8fc31760c49d4a" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="id93d0506fd274817bb8fc31760c49d4a"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Castle Biosciences, Inc. (the &#8216;&#8216;Company,&#8217;&#8217; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve health outcomes. We are based in Friendswood, Texas (a suburb of Houston, Texas) and our laboratory operations are conducted at our facilities located in Phoenix, Arizona, Pittsburgh, Pennsylvania and San Diego, California.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the COVID-19 pandemic began in March 2020, we have maintained uninterrupted business operations with no interruption in turnaround times for delivery of test reports, but we have experienced declines in test report volume in certain periods, which we believe is linked to delays and/or cancellations in patient visits in response to COVID-19, resulting in reduced diagnostic biopsies and thus reduced diagnoses of cutaneous melanoma and test reports attributable to our lead product, DecisionDx&#174;-Melanoma, a test for cutaneous melanoma. The extent to which COVID-19 may further impact our business, consolidated results of operations, consolidated financial condition and consolidated cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_34"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTE0MQ_0837339e-5764-4f54-ba49-972bbdf28a2d" continuedAt="iccba083f9ff448bd879cc6ff53d79738" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iccba083f9ff448bd879cc6ff53d79738" continuedAt="i5af72df20124448aba139d11fcca90b3"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyMg_1e717b88-88e8-4f53-97bd-e83b4de47c99" escape="true">Our unaudited condensed consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8216;&#8216;U.S. GAAP&#8217;&#8217;).</ix:nonNumeric> <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyNQ_32267c9f-ebe2-407d-b003-c46e0dc51a44" escape="true">All intercompany accounts and transactions have been eliminated in consolidation.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of&#160;June&#160;30, 2022; the condensed consolidated statements of operations and comprehensive loss, the condensed consolidated statements of stockholders&#8217; equity for the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021; and the condensed consolidated statements of cash flows for the&#160;six&#160;months ended&#160;June&#160;30, 2022&#160;and&#160;2021&#160;are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of our consolidated financial position as of&#160;June&#160;30, 2022, the results of our consolidated operations for the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021 and our consolidated cash flows for the&#160;six&#160;months ended&#160;June&#160;30, 2022&#160;and&#160;2021. The financial data and other information disclosed in these notes related to the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021&#160;are also unaudited. The results for the three and six months ended June&#160;30, 2022&#160;are not necessarily indicative of results to be expected for the year ending&#160;December&#160;31, 2022, any other interim periods, or any future year or period. The balance sheet as of&#160;December&#160;31, 2021&#160;included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the unaudited interim consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the Securities and Exchange Commission on February 28, 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzMw_bc2f7308-b9bc-4bbd-aebf-cd1c73d864ab" escape="true">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i5af72df20124448aba139d11fcca90b3" continuedAt="ia001bf182fbf4597b4130ade2d85ae61"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents including Concentrations of Credit Risk</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzOA_bd256b83-ebd5-461e-83cf-b6df18c41291" escape="true">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), that are primarily invested in short-term U.S. government obligations.</ix:nonNumeric> <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTExOQ_ddd872e8-a03a-4b5f-a148-e4bcc569f215" escape="true">Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:3pt;margin-top:6pt"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyOQ_7a0b49a9-8b88-478f-ad07-933fda2082b0" continuedAt="i113db40320ad455e9472146b2fa0d5cb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;) Accounting Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i113db40320ad455e9472146b2fa0d5cb">(&#8216;&#8216;ASC 606&#8217;&#8217;). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration.</ix:continuation> See Note 3 for further details.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyMA_c95fef6e-5eb7-40d8-8ac1-323c98e6d9c5" escape="true">We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as noncurrent assets. The estimated timing of payment utilized as a basis for classification as noncurrent is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzMA_e7c86523-1a23-4fd3-aa83-baeb363778db" escape="true">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers&#8217; financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was <ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNjg1Ng_621e940a-27d9-431b-b9de-f64c1b5aae2c"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNjg1Ng_98778528-98ad-4a0f-9b44-8284761a183e">zero</ix:nonFraction></ix:nonFraction> as of June&#160;30, 2022, and December&#160;31, 2021. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:6pt"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNjU5NzA2OTc4NzEzMQ_e4703278-89d5-4b6e-9b68-3038c5d5b5a9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. In accordance with ASC Topic 350,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that it may be impaired. We perform annual impairment reviews of our goodwill balance during the fourth quarter of each year. We may perform a qualitative assessment to determine if it is necessary to perform a quantitative impairment test. If we determine that a quantitative impairment test is necessary, we apply the guidance in Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, by comparing the fair value of the reporting unit to its carrying value, including the goodwill. If the carrying value exceeds the fair value, we recognize an impairment loss for the amount by which the carrying value exceeds fair value, up to the total amount of goodwill allocated to the reporting unit. We did <ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_0302bc45-b05f-419d-bed7-38b0c0aeb383"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_7b66858e-d23f-4817-b968-6c786e7ec452"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_d567d600-23cc-4719-b7bf-39ba3371ffea"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_ec4d5509-1961-4ddd-9680-7ad474b0964b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t incur any goodwill impairment losses in any of the periods presented.</span></ix:nonNumeric></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="cstl:BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzMg_437abe9d-f465-4cb7-ab54-62638240dd0a" continuedAt="i9b434b0ab0414ce69cf65f23cbaa9d6c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess acquisitions under ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (&#8220;ASC 805&#8221;) to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual </span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ia001bf182fbf4597b4130ade2d85ae61"><ix:continuation id="i9b434b0ab0414ce69cf65f23cbaa9d6c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, in accordance with ASC 805, contingent consideration is recorded at fair value as of the acquisition date and classified as liabilities or equity based on applicable U.S. GAAP. For contingent consideration classified as liabilities, we remeasure the contingent consideration at fair value each period with changes in fair value recorded in the statements of operations and comprehensive loss each period.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration in transactions that are not business combinations, we apply applicable U.S. GAAP. With respect to the additional consideration that may be payable in connection with the acquisitions of Cernostics, Inc. (&#8220;Cernostics&#8221;), an asset acquisition we completed on December 3, 2021, we account for the contingent consideration as a liability in accordance with ASC Topic 480,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is classified as current or noncurrent in our condensed consolidated balance sheets based on the contractual timing of future settlement. For additional information on contingent consideration, see Notes 5 and 10.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Compensation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyMw_4aa71561-cf42-4827-bedb-b50363571c87" escape="true">We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. Our board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of June&#160;30, 2022 and December&#160;31, 2021, we accrued $<ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfODYzMg_926c0c2f-d482-4158-acdb-e4ffbdbacf91">9,835,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfODYzOQ_b15a9e9e-b9c6-481e-8932-b28f0002b21e">12,071,000</ix:nonFraction>, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the condensed consolidated balance sheets based on the expected timing of payment.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTE0MA_487c3f6e-80c4-49e1-92d1-a9a5f8336def" escape="true">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources.</ix:nonNumeric> Our comprehensive loss was the same as our reported net loss for all periods presented.</span></div></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_37"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNzQzMA_794166e5-0cd1-4e11-b214-5a129a05e499" continuedAt="ie3df336c26c340649a5f05545f98103e" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="ie3df336c26c340649a5f05545f98103e" continuedAt="i798efa87a6a944f3bef23605983f4309"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to our DecisionDx&#174;-Melanoma test for cutaneous melanoma. We also provide a test for uveal melanoma, DecisionDx&#174;-UM, a test for patients with cutaneous squamous cell carcinoma, DecisionDx&#174;-SCC, two tests for use in patients with suspicious pigmented lesions, MyPath&#174; Melanoma and DiffDx&#174;-Melanoma, and a test for patients diagnosed with Barrett&#8217;s esophagus (&#8220;BE&#8221;), the TissueCypher&#174; Barrett&#8217;s Esophagus Assay. We also began offering a pharmacogenomics (&#8220;PGx&#8221;) testing service focused on mental health, IDgenetix&#174;, following a business combination completed in April 2022. Information on the disaggregation of revenues is included below. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a positive coverage policy, with or without a contractually committed reimbursement rate, with a commercial carrier or governmental program, our diagnostic tests may or may not be paid by these entities. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare claims that are covered by policy under a Local Coverage Determination (&#8220;LCD&#8221;) or otherwise are generally paid at a rate established on Medicare&#8217;s Clinical Laboratory Fee Schedule or by the respective Medicare contractor within <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="cstl:ContractWithCustomerCustomerPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfMjI2NA_92b7627c-8778-4d78-8377-d8fd44b57636">30</ix:nonNumeric> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i798efa87a6a944f3bef23605983f4309" continuedAt="ic814f59570ad459bbd6a8167c46741a3"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD or other coverage commencement date or are not covered but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed &#8216;&#8216;redetermination&#8217;&#8217;), second (termed &#8216;&#8216;reconsideration&#8217;&#8217;) or third level of appeal (de novo hearing with an Administrative Law Judge (&#8220;ALJ&#8221;)). A successful appeal at any of these levels may result in prompt payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of LCD coverage, contractually established reimbursements rates or other coverage, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the &#8216;&#8216;most likely amount&#8217;&#8217; method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Variable consideration for Medicare claims that are not covered by an LCD or otherwise, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the three months ended June 30, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNDg3NQ_53fbf0ed-0dba-40b4-934e-c1b81ac524a1">578,000</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNDg4Mg_4a77f1b8-d97f-4eef-89b1-6e66012f7e86">166,000</ix:nonFraction>), respectively, of net positive (negative) revenue adjustments associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Such amounts of variable consideration for the six months ended June 30, 2022 and 2021 were $(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfMTA5OTUxMTYzNjYwOA_49badc8d-670f-49fd-ad77-33f14a4d667c">300,000</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfMTA5OTUxMTYzNjYyMQ_d4d9e85a-2155-45a5-8501-a845df80e110">5,092,000</ix:nonFraction>, respectively, of net (negative) positive revenue adjustments. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of our contracts. Contract balances consisted solely of accounts receivable (both current and noncurrent) as of June&#160;30, 2022 and December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNzQzMQ_05874ef0-9971-420c-9c36-2401fafebbff" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the disaggregation of revenue by type (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5cf2e6b2e24c06be4b1939e1daf492_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0xLTEtMS05ODAyOQ_125570a3-dddc-459c-9121-4a433bf56a17">31,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa26bc228544c24a0666ef5b1bd5976_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0zLTEtMS05ODAyOQ_b6f919ef-b297-4b42-ae76-d99184e19216">20,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9947a18f7d40039c6b420a80007dba_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0xLTEtMS05NzI3Mg_0619c80f-4add-4144-87a2-f4050c17a1d3">56,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia03e51765e914b8a9011d48a1ca77348_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0zLTEtMS05NzI3Mg_231e7ed3-e853-4525-8728-4bc885516af1">41,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8336c818a9d24de1b01f985248828ffd_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0xLTEtMS05ODAyOQ_3a7e138f-a53d-4d01-9f10-784cc56d76c1">2,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i131a7e641770456ba0f7359e16012f93_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0zLTEtMS05ODAyOQ_82a7f983-134e-4dc2-a511-21ec30c3567b">2,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743fbc9ec6194ca792d7d9caf96f471a_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0xLTEtMS05NzI3Mg_2b51ba1d-cd45-4ec1-b661-60c36a79e2be">5,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0183c80be36439e982930171a859a72_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0zLTEtMS05NzI3Mg_c7cb25c7-f52a-4c8f-bf10-a463b2ae1e28">4,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0xLTEtMS05ODAyOQ_e7959d99-9ba6-4008-89a6-59d49985bf06">34,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0zLTEtMS05ODAyOQ_ccc6111a-77cc-4822-b23b-2d283633c0aa">22,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0xLTEtMS05NzI3Mg_091d6816-cb12-4151-9cb6-70af51bcc5e6">61,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0zLTEtMS05NzI3Mg_8e7606fd-f109-4603-8078-38434526ac9e">45,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payor Concentration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our diagnostic and prognostic tests.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ic814f59570ad459bbd6a8167c46741a3"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNzQzMg_373c35e3-04c9-4762-8b73-67a2ba9cce0c" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(current)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(noncurrent)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia301a48e31e3464b850d1a0710a2fb2e_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy0xLTEtMS05NzI3Mg_fb4f5e1e-0ee6-4640-811f-3862362f4603">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb4d6409a095497989a2cb7fb57c9812_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy0zLTEtMS05NzI3Mg_ec1f3e25-40a9-4a13-aa7b-c6c3b636bd7f">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05824dd7aebb44438f53e1deb76ad500_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy01LTEtMS05NzI3Mg_75bcde44-de3d-40f9-ae22-df3969ae7b34">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94472029ae74477fb2fffb4ece2766a6_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy03LTEtMS05NzI3Mg_f208846f-7dd8-4c28-8324-9f02700c5336">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i323f1187bec8480581a9940120e35818_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy05LTEtMS05NzI3Mg_c7d9ec0c-1b62-4553-8acf-96ec82253c06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fb78aa5b5c14c7cad3c10b3fed78ccd_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy0xMS0xLTEtOTcyNzI_d11a4f04-86b1-4c35-8907-9fbdbcd5cfb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8aeb153e06f4174a607042caec7e398_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC0xLTEtMS05NzI3Mg_1e631a25-b48f-4fc7-b4b9-90ec76e6405d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f647f897a49453e97a9bc858216da0d_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC0zLTEtMS05NzI3Mg_679ad0ba-8aeb-4884-bf7b-adc138441093">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8647297e768439fa24eb3a61573953f_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC01LTEtMS05NzI3Mg_a9ee5a5b-c910-4b70-9f8b-a2880976084e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdf616ceceff4a9789bd794cf9f29b01_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC03LTEtMS05NzI3Mg_133a0b20-4ffe-451e-974e-9a4cf3826706">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i202ecb6dff6b4729b49d234fb2bef137_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC05LTEtMS05NzI3Mg_82180988-d481-4dd3-8fce-63f3ca971d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8ef15e282314f3d8fec2981a454d8a4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC0xMS0xLTEtOTcyNzI_d5815891-3042-4efe-b474-c7522024f4a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlueCross BlueShield plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id36b4a825e7f469b8fd2f597b3af8390_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS0xLTEtMS05NzI3Mg_90f1be8f-301f-404a-a5fe-6d61832e562b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfdb2a1c4c384d149ee8bca6e20af292_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS0zLTEtMS05NzI3Mg_15523fb2-1087-4590-9478-e6fa10708592">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee1f44ce249142beac6ca7381822ec8b_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS01LTEtMS05NzI3Mg_2a167c24-7100-4c76-99c4-d248b4c6c722">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7cc96b39f3484f47995755bc11a69ddc_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS03LTEtMS05NzI3Mg_52218c30-cc2f-453c-ae6b-b8bc69dfe1be">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0135a04774dc4b219792a238d8bafb56_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS05LTEtMS05NzI3Mg_dcde8ddb-e182-4431-b7e1-9a754eb3bbee">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4caeb8a1e254252b6c25709ec4ec9d4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS0xMS0xLTEtOTcyNzI_9e63b909-5c09-42b3-9079-dfea3465312e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_40"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RleHRyZWdpb246ZmQyNThhZjMyNzU2NDQzODk2YzNkNDFkYjI5MDVhZjVfMTM1MQ_d0a89ab4-109b-419c-aef8-014a6005d84d" continuedAt="i56c9a50b053342b3b7bdb4192d6de6eb" escape="true">Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i56c9a50b053342b3b7bdb4192d6de6eb"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or purchases under the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we reported a net loss for all periods presented, all potentially dilutive securities are antidilutive and are excluded from the computation of diluted loss per share for such periods.</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RleHRyZWdpb246ZmQyNThhZjMyNzU2NDQzODk2YzNkNDFkYjI5MDVhZjVfMTM1Ng_469af7c7-bdb0-4573-a4a4-49e9919bd1ad" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the three and six months ended June&#160;30, 2022 and 2021 because to do so would be antidilutive (in thousands): </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units (&#8220;RSUs&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3851b8892a64a6bb5ee4d6a59a6d586_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi0xLTEtMS05NzI3Mg_79c982bf-f027-406d-9fac-ea1dde09bca2">4,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1e593f0419b463ab2feaebd198a1f36_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi0zLTEtMS05NzI3Mg_2b8aecf6-d371-4cd5-9ab2-d4a6803c921d">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c32637b65384bdb811ce3fde43efe9c_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi01LTEtMS05NzI3Mg_98fdcdc9-b096-4c06-bd02-e5b932564d2a">4,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0fa44c09bb549a8bab2bb18b6137f27_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi03LTEtMS05NzI3Mg_7f4df2f8-07a9-43fe-9fb2-46aec77505d7">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae420fb56f4e41199cef237838e485c7_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy0xLTEtMS05NzI3Mg_f1c002ce-552b-4122-8e26-682cb1a3aa7d">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec43d4abf35e401b9ee6ac4b9e162d95_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy0zLTEtMS05NzI3Mg_cb4fd98a-bbfa-4775-aa16-f6bee7c7760f">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id190812a859648c4aa204468be09784d_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy01LTEtMS05NzI3Mg_0c081f8b-a61b-4488-98e3-683addc662e5">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e027d558f18441ebd34443aff9c0b0e_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy03LTEtMS05NzI3Mg_a25fadc9-6993-4495-a1b4-f09efe3e0ba1">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC0xLTEtMS05NzI3Mg_0a019e18-c599-4eec-a97f-68fa0b7b2be5">5,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC0zLTEtMS05NzI3Mg_f61fdf73-a198-4739-b139-271358d3be88">3,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC01LTEtMS05NzI3Mg_3d5d11c8-6e59-4f07-9925-8067f7636c7f">4,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC03LTEtMS05NzI3Mg_bdc7c490-ef25-4b97-9a43-a1a2e80bfb99">3,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the acquisitions of Cernostics and AltheaDx, Inc. (&#8220;AltheaDx&#8221;), we may issue, or may be required to issue, shares of our common stock to satisfy our contingent consideration obligations, pending the outcome of certain commercial and regulatory milestones, as required by the respective definitive agreements. See Notes 5 and 10 for additional information.</span></div></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_1385"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzcyOTcx_7ea423d0-3c4c-4afc-b690-40e212e153ae" continuedAt="i2e44779f293b4346845bcb2455b29c92" escape="true"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:AssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzcyOTcx_92550b21-9420-4e77-ac4e-0e4036548958" continuedAt="i7453acc4e95c4b20ac6b46487edcc2d4" escape="true">Acquisitions</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i2e44779f293b4346845bcb2455b29c92" continuedAt="i722bb88862c54b87b3615d6addb12bc4"><ix:continuation id="i7453acc4e95c4b20ac6b46487edcc2d4" continuedAt="i8ed03bc27aaf47f0869a7d333b4b9cda"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Myriad myPath, LLC</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City, for a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="i2d5c289e6d474738890e1b72e04b9576_D20210528-20210528" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4MzQw_257ef41c-e348-42d1-acea-c5ceecb7a2f7">32,500,000</ix:nonFraction>. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the developed technology, and therefore the transaction represents an asset acquisition rather than a business combination.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cernostics, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, we completed the acquisition of Cernostics, which offers the TissueCypher Barrett&#8217;s Esophagus Assay for patients with BE, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4MzUz_cccb504b-1fd2-45b7-835f-23d600cd0a4c">49,019,000</ix:nonFraction>, consisting of cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203" decimals="-3" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4MzY2_afc379b2-5092-49de-abff-2f8d639fe6d0">30,732,000</ix:nonFraction> and contingent consideration with an acquisition date fair value of $<ix:nonFraction unitRef="usd" contextRef="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4Mzc5_bb94f97c-68ec-49e3-a62f-4a04a16b6def">18,287,000</ix:nonFraction>. In connection with the acquisition, we recorded a receivable as of the acquisition date for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital. During the three months ended June 30, 2022, we received cash of $<ix:nonFraction unitRef="usd" contextRef="i36d6bf4b13ce4a24ae2fea8c910f9894_D20220401-20220630" decimals="-3" name="cstl:ProceedsFromPreviousAssetAcquisition" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4Mzky_72d6ec98-7db9-4271-b9aa-d0bc00f03a8e">547,000</ix:nonFraction> in settlement of this receivable. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i722bb88862c54b87b3615d6addb12bc4" continuedAt="ibc3ae6eec78748d982b556d735c5f238"><ix:continuation id="i8ed03bc27aaf47f0869a7d333b4b9cda" continuedAt="i7014b935fd4e4ecd8fa27bc2820f1ebb"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AltheaDx, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, we completed the acquisition of <ix:nonFraction unitRef="number" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODExODY2_9625df9b-3380-44b2-9ff6-963f81f33622">100</ix:nonFraction>% of the equity interests in AltheaDx. AltheaDx offers the IDgenetix test, a PGx test focused on mental health. We believe this acquisition enables us to expand upon our existing portfolio of testing solutions in support of our growth strategy. We have concluded that the transaction represents a business combination under ASC 805. The financial results of AltheaDx have been included in our unaudited condensed consolidated financial statements since the date of the acquisition. The amount of revenue from AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was not material. The loss attributable to AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was approximately $<ix:nonFraction unitRef="usd" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="-3" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8xMDk5NTExNjczNDM0_2523b039-49c2-41a4-b46c-51257eab71d1">3,383,000</ix:nonFraction>. This amount does not reflect transaction costs from the acquisition or the effects of the valuation allowance reduction discussed in Note 13. Transaction costs associated with the acquisition were $<ix:nonFraction unitRef="usd" contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630" decimals="-3" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjk4OTEw_9fccb104-4f4b-4598-a1bc-eab5f51eaf1f"><ix:nonFraction unitRef="usd" contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630" decimals="-3" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjk4OTEw_f2ec3d9c-aa13-40dd-a0ac-ca25d251df33">1,711,000</ix:nonFraction></ix:nonFraction> for both the three and six months ended June 30, 2022 and were recognized as expenses in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDE1_eb427069-4173-4b33-932f-ff8d529e5d00" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8xLTItMS0xLTExMTU2NA_d6736b3c-f36a-47c1-9831-35e2bb83445a">30,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock (<ix:nonFraction unitRef="shares" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8yLTAtMS0xLTExMTU2Ni90ZXh0cmVnaW9uOjE2NDVmMzFjNjA3OTQxYjhiM2JiNWY0OWFmYTI1ZGVjXzQzOTgwNDY1MTExNTQ_5a0d71f0-964c-45c2-98b5-e852530f652b">763,887</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8yLTItMS0xLTExMTU2NA_f30cc81a-bd9c-41c0-80b9-bcb171f8fc8f">17,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8zLTItMS0xLTExMTU2NA_277d1897-0310-44a3-880c-bfb822663cc8">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml80LTItMS0xLTExMTU2NA_cdfdcca8-1b1d-4955-a068-c354c585c114">49,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the common stock issued was measured using the April 26, 2022 closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODEyODc5_d9b0f2ad-1528-4705-946f-37562121f158">22.40</ix:nonFraction> per share, as reported by the Nasdaq Global Market.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the contingent consideration, we may be required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDEx_1abfb321-e782-4218-b256-fc26b4889069">75.0</ix:nonFraction> million in cash and common stock in connection with the achievement of certain milestones based on 2022, 2023 and 2024 performance and expanded Medicare coverage for the IDgenetix test (the &#8220;AltheaDx Earnout Payments&#8221;). Upon achievement of each relevant milestone event, each milestone will be paid <ix:nonFraction unitRef="number" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="INF" name="cstl:BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDE4_4ba03927-4b6d-4b55-854a-a844942cc9f1">50</ix:nonFraction>% in cash and <ix:nonFraction unitRef="number" contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426" decimals="INF" name="cstl:BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDIy_30729379-3b88-4157-9558-9a6ade798661">50</ix:nonFraction>% in shares of our common stock based on a price per share equal to the volume-weighted-average price of our common stock for the <ix:nonFraction unitRef="tradingday" contextRef="i4208ab3203fb45e2b40efa980b003a60_I20220426" decimals="INF" name="cstl:CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzcyOTc0_c5f4b8ea-52cc-4bfe-9240-bc47589bb802">20</ix:nonFraction> trading days as of the applicable milestone determination date. In accordance with the terms of the definitive agreement governing the acquisition of AltheaDx, the maximum number of shares of our common stock issuable to former AltheaDx security holders may not exceed <ix:nonFraction unitRef="shares" contextRef="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDE3_99b23838-795b-40d1-a4ac-1972b56bb77f">1,271,718</ix:nonFraction> shares. Therefore, taking into consideration the number of shares already issued at closing, a maximum of <ix:nonFraction unitRef="shares" contextRef="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426" decimals="INF" name="cstl:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDI4_a2808c38-b74c-4185-8d7e-0b6da8b8d702">507,831</ix:nonFraction> additional shares of our common stock remain issuable with respect to the AltheaDx Earnout Payments. In the event a number of shares in excess of <ix:nonFraction unitRef="shares" contextRef="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426" decimals="INF" name="cstl:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDM3_0b3b87f0-68ea-46a8-9e53-e3853da5e32a">507,831</ix:nonFraction> would otherwise be issuable in connection with the AltheaDx Earnout Payments, we will issue shares up to the maximum number permitted and pay cash for the remaining portion of the obligation. See Note 10 for additional information on the measurement of the contingent consideration. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ibc3ae6eec78748d982b556d735c5f238" continuedAt="i34b8e6e7c5394ed58c893ec133d6d313"><ix:continuation id="i7014b935fd4e4ecd8fa27bc2820f1ebb" continuedAt="i9b2f58d63e3a4ebe97fff6618ff81df3"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzczNjQw_2b173848-8767-4828-bfd4-8928c673fe1c" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xLTItMS0xLTEwMzMxNQ_d2fc2510-5749-4603-9243-e872765eade5">3,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8yLTItMS0xLTEwMzMxNQ_207c002a-11b4-423a-a34e-f90dcc51b166">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8zLTItMS0xLTEwNzMyOA_df77b561-632d-4a7a-ad4e-7485267cab75">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8zLTItMS0xLTEwMzMxNQ_fb8348c2-6dcd-4e55-a5a8-3f9adc1a6ddb">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl80LTItMS0xLTEwMzMxNQ_66d9fead-3b73-48b5-a02d-1b219bd1bf00">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl81LTItMS0xLTEwMzMxNQ_e8485f0a-36d9-4282-ade6-1127f16a5c28">37,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl83LTItMS0xLTEwNzMyOA_795e8e7f-6f25-4562-a622-5393732ccb26">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl82LTItMS0xLTEwMzMxNQ_74bd5e6e-c8e3-469c-badd-fde9dbaf09e6">231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="cstl:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl83LTItMS0xLTEwMzMxNQ_436e54fb-5a23-43a5-98d9-5bc047282e70">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl84LTItMS0xLTEwMzMxNQ_2092efef-730d-4c8f-b706-d3f896f9a8a0">532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xMy0yLTEtMS0xMTM3MTI_181018fd-e89f-4b21-b042-317ae29dc027">1,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xNC0yLTEtMS0xMTQzMTI_abf9c856-2463-4789-b587-f649804f186e">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xMS0yLTEtMS0xMDMzMTU_91438950-5a87-4bbd-ba02-01276dd6762a">38,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xNS0yLTEtMS0xMDczMjg_943f7810-6cd8-4ad5-b752-c7cc965ff152">10,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xNi0yLTEtMS0xMDczMjg_a60542e8-a087-40cb-8a8b-8e0a5f0e1557">49,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset is comprised of developed technology with an estimated useful life of <ix:nonNumeric contextRef="idc558f1bcfcf460c9f62c48b28e4c8cd_D20220426-20220426" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDgx_3c53addf-28e7-4805-9ea0-37c05eba890b">15</ix:nonNumeric> years and is being amortized on a straight-line basis. The goodwill, which is not expected to be deductible for income tax purposes, was primarily attributable to potential future growth opportunities and the organized workforce.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our calculations of the consideration transferred and the purchase price allocation for the acquisition of AltheaDx are based on a preliminary valuation and are subject to revision as the valuation is finalized and additional information about the fair value of the assets and liabilities becomes available. The primary areas that are not yet finalized are income taxes, intangible assets, contingent consideration and the resulting goodwill. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information for the three and six months ended June 30, 2022 and 2021 combines our historical financial results and the results of AltheaDx, assuming that the companies were combined as of January 1, 2021, and includes adjustments for amortization expense from the acquired intangible assets and additional stock-based compensation expense. Nonrecurring pro forma adjustments consist of acquisition-related transaction costs of $<ix:nonFraction unitRef="usd" contextRef="iba6c475c71e34bab977bbfc04f289e75_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8xMjY0NDM4Mzc2NjYxNQ_2d7d4468-7a93-4a0d-9e77-5655e3c4ebdf">1,711,000</ix:nonFraction> and an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i342fb6e319104d52a2a096369c394d0a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8xMjY0NDM4Mzc2NjYyNw_cf64a4d4-19f4-45a8-9e3d-6c809fcf86f5">1,769,000</ix:nonFraction>, both assumed to have been recognized during the six months ended June 30, 2021 and therefore removed from the three and six months ended June 30, 2022. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDQ1_81135d1c-440a-426a-9a49-b256ab1c99a2" continuedAt="i407fb6013be5407ca3c39aac4f376bf0" escape="true">The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt"><ix:continuation id="i407fb6013be5407ca3c39aac4f376bf0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro Forma Data</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTItMS0xLTExMjc0Nw_1fd11a32-6b1c-43e0-a540-3fa45c6af9d8">35,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18246336ddbc4d7d82e4f43fbb8713f5_D20210401-20210630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTQtMS0xLTExMjc2Ng_7436abee-b71f-4403-8ac7-40d0696993fd">22,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTItMS0xLTExMTU5MA_7e7e9334-f5fa-4c6a-8a43-f9aed0189180">62,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a6d97ebe2b4ac8ac03f0f597e399e8_D20210101-20210630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTQtMS0xLTExMTU5Mg_68dc503c-21ff-41f6-ab63-783802763e14">45,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTItMS0xLTExMjc0Nw_96cf722c-32ff-4f0f-946c-4c94240f783c">4,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18246336ddbc4d7d82e4f43fbb8713f5_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTQtMS0xLTExMjc2Ng_6de1966b-333e-44a3-b9c4-6115a0b8af05">11,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTItMS0xLTExMTU5MA_50fc75b6-816f-4231-8f98-8a40496dc482">32,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5a6d97ebe2b4ac8ac03f0f597e399e8_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTQtMS0xLTExMTU5Mg_1680a610-c94b-4162-8c34-95461574ef2b">17,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derek J. Maetzold, our President and Chief Executive Officer, and a member of our board of directors, and Daniel M. Bradbury, the Chairperson of our board of directors, each served on the board of directors of AltheaDx until the acquisition of AltheaDx was completed, were direct or indirect beneficial owners of AltheaDx securities and received consideration in the </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i34b8e6e7c5394ed58c893ec133d6d313"><ix:continuation id="i9b2f58d63e3a4ebe97fff6618ff81df3">transaction. Further, Frank Stokes, our Chief Financial Officer; Tobin W. Juvenal, our Chief Commercial Officer; Kristen Oelschlager, our Chief Operating Officer and certain immediate family members of Mr. Maetzold and Ms. Oelschlager were direct or indirect beneficial owners of AltheaDx securities and received consideration in the transaction. These individuals may receive additional consideration in the form of AltheaDx Earnout Payments if the relevant commercial and regulatory milestone events occur. Our entry into the definitive agreement to acquire AltheaDx was approved by our board of directors based upon the unanimous recommendation of a special transaction committee comprised entirely of independent members of our board of directors without any financial interest in AltheaDx or any conflict of interest with respect to the acquisition of AltheaDx.</ix:continuation></ix:continuation></span></div><div id="i85ed73ce88b34118965f36f66c298ae1_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMzY5_30ed5562-413f-4dd1-b189-1bf5e52641a9" continuedAt="iac4d02dce1384aa58d8cdd34f9121d34" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="iac4d02dce1384aa58d8cdd34f9121d34"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMzcw_6b6505f3-984f-4e4f-877b-6100c0b89356" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19966e00f06e4894824f928b10bfb6ea_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0xLTEtMS0xMDg1MDQ_e37f745b-9dcf-4f02-8240-3f313b564dcc">6,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3cbac6e564649baabb13f60dd0dd0e4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0zLTEtMS0xMDg1MTE_e98a06a4-1c1d-458c-9097-dff2dd733d4a">3,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5070d2dd0947412eb17de036ae48867f_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0xLTEtMS05NzI3Mg_f4c115e3-6df4-4457-aa41-2cd3adb913a4">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id512a2f4079a4e7f8d0d10261566c191_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0zLTEtMS05NzI3Mg_38f279e8-8b1c-4056-9634-55e26dc11d8b">5,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20d1fba04ed24847a7ae1ad277983eb2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMy0xLTEtMS05NzI3Mg_97c42c35-2edc-4f74-a56f-5db43182534f">4,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c244a39341a448791b5db69d1b41724_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMy0zLTEtMS05NzI3Mg_2b7474e1-0fa3-44a8-9af0-6fd6e7c42707">2,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia64acefec6184784b9890c8d9573b5ac_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNC0xLTEtMS05NzI3Mg_e63e4bde-5ce4-4541-af6b-03b5f731d0e2">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd539bbaa4f45da97e6726e6d501957_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNC0zLTEtMS05NzI3Mg_58ffb319-72c3-47d9-b3e1-769b917fbf3c">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2fa89ae0cb4fa7942493ffe73929b4_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNS0xLTEtMS05NzI3Mg_75ec259a-4a27-46eb-a11c-b8338be19f8f">703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55d01cabd3e4dfd8fc8d7634ccc3e6d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNS0zLTEtMS05NzI3Mg_967595be-cd07-44cb-84dd-7e1223605512">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNi0xLTEtMS05NzI3Mg_d6637215-8357-439d-a508-109e4bff9a6e">17,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNi0zLTEtMS05NzI3Mg_8e25613b-ea67-40a2-ad1a-cddba69b42c4">12,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNy0xLTEtMS05NzI3Mg_cadfea3a-b7b2-4e07-8142-02b358d1c7b3">6,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNy0zLTEtMS05NzI3Mg_71ab1713-3347-4393-9f37-e7cd82e4d21a">3,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfOC0xLTEtMS05NzI3Mg_8b49c6dc-5e20-45da-8ac6-2b8325b90857">11,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfOC0zLTEtMS05NzI3Mg_21020a64-8949-480f-80f0-09b5e141d6da">9,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes lab equipment under a finance lease of $<ix:nonFraction unitRef="usd" contextRef="i19966e00f06e4894824f928b10bfb6ea_I20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMTYz_b502a108-f34f-4cfd-82e8-20a849425543">369</ix:nonFraction> thousand and accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i19966e00f06e4894824f928b10bfb6ea_I20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMjA3_93413d97-6442-458c-bdd6-3cdfce16edd7">66</ix:nonFraction> thousand.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was recorded in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.939%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f3cc6a21d0455faa3a247ed3871fc2_D20220401-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi0xLTEtMS05NzI3Mg_6fa95dbb-6649-44b0-8930-d0d83bd3f3a2">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695763ce94f847ecb79699e832614ae4_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi0zLTEtMS05NzI3Mg_f95cc78a-df9a-4dbc-bbfa-eca8df0643fc">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5660ce4bef94584b72a1722257e6ddd_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi01LTEtMS05NzI3Mg_6a1904b5-a108-4583-ae09-cc9ba66dd925">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf326b10a224bb6a24085924905410c_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi03LTEtMS05NzI3Mg_aa9ebdab-a26a-40a9-8daa-988aeee01d5c">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90b080f71e6434ea6c9ba3acadadcef_D20220401-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy0xLTEtMS05NzI3Mg_bbf463fa-b15c-4792-a93d-2843e3556bae">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfa896825f1413cb48c6b0e5e4b5954_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy0zLTEtMS05NzI3Mg_dd0b8b9f-9d88-4ae6-a56e-f0fe6b54d207">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7c25b470c347d698685f93340964f3_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy01LTEtMS05NzI3Mg_ec6d7fc2-74e9-4464-87fa-2099af8625d0">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3700a82a151f4c0a8bda6c74f43fe33d_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy03LTEtMS05NzI3Mg_d404a634-e88f-474e-b419-7990dbaf3f27">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb27d09e15f1493bafb7c9641c3f51aa_D20220401-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC0xLTEtMS05NzI3Mg_b7970fd2-1d83-4cf8-924c-f9a43e49f366">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2f11e2e9a840b5a7a47d3f927f7647_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC0zLTEtMS05NzI3Mg_3a423808-bc7f-4454-9039-7d493ba89aba">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95b5f253eb44af8b25296728af91542_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC01LTEtMS05NzI3Mg_b20a1187-dca0-4f9f-85a5-c0d1f8c0826e">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b3a400ca564d61a070f1edf776917a_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC03LTEtMS05NzI3Mg_8c279322-f7b6-43b4-9ca5-727c5f0e62b5">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS0xLTEtMS05NzI3Mg_53c5df43-506f-4e55-99d6-54921617a754">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS0zLTEtMS05NzI3Mg_b20af53d-749f-4925-902b-edbe4b5b9ff4">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS01LTEtMS05NzI3Mg_24085432-3f21-4961-ac65-52dc7912ad8e">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS03LTEtMS05NzI3Mg_fa451287-3cf4-4682-8e17-87ffd8545b58">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_46"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMzU1_12b55e97-89d0-4a30-8ccd-0f39857023d6" continuedAt="ia63f81075a574de8bb1c0861188da312" escape="true">Goodwill and Other Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="ia63f81075a574de8bb1c0861188da312" continuedAt="i84676c4a23f547928aaa15af784d58d9"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfNjU5NzA2OTc2OTEyNA_69bd5009-ec1b-4cad-aa6a-b39f9ba7899d" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on the change in carrying value of our goodwill is presented below (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjUwMTJjYzE4NThmZTQ1NjVhNzc1ZTY0NjI3MzE2YzYxL3RhYmxlcmFuZ2U6NTAxMmNjMTg1OGZlNDU2NWE3NzVlNjQ2MjczMTZjNjFfMS0yLTEtMS0xMDU4NjU_4e774824-9193-47cb-945c-6bcf0264182d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AltheaDx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjUwMTJjYzE4NThmZTQ1NjVhNzc1ZTY0NjI3MzE2YzYxL3RhYmxlcmFuZ2U6NTAxMmNjMTg1OGZlNDU2NWE3NzVlNjQ2MjczMTZjNjFfMi0yLTEtMS0xMDU5Nzg_46155c1c-1abc-48a6-956c-a069772298d4">10,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjUwMTJjYzE4NThmZTQ1NjVhNzc1ZTY0NjI3MzE2YzYxL3RhYmxlcmFuZ2U6NTAxMmNjMTg1OGZlNDU2NWE3NzVlNjQ2MjczMTZjNjFfNC0yLTEtMS0xMDU5Nzg_e508b178-0692-4523-860a-e72b5042f1e6">10,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfNjU5NzA2OTc2OTEyNg_22d9bfb8-be1a-4d54-baef-6f26570bf43a"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfNjU5NzA2OTc2OTEyNg_d4511802-060c-4658-a7cf-ebf30cf1b41c">no</ix:nonFraction></ix:nonFraction> accumulated impairments of goodwill as of June 30, 2022 or December 31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i84676c4a23f547928aaa15af784d58d9"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets, Net</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMzU2_7f5b73d9-4507-4b93-91fe-ca3bb8c2a296" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other intangible assets, net consists of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901262209e794dce8a44fee61a9bfe50_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi0xLTEtMS05NzI3Mg_5f1015fe-99d4-4569-9604-2da683753e40">127,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i901262209e794dce8a44fee61a9bfe50_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi0zLTEtMS05NzI3Mg_34250057-0939-49fc-b338-bb6ed15c5aeb">5,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901262209e794dce8a44fee61a9bfe50_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi01LTEtMS05NzI3Mg_ae31c3f5-0746-43c2-87ad-305b20d8aafb">121,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie686513e9d7f42f78dcefb7c17ec2bc3_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi03LTEtMS05NzI3Mg_e959ce42-7a3a-45f7-872d-4cecf2c0417a">13.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy0xLTEtMS05NzI3Mg_1c317839-fd6d-425f-8d87-71c0bb430577">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy0zLTEtMS05NzI3Mg_911d4efd-699f-49e2-982d-f742b704d338">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy01LTEtMS05NzI3Mg_9644956d-2aa5-424a-b6e5-6816ea771f7f">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2da820ae08bd4d858fbbc2c1c5bb1868_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy03LTEtMS05NzI3Mg_c2c79a57-30e3-4948-b23d-a8e4db27e112">4.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfNC0xLTEtMS05NzI3Mg_a1ae60cc-e865-4ccb-ab28-443e7a84cd76">127,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfNC0zLTEtMS05NzI3Mg_47da4849-efad-4f01-a434-b607803ded92">5,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfNC01LTEtMS05NzI3Mg_fca3954b-3639-41ba-afa1-20feaace9905">122,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4cd64260f474238bc48f5f8fbf709cc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi0xLTEtMS05NzI3Mg_c61f09e6-5dd1-4d25-af57-7e1bf4572750">90,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4cd64260f474238bc48f5f8fbf709cc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi0zLTEtMS05NzI3Mg_b3d7e94e-fc28-4f07-a3e6-2da405079992">1,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4cd64260f474238bc48f5f8fbf709cc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi01LTEtMS05NzI3Mg_cfed44bf-0a9f-40a3-a85a-609c0c773012">88,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8dca6d7270d44eda30a928ed849ac36_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi03LTEtMS05NzI3Mg_76881b9c-6ea4-44c9-bd5d-8bdeee8c984d">13.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy0xLTEtMS05NzI3Mg_25bb62d3-3f98-4ded-8a06-ea39667da28b">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy0zLTEtMS05NzI3Mg_dc94d809-edc7-4e50-8ba2-225d1de84ad1">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy01LTEtMS05NzI3Mg_19d2ba41-a755-4e18-a4ac-51ac14d5f62f">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i697af5026be14ac08242de05f2632427_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy03LTEtMS05NzI3Mg_a33874f3-1ee5-4f9d-9d05-5076c6ac2458">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfNC0xLTEtMS05NzI3Mg_f8dd4477-3a67-4ccb-b186-bf36a0a3fbf5">90,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfNC0zLTEtMS05NzI3Mg_fdc02c8e-0066-412e-b5ad-ad75b63e35b2">1,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfNC01LTEtMS05NzI3Mg_df5cc6b7-444c-4a01-b167-f84732f1d34c">88,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMzU3_909abfb6-cf7d-4bc9-85b6-a1195a971310" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future aggregate amortization expense as of June&#160;30, 2022 is as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder of year)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfMS0yLTEtMS05NzI3Mg_d57fa1a8-8e8a-4b89-9c12-4d2d1dc5d4fd">4,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfMi0yLTEtMS05NzI3Mg_61533ec7-77f2-4bed-86b4-32434a01369f">9,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfMy0yLTEtMS05NzI3Mg_16f66151-51c5-421a-bd0f-37aa3b9eb2e1">9,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNC0yLTEtMS05NzI3Mg_5cf55d40-b05e-42a5-b25e-278f9ecf95a2">9,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNS0yLTEtMS05NzI3Mg_645a4943-00b8-4f62-b637-19cfef87f548">9,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="cstl:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNi0yLTEtMS05NzI3Mg_34ab2a65-8f66-4be7-b8c5-53094f1c5eb8">80,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNy0yLTEtMS05NzI3Mg_558090a5-bc34-4556-b8d0-0e4fc5f67005">122,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMjQz_b99a1b7e-6d34-4009-be8f-3339086a71ef">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMjE5OTAyMzI1NjMxOQ_97a48537-5e36-42de-bd03-9635a1c5333a">3.7</ix:nonFraction> million for the three and six months ended June&#160;30, 2022, respectively. Amortization expense of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMTA5OTUxMTYyODUwMA_6123d1c1-87e0-4eeb-be89-72ee4625a4c5"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMTA5OTUxMTYyODUwMA_b905310e-fb38-4a0a-81cb-253327ce7d9b">0.3</ix:nonFraction></ix:nonFraction> million for each of the three and six months ended June&#160;30, 2021.</span></div></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_49"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RleHRyZWdpb246ZTZjYjZhM2NiMzUwNGFlOWE4OTE1NTliNGI0ODYwZWFfMTE1_f0f8a6e9-a24b-4e50-83bc-bc898d795674" continuedAt="i0b064dc3f05d4be4a5b8b95fb80e245d" escape="true">Other Accrued and Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i0b064dc3f05d4be4a5b8b95fb80e245d"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RleHRyZWdpb246ZTZjYjZhM2NiMzUwNGFlOWE4OTE1NTliNGI0ODYwZWFfMTE2_7a76810c-57c9-411f-bb6c-0845f7fd07f7" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued service fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMS0xLTEtMS05NzI3Mg_fa7f2907-99ce-430c-a507-1470dec617ab">3,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMS0zLTEtMS05NzI3Mg_4a2a1194-5771-4100-94a5-540f73b16520">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="cstl:AccruedClinicalStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMi0xLTEtMS05NzI3Mg_1117f77d-57b6-4404-b304-8002f1789998">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="cstl:AccruedClinicalStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMi0zLTEtMS05NzI3Mg_fb4ee100-32d9-42e6-af84-3a32261e882f">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMy0xLTEtMS05NzI3Mg_bddfa37b-87b5-46f9-9846-3d75e6d9a1eb">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMy0zLTEtMS05NzI3Mg_09208719-ec7d-431d-9cb4-6c65a80b470d">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNC0xLTEtMS05NzI3Mg_8eb199de-e9d8-42a1-bdfd-b8ae86f72ced">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNC0zLTEtMS05NzI3Mg_56eaf3d1-65e5-44ee-beae-0e88ebf82213">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued fixed asset purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="cstl:AccruedFixedAssetPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0xLTEtMS0xMDkxMjI_e803ee35-51c0-4cac-b33c-86c29cf334ba">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="cstl:AccruedFixedAssetPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0zLTEtMS0xMDkxMjI_014a2194-a40b-4cc5-8a26-e3a5927cecfa">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration payable for business acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="cstl:BusinessCombinationConsiderationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0xLTEtMS0xMTI0NTk_81b3d1d8-cfe4-434d-add8-5e10eda99683">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="cstl:BusinessCombinationConsiderationPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0zLTEtMS0xMTI0NjY_1b98e013-3ed4-4eb2-874e-df4b45f4b457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNy0xLTEtMS0xMTI1MTk_03644f77-7aac-4dee-9e1f-05ebe74db7db">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNy0zLTEtMS0xMTI1MTk_6bc1a4ba-700d-48c7-bb26-e2e026f08c1d">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0xLTEtMS05NzI3Mg_958bec7f-b617-4f15-b8cc-a9fc219e23d0">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0zLTEtMS05NzI3Mg_ffc33c8a-c105-4901-b982-270627b6a8b4">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0xLTEtMS05NzI3Mg_0d50710f-6e0b-4138-919d-f87647c8ae5d">8,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0zLTEtMS05NzI3Mg_57cc06ef-6d28-497d-8a36-f7ebd2f53c11">5,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTg5Ng_c10548b8-480d-4330-a9cb-b24dfe609fc0" continuedAt="i9f7cb18e05de4334a65de429a851dc19" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i9f7cb18e05de4334a65de429a851dc19"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of ASC 842</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we adopted ASU No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842), and ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the modified retrospective approach with an effective date of January 1, 2021. The adoption had no effect on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2021. Net cash (used in) provided by operating activities, investing activities or financing activities for the six months ended June 30, 2021 were also unchanged, but the presentation of certain prior period amounts within the operating activities section of the condensed consolidated statements of cash flows has been retrospectively adjusted to give effect to the adoption of ASC 842. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTg5Nw_09ab88fb-db53-4395-8c1d-71176876b7b2" continuedAt="ifa3fe8f22c394ea983e135a14d5c4748" escape="true">The changes are set forth in the table below (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><ix:continuation id="ifa3fe8f22c394ea983e135a14d5c4748"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Before Adoption of ASC 842</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Adoption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After Adoption of ASC 842</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effect on Condensed Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNS0xLTEtMS05NzI3Mg_cb0662dc-cf13-4f11-82db-350827da1c87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1494102bc084aa0a7b78f886f46a23c_I20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNS0zLTEtMS05NzI3Mg_76a32381-8331-4172-8dcc-af19a7177078">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a424bc53f249fd89099cba54892a4c_I20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNS01LTEtMS05NzI3Mg_67c43214-b04f-42ff-bb7b-09aa6f9853b5">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNi0xLTEtMS05NzI3Mg_4140c293-33be-4fcc-93cb-15fb8fd6c988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1494102bc084aa0a7b78f886f46a23c_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNi0zLTEtMS05NzI3Mg_e33003a9-9542-4460-b5f3-a56a67d38ef9">590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0a424bc53f249fd89099cba54892a4c_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNi01LTEtMS05NzI3Mg_46a947fd-2b45-4ee4-afa1-12fe30b6a2de">590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630" decimals="-3" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNy0xLTEtMS05NzI3Mg_bc3335ff-88ef-449f-b6b6-6867aac5a20d">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1494102bc084aa0a7b78f886f46a23c_I20210630" decimals="-3" sign="-" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNy0zLTEtMS05NzI3Mg_c671473d-8b6e-4d70-9ba3-eb0d167972e0">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a424bc53f249fd89099cba54892a4c_I20210630" decimals="-3" name="us-gaap:OtherLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNy01LTEtMS05NzI3Mg_544c01f1-0ae0-4106-a62b-99251bab4b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the condensed consolidated statement of stockholders&#8217; equity for the three and six months ended June 30, 2021 has been retrospectively adjusted to reflect a credit to accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i50e94943a8f84b59ae78cc37b86399dd_I20210101" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTA4NQ_1cd23400-e8e9-4b04-a4de-e5951aadfea8">21,000</ix:nonFraction> in connection with the adoption of ASC 842 effective January 1, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Amendment</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2022, we amended one of our operating leases to expand rentable space in Phoenix, Arizona. We intend to use the additional space for general office and laboratory use. The term of the amended lease will begin upon the completion of certain leasehold improvements by the Phoenix landlord (the &#8220;Phoenix Commencement Date&#8221;) and continue for an initial term of <ix:nonNumeric contextRef="if08210db194a470bb8c79782f96d1583_I20220311" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTU0NQ_d4d16a36-ae72-48eb-a834-ed12ae98ef47">10.3</ix:nonNumeric> years from the Phoenix Commencement Date. Total undiscounted future minimum payment obligations as of June&#160;30, 2022 associated with the lease amendment totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-5" name="cstl:LesseeOperatingLeaseLeaseNotYetCommencedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTcxNw_158f9e90-bc87-480b-9e7e-197c52ef6a6f">1.4</ix:nonFraction>&#160;million. As of June&#160;30, 2022, we have not recorded the lease amendment on our condensed consolidated balance sheet because we do not have possession or control of the underlying asset.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pittsburgh Lease</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we entered into a lease agreement (the &#8220;Pittsburgh Lease&#8221;) for the lease of certain office space in Pittsburgh, Pennsylvania. We intend to use such space for general office and laboratory use. The term of the Pittsburgh Lease will begin upon the completion of certain leasehold improvements by the landlord (the &#8220;Pittsburgh Commencement Date&#8221;) and continue for an initial period of <ix:nonNumeric contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjczMg_c9048e30-d749-4ded-96bc-d576c97cf309">10.5</ix:nonNumeric> years from the Pittsburgh Commencement Date. During the first six months of the lease term, we are required to remit base rent of $<ix:nonFraction unitRef="usd" contextRef="ib08a4fbd714c45cdbc0c0ef66a81837b_D20220401-20220401" decimals="-2" name="cstl:LesseeOperatingLeaseBaseRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjczNA_0fbfe551-620a-429a-b27a-6080714e4762">37,800</ix:nonFraction> for the period. Beginning with month seven, the base rent will be $<ix:nonFraction unitRef="usd" contextRef="id35ad05f10784973b277cc9339184bd2_D20220401-20220401" decimals="-5" name="cstl:LesseeOperatingLeaseBaseRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc4NQ_5c50134a-5b95-433d-932f-d6f9c8bc2b52">0.6</ix:nonFraction>&#160;million per year with annual increases ultimately resulting in base rent obligations totaling $<ix:nonFraction unitRef="usd" contextRef="i1f9e74951a454794934048985403ea08_D20220401-20220401" decimals="-5" name="cstl:LesseeOperatingLeaseMaximumBaseRent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc0Mw_faeb4415-700a-4d8a-a762-18449b1e1b6b">1.5</ix:nonFraction>&#160;million per year. The landlord under the Pittsburgh Lease has agreed to contribute up to $<ix:nonFraction unitRef="usd" contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401" decimals="-5" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc1Nw_5ef4bcf3-a834-4e54-960b-f3a0a18eee4d">2.5</ix:nonFraction>&#160;million towards the cost of the leasehold improvements and we will be responsible for any costs exceeding this amount. The Pittsburgh Lease also provides us a <ix:nonFraction unitRef="claim" contextRef="i1f9e74951a454794934048985403ea08_D20220401-20220401" decimals="INF" name="cstl:LesseeOperatingLeaseNumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc5OA_2b8e727f-7790-41c1-82e5-ed1b36d93ba8">one</ix:nonFraction>-time option that would terminate the lease effective at the end of the <ix:nonNumeric contextRef="i1f9e74951a454794934048985403ea08_D20220401-20220401" name="cstl:LesseeOperatingLeaseOptionToTerminateTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjgwOQ_c4429703-0c1a-42aa-bef4-234cd89dd4b3">90</ix:nonNumeric>th month following the Pittsburgh Commencement Date, subject to certain conditions. If exercised, we would pay an early termination fee of $<ix:nonFraction unitRef="usd" contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401" decimals="-5" name="cstl:LesseeOperatingLeaseEarlyTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc3MQ_1e8d07db-448e-4357-ba81-43d8f3cd7600">2.3</ix:nonFraction>&#160;million, subject to adjustment in the event the Pittsburgh Lease is amended to adjust the base rent. The Pittsburgh Lease provides us one <ix:nonNumeric contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjgxMg_885537ce-1f68-4df2-a53b-ed4bd2bef245">five-year</ix:nonNumeric> renewal option and also provides us a right of first refusal with respect to the lease of certain additional space in the same building. As of June&#160;30, 2022, we have not recorded the Pittsburgh Lease on our condensed consolidated balance sheet because we do not have possession or control of the underlying asset.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjM3NA_b9893214-23fa-4430-ad70-6a21696464b5" continuedAt="i0085598edec34a4c97bb98dbc70cfee4" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i0085598edec34a4c97bb98dbc70cfee4" continuedAt="ieda5626877ab41fa86bb82069d153c7d"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjM3NQ_f680dee7-4cbf-418b-b50b-6d4ee45d5852" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information, by level within the fair value hierarchy, of our financial assets and financial liabilities that are accounted for at fair value on a recurring basis as of&#160;June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8ceb3988914d2f9c2a79143d8fb4b7_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy0xLTEtMS05NzI3Mg_940967af-6ca2-437a-8dc6-503ef8f2b67e">266,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21125ac2093648aea31470a65bc3c38d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy0zLTEtMS05NzI3Mg_ebe08de6-ab78-464f-8b15-8d2d756fa471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104f7bbc8cb7403d8a1ec5e1df30fa49_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy01LTEtMS05NzI3Mg_41f4bd2a-7ddc-47eb-94e8-df52c96b47fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6324a446c6ed44dcb012258eeb725d85_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy03LTEtMS05NzI3Mg_80439928-c1af-407f-a3f5-96326b45bf34">266,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8ceb3988914d2f9c2a79143d8fb4b7_I20220630" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS0xLTEtMS05NzI3Mg_cb2fef24-c344-4329-8abf-40d6ca7e8a9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21125ac2093648aea31470a65bc3c38d_I20220630" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS0zLTEtMS05NzI3Mg_4a7e09ce-bc2b-48d5-962c-05bb99e60a4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104f7bbc8cb7403d8a1ec5e1df30fa49_I20220630" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS01LTEtMS05NzI3Mg_e5b4a821-7e8d-41f2-928d-f4f973f0fad9">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6324a446c6ed44dcb012258eeb725d85_I20220630" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS03LTEtMS05NzI3Mg_3682ba9c-bd7c-41a6-9d1f-d50f9c076e54">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide11ef39260549e8a2e5914ad0f0afcf_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy0xLTEtMS05NzI3Mg_28bff3f5-5c64-43e1-9e3a-59d89e61cedb">327,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ff935b4508458d896d72b6072dda6d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy0zLTEtMS05NzI3Mg_731fd8a3-6f5e-496d-9e67-565f16ce1ae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb402740817463da336bf3ad4500350_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy01LTEtMS05NzI3Mg_b6a18a57-3682-4d5a-b092-bbdba6eb5dc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i684e2cbe0aee4089866a63e63228dd12_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy03LTEtMS05NzI3Mg_afda9244-3768-490f-969c-cce82b665125">327,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide11ef39260549e8a2e5914ad0f0afcf_I20211231" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS0xLTEtMS05NzI3Mg_f1489515-f728-40da-a56c-1d4990bf2d97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8ff935b4508458d896d72b6072dda6d_I20211231" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS0zLTEtMS05NzI3Mg_90988484-586f-4536-ba44-a27954db454a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb402740817463da336bf3ad4500350_I20211231" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS01LTEtMS05NzI3Mg_dd159ebb-3538-47aa-bbac-02bd19ec7b72">18,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i684e2cbe0aee4089866a63e63228dd12_I20211231" decimals="-3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS03LTEtMS05NzI3Mg_e35a76d3-a43f-4f43-8d2e-30d4647d7e53">18,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Classified as &#8220;Cash and cash equivalents&#8221; in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Current portion, if any, classified as &#8220;Other accrued and current liabilities&#8221; in the condensed consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Cernostics, we have recorded a contingent consideration liability for the additional consideration of up to $<ix:nonFraction unitRef="usd" contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630" decimals="-5" name="cstl:AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjM5OQ_b8387e0d-31c8-4df4-a139-67c82b995ae7">50.0</ix:nonFraction> million that may become payable based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 (&#8220;Cernostics Earnout Payments&#8221;). The Cernostics Earnout Payments may be settled in cash or shares of our common stock, at our sole discretion. The portion of any Cernostics Earnout Payments that may be settled in shares of our common stock is subject to certain limitations and the aggregate number of shares that may be issued for the Cernostics Earnout Payments may not exceed <ix:nonFraction unitRef="shares" contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630" decimals="INF" name="cstl:AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjQwNg_e30ed576-eff4-4cc1-b7a8-29dc093ded87">5,034,653</ix:nonFraction> shares. Any Cernostics Earnout Payments in shares of our common stock will be based on the volume weighted-average price of our common stock for the <ix:nonFraction unitRef="tradingday" contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630" decimals="INF" name="cstl:AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjQxMQ_6a39714e-827f-4c18-9e72-e913d915fa0e">15</ix:nonFraction> trading days ending December 30, 2022. If the settlement were to occur as of June&#160;30, 2022, we would make no Cernostics Earnout Payments based on the achievement of the performance conditions to date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of AltheaDx, we have also recorded a contingent consideration liability for the additional consideration of up to $<ix:nonFraction unitRef="usd" contextRef="ib99692ae97b9426581ef0e9d0e18336f_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjM4MA_4823b8f8-db0b-42d7-83ac-94fb84a72416">75.0</ix:nonFraction> million that may become payable based on the achievement of certain commercial milestones relating to the years ending December 31, 2022, 2023, and 2024, as discussed further in Note 5. If the settlement were to occur as of June 30, 2022, we would make no AltheaDx Earnout Payments based on the achievement of the performance conditions to date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis for the Cernostics Earnout Payments uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate, which were <ix:nonFraction unitRef="number" contextRef="i02b6b0adf1ed4564ab66d5e6c116b521_D20220101-20220630" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc0OA_47b380e2-b45a-4ba5-82a6-82c2bce668a2">40.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i02dfd58348864c25bf52e8044eb44e80_D20220101-20220630" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc1Mw_2215c52f-33c0-448f-a9a9-380333b95311">20.2</ix:nonFraction>%, respectively, as of June&#160;30, 2022, and <ix:nonFraction unitRef="number" contextRef="i64336bd6bad643a38e66641fec94637b_D20210101-20211231" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc2MQ_b79d0202-a8d1-4f65-bea9-70ee645964b5">20.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if05f1698a24e4537b9b6e321a862849e_D20210101-20211231" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc2OQ_4fd7955a-c278-48b3-92cb-559c4f4ae8d2">16.1</ix:nonFraction>%, respectively, as of December 31, 2021. The assumptions for expected volatility of the financial metrics used in the analysis for the AltheaDx Earnout Payments was <ix:nonFraction unitRef="number" contextRef="iab51d3dc6bd949c99033fd013c8820dd_D20220101-20220630" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzk5OA_23e1f0e4-19ea-4484-a5c2-5f227991067b">36.0</ix:nonFraction>% as of June&#160;30, 2022. The risk-adjusted discount rate for years 2022, 2023, and 2024 were <ix:nonFraction unitRef="number" contextRef="i3d374e88975f4250b70acfc62ee7b455_D20220101-20221231" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzNTcwMg_fabc4e74-4c7a-4cda-8154-bcdcac71001f">6.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i683d8e181278402690a483021f8294d6_D20230101-20231231" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzNTcwNw_ce1b5525-01b8-48a9-b8ca-71a064fa4acf">7.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3f8aa2919a654f9fb404a6244f4977b1_D20240101-20241231" decimals="3" name="cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzNTcxNg_77464cd9-e090-4bf1-89da-eabfa07c22a9">7.5</ix:nonFraction>%, respectively. The contingent consideration liability is remeasured at fair value at </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ieda5626877ab41fa86bb82069d153c7d"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each reporting period taking into account any updated assumptions or changes in circumstances. Any changes in the fair value are recorded as gains or losses in our condensed consolidated statement of operations and comprehensive loss. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjM3Mw_437a8385-ca0f-454a-bb01-8ad2f23a735c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs as of June&#160;30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cernostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AltheaDx</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b51146ced54358bef8f0e24c5ad59a_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMS0yLTEtMS05NzI3Mg_2d5cc0e8-8822-4636-a528-1bff03958b6c">18,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec0ab012cf684932bc3842b6be81dc6b_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMS00LTEtMS0xMDM2NjA_47956f86-1598-4930-9095-2b91a2e9bf83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMS02LTEtMS0xMDM2Njc_8863d054-58d5-43fb-b8ac-1495f3533b0e">18,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AltheaDx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a1bb97eb834ce49721240374fb0bcd_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMi0yLTEtMS05NzI3Mg_385855f1-4f74-4207-b9ee-954963e6423f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMi00LTEtMS0xMDM2NjA_4c1e74a2-6643-4b57-90be-40207cad1f23">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMi02LTEtMS0xMDM2Njc_d118c17a-de06-49e6-afcc-ef3b4b8a4120">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30a1bb97eb834ce49721240374fb0bcd_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMy0yLTEtMS05NzI3Mg_da55a4e3-7e82-4e9f-9718-1d4c7032043a">18,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMy00LTEtMS0xMDM2NjA_bb582042-f129-4227-a448-6958b0b6b00f">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMy02LTEtMS0xMDM2Njc_cde43905-e0e1-442e-bdca-d97acad10c42">17,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfNC0yLTEtMS05NzI3Mg_72fbcf00-6cf0-4867-adee-ee20f70c47f0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99692ae97b9426581ef0e9d0e18336f_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfNC00LTEtMS0xMDM2NjA_19ba3b63-db64-4160-b3c7-f2e1434ed615">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfNC02LTEtMS0xMDM2Njc_a57add8f-199c-4981-bd40-221e6c06078f">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i85ed73ce88b34118965f36f66c298ae1_58"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81OC9mcmFnOjllZTM3NWQ3MTE0NzQyYjM4NjNkNDI3MzkyYTM3Yjg1L3RleHRyZWdpb246OWVlMzc1ZDcxMTQ3NDJiMzg2M2Q0MjczOTJhMzdiODVfMzQ5_32204fb9-6f0c-4ad5-85e0-f74aa4cc70fd" continuedAt="i791408c71d5d46279bedd1c416984740" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i791408c71d5d46279bedd1c416984740">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.</ix:continuation></span></div><div id="i85ed73ce88b34118965f36f66c298ae1_61"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMg_80878a23-780d-4d3e-b0ec-bdb36d7eb6a5" continuedAt="i00e460b6813540f9a88bd4d5ec54e7af" escape="true">Stock Incentive Plans and Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i00e460b6813540f9a88bd4d5ec54e7af" continuedAt="i005a3b7a9dee4c3a9db80a870502d59f"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plans</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, an additional <ix:nonFraction unitRef="shares" contextRef="iedeeba3b13c34684a6126c12757e02db_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMTIz_c33a6263-f539-41f7-a3df-b3e35962a615">1,268,926</ix:nonFraction> shares became available under our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) pursuant to an automatic annual increase. As of June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i4e3ed91cdcfc41dfa12bd21a3ade3077_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjU3_ef50f65d-a376-4f9e-a2f6-b35d4f06a41e">586,155</ix:nonFraction> shares remained available for grant under the 2019 Plan.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMw_33039886-3f83-4f8c-ae9e-c3a76b0952dc" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under our stock plans for the six months ended June&#160;30, 2022 is set forth below:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfMi0yLTEtMS05NzI3Mg_050ba082-71ce-4517-918a-8df337d34a42">3,586,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfMi00LTEtMS05NzI3Mg_0b8e2e2b-07bf-4e41-998d-5741f9ae09cb">34.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNC0yLTEtMS05NzI3Mg_17041232-941f-4fa7-aa04-b81356175c79">231,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNC00LTEtMS05NzI3Mg_16255d20-77e6-4828-bd70-c8364ec26915">22.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNS0yLTEtMS05NzI3Mg_530a64b1-177a-44c2-9f4a-a41034d51efd">98,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNS00LTEtMS05NzI3Mg_d3584943-9953-46ff-9a16-1abd025652e9">5.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNi0yLTEtMS05NzI3Mg_4ae14122-a8d6-47f7-b1c3-0c3ee5ef8a39">140,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNi00LTEtMS05NzI3Mg_9928c285-7afe-439b-bf98-2c68cd8f9f54">35.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy0yLTEtMS05NzI3Mg_06191fae-d532-49e2-be10-03e5b3d7f401">3,578,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy00LTEtMS05NzI3Mg_2a8705c9-d817-4361-91d6-29a4f55cc057">34.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy02LTEtMS05NzI3Mg_3bf3d4e1-3735-4f11-bd5e-3bb995c579ef">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy04LTEtMS05NzI3Mg_633b52ac-c35c-4241-9a1d-cb99a4e2294c">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC0yLTEtMS05NzI3Mg_da66b5b8-9bdb-416f-b0f6-a9b9dbd81daa">1,599,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC00LTEtMS05NzI3Mg_e1b3f086-944b-4ea2-b373-9a11d4668c91">26.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC02LTEtMS05NzI3Mg_8228203b-e7de-47a0-98cb-9f99f1ece1f5">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC04LTEtMS05NzI3Mg_ad62da32-44c6-417b-9f2f-2c693aa56520">10,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMQ_82e2e4f8-1512-4beb-b081-c654038722a2" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity for the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id49668ed558840d8a0b90ca6b883101e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMS0xLTEtMS05NzI3Mg_06e94292-5ad5-4d9c-80a8-a3c45ec14fd5">1,050,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id49668ed558840d8a0b90ca6b883101e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMS0zLTEtMS05NzI3Mg_8ad5388a-2d88-4eed-9423-ed52feebb510">44.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMi0xLTEtMS05NzI3Mg_922992f6-a20f-427c-a099-8622beda61ba">705,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMi0zLTEtMS05NzI3Mg_0c9ea49a-6088-4543-9c4b-85fc7d8f2024">23.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMy0xLTEtMS05NzI3Mg_5a2740ac-276a-4356-a8d4-956298ab1ad9">11,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMy0zLTEtMS05NzI3Mg_79aa9022-2dbb-4f6f-b9fa-98e5f55f026b">69.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNC0xLTEtMS05NzI3Mg_42c9ec20-dc25-4322-a830-4bdc80a4eea6">64,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNC0zLTEtMS05NzI3Mg_1c247027-2de1-4f9b-8b7e-888add3578f9">35.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4165eb4a39cb4beb89cc3cbf69e6654d_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNS0xLTEtMS05NzI3Mg_95c7dff1-e841-471b-bd4e-9b815a68a227">1,679,954</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4165eb4a39cb4beb89cc3cbf69e6654d_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNS0zLTEtMS05NzI3Mg_53ff0b86-976b-4bce-add5-6b31e8e768af">35.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i005a3b7a9dee4c3a9db80a870502d59f" continuedAt="i764d750651094617b899a8671c6586c6"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides for certain automatic increases in the number of shares of common stock reserved for issuance, which resulted in an additional <ix:nonFraction unitRef="shares" contextRef="i7805af27e10c4b63a1bc23dc07855219_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfNjk5_1350180a-6f45-4c71-ac31-0357d074980e">253,785</ix:nonFraction> shares becoming available under the ESPP effective January 1, 2022. During the six months ended June&#160;30, 2022, we issued <ix:nonFraction unitRef="shares" contextRef="i11a61c8eb4b741ceae0ea9615e6fd60b_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfODEx_2bbf3027-4982-45cf-98c6-ab6d2d5f2e7c">42,332</ix:nonFraction> of common stock pursuant to scheduled purchases under the ESPP. As of June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i6684a747cbc242f286866f7a3ae50ae7_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfODg4_986f3a4b-03f6-4087-8030-e30e6f69f263">850,919</ix:nonFraction> shares remained available for issuance under the ESPP.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Fair Value - Summary of Assumptions</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzNQ_ccb254b1-630b-44d4-8f5e-76581ec7cdac" continuedAt="icaad32bb2c034df09d892e9345055e76" escape="true">The following table sets forth the assumptions used to determine the fair value of stock options:</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><ix:continuation id="icaad32bb2c034df09d892e9345055e76"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMi0xLTEtMS05NzI3Mg_5c092225-f8e3-4c88-afb6-be5cc3e99b32">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMi0zLTEtMS05NzI3Mg_9e1221d3-85c2-408f-9962-d36cdaaa84f9">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjk5MzE2NzAzMzA2NDQ1MWNiNGNkNzFjYmJjNTRkMGJiXzQ_6b332243-0add-44d4-b2cd-c6cd6ded4182">68.34</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjk5MzE2NzAzMzA2NDQ1MWNiNGNkNzFjYmJjNTRkMGJiXzk_90660bb2-3afc-4f96-9dee-9e23baf13386">71.58</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmNkMzY1MGFjMzJlZjQ5ZmY5YTI3YjFmMzgyYWQzNmI4XzQ_c38e501f-f286-487f-817e-32c067bb4efd">66.94</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmNkMzY1MGFjMzJlZjQ5ZmY5YTI3YjFmMzgyYWQzNmI4Xzk_baba71e4-ceb7-4fdd-8d27-50b5c82940d9">67.98</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjVlOTFhN2U3NDY1YTQ2OWE5ZmVjNjRiYWNhNTcwMzU5XzQ_7a74c666-dd51-4461-a3ab-3d0c8efc6a5f">1.54</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjVlOTFhN2U3NDY1YTQ2OWE5ZmVjNjRiYWNhNTcwMzU5Xzk_729b5f90-2922-4979-93aa-38240300f738">2.91</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjE0NzUyNWE3YWNiMTQwZWE5MjU1ZmI4YWI2ZDJkMjFiXzQ_2b3b71f2-54a3-4bee-8a0c-cce9089b4b01">0.51</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjE0NzUyNWE3YWNiMTQwZWE5MjU1ZmI4YWI2ZDJkMjFiXzk_41874965-446c-439b-af5d-dbdf79246505">1.09</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNS0xLTEtMS05NzI3Mg_ee46c70c-6b4a-4378-ac8e-67f637350bf8">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNS0zLTEtMS05NzI3Mg_8db0b5f7-9423-432b-ba1d-7431b344fa77">&#8212;</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzNg_ea03fdc0-16ee-4989-bda3-08683fe47cb9" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMi0xLTEtMS05NzI3Mg_f47d50dc-1bed-41c2-b425-88f43cf47803">1.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMi0zLTEtMS05NzI3Mg_8e01065f-d415-4fc8-8d78-932ec9e6b767">1.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmI1ZmMwNTMwMjExODQ2MWI5MWQ0Zjk0M2VkNThlMzcwXzQ_c2cc72dd-7fae-4224-81c6-4bb6339ce725">62.98</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmI1ZmMwNTMwMjExODQ2MWI5MWQ0Zjk0M2VkNThlMzcwXzk_00cb99b1-8596-4883-bbd2-5fab2ac97243">66.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmQ5OWM1MTE1NDA4YjQ2YjdiZmU2MDU1YjAwNDE1YWNkXzQ_72f0a011-996b-48b3-8cd1-6794f646d7a8">68.43</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmQ5OWM1MTE1NDA4YjQ2YjdiZmU2MDU1YjAwNDE1YWNkXzk_66355d15-95c6-459b-8fc4-51ce3df7ed57">86.50</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjAwNDczZDFiNWYxZTQzYjE4YWYxZTA5MWZkNTM4ZTYyXzQ_98c9e6f1-e56c-4f08-b965-dae27bd62858">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjAwNDczZDFiNWYxZTQzYjE4YWYxZTA5MWZkNTM4ZTYyXzk_285ada11-d712-4428-a110-d8cccb2db4cf">1.30</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmUyYmFhNjE3NjNhMDQxNmViYmNmNjI4MDhhZWJlOWFjXzQ_a1c4a227-0205-4383-8b6f-f8b88c790ac0">0.07</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmUyYmFhNjE3NjNhMDQxNmViYmNmNjI4MDhhZWJlOWFjXzk_945500b5-9e53-4e4a-b2ce-5764239579f3">0.13</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNS0xLTEtMS05NzI3Mg_03851f15-ab46-40da-8da8-0f1b7eae1f66">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNS0zLTEtMS05NzI3Mg_a1bd96d6-53e9-466a-b96e-0ef1ec704de3">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our common stock is also an assumption used to determine the fair value of stock options and purchase rights under the ESPP. The fair value of our common stock is the closing price per share, as reported by the Nasdaq Global Market, on the date of grant or other relevant determination date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the ESPP purchase right and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the closing price of our common stock on the date of grant to determine the fair value of RSUs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzNA_62a5bdc4-0f4d-4534-9d25-47709d609415" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options, RSUs and the ESPP is included in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f3cc6a21d0455faa3a247ed3871fc2_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi0xLTEtMS05NzI3Mg_91bf37e5-8342-4b8d-816a-d8a5559bf94b">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695763ce94f847ecb79699e832614ae4_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi0zLTEtMS05NzI3Mg_6de08957-ddd4-47bd-99be-ac6ebcc48dac">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5660ce4bef94584b72a1722257e6ddd_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi01LTEtMS05NzI3Mg_45137ba9-e6a2-4b38-af54-9c2b3735a3c7">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf326b10a224bb6a24085924905410c_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi03LTEtMS05NzI3Mg_34975c32-ffa9-4ee4-adf1-cfc60b481bed">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90b080f71e6434ea6c9ba3acadadcef_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy0xLTEtMS05NzI3Mg_dd758946-9f40-4fe2-ab18-2bc8efe14569">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfa896825f1413cb48c6b0e5e4b5954_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy0zLTEtMS05NzI3Mg_66cb1cb4-2f3d-4764-b7b1-d5d4dd588d4f">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7c25b470c347d698685f93340964f3_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy01LTEtMS05NzI3Mg_06d922d9-17e5-4724-81b6-9d1959b9a4ba">3,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3700a82a151f4c0a8bda6c74f43fe33d_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy03LTEtMS05NzI3Mg_8c1ec7d0-6114-490c-88ba-e148c67a5711">2,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb27d09e15f1493bafb7c9641c3f51aa_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC0xLTEtMS05NzI3Mg_72977626-4248-4ec6-bb3d-bb08894b63bf">6,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2f11e2e9a840b5a7a47d3f927f7647_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC0zLTEtMS05NzI3Mg_4e705788-366a-495c-a65b-fb639543a37c">3,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id95b5f253eb44af8b25296728af91542_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC01LTEtMS05NzI3Mg_48890376-0119-4a6e-998b-30a7acb8afe9">11,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b3a400ca564d61a070f1edf776917a_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC03LTEtMS05NzI3Mg_3809dae0-259b-4950-92e9-071962270c79">6,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS0xLTEtMS05NzI3Mg_1488b25e-830b-4675-95c2-2eeaf3ce4b76">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS0zLTEtMS05NzI3Mg_3cb3fa1d-11ab-4a30-9aeb-38235ddd55dd">4,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS01LTEtMS05NzI3Mg_f357d2c9-8c5e-4400-bdae-5b381e0597f6">17,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS03LTEtMS05NzI3Mg_fe8c6e28-c005-4561-9901-79e37c2e58dc">9,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASTLE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i764d750651094617b899a8671c6586c6">For the six months ended June 30, 2022 and 2021, the weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjY2Mw_189d78c8-aa18-4092-bc9b-45e98c6a86e7">14.07</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjY3MA_7b538fd6-10ab-4bbf-9e80-95804ae8cb21">41.35</ix:nonFraction> per option, respectively, and the weighted-average grant date fair value of the purchase rights granted under the ESPP was $<ix:nonFraction unitRef="usdPerShare" contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjc5Ng_7662c63c-2488-4dd4-9570-024eba17f0c4">19.91</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjgwMw_6bd17255-0c12-4ed9-925d-7e9547ff68d2">39.26</ix:nonFraction> per share, respectively. As of June&#160;30, 2022, the total unrecognized compensation cost related to outstanding awards was $<ix:nonFraction unitRef="usd" contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjkxNg_df40f035-2713-4d7a-badf-61e4bebff14a">99,493,000</ix:nonFraction>, which is expected to be recognized on a straight-line basis over a weighted-average period of <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMA_e54ce461-4b2a-4dd8-a91b-64d81c4f7ae6">3.0</ix:nonNumeric> years. The total unrecognized compensation cost will be adjusted for forfeitures in future periods as they occur.</ix:continuation> </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_1574"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl82NTk3MDY5NzY4NTkz_0cab010f-1dee-4c5b-881b-d4270fcc9cf3" continuedAt="icfbb3256e01243a7b0b227e68c5da40e" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:6pt"><ix:continuation id="icfbb3256e01243a7b0b227e68c5da40e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of AltheaDx, we recorded $<ix:nonFraction unitRef="usd" contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl8xMjY0NDM4MzcyMTM2Ng_efa6077b-6c96-45ff-a41c-7fa2872d7351">1,819,000</ix:nonFraction> in deferred tax liabilities based on our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary allocation of the fair values of assets acquired and liabilities assumed. As a result of these additional deferred tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that $<ix:nonFraction unitRef="usd" contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl8xMjY0NDM4MzcyMTQ2MQ_06997d0f-6220-43bb-91b9-ef694c6d4a49"><ix:nonFraction unitRef="usd" contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl8xMjY0NDM4MzcyMTQ2MQ_d2a67117-e2bc-4781-9879-25f0fce5b6a9">1,769,000</ix:nonFraction></ix:nonFraction> of our existing valuation allowance on deferred tax assets should be reduced, which was reflected in our income tax benefit on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 as a discrete item.</span></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of financial condition and results of operations together&#160;with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto as of and for the years ended December 31, 2021 and 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, including the section entitled &#8220;Critical Accounting Estimates,&#8221; included&#160;in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 28, 2022. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;Castle,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Castle Biosciences, Inc.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_70"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning the impacts of COVID-19 on our business, our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions or expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A., &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_73"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Castle Biosciences is improving health through innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our diagnostic and prognostic (or risk stratification) tests provide. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market six proprietary multi-analyte assays with algorithmic analysis designed to answer clinical questions in dermatologic cancers, uveal melanoma (&#8220;UM&#8221;) (a rare cancer of the eye) and Barrett&#8217;s esophagus (&#8220;BE&#8221;). We also offer a proprietary pharmacogenomic (&#8220;PGx&#8221;) test to guide optimal drug treatment for patients suffering from depression, anxiety and other mental health conditions following our acquisition of AltheaDx, Inc. (&#8220;AltheaDx&#8221;) in April 2022, as discussed below. Our revenue is primarily generated by our DecisionDx&#174;-Melanoma risk stratification test for cutaneous melanoma, a deadly skin cancer, and our DecisionDx&#174;-UM risk stratification test for UM.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foundation of our business is our dermatologic cancer franchise, and our lead product is DecisionDx-Melanoma, a proprietary risk stratification gene expression profile (&#8220;GEP&#8221;) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma. In the management of melanoma, as with nearly all diseases, treatment plans are directed by patient risk stratification. This test has two distinct, complementary clinically actionable uses. The first revolves around predicting the likelihood of having a sentinel lymph node (&#8220;SLN&#8221;) negative biopsy result so that physicians and patients can discuss the risk and benefit of undergoing the SLN biopsy (&#8220;SLNB&#8221;) surgical procedure. The second use is to inform the appropriate treatment plan during the initial five years post-diagnosis, regardless of the decision to undergo or avoid invasive SLNB surgery. In a typical year, we estimate approximately 130,000 patients are diagnosed with invasive cutaneous melanoma in the United States, representing an estimated U.S. total addressable market (&#8220;TAM&#8221;) of approximately $540 million. We launched DecisionDx-Melanoma in May 2013. Based on the substantial clinical evidence that we have developed, we have received Medicare coverage for DecisionDx-Melanoma, which represents approximately 50% of the addressable patient population for this test.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, we commercially launched our cutaneous squamous cell carcinoma (&#8220;SCC&#8221;) proprietary GEP test, DecisionDx&#174;&#8209;SCC, for use in patients with one or more risk factors (also referred to as &#8220;high-risk&#8221; SCC). We estimate 20% of SCC patients, or 200,000 annually in the United States, are classified as high risk, representing an estimated U.S. TAM of approximately $820 million.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2020, we commercially launched our proprietary GEP test for difficult-to-diagnose melanocytic lesions, DiffDx&#174;-Melanoma, for use in patients with a melanocytic lesion and uncertainty related to the malignancy of the lesion. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further expanded our commercially available dermatologic portfolio in May 2021 when we acquired Myriad myPath, LLC (the &#8220;Myriad MyPath Laboratory&#8221;) from Myriad Genetics, Inc. for a cash purchase price of $32.5 million. MyPath&#174; Melanoma is a clinically validated GEP test that addresses the same unmet clinical need as our DiffDx-Melanoma test. Today, we offer both our MyPath Melanoma test and our DiffDx-Melanoma test under an offering that we refer to as our Diagnostic GEP offering. We believe we have demonstrated that offering both tests can lead to an improvement in actionable test results for patients with difficult-to-diagnose melanocytic lesions. Of the two million suspicious pigmented lesions biopsied annually in the United States, we estimate approximately 300,000 of those present a difficult-to-diagnose melanocytic lesion, representing an estimated U.S. TAM of approximately $600 million associated with these two tests. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we announced the launch of our innovative pipeline initiative to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. In the United States alone, there are approximately 18 million patients diagnosed with psoriasis and atopic dermatitis. Approximately 450,000 of these patients annually are eligible for systemic therapies. If successful, this inflammatory skin disease pipeline test has the potential to add approximately $1.9 billion to our current estimated U.S. total addressable market (&#8220;TAM&#8221;). In 2021, we initiated a 4,800 patient, prospective, multi-center clinical study to develop and validate this pipeline test and have 54 committed sites and approximately 303 patients enrolled. Based upon our current development and validation timelines, we expect to have initial validation and development data in 2023 and to commercialize this pipeline test by the end of 2025.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our dermatologic franchise, we also market a test for patients diagnosed with UM. DecisionDx-UM is a proprietary, risk stratification GEP test that predicts the risk of metastasis for patients with UM. We believe DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States. We launched DecisionDx-UM in January 2010. Based on the substantial clinical evidence that we have developed, we have received Medicare coverage for DecisionDx-UM, which represents approximately 50% of the addressable patient population for this test. We estimate approximately 2,000 patients in the United States are diagnosed annually with a uveal melanoma, representing an estimated U.S. TAM of approximately $10 million.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we extended our commercial portfolio of proprietary tests into the gastroenterology market through our acquisition of Cernostics, Inc. (&#8220;Cernostics&#8221;) and the TissueCypher&#174; platform. The TissueCypher platform focuses on unlocking, in the case of the initial test for use in patients with BE, the importance of the location of the expression of proteins or lack thereof within the morphology of the disease (also known as spatialomics). This &#8220;spatialomic&#8221; information is then interpreted using artificial intelligence approaches to predict the likelihood of progression to high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite or low-grade dysplasia BE. We estimate approximately 384,000 patients annually undergo an endoscopic biopsy with a subsequent diagnosis of non-dysplastic, indefinite or low-grade dysplastic BE, representing an estimated U.S. TAM of approximately $1 billion.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, we completed our acquisition of AltheaDx, a commercial-stage molecular diagnostics company specializing in the field of PGx testing services that are focused on mental health, and the provider of IDgenetix&#174;, a PGx test for mental health conditions. This acquisition enables us to offer a testing solution that we believe has the potential to accelerate our impact on patient care in an area of high unmet clinical need, significantly expand our in-market estimated U.S. TAM by approximately $5 billion and offer incremental value to patients and clinicians over the standard of care trial-and-error approach. A randomized controlled trial showed that patients diagnosed with depression, who were assessed with the IDgenetix test, showed a 2.5 times improvement in remission rates compared to those who did not have their genes tested.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of test reports we generate is a key indicator that we use to assess our business. A test report is generated when we receive a sample in our laboratory, and then the relevant test information is entered into our Laboratory Information Management System, the expression of the biomarkers is measured, then a proprietary algorithmic analysis of the combined biomarkers is performed to generate a report providing the results of that analysis, which is sent to the clinician who ordered the test. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of GEP test reports delivered by us during the six months ended June 30, 2022 and 2021 and for the year ended December 31, 2021 are presented in the table below:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Proprietary Dermatologic GEP Tests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DecisionDx-<br/>Melanoma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DecisionDx-SCC</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diagnostic GEP offering </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dermatologic Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DecisionDx-UM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TissueCypher Barrett&#8217;s Esophagus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IDgenetix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grand Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q2 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the six months ended June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,539&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q2 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the six months ended June 30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For year ended December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes DiffDx-Melanoma and MyPath Melanoma. We began offering MyPath Melanoma following our acquisition of the Myriad MyPath Laboratory on May 28, 2021. We offer both MyPath Melanoma and DiffDx-Melanoma under our Diagnostic GEP offering.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:6.34pt">We began offering the TissueCypher Barrett&#8217;s Esophagus Assay on December 3, 2021, following the completion of our acquisition of Cernostics.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:7.52pt">We began offering the IDgenetix test on April 26, 2022, following our acquisition of AltheaDx. Includes both single-gene and multi-gene tests.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June 30, 2022, our dermatologic test report volume increased by 44.1% and 54.6%, respectively, compared to the prior period in 2021, largely driven by continued growth from our DecisionDx-Melanoma test. For a discussion of how we recognize revenue derived from our tests, refer to &#8220;Net Revenues&#8221; under &#8220;Components of Results of Operations&#8221; below.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal focus of our current commercial efforts is to educate clinicians and pathologists on the value of our molecular diagnostic testing products through our direct sales force in the United States. During the second quarter of 2021, we expanded our dermatologic commercial team, bringing our dermatologic sales force to the mid-60s. Starting in September 2022, we plan to have a new commercial sales team dedicated to our Diagnostic GEP offering, with the current dermatologic commercial team shifting to focus solely on DecisionDx-Melanoma and DecisionDx-SCC. In connection with our acquisition of Cernostics in December 2021, we hired an initial commercial team of approximately 14 outside sales territories, along with commensurate internal sales associates and medical science liaisons, to support our launch of the TissueCypher Barrett&#8217;s Esophagus Assay. This dedicated team focuses on gastroenterology specialists that diagnose and manage patients with BE. Beginning in September 2022, we plan to add additional outside territories for our TissueCypher Barrett&#8217;s Esophagus Assay. Similar to our dermatologic commercial team, we will continue to assess market response in determining further commercial expansions. AltheaDx, which we acquired in late April 2022, had a commercial team covering approximately 20 outside sales territories.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to see new clinicians order our dermatologic tests for the first time. For the three months ended June 30, 2022, we saw 608 new ordering clinicians for our dermatologic tests compared to 462 during the same period of 2021. For the six months ended June 30, 2022 and 2021, we saw 1,200 and 872, respectively, new ordering clinicians for our dermatologic tests. Total ordering clinicians for our dermatologic tests were 5,661 and 3,879 for the six months ended June 30, 2022 and 2021, respectively, and 2,032 and 1,423 for the three months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the metrics we disclose, refer to &#8220;Information About Certain Metrics&#8221; below.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In developing our DecisionDx-SCC and DiffDx-Melanoma tests, we believed that in addition to addressing significant unmet clinical needs, we would see strategic opportunities for leverage, as many of the clinicians currently ordering DecisionDx-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Melanoma would likely be the same clinicians who would find value in these other dermatologic GEP tests. For example, we found that for the six months ended June 30, 2022, approximately 68% of all clinicians ordering DecisionDx-SCC had also ordered our DecisionDx-Melanoma test during that same period.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bill third-party payors and patients for the tests we perform. The majority of our revenue collections is paid by third-party insurers, including Medicare. We have received local coverage determinations (&#8220;LCDs&#8221;), which provide coverage for our DecisionDx-Melanoma, MyPath Melanoma, DecisionDx-UM and IDgenetix tests that meet certain criteria for Medicare and Medicare Advantage beneficiaries, representing approximately 60 million covered lives. In 2022, DecisionDx-UM received coverage from United Healthcare that represents approximately 43 million covered lives. A &#8216;&#8216;covered life&#8217;&#8217; means a subscriber, or a dependent of a subscriber, who is insured under an insurance carrier&#8217;s policy. The TissueCypher Barrett&#8217;s Esophagus Assay is paid by Medicare at the rate published on Medicare&#8217;s Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;) for the test. Effective March 24, 2022, we received Advanced Diagnostic Laboratory Test (&#8220;ADLT&#8221;) status for our TissueCypher test, as discussed further below. ADLT status exempts TissueCypher from what is called the &#8220;14-day rule,&#8221; which simplifies the billing process for Medicare patients.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Palmetto GBA MolDX (&#8220;Palmetto&#8221;), the Medicare Administrative Contractor (&#8220;MAC&#8221;) responsible for administering MolDX, the program that assesses molecular diagnostic technologies, issued a final expanded LCD for DecisionDx-Melanoma, effective November 22, 2020. With this expanded LCD and the accompanying billing and coding articles, we estimate that a significant majority of the DecisionDx-Melanoma tests performed for Medicare patients will meet the coverage criteria. Noridian Healthcare Solutions, LLC (&#8220;Noridian&#8221;), the MAC responsible for administering claims for laboratory services performed in Arizona, has adopted the same coverage policy as Palmetto and also issued an expanded final LCD for DecisionDx-Melanoma, effective December 6, 2020.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, Palmetto and the other MACs that participate in the MolDX program each released a revised draft LCD for DecisionDx-Melanoma. The draft LCD included commentary about two publications regarding the clinical utility of GEP tests and included an assessment stating that the new data is not sufficient to change the coverage criteria. There was an open public comment period, and we submitted comments in support of Medicare coverage. The comment period ended on August 8, 2021. Palmetto issued a final LCD on May 19, 2022 with Noridian issuing the same on June 16, 2022. The final LCDs did not result in any change in coverage. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, Palmetto issued a final LCD for DecisionDx-UM, which became effective in July 2017, and Noridian issued a similar LCD that became effective in September 2017. Noridian&#8217;s LCD provides for coverage to determine metastatic risk in connection with the management of a patient&#8217;s newly diagnosed UM and to guide surveillance and referral to medical oncology for those patients.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2019, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) determined that DecisionDx-UM meets the criteria for &#8220;existing ADLT&#8221; status. Since 2021, our rate is set annually based upon the median private payor rate for the first half of the second preceding calendar year. Our rate for 2022 continues to be at $7,776, based on the calculation of the median private payor rate.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on May 17, 2019, CMS determined that DecisionDx-Melanoma meets the criteria for &#8220;new ADLT&#8221; status. Initially, the Medicare reimbursement rate was equal to the initial list price of $7,193. Since 2022, the rate is set annually based upon the median private payor rate for the first half of the second preceding calendar year. Our rate for 2022 continues to be $7,193, based on the median private payor rate.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MyPath Melanoma is currently covered under a MolDX LCD policy through Noridian, which oversees laboratories in both Utah and Arizona. Noridian issued an LCD that became effective in June 2019. On September 6, 2019, MyPath Melanoma was approved as a new ADLT. The rate for 2022 is $1,950, based on the median private payor rate.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2023, the rates for DecisionDx-Melanoma, DecisionDx-UM, and MyPath Melanoma tests will be set annually based upon the median private payor rate for the first half of the second preceding calendar year. For example, the rate for 2023 will be set using median private payor rate data from January 1, 2021 to June 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TissueCypher test is processed in our Pittsburgh, Pennsylvania laboratory and falls under the Medicare jurisdiction that is managed by Novitas Solutions (&#8220;Novitas&#8221;). Novitas previously reviewed TissueCypher and we are receiving payments for claims according to the CLFS. For 2022, CMS published in its CLFS a payment rate of $2,513 for the test. On March 24, 2022, CMS determined that TissueCypher meets the criteria for &#8220;new ADLT&#8221; status. From April 1, 2022 through December 31, 2022, CMS has set the initial period rate equal to the original list price of $2,350, subject to the possible recoupment provision described below. Effective January 1, 2023, the rate will be based on the median private payor rates received between April 1, 2022 and August 31, 2022. However, for TissueCypher tests reported for April 1, 2022 through December 31, 2022, CMS has the right to recoup the difference between the actual list price and 130% of the weighted-median if the original list price is greater than 130% of the weighted-median of private payor rates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IDgenetix is currently covered under an LCD policy through MolDX and an accompanying billing and coding article through Noridian, which oversees laboratories in California. The Medicare coverage includes depression and was recently expanded for the following seven additional mental health conditions beyond major depressive disorder: schizophrenia, bipolar disorder, anxiety disorders, panic disorder, obsessive-compulsive personality disorder, post-traumatic stress disorder and attention deficit hyperactivity disorder. The IDgenetix multi-gene panel is currently reimbursed by Medicare at approximately $1,500.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, we submitted our technical assessment dossier for DecisionDx-SCC to Palmetto and Noridian. The dossier was accepted as complete in the third quarter of 2020. In early 2021, we submitted our technical assessment dossier for DiffDx-Melanoma. The dossier was accepted as complete in the first quarter of 2021. In June 2022, Palmetto and Noridian each posted a draft LCD that would provide coverage criteria for DiffDx-Melanoma. We believe the LCD for DiffDx-Melanoma will be finalized by the end of the second quarter of 2023. However, there is no assurance that any draft or final LCD will match our expectations, be posted in a timeframe consistent with our historical experience or will be posted at all. Regarding DecisionDx-SCC, no draft LCD has been posted by Palmetto or Noridian to date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, following the completion of a requested medical review and pricing of our DecisionDx-SCC test by Novitas, we have been receiving reimbursement from Novitas on DecisionDx-SCC at a rate of approximately $3,800 per test. On June 9, 2022, Novitas posted a draft oncology biomarker LCD that proposes to rely upon evidentiary reviews sourced from three databases: ClinGen, OncoKB and National Comprehensive Cancer Network (&#8220;NCCN&#8221;). Two of the databases do not review gene expression profile tests and NCCN has not yet, to our knowledge, reviewed DecisionDx-SCC. As such, if finalized as proposed, then DecisionDx-SCC would not be included as a covered test in the associated billing and coding article. We cannot predict whether this draft LCD will be finalized as proposed or what the timing of any final LCD might be.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since becoming a public company, we have financed our operations with the revenue generated from the sale of our products, proceeds from our initial public offering of our common stock (our &#8220;IPO&#8221;) that closed in July 2019, follow-on public offerings of common stock in June 2020 and December 2020 and bank debt, which has since been repaid in full. We believe that our existing cash and cash equivalents and anticipated cash generated from sales of our products will be sufficient to fund our operations for the next 12 months and into the foreseeable future. However, we have based these estimates on assumptions which may prove to be wrong and could result in us depleting our capital resources sooner than expected.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net (loss) income may fluctuate significantly from period to period, depending on the timing of our planned development activities, the growth of our sales and marketing activities, the effects of acquisitions and the timing of revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;). We expect our expenses will increase substantially over time as we:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">execute clinical studies to generate evidence supporting our current and future product candidates;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">execute our commercialization strategy for our current and future commercial products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">continue our ongoing and planned development of new products in our pipeline;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek to discover and develop additional product candidates;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">hire additional scientific and research and development staff; </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete acquisitions of businesses, assets, products or technologies; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">add additional operational, financial and management information systems and personnel.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_76"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to closely monitor the impact of the ongoing COVID-19 pandemic on our business and taking proactive efforts designed to protect the health and safety of our workforce, continue our business operations and advance our corporate objectives. We are providing the following update with respect to the impact of COVID-19 on our business:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have maintained and expect to continue to maintain uninterrupted business operations, with adequate access to reagents and consumables needed for testing patient samples and normal turnaround times for our delivery of test reports. We have continued to maintain our previously implemented adjustments to our operations designed to keep employees safe and comply with federal, state and local guidelines, including those regarding social distancing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following the onset of the COVID-19 pandemic, we experienced declines in orders and test report volume in certain periods. For example, in the second quarter of 2020, test reports delivered for our lead product, DecisionDx-Melanoma, decreased 18.5% compared to the second quarter of 2019. We believe these decreases in our test report volume were linked to delays and/or cancellations in patient visits, resulting in fewer diagnostic biopsies and thus a reduction in the number of diagnoses of cutaneous melanoma in response, as well as the cumulative impact on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promotional responsiveness as a result of reduced sales calls per day and in-person sales calls during the ongoing COVID-19 pandemic. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial team uses a combination of in-person, virtual and non-personal promotional and educational efforts. Since the beginning of 2021, we have seen improvements in the number of promotional calls per day, as well as a continued shift from virtual to in-person sales calls. During the three months ended June 30, 2022 and 2021, in-person sales calls accounted for over 99% and 90% of all calls during such periods, respectively. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future results will be dependent upon the extent and duration of the COVID-19 crisis, including the emergence and spread of variants of the virus, and government restrictions, which are beyond our control. Although state and local government restrictions put in place to slow the spread of the virus have been eased in most locations, restrictions may be reinstated from time to time in various regions depending on the circumstances, potentially impacting the flow of future patient visits as well as access to our sales targets. Even with the easing of state and local restrictions and the availability of vaccinations, patient visits and diagnoses of the diseases covered by our diagnostic and prognostic tests may be impacted by continued apprehension regarding possible exposure to the virus as well as a general shift from in-person clinical visits to telehealth approaches, which may result in missed or delayed diagnoses of skin cancer and other diseases.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As conditions are evolving, we are unable to predict how our future test report volume will be impacted, or the extent to which our results of operations, financial condition or cash flows will be impacted, by the ongoing COVID-19 pandemic or other future public health crises. Accordingly, the test report data presented above is not necessarily indicative of our results of operations that can be expected for future periods. For more information on the potential impact of the ongoing COVID-19 pandemic on our business, see the risk factors included under &#8220;Risks Related to Our Business&#8221; and the other risk factors included in Part II, Item 1A., &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_79"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors affecting our performance</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted, and that we expect will continue to impact, our operating performance and results of operations, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Report volume. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the number of reports we deliver to physicians is an important indicator of the growth of adoption among the healthcare provider community. Our revenue and costs are affected by the volume of testing and mix of customers. Our performance depends on our ability to retain and broaden adoption with existing prescribing physicians, as well as attract new physicians. Our report volume could be negatively impacted by developments related to the ongoing COVID-19 pandemic or other future public health crises, as discussed above.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Reimbursement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that expanding reimbursement is an important indicator of the value of our products. Payors require extensive evidence of clinical utility, clinical validity, patient outcomes and health economic benefits in order to provide reimbursement. Our revenue depends on our ability to demonstrate the value of our diagnostic and prognostic tests to these payors.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Gross margin. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our gross margin is an important indicator of the operating performance of our business. Higher gross margins reflect the average selling price of our tests, as well as the operating efficiency of our laboratory operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">New product development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant aspect of our business is our investment in research and development activities, including activities related to the development of new products. In addition to the development of new product candidates, we believe these studies are critical to gaining physician adoption of new products and driving favorable coverage decisions by payors for such products.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_82"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information About Certain Metrics</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides additional information about certain metrics we have disclosed in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Test reports delivered for DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma/DiffDx-Melanoma, DecisionDx-UM, TissueCypher and IDgenetix represents the number of completed test reports delivered by us during the reporting period indicated. The period in which a test report is delivered does not necessarily correspond with the period the related revenue, if any, is recognized, due to the timing and amount of adjustments for variable consideration under ASC 606. We use this metric to evaluate the growth in adoption of our tests and to measure against our internal performance objectives. We believe this metric is useful to investors in evaluating the volume of our business activity from period-to-period that may not be discernible from our reported revenues under ASC 606. We also sometimes present, on a limited basis, data on the number of orders received. We believe order data can provide additional insight on current demand trends, particularly during the ongoing COVID-19 pandemic and with respect to new product launches, when considered in conjunction with test report volume. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, orders received in a particular period do not necessarily correspond with actual delivered test reports or reported revenues for the same period or subsequent periods. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New ordering clinicians for our dermatologic tests represents the number of clinicians who ordered a dermatologic test from us for the first time during the reporting period specified. Our dermatologic tests consist of DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma and DiffDx-Melanoma. We believe this metric is useful in evaluating the effectiveness of our sales and marketing efforts in establishing new relationships with clinicians and increasing the adoption of our suite of dermatologic tests. We also believe this metric provides useful information to investors in assessing our ability to expand the use of our dermatologic tests. Since this metric is based upon the reporting period in which an order is placed, it does not necessarily correspond to the reporting period in which either a test report was delivered or revenue was recognized. </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_85"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of the Results of Operations</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from the sale of our products. Currently, our revenues are primarily derived from the sale of DecisionDx-Melanoma and DecisionDx-UM. We bill third-party payors and patients for the tests we perform.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, we recognize revenue at the amount we expect to be entitled, subject to a constraint for variable consideration, in the period in which our tests are delivered to the treating physicians. We have determined that our contracts contain variable consideration under ASC 606 because the amounts paid by third-party payors may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration is recognized only to the extent it is probable that a significant reversal of revenue will not occur in future periods when the uncertainties are resolved. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Variable consideration for Medicare claims that are not covered by an LCD or otherwise, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. For these fully constrained claims, we generally recognize revenue in the period the uncertainty is favorably resolved, if at all. Due to potential future changes in Medicare coverage policies and appeal cycles, insurance coverage policies, contractual rates and other trends in the reimbursement of our tests, our revenues may fluctuate significantly from period to period. Our ability to recognize revenue for a test is dependent on the development of reimbursement experience and obtaining coverage decisions. For tests with limited reimbursement experience or no coverage, we recognize revenues on the basis of actual cash collections.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our revenues will depend on our ability to further penetrate our target markets, and, in particular, generate sales through our direct sales force, develop and commercialize additional tests, including through acquisitions, obtain reimbursement from additional third-party payors and increase our reimbursement rate for tests performed. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales (exclusive of amortization of acquired intangible assets)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our cost of sales are material and service costs associated with testing samples, personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), electronic medical record set up costs, order and delivery systems, shipping charges to transport samples, third-party test fees, and allocated overhead including rent, information technology costs, equipment and facilities depreciation and utilities. Costs associated with testing samples are recorded when the test is processed regardless of whether and when revenues are recognized with respect to that test. As a result, our cost of sales as a percentage of revenues may vary significantly from period to period because we do not recognize all revenues in the period in which the associated costs are incurred. We expect cost of sales in absolute dollars to increase as the number of tests we perform increases. Additionally, we expect cost of sales to increase with the expansion of laboratory capacity and staffing in advance of the anticipated growth of our recently launched tests and tests acquired through acquisitions.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin and gross margin percentage are key indicators we use to assess our business. See the tables in &#8220;Results of Operations&#8212;Comparison of the three months ended June 30, 2022 and 2021&#8221; and &#8220;Results of Operations&#8212;Comparison of the six months ended June 30, 2022 and 2021&#8221; for details.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs incurred to develop our diagnostic and prognostic tests, collect clinical samples and conduct clinical studies to develop and support our products. These costs consist of personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), prototype materials, laboratory supplies, consulting costs, regulatory costs, electronic medical records set up costs, costs associated with setting up and conducting clinical studies and allocated overhead, including rent, information technology, equipment depreciation and utilities. We expense all research and development costs in the periods in which they are incurred. We expect our research and development expenses to increase in absolute dollars as we continue to invest in research and development activities related to developing enhanced and new products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to use a portion of our cash and cash equivalents to further support and accelerate our research and development activities, including two important studies that are underway to support our DecisionDx-Melanoma test. The first is the CONNECTION study, which is collecting long-term outcomes for up to 10,000 patients who have been tested with DecisionDx-Melanoma. The second is the DECIDE study, which is designed to determine the association of GEP test results with SLNB surgical decisions in patients eligible for SLNB as well as to track outcomes for patients who did and did not undergo SLNB. Also, as noted above, in 2021, we initiated our 4,800 patient, prospective, multi-center clinical study to develop, validate and bring to market a pipeline test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. We have also initiated two additional disease studies for pipeline tests for new indications. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously funded the PERSONALize study, which was evaluating the use of DecisionDx-Melanoma in patients eligible for adjuvant therapy. Other of our sponsored studies are designed to provide risk stratification analyses within various subgroups. These studies have shown statistically and clinically significant risk stratification separation. Based upon this currently available and anticipated future data, we have decided to close the PERSONALize study.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses include executive, selling and marketing, legal, finance and accounting, human resources, billing and client services. These expenses consist of personnel costs (including salaries, bonuses, benefits and stock-based compensation expense), direct marketing expenses, audit and legal expenses, consulting costs, training and medical education activities, payor outreach programs and allocated overhead, including rent, information technology, equipment depreciation, and utilities. We expect continued increases in SG&amp;A expenses related to compliance with the rules and regulations of the SEC and The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). Other administrative and professional services expenses within SG&amp;A are expected to increase with the scale of our business, but selling and marketing-related expenses are expected to increase significantly, consistent with our growth strategy. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets are primarily associated with developed technology obtained through acquisitions, such as our acquisitions of the Myriad MyPath Laboratory in May 2021, Cernostics in December 2021 and AltheaDx in April 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration is associated with our acquisitions of Cernostics and AltheaDx and the related additional consideration of up to $50.0 million and $75.0 million, respectively, that may become payable based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 in the case of Cernostics, and the years ending December 31, 2022, 2023 and 2024, in the case of AltheaDx (collectively, the &#8220;Earnout Payments&#8221;).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of earnings on cash and cash equivalents, primarily money market funds.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is primarily attributable to finance leases.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax (Benefit) Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of AltheaDx in April 2022, and taking into consideration the additional deferred tax liabilities resulting from such acquisition, we determined that a portion of our valuation allowance should be reduced, which is reflected in our income tax benefit for the three and six months ended June 30, 2022. Our consolidated financial statements do not reflect any federal or state income tax benefits attributable to the pre-tax losses we have incurred, due to the uncertainty of realizing a benefit from those items. As of December 31, 2021, we had federal net operating loss carryforwards of $99.4 million, of which $43.5 million will begin to expire in 2030 if not utilized to offset federal taxable income, and $55.9 million may be carried forward indefinitely. Also, as of December 31, 2021, we had state net operating loss carryforwards of $67.5 million, which begin to expire in 2028 if not utilized to offset state taxable income.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_91"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended June 30, 2022 and 2021</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses and other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,398)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,809&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,971)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,810)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,605)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,786)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,791)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NA = Not applicable</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = Not meaningful</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a disaggregation of net revenues by type (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.883%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic GEP offering.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists primarily of DecisionDx-UM. Also includes TissueCypher and IDgenetix.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of gross margin (in thousands, except percentages):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,805&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin percentage</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the amount of stock-based compensation expense (non-cash) reflected in the line items above (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,017&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span><br/></span></div><div id="i85ed73ce88b34118965f36f66c298ae1_94"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for the three months ended June 30, 2022 increased by $12.1 million, or 53.1%, to $34.8 million compared to the three months ended June 30, 2021, primarily due to a $11.5 million increase in revenue from our dermatologic tests, primarily DecisionDx-Melanoma and DecisionDx-SCC. The increase in dermatologic revenue was primarily attributable to a 44.1% increase in test volumes, with higher test reports delivered across each of our dermatologic offerings, due to a combination of the effects of our dermatologic sales force expansion during the second quarter of 2021 and increased patient flow potentially attributable to the easing of COVID-19 restrictions. The higher revenues also reflect Medicare payments on DecisionDx-SCC, as discussed above, and the effect of higher positive (negative) revenue adjustments related to tests delivered in previous periods, associated with changes in estimated variable consideration, which were $0.6 million for the three months ended June 30, 2022 compared to $(0.2) million for the three months ended June 30, 2021. The increase in revenue from our other tests (non-dermatologic) of $0.6 million was primarily attributable to our acquisitions of Cernostics in December 2021 and AltheaDx in April 2022.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_97"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales (exclusive of amortization of acquired intangible assets)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (exclusive of amortization of acquired intangible assets) for the three months ended June 30, 2022 increased by $4.0 million, or 107.9%, compared to the three months ended June 30, 2021, primarily due to higher personnel costs and increased costs of supplies and third-party services. Personnel costs have increased with additions in headcount in our laboratory testing operations, including headcount attributable to our acquisitions of Cernostics and AltheaDx. The increased personnel costs also reflect higher salaries and wages for existing employees. Supply and services expense have increased due to higher laboratory activity, which is attributable to higher test volumes. Due to the nature of our business, a significant portion of our cost of sales expenses represents fixed costs associated with our testing operations. Accordingly, our cost of sales expense will not necessarily increase or decrease commensurately with the change in net revenues from period to period. We expect our cost of sales expenses (exclusive of amortization of acquired intangible assets) to continue to increase in future periods as we hire additional laboratory personnel and related resources to support our expected growth in volume for our dermatologic, gastrointestinal, mental health and pipeline tests.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_100"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin percentage was 71.9% for the three months ended June 30, 2022, compared to 82.6% for the same period in 2021. The decrease was primarily due to this year&#8217;s additional investments in laboratory headcount, higher salaries and wages, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and higher amortization expense associated with our acquired intangible assets. In the near term, we expect that our gross margin percentage will decline, compared to prior periods, as we invest in additional laboratory personnel and related resources to support the anticipated growth in our test report volumes in advance of obtaining reimbursement coverage. Additionally, our gross margin percentage will continue to be negatively impacted by amortization of intangible assets associated with recent acquisitions. </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_103"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $5.1 million, or 75.6%, for the three months ended June 30, 2022, compared to the three months ended June 30, 2021. Approximately 50.1% of the increase is attributable to higher personnel costs, primarily due to expansions in headcount in support of our growth, higher salaries and wages, and higher stock-based compensation expense, and approximately 23.6% is attributable to higher costs for clinical studies, including costs related to the PERSONALize, CONNECTION and DECIDE studies. In the second quarter of 2022, we decided to close our PERSONALize study. The remainder of the increase is primarily associated with higher costs incurred for outside legal fees. We expect to continue to increase our research and development expenses as we fund ongoing evidence development for our existing products as well as additional pipeline programs.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_106"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakdown of SG&amp;A expenses (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses increased by $9.7 million, or 81.8%, for the three months ended June 30, 2022, compared to three months ended June 30, 2021. Approximately $5.2 million, or 53.6%, of the increase is attributable to higher personnel costs including salaries, bonuses and stock-based compensation. Personnel costs have increased through the expansion of our dermatology-facing commercial team headcount to the mid-60s in the second quarter of 2021 and through our acquisitions of Cernostics in December 2021 and AltheaDx in April 2022. Following our acquisition of Cernostics in December 2021, we hired an initial commercial team of approximately 14 outside sales territories, along with commensurate internal sales associates and other personnel, to support our launch of the TissueCypher Barrett&#8217;s Esophagus Assay and to serve as a dedicated team focused on gastroenterology specialists that diagnose and manage patients with BE. Through our acquisition of AltheaDx, we added a commercial team of approximately 20 outside sales territories to support our launch of the IDgenetix test. In addition to increases through sales force expansion, higher personnel costs also reflect salary increases for members of our existing sales force. The remainder of the increase in sales and marketing expenses was primarily associated with training events, meetings, travel and other general increases. The higher expenses for training events and travel reflect an increase in our sales and commercial operations related to our expanded headcount and expanded test offerings, as well a return to more in-person activities resulting from the continued easing of COVID-19 restrictions. Stock-based compensation expense included in sales and marketing expense was $2.9 million for the three months ended June 30, 2022, compared to $1.5 million for the three months ended June 30, 2021.We expect sales and marketing expenses to increase in future periods as we intend to expand our outside sales territories and sales force further during 2022, as discussed under &#8220;Overview&#8221; above.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $7.0 million, or 77.7%, for the three months ended June 30, 2022, compared to three months ended June 30, 2021. The increase is primarily attributable to $3.6 million in higher personnel costs including salaries, bonuses and stock-based compensation. The higher personnel costs reflect expanded headcount in our administrative support functions, including that related to the acquisitions of Cernostics and AltheaDx, as well as higher rates of pay. Stock-based compensation expense included in general and administrative expense was $3.2 million for the three months ended June 30, 2022, compared to $1.8 million for the three months ended June 30, 2021. Furthermore, we incurred $1.7 million of transaction costs associated with our acquisition of AltheaDx. The remainder of the increase in general and administrative expenses was primarily associated with professional fees and other general increases.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_109"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets increased by $1.8 million for the three months ended June 30, 2022, compared to the three months ended June 30, 2021. The increase is primarily associated with amortization of developed technology attributable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the acquisitions of the Myriad MyPath Laboratory, Cernostics, and AltheaDx in May 2021, December 2021 and April 2022, respectively.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_112"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration for the three months ended June 30, 2022 of $20.4 million, a net gain, is primarily related to the remeasurement of the Earnout Payments associated with our acquisition of Cernostics and reflects changes in management&#8217;s projections regarding attainment of certain commercial milestones. There was no such activity during the three months ended June 30, 2021.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_115"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $0.3&#160;million for the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily as a result of higher interest rates. </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2748779071036"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax (Benefit) Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax benefit was $2.0&#160;million for the three months ended June 30, 2022 and was primarily attributable to a reduction of $1.8 million in our valuation allowance on net deferred tax assets resulting from our acquisition of AltheaDx in April 2022. Specifically, we took into consideration the additional deferred tax liabilities resulting from the acquisition and determined that a portion of our existing valuation allowance should be reduced. Other than this item, we recorded minimal amounts in income tax benefit because in both the three months ended June 30, 2022 and 2021, the income tax benefit of the pre-tax loss was largely offset by corresponding changes in the valuation allowance on net deferred tax assets, as we have determined that it is more likely than not that these benefits will not be realized.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_121"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense, which is allocated among cost of sales, research and development expense and SG&amp;A expense, totaled $8.8 million for the three months ended June 30, 2022, compared to $4.8 million for the three months ended June 30, 2021. We expect material increases in stock-based compensation expense in future periods, reflecting mainly higher awards outstanding due to growth in our headcount. As of June&#160;30, 2022, we had 482 employees compared to 292 as of June 30, 2021. As of June&#160;30, 2022, the total unrecognized stock-based compensation cost related to outstanding awards was $99.5 million, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.0 years. We expect to continue granting stock-based compensation awards, which we expect to further contribute to increases in stock-based compensation expense in future periods.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023256966"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the six months ended June 30, 2022 and 2021</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses and other operating income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,665&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,487)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,094)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,094)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,066)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,028)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,271)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,071)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,200)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NA = Not applicable</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM = Not meaningful</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a disaggregation of net revenues by type (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.883%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of DecisionDx-Melanoma, DecisionDx-SCC and Diagnostic GEP offering.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists primarily of DecisionDx-UM. Also includes TissueCypher and IDgenetix.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of gross margin (in thousands, except percentages):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin percentage</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.7&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the amount of stock-based compensation expense (non-cash) reflected in the line items above (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023256978"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for the six months ended June 30, 2022 increased by $16.1 million, or 35.4%, to $34.8 million compared to the six months ended June 30, 2021, primarily due to a $14.9 million increase in revenue from our dermatologic tests, primarily DecisionDx-Melanoma and DecisionDx-SCC, and to a lesser extent, a $1.2 million increase in revenue from our other tests (non-dermatologic). The increase in dermatologic revenue was primarily attributable to a 54.6% increase in test volumes, with higher test reports delivered across each of our dermatologic offerings, due to a combination of the effects of our dermatologic sales force expansion during the second quarter of 2021 and increased patient flow potentially attributable to the easing of COVID-19 restrictions. The higher revenues also reflect Medicare payments on DecisionDx-SCC, as discussed above. The higher volumes were partially offset by the effect of lower positive (negative) revenue adjustments related to tests delivered in previous periods, associated with changes in estimated variable consideration, which were $(0.3) million for the six months ended June 30, 2022 compared to $5.1 million for the six months ended June 30, 2021. The year-over-year decrease is primarily attributable to the effect of favorable adjustments related to the settlement and collection during the six months ended June 30, 2021 of certain groups of receivables from prior years that did not recur during the six months ended June 30, 2022. The increase in revenue from our other tests (non-dermatologic) of $1.2 million was primarily attributable to higher test report volume of DecisionDx-UM and the acquisitions of Cernostics in December 2021 and AltheaDx in April 2022.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023256990"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales (exclusive of amortization of acquired intangible assets)</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (exclusive of amortization of acquired intangible assets) for the six months ended June 30, 2022 increased by $6.9 million, or 102.7%, compared to the six months ended June 30, 2021, primarily due to higher personnel costs and increased costs of supplies and third-party services. Personnel costs have increased with additions in headcount in our laboratory testing operations, including headcount attributable to our acquisitions of Cernostics and AltheaDx. The increased personnel costs also reflect higher salaries and wages for existing employees. Supply and service expenses have increased due to higher laboratory activity, which is attributable to higher test volumes. Due to the nature of our business, a significant portion of our cost of sales expenses represents fixed costs associated with our testing operations. Accordingly, our cost of sales expense will not necessarily increase or decrease commensurately with the change in net revenues from period to period. We expect our cost of sales expenses (exclusive of amortization of acquired intangible assets) to continue to increase in future periods as we hire additional laboratory personnel and related resources to support our expected growth in volume for our dermatologic, gastrointestinal, mental health and pipeline tests.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257002"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin percentage was 71.8% for the six months ended June 30, 2022, compared to 84.7% for the same period in 2021. The decrease was primarily due to lower revenue adjustments related to tests delivered in previous periods, higher personnel costs attributable to investments in laboratory headcount as well as higher salaries and wages, and higher amortization expense associated with our acquired intangible assets. In the near term, we expect that our gross margin percentage will decline, compared to prior periods, as we invest in additional laboratory personnel and related resources to support the anticipated growth in our report volumes for tests in advance of obtaining reimbursement coverage. Additionally, our gross margin percentage will continue to be negatively impacted by amortization of intangible assets associated with recent acquisitions. </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257006"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $10.0 million, or 78.6%, for the six months ended June 30, 2022, compared to the six months ended June 30, 2021. Approximately 50.7% of the increase is attributable to higher personnel costs, primarily due to expansions in headcount in support of our growth, higher pay rates and higher stock-based compensation expense, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 22.0% is attributable to higher costs for clinical studies, including costs related to the PERSONALize, CONNECTION and DECIDE studies. In the second quarter of 2022, we decided to close our PERSONALize study. The remainder of the increase is primarily associated with meeting costs and travel expenses. We expect to continue to increase our research and development expenses as we fund ongoing evidence development for our existing products as well as additional pipeline programs.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257018"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakdown of SG&amp;A expenses (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.695%"><tr><td style="width:1.0%"></td><td style="width:53.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,951&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,983&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses increased by $18.3 million, or 84.9%, for the six months ended June 30, 2022, compared to six months ended June 30, 2021. Approximately $10.6 million, or 57.9%, of the increase is attributable to higher personnel costs including salaries, bonuses and stock-based compensation. Personnel costs have increased through the expansion of our dermatology-facing commercial team headcount to the mid-60s during the second quarter of 2021 and through our acquisitions of Cernostics in December 2021 and AltheaDx in April 2022. Following our acquisition of Cernostics, we hired an initial commercial team of approximately 14 outside sales territories, along with commensurate internal sales associates and other personnel, to support our launch of the TissueCypher Barrett&#8217;s Esophagus Assay and to serve as a dedicated team focused on gastroenterology specialists that diagnose and manage patients with BE. Through our acquisition of AltheaDx, we added a commercial team of approximately 20 outside sales territories to support our launch of the IDgenetix test. In addition to increases through sales force expansion, higher personnel costs also reflect salary increases for members of our existing sales force. The remainder of the increase in sales and marketing expenses was primarily associated with training events, meetings, travel and other general increases. The higher expenses for training events and travel reflect an increase in our sales and commercial operations related to our expanded headcount and expanded test offerings, as well a return to more in-person activities resulting from the continued easing of COVID-19 restrictions. Stock-based compensation expense included in sales and marketing expense was $5.7 million for the six months ended June 30, 2022, compared to $3.0 million for the six months ended June 30, 2021. We expect sales and marketing expenses to increase in future periods as we intend to expand our outside sales territories and sales force further during 2022, as discussed under &#8220;Overview&#8221; above.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $10.7 million, or 61.2%, for the six months ended June 30, 2022, compared to six months ended June 30, 2021. The increase is primarily attributable to $6.3 million in higher personnel costs including salaries, bonuses and stock-based compensation. The higher personnel costs reflect expanded headcount in our administrative support functions, including that related to the acquisitions of Cernostics and AltheaDx, as well as higher rates of salaries and wages. Stock-based compensation expense included in general and administrative expense was $6.1 million for the six months ended June 30, 2022, compared to $3.6 million for the six months ended June 30, 2021. Furthermore, we incurred $1.7 million of transaction costs associated with our acquisition of AltheaDx. The remainder of the increase in general and administrative expenses was primarily associated with professional fees and other general increases.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257030"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets increased by $3.5 million for the six months ended June 30, 2022, compared to the six months ended June 30, 2021. The increase is primarily associated with amortization of developed technology attributable to the acquisitions of the Myriad MyPath Laboratory, Cernostics, and AltheaDx in May 2021, December 2021 and April 2022, respectively.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257034"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration for the six months ended June 30, 2022 of $17.8 million, a net gain, is primarily related to the remeasurement of the Earnout Payments associated with our acquisition of Cernostics and reflects changes in management&#8217;s projections regarding attainment of certain commercial milestones. There was no such activity during the six months ended June 30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257038"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income increased by $0.3&#160;million for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2021</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily as a result of higher interest rates. </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2748779071050"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax (Benefit) Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax benefit was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8 million</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022, and was primarily attributable to </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a reduction of $1.8 million in our valuation allowance on net deferred tax assets resulting from our acquisition of AltheaDx in April 2022. Specifically, we took into consideration the additional deferred tax liabilities resulting from the acquisition and determined that a portion of our existing valuation allowance should be reduced. Other than this item, we recorded minimal amounts in income tax benefit because in both the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2021, the income tax benefit of the pre-tax loss was largely offset by corresponding changes in the valuation allowance on net deferred tax assets, as we have determined that it is more likely than not that these benefits will not be realized.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_2199023257055"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense, which is allocated among cost of sales, research and development expense and SG&amp;A expense, totaled $17.2 million for the six months ended June 30, 2022, compared to $9.7 million for the six months ended June 30, 2021. We expect material increases in stock-based compensation expense in future periods, reflecting mainly higher awards outstanding due to growth in our headcount. As of June&#160;30, 2022, we had 482 employees compared to 292 as of June&#160;30, 2021. As of June&#160;30, 2022, the total unrecognized stock-based compensation cost related to outstanding awards was $99.5 million, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.0 years. We expect to continue granting stock-based compensation awards, which we expect to further contribute to increases in stock-based compensation expense in future periods.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_124"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our cash and cash equivalents and cash generated from the sale of our products. As of June&#160;30, 2022 and December 31, 2021, we had cash and cash equivalents of $273.2 million and $329.6 million, respectively. In addition to the revenue generated from the sale of our commercial products, we have financed our operations through our IPO in July 2019, two follow-on public offerings of common stock in June 2020 and December 2020, and a $25.0 million secured term loan credit facility, which we repaid in full in December 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, we filed an automatically effective shelf registration statement on Form S-3 (File No. 333-251331) (our &#8220;Shelf Registration Statement&#8221;) with the SEC as a &#8220;well-known seasoned issuer.&#8221; The Shelf Registration Statement allows us to issue an indeterminate number or amount of common stock, preferred stock, debt securities and warrants from time to time in one or more offerings. However, there can be no assurance that we will complete any further offerings of securities under our Shelf Registration Statement. Any future offerings under our Shelf Registration Statement will be dependent upon, among other factors, market conditions, available pricing, our financial condition, investor perception of our prospects, our capital needs and our ability to maintain status as a well-known seasoned issuer. Our market capitalization as of August 1, 2022 is below the level required to maintain status as well-known seasoned issuer in the future.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, we expect to use a portion of our cash and cash equivalents, including any proceeds from subsequent offerings under our Shelf Registration Statement, to further support and accelerate our research and development activities, including the clinical studies noted above in &#8220;Components of the Results of Operations&#8212;Research and Development.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical research and development services, laboratory operations, equipment and related supplies, legal and other regulatory expenses, general administrative costs and, from time to time, expansion of our laboratory and office facilities in support of our growth. We anticipate that a substantial portion of our cash requirements in the foreseeable future will relate to the further commercialization of our currently marketed products, the development of our future product candidates in our pipeline and the potential commercialization of these pipeline products, should their development be successful. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we acquired Cernostics for $30.7 million in cash and in April 2022, we acquired AltheaDx, for $30.5 million in cash and $17.1 million in shares of our common stock. Under the definitive agreement to acquire Cernostics, we also agreed to pay up to an additional $50.0 million of Earnout Payments, based on the achievement of certain commercial milestones relating to the year ending December 31, 2022. With respect to AltheaDx, we agreed to pay up to an additional $75.0 million, 50% in cash and 50% in common stock, based on the achievement of certain commercial milestones relating to the years ending December 31, 2022, 2023 and 2024. In each case, the number of shares of our common stock that may be issued in connection with the Earnout Payments is subject to limitations, as discussed in Notes 5 and 10 to the unaudited </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated financial statements. Our actual liability with respect to these commercial milestone payments from our acquisitions will depend, in part, on our ability to successfully integrate the TissueCypher Barrett&#8217;s Esophagus Assay (acquired from Cernostics) and IDgenetix (acquired from AltheaDx) into our suite of commercial product offerings and the timing thereof.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have generally incurred significant losses and negative cash flows. For the year ended December 31, 2021 we had a net loss of $31.3 million and an accumulated deficit of $93.8 million as of December 31, 2021. For the six months ended June 30, 2022, we had a net loss of $26.3 million and an accumulated deficit of $120.0 million as of June&#160;30, 2022. Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful commercialization of our currently marketed products and the products we plan to launch in the future as well as our spending on research and development activities. We expect to incur additional expenses and losses in the future as we invest in the commercialization of our existing products, the development of our future product candidates and the commercialization of our product candidates. Further, we expect that any acquisitions of businesses, products, assets or technologies will also increase our expenses. We believe that our existing cash and cash equivalents and anticipated cash generated from the sale of our commercial products will be sufficient to fund our operations for the next twelve months. We believe we will meet longer-term expected cash requirements and obligations through a combination of existing cash and cash equivalents, anticipated cash generated from sales of our products and issuances of equity securities or debt offerings, including through our Shelf Registration Statement. However, we have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. There are numerous risks and uncertainties associated with developing genomic tests, including, among others, the uncertainty of:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful commencement and completion of clinical study protocols;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful identification and acquisition of tissue samples;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development and validation of genomic classifiers; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new genomic tests by physicians, patients and third-party payors.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate our exact working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including those listed above as well as those listed in Part II, Item 1A., &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any committed external source of funds. In the event additional funding is required, we expect that we would use a combination of equity and debt financings, which may not be available to us when needed, on terms that we deem to be favorable or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. Any disruptions to, or volatility in, the credit and financial markets or any deterioration in overall economic conditions may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If we are unable to raise additional funds through debt or equity financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product discovery and development activities or future commercialization efforts.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various operating and finance leases, which are primarily associated with our laboratory facilities and office space. Total undiscounted future minimum payment obligations under our operating leases and finance leases as of June&#160;30, 2022 totaled approximately $10.1 million, of which $0.7 million is payable through the remainder of 2022 and $9.4 million through the end of 2033. The leases expire on various dates through 2033 and provide certain options to renew for additional periods. On March 11, 2022, we amended an existing lease agreement to lease additional laboratory space in Phoenix, Arizona. On April 1, 2022, we entered into a new lease agreement with an initial term of 10.5 years for laboratory and office space located in Pittsburgh, Pennsylvania. As of June&#160;30, 2022, neither of the two leases had commenced. Upon commencement, we expect these two leases to increase our undiscounted future minimum payment obligations by a total of approximately $13.8 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,467)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $30.4 million for the six months ended June 30, 2022, and was primarily attributable to the net loss of $26.3 million, the change in fair value of contingent consideration of $17.8 million, increases in accounts receivable of $5.6 million and deferred income taxes of $1.8 million, partially offset by non-cash stock compensation expense of $17.2 million and depreciation and amortization of $4.8 million.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $10.1 million for the six months ended June 30, 2021, and was primarily attributable to the net loss of $13.1 million, increases in accounts receivable of $5.3 million and recoupment of $2.2 million of an advance payment from CMS under its Accelerated and Advance Payment Program, partially offset by non-cash stock compensation expense of $9.7 million and decreases in prepayments and other current assets of $1.3 million.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $20.4 million additional net cash used in operating activities for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 is primarily due to cash requirements associated with the increases in operating expenses, the majority of which were attributable to salaries, bonuses and benefits due to our growth in headcount, as discussed in further detail under &#8220;Results of Operations&#8212;Comparison of the six months ended June 30, 2022 and 2021&#8221; above. The effect of the higher expenses on net cash used in operating activities was partially offset by cash inflows from the higher revenues.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $27.9 million for the six months ended June 30, 2022 and consisted primarily of the cash portion of the AltheaDx purchase consideration of $26.7 million (net of cash and cash equivalents acquired) and purchases of property and equipment of $1.8 million. Net cash used in investing activities was $34.8 million for the six months ended June 30, 2021 and consisted primarily of the purchase of Myriad MyPath Laboratory of $33.2 million (including transaction costs) and purchases of property and equipment of $1.7 million.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $1.9 million for the six months ended June 30, 2022, and primarily consisted of $1.5 million in proceeds from contributions to the employee stock purchase plan and $0.5&#160;million in proceeds from the exercise of stock options.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $3.4 million for the six months ended June 30, 2021, and primarily consisted of $2.3 million in proceeds from the exercise of stock options and $1.4 million in proceeds from contributions to the employee stock purchase plan.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_127"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the rate of inflation in the United States began to increase and has since risen to levels not experienced in over 40 years. We are experiencing inflationary pressures, primarily in personnel costs, and we anticipate impacts on other cost areas within the next twelve months. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and the extent to which the rate of inflation further increases, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, the purchasing power of our cash and cash equivalents may be diminished, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our payors may be unwilling or unable to increase reimbursement rates to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensate for inflationary impacts. As such, the effects of inflation may adversely impact our results of operations, financial condition and cash flows.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_130"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;six months ended June 30, 2022, except as noted below, there were no significant changes to the information discussed under &#8220;Critical Accounting Estimates&#8221; included in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section of our Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is an updated discussion of our critical accounting estimates related to contingent consideration. This information should be read in conjunction with our other information on critical accounting estimates included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, in accordance with to ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration is recorded at fair value as of the acquisition date and classified as liabilities or equity based on applicable accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). For contingent consideration classified as liabilities, we remeasure the contingent consideration at fair value each period with changes in fair value recorded in the statements of operations and comprehensive loss each period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration in transactions that are not business combinations, we apply applicable U.S. GAAP. With respect to the additional consideration that may be payable in connection with the acquisition of Cernostics, an asset acquisition we completed on December 3, 2021, we account for the contingent consideration as liability in accordance with ASC 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the condensed consolidated statements of operations and comprehensive loss each period. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for contingent consideration are classified as a &#8220;Level 3&#8221; fair value measurements (as defined in Note 11 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021) due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis also uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate. The assumptions and estimates we use in the Monte Carlo simulation require considerable judgment and may change in future periods as a result of new information. For example, during the three months ended June 30, 2022, as a result of a change in management&#8217;s projections regarding the outcome of certain commercial milestones associated with our acquisition of Cernostics, the fair value of the related contingent consideration liability decreased by $20.8 million.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_136"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide the information required by this Item.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_139"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) under the Exchange Act) that occurred during the second quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_142"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_145"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no pending or threatened litigation that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_148"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors Summary</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face many risks and uncertainties, as more fully described in this section under the heading &#8220;Risk Factors.&#8221; Some of these risks and uncertainties are summarized below. The summary below does not contain all of the information that may be important to you, and you should read this summary together with the more detailed discussion of these risks and uncertainties contained in &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Related to our Financial Condition</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely upon a small number of third-party payors for a significant portion of our revenue.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our method of recognizing revenue may not reflect our underlying business.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception, and we may never achieve profitability.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our financial results could fluctuate in the future, causing the market price of our stock to decline substantially.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our internal control over financial reporting is ineffective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to raise additional capital to commercialize new products, to expand operations or to fund existing operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our revenue heavily relies upon the sale of a single product and our current or future products may not achieve or maintain significant commercial market acceptance. </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have been, and may continue to be, adversely impacted by the COVID-19 pandemic, which has, at times, caused decreased test report volume.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Billing for our products is complex and we require substantial time and resources to collect payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties for sample collection, preparation and delivery.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A depletion or loss of our sample database could significantly harm our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our primary clinical laboratory facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to conduct our laboratory work for our commercial products and pursue our research and development efforts may be jeopardized.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New product development is lengthy and complex, and our revenues could be limited if we are unable to increase and support adoption of our products by both physicians and other healthcare providers.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on limited or sole suppliers for some of the reagents, equipment, chips and other materials used by our products, and we may not be able to find replacements or transition to alternative suppliers if these suppliers are unable or unwilling to continue providing these materials.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sizes of the addressable markets for our current and future products have not been established with precision and may be smaller than we estimate.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The diagnostic testing industry is subject to rapid change, which could make our current or future products obsolete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Reimbursement and Government Regulation</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have limited reimbursement coverage for our lead product, DecisionDx-Melanoma, and if third-party payors, including government and commercial payors, do not provide sufficient coverage of, or adequate reimbursement for, our products, our commercial success, including revenue, will be negatively affected.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We conduct business in a heavily regulated industry and failure to comply with regulatory requirements, including those established by the CMS, and the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or changes in enforcement discretion for laboratory developed tests could harm our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data from our clinical studies may change materially, which could harm our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in healthcare policy, statutes or regulations, or our ability to comply with applicable healthcare requirements, could have a material adverse effect on our business and operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for our technology, our ability to successfully commercialize our products may be impaired.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on information technology systems that we license from third parties and other royalty-bearing license agreements.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are highly dependent on the services of our key personnel, including our President and Chief Executive Officer.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees and any current or potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have, and may continue to, engage in strategic transactions, such as the acquisition of businesses, assets, products or technologies, which could be disruptive to our existing operations, divert the attention of our management team and adversely impact our liquidity, cash flows, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business may be negatively impacted by cybersecurity threats, natural disasters and public health crises.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product or professional liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock may be volatile or may decline regardless of our operating performance, and you may lose all or part of your investment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have broad discretion in the use of working capital and may not use it effectively or in ways that increase our share price.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Related party transactions that create conflicts of interest, or the appearances of conflicts of interest, may harm our business and cause our stock price to decline.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks described below, as well as the other information in this Quarterly Report on Form 10&#8209;Q, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">time to time. You should consider all of the factors described as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) are new or contain changes to the similarly titled risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2021. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_151"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance upon a small number of third-party payors for a significant portion of our revenue may materially adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from a small number of third-party payors, primarily Medicare. Our revenue for our test reports provided for patients covered by Medicare and Medicare Advantage plans as a percentage of total revenue, was 57% and 28%, respectively, for the year ended December 31, 2021 and 58% and 29%, respectively, for the year ended December 31, 2020. If our largest current payors were to significantly reduce, or cease to pay, the amount they reimburse for our products, or if they do not reach favorable coverage and reimbursement decisions for our products, or attempt to recover amounts they had already paid, it could have a material adverse effect on our business, financial condition and results of operations and cause significant fluctuations in our results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to how we recognize revenue, our quarterly revenues may not reflect our underlying business.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the &#8216;&#8216;most likely amount&#8217;&#8217; method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Determining variable consideration through a consideration of these factors involves a significant level of estimation uncertainty, and our estimations may turn out to be incorrect. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Variable consideration for Medicare claims that are not covered by an LCD or otherwise, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. As a result of the timing and amount of adjustments for variable consideration, our operating results and comparisons of such results on a period-to-period basis may be difficult to understand and may not be meaningful. In addition, these fluctuations in revenue may make it difficult for us, for research analysts and for investors to accurately forecast our revenue and operating results. If our revenue or operating results fall below expectations, the price of our common stock would likely decline.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, and we may never achieve profitability.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have had a history of net losses. For the year ended December 31, 2021 we had a net loss of $31.3 million and an accumulated deficit of $93.8 million as of December 31, 2021. For the six months ended June 30, 2022, we had a net loss of $26.3&#160;million. As of June&#160;30, 2022, we had an accumulated deficit of $120.0 million. We cannot predict if we will achieve profitability in the near future or at all. We expect to incur losses in the future as we plan to invest significant additional funds toward the expansion of our commercial organization, the conduct of clinical utility and validity studies to support adoption of our products and the development or acquisition of additional products. We also expect significant increases in our stock-based compensation expense in future periods, reflecting higher stock option valuations as a public company and additional awards outstanding due to increased headcount. Additionally, our performance could be affected by the impacts of the ongoing COVID-19 pandemic, the invasion of Ukraine by Russia, economic slowdowns, recessions or market corrections, inflation, rising interest rates and tightening of credit markets resulting from the pandemic, the conflict or another cause. Due to the requirements associated with being a public company, including those associated with no longer qualifying as an emerging growth company, we expect to continue incur significant additional legal, accounting and other expenses. We also expect that any acquisitions of businesses, assets, products or technologies will increase our expenses. These increased expenses will make it harder for us to achieve future profitability. We may also incur significant losses in the future for a number of reasons, many </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which are beyond our control, including the other risks described in this Quarterly Report on Form 10&#8209;Q, adoption of our products, coverage of and reimbursement rates for our products from third-party payors, and future research and development activities. Our failure to achieve profitability in the future could cause the market price of our common stock to decline and make it more difficult or costly for us to raise additional capital.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early, commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an early commercial-stage company and have a limited operating history. Our limited operating history may make it difficult to evaluate our current business and this makes predictions about our future success or viability subject to significant uncertainty. In particular, we intend to use a portion of our working capital to increase our headcount, including through the expansion of our sales and marketing and research and development teams, which will increase our operating costs in a manner not historically reflected in our consolidated financial statements. In combination with our other anticipated increased operating expenses in connection with the ongoing demands of a public company, these anticipated changes in our operating expenses may make it difficult to evaluate our current business, assess our future performance relative to prior performance and accurately predict our future performance.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to encounter risks and difficulties frequently experienced by early commercial-stage companies, including those associated with increasing the size of our organization and the prioritization of our commercial, research and business development activities. If we do not address these risks successfully, our business could suffer.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting principles generally accepted in the United States of America are subject to interpretation by the Financial Accounting Standards Board, the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing rules or the questioning of current practices may adversely affect our reported financial results or the way we conduct our business. As of December 31, 2021, we are no longer an emerging growth company and now apply public company adoption dates for new or revised accounting standards.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results and cash flows may fluctuate in the future, which could cause the market price of our stock to decline substantially.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous factors, many of which are outside our control may cause or contribute to significant fluctuations in our quarterly and annual operating results. For example, following the onset of the COVID-19 pandemic in 2020 we experienced decreases in revenue and test report volumes. These fluctuations may make financial planning and forecasting uncertain. In addition, these fluctuations may result in unanticipated decreases in our available cash, which could negatively affect our business and prospects. In addition, one or more of such factors may cause our revenue or operating expenses in one period to be disproportionately higher or lower relative to the others. As a result, comparing our operating results on a period-to-period basis may be difficult to understand and may not be meaningful. You should not rely on our past results as indicative of our future performance.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant portion of our operating expense is relatively fixed in nature, and planned expenditures are based in part on expectations regarding future revenue. Accordingly, unexpected revenue shortfalls could decrease our gross margins and cause significant changes in our operating results from quarter to quarter. If this occurs, the trading price of our stock could fall substantially.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This variability and unpredictability caused by factors such as those described above could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our internal control over financial reporting is not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause adverse effects on our business and may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim consolidated financial statements will not be prevented or detected on a timely basis. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to adequately staff our accounting and finance function or fail to maintain adequate internal control over financial reporting, any new or recurring material weaknesses could prevent our management from concluding our internal control over financial reporting is effective and could result in our auditor issuing an adverse opinion on our internal control over financial reporting. If we identify any future significant deficiencies or material weaknesses, the accuracy and timeliness of our financial reporting may be adversely affected, our ability to prevent material misstatements in our consolidated financial statements could be impaired, a material misstatement in our consolidated financial statements could occur and we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports, which could cause our business to suffer and our stock price to decline.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since becoming a publicly traded company in 2019, we have increased the headcount of our accounting and finance functions to further support the demands placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley&#8221;). We expect to continue expending significant time and resources related to our internal control over financial reporting, including by further expanding our finance and accounting staff over time, but there can be no assurance our efforts will be effective.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital to fund our existing operations, commercialize new products or expand our operations.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash and cash equivalents and anticipated cash generated from sales of our products will be sufficient to fund our operations for the foreseeable future. If our available cash and cash equivalents and anticipated cash generated from sales of our products are insufficient to satisfy our liquidity requirements including because of lower demand for our products, lower than currently expected rates of reimbursement from third-party payors or other risks described in this Quarterly Report on Form 10&#8209;Q, we may finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our sales and marketing efforts for the DecisionDx-Melanoma, DecisionDx-SCC, DiffDx-Melanoma, MyPath Melanoma, DecisionDx-UM, TissueCypher and IDgenetix tests and address competitive developments among these or future commercial products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fund ongoing evidence development for our existing products as well as additional pipeline programs;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our laboratory testing facility and related testing capacity;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our technologies into other types of skin cancer, ocular cancer, gastrointestinal or mental health management and detection products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire, license or invest in technologies;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or invest in complementary businesses or assets; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">finance capital expenditures and general and administrative expenses.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve revenue growth;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rate of progress in establishing payor coverage and reimbursement arrangements with third-party payors;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rate of progress in, and cost of the sales, marketing, coverage and reimbursement activities associated with, establishing adoption of our lead product, DecisionDx-Melanoma, among our other products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of expanding our laboratory operations and offerings, including our sales, marketing, coverage and reimbursement efforts;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rate of progress in, and cost of research and development activities associated with, diagnostic products in research and early development;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential cost of, and delays in, the development of new products as a result of changes in regulatory oversight applicable to our products; </span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions of businesses, assets, products or technologies;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the duration and effects of elevated inflation;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects on our operations of general political and economic conditions, including the COVID-19 pandemic, the invasion of Ukraine by Russia, economic slowdowns, recessions or market corrections, the duration and effects of elevated inflation, rising interest rates and tightening of credit markets resulting from the pandemic, the conflict or another cause; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or products, or grant licenses on terms that may not be favorable to us. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruptions to, or volatility in, the credit and financial markets or any deterioration in overall economic conditions, resulting from the pandemic, the conflict or another cause, may make any necessary debt or equity financing more difficult to obtain, more costly and/or more dilutive. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our commercialization, research and development efforts or grant rights to third parties to market and/or develop products that we would otherwise prefer to market and develop ourselves.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_154"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue currently depends primarily on sales of DecisionDx-Melanoma, and we will need to generate sufficient revenue from this and other products to grow our business.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our revenue in 2021 and 2020 was derived from the sale of our lead product, DecisionDx-Melanoma. While we also derive revenue from DecisionDx-UM, DecisionDx-SCC, our Diagnostic GEP offering (which consists of MyPath Melanoma and DiffDx-Melanoma), the TissueCypher Barrett&#8217;s Esophagus Assay and the IDgenetix test, we expect that the majority of our revenue for the foreseeable future will be derived from sales of DecisionDx-Melanoma. Further, we believe that our long-term commercial success will depend on our ability to develop and market additional products. Our ability to derive revenue from DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, the TissueCypher Barrett&#8217;s Esophagus Assay, the IDgenetix test and any future products that we commercialize or acquire is uncertain and depends on favorable coverage and reimbursement policies from government payors, such as Medicare, and from private payors, such as insurance companies. Without positive coverage policies, our products may not be reimbursed and we may not be able to recognize revenue. If we are unable to increase sales and expand coverage and reimbursement for DecisionDx-Melanoma, develop and commercialize other products, and successfully obtain coverage and adequate reimbursement for such products, our revenue and our ability to achieve profitability would be impaired, and the market price of our stock could decline substantially.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has adversely impacted and could continue to adversely impact our business, including the demand for our test reports, as well as the business or operations of physicians and other healthcare providers who order our test reports and the third-party payors responsible for reimbursement for our tests, customers and other third parties with whom we conduct business.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks have adversely impacted and could continue to adversely impact our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the ongoing COVID-19 pandemic, or public health crises, and federal, state and local government responses to these events, we have and/or may in the future experience disruptions that could adversely impact our business, including, but not limited to:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased test report volume due to a decline in orders of DecisionDx-Melanoma and DecisionDx-UM tests as patient visits for routine examinations and biopsies have been, and may continue to be, delayed and/or canceled;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our sales and commercialization activities due to limitations on our ability to communicate with physicians as a result of travel restrictions and hindered means of communicating with physicians;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions by third parties in the collection, preparation or delivery of the tumor samples that we test;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in delivering test reports, interruptions in research and development and other limitations of key business activities due to members of our workforce becoming ill, compliance with applicable vaccination mandates and/or stay-at-home or other similar orders imposed by or that may be imposed by state and local governments, including at our Phoenix, Arizona, San Diego, California, Pittsburgh, Pennsylvania and Friendswood, Texas locations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delayed reimbursement from third-party payors, disruption in our supply channel and other adverse impacts on our business resulting from the negative effects of the COVID-19 pandemic on our suppliers, service providers and other third parties on whom we rely; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delayed or postponed interactions with regulators and other important agencies and contractors, due to limitations in employee resources, travel restrictions or forced furlough of government employees.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the onset of the COVID-19 pandemic, we experienced declines in orders and test report volume in certain periods. For example, in the second quarter of 2020, test reports delivered for our lead product, DecisionDx-Melanoma, decreased 18.5% compared to the second quarter of 2019. We believe these decreases in our test report volume were linked to delays and/or cancellations in patient visits, resulting in fewer diagnostic biopsies and thus a reduction in the number of diagnoses of cutaneous melanoma in response, as well as the cumulative impact on promotional responsiveness as a result of reduced sales calls per day and in-person sales calls during the ongoing COVID-19 pandemic. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future results will be dependent upon the extent and duration of the COVID-19 crisis, including the emergence and spread of variants of the virus, and government restrictions, which are beyond our control. Although state and local government restrictions put in place to slow the spread of the virus have been eased in most locations, restrictions may be reinstated from time to time in various regions depending on the circumstances, potentially impacting the flow of future patient visits as well as access to our sales targets. Even with the easing of state and local restrictions and the availability of vaccinations, patient visits and diagnoses of the diseases covered by our diagnostic and prognostic tests may be impacted by continued apprehension regarding possible exposure to the virus as well as a general shift from in-person clinical visits to telehealth approaches, which may result in missed or delayed diagnoses of skin cancer and other diseases.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under legislation enacted (or that may be enacted) by the United States federal government to respond to COVID-19, we have received and may receive in the future, cash payments or other forms of assistance allocated to healthcare and other companies. The eligibility requirements for any such payments or other assistance may be subject to restrictive terms and conditions, which may be ambiguous or subject to further modification, interpretation and guidance issued by government agencies on an ongoing basis. In the event we fail to comply with any of the terms or conditions associated with a payment we receive or if the terms and conditions or related interpretations change, we may be required to return it. The receipt of government payments or other assistance during the COVID-19 crisis has generated negative publicity for some companies and may continue to generate negative publicity for companies in the future. If we receive any negative publicity as a result of receiving or accepting a government payment or other assistance, such as the $1.9 million in provider relief funds we received from The U.S. Department of Health and Human Services (&#8220;HHS&#8221;) on April 16, 2020, it could harm our reputation, trigger a review or audit by applicable government agencies and/or adversely impact our stock price.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 crisis continues to evolve. The extent to which COVID-19 will further impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the crisis, resurgences of the virus, the emergence and spread of variants of the virus, vaccination rates, vaccination mandates, vaccination effectiveness, therapeutic treatments, the use of telemedicine, travel restrictions, stay-at-home or other similar orders and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the virus. Any of these factors, individually or in combination, could materially and adversely affect our business, results of operations, financial condition or cash flows. In addition, the current and potential adverse impacts of the COVID-19 crisis on our business, financial condition, results of operations and growth prospects, may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing for our products is complex and requires substantial time and resources to collect payment.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for clinical laboratory testing services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payors, including Medicare, Medicaid, private insurance companies, private healthcare institutions, and patients, all of which have different billing requirements. We generally bill third-party payors for products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of accounts receivable and long collection cycles, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several factors make the billing process complex, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences between the billing rates and reimbursement rates for our products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare, Medicaid, Veterans Health Administration and TRICARE;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk of government audits related to billing;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes among payors as to which party is responsible for payment;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differences in coverage and information and billing requirements among payors, including the need for prior authorization and/or advanced notification;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of patient co-payments or co-insurance and our ability to collect such payments from patients;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to billing codes used for our products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to requirements related to our current or future clinical studies, including our registry studies, which can affect eligibility for payment;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing monitoring provisions of LCDs for our products, which can affect the circumstances under which a claim would be considered medically necessary;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incorrect or missing billing information; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use standard industry billing codes, known as Current Procedural Terminology codes, to bill for our products. If these codes were to change, there is a risk of an error being made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment we receive.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we introduce new products, we may need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. When payors deny our claims, we may challenge the reason, low payment amount or payment denials. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) requires providers and suppliers to report and return any overpayments received from government payors under the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under federal false claims laws. These billing complexities, and the related uncertainty in obtaining payment for our products, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the complexities noted above, we rely upon a third-party software application in the administration of our billing and collection process. Any significant disruption in our billing operations or the discovery of a deficiency in the design of our billing process could adversely impact our ability to generate and send invoices, calculate revenues, track payments and collect our accounts receivable. Although to date we have not experienced any disruptions or identified any deficiencies with our billing process or billing system, there can be no assurances that any disruptions or deficiencies will not occur in the future. Additionally, any failure in the design or operation of our internal controls related to our billing and collection processes could adversely impact our ability to conclude on the effectiveness of our internal control over financial reporting and could cause our auditor to issue an adverse opinion on our internal control over financial reporting.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties for tissue sample collection, preparation and delivery. Any defects in sample collection or preparation by such third parties and any delays in delivery of such samples could cause errors in our test reports and delay our ability to deliver test reports in a timely manner, which could significantly harm our business.* </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tissue samples that we test are biopsied, preserved, prepared and delivered to us by third parties, including dermatopathologists and laboratory facilities. As such, we rely on these third parties to prepare, label and deliver the tissue samples that we test in compliance with applicable laws and guidelines, and in a timely manner. Therefore, the accuracy and correctness of the test reports that we deliver are dependent on proper chain of custody and appropriate methods of sample collection or preparation utilized by these third parties, and our ability to timely deliver reports is dependent upon the ability of these third parties to provide these samples to us in a timely manner. The ability of these third parties to provide these samples to us in a timely manner could be delayed by events beyond our control, including but not limited to natural disasters and public health epidemics, such as the COVID-19 pandemic. Any errors in any part of the sample collection or preparation process could cause us to deliver incorrect test reports, potentially resulting in harm to patients whose physicians implement a change in treatment decisions based upon our test report. If we are unable to timely deliver test reports, physicians may be less likely to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommend and order our products. The occurrence of any of the foregoing could significantly harm our reputation and our results of operations, causing significant harm to our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our database of samples for the development and improvement of our products. Depletion or loss of our samples could significantly harm our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and validation of accurate products is a complex process that requires access to tissue specimens and long-term outcomes data. Our research and development efforts to improve our existing commercial products and develop new pipeline products may require the depletion of our existing database of samples. If our samples are lost or destroyed, or substantially depleted before we are able to generate meaningful data, we may be unable to improve our existing products, continue the development of pipeline products or validate product candidates. While we have historically been able to create and maintain a large sample bank to expand the clinical use of our products and develop new products, we may be unable to do so in the future. If we were unable to maintain or replenish our sample bank, we may be unable to improve our products or develop new products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our primary clinical laboratory facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to conduct our laboratory analysis and pursue our research and development efforts may be jeopardized.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently perform most of our testing and store our database of tumor samples at our primary clinical laboratory facility in Phoenix, Arizona. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure, terrorism, burglary, public health crises (including restrictions that may be imposed on businesses by state and local governments under stay-at-home or similar orders and mandates) or other events, which may make it difficult or impossible for us to perform our testing services for some period of time or to receive and store samples. The inability to perform tests or to reduce the backlog of sample analysis that could develop if our facility becomes inoperable, for even a short period of time, may result in the loss of revenue, loss of customers or harm to our reputation, and we may be unable to regain that revenue, those customers or repair our reputation in the future. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters and man-made disasters or other sudden, unforeseen and severe adverse events.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the loss of our tissue samples due to such events could limit or prevent our ability to conduct research and development analysis on existing tests as well as tests in active pipeline development.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have a business continuity plan in place, and have an additional laboratory facility in close proximity to our primary facility to support our growth and provide certain operational redundancy, our facilities and the equipment we use to perform our testing and research and development could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify a new facility, replace certain pieces of equipment or license or transfer our proprietary technology to a third-party, particularly in light of licensure and accreditation requirements. Even in the unlikely event that we are able to find a third party with such qualifications to enable us to resume our operations, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future products may not achieve or maintain significant commercial market acceptance.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our commercial success is dependent upon our ability to continue to successfully market and sell our products, to continue to expand our current relationships and develop new relationships with healthcare providers, to expand and maintain coverage for our products, and to develop and commercialize new products. Our ability to achieve and maintain commercial market acceptance of our existing and future products will depend on a number of factors, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to increase awareness of our products through successful clinical utility and validity studies;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of adoption of our products by physicians and other healthcare providers;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve guideline inclusion for our products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timeliness with which we can provide our clinical reports to the ordering physician;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and scope of any regulatory approval for our products, if such approvals become required, and maintaining ongoing compliance with regulatory requirements;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain positive coverage decisions for our products from government and commercial payors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain adequate reimbursement from third-party payors, including Medicare, Medicare Advantage plans and BlueCross BlueShield plans, which accounted for an aggregate of approximately 92% and 93% of our total revenue for the years ended December 31, 2021, and 2020, respectively;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of our investments in research and development and commercial growth;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative publicity regarding our or our competitors&#8217; products resulting from scientific publications, or defects or errors in the products; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to further validate our products through clinical research and accompanying publications.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that we will be successful in addressing each of these factors or other factors that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining market acceptance of our products, our business and results of operations will suffer.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New product development involves a lengthy and complex process, and we may be unable to develop and commercialize, or receive reimbursement for, on a timely basis, or at all, new products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually seek to develop new product offerings, which requires us to devote considerable resources to research and development. Before we can commercialize a new pipeline product, we will need to expend significant resources in order to conduct substantial research and development, including clinical utility and validity studies, and further develop and scale our laboratory processes and infrastructure to accommodate additional products. For example, in 2021, we launched our innovative pipeline to develop a genomic test aimed at predicting response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related inflammatory skin conditions. We have initiated a 4,800 patient, prospective, multi-center clinical study to develop and validate this inflammatory skin disease pipeline test with the expectation of having initial validation and development data in 2023 and in launching this pipeline test by the end of 2025.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development process takes time and involves a high degree of risk, and such development efforts may fail for many reasons, including failure of the product to perform as expected, failure to successfully complete analytic and clinical validation, or failure to demonstrate the clinical utility of the product.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop new products, we will have to make significant investments in research and development, marketing, selling, coverage and reimbursement activities. Typically, few research and development projects result in a commercialized product, and there can be no assurance that we will be able to successfully develop new products that can be commercialized. At any point, we may abandon development of a product or we may be required to expend considerable resources conducting research, which would adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study or if we fail to sufficiently demonstrate analytical validity or clinical utility, we might choose to abandon the development of the product, which could harm our business. In addition, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience limits on our revenue if we are unable to increase and support adoption of our products by physicians and other healthcare providers.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians and other healthcare providers may be unwilling to adopt our products due to their reliance on existing traditional clinical and pathology staging criteria and our ability to generate revenue from our products would be significantly impaired if we were unable to educate physicians, healthcare providers, patients and third-party payors about the benefits and advantages of our products. The COVID-19 crisis has impacted our in-person healthcare interactions, such as field-based sales and medical affairs, and we have had to convert visits, programs and projects to be performed online and by telephone. Although our in-person healthcare interactions have returned to more normal levels, they may become subject to restrictions or cancellations from time to time, due to the uncertainties surrounding the duration, extent and ongoing impacts of the COVID-19 crisis, possibly impacting the effectiveness of our efforts. We will need to continue to educate physicians and pathologists about the benefits and cost-effectiveness of our products through published papers, presentations at scientific conferences, one-on-one marketing efforts by our sales force and one-on-one education by our medical affairs team. However, physicians and other healthcare providers may be reluctant to adopt our products in circumstances where our products are not incorporated into the current standard of care or practice guidelines. For example, while clinical utility of DecisionDx-Melanoma has been demonstrated in peer-reviewed publications, the SLNB surgery is the most widely used staging tool for determining a cutaneous melanoma patient&#8217;s metastatic risk. Whether healthcare providers adopt DecisionDx-Melanoma as a complementary or triage diagnostic method relative to the SLNB surgery will depend on our ability to increase awareness of DecisionDx-Melanoma and its clinical validation.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all of our testing services are performed by our certified laboratories located in Phoenix, Arizona, San Diego, California and Pittsburgh, Pennsylvania, under the Clinical Laboratory Improvement Amendments of 1988 (&#8220;CLIA&#8221;) rather </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than by local laboratory or pathology practices. Accordingly, it may be difficult for us to collect samples from pathologists, and pathologists may be reluctant to support our testing services.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on limited or sole suppliers for some of the reagents, equipment, chips and other materials used by our products, and we may not be able to find replacements or transition to alternative suppliers.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on limited or sole suppliers for certain reagents and other materials and components that we use for our products. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. If these suppliers can no longer provide us with the materials we need, if the materials do not meet our quality specifications or are otherwise unusable, if we cannot obtain acceptable substitute materials, or if we elect to change suppliers, an interruption in laboratory operations could occur, we may not be able to deliver patient reports on a timely basis, or at all, and we may incur higher one-time switching costs. Any such interruption may significantly affect our future revenue, cause us to incur higher costs, and harm our customer relationships and reputation. In addition, in order to mitigate these risks, we maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available. If our testing volume decreases or we switch suppliers, we may hold excess supplies with expiration dates that occur before use which would adversely affect our losses and cash flow position. As we introduce any new products, we may experience supply issues as we ramp up test volume, or encounter additional disruptions to trade, commerce, pricing stability, credit availability and global supply chain continuity as a result of the invasion of Ukraine by Russia, particularly if we contract with suppliers with operations or commercial relationships in Eastern Europe or to the extent the conflict escalates to involve additional countries, further economic sanctions or wider military conflict. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment, reagents or other materials we require for our products, our business, financial condition, results of operations and reputation could be adversely affected.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products do not meet the expectations of physicians and patients, our operating results, reputation and business could suffer.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on physician and patient confidence that we can provide reliable, high-quality information that will improve treatment outcomes, lower healthcare costs and enable better patient care. We believe that patients, physicians and other healthcare providers are likely to be particularly sensitive to defects and errors in our products, including if our products fail to accurately predict risk of metastasis with high accuracy from samples, and there can be no guarantee that our products will meet their expectations. As a result, the failure of our products to perform as expected could significantly impair our operating results and our reputation, including if we become subject to legal claims arising from any defects or errors in our products or reports.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to compete successfully, our business will suffer and we may be unable to increase or sustain our revenue or achieve profitability.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from companies and academic institutions that have either developed or may seek to develop products intended to compete with our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may develop their own versions of our solutions in countries where we do not have patents or where our intellectual property rights are not recognized and compete with us in those countries, including encouraging the use of their solutions by physicians in other countries.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some potential competitors may have longer operating histories, larger customer bases, greater brand recognition and market penetration, substantially greater financial, technological and research and development resources and selling and marketing capabilities, and more experience dealing with third-party payors. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their products than we do or sell their products at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations. Increased competition and cost-saving initiatives on the part of governmental entities and other third-party payors are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain potential competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to test development than we can. In addition, companies or governments that control access to testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain services. If we are unable to compete successfully against current and future competitors, our business will suffer and we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline. As we add new tests and services, we will face many of these same competitive risks for these new tests.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the total addressable markets for the DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher and IDgenetix tests are based on a number of internal and third-party estimates, including, without limitation, the annual rate of patients with the applicable indications, the list price of our products relative to the reimbursement we expect to receive from third-party payors and the assumed prices at which we can sell our products in markets that have not been established. For example, we estimate that the total addressable market for DecisionDx-Melanoma is approximately $540 million, which is based, in part, on our review of multiple publications which show that diagnosis of melanoma is underreported by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30% to 72%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell future products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The diagnostic testing industry is subject to rapid change, which could make our current or future products obsolete.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current products and the other products we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of physicians and patients on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our existing products and develop new products to keep pace with evolving standards of care. If we do not update our products to reflect new scientific knowledge about cancer biology, information about new cancer therapies or relevant clinical studies, our products could become obsolete and sales of our current products and any new products we develop could decline or fail to grow as expected.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_157"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reimbursement and Government Regulation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have limited reimbursement coverage for our lead product, DecisionDx-Melanoma, and if third-party payors, including government and commercial payors, do not provide sufficient coverage of, or adequate reimbursement for, our products, our commercial success, including revenue, will be negatively affected.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends on achieving broad coverage and adequate reimbursement for our products from third-party payors, including both government and commercial third-party payors. If third-party payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the list price of our products, we may need to seek additional payment from the patient beyond any co-payments and deductibles, which may adversely affect demand for our products. Coverage determinations by a third-party payor may depend on a number of factors, including, but not limited to, a third-party payor&#8217;s determination of whether our products are appropriate, medically necessary or cost-effective. If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our products, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our products may decrease as we encounter pricing pressure from these competitors.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since each third-party payor makes its own decision as to whether to establish a policy to cover our products, enter into a contract with us and set the amount it will reimburse for a product, these negotiations are a time-consuming and costly process, and they do not guarantee that the third-party payor will provide coverage or adequate reimbursement for our products. In addition, the determinations by a third-party payor whether to cover our products and the amount it will reimburse for them are often made on an indication-by-indication basis.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the product, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our claims for reimbursement from third-party payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive and may not result in payment. Third-party payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the third-party payors believe the funds were paid in error or determine that our products were medically unnecessary. If a third-party payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial third-party payors for whom we are not a participating provider may elect at any time </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to review claims previously paid and determine the amount they paid was too much. In these situations, the third-party payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We cannot predict when, or how often, a third-party payor might engage in these reviews and we may not be able to dispute these retroactive adjustments. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, we recognize revenue at the amount we expect to be entitled, subject to a constraint for variable consideration, in the period in which our tests are delivered to the treating physician. We have determined that our contracts contain variable consideration under ASC 606 because the amounts paid by third-party payors may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration is recognized only to the extent it is probable that a significant reversal of revenue will not occur in future periods when the uncertainties are resolved. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Variable consideration for Medicare claims that are not covered by an LCD or otherwise, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. For these fully constrained claims, we generally recognize revenue in the period the uncertainties are resolved, if favorable. Due to potential future changes in Medicare coverage policies and appeal cycles, insurance coverage policies, contractual rates and other trends in the reimbursement of our tests, our revenues may fluctuate significantly from period to period.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are an in-network participating provider with some commercial third-party payors, including several Blue Cross Blue Shield plans, and certain large, national commercial third-party payors, including Aetna, other commercial third-party payors have issued non-coverage policies that currently categorize our tests as experimental or investigational. If we are not successful in obtaining coverage from third-party payors, in reversing existing non-coverage policies, or if other third-party payors issue similar non-coverage policies, this could have a material adverse effect on our business and operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Palmetto, the MAC responsible for administering MolDX, the program that assesses molecular diagnostic technologies, issued a final LCD for DecisionDx-Melanoma, which became effective on December 3, 2018, and issued a final expanded LCD effective November 22, 2020. This LCD provides for coverage of DecisionDx-Melanoma for certain SLNB-eligible patients with cutaneous melanoma tumors with clinically negative sentinel node basins who are being considered for SLNB to determine eligibility for adjuvant therapy. The final expanded LCD also covers use of DecisionDx-Melanoma by physicians for assessment of appropriate treatment plans, regardless of the decision to undergo or avoid the SLNB surgery. In the second quarter of 2021, Palmetto and the other MACs that participate in the MolDX program each released a revised draft LCD for DecisionDx-Melanoma. The draft LCD included commentary about two publications regarding the clinical utility of GEP tests and included an assessment stating that the new data is not sufficient to change the coverage criteria. There was an open public comment period, and we submitted comments in support of Medicare coverage. The comment period ended on August 8, 2021. Palmetto issued a final LCD on May 19, 2022 with Noridian issuing the same on June 16, 2022. The final LCDs did not result in any change in coverage. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, Palmetto issued a final LCD for DecisionDx-UM effective July 10, 2017. This LCD provides for coverage of DecisionDx-UM to determine metastatic risk in connection with the management of a patient&#8217;s newly diagnosed UM and to guide surveillance and referral to medical oncology for those patients. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We worked with Palmetto to obtain these positive coverage decisions through the submission of a detailed dossier of analytical and clinical data to substantiate that the tests meet Medicare&#8217;s medical necessity requirements. Per their joint operating agreement, Noridian, the MAC responsible for administering claims for laboratory services performed in Arizona, has adopted the same coverage policy as Palmetto for DecisionDx-UM and DecisionDx-Melanoma. This coverage process is lengthy, time-consuming, has changed over time, may change in the future and requires significant dedication of resources, and as we develop new products, we may be unsuccessful in receiving LCD determinations for those products or in maintaining our current LCDs. On a periodic basis, CMS requests bids for its MAC services, and MAC jurisdictions have changed in the past. A change in our MAC, or future changes in the MolDX program, the elimination of the program, or a change in the administrator of that program, may affect our ability to obtain Medicare coverage and reimbursement for products for which we have coverage, for products for which we do not yet have coverage, or for any products we may launch in the future, or delay payments for our tests.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare, payment for products like ours is generally made under the CLFS with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;) which included substantial changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, certain laboratories are required to report to CMS commercial third-party payor payment rates and volumes for each test they perform. CMS uses this data to calculate a weighted median payment rate for each test, which will be used to establish revised Medicare CLFS reimbursement rates for the test. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. We bill Medicare for our products, and therefore we are subject to reporting requirements under PAMA.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, we submitted our technical assessment dossier for DecisionDx-SCC to Palmetto and Noridian. The dossier was accepted as complete in the third quarter of 2020. In early 2021, we submitted our technical assessment dossier for DiffDx-Melanoma. The dossier was accepted as complete in the first quarter of 2021. In June 2022, Palmetto and Noridian each posted a draft LCD that would provide coverage criteria for DiffDx-Melanoma. We believe the LCD for DiffDx-Melanoma will be finalized by the end of the second quarter of 2023. However, there is no assurance that any draft or final LCD will match our expectations, be posted in a timeframe consistent with our historical experience or will be posted at all. Regarding DecisionDx-SCC, no draft LCD has been posted by Palmetto or Noridian to date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, following the completion of a requested medical review and pricing of our DecisionDx-SCC test by Novitas, we have been receiving reimbursement from Novitas on DecisionDx-SCC at a rate of approximately $3,800 per test. On June 9, 2022, Novitas posted a draft oncology biomarker LCD that proposes to rely upon evidentiary reviews sourced from three databases: ClinGen, OncoKB and NCCN. Two of the databases do not review gene expression profile tests and NCCN has not yet, to our knowledge, reviewed DecisionDx-SCC. As such, if finalized as proposed, then DecisionDx-SCC would not be included as a covered test in the associated billing and coding article. We cannot predict whether this draft LCD will be finalized as proposed or what the timing of any final LCD might be.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain and maintain adequate reimbursement rates from commercial third-party payors, this may adversely affect our Medicare rate. It is unclear what impact new pricing structures, such as those adopted under PAMA, may have on our business, financial condition, results of operations or cash flows.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government continues to show significant interest in pursuing healthcare reform and reducing healthcare costs. Similarly, commercial third-party payors may seek to reduce costs by limiting coverage or reducing reimbursement for our products. Any government-adopted reform measures or changes to commercial third-party payor coverage and reimbursement policies could cause significant pressure on the pricing of, and reimbursement for, healthcare products and services, including our products, which could decrease demand for our products, and adversely affect our sales and revenue.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some third-party payors have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it could have a negative impact on our revenue in the short term. It is possible that third-party payors will resist reimbursement for the products that we offer, in favor of less expensive products, may require pre-approval for our products or may impose additional pricing pressure on and substantial administrative burden for reimbursement for our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to focus substantial resources on increasing coverage and reimbursement for our current products and any future products we may develop. We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of third-party payors for our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we cannot predict whether, under what circumstances, or at what payment levels third-party payors will cover and reimburse our products. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for, our products, our ability to generate revenue could be harmed and our future prospects and our business could suffer.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are currently marketed as laboratory developed tests, and any changes in regulations or the FDA&#8217;s enforcement discretion for laboratory developed tests, or violations of regulations by us, could adversely affect our business, prospects, results of operations or financial condition.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diagnostics industry is highly regulated, and we cannot assure you that the regulatory environment in which we operate will not change significantly and adversely in the future. In many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are designed, manufactured and used within a single laboratory. These tests are referred to as laboratory developed tests (&#8220;LDTs&#8221;). We currently market our products as LDTs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has adopted a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively require premarket review of LDTs or otherwise impose its requirements applicable to other medical devices on LDTs. However, the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. The FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of additional regulatory requirements. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs. If and when such changes to the regulatory framework occur, we could for the first time be subject to enforcement of regulatory requirements as a device manufacturer such as registration and listing requirements, medical device reporting requirements and the requirements of the FDA&#8217;s Quality System Regulation. We may be required to conduct clinical trials prior to continuing to sell our existing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or launching any other products we may develop. This may increase the cost of conducting, or otherwise harm, our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if the FDA does not modify its policy of enforcement discretion, the FDA may disagree that we are marketing our LDTs within the scope of its policy of enforcement discretion and may impose significant regulatory requirements. While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure you that the FDA will agree with our determination. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA begins to actively regulate our diagnostic products, we may be required to obtain premarket clearance under Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;) or a premarket approval (&#8220;PMA&#8221;). The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer, and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. Despite the time, effort and expense expended, there can be no assurance that a particular device ultimately will be cleared or approved by the FDA through either the 510(k) clearance process or the PMA process on a timely basis, or at all. Moreover, there can be no assurance that any cleared or approved labeling claims will be consistent with our current claims or adequate to support continued adoption of and reimbursement for our products. If premarket review is required for some or all of our products, the FDA may require that we stop selling our products pending clearance or approval, which would negatively impact our business. Even if our products are allowed to remain on the market prior to clearance or approval, demand or reimbursement for our products may decline if there is uncertainty about our products, if we are required to label our products as investigational by the FDA, or if the FDA limits the labeling claims we are permitted to make for our products. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our products, or from other pipeline products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA imposes significant changes to the regulation of LDTs it could reduce our revenues or increase our costs and adversely affect our business, prospects, results of operations or financial condition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We conduct business in a heavily regulated industry, and failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diagnostics industry is highly regulated, and the laws and regulations governing the marketing of diagnostic tests are extremely complex. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws applicable to test ordering, documentation of tests ordered, billing practices and claims payment and/or regulatory agencies enforcing those laws and regulations;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state fraud and abuse laws;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laboratory anti-mark-up laws;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement levels by Medicare, Medicaid, other governmental payors and private insurers;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on coverage of and reimbursement for tests;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws governing laboratory testing, including CLIA, and state licensing laws and accreditation requirements;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws and enforcement policies governing the development, use and distribution of diagnostic medical devices, including LDTs;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state and local laws governing the handling and disposal of medical and hazardous waste;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state Occupational Safety and Health Administration rules and regulations; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and similar state health data privacy laws.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the FDCA defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our products are considered by the FDA to be subject to regulation as medical devices, and marketed under FDA&#8217;s policy of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcement discretion for LDTs. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices manufactured between the United States and international markets.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations establish specific standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. Any testing subject to CLIA regulation must be performed in a CLIA-certified or accredited lab. CLIA certification or accreditation is also required in order for us to be eligible to bill state and federal healthcare programs, as well as commercial third-party payors, for our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a current CLIA accreditation under the College of American Pathologists (&#8220;CAP&#8221;) program to conduct our tests at our clinical reference laboratory in Phoenix, Arizona. In April 2022, we acquired a laboratory in San Diego, California which is currently CLIA-certified and CAP accredited. Additionally, our laboratory in Pittsburgh, Pennsylvania, which we acquired in December of 2021, is currently CLIA-certified and we are working through the application and inspection process toward CAP accreditation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAP maintains a clinical laboratory accreditation program. While not required for the operation of a CLIA-certified laboratory, many private insurers require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. In addition, some countries outside the United States require CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens. CAP accredited laboratories are surveyed for compliance with CAP standards every two years in order to maintain accreditation. Failure to maintain CAP accreditation could have a material adverse effect on the sales of our products and the results of our operations. Therefore, to maintain our CLIA accreditation, we have elected to be subject to survey and inspection every two years by CAP. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most recent CAP inspection occurred in March 2022 for our Phoenix, Arizona laboratory. Our CLIA accreditation certificate for our Pittsburgh, Pennsylvania laboratory expires on December 20, 2022, and the certificate for our San Diego, California laboratory expires in 2024. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain states require our laboratory to be licensed in such states in order to test specimens from those states. Accordingly, our laboratory is also licensed by California, Maryland, New York, Pennsylvania and Rhode Island. Other states may have similar requirements or may adopt similar requirements in the future.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to test specimens from New York, LDTs must be approved by the New York State Department of Health (&#8220;NYSDOH&#8221;) on a test-by-test basis before they are offered. Our laboratory director must also be separately qualified to be a laboratory director in New York. DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-SCC, DiffDx-Melanoma and IDgenetix have each been formally approved. In July 2022, we submitted TissueCypher for review by NYSDOH and expect a response in the first quarter of 2023. Our laboratory director has been qualified by NYSDOH. We are subject to periodic inspection by NYSDOH and are required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to remedy such non-compliance, the State of New York could withdraw approval for our products. We will need to seek NYSDOH approval of any future LDTs we develop and want to offer for clinical testing to New York residents, and there can be no assurance that we will be able to obtain such approval.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our products or such jurisdictions adopt new licensure requirements, which may require review of our products in order to offer them or may have other limitations such as restrictions on the transport of human tissue samples necessary for us to perform our tests that may limit our ability to make our products available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA accreditation and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory&#8217;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA accreditation, or a state or foreign license, could have a material adverse effect on our business, financial condition </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business with the public sector, including the U.S. government, subjects us to risk of audits, investigations, sanctions and penalties.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may enter into in the future, contracts with the U.S. government or other governmental entities, and this subjects us to statutes and regulations applicable to companies doing business with the government. Government contracts normally contain additional requirements that may increase our costs of doing business, reduce our profits (or increase our losses) and expose us to liability for failure to comply with these terms and conditions. Such requirements may include mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action programs and environmental compliance requirements. Being a government contractor also subjects us to reviews, audits and investigations regarding our compliance. If we fail to comply with our obligations associated with being a government contractor, our contracts may be subject to termination, and we may be subject to financial and/or other liability under our contracts, which could adversely affect our results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may modify its enforcement discretion policy with respect to LDTs in a risk-based manner, and we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA changes or ends its policy of enforcement discretion with respect to LDTs, and our products become subject to the FDA&#8217;s requirements for premarket review of medical devices, we may be required to cease commercial sales of our products and conduct clinical trials prior to making submissions to the FDA to obtain premarket clearance or approval. If we are required to conduct such clinical trials, delays in the commencement or completion of clinical trials could significantly increase our product development costs and delay commercialization of any currently marketed testing that we may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices, known as the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; labeling regulations, including the FDA&#8217;s general prohibition against promoting products for unapproved or &#8216;&#8216;off-label&#8217;&#8217; uses; and the reports of corrections and removals regulation, which requires manufacturers to report to the FDA if a device correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we were able to obtain FDA clearance or approval for one or more of our products, if required, a diagnostic test may be subject to limitations on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the test.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approvals. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing authorization that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical studies that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical studies that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and marketing efforts.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including healthcare providers or payors, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding our business. If the topline or interim data that we report differ from actual results, or if others, including healthcare providers or payors, disagree with the conclusions reached, our ability to commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare policy could increase our costs, decrease our revenues and impact sales of and reimbursement for our products.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA became law. This law substantially changed the way healthcare is financed by both government and commercial third-party payors, and significantly impacted our industry. The ACA contains a number of provisions that are expected to impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in state and federal healthcare programs, reimbursement changes and fraud and abuse, which impact existing state and federal healthcare programs and will result in the development of new programs. Among other things, the ACA required medical device manufacturers to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices, and began to apply to sales of taxable medical devices after December 31, 2012, but was suspended in 2016. Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the medical device tax and &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and, effective January 1, 2021, also eliminated the health insurer tax.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, there have been efforts to repeal all or part of the ACA, and the previous administration and the U.S. Congress have taken action to roll back certain provisions of the ACA.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect through 2030, unless additional Congressional action is taken. The CARES Act and other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020, through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures as part of other reform initiatives.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial third-party payors to reduce costs while expanding individual healthcare benefits. For example, it is possible that additional governmental action is taken in response to the COVID-19 crisis. Certain of these changes could impose additional limitations on the prices we will be able to charge for our products, the coverage of or the amounts of reimbursement available for our products from third-party payors, including government and commercial payors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to numerous federal and state healthcare statutes and regulations, and complying with laws pertaining to our business is an expensive and time-consuming process. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties and a material adverse effect to our business and operations.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians, other healthcare providers and third-party payors play a primary role in the recommendation of our products. Our arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that affect the business and financial arrangements and relationships through which we market and sell our products. The laws that affect our ability to operate include, but are not limited to:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute (&#8220;AKS&#8221;), which prohibits, among other things, any person or entity from knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8216;&#8216;remuneration&#8217;&#8217; has been broadly interpreted to include anything of value, such as specimen collection materials or test kits. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, however these are drawn narrowly. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and monetary penalties of up to $100,000 for each violation, plus up to three times the remuneration involved, imprisonment of up to ten years and exclusion from government healthcare programs. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act (&#8220;FCA&#8221;);</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, civil monetary penalties and exclusion from the federal healthcare programs. Failure to refund amounts received as a result of a prohibited referral on a timely basis may constitute a false or fraudulent claim and may result in civil penalties and additional penalties under the FCA;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, such as the FCA, which can be enforced by private citizens through civil qui tam action, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented through distribution of template medical necessity language or other coverage and reimbursement information, false, fictitious or fraudulent claims for payment or approval by the federal government, including federal healthcare programs, such as Medicare and Medicaid, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Private individuals can bring False Claims Act &#8216;&#8216;qui tam&#8217;&#8217; actions, on behalf of the government and such individuals, commonly known as &#8216;&#8216;whistleblowers,&#8217;&#8217; may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;) prohibits payments for referrals to recovery homes, clinical treatment facilities, and laboratories. EKRA&#8217;s reach extends beyond federal healthcare programs to include private insurance (i.e., it is an &#8220;all payor&#8221; statute). For purposes of EKRA, the term &#8220;laboratory&#8221; is defined broadly and without reference to any connection to substance use disorder treatment. The law includes a limited number of exceptions, some of which closely align with corresponding federal Anti-Kickback Statute exceptions and safe harbors, and others that materially differ;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, in connection with the delivery of or payment for healthcare benefits, items or services. Like the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, which imposes privacy, security and breach reporting obligations with respect to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform services for them that involve individually identifiable health information as well as their covered subcontractors. Failure to comply with the HIPAA&#8217;s obligations can result in civil monetary penalties, and, in certain circumstances, criminal penalties. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that prohibit other specified practices, such as billing physicians for tests that they order or providing tests at no or discounted cost to induce physician or patient adoption; insurance fraud laws; waiving coinsurance, copayments, deductibles, and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other third-party payors employing, exercising control over or splitting professional fees with licensed professionals in violation of state laws prohibiting fee splitting or the corporate practice of medicine and other professions;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal transparency requirements under the Physician Payments Sunshine Act, created under the ACA, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to annually report to CMS information related to payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals and information regarding physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members. Failure to submit required information may result in civil monetary penalties for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations. We believe that we are exempt from these reporting requirements. We cannot assure you, however, that our regulators, principally the federal government, will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other part;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by any non-governmental third-party payors, including private insurers; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state, local and foreign laws that govern the privacy and security of health information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical laboratory, our business practices may face additional scrutiny from government regulatory agencies such as the Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General (&#8220;OIG&#8221;) and CMS. Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory, as well as the decision to order laboratory tests, typically are made or strongly influenced by the physician, with little or no input from patients. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an applicable exception. The government has been active in enforcement of these laws as they apply to clinical laboratories.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into consulting and scientific advisory board arrangements, speaking arrangements and clinical research agreements with physicians and other healthcare providers, including some who could influence the use of our products. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use of our products to be in violation of applicable laws.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare companies, healthcare providers and other third parties, including charitable foundations, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities may conclude that our business practices, including our consulting arrangements with physicians, as well as our financial assistance programs, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. Responding to investigations can be time and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations is costly. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations and may become subject to their similar foreign equivalents. We can face serious consequences for violations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations prohibit, among other things, companies and their employees, agents, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect that we may engage in non-U.S. activities over time. We expect to rely on third-party suppliers and/or third parties to obtain necessary permits, licenses, and patent registrations. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing state, federal, local, foreign, and other privacy and security laws, regulations, rules, contractual obligations, policies and other obligations, and our failure to comply or perceived failure to comply with those obligations could result in regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, store, use, transmit, disclose, or otherwise process (&#8220;Process&#8221;) confidential, proprietary, and sensitive data, including PHI, personal information, credit card and other financial information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, payors and other parties. Our data processing activities may subject us to numerous data privacy and security obligations, such as laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts and other obligations that govern the Processing of personal information by us and on our behalf. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal, state, and local governments have enacted data privacy and security laws, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, California has enacted several laws governing the Processing of personal information, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), which provides California residents certain rights relate to their personal information, the California Rights Privacy Act of 2020 (&#8220;CPRA&#8221;), effective January 1, 2023, which will expand the CCPA, and the California Confidentiality of Medical Information Act, which restricts the use and disclosure of health information and other personal information. Although the CCPA exempts some personal information processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase compliance costs and potential liability with respect to other personal information we maintain about California residents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other states have enacted or proposed privacy laws, further complicating compliance efforts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, there are also an increasing number of laws, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations, industry standards and other obligations concerning privacy and security, including for example the European Union&#8217;s (&#8220;EU&#8221;) General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;). </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, certain jurisdictions have enacted data localization laws and cross-border personal information transfer laws, which could make it more difficult to transfer personal information across jurisdictions (such as transferring or receiving personal information that originates in the EU).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Existing mechanisms that may facilitate cross-border personal information transfers may change or be invalidated. The more reliant our business is on the ability to effectuate cross-border data transfers, the more impact we may experience in light of any changes in the legal landscape.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, privacy advocates and industry groups have proposed, and may in the future propose, standards with which we are legally or contractually bound to comply. In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. For example, we may also be subject to the Payment Card Industry Data Security Standard (&#8220;PCI DSS&#8221;). The PCI DSS requires companies to adopt certain measures to ensure the security of cardholder information, including using and maintaining firewalls, adopting proper password protections for certain devices and software, and restricting data access. Noncompliance with PCI-DSS can result in penalties ranging from $5,000 to $100,000 per month by credit card companies, litigation, damage to our reputation, and revenue losses. We may also rely on vendors to process payment card data, and those vendors may be subject to PCI DSS, and our business may be negatively affected if our vendors are fined or suffer other consequences as a result of PCI DSS noncompliance </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, we may also bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers. Additionally, we may publish privacy policies and other statements regarding data privacy and security, and, if these policies or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we could experience adverse consequences.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. These laws may be subject to varying interpretations, creating complex compliance issues for us and our clients. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal information on our behalf.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these obligations may require us to change our business model or to take on more onerous obligations in our contracts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we endeavor to comply with all applicable obligations, we may, at times, fail or be perceived to have failed to do so.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, despite our efforts, our personnel or third parties upon whom we rely on may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Failure or perceived failure to comply with these obligations could result in significant consequences, including but not limited to government enforcement actions (which could include civil, criminal, and administrative penalties), private litigation, additional reporting requirements and/or oversight, bans on processing personal information, and orders to destroy or not use personal information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: increase our cost of providing our services, decrease demand for our services, reduce our revenue, interrupt our business operations, limit our ability to develop our services, expenditure of time and resources to defend any claim or inquiry, and adverse publicity.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal and social concerns related to the use of genetic information could reduce demand for our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic testing has raised ethical, legal, and social issues regarding privacy and the appropriate uses of the resulting information. Governmental authorities have, through the Genetic Information Nondisclosure Act of 2008, and could further, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Ethical and social concerns may also influence governmental authorities to deny or delay the issuance of patents for technology relevant to our business. While we do not currently perform genetic tests for genetic predisposition to certain conditions, these concerns may lead patients to refuse to use, or clinicians to be reluctant to order, our genomic tests or genetic tests for somatic mutations even if permissible. These and other ethical, legal and social concerns may limit market acceptance of our products or reduce the potential markets for our products, either of which could have an adverse effect on our business, financial condition, or results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_160"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize diagnostic tests similar or identical to ours, and our ability to successfully commercialize our products may be impaired.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection as well as nondisclosure, confidentiality and other contractual restrictions to protect our brands and proprietary tests and technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other life science companies, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely or jointly with others or in-license from others, particularly patents, in the United States and other countries with respect to our products and technologies. We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing life sciences patents is costly, time-consuming and complex, and we may fail to apply for patents on important tests, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio as of December 31, 2021 includes 12 issued U.S. patents and ten pending U.S. patent applications, with foreign counterparts. It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable tests or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our future patented technologies. We may not be successful in defending any such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents and increased competition to our business. Even if our patents are held valid and enforceable, they may still be found insufficient to provide protection against competing products and services sufficient to achieve our business objectives. We may have to challenge the patents or patent applications of third parties, such as to counter infringement or unauthorized use. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to enjoin the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. Even if we prevail against an infringer in a U.S. district court or foreign trial-level court, there is always the risk that the infringer will file an appeal and the initial court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies&#8217; patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the life sciences field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing DNA sequences.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of genetic diagnostics tests would be considered natural laws. Accordingly, the evolving case law in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to life science technologies, which could make it difficult for us to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition, and our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology, but that are not covered by the claims of the patents that we own or control, assuming such patents have issued or do issue;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive tests for sale in our major commercial markets;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without obtaining a proper license;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or in-license additional proprietary technologies that are patentable;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other life sciences companies, our success is heavily dependent on intellectual property, particularly patents relating to our research programs and products. Obtaining and enforcing patents in the life sciences industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or the United States Patent and Trademark Office (&#8220;USPTO&#8221;) rules and regulations could increase these uncertainties and costs. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (&#8220;AIA&#8221;), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The AIA includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent in USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review, and derivation proceedings. For applications filed after March 15, 2013 that do not claim the benefit of applications filed before that date, the AIA transitioned the United States from a first to invent system to a first-inventor-to-file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our in-licensed intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8216;&#8216;march-in&#8217;&#8217; rights, certain reporting requirements and a preference for U.S.-based companies, and compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights that have been in-licensed pursuant to a license agreement (the &#8220;License Agreement&#8221;) with The Washington University in St. Louis, Missouri (&#8220;WUSTL&#8221;) have been generated through the use of U.S. government funding, and are therefore subject to certain federal regulations. As a result, the United States federal government may retain certain rights to intellectual property embodied in our current or future product candidates under the Bayh-Dole Act. These federal government rights include a &#8216;&#8216;nonexclusive, nontransferable, irrevocable, paid-up license&#8217;&#8217; to use inventions for any governmental purpose. The Bayh-Dole Act also provides federal agencies with &#8216;&#8216;march-in rights.&#8217;&#8217; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8216;&#8216;nonexclusive, partially exclusive, or exclusive license&#8217;&#8217; to a &#8216;&#8216;responsible applicant or applicants&#8217;&#8217; if it determines that (1) adequate steps have not been taken to commercialize the invention, (2) government action is necessary to meet public health or safety needs or (3) government action is necessary to meet requirements for public use under federal regulations. If the patent owner refuses to do so, the government may grant the license itself.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government also has the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States, and the License Agreement requires that we comply with this requirement. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or future in-licensed intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our products and related technologies could be found invalid or unenforceable if challenged.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) have been, are being or may be challenged at a future point in time in an opposition, nullification, derivation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review, post-grant review or interference action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. Any successful third-party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents, which may lead to increased competition to our business, which could harm our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be aware of all third-party intellectual property rights potentially relating to our products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., U.S. applications for which a request not to publish has been filed), not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we have and may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. We can give no assurance that all of the potentially relevant art relating to our patents and patent applications has been found; overlooked prior art could be used by a third party to challenge the validity, enforceability and scope of our patents or prevent a patent from issuing from a pending patent application. As a result, we may not be able to obtain or maintain protection for certain inventions. No assurance can be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Therefore, the validity, enforceability and scope of our patents in the United States and other countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against our competitors. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is subject to rapid technological change and substantial litigation regarding patent and other intellectual property rights. Our potential competitors in both the United States and abroad, may have substantially greater resources and are likely to make substantial investments in patent portfolios and competing technologies, and may apply for or obtain patents that could prevent, limit or otherwise interfere with our ability to make, use and sell our products. Numerous third-party patents exist in fields relating to our products and technologies, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our products and technologies. Moreover, because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that cover our products and technologies.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from using our technology. Our failure to obtain or maintain a license to any technology that we require may materially harm our business, financial condition and results of operations. Furthermore, we would be exposed to a threat of litigation.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be party to, or threatened with, litigation or other proceedings with third parties, including non-practicing entities, who allege that our products, components of our products, and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. The types of situations in which we may become a party to such litigation or proceedings include:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or technologies do not infringe those third parties&#8217; patents;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may participate at substantial cost in International Trade Commission proceedings to abate importation of products that would compete unfairly with our products or technologies;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a competitor files patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, derivation or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation claiming that our products or technologies infringe their patent or other intellectual property rights, we will need to defend against such proceedings;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their products, services, or technologies do not infringe our patents or patents licensed to us, we will need to defend against such proceedings;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to ownership disputes relating to intellectual property, including disputes arising from conflicting obligations of consultants or others who are involved in developing our products and technologies; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our products or technologies infringe or misappropriate its patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we would need to defend against such proceedings.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits and proceedings, regardless of merit, are time-consuming and expensive to initiate, maintain, defend or settle, and could divert the time and attention of managerial and technical personnel, which could materially adversely affect our business. Any such claim could also force us to do one or more of the following:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur substantial monetary liability for infringement or other violations of intellectual property rights, which we may have to pay if a court decides that the diagnostic test or technology at issue infringes or violates the third party&#8217;s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the third party&#8217;s attorneys&#8217; fees;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stop manufacturing, offering for sale, selling, using, importing, exporting or licensing the diagnostic test or technology incorporating the allegedly infringing technology or stop incorporating the allegedly infringing technology into such test or technology;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain from the owner of the infringed intellectual property right a license, which may require us to pay substantial upfront fees or royalties to sell or use the relevant technology and which may not be available on commercially reasonable terms, or at all;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesign our products and technologies so they do not infringe or violate the third party&#8217;s intellectual property rights, which may not be possible or may require substantial monetary expenditures and time;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into cross-licenses with applicable third party, which could weaken our overall intellectual property position;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lose the opportunity to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">find alternative suppliers for non-infringing technologies, which could be costly and create significant delay; or</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relinquish rights associated with one or more of our patent claims if our claims are held invalid or otherwise unenforceable.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may be able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity, adversely impact our business, cause delays, or prohibit us from marketing or otherwise commercializing our products and technologies. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operation, financial condition or cash flows.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our common stock. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on information technology systems that we license from third parties. Any failure of such systems or loss of licenses to the software that comprises an essential element of such systems could significantly harm our business.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on information technology systems for significant elements of our operations, such as our Laboratory Information Management System, including test validation, specimen tracking and quality control, our bioinformatics analytical software systems, our test report generating systems and billing systems. Essential elements of these systems depend on software that we license from third parties. If we are unable to maintain the licenses to this software or our software providers discontinue or alter the programs on which we rely, it could render our test reports unreliable or hinder our ability to generate accurate test reports, among other things. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on licenses from third parties, and if we lose these licenses or are not able to obtain licenses to third-party technology on reasonable grounds or at all, then we may not be able to continue to commercialize existing diagnostic tests, be subjected to future litigation and may not be able to commercialize new diagnostic tests in the future.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to certain royalty-bearing license agreements that grant us rights to use certain intellectual property, including patents and patent applications, in certain specified fields of use. Although we intend to develop products and technologies through our own internal research, we may need to obtain additional licenses from others to advance our research, development and commercialization activities. Our license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization and other obligations on us.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may identify third-party technology we may need, including to develop or commercialize new diagnostic tests or services. In return for the use of a third party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of the cost of our products or services and affect our margins. We may also need to negotiate licenses to patents or patent applications before or after introducing a commercialized test. The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights for technologies that we may consider attractive or necessary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may not be able to obtain necessary or strategic licenses to patents or patent applications, and our business may suffer if we are unable to enter into these licenses on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize tests and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to seek regulatory approval of, and to market, tests identical to ours and we may be required to cease our development and commercialization activities. For example, we license certain intellectual property from WUSTL that is incorporated into DecisionDx-UM. In 2021, we provided over 1,600 test reports for DecisionDx-UM. If this license agreement were terminated, we would be unable to continue to issue test reports and thus sales of DecisionDx-UM. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise with respect to any one of our licensing agreements, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not prevail in such disputes, we may lose any of such license agreements.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected diagnostic tests, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to maintain such licenses could have a material adverse effect on our business, financial condition and results of operations. Any of these licenses could be terminated, such as if either party fails to abide by the terms of the license, or if the licensor fails to prevent infringement by third parties or if the licensed patents or other rights are found to be invalid or unenforceable. Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs and be a distraction to management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#8217; fees, costs and expenses, royalties or, be enjoined from selling our products or services, including DecisionDx-Melanoma and DecisionDx-UM, which could adversely affect our ability to offer our products or services, our ability to continue operations and our financial condition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own tests or products and may also export infringing tests or products to territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our products. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to life science technologies, which could make it difficult for us to stop the infringement of our patents in such countries. We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce our patent rights could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to stop a competitor from marketing and selling in foreign countries tests, products and services that are the same as or similar to our products and technologies, in which case our competitive position in the international market would be harmed.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to pursuing patents on our technology, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We take steps to protect our trade secrets, in part, by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and once disclosed, we are likely to lose trade secret protection and may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do and may employ individuals who previously worked with universities or other companies, including potential competitors. We could in the future be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of current or former employers or competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may become subject to claims that we caused an individual to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a current or former employer or competitor. Although, we are currently not subject to any such claims.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management and other employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the current or former employers. Therefore, we could be required to obtain a license from such third-party employer to commercialize our products or technology. Such a license may not be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet registered certain of our trademarks in all of our potential markets, although we have registrations for, among others, the DiffDx-Melanoma, DecisionDx-UM, DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher and IDgenetix tests in the United States. Our current or future registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In addition, third parties have used trademarks similar and identical to our trademarks in foreign jurisdictions and have filed or may in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Although these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our products. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, right to use, or right to exclude others from using, intellectual property that is important to our products. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications must be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partial or complete loss of patent rights in the relevant jurisdiction, such as failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we, or our licensors, fail to maintain the patents and patent applications covering our products and technologies, potential competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan, and the protection patents afford is limited. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents covering our products are obtained, once the patent term has expired, we may be open to competition from competitive tests or products. Given the amount of time required for the development, testing and regulatory review of potential new tests or products, patents protecting such tests or products might expire before or shortly after such tests or products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing tests or other products similar or identical to ours.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_163"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the services of our key personnel.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the services of our key personnel, including Derek J. Maetzold, our President and Chief Executive Officer. Although we have entered into agreements with our key personnel regarding their employment, they are not for a specific term and each of may terminate their employment with us at any time, though we are not aware of any present intention of any of these individuals to leave us.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our laboratory facilities and office spaces located in Phoenix, Arizona, Pittsburgh, Pennsylvania, San Diego, California and our corporate headquarters in Friendswood, Texas. This competition has become exacerbated by the increase in employee resignations currently taking place throughout the United States as a result of the COVID-19 pandemic, which is commonly referred to as the &#8220;great resignation.&#8221; We may also experience employee turnover as a result of the ongoing &#8220;great resignation.&#8221; In response to competition, rising inflation rates and labor shortages, we may need to adjust employee cash compensation, which would affect our operating costs and our margins, or equity compensation, which would affect our outstanding share count and cause dilution to existing stockholders. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, clinical investigators, consultants, speakers, vendors and any current or potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, clinical study investigators, consultants, speakers, vendors and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: federal laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information; manufacturing standards; federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the United States and abroad; sexual harassment and other workplace misconduct; or laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional integrity </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting and oversight obligations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant revenue growth in a short period of time. We may not achieve similar growth rates in future periods. You should not rely on our operating results for any prior periods as an indication of our future operating performance. To effectively manage our anticipated future growth, we must continue to maintain and enhance our financial, accounting, human resources, laboratory operations, customer support and sales administration systems, processes and controls. Failure to effectively manage our anticipated growth could lead us to over-invest or under-invest in development, operational and administrative infrastructure, result in weaknesses in our infrastructure, systems, or internal controls, give rise to operational mistakes, losses, loss of customers, productivity or business opportunities, and result in loss of employees and reduced productivity of remaining employees.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also anticipate further growth in our business operations. For example, since May 2021, we have completed the acquisitions of Myriad MyPath Laboratory, Cernostics and AltheaDx, each of which we expect will contribute to our future growth. These acquisitions and other future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue increasing our headcount and hire more specialized personnel in the future as we grow our business and expand our product offerings. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain our technology to effectively manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our anticipated growth could require significant capital expenditures and might divert financial resources from other projects such as the development of new diagnostic tests and services. As we commercialize additional diagnostic and prognostic tests, we may need to incorporate new equipment, implement new technology systems, or hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher costs, declining quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to maintain the quality or expected turnaround times of our products, or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could adversely affect our operations. If our management is unable to effectively manage our anticipated growth, our expenses may increase more than expected, our revenue could decline or grow more slowly than expected and we may be unable to implement our business strategy. The quality of our products and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions, such as the acquisition of businesses, assets, products or technologies, which could be disruptive to our existing operations, divert the attention of our management team and adversely impact our liquidity, cash flows, financial condition and results of operations.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic opportunities and engage in transactions such as acquisitions of businesses, assets, products or technologies, as well as technology licenses or investments in complementary businesses. For example, in May 2021, December 2021 and April 2022, we completed the acquisitions of the Myriad MyPath Laboratory, Cernostics and AltheaDx, respectively. These and any other strategic acquisition transactions may entail numerous operational and financial risks, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays, difficulties and higher than expected costs associated with integration activities, such as those involving operational processes, regulatory and licensure compliance, personnel and information technology systems;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disruption of our existing business operations and diversion of management&#8217;s time, focus and attention;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">decreases in our liquidity and operating cash flows, increases in our overall operating costs, substantial amounts of amortization expense, increased capital expenditure requirements and non-recurring charges, including possible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairments of acquired assets and losses on the remeasurement of contingent consideration;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">incurrence of substantial debt or dilutive issuances of equity securities, the assumption of additional liabilities and exposure to unknown liabilities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to retain key personnel of any acquired businesses; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to realize any of the anticipated revenues, synergies, efficiencies or other benefits of a transaction within our estimated time frame or at all.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to our acquisitions of the Myriad MyPath Laboratory, Cernostics and AltheaDx, actual results may differ materially from our plans and expectations. For example, there can be no assurances regarding our ability to successfully scale and integrate the MyPath Melanoma, TissueCypher and IDgenetix tests into our commercial offerings and the ability of the combined strengths of Castle, the Myriad MyPath Laboratory, Cernostics or AltheaDx to position us for continued growth and success as a leader in the diagnostics space. Further, there are inherent execution and business risks associated with managing the integration and growth objectives of more than one acquisition at the same time and such circumstances may have the effect of heightening the operational and financial risks related to acquisitions noted above and the other risks described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the timing, size or nature of any future transactions, whether they will be completed or financed on favorable terms, if at all, or what the impact of those transactions might be on our financial results, including if such transactions are not effectively and profitably integrated into our business. Our failure to successfully complete the integration of any business that we acquire could have an adverse effect on our prospects, business activities, cash flows, financial condition, results of operations and stock price. Additionally, our ability to successfully integrate, manage and derive financial and other benefits from any acquired business, asset, product or technology is unproven.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to limitations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $99.4 million, of which $43.5 million will begin to expire in 2030 if not utilized to offset taxable income, and $55.9 million may be carried forward indefinitely. Also, as of December 31, 2021, we had state net operating loss carryforwards of $67.5 million, which begin to expire in 2028 if not utilized to offset state taxable income.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the legislation known as the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;), as modified by the CARES Act, federal NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such NOL carryforwards in taxable years beginning after December 31, 2020 is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the TCJA or the CARES Act. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8216;&#8216;ownership change&#8217;&#8217; (which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have experienced ownership </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in the past and we may also experience additional ownership changes in the future as a result of subsequent shifts in o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we Process proprietary, confidential, and sensitive information (including but not limited to intellectual property, proprietary business information and personal information). We manage and maintain our applications and information utilizing a combination of on-site systems, managed data centers, and cloud-based data centers, and we are increasingly dependent upon information technology systems, infrastructure and information to operate our business. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is critical that we do so in a secure manner to maintain the confidentiality, availability and integrity of such information. We also have outsourced elements of our operations to third parties, including third-party service providers and technologies to help operate critical business systems to Process proprietary, confidential and sensitive information, and as a result we manage a number of third-party contractors who have access to our proprietary, confidential and sensitive information. Our ability to monitor these third parties&#8217; cybersecurity information security practices is limited, and these third parties may not have adequate information security measures in place.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent, continue to increase, and are becoming increasingly difficult to detect. Threat actors, personnel (such as through theft or misuse), hacktivist, sophisticated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nation-states, and nation-state-supported actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services. Despite the implementation of security measures designed to protect against a security incident, we and our contractors and consultants are vulnerable to a variety of evolving threats including but not limited to service interruptions, system malfunction, natural disasters, terrorism, war, public health crises, telecommunication and electrical failures, malware (including as a result of advanced persistent threat intrusions), malicious code, ransomware, supply chain attacks, denial-of-service attacks (such as credential stuffing), social engineering and other attempts to affect service reliability and threaten the confidentiality, integrity and availability of our proprietary, confidential and sensitive information. In particular, ransomware attacks have become increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Supply-chain attacks have also increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including our services) or the third-party information technology systems that support us and our services. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Any of the previously identified or similar threats could cause a disruption or security incident, which could result in unauthorized, unlawful, or accidental loss of, damage to, modification of, destruction of, alteration of, encryption of, disclosure of, access to, or acquisition of our information and could interrupt our ability to provide our services.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any such system failure, accident or material security incident to date, we cannot assur</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e you </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that our data protection efforts and our investment in information technology have or will prevent security incidents, and we may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents, including affected individuals, the Secretary of the HHS, states Attorneys General and others.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such disclosures are costly, and the disclosures or failure to comply could lead to adverse consequences.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a third party upon whom we rely experience a security incident or are perceived to have experienced a security incident, we may experience government enforcement actions, additional reporting requirements and/or oversight, restrictions on Processing data (including personal information), litigation, indemnification obligations, negative publicity, reputational harm, monetary fund diversions, interruptions in our operations, and other harms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such consequences may disrupt our operations (including our ability to conduct our analyses, provide test results, bill payors or patients, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process, and prepare company financial information, provide information about our products and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business), damage our reputation, negatively impact our ability to grow our business, and others. For example, we maintain a tumor specimen database comprised of over 60,000 samples.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these samples were used to develop and validate DecisionDx-Melanoma, and, of those, some are currently being used to improve upon the test and some will be used in the future. If we were to lose this database, our ability to further validate, improve and therefore maintain and grow sales of DecisionDx-Melanoma could be significantly impaired.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and there can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, information loss, regulatory actions or material adverse impacts arising out of our privacy and security practices, Processing or security incidents we may experience, or that such coverage will continue to be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product or professional liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of our products.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product and professional liability exposure related to our products. The marketing, sale and use of our products could lead to the filing of product liability claims were someone to allege that our products identified or reported inaccurate or incomplete information, or otherwise failed to perform as designed. We may also be subject to liability for errors </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against claims that our products caused injury or otherwise failed to function properly, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our current tests any tests that we may develop, and the inability to commercialize such tests;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reluctance of experts willing to conduct our clinical studies;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation and diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to study subjects or patients;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, or marketing or promotional restrictions; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently carry product liability insurance. However, the amount of this insurance may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently accept orders from customers outside of the United States, our historical business strategy has been directed toward customers within the United States. Our long-term business strategy contemplates potential international expansion. Doing business internationally involves a number of risks, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limits in our ability to penetrate international markets if we are not able to perform tests locally;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation delays;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing foreign operations;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain regulatory approvals for the commercialization of our products in various countries;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) its books and records provisions, or its anti-bribery provisions.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, financial markets around the world experienced volatility following the invasion of Ukraine by Russia in February 2022. In response to the invasion, the United States, United Kingdom and EU, along with others, imposed significant new sanctions and export controls against Russia, Russian banks and certain Russian individuals and may implement additional sanctions or take further punitive actions in the future. The full economic and social impact of the sanctions imposed on Russia (as well as possible future punitive measures that may be implemented), as well as the counter measures imposed by Russia, in addition to the ongoing military conflict between Ukraine and Russia, which could conceivably expand into the surrounding region, remains uncertain; however, both the conflict and related sanctions have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability, and/or supply chain continuity, in both Europe and globally, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has introduced significant uncertainty into global markets. While we do not operate in Russia, Ukraine or Eastern Europe, as the adverse effects of this conflict continue to develop and potentially spread, both in Europe and throughout the rest of the world, our business and results of operations may be adversely affected, particularly to the extent this conflict escalates to involve additional countries, further economic sanctions or wider military conflict. Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements associated with being a public company will continue to increase our costs as well as divert significant company resources and management attention.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act or the other rules and regulations of the SEC and any securities exchange relating to public companies. Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8216;&#8216;say on pay&#8217;&#8217; voting requirements that now apply to us since we are no longer an emerging growth company effective December 31, 2021. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. We were previously afforded exemptions from certain public company reporting requirements as a result of our status as an emerging growth company. Effective December 31, 2021, we ceased to be an emerging growth company. If we are unable to comply with these requirements on a timely basis or if the attention of our management and personnel is diverted from other business concerns, it could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss or decrease our net income, and may require us to reduce costs in other areas of our business or increase the prices of our products. In addition, as we expand, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#8217; and officers&#8217; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and the third parties with whom we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely impacted by inflation.*</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the rate of inflation in the United States began to increase and has since risen to levels not experienced in over 40 years. We are experiencing inflationary pressures, primarily in personnel costs, and we anticipate impacts on other cost areas within the next twelve months. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and the extent to which the rate of inflation further increases, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, the purchasing power of our cash and cash equivalents may be diminished, our expenses could increase </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our payors may be unwilling or unable to increase reimbursement rates to compensate for inflationary impacts. As such, the effects of inflation may adversely impact our results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by natural disasters, public health epidemics and other events beyond our control.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain crisis management plans, our business operations are subject to interruption by natural disasters and other events and catastrophes beyond our control, including, but not limited to, earthquakes, floods, fires, tornadoes, hurricanes, power or other utility outages, telecommunications failures and public health crises. Further, outbreaks of epidemic diseases, such as the COVID-19 pandemic discussed above, or Russia&#8217;s invasion of Ukraine in February 2022, or the fear of such events, could provoke responses, including government-imposed travel restrictions that could impede the mobility and effectiveness of our sales force, disrupt our operations or those of our suppliers and service providers. The ultimate impact of any of these or similar events is highly uncertain and could have a material adverse impact on our operations.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_166"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile or may decline regardless of our operating performance, and you may lose all or part of your investment.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operating performance and the performance of other similar companies;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in marketing and selling our products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reimbursement determinations by third-party payors and reimbursement rates for our products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to product development and clinical studies for our products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve product development goals in the timeframes we announce;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of clinical study results, regulatory developments, acquisitions, strategic alliances or significant agreements by us or by our competitors;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or failure of our efforts to acquire, license or develop additional tests;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruitment or departure of key personnel;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions and market conditions specific to our industry;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rates and the rate of inflation;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent and duration of the impacts on our operations of general political and economic conditions, including the COVID-19 pandemic, the invasion of Ukraine by Russia, economic slowdowns, recessions or market corrections, the duration and effects of elevated inflation, rising interest rates and tightening of credit markets resulting from the pandemic, the conflict or another cause;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading activity by a limited number of stockholders who together beneficially own a significant percentage of our outstanding common stock;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of our market float; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other factors discussed in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, following our April 4, 2022 announcement of our entry into a definitive agreement to acquire AltheaDx, our stock price decreased 16.5% the next day and experienced further declines in the days that followed. In addition, the stock market in general, and diagnostic and life sciences companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our securities, regardless of our actual operating performance. In the past, stockholders of other companies have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If there are substantial sales of shares of our common stock, the price of our common stock could decline.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and significant stockholders, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. Shares held by directors, executive officers and other affiliates are subject to volume limitations under Rule 144 under the Securities Act.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our stockholders have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders. We filed such a registration statement in January 2022 to register the resale of shares of our common stock issuable in connection with our acquisition of Cernostics in December 2021. In June 2022, we filed a registration statement to register the resale of shares of our common stock that were issued and that may be issuable in connection with our acquisition of AltheaDx in April 2022. We have registered shares of common stock that we have issued and may issue under our employee equity incentive plans. As a result, these shares will be able to be sold freely in the public market upon issuance. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or the perception in the market that the holders of a large number of shares intend to sell their shares.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of working capital and may not use it effectively or in ways that increase our share price.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot specify with any certainty the particular uses of working capital, but we currently expect such uses will include: funding selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of current and future products; research and development related to the continued support of our current products, as well as the development of our product pipeline; and other general corporate purposes, including acquisitions and the costs associated with being a public company. The failure by our management to apply our working capital effectively could adversely affect our business and financial condition. Pending its use, we may invest working capital in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a risk management program or processes or procedures for identifying and addressing risks to our business in other areas.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have and may continue to enter into related party transactions that create conflicts of interest, or the appearances of conflicts of interest, which may harm our business and cause our stock price to decline.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into related party transactions that create conflicts of interest between our interests and the interests of our directors and executive officers. For example, we employ three children and a brother-in-law of Derek J. Maetzold, our President and Chief Executive Officer, three children and a son-in-law of Kristen M. Oelschlager, our Chief Operating Officer, and the son of Tobin W. Juvenal, our Chief Commercial Officer, in each case in non-officer positions. Additionally, Derek J. Maetzold and Daniel M. Bradbury, the chairperson of our board of directors, each served on the board of directors of AltheaDx, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a commercial-stage molecular diagnostics company that we acquired in April 2022. Further, each of the following individuals was a direct or indirect beneficial owner of AltheaDx securities and received consideration in the transaction: Mr. Bradbury; Mr. Maetzold; Thomas Sullivan, John Maetzold and Peter Maetzold, immediate family members of Mr. Maetzold; Frank Stokes, our Chief Financial Officer; Tobin Juvenal, our Chief Commercial Officer; Kristen Oelschlager, our Chief Operating Officer; and Joshua Albers and Allysa Topel, immediate family members of Ms. Oelschlager. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These types of related party arrangements are required to be disclosed in our annual proxy statement and/or in the notes to our consolidated financial statements based on certain criteria. We may engage in other transactions in the future involving our executive officers, directors and their family members and/or entities which they control or are affiliated, which could cause individuals in our management to seek to advance their economic interests or the economic interests of certain related parties above ours. Although we have a written policy on related party transactions that involves independent review and oversight by the audit committee of our board of directors, there can be no assurances that conflicts of interest will not exist, or that we will be able to adequately address or mitigate any actual or perceived conflicts of interest, and stockholders, analysts, proxy advisory firms, the news media and other parties may view these transactions as representing conflicts of interest or as otherwise inappropriate, which may result in negative public perception and reputational harm, and could impair our ability to enter into new customer relationships or attract and retain employees. Potential, perceived and actual conflicts of interest could cause investors to question the independence of our management, the adequacy and effectiveness of our disclosure controls and procedures or the integrity of our corporate governance procedures and compensation practices, which could have a material adverse effect on the trading price of our common stock and our business, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company and we cannot be certain if the scaled disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of June 30, 2022, we have requalified as a smaller reporting company as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies beginning with this Quarterly Report on Form 10-Q and will be able to take advantage of these scaled disclosures for so long as the market value of our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict if investors will find our common stock less attractive because we will rely on these scaled disclosures. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future. Consequently, stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The concentration of our stock ownership will likely limit your ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval.*</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon shares outstanding as of June&#160;30, 2022, our executive officers, directors and the known holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 27%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our common stock. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divide our board of directors into three classes;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meetings of stockholders and not be taken by written consent;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that special meetings of our stockholders may be called only by the chairperson of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions of our amended and restated certificate of incorporation and amended and restated bylaws will not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or amended and restated bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants; provided these provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation and amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. </span></div><div id="i85ed73ce88b34118965f36f66c298ae1_169"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from IPO of Common Stock</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2019, we completed the IPO, pursuant to which we issued and sold 4,600,000 shares of our common stock, including 600,000 shares associated with the full exercise of the underwriters&#8217; option to purchase additional shares, at a price to the public of $16.00 per share.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The offer and sale of all of the shares of our common stock in the IPO were registered under the Securities Act pursuant to our Registration Statements on Form S-1, as amended (File Nos. 333-232369 and 333-232796), which were declared or became effective on July&#160;24,&#160;2019. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed with the SEC on July 26, 2019, relating to our Registration Statements on Form S-1 (File Nos. 333-232369 and 333-232796).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the effective date of our registration statement through June&#160;30, 2022, we have not used any of the net proceeds from the IPO. Pending such uses, we have invested, and plan to continue to invest, the balance of the net proceeds from the IPO in cash and cash equivalent securities or highly liquid investment securities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_175"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_178"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i85ed73ce88b34118965f36f66c298ae1_181"></div><div style="-sec-extract:summary;margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of document</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.1#+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000114036121040395/brhc10031497_ex2-1.htm">Agreement and Plan of Merger, dated October 18, 2021, by and among the Registrant, Space Merger Sub, Inc., Cernostics, Inc., and Shareholder Representative Services LLC, incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K, as amended, originally filed with the SEC on December 6, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2#+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000114036122012901/ny20003735x1_ex2-1.htm">Agreement and Plan of Merger, dated April 4, 2022, by and among the Registrant, AltheaDx, Inc., Acorn Merger Sub, Inc. and Fortis Advisors LLC, incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on April 4, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000114036119013617/nc10003561x1_ex3-1.htm">Amended and Restated Certificate of Incorporation of the Registrant, incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000114036119013617/nc10003561x1_ex3-2.htm">Amended and Restated Bylaws of the Registrant, incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000114036119012901/nt10000802x4_ex4-1.htm">Form of Common Stock Certificate of the Registrant, incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232369), as amended, originally filed with the SEC on June 26, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000114036119012901/nt10000802x4_ex4-2.htm">Sixth Amended and Restated Investors&#8217; Rights Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders, incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-232369), as amended, originally filed with the SEC on June 26, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447362/000144736222000085/exhibit103-acaconcourseeas.htm">Lease Agreement, dated April 1, 2022, by and between the Registrant and ACA Concourse East Unit 3 LLC, incorporated by reference to Exhibit 10.3 of the Registrant's Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-q22022.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-q22022.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-q22022.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) or 15d-14(b) of the Exchange Act, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document&#8212;the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">#&#160;&#160;&#160;&#160;Schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request; provided, however, that we may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Pursuant to Item 601(b)(2) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#8220;[***]&#8221;) because we have determined that the information is not material and is the type that we treat as private or confidential. In addition, certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request; provided, however, that we may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i85ed73ce88b34118965f36f66c298ae1_184"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85ed73ce88b34118965f36f66c298ae1_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CASTLE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Derek J. Maetzold</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derek J. Maetzold<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Frank Stokes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Frank Stokes<br/>Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-q22022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibb9f04499ee04f59aae9762618dab69e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)&#47;15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:2.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Derek J. Maetzold, certify that&#58;</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Castle Biosciences, Inc.&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:5.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Derek J. Maetzold</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derek J. Maetzold<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-q22022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0078e830c1d645ebb6fc1d343852bcf9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)&#47;15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:2.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Frank Stokes, certify that&#58;</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Quarterly Report on Form 10-Q of Castle Biosciences, Inc.&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:5.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Frank Stokes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Frank Stokes<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-q22022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id746afe6c4e340698c05e6ced32c551b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Quarterly Report on Form&#160;10-Q for the quarterly period ended June&#160;30, 2022 of Castle Biosciences,&#160;Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Derek J. Maetzold, President and Chief Executive Officer of the Company, and Frank Stokes, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to their knowledge&#58;</font></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended (the&#34;Exchange Act&#34;)&#59; and</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.936%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2022</font></td><td colspan="3" rowspan="4" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Derek J. Maetzold</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Frank Stokes</font></td></tr><tr style="height:26pt"><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derek J. Maetzold<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Frank Stokes<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Castle Biosciences, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cstl-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c77279c-977d-402a-b1b2-5d29ed09603d,g:da8c0f38-2da3-40ff-b133-9fd71c151e0e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cstl="http://www.castlebiosciences.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.castlebiosciences.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cstl-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cstl-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cstl-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cstl-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.castlebiosciences.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.castlebiosciences.com/role/Revenue">
        <link:definition>2105103 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueTables" roleURI="http://www.castlebiosciences.com/role/RevenueTables">
        <link:definition>2306301 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/RevenueNarrativeDetails">
        <link:definition>2407402 - Disclosure - Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueDisaggregationofRevenueDetails" roleURI="http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails">
        <link:definition>2408403 - Disclosure - Revenue - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueConcentrationofRiskbyRiskFactorDetails" roleURI="http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails">
        <link:definition>2409404 - Disclosure - Revenue - Concentration of Risk, by Risk Factor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.castlebiosciences.com/role/LossPerShare">
        <link:definition>2110104 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareTables" roleURI="http://www.castlebiosciences.com/role/LossPerShareTables">
        <link:definition>2311302 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>2412405 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.castlebiosciences.com/role/Acquisitions">
        <link:definition>2113105 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.castlebiosciences.com/role/AcquisitionsTables">
        <link:definition>2314303 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2415406 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAcquisitionofconsiderationtransferredDetails" roleURI="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails">
        <link:definition>2416407 - Disclosure - Acquisitions - Acquisition of consideration transferred (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2417408 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails" roleURI="http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails">
        <link:definition>2418409 - Disclosure - Acquisitions - Schedule of Unaudited Pro forma Financial Information and Net Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNet">
        <link:definition>2119106 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables">
        <link:definition>2320304 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetPropertyandEquipmentDetails" roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails">
        <link:definition>2421410 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDepreciationExpenseDetails" roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails">
        <link:definition>2422411 - Disclosure - Property and Equipment, Net - Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNet" roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet">
        <link:definition>2123107 - Disclosure - Goodwill and Other Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNetTables" roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables">
        <link:definition>2324305 - Disclosure - Goodwill and Other Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails" roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails">
        <link:definition>2425412 - Disclosure - Goodwill and Other Intangible Assets, Net - Schedule of Change in Carrying Value of Our Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNetNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails">
        <link:definition>2426413 - Disclosure - Goodwill and Other Intangible Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails">
        <link:definition>2427414 - Disclosure - Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>2428415 - Disclosure - Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets, Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedandCurrentLiabilities" roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities">
        <link:definition>2129108 - Disclosure - Other Accrued and Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedandCurrentLiabilitiesTables" roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables">
        <link:definition>2330306 - Disclosure - Other Accrued and Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedandCurrentLiabilitiesDetails" roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails">
        <link:definition>2431416 - Disclosure - Other Accrued and Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.castlebiosciences.com/role/Leases">
        <link:definition>2132109 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.castlebiosciences.com/role/LeasesTables">
        <link:definition>2333307 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAssetsAndLiabilitiesDetails" roleURI="http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails">
        <link:definition>2434417 - Disclosure - Leases - Assets And Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/LeasesNarrativeDetails">
        <link:definition>2435418 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.castlebiosciences.com/role/FairValueMeasurements">
        <link:definition>2136110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsTables">
        <link:definition>2337308 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>2438419 - Disclosure - Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2439420 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
        <link:definition>2440421 - Disclosure - Fair Value Measurements - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.castlebiosciences.com/role/CommitmentsandContingencies">
        <link:definition>2141111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensation" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation">
        <link:definition>2142112 - Disclosure - Stock Incentive Plans and Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensationTables" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables">
        <link:definition>2343309 - Disclosure - Stock Incentive Plans and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensationNarrativeDetails" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails">
        <link:definition>2444422 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails">
        <link:definition>2445423 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Activity Under Stock Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>2446424 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails">
        <link:definition>2447425 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>2448426 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.castlebiosciences.com/role/IncomeTaxes">
        <link:definition>2149113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.castlebiosciences.com/role/IncomeTaxesDetails">
        <link:definition>2450427 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cstl_AssembledWorkforceMember" abstract="true" name="AssembledWorkforceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_AccountsReceivableCurrentMember" abstract="true" name="AccountsReceivableCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_ProceedsFromPreviousAssetAcquisition" abstract="false" name="ProceedsFromPreviousAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" abstract="false" name="BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cstl_LesseeOperatingLeaseEarlyTerminationFee" abstract="false" name="LesseeOperatingLeaseEarlyTerminationFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_OperatingExpensesNetOfOtherOperatingIncome" abstract="false" name="OperatingExpensesNetOfOtherOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" abstract="false" name="CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cstl_AccruedFixedAssetPurchases" abstract="false" name="AccruedFixedAssetPurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" abstract="false" name="LesseeOperatingLeaseNumberOfOptionsToRenew" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cstl_AltheaDxIncMember" abstract="true" name="AltheaDxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_BusinessCombinationNoncashContingentConsiderationGiven" abstract="false" name="BusinessCombinationNoncashContingentConsiderationGiven" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_ContractWithCustomerCustomerPaymentTerms" abstract="false" name="ContractWithCustomerCustomerPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_AccountsReceivableNoncurrentMember" abstract="true" name="AccountsReceivableNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_BlueCrossBlueShieldPlansMember" abstract="true" name="BlueCrossBlueShieldPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_PittsburghLeaseFirstSixMonthsMember" abstract="true" name="PittsburghLeaseFirstSixMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" abstract="false" name="AcquisitionContingentConsiderationLiabilityMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cstl_BusinessCombinationConsiderationPayableCurrent" abstract="false" name="BusinessCombinationConsiderationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_PittsburghLeaseMember" abstract="true" name="PittsburghLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" abstract="false" name="BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cstl_LesseeOperatingLeaseOptionToTerminateTerm" abstract="false" name="LesseeOperatingLeaseOptionToTerminateTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_PittsburghLeaseAfterSixMonthsMember" abstract="true" name="PittsburghLeaseAfterSixMonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" abstract="false" name="AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_TwoThousandNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_MedicareAdvantagePlansMember" abstract="true" name="MedicareAdvantagePlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_MyriadMyPathLLCMember" abstract="true" name="MyriadMyPathLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_IncomeTaxAdjustmentMember" abstract="true" name="IncomeTaxAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" abstract="false" name="AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_ThirdPartyPayorConcentrationRiskMember" abstract="true" name="ThirdPartyPayorConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" abstract="false" name="BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cstl_AccruedClinicalStudiesCurrent" abstract="false" name="AccruedClinicalStudiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" abstract="false" name="AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cstl_CernosticsIncMember" abstract="true" name="CernosticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_LesseeOperatingLeaseMaximumBaseRent" abstract="false" name="LesseeOperatingLeaseMaximumBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" abstract="true" name="OperatingExpensesAndOtherOperatingIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cstl_DermatologicMember" abstract="true" name="DermatologicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cstl-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c77279c-977d-402a-b1b2-5d29ed09603d,g:da8c0f38-2da3-40ff-b133-9fd71c151e0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8b4048fe-d31e-4407-a3cd-70c61a4f118b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f615aa1-486e-4995-bd46-2da129dcda6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8b4048fe-d31e-4407-a3cd-70c61a4f118b" xlink:to="loc_us-gaap_LiabilitiesCurrent_9f615aa1-486e-4995-bd46-2da129dcda6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8006b9f7-a4e8-4597-b236-001de34eb595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8b4048fe-d31e-4407-a3cd-70c61a4f118b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8006b9f7-a4e8-4597-b236-001de34eb595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65053b82-1bfa-4f42-b97c-f4ff66b747ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8b4048fe-d31e-4407-a3cd-70c61a4f118b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65053b82-1bfa-4f42-b97c-f4ff66b747ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_44804c94-4c85-40d5-b397-5cb44da58da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8b4048fe-d31e-4407-a3cd-70c61a4f118b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_44804c94-4c85-40d5-b397-5cb44da58da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb4093b4-c605-4d82-bd35-29a43788347e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8b4048fe-d31e-4407-a3cd-70c61a4f118b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb4093b4-c605-4d82-bd35-29a43788347e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_296fc9a5-6b1a-4378-86fc-1fca2719b389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_f0917db3-d4cf-459a-b59d-e0fd70a4d296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_296fc9a5-6b1a-4378-86fc-1fca2719b389" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_f0917db3-d4cf-459a-b59d-e0fd70a4d296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_2b792d89-895c-4b78-adcb-3a58c22ff523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_296fc9a5-6b1a-4378-86fc-1fca2719b389" xlink:to="loc_us-gaap_CommonStockValueOutstanding_2b792d89-895c-4b78-adcb-3a58c22ff523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d0af62d2-c909-4259-a21e-629e9be864df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_296fc9a5-6b1a-4378-86fc-1fca2719b389" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d0af62d2-c909-4259-a21e-629e9be864df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f994f877-66f6-4cd2-a751-fe5ff90ef1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_296fc9a5-6b1a-4378-86fc-1fca2719b389" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f994f877-66f6-4cd2-a751-fe5ff90ef1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_45e9a144-3488-4d28-afd7-a8d527fbe4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b7397c25-01ac-432f-9a59-64550e99c834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_45e9a144-3488-4d28-afd7-a8d527fbe4d2" xlink:to="loc_us-gaap_AccountsPayableCurrent_b7397c25-01ac-432f-9a59-64550e99c834" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5625c136-c370-48c1-b13b-fb7d35b99b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_45e9a144-3488-4d28-afd7-a8d527fbe4d2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5625c136-c370-48c1-b13b-fb7d35b99b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_90fcabf3-1258-4174-9a9c-76c18bc031e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_45e9a144-3488-4d28-afd7-a8d527fbe4d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_90fcabf3-1258-4174-9a9c-76c18bc031e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75cb5e60-19ce-4cd7-87a2-1996cffd4466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_45e9a144-3488-4d28-afd7-a8d527fbe4d2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75cb5e60-19ce-4cd7-87a2-1996cffd4466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_12dd1c04-03de-4ac5-9bad-4adb57cd2454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:to="loc_us-gaap_AssetsCurrent_12dd1c04-03de-4ac5-9bad-4adb57cd2454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_024b7294-4926-4ccc-b5b9-21f7a418a25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_024b7294-4926-4ccc-b5b9-21f7a418a25a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_193cc2a0-4ec1-44e8-93a8-dea43bec086a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_193cc2a0-4ec1-44e8-93a8-dea43bec086a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2a24d6a2-774d-470e-b2f7-215e4b84486b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2a24d6a2-774d-470e-b2f7-215e4b84486b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_56bab2d8-c786-4a83-9d99-8263dbcf8521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_56bab2d8-c786-4a83-9d99-8263dbcf8521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95298f83-5ef8-42ca-8c83-a15999e6b141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4f02828-1f36-4b49-b556-39ab33a0dd7d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95298f83-5ef8-42ca-8c83-a15999e6b141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e476da24-428a-4b38-aba4-6d15f84edf39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6f912bc6-7ca5-4a54-a9cb-f0992a5cd629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e476da24-428a-4b38-aba4-6d15f84edf39" xlink:to="loc_us-gaap_Liabilities_6f912bc6-7ca5-4a54-a9cb-f0992a5cd629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c2cc68d3-cd58-465a-a2b0-c4770e48274c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e476da24-428a-4b38-aba4-6d15f84edf39" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c2cc68d3-cd58-465a-a2b0-c4770e48274c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eaa285d7-4e5a-4bd1-93a6-cb5adc469fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e476da24-428a-4b38-aba4-6d15f84edf39" xlink:to="loc_us-gaap_StockholdersEquity_eaa285d7-4e5a-4bd1-93a6-cb5adc469fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ef0decbe-10d9-47f1-b7e3-a7eca8de1c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8500ece7-a2f9-4f7e-94ce-8f4721da8179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef0decbe-10d9-47f1-b7e3-a7eca8de1c6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8500ece7-a2f9-4f7e-94ce-8f4721da8179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b852d63c-40fc-491a-8c84-907eafd73657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef0decbe-10d9-47f1-b7e3-a7eca8de1c6a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b852d63c-40fc-491a-8c84-907eafd73657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_356307a1-2928-4689-9978-42bfa8d31775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef0decbe-10d9-47f1-b7e3-a7eca8de1c6a" xlink:to="loc_us-gaap_InventoryNet_356307a1-2928-4689-9978-42bfa8d31775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5c08d65-edbd-45b8-8d1f-8c9ed20d6ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ef0decbe-10d9-47f1-b7e3-a7eca8de1c6a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5c08d65-edbd-45b8-8d1f-8c9ed20d6ec7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ea88fde-5f6d-46ff-b8bd-0bbd49446a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d8a8d540-565a-4d48-acc1-e78cb9f18733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ea88fde-5f6d-46ff-b8bd-0bbd49446a57" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d8a8d540-565a-4d48-acc1-e78cb9f18733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb9f9f2a-38a1-47d2-a45d-315c79e3f0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ea88fde-5f6d-46ff-b8bd-0bbd49446a57" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cb9f9f2a-38a1-47d2-a45d-315c79e3f0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_cbeee5f9-bba0-49b9-bc9e-fb7cb8e90d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_26a6b94d-de79-4ecb-9547-7ee0ce2075c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cbeee5f9-bba0-49b9-bc9e-fb7cb8e90d8f" xlink:to="loc_us-gaap_OperatingIncomeLoss_26a6b94d-de79-4ecb-9547-7ee0ce2075c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4cf602cd-8ee0-495f-b535-a864b6973194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cbeee5f9-bba0-49b9-bc9e-fb7cb8e90d8f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4cf602cd-8ee0-495f-b535-a864b6973194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_521042f1-a415-4d68-b291-46be9e7670c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_cbeee5f9-bba0-49b9-bc9e-fb7cb8e90d8f" xlink:to="loc_us-gaap_InterestExpense_521042f1-a415-4d68-b291-46be9e7670c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_587a2c5a-7d6d-4a4f-a454-3c4705c9897d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_025bfee0-928f-46e4-a85b-574de643964a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_587a2c5a-7d6d-4a4f-a454-3c4705c9897d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_025bfee0-928f-46e4-a85b-574de643964a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_df0be2bc-8f38-406c-a117-2c75afeef53b" xlink:href="cstl-20220630.xsd#cstl_OperatingExpensesNetOfOtherOperatingIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_587a2c5a-7d6d-4a4f-a454-3c4705c9897d" xlink:to="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_df0be2bc-8f38-406c-a117-2c75afeef53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_0694be29-0dda-4edb-b8fc-db6f43bc6d30" xlink:href="cstl-20220630.xsd#cstl_OperatingExpensesNetOfOtherOperatingIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3a75c99c-7d0a-4842-b4ad-6e33c11488d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_0694be29-0dda-4edb-b8fc-db6f43bc6d30" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3a75c99c-7d0a-4842-b4ad-6e33c11488d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba4ded3d-2650-4987-96f4-ee83cd77a094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_0694be29-0dda-4edb-b8fc-db6f43bc6d30" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba4ded3d-2650-4987-96f4-ee83cd77a094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_14103e8d-0a68-46e3-b613-f9f7080aa611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_0694be29-0dda-4edb-b8fc-db6f43bc6d30" xlink:to="loc_us-gaap_CostOfRevenue_14103e8d-0a68-46e3-b613-f9f7080aa611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cbebdc23-be90-42f8-913d-11566c827861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_0694be29-0dda-4edb-b8fc-db6f43bc6d30" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cbebdc23-be90-42f8-913d-11566c827861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6a9c477a-1a56-400e-9871-2f74dbd276ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_0694be29-0dda-4edb-b8fc-db6f43bc6d30" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6a9c477a-1a56-400e-9871-2f74dbd276ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86b5453b-d033-402d-93e3-6cd5e753b454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_564910f8-30ac-4996-adba-d1f1eb59f534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86b5453b-d033-402d-93e3-6cd5e753b454" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_564910f8-30ac-4996-adba-d1f1eb59f534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_febc3ba4-f3bd-411d-b3f3-0c7066094f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86b5453b-d033-402d-93e3-6cd5e753b454" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_febc3ba4-f3bd-411d-b3f3-0c7066094f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a30ca576-db85-4214-8294-fe3e8809d444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86b5453b-d033-402d-93e3-6cd5e753b454" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a30ca576-db85-4214-8294-fe3e8809d444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b08128-d00f-4623-a25a-4964546e48ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6a50ee20-e7c3-4369-a5e9-623bada1dace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b08128-d00f-4623-a25a-4964546e48ca" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6a50ee20-e7c3-4369-a5e9-623bada1dace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e773fdef-74a5-4923-9b55-fa3c029fb81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b08128-d00f-4623-a25a-4964546e48ca" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e773fdef-74a5-4923-9b55-fa3c029fb81f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a7597823-1cd7-43b7-aa0b-292b1ccc4935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b08128-d00f-4623-a25a-4964546e48ca" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a7597823-1cd7-43b7-aa0b-292b1ccc4935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e9f86c96-395f-4a02-ab92-47e2156fd4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b08128-d00f-4623-a25a-4964546e48ca" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e9f86c96-395f-4a02-ab92-47e2156fd4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ae3cd8c2-f49d-4d61-85be-2c8c2c7f0172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_77b08128-d00f-4623-a25a-4964546e48ca" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ae3cd8c2-f49d-4d61-85be-2c8c2c7f0172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f362cf62-4028-4d9a-96fd-3b8e840ec27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_NetIncomeLoss_f362cf62-4028-4d9a-96fd-3b8e840ec27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c3540a37-6a02-41b6-9cae-f98084b69576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_ShareBasedCompensation_c3540a37-6a02-41b6-9cae-f98084b69576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_304f5bf3-50a9-44e4-99fc-c0444bc0e62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_304f5bf3-50a9-44e4-99fc-c0444bc0e62d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a753735-b569-4f7f-bc7a-aced14d698f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6a753735-b569-4f7f-bc7a-aced14d698f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e571a233-3752-426a-8ed1-259d986fc34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e571a233-3752-426a-8ed1-259d986fc34e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fa2f506e-0f54-4fa1-9b22-79d8c2303270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fa2f506e-0f54-4fa1-9b22-79d8c2303270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_628e2a90-9c6f-4f4c-b8b6-61702784faf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_628e2a90-9c6f-4f4c-b8b6-61702784faf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75d51fee-cabe-4560-aacc-b0a57694c4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_75d51fee-cabe-4560-aacc-b0a57694c4a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_865052db-2d3b-46df-9dea-1f1eb5107097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_865052db-2d3b-46df-9dea-1f1eb5107097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_5ac57be4-e59d-4174-831b-543d69dc4442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_5ac57be4-e59d-4174-831b-543d69dc4442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0e1423da-6ab6-471f-abfd-e8c09888ce4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0e1423da-6ab6-471f-abfd-e8c09888ce4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_87475133-589b-4c21-8681-f56694d4c6f7" xlink:href="cstl-20220630.xsd#cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_87475133-589b-4c21-8681-f56694d4c6f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3bbf64bf-1479-4a8f-94cf-d681134b1cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3bbf64bf-1479-4a8f-94cf-d681134b1cbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ddeb59b-5a0e-44b7-8205-b673f9e235d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3ddeb59b-5a0e-44b7-8205-b673f9e235d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7c85c06e-6ae8-4dbe-b71e-baf675074311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7c85c06e-6ae8-4dbe-b71e-baf675074311" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_33f60d66-375a-4c90-8470-6036cf17b6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46e1c6f4-82f0-4f26-aac2-13948cd596e7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_33f60d66-375a-4c90-8470-6036cf17b6ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d842ea9f-95d5-4c9b-85b1-c6dd65fc2799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b3787c4-51cb-4e63-9c9f-7289eb02ff22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d842ea9f-95d5-4c9b-85b1-c6dd65fc2799" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0b3787c4-51cb-4e63-9c9f-7289eb02ff22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_d73d5328-3f9b-495d-9cb2-a3c743027ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d842ea9f-95d5-4c9b-85b1-c6dd65fc2799" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_d73d5328-3f9b-495d-9cb2-a3c743027ff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d99a9510-436d-4dbe-a965-dbf2a1754da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d842ea9f-95d5-4c9b-85b1-c6dd65fc2799" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d99a9510-436d-4dbe-a965-dbf2a1754da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79e4643f-45c0-4bf6-9b0c-0da97205a4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d842ea9f-95d5-4c9b-85b1-c6dd65fc2799" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_79e4643f-45c0-4bf6-9b0c-0da97205a4b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ProceedsFromPreviousAssetAcquisition_b04362a7-b078-4379-88f3-b9085476d6ef" xlink:href="cstl-20220630.xsd#cstl_ProceedsFromPreviousAssetAcquisition"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d842ea9f-95d5-4c9b-85b1-c6dd65fc2799" xlink:to="loc_cstl_ProceedsFromPreviousAssetAcquisition_b04362a7-b078-4379-88f3-b9085476d6ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsAcquisitionofconsiderationtransferredDetails"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b5bba314-572d-41d1-a6b2-239a91128939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c8a841b-c069-4d1f-8ff6-84466208c227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b5bba314-572d-41d1-a6b2-239a91128939" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c8a841b-c069-4d1f-8ff6-84466208c227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3b5aa9e1-6603-4c6d-939c-0349e3ba16cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b5bba314-572d-41d1-a6b2-239a91128939" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_3b5aa9e1-6603-4c6d-939c-0349e3ba16cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6f577c67-f5b5-4240-975f-dda98f03afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_b5bba314-572d-41d1-a6b2-239a91128939" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6f577c67-f5b5-4240-975f-dda98f03afe8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d109fb32-4112-43fe-8a9e-648ad896398f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d109fb32-4112-43fe-8a9e-648ad896398f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_72a92458-0268-4de4-a618-3aadcec0471f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_72a92458-0268-4de4-a618-3aadcec0471f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_d2c36215-fc16-4904-b7c8-81aaa9d0b0ec" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_d2c36215-fc16-4904-b7c8-81aaa9d0b0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_781facc8-7939-4163-95e8-6c51982bca38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_781facc8-7939-4163-95e8-6c51982bca38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_774a2e67-1879-4b08-94fa-4d7accb646f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_774a2e67-1879-4b08-94fa-4d7accb646f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6465847b-1129-48d1-a07a-a22390f5a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6465847b-1129-48d1-a07a-a22390f5a13a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_37794f6c-3683-4bf0-b0ab-9d1be4454825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_37794f6c-3683-4bf0-b0ab-9d1be4454825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0df248f1-450c-42c1-a5bb-1723aa2b2293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0df248f1-450c-42c1-a5bb-1723aa2b2293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_9a2617ec-e71c-46cc-a7cb-5627a4ae9fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_9a2617ec-e71c-46cc-a7cb-5627a4ae9fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b5206fee-957b-40d3-92e3-39dee3ffb472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_b5206fee-957b-40d3-92e3-39dee3ffb472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_671d8a44-7272-4574-b254-2c7674d486a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_671d8a44-7272-4574-b254-2c7674d486a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_51e5426a-2dfa-4f16-a1e1-51e0c2d021c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_fb4f4a70-71a5-49e1-9f53-8a5024e6203b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_51e5426a-2dfa-4f16-a1e1-51e0c2d021c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_86da5c7d-0ccc-4e09-a08e-ad68ea9a173c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_88e6d64c-3966-452f-ac0c-adc1c093d070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_86da5c7d-0ccc-4e09-a08e-ad68ea9a173c" xlink:to="loc_us-gaap_Goodwill_88e6d64c-3966-452f-ac0c-adc1c093d070" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9969f7f7-fe3f-47f7-9f3e-a13d9d822fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_86da5c7d-0ccc-4e09-a08e-ad68ea9a173c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9969f7f7-fe3f-47f7-9f3e-a13d9d822fc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNetPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_16c19e58-da10-4db9-ab1c-e41c60a9d89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b63027ae-1dc0-4856-bdcd-0cc6d1cb56d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_16c19e58-da10-4db9-ab1c-e41c60a9d89e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b63027ae-1dc0-4856-bdcd-0cc6d1cb56d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4fffa021-7d8f-46b5-b81a-7b2e31dc7312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_16c19e58-da10-4db9-ab1c-e41c60a9d89e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4fffa021-7d8f-46b5-b81a-7b2e31dc7312" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a0c5584a-3a26-453a-9e68-c1c34333c147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d4ffa334-8e4d-4c37-8f25-44979f702039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a0c5584a-3a26-453a-9e68-c1c34333c147" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d4ffa334-8e4d-4c37-8f25-44979f702039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ea248ace-417c-483d-b992-b91924f88a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a0c5584a-3a26-453a-9e68-c1c34333c147" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ea248ace-417c-483d-b992-b91924f88a86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_f0330295-adec-4113-b02e-c6c8625ba522" xlink:href="cstl-20220630.xsd#cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:to="loc_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_f0330295-adec-4113-b02e-c6c8625ba522" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_dc74e9c8-9301-4633-9830-76737f0e0fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_dc74e9c8-9301-4633-9830-76737f0e0fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5a92e86a-c524-4a2d-ae26-bd95292e35e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5a92e86a-c524-4a2d-ae26-bd95292e35e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29c7305b-6442-43b1-a2a8-c5ed7781743f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29c7305b-6442-43b1-a2a8-c5ed7781743f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7be49a2f-ba42-46c0-9f45-28d67d9b0187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7be49a2f-ba42-46c0-9f45-28d67d9b0187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0ded5a07-ea42-4b89-8d48-1eb5de96a7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8857e0cf-435c-43ae-8569-61a5d2bf7901" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0ded5a07-ea42-4b89-8d48-1eb5de96a7c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#OtherAccruedandCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_74cf90ef-6f68-4540-a911-8b42b04b6793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_74cf90ef-6f68-4540-a911-8b42b04b6793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccruedClinicalStudiesCurrent_07326b06-54d6-4921-980f-0aa7f6f35340" xlink:href="cstl-20220630.xsd#cstl_AccruedClinicalStudiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_cstl_AccruedClinicalStudiesCurrent_07326b06-54d6-4921-980f-0aa7f6f35340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_440afb7c-3cd0-417b-8fa8-d80ab2255c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_440afb7c-3cd0-417b-8fa8-d80ab2255c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3d7acd82-576a-44d5-bfa1-d2a9a59383ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3d7acd82-576a-44d5-bfa1-d2a9a59383ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_005b398f-e982-4013-a6fd-0fc5481c1af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_005b398f-e982-4013-a6fd-0fc5481c1af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccruedFixedAssetPurchases_3d10f727-88e8-4399-a66b-4feaa40324ba" xlink:href="cstl-20220630.xsd#cstl_AccruedFixedAssetPurchases"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_cstl_AccruedFixedAssetPurchases_3d10f727-88e8-4399-a66b-4feaa40324ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_eda940b8-34cb-44d4-b6c2-2ee33ace9fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_eda940b8-34cb-44d4-b6c2-2ee33ace9fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationPayableCurrent_ab92dc06-4c43-4c5e-a62d-1b679071ca84" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationPayableCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_22fb1be9-da1f-4ab5-b566-9a2bff396fba" xlink:to="loc_cstl_BusinessCombinationConsiderationPayableCurrent_ab92dc06-4c43-4c5e-a62d-1b679071ca84" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cstl-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c77279c-977d-402a-b1b2-5d29ed09603d,g:da8c0f38-2da3-40ff-b133-9fd71c151e0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i79a43d52671b45eaa3cf3fc81a3acd23_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d652d09d-7afa-40e4-9e7b-af05d6f5b1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_SharesOutstanding_d652d09d-7afa-40e4-9e7b-af05d6f5b1e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b176e266-664b-42e3-9dfe-32e5ec2e8c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockholdersEquity_b176e266-664b-42e3-9dfe-32e5ec2e8c1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_d5ef7468-4c3b-407f-894f-59fafdefdd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_d5ef7468-4c3b-407f-894f-59fafdefdd55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c609b6bc-b993-40d2-8bc6-a07b931f3769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c609b6bc-b993-40d2-8bc6-a07b931f3769" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7425146-bca3-4a6f-9fbc-5e4fede8452c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7425146-bca3-4a6f-9fbc-5e4fede8452c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69999b7b-98e0-49fc-996f-961626561753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69999b7b-98e0-49fc-996f-961626561753" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4c7895e-5fb0-4b59-9230-8baf185aa6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4c7895e-5fb0-4b59-9230-8baf185aa6e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fd405b8-ae90-4dfb-bf38-9db648004d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fd405b8-ae90-4dfb-bf38-9db648004d8b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a6b513b9-b0b0-4e5d-b2cb-ae2cc7428b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a6b513b9-b0b0-4e5d-b2cb-ae2cc7428b95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_96748808-742c-48b3-bccc-585a446a6394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_96748808-742c-48b3-bccc-585a446a6394" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd52f260-cd9d-4a04-bdbb-782299ab18d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd52f260-cd9d-4a04-bdbb-782299ab18d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e6b0fcdd-8c96-4b96-9a34-7869f4f94d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e6b0fcdd-8c96-4b96-9a34-7869f4f94d79" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa6c18c0-f4db-4a39-b467-a1658ef4a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_NetIncomeLoss_fa6c18c0-f4db-4a39-b467-a1658ef4a692" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f69529af-97d0-4a77-bd89-bbd1dcccf6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89b84f6f-e80b-4f57-b956-97c4431a17c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f941f464-d2bb-4fad-8d22-d8e24eebec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f941f464-d2bb-4fad-8d22-d8e24eebec12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:to="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3dec389d-b535-46ae-8736-5b23f05d3863_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:to="loc_us-gaap_EquityComponentDomain_3dec389d-b535-46ae-8736-5b23f05d3863_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:to="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1bac6746-e34e-43c7-a325-3f7a3bb30b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_PreferredStockMember_1bac6746-e34e-43c7-a325-3f7a3bb30b33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0a093c4d-0711-4548-bb70-0dd91fce6bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_CommonStockMember_0a093c4d-0711-4548-bb70-0dd91fce6bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ba5b88e3-69bd-4b1d-b62f-00c9e98f8ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ba5b88e3-69bd-4b1d-b62f-00c9e98f8ce4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b9fe2500-e7e7-4db2-9f35-d54b606a4276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_RetainedEarningsMember_b9fe2500-e7e7-4db2-9f35-d54b606a4276" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_669f7b60-ad10-477e-9d0b-a4dbe856ca84_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_669f7b60-ad10-477e-9d0b-a4dbe856ca84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_394151d0-4356-460a-925f-edf0e69395d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_394151d0-4356-460a-925f-edf0e69395d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b996aae4-db7d-448c-925c-8ba1dc31faf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_394151d0-4356-460a-925f-edf0e69395d5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b996aae4-db7d-448c-925c-8ba1dc31faf3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#RevenueDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="extended" id="ie97968eb963043dba657432915c9575e_RevenueDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_75b03ef6-453e-4bc6-8f21-4e1c891d1383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a9ef0c4-2cbc-49f3-971c-b79021f44162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_75b03ef6-453e-4bc6-8f21-4e1c891d1383" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a9ef0c4-2cbc-49f3-971c-b79021f44162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_75b03ef6-453e-4bc6-8f21-4e1c891d1383" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:to="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:to="loc_srt_ProductsAndServicesDomain_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:to="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_DermatologicMember_f3cb8f96-192d-4340-854b-5ddea67b14e5" xlink:href="cstl-20220630.xsd#cstl_DermatologicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:to="loc_cstl_DermatologicMember_f3cb8f96-192d-4340-854b-5ddea67b14e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_ad4883e4-513f-4855-b6b2-252e56167253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:to="loc_us-gaap_ServiceOtherMember_ad4883e4-513f-4855-b6b2-252e56167253" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#RevenueConcentrationofRiskbyRiskFactorDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails" xlink:type="extended" id="ie321845d6204481a98d8bda4a9af3563_RevenueConcentrationofRiskbyRiskFactorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1c8fb64e-8834-45c6-939e-7405c6b3ba76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_51c7a786-19c5-4f66-a00c-047bbba90de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1c8fb64e-8834-45c6-939e-7405c6b3ba76" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_51c7a786-19c5-4f66-a00c-047bbba90de6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1c8fb64e-8834-45c6-939e-7405c6b3ba76" xlink:to="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4435cc8-a0d5-436e-a40b-4732eff184c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4435cc8-a0d5-436e-a40b-4732eff184c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MedicareMember_7a742e0a-3bfd-4464-9d8f-7fb148d3c1c8" xlink:href="cstl-20220630.xsd#cstl_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:to="loc_cstl_MedicareMember_7a742e0a-3bfd-4464-9d8f-7fb148d3c1c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MedicareAdvantagePlansMember_f843d579-6e16-42f1-be9c-fcaf607ffb08" xlink:href="cstl-20220630.xsd#cstl_MedicareAdvantagePlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:to="loc_cstl_MedicareAdvantagePlansMember_f843d579-6e16-42f1-be9c-fcaf607ffb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BlueCrossBlueShieldPlansMember_42ef9939-9de0-4df6-92d0-affb69edf1c0" xlink:href="cstl-20220630.xsd#cstl_BlueCrossBlueShieldPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:to="loc_cstl_BlueCrossBlueShieldPlansMember_42ef9939-9de0-4df6-92d0-affb69edf1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1eb291a0-f7c1-4e1e-9cc8-0f58e695733b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1eb291a0-f7c1-4e1e-9cc8-0f58e695733b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccountsReceivableCurrentMember_41e09fa4-4b7b-4105-aa4f-6737069e43a0" xlink:href="cstl-20220630.xsd#cstl_AccountsReceivableCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:to="loc_cstl_AccountsReceivableCurrentMember_41e09fa4-4b7b-4105-aa4f-6737069e43a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccountsReceivableNoncurrentMember_06d11c56-6cf3-4dc2-a3a7-f8dd0740fd19" xlink:href="cstl-20220630.xsd#cstl_AccountsReceivableNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:to="loc_cstl_AccountsReceivableNoncurrentMember_06d11c56-6cf3-4dc2-a3a7-f8dd0740fd19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0779277f-5ee6-46eb-86b3-07a07739a1bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0779277f-5ee6-46eb-86b3-07a07739a1bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a6cf4e9e-5445-467b-b132-f461645dbe14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a6cf4e9e-5445-467b-b132-f461645dbe14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ThirdPartyPayorConcentrationRiskMember_f3ca8f6d-85c4-4333-a47c-afb51356b99e" xlink:href="cstl-20220630.xsd#cstl_ThirdPartyPayorConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a6cf4e9e-5445-467b-b132-f461645dbe14" xlink:to="loc_cstl_ThirdPartyPayorConcentrationRiskMember_f3ca8f6d-85c4-4333-a47c-afb51356b99e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i0e4be8e610834d7a852d4358b2937d04_LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c56fc4de-ef0d-4dcb-add7-678fa9c58fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b2c37d43-5b8f-4be5-aaeb-35f6e1a81d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c56fc4de-ef0d-4dcb-add7-678fa9c58fe9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b2c37d43-5b8f-4be5-aaeb-35f6e1a81d24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c56fc4de-ef0d-4dcb-add7-678fa9c58fe9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d46de277-787e-49f4-acb5-dc19b08d382b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d46de277-787e-49f4-acb5-dc19b08d382b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_783b6da4-7238-42a4-b5d8-3c1a32139f77" xlink:href="cstl-20220630.xsd#cstl_StockOptionsAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:to="loc_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_783b6da4-7238-42a4-b5d8-3c1a32139f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_499de9d6-b00e-451a-8e2e-1c959596a244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:to="loc_us-gaap_EmployeeStockMember_499de9d6-b00e-451a-8e2e-1c959596a244" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i03862ff3eb934d2fb6a92886fbf9728d_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_5c123a3a-d399-402c-a698-f2a83294ab9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_5c123a3a-d399-402c-a698-f2a83294ab9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_46b7aff2-27bc-4e25-bc5b-bf10299138a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_46b7aff2-27bc-4e25-bc5b-bf10299138a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f5c08c21-4d15-4eb5-9562-45aaafece550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f5c08c21-4d15-4eb5-9562-45aaafece550" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ProceedsFromPreviousAssetAcquisition_79ddd8ad-8e87-4998-a90d-6da3bb49e8bf" xlink:href="cstl-20220630.xsd#cstl_ProceedsFromPreviousAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_ProceedsFromPreviousAssetAcquisition_79ddd8ad-8e87-4998-a90d-6da3bb49e8bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1c166964-a3ce-4eef-b306-43e6bd423707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1c166964-a3ce-4eef-b306-43e6bd423707" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fdd43196-5823-43e1-91b3-6f91718acb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fdd43196-5823-43e1-91b3-6f91718acb75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_6b29a9c2-8a25-4eef-8883-c4ef8fb46352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_6b29a9c2-8a25-4eef-8883-c4ef8fb46352" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7066f268-8d01-411c-addd-9a420a5ba0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_SharePrice_7066f268-8d01-411c-addd-9a420a5ba0e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5be0e44a-63d7-4532-8dea-d0e9c6488a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5be0e44a-63d7-4532-8dea-d0e9c6488a73" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_b359bce8-9303-4cb1-a545-812ce959bc8e" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_b359bce8-9303-4cb1-a545-812ce959bc8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_683825c6-549a-4a5d-858d-6830b5cb2a64" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_683825c6-549a-4a5d-858d-6830b5cb2a64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_816c1d3e-d869-46e3-9c8a-4d7cf72240e9" xlink:href="cstl-20220630.xsd#cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_816c1d3e-d869-46e3-9c8a-4d7cf72240e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_542bf3be-2792-4911-9c74-46c64986698f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_542bf3be-2792-4911-9c74-46c64986698f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_12a7d924-5823-4759-a505-f5a3f204726a" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_12a7d924-5823-4759-a505-f5a3f204726a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6581685d-5f80-4878-a585-b0dbf0ac1330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6581685d-5f80-4878-a585-b0dbf0ac1330" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ee5f9428-130e-444a-9453-e847a7309873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ee5f9428-130e-444a-9453-e847a7309873" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c94c99-2917-4367-8c97-ab90566d3d99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c94c99-2917-4367-8c97-ab90566d3d99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16ee83c2-aed8-4077-a301-9f40e9f5e71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16ee83c2-aed8-4077-a301-9f40e9f5e71f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_f5ed17ac-f3ef-42d7-af1f-2f3d03a6da64" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16ee83c2-aed8-4077-a301-9f40e9f5e71f" xlink:to="loc_cstl_AltheaDxIncMember_f5ed17ac-f3ef-42d7-af1f-2f3d03a6da64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9db4a460-498a-469f-a3da-3b2523dce11c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:to="loc_us-gaap_EquityComponentDomain_9db4a460-498a-469f-a3da-3b2523dce11c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_23c27336-0588-4750-92f3-1ff26dec4c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:to="loc_us-gaap_EquityComponentDomain_23c27336-0588-4750-92f3-1ff26dec4c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a8f5d622-1936-409f-a9a7-c7a81ac80b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_23c27336-0588-4750-92f3-1ff26dec4c5f" xlink:to="loc_us-gaap_CommonStockMember_a8f5d622-1936-409f-a9a7-c7a81ac80b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04591525-4d56-49fb-a31d-f91144aa88ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04591525-4d56-49fb-a31d-f91144aa88ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94796909-927d-4b83-b1a0-eae5a953df1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94796909-927d-4b83-b1a0-eae5a953df1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b20fa873-2ba7-49a9-93a7-6434d15599a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94796909-927d-4b83-b1a0-eae5a953df1e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b20fa873-2ba7-49a9-93a7-6434d15599a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1834f5fd-0c88-4c85-af98-86e3ab6579ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1834f5fd-0c88-4c85-af98-86e3ab6579ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MyriadMyPathLLCMember_18ebaa1f-1779-4ed2-b94a-78b6486319a6" xlink:href="cstl-20220630.xsd#cstl_MyriadMyPathLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:to="loc_cstl_MyriadMyPathLLCMember_18ebaa1f-1779-4ed2-b94a-78b6486319a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember_08aec8f5-e929-4639-87d0-7d06bc7854e6" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:to="loc_cstl_CernosticsIncMember_08aec8f5-e929-4639-87d0-7d06bc7854e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_21b783d0-61aa-4721-9d80-65a098ce8cb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_21b783d0-61aa-4721-9d80-65a098ce8cb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_7f21a246-3f41-45b1-af39-1ff8d17a5170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_7f21a246-3f41-45b1-af39-1ff8d17a5170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_IncomeTaxAdjustmentMember_fcb98653-5887-493d-842f-10944952281b" xlink:href="cstl-20220630.xsd#cstl_IncomeTaxAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:to="loc_cstl_IncomeTaxAdjustmentMember_fcb98653-5887-493d-842f-10944952281b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsAcquisitionofconsiderationtransferredDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails" xlink:type="extended" id="i86a2c9da03c44c2785b7e37388aabced_AcquisitionsAcquisitionofconsiderationtransferredDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d4d5ca5b-39bb-4a18-8e19-a7f20c305ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d4d5ca5b-39bb-4a18-8e19-a7f20c305ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_dfdd29e2-99d4-43bb-88f8-75335fa0cae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_dfdd29e2-99d4-43bb-88f8-75335fa0cae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5d44a9f7-6fbb-4b1f-9f50-4245e8417179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5d44a9f7-6fbb-4b1f-9f50-4245e8417179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e0366e68-8c9d-4b07-962b-8fd44c7c8492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e0366e68-8c9d-4b07-962b-8fd44c7c8492" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8ace582b-77cd-40f1-b195-1a2a2d3d5f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8ace582b-77cd-40f1-b195-1a2a2d3d5f35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_546fca38-8949-42f5-917b-b09a34b66d22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_546fca38-8949-42f5-917b-b09a34b66d22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da7db6d-4122-42ad-b24b-9c92b965beed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da7db6d-4122-42ad-b24b-9c92b965beed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_ab3a782c-7d6f-4c70-b4fc-02bcfbb9aca7" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da7db6d-4122-42ad-b24b-9c92b965beed" xlink:to="loc_cstl_AltheaDxIncMember_ab3a782c-7d6f-4c70-b4fc-02bcfbb9aca7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i153b3a6a57e54aa8bc37c3390dc8a6e4_AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_569fd8cc-f6c8-41f3-89e1-6454a4050820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_569fd8cc-f6c8-41f3-89e1-6454a4050820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d2dc1ce-7b3d-4517-8b3d-960d1fe22966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d2dc1ce-7b3d-4517-8b3d-960d1fe22966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eb707f84-c605-4878-8c36-c86deeeb15da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eb707f84-c605-4878-8c36-c86deeeb15da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_87bdeeed-b432-4061-a111-b115c3bb38bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_87bdeeed-b432-4061-a111-b115c3bb38bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a81053cb-ea02-46e7-9d92-35c68fcfc5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a81053cb-ea02-46e7-9d92-35c68fcfc5a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b5acda19-c0bd-4a58-9397-6ab3591c501e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b5acda19-c0bd-4a58-9397-6ab3591c501e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a6aa46f3-80d8-4397-ae4f-310671f5fa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a6aa46f3-80d8-4397-ae4f-310671f5fa09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_33ec08a5-fea9-4259-b749-ed5ff6f6600d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_33ec08a5-fea9-4259-b749-ed5ff6f6600d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_ff96f8d5-2eb5-41e4-9671-d3f99cd2664c" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_ff96f8d5-2eb5-41e4-9671-d3f99cd2664c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_7f01bc02-6360-42a9-b593-1b8ca5686a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_7f01bc02-6360-42a9-b593-1b8ca5686a14" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee255a01-ef3e-428e-83d9-1a9721c8193f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee255a01-ef3e-428e-83d9-1a9721c8193f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6f3ce1bf-b6a6-438e-9dc5-a9f414995292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6f3ce1bf-b6a6-438e-9dc5-a9f414995292" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c30bae06-05c5-48d4-baea-b887b85abdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c30bae06-05c5-48d4-baea-b887b85abdfa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_239dad33-4cd7-46cb-b9b4-ad661bd48793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_Goodwill_239dad33-4cd7-46cb-b9b4-ad661bd48793" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0823335a-12a1-4e4d-b661-54a0adce0cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0823335a-12a1-4e4d-b661-54a0adce0cd4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cfd3924-faad-4a68-a886-f40fe0cac1b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1cfd3924-faad-4a68-a886-f40fe0cac1b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0825c352-30b0-4973-a6e5-6eb5106c7ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0825c352-30b0-4973-a6e5-6eb5106c7ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_828d05aa-cd39-429d-8cc1-11ca8cd31f1e" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0825c352-30b0-4973-a6e5-6eb5106c7ad9" xlink:to="loc_cstl_AltheaDxIncMember_828d05aa-cd39-429d-8cc1-11ca8cd31f1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails" xlink:type="extended" id="ib9d1d06bd3de4f25ada6fd7bfc9b857f_AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9d2137ea-e495-4cbe-90c1-7aa0629364df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9d2137ea-e495-4cbe-90c1-7aa0629364df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_47540580-c2b6-4284-bb60-4473d0e04bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_47540580-c2b6-4284-bb60-4473d0e04bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_927a57b5-8766-46e8-b59e-ee08733fb701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_927a57b5-8766-46e8-b59e-ee08733fb701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_1af633c1-72b6-447e-824d-237d24d97c2a" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_927a57b5-8766-46e8-b59e-ee08733fb701" xlink:to="loc_cstl_AltheaDxIncMember_1af633c1-72b6-447e-824d-237d24d97c2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNetPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="extended" id="ifa193b45b6764de2b0cff936c8ec599d_PropertyandEquipmentNetPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_60718945-a029-47be-98a7-1c4d8abd061f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_60718945-a029-47be-98a7-1c4d8abd061f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0b0babd7-bf2f-4dc7-b2dd-df46d984e140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0b0babd7-bf2f-4dc7-b2dd-df46d984e140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1e88ba23-4c65-492f-851c-5908e6a1b989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1e88ba23-4c65-492f-851c-5908e6a1b989" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_be561971-bb65-4787-ad25-fbfa28db8d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_be561971-bb65-4787-ad25-fbfa28db8d56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_907d54cd-08a9-48b0-917f-61df6d5dbbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_907d54cd-08a9-48b0-917f-61df6d5dbbbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_babf2dc2-b8b8-4217-837d-d735beea6cd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_babf2dc2-b8b8-4217-837d-d735beea6cd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5bc23c25-f345-4f83-b6d3-dbd3bd8ade64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_EquipmentMember_5bc23c25-f345-4f83-b6d3-dbd3bd8ade64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7a7a392d-952e-4d92-b115-988136c31d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7a7a392d-952e-4d92-b115-988136c31d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_16ca3920-1bd7-4f9d-b295-0446a2743f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_ComputerEquipmentMember_16ca3920-1bd7-4f9d-b295-0446a2743f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_45a5d3d3-4cf7-498b-88ee-9aa2b7f4b87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_45a5d3d3-4cf7-498b-88ee-9aa2b7f4b87a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_5092e69f-cab2-4ce2-ad3a-923dbfdf21eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_ConstructionInProgressMember_5092e69f-cab2-4ce2-ad3a-923dbfdf21eb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNetDepreciationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails" xlink:type="extended" id="idcce163cc3fe4261b3a911dbedab960c_PropertyandEquipmentNetDepreciationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d0755ad-38ad-446c-99fd-4000bf4e380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_90f1d054-bde8-4ccd-9370-33f368de0085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d0755ad-38ad-446c-99fd-4000bf4e380c" xlink:to="loc_us-gaap_Depreciation_90f1d054-bde8-4ccd-9370-33f368de0085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d0755ad-38ad-446c-99fd-4000bf4e380c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bcc0997d-0468-4d82-965b-a2d276a864b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bcc0997d-0468-4d82-965b-a2d276a864b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_db2e154f-225f-48c8-bbff-f374982bd40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:to="loc_us-gaap_CostOfSalesMember_db2e154f-225f-48c8-bbff-f374982bd40f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0447b909-0978-4c85-8249-59a71bf82ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0447b909-0978-4c85-8249-59a71bf82ef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2ed263d5-d75a-456b-b40e-e77aaaf49d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2ed263d5-d75a-456b-b40e-e77aaaf49d98" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" xlink:type="extended" id="i2bfd0a72dd62492a876f8d3926f20497_GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e5b71324-f1d1-4e66-baef-53ec24d2e7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e5b71324-f1d1-4e66-baef-53ec24d2e7d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3af2e72b-3fcf-46cc-8f14-0dd42f74683e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3af2e72b-3fcf-46cc-8f14-0dd42f74683e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2de323c8-8161-4e0b-99c4-9c50e4af3a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2de323c8-8161-4e0b-99c4-9c50e4af3a5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b8fd622a-2a2a-46c2-a19b-3d21e32aeded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b8fd622a-2a2a-46c2-a19b-3d21e32aeded" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_894a2fcd-17a2-4399-9729-ecd878935bef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_894a2fcd-17a2-4399-9729-ecd878935bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4638446b-ac0a-4828-9da0-e93563121900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4638446b-ac0a-4828-9da0-e93563121900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssembledWorkforceMember_28e96ef1-3201-4f4a-bfab-f5ae6ac52cd2" xlink:href="cstl-20220630.xsd#cstl_AssembledWorkforceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:to="loc_cstl_AssembledWorkforceMember_28e96ef1-3201-4f4a-bfab-f5ae6ac52cd2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#LeasesAssetsAndLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails" xlink:type="extended" id="i45f77b77264a4980bdad7c933ff4a6b7_LeasesAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c9c29df-428d-4cad-b352-90f91e66dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c9c29df-428d-4cad-b352-90f91e66dcd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7766b1b1-7d53-4783-9836-ca5505b99865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_OperatingLeaseLiability_7766b1b1-7d53-4783-9836-ca5505b99865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_b64933a9-5ff4-497f-b946-3564559b03c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_OtherLiabilities_b64933a9-5ff4-497f-b946-3564559b03c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f0054aa2-d517-43c4-9fcf-2585115c50a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f0054aa2-d517-43c4-9fcf-2585115c50a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_806166c4-4f5d-4626-84a0-77df602c2060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_806166c4-4f5d-4626-84a0-77df602c2060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_f08c13ba-185e-4b86-ba90-113a97b8edfc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_f08c13ba-185e-4b86-ba90-113a97b8edfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_17abf0f6-9f5d-481e-b61e-640eb2662e21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:to="loc_us-gaap_TypeOfAdoptionMember_17abf0f6-9f5d-481e-b61e-640eb2662e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_24080500-73eb-4c1c-b64f-c9b17d6ea20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:to="loc_us-gaap_TypeOfAdoptionMember_24080500-73eb-4c1c-b64f-c9b17d6ea20b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_88603de8-b9a3-47d8-b873-6621954ab7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_24080500-73eb-4c1c-b64f-c9b17d6ea20b" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_88603de8-b9a3-47d8-b873-6621954ab7f3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i9c4cb4c84ad0436492d2d346adeb1849_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06158c39-51c3-4d50-9789-f5cf3ba98ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06158c39-51c3-4d50-9789-f5cf3ba98ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_d497fdd1-5d58-401b-b6ee-426fcea2826c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_d497fdd1-5d58-401b-b6ee-426fcea2826c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a50ab5b-87b0-49df-94a7-04070d8843d2" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a50ab5b-87b0-49df-94a7-04070d8843d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9855cefd-75d0-4191-9eda-895542f780f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9855cefd-75d0-4191-9eda-895542f780f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseBaseRent_356599ff-4edc-42c3-8b47-2b6d9f13f485" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseBaseRent_356599ff-4edc-42c3-8b47-2b6d9f13f485" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseMaximumBaseRent_ad323329-3971-48c8-b454-e05d17d8a098" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseMaximumBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseMaximumBaseRent_ad323329-3971-48c8-b454-e05d17d8a098" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_5154deeb-1f04-4e63-95fb-61d62a927da4" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseNumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_5154deeb-1f04-4e63-95fb-61d62a927da4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_6fa9f59e-bcdc-42a7-bdd1-389835552568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_TenantImprovements_6fa9f59e-bcdc-42a7-bdd1-389835552568" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseOptionToTerminateTerm_88829098-5397-4ba5-8044-69ee441d7efa" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseOptionToTerminateTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseOptionToTerminateTerm_88829098-5397-4ba5-8044-69ee441d7efa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseEarlyTerminationFee_fa5cafc8-323e-417f-a18f-c61f0d35ac47" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseEarlyTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseEarlyTerminationFee_fa5cafc8-323e-417f-a18f-c61f0d35ac47" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a0a72fab-ae70-4fed-97aa-8858e0d0d52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a0a72fab-ae70-4fed-97aa-8858e0d0d52f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a1670a38-e8fb-4ea4-87b7-829809809d03_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a1670a38-e8fb-4ea4-87b7-829809809d03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b775c9bb-ee21-419a-bd3c-4d39e7ea0d1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b775c9bb-ee21-419a-bd3c-4d39e7ea0d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ea69e2f9-bf38-47e9-8cc2-ac3759f4cf7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b775c9bb-ee21-419a-bd3c-4d39e7ea0d1f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ea69e2f9-bf38-47e9-8cc2-ac3759f4cf7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:to="loc_us-gaap_LeaseContractualTermDomain_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ffdfcd00-4d2d-4b55-bf65-5e2193ad62cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ffdfcd00-4d2d-4b55-bf65-5e2193ad62cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ffdfcd00-4d2d-4b55-bf65-5e2193ad62cd" xlink:to="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseFirstSixMonthsMember_790f3468-a7c8-4246-9f3f-30d4a5973426" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseFirstSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:to="loc_cstl_PittsburghLeaseFirstSixMonthsMember_790f3468-a7c8-4246-9f3f-30d4a5973426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseAfterSixMonthsMember_f2df16c0-0d8c-4618-85a7-598da948df6e" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseAfterSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:to="loc_cstl_PittsburghLeaseAfterSixMonthsMember_f2df16c0-0d8c-4618-85a7-598da948df6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_157b7ceb-eed6-4057-90a5-e09eaa1e30b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_157b7ceb-eed6-4057-90a5-e09eaa1e30b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_463e3ac4-a87d-4289-9ebe-a089b2e15efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_463e3ac4-a87d-4289-9ebe-a089b2e15efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_3c848364-1f72-4acc-9b2d-35fb1595da44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_463e3ac4-a87d-4289-9ebe-a089b2e15efb" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_3c848364-1f72-4acc-9b2d-35fb1595da44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="i7f470e96055342fda698c6a00fcda088_FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e64d4dd-220b-4440-9cf6-5566c6cd6e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e64d4dd-220b-4440-9cf6-5566c6cd6e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_bd1e0892-9efd-4c05-a72b-7bf1cd53b6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_bd1e0892-9efd-4c05-a72b-7bf1cd53b6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_473893f8-8c5b-468c-a505-3732ea419371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_473893f8-8c5b-468c-a505-3732ea419371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fffa3b5-13d4-458e-ac9f-83d638cad29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fffa3b5-13d4-458e-ac9f-83d638cad29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cd61124c-a239-4cd9-b8f9-2ad5b58e50dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fffa3b5-13d4-458e-ac9f-83d638cad29c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cd61124c-a239-4cd9-b8f9-2ad5b58e50dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5302db97-6299-4fe1-ac69-dc95e35d986e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5302db97-6299-4fe1-ac69-dc95e35d986e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_557d609b-54ef-4924-af0b-950ffbc61ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_557d609b-54ef-4924-af0b-950ffbc61ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7b8e49b6-9723-4ebf-83b0-d9fae0d564cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7b8e49b6-9723-4ebf-83b0-d9fae0d564cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6a033941-f3d0-4ea2-8355-7590583608a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6a033941-f3d0-4ea2-8355-7590583608a0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i35a1ee10d2aa4f44b65aafcef5f815d4_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0ed5dc8e-7692-49d2-bc34-62e2f0316b78" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0ed5dc8e-7692-49d2-bc34-62e2f0316b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_65dd7a13-7d9c-4d0e-a228-bde75a95b062" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_65dd7a13-7d9c-4d0e-a228-bde75a95b062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_778bf78a-6783-4f68-98e6-30992acc1802" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_778bf78a-6783-4f68-98e6-30992acc1802" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1f64bafe-e05c-464a-9392-51907cdfff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1f64bafe-e05c-464a-9392-51907cdfff2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_246b181d-8c5e-4b6b-9e74-9ca486ff952d" xlink:href="cstl-20220630.xsd#cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_246b181d-8c5e-4b6b-9e74-9ca486ff952d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e459deec-c54a-4dad-8cb7-a59ec611f16e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e459deec-c54a-4dad-8cb7-a59ec611f16e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_04fb4006-c3c3-45e5-8f6c-0d8ddaafbdff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_04fb4006-c3c3-45e5-8f6c-0d8ddaafbdff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember_5aa163a8-703e-4029-b15b-fdd592eb7876" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_04fb4006-c3c3-45e5-8f6c-0d8ddaafbdff" xlink:to="loc_cstl_CernosticsIncMember_5aa163a8-703e-4029-b15b-fdd592eb7876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5852ff90-b204-4ea6-9eaf-e92a29691fdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5852ff90-b204-4ea6-9eaf-e92a29691fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_35af7968-ec6e-41a5-980b-8ce05f2a5cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_35af7968-ec6e-41a5-980b-8ce05f2a5cb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b49c9419-2b07-4aa0-b8c6-4175a5e17a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b49c9419-2b07-4aa0-b8c6-4175a5e17a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_618d689c-53ba-49c0-91bc-905a2f6cc8d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_618d689c-53ba-49c0-91bc-905a2f6cc8d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_09f33b67-9c0a-45c6-95ee-2bf655b5662f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_09f33b67-9c0a-45c6-95ee-2bf655b5662f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_08d6c339-5bb0-4af0-abdc-4653077f1999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_09f33b67-9c0a-45c6-95ee-2bf655b5662f" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_08d6c339-5bb0-4af0-abdc-4653077f1999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_72a7046b-6592-4bfa-bec1-b5d271b5e5c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_72a7046b-6592-4bfa-bec1-b5d271b5e5c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17fdc4bf-acbe-479d-8da5-643c4ee7ecaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17fdc4bf-acbe-479d-8da5-643c4ee7ecaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2a11ddbf-d294-4ef8-b76d-a143f3daf084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_17fdc4bf-acbe-479d-8da5-643c4ee7ecaa" xlink:to="loc_srt_ScenarioForecastMember_2a11ddbf-d294-4ef8-b76d-a143f3daf084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b33a6a-0309-4c0c-a855-5bf0348b90de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b33a6a-0309-4c0c-a855-5bf0348b90de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_3c3f8429-25d3-475d-b87c-611f6f09de51" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b33a6a-0309-4c0c-a855-5bf0348b90de" xlink:to="loc_cstl_AltheaDxIncMember_3c3f8429-25d3-475d-b87c-611f6f09de51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended" id="i6083701a11f142a385a5631915982c45_FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d8c4a89f-e6c4-4ccf-972d-4aa1cc5fcc36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d8c4a89f-e6c4-4ccf-972d-4aa1cc5fcc36" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6356462-001d-47e4-bfc2-98e01fc6d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6356462-001d-47e4-bfc2-98e01fc6d273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_254f4feb-669c-40b0-b9b2-6c76cccea154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_254f4feb-669c-40b0-b9b2-6c76cccea154" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ced5bcdf-43f5-4b6e-b8f7-1d15028e4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ced5bcdf-43f5-4b6e-b8f7-1d15028e4fcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_abfe7d82-27c0-4de8-a0d1-cc74ef085a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d8c4a89f-e6c4-4ccf-972d-4aa1cc5fcc36" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f98d810c-585f-46b9-a307-922ce324d211_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f98d810c-585f-46b9-a307-922ce324d211_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_48098c43-4713-43d3-8286-19659a505585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:to="loc_us-gaap_AssetAcquisitionDomain_48098c43-4713-43d3-8286-19659a505585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember_66a97eeb-0e64-41f8-941a-c4199cb2e8a3" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_48098c43-4713-43d3-8286-19659a505585" xlink:to="loc_cstl_CernosticsIncMember_66a97eeb-0e64-41f8-941a-c4199cb2e8a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b664ef-2281-4f55-abd9-ed5257372307_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b664ef-2281-4f55-abd9-ed5257372307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76daaed2-68d8-443b-bd00-9a5771fb2ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76daaed2-68d8-443b-bd00-9a5771fb2ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_b5bde9dd-5947-43b5-b875-6faf718bc6c0" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76daaed2-68d8-443b-bd00-9a5771fb2ba3" xlink:to="loc_cstl_AltheaDxIncMember_b5bde9dd-5947-43b5-b875-6faf718bc6c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" xlink:type="extended" id="i84db271f471044febc88e28c0d2a2613_StockIncentivePlansandStockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51e332c9-1480-4734-9f25-dd08b22ece62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51e332c9-1480-4734-9f25-dd08b22ece62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_47343c6c-0829-4e0b-88f0-0e77b1594a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_47343c6c-0829-4e0b-88f0-0e77b1594a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5aa623c-097c-489e-aa8b-ff9fea3c57ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5aa623c-097c-489e-aa8b-ff9fea3c57ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c1dfb0b-9fa7-450c-8498-ef99885410d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c1dfb0b-9fa7-450c-8498-ef99885410d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_85dde78e-bc34-465d-8de9-41819f5786c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_85dde78e-bc34-465d-8de9-41819f5786c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c87f7c0-74e4-446e-ad59-b3ce7eb0f10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c87f7c0-74e4-446e-ad59-b3ce7eb0f10b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:to="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7204fa79-16ad-413d-88a9-d29a3a5f845a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:to="loc_us-gaap_PlanNameDomain_7204fa79-16ad-413d-88a9-d29a3a5f845a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:to="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_TwoThousandNineteenEquityIncentivePlanMember_48739080-d1ae-4bc2-ae39-a727a1e1455f" xlink:href="cstl-20220630.xsd#cstl_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:to="loc_cstl_TwoThousandNineteenEquityIncentivePlanMember_48739080-d1ae-4bc2-ae39-a727a1e1455f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_EmployeeStockPurchasePlanMember_d4bb217a-2170-49f0-aa03-2faf079619f1" xlink:href="cstl-20220630.xsd#cstl_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:to="loc_cstl_EmployeeStockPurchasePlanMember_d4bb217a-2170-49f0-aa03-2faf079619f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:to="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13fb6cb3-3590-4005-a2c9-995267f9c37a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13fb6cb3-3590-4005-a2c9-995267f9c37a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b3a051a4-e056-4f9a-a666-85a1399945f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:to="loc_us-gaap_EmployeeStockMember_b3a051a4-e056-4f9a-a666-85a1399945f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_527681c3-bb8f-4549-9014-ab99a574d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_527681c3-bb8f-4549-9014-ab99a574d26c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="ib5e9ff17f16847e39698b7a5510f510c_StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_a14c0a29-97b8-4b61-acde-a9de69c61c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_a14c0a29-97b8-4b61-acde-a9de69c61c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_cc095b72-62ff-49e5-88bc-0473c0ce82e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_cc095b72-62ff-49e5-88bc-0473c0ce82e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78f9b3fa-3e8f-4e7c-a794-4bffa2219b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78f9b3fa-3e8f-4e7c-a794-4bffa2219b86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_b5eb156b-c0c6-4eea-a458-2df44c860b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_b5eb156b-c0c6-4eea-a458-2df44c860b98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_4fff0474-9421-4073-abbb-9e19f7f3f717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef6bd7b2-06ec-4fab-a060-7850666ea808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef6bd7b2-06ec-4fab-a060-7850666ea808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d393e2a-d364-4894-a155-3ad9ed35f73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d393e2a-d364-4894-a155-3ad9ed35f73e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ec9c7b31-50a9-49f2-88b0-077ecc506f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ec9c7b31-50a9-49f2-88b0-077ecc506f72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ad0fb33-1d7a-416b-b9f1-2b466c96c162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ad0fb33-1d7a-416b-b9f1-2b466c96c162" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3448871a-c7e5-4a75-954c-071816d3b919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:to="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af451414-99d2-4df7-9fff-831856b515c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af451414-99d2-4df7-9fff-831856b515c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ab37fd88-b6a8-4119-84ba-cd774cf3eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af451414-99d2-4df7-9fff-831856b515c7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ab37fd88-b6a8-4119-84ba-cd774cf3eb3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" xlink:type="extended" id="i45874089160a484cb0a425e83da0af46_StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6afedf36-03d3-4283-9e07-e6363b37f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6afedf36-03d3-4283-9e07-e6363b37f5e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37d4b825-aaf2-46e7-a3a4-532c1f88d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37d4b825-aaf2-46e7-a3a4-532c1f88d7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14569b2b-0a3e-466a-8835-4c28be855e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14569b2b-0a3e-466a-8835-4c28be855e3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8d5f03a3-96a7-4a67-be5e-8555f4d232b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8d5f03a3-96a7-4a67-be5e-8555f4d232b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5c331d91-46b4-49e6-ba2b-63b98aa12f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5c331d91-46b4-49e6-ba2b-63b98aa12f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b39c8375-89dd-4746-9553-35469a5477e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b39c8375-89dd-4746-9553-35469a5477e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:to="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c703b02d-5772-4a7c-8e5e-95ec7add2864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c703b02d-5772-4a7c-8e5e-95ec7add2864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bb892b1-51d5-4cc1-94b0-03ac3e79db86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bb892b1-51d5-4cc1-94b0-03ac3e79db86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8ebf1b1-dad9-4039-934a-4431546e0a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bb892b1-51d5-4cc1-94b0-03ac3e79db86" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8ebf1b1-dad9-4039-934a-4431546e0a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:to="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1f165c9e-d3e4-4c90-af81-60da3f054bec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:to="loc_us-gaap_PlanNameDomain_1f165c9e-d3e4-4c90-af81-60da3f054bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a20175cb-55bc-40c9-835b-5672fe9e9243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:to="loc_us-gaap_PlanNameDomain_a20175cb-55bc-40c9-835b-5672fe9e9243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_EmployeeStockPurchasePlanMember_715ef502-5132-43bd-a998-627e49db71a5" xlink:href="cstl-20220630.xsd#cstl_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a20175cb-55bc-40c9-835b-5672fe9e9243" xlink:to="loc_cstl_EmployeeStockPurchasePlanMember_715ef502-5132-43bd-a998-627e49db71a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i2e95a3a318c6441db4e304d2f18bfeb1_StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_103699d8-8e55-4cbd-9b78-5962d9f901d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_86d71c40-8e6d-4ab0-828c-70516224ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_103699d8-8e55-4cbd-9b78-5962d9f901d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_86d71c40-8e6d-4ab0-828c-70516224ae67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_103699d8-8e55-4cbd-9b78-5962d9f901d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9bbaeb15-8969-487c-a334-892a8cebed90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9bbaeb15-8969-487c-a334-892a8cebed90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bb42ab62-4cec-480c-8dee-3c206780bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:to="loc_us-gaap_CostOfSalesMember_bb42ab62-4cec-480c-8dee-3c206780bfcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_44d8d27e-c625-4f91-a69b-706ca54d26ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_44d8d27e-c625-4f91-a69b-706ca54d26ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_658f1311-846f-4ebb-8e42-90d253390696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_658f1311-846f-4ebb-8e42-90d253390696" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.castlebiosciences.com/role/IncomeTaxesDetails" xlink:type="extended" id="id512651137b34eefb23aa64a0cbb65be_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b89f8991-0851-45d4-97be-42e89efb4296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b89f8991-0851-45d4-97be-42e89efb4296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_16e8c7d0-7479-4bb7-8636-20a545421046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_16e8c7d0-7479-4bb7-8636-20a545421046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa0f9606-950b-402e-8194-57eaee04fbd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa0f9606-950b-402e-8194-57eaee04fbd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6ce937ff-ee43-4196-886b-7943fd3bef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6ce937ff-ee43-4196-886b-7943fd3bef3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_edef5c3b-95b3-4a6d-b1ac-a5487b56d567" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6ce937ff-ee43-4196-886b-7943fd3bef3f" xlink:to="loc_cstl_AltheaDxIncMember_edef5c3b-95b3-4a6d-b1ac-a5487b56d567" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cstl-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c77279c-977d-402a-b1b2-5d29ed09603d,g:da8c0f38-2da3-40ff-b133-9fd71c151e0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e28f37f4-43f0-4d68-91f5-0a43268e6c5f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fc1cdbd3-f3c6-4e63-9b7c-d3b55af9ddf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_092ba6b9-afcf-42fb-bf40-97d1db0a0029_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_61efbefa-f78f-489d-a970-ac6ffa1abc3b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8bcb786a-b151-4996-8a16-b6d8ad94255b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_66b512c6-eb66-4ee1-9956-409804fa8221_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_43a575fc-e74a-41f6-9024-85fe0c293bfc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_2cfda5f6-6466-415e-9a2e-0172cd91e657_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_960cfef7-a9b4-4abe-beaa-df6736e9eb0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan contributions</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ff9bcaf1-4be8-4830-a2a7-0aba7a932483_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_3fbaa882-6f37-4895-bf8a-6810559a0ef7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration adjustments included in revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_040c95a4-baac-456c-b0b5-d5d45d697334_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm_03f4f60e-00d9-4ee1-865e-6f7c6cd25f25_terseLabel_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of months to terminate lease after commencement</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm_label_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate, Term</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm_documentation_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseOptionToTerminateTerm" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseOptionToTerminateTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_LesseeOperatingLeaseOptionToTerminateTerm" xlink:to="lab_cstl_LesseeOperatingLeaseOptionToTerminateTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7320e8b4-9fc2-4a88-8f17-13b65f80e634_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_606c9ae9-6779-4498-a519-d69cd4606ee8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7eccefa2-d556-4ba3-8bf2-4d8d719f8923_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_LesseeOperatingLeaseMaximumBaseRent_0f2e9a67-053e-4142-9283-3e2f415c2f95_terseLabel_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseMaximumBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, maximum base rent</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseMaximumBaseRent_label_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseMaximumBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Maximum Base Rent</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseMaximumBaseRent_documentation_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseMaximumBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Maximum Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseMaximumBaseRent" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseMaximumBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_LesseeOperatingLeaseMaximumBaseRent" xlink:to="lab_cstl_LesseeOperatingLeaseMaximumBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c1423981-c57c-497a-8152-5610ae15649a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from vested restricted stock units and payment of employees' taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_c477eb5d-2c85-4ec1-81e3-91f8191ec145_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ac8a52f-3aa3-4759-8d1a-7a816564faf6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_36d43385-931a-4491-9fb6-2dc85b2d0417_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_75e80b4c-2f6d-4d07-a70e-8368914c21d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e25ea78a-06fc-40d5-bf5e-4bac5d591c64_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in acquisition of business (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_a811c44e-acd4-43a9-8230-261e99cc2529_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_67af673a-e02f-41a5-8e54-10e346c32ed8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_edfc7ba5-14ce-453e-8d7b-cfd6826a6140_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0084f6d0-fd71-4040-8275-ef4e379e4cd3_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_91439553-fb32-4bc0-a1b8-143818c1a403_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_282e637f-5317-4f2c-8ccb-b749e8f95a07_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5654d1ea-c81f-4710-97e8-152482655be8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_7900375d-345b-4895-8928-6d04d78bc0db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, ESPP, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0556428e-4e58-43ff-99a3-d598b87418d1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e4b2005d-8bed-4e1d-8845-64f0ffa758fb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AccruedFixedAssetPurchases_9d6c0b61-6a44-41fd-8006-afa6eb68feee_terseLabel_en-US" xlink:label="lab_cstl_AccruedFixedAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued fixed asset purchases</link:label>
    <link:label id="lab_cstl_AccruedFixedAssetPurchases_label_en-US" xlink:label="lab_cstl_AccruedFixedAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Fixed Asset Purchases</link:label>
    <link:label id="lab_cstl_AccruedFixedAssetPurchases_documentation_en-US" xlink:label="lab_cstl_AccruedFixedAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Fixed Asset Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccruedFixedAssetPurchases" xlink:href="cstl-20220630.xsd#cstl_AccruedFixedAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AccruedFixedAssetPurchases" xlink:to="lab_cstl_AccruedFixedAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_9c7d6f2f-933b-4664-bfaf-9394c26f9b08_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d0ab71fd-608f-4d72-b686-f2365db1395c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_63bd6381-d696-4bab-acec-648e4c0806c8_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_a3812534-2efb-4a93-997f-6234a904efbc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7ea34801-1cbb-4b3e-b416-61f9afa55ad5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_4d3ea562-348c-413d-82ba-23451351b92e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_7284bd03-3703-4e72-a7fc-fbbbd4ae6344_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_0ebf173e-0ff6-4450-b9ca-315e1bcf2aa5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_54c53112-98f9-4816-aa14-eca1a61ab4d1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_caba0495-c46f-4a68-97bb-779cfd421b19_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_872067ea-6988-470a-b4dc-99c6c8522435_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_24e5b616-d069-456a-a4f3-b68696d0b55a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4e90ffe9-c036-460c-8c14-d57e6d51f3e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 200,000,000 shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; 26,292,299 and 25,378,520 shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_01482210-3f9c-4dea-a9f6-a7a5dfb8ea2b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6e704640-e75f-4a55-b6dd-62c4f96c2b29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Items (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_7bc63811-541f-415c-afe2-0fe1b39e7584_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0959c40e-94a4-4605-a3ac-b0d8b645b5c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9b80cbe4-30af-4b26-92da-1627e991dd20_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_40d7c64d-9908-4b94-bf9a-620f67dfc83a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b5e2c7e7-6a38-41c2-ae0c-653b5422ce1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_8d9caa72-c961-4c3f-8818-8bb35eb456d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement on Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_32ffbc5e-3b8a-4b13-892d-bedeeb84d9cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7bc829db-740c-4a7b-89c7-52453a8068f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_17a3717f-f391-444e-9e84-f95ab7582d4a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_6ee77c42-a80c-4391-87b6-ad5d1d8f708c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e24a86a2-69fa-448c-9f64-fa020ec9fe19_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15d3efd6-52f4-4efc-b6ea-39e346a2d6a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2ac14000-2b50-4c91-a9ea-54a3caab90a7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_73afce57-a565-4be6-a369-9da101983d46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e11d429d-5d7e-4b20-8315-ea266f2b9444_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0d4f0af2-97a0-41f8-bbe6-025408d00677_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock, adjustment to offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_9d440bb5-9ce6-4a4a-ad6e-a5335ffd06d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ff6bcbdd-5785-4e64-938f-05822606ff28_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_55d210ec-d5d5-4e2c-b137-d3ebd11df5d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_310ec86c-b096-480e-b7ab-f66977939366_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AltheaDxIncMember_67716f57-3778-493f-a5db-05c608a9fc7b_terseLabel_en-US" xlink:label="lab_cstl_AltheaDxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AltheaDx, Inc</link:label>
    <link:label id="lab_cstl_AltheaDxIncMember_label_en-US" xlink:label="lab_cstl_AltheaDxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AltheaDx, Inc [Member]</link:label>
    <link:label id="lab_cstl_AltheaDxIncMember_documentation_en-US" xlink:label="lab_cstl_AltheaDxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AltheaDx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AltheaDxIncMember" xlink:to="lab_cstl_AltheaDxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6886ed04-0229-48f2-91bb-b17c7b2a79e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c55014d4-3545-47e4-8d36-501f0e164189_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_cb4eda65-b13b-4ebf-9004-4021ec43d570_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8c6e4054-1bbc-409f-94bc-4f29347c10f6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_20fefbc4-5341-4cb1-a002-fd2bb76a9ed6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_254217ae-427f-4e04-a14e-19ad4e6da284_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6412978e-fc17-47fb-ba90-f913376f355c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_063809f0-a011-47b9-a1c8-bded0ed432ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c34b390f-bc07-4f99-88c3-f71dd8d93f11_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ea35d1b4-5510-4700-b867-29bfbda230b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value at beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04a54258-9081-4532-bfde-018b2f03d502_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value at ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_9ce54a8d-24f8-47fd-850b-3cc3581833cc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b67de7e6-ec0a-4492-abd7-3b30606aeb4c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a25b9fb6-2137-4561-84dd-a47c800cf7f7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7a06d1f8-6ec3-4b10-aaa0-160be7b21dd1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_f1dd5b88-47ab-460e-88e0-19d8c27eae11_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_318ed08a-ecb8-4b98-9e1b-c0625c7ed6ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_afe83b7a-3321-499a-ae03-ccbc12db8681_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of shares issued or issuable in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_49503e5b-11c4-4844-8c3c-4ad8f43f61f9_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bea5d590-7b6c-4998-8834-9725259fdd81_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_CernosticsIncMember_4de3fab7-5f9f-476a-ad65-15a3878ca98a_terseLabel_en-US" xlink:label="lab_cstl_CernosticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cernostics, Inc.</link:label>
    <link:label id="lab_cstl_CernosticsIncMember_label_en-US" xlink:label="lab_cstl_CernosticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cernostics, Inc. [Member]</link:label>
    <link:label id="lab_cstl_CernosticsIncMember_documentation_en-US" xlink:label="lab_cstl_CernosticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cernostics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_CernosticsIncMember" xlink:to="lab_cstl_CernosticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_ProceedsFromPreviousAssetAcquisition_cd0d776b-5f0b-41e0-b2de-be59b8769488_verboseLabel_en-US" xlink:label="lab_cstl_ProceedsFromPreviousAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition</link:label>
    <link:label id="lab_cstl_ProceedsFromPreviousAssetAcquisition_942d2df7-816a-49e3-bd44-47a1a55bbcbf_terseLabel_en-US" xlink:label="lab_cstl_ProceedsFromPreviousAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from settlement of receivable</link:label>
    <link:label id="lab_cstl_ProceedsFromPreviousAssetAcquisition_label_en-US" xlink:label="lab_cstl_ProceedsFromPreviousAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Previous Asset Acquisition</link:label>
    <link:label id="lab_cstl_ProceedsFromPreviousAssetAcquisition_documentation_en-US" xlink:label="lab_cstl_ProceedsFromPreviousAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Previous Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ProceedsFromPreviousAssetAcquisition" xlink:href="cstl-20220630.xsd#cstl_ProceedsFromPreviousAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_ProceedsFromPreviousAssetAcquisition" xlink:to="lab_cstl_ProceedsFromPreviousAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_271fda7a-6d10-4d3a-8809-5bfd9f58d3d7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5b0513bb-822b-416a-9606-7281922c1dc2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_aef42fa9-816a-4c0b-a756-acf2b806cd2f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_6c7378ba-dcb9-4c85-9da9-85df6546f832_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c54a86be-0d91-454d-907e-5328c82934b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_ThirdPartyPayorConcentrationRiskMember_cea7cb6d-897b-444a-be29-fe45215b878a_terseLabel_en-US" xlink:label="lab_cstl_ThirdPartyPayorConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor Concentration Risk</link:label>
    <link:label id="lab_cstl_ThirdPartyPayorConcentrationRiskMember_label_en-US" xlink:label="lab_cstl_ThirdPartyPayorConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor Concentration Risk [Member]</link:label>
    <link:label id="lab_cstl_ThirdPartyPayorConcentrationRiskMember_documentation_en-US" xlink:label="lab_cstl_ThirdPartyPayorConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ThirdPartyPayorConcentrationRiskMember" xlink:href="cstl-20220630.xsd#cstl_ThirdPartyPayorConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_ThirdPartyPayorConcentrationRiskMember" xlink:to="lab_cstl_ThirdPartyPayorConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_eb61c8f4-0d42-4250-acb2-8e83d5370b11_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6766ac65-cd62-481e-a09a-bc2de95afbe2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_84eedb18-0ac2-4876-9ed8-2637a8eb242e_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related Costs</link:label>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionRelatedCostsMember" xlink:to="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ebab875-414e-4c9d-a599-c39573010297_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_34bf41d9-adbd-4a1d-8fdb-35bff2ba6a1e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6138485d-8f02-4e34-a3da-9b4b2ed50ebd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8098cfcd-18ab-4f9c-b33b-f091e4dadcc3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_12431b56-303f-4b36-93e5-d4e525e4e650_terseLabel_en-US" xlink:label="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units (&#8220;RSUs&#8221;)</link:label>
    <link:label id="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units (&#8220;RSUs&#8221;) [Member]</link:label>
    <link:label id="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units (&#8220;RSUs&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:href="cstl-20220630.xsd#cstl_StockOptionsAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:to="lab_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_effd0b2e-a65a-4fc6-82b2-c407d91fd877_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3fa4ceb9-f1b7-45d4-a1bb-b8fc9d63824e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_81b965a9-b5de-44e6-814b-4d4230e5621a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_952a1b50-77ca-4228-9779-9cd095ff7da3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c1bf91cd-21f8-4fb5-a870-d9b91a92a148_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c46b9282-bbb8-4495-a0bf-7ede7e0d3670_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7f7e91ca-4f2d-4475-8854-b6eafb742224_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e8a9619-41db-4447-9758-a8aec454a93b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90f89d3a-98a2-4bf0-90e0-0344c3093af6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_abf2a78b-b534-43de-9595-c08b46c5678c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e0b2db4f-1c6c-4c32-9a53-e5d9f4509c99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_79cabf60-46ab-4f88-bd8f-30ce1682670b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from contributions to the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_edf1bb2b-dd4a-44e9-9abd-921e83c43535_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_fb6410ae-1c83-4c96-a696-86700cc9bd5a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_984f1082-6d60-4acb-adc3-0bb57e625936_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_50e68876-35de-4883-ad9e-8ce637e7ed8a_terseLabel_en-US" xlink:label="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING EXPENSES AND OTHER OPERATING INCOME</link:label>
    <link:label id="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_label_en-US" xlink:label="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses And Other Operating Income [Abstract]</link:label>
    <link:label id="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_documentation_en-US" xlink:label="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses And Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" xlink:href="cstl-20220630.xsd#cstl_OperatingExpensesAndOtherOperatingIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" xlink:to="lab_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_b71afd28-1586-4975-8b4a-bd31eeebb6db_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1b6d68cc-fe72-4992-a323-616766d18843_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b5e80acd-6c19-42be-b0bc-9cfc4643d314_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_53a2a9f9-8429-4fc8-82d4-b1b9e0407036_terseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, number of remaining shares authorized to be issued (in shares)</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_label_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Number Of Remaining Shares Authorized To Be Issued</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Number Of Remaining Shares Authorized To Be Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" xlink:to="lab_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0abca208-a824-487d-9c1b-96097ad66b6e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_115a190d-bdef-4345-8f38-b157cca1126c_terseLabel_en-US" xlink:label="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares payable in earnout payment (in shares)</link:label>
    <link:label id="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_label_en-US" xlink:label="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares</link:label>
    <link:label id="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_documentation_en-US" xlink:label="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" xlink:to="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_76c0cbb8-333e-4fce-8f8f-11b54d424b48_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements to be contributed by landlord</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_eeaa01a0-bc1c-4f96-8908-a08cc8d3bc4b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_45b416f1-1703-4d1d-bb1f-5179e0d2893e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from vested restricted stock units and payment of employees&#8217; taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_17aac742-4102-4825-b21d-58b4dd9a2cde_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_18aa923b-d4e4-4988-8ceb-24d919946a7e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_62aa70f0-1c09-421c-957f-b3eed412f257_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_fcda5341-a668-406e-b7d1-8678cac1d4f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_163dd7ba-87e1-4900-b54a-063c2601b151_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2405eb1d-34cd-407d-b86b-b2cc7d8da5fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_PittsburghLeaseMember_b74816a0-09fa-4e04-bcf1-0a86353b9c5a_terseLabel_en-US" xlink:label="lab_cstl_PittsburghLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease</link:label>
    <link:label id="lab_cstl_PittsburghLeaseMember_label_en-US" xlink:label="lab_cstl_PittsburghLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease [Member]</link:label>
    <link:label id="lab_cstl_PittsburghLeaseMember_documentation_en-US" xlink:label="lab_cstl_PittsburghLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseMember" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_PittsburghLeaseMember" xlink:to="lab_cstl_PittsburghLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AccountsReceivableNoncurrentMember_c587bc72-3292-4227-a013-1a0debe4fdad_terseLabel_en-US" xlink:label="lab_cstl_AccountsReceivableNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Accounts Receivable (noncurrent)</link:label>
    <link:label id="lab_cstl_AccountsReceivableNoncurrentMember_label_en-US" xlink:label="lab_cstl_AccountsReceivableNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent [Member]</link:label>
    <link:label id="lab_cstl_AccountsReceivableNoncurrentMember_documentation_en-US" xlink:label="lab_cstl_AccountsReceivableNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccountsReceivableNoncurrentMember" xlink:href="cstl-20220630.xsd#cstl_AccountsReceivableNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AccountsReceivableNoncurrentMember" xlink:to="lab_cstl_AccountsReceivableNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_eff58477-a8ed-4a60-b5fd-f7fce40eb053_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_c9932549-ba1b-46e3-a728-51a293dc7587_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_4591773c-be44-48e4-95d2-4bbb0ee05fdc_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_413433b0-abc1-4f91-b250-5034d1843ec1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b0777149-050c-45a1-bf8c-c787170fb589_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_6302a870-1f60-4225-addd-f3308569332f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_fac859dc-f8af-4be5-b0dc-bce254bf919f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f618e354-4eb7-4008-a8e6-92b26f5c3ac6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b07f96e8-096a-44d9-a97f-7e56039d372f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_8f07a53f-0ea8-43dd-865e-90210442ff85_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven_99f5b9d4-d835-4839-ba52-8ec2152046f4_terseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration in acquisition of business</link:label>
    <link:label id="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven_label_en-US" xlink:label="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncash Contingent Consideration Given</link:label>
    <link:label id="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncash Contingent Consideration Given</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationNoncashContingentConsiderationGiven" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationNoncashContingentConsiderationGiven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationNoncashContingentConsiderationGiven" xlink:to="lab_cstl_BusinessCombinationNoncashContingentConsiderationGiven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_55844a1b-bd80-4bd2-80bc-ff02639b646b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs expensed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_12d32103-d29f-4a84-8a5b-0574e903fa8a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_638229d7-04c4-4105-8e1f-e40cacda92fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_da9c7f2f-6f59-4bf2-8f9a-5b4327ad6dde_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_83068e4c-a362-4fb9-9aae-e9d0da2206ec_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_211abfac-11a2-4a62-8568-3c2c1c4033ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_194fe791-bc28-4275-9f07-95ab427b0405_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_57418560-8a5a-4f20-b186-84d5633b9daa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9afa54ce-d5fd-4627-8809-5970b7462b86_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8a02d969-8021-49c9-ae6d-8bc21673318f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ec348631-06ca-40e5-9608-1df6a39e00e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4e26b2ce-6f74-44a0-9bb3-58fc4f65f3e1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8e274166-24a2-4904-9aed-c03307341e42_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d2aa9abc-51a9-4579-9ea6-5ea1c61d258a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_899fe3d3-2b7a-42e6-8508-4a50120f7a97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_ae83a9ef-ff00-47b0-9074-e1f0d2946be9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d9482364-9bc0-4c9c-9bb8-c2314ce15082_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_79a016be-5938-4c42-9868-e7b3b7d39fbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_50e3cf29-8901-467f-bbe9-e5f97de01ed7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_22b5bd39-a763-45ba-8a60-c0e7acfc529b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_ff535f5e-4aef-433f-837a-39061f8e914a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Carrying Value of Our Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_65432530-f67c-49e2-a615-691f9b9871e7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_f59f3c3f-e766-487e-8e0a-cda462c7a4cc_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9f1eb680-ab7a-483f-bc9f-f255eb097e23_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_6752ffc3-63e7-4840-b48d-aa341f046332_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_10f6dbb0-5605-433d-87a3-f6cfebd6d0b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_701ef3b4-5c21-4291-b123-39bce7068304_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8cde38de-3469-4aa1-8ef4-19cdb8f8ecd7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d3510c9d-c800-4486-a2f8-91d01ebf70dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_46704af1-14d5-4a3d-af33-d7f632060bee_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_MedicareMember_661be084-8e29-4a12-af2f-4caad4688b55_terseLabel_en-US" xlink:label="lab_cstl_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_cstl_MedicareMember_label_en-US" xlink:label="lab_cstl_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_cstl_MedicareMember_documentation_en-US" xlink:label="lab_cstl_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MedicareMember" xlink:href="cstl-20220630.xsd#cstl_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_MedicareMember" xlink:to="lab_cstl_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8734c920-b4c2-4f74-afb8-da2996f7efe8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited / Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_2c9c25ff-b90a-4085-b79f-8858a4de445f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5ee0cbf2-d39e-4bd6-89ec-a66f972f25a6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_899797b1-3b5c-4622-9c98-f5b41c18bbc6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c885463e-ec96-4f6d-a66f-8074285d1aa2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e73b4c8f-5a1a-4585-86c0-cbfbc5dbdb61_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3da72ba0-f0c8-422e-857a-5d71b1fd9268_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2b26cf70-afca-48ff-9e67-e71c07e335db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1ca3830a-27da-4772-bc7a-c01d82cf5d0a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2f7099d2-4511-40cc-a355-54102e9c3ff8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8326f83c-fa00-4e0f-821f-1f2836da292b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_df779789-5ad1-4581-9cb0-322af38d0f05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_cb4d5289-fef4-4f32-b291-d4c5227f2669_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration in acquisition of business</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AccountsReceivableCurrentMember_741d0a8a-40d4-4c1d-9ac0-a3b344a6c341_terseLabel_en-US" xlink:label="lab_cstl_AccountsReceivableCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Accounts Receivable (current)</link:label>
    <link:label id="lab_cstl_AccountsReceivableCurrentMember_label_en-US" xlink:label="lab_cstl_AccountsReceivableCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Current [Member]</link:label>
    <link:label id="lab_cstl_AccountsReceivableCurrentMember_documentation_en-US" xlink:label="lab_cstl_AccountsReceivableCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccountsReceivableCurrentMember" xlink:href="cstl-20220630.xsd#cstl_AccountsReceivableCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AccountsReceivableCurrentMember" xlink:to="lab_cstl_AccountsReceivableCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f9909e0a-dd9e-4cfb-8fa3-0fba5ec270bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ceba97a1-ad0c-40fe-bda8-e3e5c7212887_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_64729293-f8de-4350-b758-595b04b72bdf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in acquisition of business</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_MedicareAdvantagePlansMember_59c06c8f-1631-40cf-8165-28e9b4975702_terseLabel_en-US" xlink:label="lab_cstl_MedicareAdvantagePlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage plans</link:label>
    <link:label id="lab_cstl_MedicareAdvantagePlansMember_label_en-US" xlink:label="lab_cstl_MedicareAdvantagePlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage Plans [Member]</link:label>
    <link:label id="lab_cstl_MedicareAdvantagePlansMember_documentation_en-US" xlink:label="lab_cstl_MedicareAdvantagePlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MedicareAdvantagePlansMember" xlink:href="cstl-20220630.xsd#cstl_MedicareAdvantagePlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_MedicareAdvantagePlansMember" xlink:to="lab_cstl_MedicareAdvantagePlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4c1c3275-1c06-48df-abe5-c8b5d7136109_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f9406e1b-c27e-44e7-9a47-c96f8ac3dc3e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_94733bba-212e-4a80-8705-60b74ae82a9a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bde71285-c4ad-4ecb-a902-afa3cf37d85b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_275fdd42-8b60-4f86-8d96-08aa34a0f3e2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_cf805a63-f337-4ebb-9ef4-c282e1cf428b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_b5529f86-59ae-4079-8526-f76e6086e90d_terseLabel_en-US" xlink:label="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional consideration payable based on achievement of certain commercial milestones</link:label>
    <link:label id="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label id="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_documentation_en-US" xlink:label="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_05ab2e07-ec32-4d10-aed7-185d335ca039_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_219d53d2-6f6e-4085-9822-d7ac61f5dc4b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f753cc9d-7c46-4f02-bb8a-15796417dd05_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6cedd80b-1f30-4db2-89ea-4aa02d0e77a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5eccd59-d730-407c-a4e2-a4e111cb85d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_124dc38c-1c4b-4416-b4a4-e9086d6bec60_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_43c22a34-5d16-46a7-9a3e-eb8f318dbe6a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f6359f58-7cc6-49e4-a9cb-c184531b586f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8a9966f5-06f6-4841-af27-81d1d507fe62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5f040c5f-234f-4cdb-bf64-996897eb91ba_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_1e5db305-94c7-41a3-8212-633bf0ff0265_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unaudited Pro forma Financial Information and Net Income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_11162794-be8e-4fcc-979b-f254ad92eb42_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6b46ac12-81af-4846-8040-b312668b2569_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_abff9d6c-d478-499d-aae7-5a366b0ff07b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_74345f23-ba99-4770-a86f-416b345459b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_621f601f-01a5-4e53-8226-e55bc88eaf91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_516d6060-073f-4325-91ea-3e2b59d0d93c_negatedTerseLabel_en-US" xlink:label="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Assets</link:label>
    <link:label id="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="cstl-20220630.xsd#cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_586f6b9c-ac1e-4acd-94dc-475eadc02287_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_800c41ab-4dea-4416-a72e-f690479451af_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5fa6a85e-327f-4f0d-baa6-ff6f24753d0c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_59e2a65c-c370-45fb-b97a-9d97107c6b90_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_093fc6b5-ae61-4f56-9a5d-d4b3a31d31b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_3ca7aa15-be40-4e86-ade6-98b3a6ec5c6e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_943d83f0-0cce-4032-8385-60da7edc0905_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_1af16cfe-4099-4456-9dfa-a38019325b22_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire productive assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7a6986af-fc9f-4570-b5c6-4e485bd54f39_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4d274d8a-941a-4161-861d-d69d54a8cc31_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16d24a90-a406-429d-98f2-da9f74692c78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement on Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c792fa66-b55a-4ea4-bb06-8308f298c67f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_deae0591-dc59-43ae-9bfc-acd622babd86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_PittsburghLeaseAfterSixMonthsMember_96b6758d-7a9c-4e5b-93e0-822b326e889a_terseLabel_en-US" xlink:label="lab_cstl_PittsburghLeaseAfterSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease, After First Six Months</link:label>
    <link:label id="lab_cstl_PittsburghLeaseAfterSixMonthsMember_label_en-US" xlink:label="lab_cstl_PittsburghLeaseAfterSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease, After Six Months [Member]</link:label>
    <link:label id="lab_cstl_PittsburghLeaseAfterSixMonthsMember_documentation_en-US" xlink:label="lab_cstl_PittsburghLeaseAfterSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease, After Six Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseAfterSixMonthsMember" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseAfterSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_PittsburghLeaseAfterSixMonthsMember" xlink:to="lab_cstl_PittsburghLeaseAfterSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2bcd9bc2-4648-47a3-9b66-a7401c85d752_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0ae4c7fb-8825-4ff5-96ba-ea8114b86448_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bdd28509-4a93-4b10-ade7-1ffff3bb2244_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_f4f266d0-12a4-4611-8093-031c2673fc04_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_13e6b56c-23dc-4e19-96f3-ce57d2e15817_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4dbfece8-e94f-41b0-b451-1be0f7356e6a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80b1a8ca-9fdf-4437-bcd0-7beb077bfb0c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_df55c062-0a79-449f-bf5d-f98f4668228b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2a18acf8-8e3e-404a-97e3-88cfca3b8165_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_ff658ed9-aba1-4e74-a2b7-148894e1c345_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4dd20566-4cc3-4c11-b134-ab12dc9e1147_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e16a7c9f-00d2-409b-8c06-45af1efea503_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f26f60bd-a554-4b3d-aa01-3f4cfad40e83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d32f6996-40c4-433b-a361-e644af13ce05_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8a1b6a1a-0e1c-4e76-a455-9f82bd7666e5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_fafdb2e6-c4b7-4551-84b5-1eb730f31aff_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Adoption of ASC 842</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f494a435-cef4-4038-b03c-4cc1fe8b39f0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8aa87287-3733-4e77-9a64-da4527e00ce0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome_1ff3a7e9-5dec-4efe-a66f-3c03ff4dec26_totalLabel_en-US" xlink:label="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses, net</link:label>
    <link:label id="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome_label_en-US" xlink:label="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses, Net Of Other Operating Income</link:label>
    <link:label id="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome_documentation_en-US" xlink:label="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses, Net Of Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome" xlink:href="cstl-20220630.xsd#cstl_OperatingExpensesNetOfOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome" xlink:to="lab_cstl_OperatingExpensesNetOfOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_69cf1007-4328-497e-a7c4-5311f0194ff6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9af72511-f34e-46b1-97be-312a2d982c1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Adoption of Accounting Standards Update</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_93b451d7-1e74-4e01-9293-593dfc1464e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration payable in acquisition of business</link:label>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_label_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Given</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_LesseeOperatingLeaseBaseRent_4c12f01d-7530-4265-b3b6-92f18c906193_terseLabel_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, base rent</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseBaseRent" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_LesseeOperatingLeaseBaseRent" xlink:to="lab_cstl_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_26b7beae-d4ec-456a-bb42-b952d9f5df10_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_fbe4c169-f060-4f53-8375-5ba1a7226c3a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70f7164f-6490-4d86-bb1d-cedd51fbf74f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_360bebd8-8de2-4b0f-87c7-d417845f7473_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a8e52239-68f2-425b-bc07-7937709947a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e562892d-24ad-4295-be8a-f8eef959c3d0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ea4f8618-4f1b-4a87-aa11-1b6c54e42775_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47078e2d-8d49-4a01-90c5-0b614b9e3088_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b301b074-5424-4129-9393-4225900a553d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_DermatologicMember_abff8892-93a7-4c42-a24c-72030bfd8283_terseLabel_en-US" xlink:label="lab_cstl_DermatologicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatologic</link:label>
    <link:label id="lab_cstl_DermatologicMember_label_en-US" xlink:label="lab_cstl_DermatologicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatologic [Member]</link:label>
    <link:label id="lab_cstl_DermatologicMember_documentation_en-US" xlink:label="lab_cstl_DermatologicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatologic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_DermatologicMember" xlink:href="cstl-20220630.xsd#cstl_DermatologicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_DermatologicMember" xlink:to="lab_cstl_DermatologicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bc46e45d-b537-4190-947a-4bac5ceead93_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_36489a22-69f0-4534-a445-e2c3c053cc85_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill accumulated impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f75dadfa-c03d-4b25-8fd9-8820e6c1c20e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0f93951e-6e62-4405-a4ce-069825b31077_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_14d04bde-8c60-4e3c-8b96-a750c50300a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_05e73888-98ae-4f78-b8f7-598a7484cab5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of AltheaDx</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_db553bdd-39f1-45cf-b09b-c5db5acb4f06_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent_4c3e223b-7a42-47ee-8c98-add79f3e006b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_186c46b0-a9ce-4069-b851-f5bec27f6268_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Adoption</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a5baca0b-4e88-49d8-9548-e21ef2d71ae9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c07bf045-8c7f-42e2-90eb-f3c36c379404_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_1e554ae3-3d00-4e53-aeeb-56734cc83994_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7a324fbe-40a8-4ab7-8fdc-1d184a8c70ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_adcca67c-c13d-4f1c-af1a-4ba709dc9db7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e561b29d-2384-4ead-9205-d289be9d267e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_fdf9c387-7456-4425-a4a9-0bfc239f6aa9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4f3edec5-7a4d-4c15-a0e5-278e108a98d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8a9a0930-8458-4631-8cd3-451dfb737a95_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_bf147b4d-efd0-4261-9ee0-ef79d2f48bad_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of AltheaDx</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_42083465-55d3-48fd-9850-556fa491eddf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_4b6e83ee-b3ac-4409-a0c6-f86d6ca0c036_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8937af20-bb5b-41c7-8f2f-eec470232577_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_da1da9e4-ae5c-4ba4-94dd-964f6e34d5e6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_6febb947-5843-4eb2-b086-855dd1c109c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_78621e8a-c68f-472b-af2d-98558e7f8b88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a3e20fcb-7391-4872-b961-7ac8ca83c76e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets &#8211; long-term</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_EmployeeStockPurchasePlanMember_c2663d61-201a-42f1-b256-e7ef92a9ca1e_terseLabel_en-US" xlink:label="lab_cstl_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_cstl_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_cstl_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cstl_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_cstl_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_EmployeeStockPurchasePlanMember" xlink:href="cstl-20220630.xsd#cstl_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_EmployeeStockPurchasePlanMember" xlink:to="lab_cstl_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_17b27c69-72b7-4cc0-b3e0-ee06e91daf9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_44612f60-38bf-4858-bf93-252507181285_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8f4626b7-1580-4488-9988-2ac673034633_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_429410f4-18ce-42a1-a2f4-8eb4b087f180_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_80ad8271-6b49-4c0a-8271-93e5c086db78_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_161672c1-2041-429d-bc37-3b358f2ea8da_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_7f9b145a-3591-41ca-b4fc-ad023e13668f_terseLabel_en-US" xlink:label="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label id="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" xlink:href="cstl-20220630.xsd#cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_7cceeb84-6c40-4a21-b2de-e43f6323550c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_21c74557-6c27-41a0-bee8-e6ae90ab1e02_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under the employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_699b5b34-9df4-42f1-b54f-f001e5614ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_cfcfc168-1763-4a32-8706-bca64884583a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c92c1481-14c6-4d56-964a-10ec92b3d1f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8ac7d2f3-6664-45ea-8911-abed9a7c4c60_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1fa13061-9228-4f3c-a10a-ee4e554dfde3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued and Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_55d914b9-3064-4c01-8911-056761ef91af_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_24efdd80-9063-4f25-aa93-92a72f200aee_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9eb2274f-03ec-4530-af89-269b991776f8_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1c311446-545e-499a-b98d-4b22a93ba3f9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_61f81e7a-05d2-4ba9-9db1-029c4f75d6d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_258bba55-cf33-494b-97ca-1a0c87238df2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c081891c-2405-4d91-88f7-0bb702ea01f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_ffe4526e-cad1-4fcf-b5de-cdf5471940f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional consideration payable based on achievement of certain commercial milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e5f2bed9-5d38-4ed4-87e6-cb4303822c5d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c1a94e1c-e6fc-4b9d-83bd-99800c190deb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bc548f6a-3cda-4417-9a4c-2eb2714e12d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_491e3e10-3c78-49f8-9b6b-e32dc54dc899_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_abe7e59d-83df-4221-aa0c-868f29ba86d2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationConsiderationPayableCurrent_80b8c66d-87f1-410c-b93e-7a9ad4960e46_verboseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration payable for business acquisition</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationPayableCurrent_label_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Payable, Current</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationPayableCurrent_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationPayableCurrent" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationConsiderationPayableCurrent" xlink:to="lab_cstl_BusinessCombinationConsiderationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AccruedClinicalStudiesCurrent_1e4a18f6-1666-44e8-8d34-3c7a49e53ec3_terseLabel_en-US" xlink:label="lab_cstl_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical studies</link:label>
    <link:label id="lab_cstl_AccruedClinicalStudiesCurrent_label_en-US" xlink:label="lab_cstl_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:label id="lab_cstl_AccruedClinicalStudiesCurrent_documentation_en-US" xlink:label="lab_cstl_AccruedClinicalStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Studies, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccruedClinicalStudiesCurrent" xlink:href="cstl-20220630.xsd#cstl_AccruedClinicalStudiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AccruedClinicalStudiesCurrent" xlink:to="lab_cstl_AccruedClinicalStudiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c24c647a-f1ca-4995-b0a6-526a0c245075_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare advance payment</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a7a7b3c5-6a2e-4730-b8d9-7208e2319a0c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b697e730-6446-41da-9a01-db7dc9866e83_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b00b3c73-09f7-4444-8533-df5c26a2784b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_20a2ecbe-704d-4b58-a3f0-8f3dce55981a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_32334a6b-872d-44ed-b103-d47b62893915_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_308bb82f-1cfc-47f0-a812-455c8ad51f6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0ef5a823-b4db-432e-b18b-2074201e7f27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2580d136-6e32-4acd-8f46-12705aaba736_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_b6930d07-02c9-4d1b-982a-9ed35f961227_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued and current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_90e8e392-5066-4a79-99da-f1f01c59750f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f61a73fe-c420-42d8-96da-1690e4664fc2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57231d25-907a-4f32-91f0-cc5747e37640_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_PittsburghLeaseFirstSixMonthsMember_1bbb4784-5124-4ade-8a22-b23bf892e210_terseLabel_en-US" xlink:label="lab_cstl_PittsburghLeaseFirstSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease, First Six Months</link:label>
    <link:label id="lab_cstl_PittsburghLeaseFirstSixMonthsMember_label_en-US" xlink:label="lab_cstl_PittsburghLeaseFirstSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease, First Six Months [Member]</link:label>
    <link:label id="lab_cstl_PittsburghLeaseFirstSixMonthsMember_documentation_en-US" xlink:label="lab_cstl_PittsburghLeaseFirstSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pittsburgh Lease, First Six Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseFirstSixMonthsMember" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseFirstSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_PittsburghLeaseFirstSixMonthsMember" xlink:to="lab_cstl_PittsburghLeaseFirstSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ae922310-c08b-4c1a-a8d3-524f9f5e6942_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b1f197f4-78e5-4b46-ab12-cd89d7876900_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_4fc120ef-740b-4841-a9f8-6285e1c30bbd_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember_e018aa9c-679b-4b6a-b3d6-39551c761f73_terseLabel_en-US" xlink:label="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="cstl-20220630.xsd#cstl_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="lab_cstl_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_970b905b-e2cd-4b02-bb17-5ebac360f13c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8423bbce-d93b-4d5b-bbbd-0d2d623d04a1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_da8619cb-06a9-4d38-a98f-68e3fa72fe9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1914656d-c011-4cb1-9930-f6afbdf1ab92_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_7831fffd-c66b-4ade-b8db-ea1c4662e3b7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, right-of-use asset, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock_569ed572-6e24-434a-a47c-a10cd18f20a5_terseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Contingent Consideration</link:label>
    <link:label id="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination And Asset Acquisitions, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination And Asset Acquisitions, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:to="lab_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_f2005178-59ac-4c38-bad7-a73595437857_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_deb1fd92-18ad-442a-be4d-34b8fcac2b4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_69531de1-1915-4e83-8310-abc8af1c9de1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_f0f2170a-5449-49f3-ab03-0d5fa37ebab5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7bda5c10-0e6a-401c-bb8e-5d16321f7c37_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_de431661-674a-4d80-9b18-9134e01fc8c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_10b91196-0467-454a-9d35-54b18d7797c2_terseLabel_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, number of options to renew</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_label_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Options To Renew</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Options To Renew</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseNumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" xlink:to="lab_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_MyriadMyPathLLCMember_160696c0-3021-4361-bcb3-d5511586fcb6_terseLabel_en-US" xlink:label="lab_cstl_MyriadMyPathLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad myPath, LLC</link:label>
    <link:label id="lab_cstl_MyriadMyPathLLCMember_label_en-US" xlink:label="lab_cstl_MyriadMyPathLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad myPath, LLC [Member]</link:label>
    <link:label id="lab_cstl_MyriadMyPathLLCMember_documentation_en-US" xlink:label="lab_cstl_MyriadMyPathLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myriad myPath, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MyriadMyPathLLCMember" xlink:href="cstl-20220630.xsd#cstl_MyriadMyPathLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_MyriadMyPathLLCMember" xlink:to="lab_cstl_MyriadMyPathLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_660af68f-d3f7-4b45-b0e5-5d7486ac2642_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6e7cc861-5471-44b3-b57c-5efcf91535d2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_499d932f-2aeb-4fb9-b0c5-1441dbc15dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_12072144-30e9-4683-aa45-b69b63e5c231_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3b14f93d-cf2e-42ca-93df-d680500598fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_53203470-e0ad-4e42-aa5b-bce6bbfadc6a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0c06629e-2fad-4897-9eb4-db3b31d12323_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d606f818-88f9-4058-9d58-8e4eced8295a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_fa530ff4-1bef-4ed0-a4c2-2941438610e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_17f06c11-9940-4ec4-9ff4-abb4224cc118_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ce80bda6-bea0-4d3d-877a-08d713933584_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a116b017-01c8-4dbd-bb6d-0dc035bb0688_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_8daac741-a2c1-4ac4-8587-2d4040061d31_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_07ab7239-63fa-4744-a7bf-dd5a41785b25_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a7c1bf23-d6e3-4440-a19d-f74bced0d55d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_59c7b0a0-4abc-44ec-9a09-8b2c5deb5266_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_105329a0-c47c-4ed3-a822-466bb7eeba1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_29355ff2-880d-4f19-b8fb-d8e664db2bde_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a6e0ecc8-9a05-4c37-a9c2-4ae5aaa847d0_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_fd3917ca-280c-464a-a0cb-6a0808503b25_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in acquisition of business</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_dd03147e-63b4-4bd6-9126-fbb930542bb6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_4dfedcdf-0522-4069-9ed9-eb97fa5f8100_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7630e7db-0c38-41ac-853a-95e346e70ca7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78af63a6-c453-4b6b-ace0-8e0db43173b9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_25cc8a8f-1c57-44b6-914b-d41175237dc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_eb6764a3-061f-4aab-8f5b-b51be998936a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5fbdaf5c-c416-4354-95a4-ba456aba0a26_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_12330bfe-2b50-4ec2-852a-e3160f2720ce_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_8b64bb38-02e3-4f0a-97c6-c58883b96dd1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_95284db9-6f73-4464-97a7-29758eb84262_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans and Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_6b995f16-149b-473e-a9c8-0bf9e681ad4e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_fcae2edc-c7a4-42f3-8645-a20870654097_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_217b1217-e816-4451-8cd0-19c62440ead3_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ad11ef89-db0e-4527-a1db-952c2e6726a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of employees&#8217; taxes on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_02dd5080-3798-4ae5-a543-a6c78966491d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d783b1ca-f0ac-487b-98ff-db8f391cda30_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08546619-744b-47c4-91a3-98b0478fcbce_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d49cab8d-8252-4e3c-a095-eba050c475f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash and cash equivalents acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d5d72505-118f-422b-855b-92735f90c80d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d9cd3924-0147-4bc0-b157-a3342138a134_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_fb4d4d24-a779-478d-8eed-9d24e2164c12_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e8a11012-359f-4459-b1cb-2c5c3372f9ca_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_69e3378f-9103-4a7d-970b-26dac3238591_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_4880b00e-970b-47ee-8fd6-19a766a689af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of common stock offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_IncomeTaxAdjustmentMember_c7813ca5-c0a2-49b1-aae5-432f4d1257d0_terseLabel_en-US" xlink:label="lab_cstl_IncomeTaxAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Adjustment</link:label>
    <link:label id="lab_cstl_IncomeTaxAdjustmentMember_label_en-US" xlink:label="lab_cstl_IncomeTaxAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Adjustment [Member]</link:label>
    <link:label id="lab_cstl_IncomeTaxAdjustmentMember_documentation_en-US" xlink:label="lab_cstl_IncomeTaxAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_IncomeTaxAdjustmentMember" xlink:href="cstl-20220630.xsd#cstl_IncomeTaxAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_IncomeTaxAdjustmentMember" xlink:to="lab_cstl_IncomeTaxAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_ca95c677-5caf-42a0-b7bf-a707644c1ecf_terseLabel_en-US" xlink:label="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, share price, volume-weighted average price, number of trading days</link:label>
    <link:label id="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_label_en-US" xlink:label="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Share Price, Volume-Weighted Average Price, Number Of Trading Days</link:label>
    <link:label id="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_documentation_en-US" xlink:label="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Share Price, Volume-Weighted Average Price, Number Of Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" xlink:href="cstl-20220630.xsd#cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" xlink:to="lab_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a31bf48b-cf79-45ea-8c46-73517d1048c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1c5a7d48-912b-4552-b263-cd54a234fc25_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c525562c-619f-4201-a846-7497d77634ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_574b960e-4d1e-45b7-bdbf-9351a4c50bfc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, right-of-use asset, before accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_d507e074-cd41-404b-8c0d-e26a09b2056a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee_a8d85a02-3b3b-446a-a2f9-9a2cdf55bb15_terseLabel_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early termination fee</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee_label_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Early Termination Fee</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee_documentation_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Early Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseEarlyTerminationFee" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseEarlyTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_LesseeOperatingLeaseEarlyTerminationFee" xlink:to="lab_cstl_LesseeOperatingLeaseEarlyTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AssembledWorkforceMember_2022d1b8-dee7-4dd9-8c31-f414ebb110df_terseLabel_en-US" xlink:label="lab_cstl_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled workforce</link:label>
    <link:label id="lab_cstl_AssembledWorkforceMember_label_en-US" xlink:label="lab_cstl_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce [Member]</link:label>
    <link:label id="lab_cstl_AssembledWorkforceMember_documentation_en-US" xlink:label="lab_cstl_AssembledWorkforceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Workforce</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssembledWorkforceMember" xlink:href="cstl-20220630.xsd#cstl_AssembledWorkforceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AssembledWorkforceMember" xlink:to="lab_cstl_AssembledWorkforceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_12224834-52f4-40d8-824e-53175e7e139b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Adoption</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_200fdcb7-05b4-4320-8d51-ceac62dde9d5_terseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid in common stock (as a percent)</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_label_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Common Stock</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" xlink:to="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_71bb275a-4c5e-4046-8267-4bcb09e87536_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_610ed4f0-7669-4e8f-b6eb-b00212e8a72d_terseLabel_en-US" xlink:label="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days to determine volume weighted-average price of common stock</link:label>
    <link:label id="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_label_en-US" xlink:label="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price</link:label>
    <link:label id="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_documentation_en-US" xlink:label="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisitions, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" xlink:to="lab_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_e8be642e-d54c-4d2e-ac29-5557b40d59c7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_ContractWithCustomerCustomerPaymentTerms_a5b13839-883a-4a1f-8ba0-5f636a8b7794_terseLabel_en-US" xlink:label="lab_cstl_ContractWithCustomerCustomerPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days contract with customer is generally paid</link:label>
    <link:label id="lab_cstl_ContractWithCustomerCustomerPaymentTerms_label_en-US" xlink:label="lab_cstl_ContractWithCustomerCustomerPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Customer, Payment Terms</link:label>
    <link:label id="lab_cstl_ContractWithCustomerCustomerPaymentTerms_documentation_en-US" xlink:label="lab_cstl_ContractWithCustomerCustomerPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Customer, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ContractWithCustomerCustomerPaymentTerms" xlink:href="cstl-20220630.xsd#cstl_ContractWithCustomerCustomerPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_ContractWithCustomerCustomerPaymentTerms" xlink:to="lab_cstl_ContractWithCustomerCustomerPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7428f1d3-ad49-4197-9297-53c73ac31abd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_789e2ab3-9a72-4a7f-9947-cf94158c77da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_97b990de-61b6-4d48-8f0a-946c0d824c35_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (exclusive of amortization of acquired intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5592e78e-17aa-4f64-bff5-d0f91aef8ee8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_8bcd7a9e-5bec-455b-999d-683f0b9ae4a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets &#8211; long-term</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c42e059d-de2c-4311-a68f-bb185fe8d12f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of existing valuation allowance on deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5d7c13b9-1c26-4cd2-86da-537d10b323a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f8a3dc57-1c7b-47ba-879c-1f40207a8780_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_44c736ee-6370-4e19-b51e-1fe753cb78c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_365462b2-e01f-4ffa-bfec-f445e3214663_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2c4fc939-bbe8-4272-aa9a-8cb97620a871_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_42eadb41-3558-4e1e-8fd4-74bceecef5a6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_a490e6ef-c304-4945-9fb6-9317d0950819_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_f6fbf4f4-d79d-4ff2-ba13-edfb4e164ef5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_701e198c-c80c-479a-af76-9f56c56c17a6_terseLabel_en-US" xlink:label="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="cstl-20220630.xsd#cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_0de09553-7448-4829-8e3a-facedfe2ad5f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_b816a77d-792f-4acb-a436-bc6891eec999_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_57f39f87-0205-4aef-9092-ec109f302328_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remainder of year)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_f7189ce7-637d-4348-8872-404e1f57c1ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_27a746f5-2339-4c7d-aa59-982fc4f2e93b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BlueCrossBlueShieldPlansMember_901484e5-65cb-48b2-9fa8-02f8149bdb91_terseLabel_en-US" xlink:label="lab_cstl_BlueCrossBlueShieldPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BlueCross BlueShield plans</link:label>
    <link:label id="lab_cstl_BlueCrossBlueShieldPlansMember_label_en-US" xlink:label="lab_cstl_BlueCrossBlueShieldPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BlueCross BlueShield Plans [Member]</link:label>
    <link:label id="lab_cstl_BlueCrossBlueShieldPlansMember_documentation_en-US" xlink:label="lab_cstl_BlueCrossBlueShieldPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BlueCross BlueShield Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BlueCrossBlueShieldPlansMember" xlink:href="cstl-20220630.xsd#cstl_BlueCrossBlueShieldPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BlueCrossBlueShieldPlansMember" xlink:to="lab_cstl_BlueCrossBlueShieldPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e4811908-6647-4c7f-894f-8b39a8a05ddc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6790d6e1-13f4-42ef-940d-e7f9592126d7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b981c37c-c33e-48f8-a138-fa85a383f280_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_74322904-f5df-4194-aaab-5276669f13bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b792ed45-4332-4539-939d-4756a28929c0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d1c6784f-83fd-47d3-9d98-a5be5f75c179_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3110cf6f-5576-4f00-a787-4a4c5db28b0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d53214bc-6992-4e02-909b-7f3b08db3c84_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e89375e-6b61-4cd6-b295-c868177d286a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_0eb15c14-7ea1-41e6-86b3-b4861c2752be_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_265dd96d-7a32-49df-9c61-c6616891fede_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_34a27bb6-9915-4859-add2-153254e37382_terseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid in cash (as a percent)</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_label_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Cash</link:label>
    <link:label id="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" xlink:to="lab_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1a036851-6a40-491b-bae3-f1238851572e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued and current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_10664a5b-a4ac-4213-8f26-f0eed71bf632_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b233e8fb-6c0a-4946-96f1-ec9d69d7b229_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_833c0c01-a6e8-449c-b257-868d20c4feb4_terseLabel_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, amount</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:label id="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_33dca0f3-cee2-4134-bedf-766c475f7ff0_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1cf81a34-bac0-442e-8167-a551ed2bc92d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_794d6cc9-4dc3-448b-a420-db7bb0d89a5e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued service fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0c8f5dd5-80f7-49d0-b4ed-ce70af17dfce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_43a42c81-73c6-4740-95b2-1a702b23f89e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_4d0db142-b30a-49a6-b02a-aab433ad0c17_negatedTerseLabel_en-US" xlink:label="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_label_en-US" xlink:label="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation</link:label>
    <link:label id="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_documentation_en-US" xlink:label="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" xlink:to="lab_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b01f9f30-b7b2-4ad8-a8b5-9c55f0da9e41_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2e2620ab-ffa1-4479-aa4e-2f37939cdd8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9191f7ee-1f15-480c-9ce2-85b6d351b93a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_227d4bee-f379-4ae4-b545-8de4408c8319_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_77e1ea3b-9af2-44b0-9587-bce82418c415_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3e399419-fb26-408b-9efe-c1c5d802d497_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0011f30a-e3de-4352-b081-a3ac3b1e9574_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_506ff904-6ca8-4b46-9bc4-1d67f8e17b22_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_08da8e61-09f0-401c-a8c2-fa6529e8c9e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_ae5999e2-68d0-45cb-93e5-22733065de9b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (exclusive of amortization of acquired intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4d32eaf7-2e30-4026-a319-f5d46986c5d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_791b5495-0855-4865-8e1c-3c6969c03d82_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cstl-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c77279c-977d-402a-b1b2-5d29ed09603d,g:da8c0f38-2da3-40ff-b133-9fd71c151e0e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/Cover" xlink:type="simple" xlink:href="cstl-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d59e9c04-1a37-42f0-be3a-e8c2f2491c39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_DocumentType_d59e9c04-1a37-42f0-be3a-e8c2f2491c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2d5d55dc-80de-4471-9c77-375efb63bb0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_DocumentQuarterlyReport_2d5d55dc-80de-4471-9c77-375efb63bb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a0bfdbeb-cbb4-4d0b-b8b8-d6c20be97330" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_DocumentPeriodEndDate_a0bfdbeb-cbb4-4d0b-b8b8-d6c20be97330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_591c5d5d-b748-4250-a735-9867e8cf724d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_DocumentTransitionReport_591c5d5d-b748-4250-a735-9867e8cf724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_22b99676-6f07-44ab-a905-cf6ed941dc71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityFileNumber_22b99676-6f07-44ab-a905-cf6ed941dc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bb80e5e9-b990-4600-b0f1-e906c915b14b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityRegistrantName_bb80e5e9-b990-4600-b0f1-e906c915b14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8ed4a587-49db-43b6-b6c1-81943aad2baf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8ed4a587-49db-43b6-b6c1-81943aad2baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4960655d-e239-4bf2-92f7-30ecf20673ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityTaxIdentificationNumber_4960655d-e239-4bf2-92f7-30ecf20673ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f9e0d21d-9b24-42b9-9251-b700ca804386" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityAddressAddressLine1_f9e0d21d-9b24-42b9-9251-b700ca804386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2a1dd8b2-9894-4b54-a103-3be1512dfcbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityAddressAddressLine2_2a1dd8b2-9894-4b54-a103-3be1512dfcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_327312f8-cb98-4400-9bdb-332f1f9e9901" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityAddressCityOrTown_327312f8-cb98-4400-9bdb-332f1f9e9901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b2f8e26b-003b-42b0-8d3e-2275584a6709" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityAddressStateOrProvince_b2f8e26b-003b-42b0-8d3e-2275584a6709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_97188c53-f1b0-4054-a486-f1e7a602cb21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityAddressPostalZipCode_97188c53-f1b0-4054-a486-f1e7a602cb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2cee8ffa-5a50-4120-9247-1875bee62cc4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_CityAreaCode_2cee8ffa-5a50-4120-9247-1875bee62cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c91da490-6c12-4c19-ad1e-cdca7cce8a72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_LocalPhoneNumber_c91da490-6c12-4c19-ad1e-cdca7cce8a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8859343e-bfa0-483a-893b-9cce84eb1abf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_Security12bTitle_8859343e-bfa0-483a-893b-9cce84eb1abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5c6c3a01-157a-42da-8cc1-b490cc1d662e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_TradingSymbol_5c6c3a01-157a-42da-8cc1-b490cc1d662e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3d065257-bdfe-40cd-b1e5-7f248b385871" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_SecurityExchangeName_3d065257-bdfe-40cd-b1e5-7f248b385871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cd0dd85b-319e-462a-9eed-4a56eb82fdae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityCurrentReportingStatus_cd0dd85b-319e-462a-9eed-4a56eb82fdae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_62c80894-f953-455b-bb4c-eb11c88012be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityInteractiveDataCurrent_62c80894-f953-455b-bb4c-eb11c88012be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_78f3ee9e-fa09-44f4-be49-9480cee62f0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityFilerCategory_78f3ee9e-fa09-44f4-be49-9480cee62f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_82126fdd-8263-4773-9039-ddab8ce16ce5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntitySmallBusiness_82126fdd-8263-4773-9039-ddab8ce16ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c76715ea-a158-462e-a709-00f4e9ac8889" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityEmergingGrowthCompany_c76715ea-a158-462e-a709-00f4e9ac8889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_65ce5a68-d69b-42be-a18e-e290bdf24d1b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityShellCompany_65ce5a68-d69b-42be-a18e-e290bdf24d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_293541f6-c604-4984-9fb9-8f18f7b64e61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_293541f6-c604-4984-9fb9-8f18f7b64e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b7afcd94-d68f-4959-aa88-bcd8b5e4be9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_EntityCentralIndexKey_b7afcd94-d68f-4959-aa88-bcd8b5e4be9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6cc69b97-6a7d-41fa-bc17-6003fa8cca60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_CurrentFiscalYearEndDate_6cc69b97-6a7d-41fa-bc17-6003fa8cca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_da792e66-1e34-4366-8632-66985b20823e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_DocumentFiscalYearFocus_da792e66-1e34-4366-8632-66985b20823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_55ce5130-8889-4ed0-9450-e8f9382e7907" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_55ce5130-8889-4ed0-9450-e8f9382e7907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cef86263-9076-43a2-834e-547642bd658f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_31b4635d-4492-4c62-9c44-d19bd9a0ed8a" xlink:to="loc_dei_AmendmentFlag_cef86263-9076-43a2-834e-547642bd658f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fc290507-a4a4-445c-9802-28f7f3f2d94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc290507-a4a4-445c-9802-28f7f3f2d94c" xlink:to="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4cd86cb7-83a5-4fc8-aeab-dc8bfcf4837c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4cd86cb7-83a5-4fc8-aeab-dc8bfcf4837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8a8dbfbe-8f48-4e95-88e5-b426b4a0508b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8a8dbfbe-8f48-4e95-88e5-b426b4a0508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0e432d83-e31d-45d8-b64b-8dd67b8eb4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:to="loc_us-gaap_InventoryNet_0e432d83-e31d-45d8-b64b-8dd67b8eb4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_492bbf74-c1bd-410c-a628-291ee762d8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_492bbf74-c1bd-410c-a628-291ee762d8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1bf3be24-297c-45cc-b7c5-a3151fce653c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cc7c1372-977d-46f2-9646-b7f2dc36705e" xlink:to="loc_us-gaap_AssetsCurrent_1bf3be24-297c-45cc-b7c5-a3151fce653c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_4eaf7a84-4677-4a91-a39c-57dcc424d670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_4eaf7a84-4677-4a91-a39c-57dcc424d670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_70e81646-6357-4386-8d0f-85ed9f402037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_70e81646-6357-4386-8d0f-85ed9f402037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa359283-eba7-4dc7-8235-6b8f36210eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fa359283-eba7-4dc7-8235-6b8f36210eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_6527c883-89d1-490f-a715-11cf39e5aaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_6527c883-89d1-490f-a715-11cf39e5aaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_70e9cfcf-cdfa-4c0b-96b7-229eee404b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_70e9cfcf-cdfa-4c0b-96b7-229eee404b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8e259742-6b11-4ca4-8346-39df1c1e5097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dfa9bc9b-19b0-4f41-bcfa-775d34c50066" xlink:to="loc_us-gaap_Assets_8e259742-6b11-4ca4-8346-39df1c1e5097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc290507-a4a4-445c-9802-28f7f3f2d94c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_abeea406-846b-4504-afeb-25f516d70ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:to="loc_us-gaap_AccountsPayableCurrent_abeea406-846b-4504-afeb-25f516d70ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1537bd8e-9aef-4f6d-bea9-5cdb801df1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1537bd8e-9aef-4f6d-bea9-5cdb801df1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_853eb696-9700-4dad-96ca-9cc002a95d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_853eb696-9700-4dad-96ca-9cc002a95d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_039ce3eb-91f5-474a-be5a-4801ea34913e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_039ce3eb-91f5-474a-be5a-4801ea34913e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d33988b3-5a0d-49f6-869a-d4b352636145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e53dac16-3207-4007-8a88-8b8d29d49075" xlink:to="loc_us-gaap_LiabilitiesCurrent_d33988b3-5a0d-49f6-869a-d4b352636145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b3614b7e-1a91-4923-b919-f189045106a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b3614b7e-1a91-4923-b919-f189045106a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8904f78b-d0ee-441a-bfa0-ec4b0490d620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8904f78b-d0ee-441a-bfa0-ec4b0490d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7f6a9063-06cf-411d-9876-46f0de85d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7f6a9063-06cf-411d-9876-46f0de85d1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3507329e-12d0-4edb-84fb-bca9b061d727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3507329e-12d0-4edb-84fb-bca9b061d727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_56994eeb-ec15-48dd-9bf9-edbbac38c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_Liabilities_56994eeb-ec15-48dd-9bf9-edbbac38c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_03afdf5b-5551-42c6-9a0a-26aae4861674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_03afdf5b-5551-42c6-9a0a-26aae4861674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_f3096293-3c9e-4cff-859c-a4d310b10241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_f3096293-3c9e-4cff-859c-a4d310b10241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_0e23238c-2ca5-48ce-b9da-9d33bbf36cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:to="loc_us-gaap_CommonStockValueOutstanding_0e23238c-2ca5-48ce-b9da-9d33bbf36cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_76d374b9-a9c6-4a31-b079-f8c9ef049e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_76d374b9-a9c6-4a31-b079-f8c9ef049e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c687c572-aa4b-4e69-8cd8-2fb24c6888f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c687c572-aa4b-4e69-8cd8-2fb24c6888f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_97a4dc4e-dc1d-4d3b-8bff-a796c37f3917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a1db1c09-93de-409a-a606-560b0de27e1d" xlink:to="loc_us-gaap_StockholdersEquity_97a4dc4e-dc1d-4d3b-8bff-a796c37f3917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_548e2dcd-72d8-4728-86d0-8d733b74aae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_737c8795-817a-4e5e-a5f1-d171e1dd8cc4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_548e2dcd-72d8-4728-86d0-8d733b74aae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_47831367-3cd4-4d27-8844-464749b40ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_47831367-3cd4-4d27-8844-464749b40ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4d07be18-923d-46be-8218-d183a4789bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4d07be18-923d-46be-8218-d183a4789bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_de8e6336-9adb-499b-bf4d-785bcd752128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_PreferredStockSharesIssued_de8e6336-9adb-499b-bf4d-785bcd752128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0de6c9f5-ef0c-41a8-bd0f-3e96a994671d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0de6c9f5-ef0c-41a8-bd0f-3e96a994671d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_97b772f9-2566-430a-bf2f-36d651960784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_97b772f9-2566-430a-bf2f-36d651960784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b5023d25-6d60-4b8a-b01f-a1e06f78871f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b5023d25-6d60-4b8a-b01f-a1e06f78871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d6ffa637-5144-4f48-b093-3ce1b08a41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_CommonStockSharesIssued_d6ffa637-5144-4f48-b093-3ce1b08a41f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_653dff88-6c5e-49d8-bbeb-e2d9bb14b687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ba9dfef-825d-479d-b915-dd52dc3a32ec" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_653dff88-6c5e-49d8-bbeb-e2d9bb14b687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_26123911-6e5a-4a69-8071-425d622ed81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_26123911-6e5a-4a69-8071-425d622ed81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:href="cstl-20220630.xsd#cstl_OperatingExpensesAndOtherOperatingIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_97733d8c-6e83-40d3-849a-a1ebe580060b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:to="loc_us-gaap_CostOfRevenue_97733d8c-6e83-40d3-849a-a1ebe580060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4bca123d-2dd5-4b38-991d-62d4b5ecfef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4bca123d-2dd5-4b38-991d-62d4b5ecfef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_644397c5-2f32-4c91-9577-dbcbaff6b975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_644397c5-2f32-4c91-9577-dbcbaff6b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_31d36289-dc6a-4a20-ac01-45566a2cd4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_31d36289-dc6a-4a20-ac01-45566a2cd4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dfd8a0f4-22d4-4c26-bb39-f617fffba1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dfd8a0f4-22d4-4c26-bb39-f617fffba1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_595ec156-705a-4fa3-a2ff-297f36c93239" xlink:href="cstl-20220630.xsd#cstl_OperatingExpensesNetOfOtherOperatingIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract_5f15c614-90f1-4860-b089-7317a3b4c0f3" xlink:to="loc_cstl_OperatingExpensesNetOfOtherOperatingIncome_595ec156-705a-4fa3-a2ff-297f36c93239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_851f576c-cfb6-4fec-8753-22a3ab77ac08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_OperatingIncomeLoss_851f576c-cfb6-4fec-8753-22a3ab77ac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_386bbe85-bf51-43b9-9b01-993a5c524e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_InvestmentIncomeInterest_386bbe85-bf51-43b9-9b01-993a5c524e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_89c66193-e302-429a-9143-d40ea3cbf0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_InterestExpense_89c66193-e302-429a-9143-d40ea3cbf0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d2b987de-8bde-4bf6-95bf-f2c7b6e7252a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d2b987de-8bde-4bf6-95bf-f2c7b6e7252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c6f5f1f8-540d-4e6d-8943-64b50e2f419c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c6f5f1f8-540d-4e6d-8943-64b50e2f419c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e8f2a01b-15d9-4731-81db-604aee0f8b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e8f2a01b-15d9-4731-81db-604aee0f8b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8b61a11-a85a-4444-bc4a-4f10081fc292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_NetIncomeLoss_b8b61a11-a85a-4444-bc4a-4f10081fc292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9994ae90-df18-4854-83f3-5cb8311f438d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_EarningsPerShareBasic_9994ae90-df18-4854-83f3-5cb8311f438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_572d2d71-82ef-441a-96e3-88e7694926ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_EarningsPerShareDiluted_572d2d71-82ef-441a-96e3-88e7694926ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e33f32fe-4436-4ce9-bddd-9040fd270067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e33f32fe-4436-4ce9-bddd-9040fd270067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e9ee5152-2a2b-4bf2-839d-baefb22c396c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91bd799e-f625-45c4-9d02-dadba70d5824" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e9ee5152-2a2b-4bf2-839d-baefb22c396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c6a815a-d5ba-4f7c-8290-881e02e596ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c6a815a-d5ba-4f7c-8290-881e02e596ef" xlink:to="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3dec389d-b535-46ae-8736-5b23f05d3863" xlink:to="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_1bac6746-e34e-43c7-a325-3f7a3bb30b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_PreferredStockMember_1bac6746-e34e-43c7-a325-3f7a3bb30b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0a093c4d-0711-4548-bb70-0dd91fce6bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_CommonStockMember_0a093c4d-0711-4548-bb70-0dd91fce6bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ba5b88e3-69bd-4b1d-b62f-00c9e98f8ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ba5b88e3-69bd-4b1d-b62f-00c9e98f8ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b9fe2500-e7e7-4db2-9f35-d54b606a4276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa99092d-eed4-486c-b6f5-18d41eff1d73" xlink:to="loc_us-gaap_RetainedEarningsMember_b9fe2500-e7e7-4db2-9f35-d54b606a4276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_394151d0-4356-460a-925f-edf0e69395d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_669f7b60-ad10-477e-9d0b-a4dbe856ca84" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_394151d0-4356-460a-925f-edf0e69395d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b996aae4-db7d-448c-925c-8ba1dc31faf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_394151d0-4356-460a-925f-edf0e69395d5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b996aae4-db7d-448c-925c-8ba1dc31faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_975c7e39-b25e-4dc6-9e5e-1d6ebbc6fa75" xlink:to="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d652d09d-7afa-40e4-9e7b-af05d6f5b1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_SharesOutstanding_d652d09d-7afa-40e4-9e7b-af05d6f5b1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b176e266-664b-42e3-9dfe-32e5ec2e8c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockholdersEquity_b176e266-664b-42e3-9dfe-32e5ec2e8c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_d5ef7468-4c3b-407f-894f-59fafdefdd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_d5ef7468-4c3b-407f-894f-59fafdefdd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c609b6bc-b993-40d2-8bc6-a07b931f3769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c609b6bc-b993-40d2-8bc6-a07b931f3769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7425146-bca3-4a6f-9fbc-5e4fede8452c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7425146-bca3-4a6f-9fbc-5e4fede8452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69999b7b-98e0-49fc-996f-961626561753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69999b7b-98e0-49fc-996f-961626561753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4c7895e-5fb0-4b59-9230-8baf185aa6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a4c7895e-5fb0-4b59-9230-8baf185aa6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fd405b8-ae90-4dfb-bf38-9db648004d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fd405b8-ae90-4dfb-bf38-9db648004d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a6b513b9-b0b0-4e5d-b2cb-ae2cc7428b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a6b513b9-b0b0-4e5d-b2cb-ae2cc7428b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_96748808-742c-48b3-bccc-585a446a6394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_96748808-742c-48b3-bccc-585a446a6394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd52f260-cd9d-4a04-bdbb-782299ab18d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd52f260-cd9d-4a04-bdbb-782299ab18d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e6b0fcdd-8c96-4b96-9a34-7869f4f94d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e6b0fcdd-8c96-4b96-9a34-7869f4f94d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa6c18c0-f4db-4a39-b467-a1658ef4a692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_NetIncomeLoss_fa6c18c0-f4db-4a39-b467-a1658ef4a692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f69529af-97d0-4a77-bd89-bbd1dcccf6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_SharesOutstanding_f69529af-97d0-4a77-bd89-bbd1dcccf6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89b84f6f-e80b-4f57-b956-97c4431a17c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_beb2e8df-3423-4fe3-9073-2eee05a5d3f6" xlink:to="loc_us-gaap_StockholdersEquity_89b84f6f-e80b-4f57-b956-97c4431a17c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f941f464-d2bb-4fad-8d22-d8e24eebec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1367c92e-a6df-4e18-b377-19faf8e7b4e1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f941f464-d2bb-4fad-8d22-d8e24eebec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cstl-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_10c5e33c-b1e3-47fb-8cfb-8bc24e170c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_10c5e33c-b1e3-47fb-8cfb-8bc24e170c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d23ad6a8-1ce6-44e6-b3c8-f710ddc6aa3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_10c5e33c-b1e3-47fb-8cfb-8bc24e170c91" xlink:to="loc_us-gaap_NetIncomeLoss_d23ad6a8-1ce6-44e6-b3c8-f710ddc6aa3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_10c5e33c-b1e3-47fb-8cfb-8bc24e170c91" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3d1ddf80-4c20-4ed8-a0c3-d9f8f5ea320b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3d1ddf80-4c20-4ed8-a0c3-d9f8f5ea320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2debff0c-7198-489d-acd3-84830decfec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:to="loc_us-gaap_ShareBasedCompensation_2debff0c-7198-489d-acd3-84830decfec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b4016296-1599-4c6c-a375-87a172a0ac19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b4016296-1599-4c6c-a375-87a172a0ac19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_312eb97d-2fe9-4663-9c75-348c67e6395c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_312eb97d-2fe9-4663-9c75-348c67e6395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c283532e-e895-4ab0-aad0-a4cee67797bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a007350f-9bd8-47c1-81ec-a462a7ae3527" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c283532e-e895-4ab0-aad0-a4cee67797bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_10c5e33c-b1e3-47fb-8cfb-8bc24e170c91" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc1a918e-ad31-467b-84fa-deaec46804a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc1a918e-ad31-467b-84fa-deaec46804a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e37a6bfd-d698-416c-bb80-6f42fbcb4b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e37a6bfd-d698-416c-bb80-6f42fbcb4b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2dcfe9bb-f37b-4759-b59d-c5bfa90e1d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2dcfe9bb-f37b-4759-b59d-c5bfa90e1d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_d93e393b-9bda-477d-87e3-c067abe82876" xlink:href="cstl-20220630.xsd#cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_d93e393b-9bda-477d-87e3-c067abe82876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4e3c1dfd-2d2c-4ba7-8a1b-4695333ee31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4e3c1dfd-2d2c-4ba7-8a1b-4695333ee31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8bb253d3-5617-4960-bf23-5808d2ffbe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8bb253d3-5617-4960-bf23-5808d2ffbe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d14f73e9-5f67-4ea0-9f05-efbce23c319c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d14f73e9-5f67-4ea0-9f05-efbce23c319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_70a6e881-b9e4-466e-9f61-df0f067fcef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_70a6e881-b9e4-466e-9f61-df0f067fcef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e77186f0-257e-49c7-bcd2-97ddd503ef0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e77186f0-257e-49c7-bcd2-97ddd503ef0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_523381c1-c8e4-464f-9cfa-7b015f8758f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33b5ce92-297c-4410-a4c5-851a32401380" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_523381c1-c8e4-464f-9cfa-7b015f8758f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a207a263-3f6a-45af-bc75-2ecabd33f10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_10c5e33c-b1e3-47fb-8cfb-8bc24e170c91" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a207a263-3f6a-45af-bc75-2ecabd33f10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a92e83b-1815-4148-9e4e-755f9db3d131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1a92e83b-1815-4148-9e4e-755f9db3d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ProceedsFromPreviousAssetAcquisition_0ae9553b-2d05-46bb-a580-5a2a695fc2f1" xlink:href="cstl-20220630.xsd#cstl_ProceedsFromPreviousAssetAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:to="loc_cstl_ProceedsFromPreviousAssetAcquisition_0ae9553b-2d05-46bb-a580-5a2a695fc2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_69033a65-16e0-4ff8-9b2f-51996fea7940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_69033a65-16e0-4ff8-9b2f-51996fea7940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_69aeebfa-ddec-452e-a53a-f0cc1320b974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_69aeebfa-ddec-452e-a53a-f0cc1320b974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7e857c5c-fa23-443f-81d0-3e4dbb2ef224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7e857c5c-fa23-443f-81d0-3e4dbb2ef224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66c0cb81-5bfb-4215-8aa0-08a91b4cbf47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17c38dbd-b916-403e-8983-a2f23cca4e63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66c0cb81-5bfb-4215-8aa0-08a91b4cbf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1fd17656-47de-41d9-964b-d2172d33e435" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1fd17656-47de-41d9-964b-d2172d33e435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4d8cecc2-f0ce-4a7b-87f7-ea02102022aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4d8cecc2-f0ce-4a7b-87f7-ea02102022aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a0c1c813-3238-4a27-ad5f-1ec86c31ed1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a0c1c813-3238-4a27-ad5f-1ec86c31ed1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_5796d221-1279-4238-b2ba-bf4ba667dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:to="loc_us-gaap_ProceedsFromStockPlans_5796d221-1279-4238-b2ba-bf4ba667dd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_95304f49-f931-46fc-a39b-1384ba80f239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_95304f49-f931-46fc-a39b-1384ba80f239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d74e682-6902-4856-bc2d-6aec42ac3ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ab9ef16-e3ec-4e81-9bc6-c343b94e2709" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d74e682-6902-4856-bc2d-6aec42ac3ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd58a395-739e-4608-b97a-5f0c921f6202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd58a395-739e-4608-b97a-5f0c921f6202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733c75f0-07d1-4def-8d77-98d49ea13392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_733c75f0-07d1-4def-8d77-98d49ea13392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e723535-ed76-404c-9adf-0981b11f2267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e723535-ed76-404c-9adf-0981b11f2267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bae8f1e3-5454-4b7d-9e9c-00e0d3d624b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3cd5027c-8ff7-4a6f-a38b-a0221f032e3b" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bae8f1e3-5454-4b7d-9e9c-00e0d3d624b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a07712e5-b6f5-408f-a108-ee7b38ab18cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bae8f1e3-5454-4b7d-9e9c-00e0d3d624b9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a07712e5-b6f5-408f-a108-ee7b38ab18cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_e4146973-0438-49a5-a570-0e98e6baa1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bae8f1e3-5454-4b7d-9e9c-00e0d3d624b9" xlink:to="loc_us-gaap_StockIssued1_e4146973-0438-49a5-a570-0e98e6baa1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationNoncashContingentConsiderationGiven_30301a5d-da0e-4fd5-9af2-532d0c7ca5ee" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationNoncashContingentConsiderationGiven"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bae8f1e3-5454-4b7d-9e9c-00e0d3d624b9" xlink:to="loc_cstl_BusinessCombinationNoncashContingentConsiderationGiven_30301a5d-da0e-4fd5-9af2-532d0c7ca5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_fad876c7-9985-47ad-8b09-b4d5fc54f7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_bae8f1e3-5454-4b7d-9e9c-00e0d3d624b9" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_fad876c7-9985-47ad-8b09-b4d5fc54f7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="cstl-20220630.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c21eaec0-9669-4ff9-8e38-6671d121c72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bb07b390-f2d5-48f1-8fd7-a766d6b9d4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c21eaec0-9669-4ff9-8e38-6671d121c72d" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_bb07b390-f2d5-48f1-8fd7-a766d6b9d4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cstl-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9dc6daa9-da34-42b7-9b3e-064451a09e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c8ca56e1-0868-421c-8b94-7b042f4c243c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9dc6daa9-da34-42b7-9b3e-064451a09e9a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c8ca56e1-0868-421c-8b94-7b042f4c243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cstl-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6884b9bd-cd14-4e43-83ae-293f675c86b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6884b9bd-cd14-4e43-83ae-293f675c86b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_b720ba72-80f8-4093-ac5b-0f11b507c11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_b720ba72-80f8-4093-ac5b-0f11b507c11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_601a7b09-c84c-4b9a-b8e0-b370705f03a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_UseOfEstimates_601a7b09-c84c-4b9a-b8e0-b370705f03a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_839d323d-1fad-4e87-aacb-cd81b9332885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_839d323d-1fad-4e87-aacb-cd81b9332885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_edc64727-e7dc-44c8-8cd1-93bf26819307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_edc64727-e7dc-44c8-8cd1-93bf26819307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c4f434a9-4a76-4926-a736-159d34b64198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c4f434a9-4a76-4926-a736-159d34b64198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_dacfa194-4fc5-4c91-a244-ece8a32719af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_dacfa194-4fc5-4c91-a244-ece8a32719af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_2e42a180-336b-4653-a96f-81c5afb1cb37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_2e42a180-336b-4653-a96f-81c5afb1cb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c49ced64-c0fb-4e75-9566-a95cef27e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_c49ced64-c0fb-4e75-9566-a95cef27e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock_6b0efd8d-d52b-4d32-accb-80b20875c92d" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock_6b0efd8d-d52b-4d32-accb-80b20875c92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_c85e7dc4-2035-4859-9f13-6ae2760ef473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_c85e7dc4-2035-4859-9f13-6ae2760ef473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fc1a5ef5-99f5-4cf7-8d5e-d71045ecbea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8bb39af6-d594-4083-984c-11abad6eab50" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fc1a5ef5-99f5-4cf7-8d5e-d71045ecbea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_54f52158-d75c-49aa-b365-8c5f72c852f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7226d4ae-fac0-485f-8b40-f04921ca361b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54f52158-d75c-49aa-b365-8c5f72c852f4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_7226d4ae-fac0-485f-8b40-f04921ca361b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_58ebaafa-147f-49a3-b166-16b72f40e23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54f52158-d75c-49aa-b365-8c5f72c852f4" xlink:to="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_58ebaafa-147f-49a3-b166-16b72f40e23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a1eab47c-5a0c-476c-a75d-15fd9aeb3ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54f52158-d75c-49aa-b365-8c5f72c852f4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a1eab47c-5a0c-476c-a75d-15fd9aeb3ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/Revenue" xlink:type="simple" xlink:href="cstl-20220630.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_08a234ec-cb87-4039-b978-1b4fcdde5450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_febfb5b6-6a18-432c-b5d6-6343f81aae76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_08a234ec-cb87-4039-b978-1b4fcdde5450" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_febfb5b6-6a18-432c-b5d6-6343f81aae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/RevenueTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#RevenueTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/RevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c22db1b-2c40-4a90-b936-54c65b2f4b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_bcb5fa97-0559-4cf1-9167-4a54bd71eb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c22db1b-2c40-4a90-b936-54c65b2f4b85" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_bcb5fa97-0559-4cf1-9167-4a54bd71eb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d1425683-624d-4f22-bc15-bfbdf95e825d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c22db1b-2c40-4a90-b936-54c65b2f4b85" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d1425683-624d-4f22-bc15-bfbdf95e825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/RevenueNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#RevenueNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/RevenueNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f72947a1-4fab-412d-ab79-8517b016360d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ContractWithCustomerCustomerPaymentTerms_2cb0cb80-c49a-4cb7-904e-42905a031172" xlink:href="cstl-20220630.xsd#cstl_ContractWithCustomerCustomerPaymentTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f72947a1-4fab-412d-ab79-8517b016360d" xlink:to="loc_cstl_ContractWithCustomerCustomerPaymentTerms_2cb0cb80-c49a-4cb7-904e-42905a031172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c2f65dc0-500b-40e9-a9c3-bb0cb4dbc7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f72947a1-4fab-412d-ab79-8517b016360d" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_c2f65dc0-500b-40e9-a9c3-bb0cb4dbc7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#RevenueDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8cdf3c1b-55e7-44ef-9134-ea3bb373f2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8cdf3c1b-55e7-44ef-9134-ea3bb373f2cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:to="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4e8bcf0a-158e-4962-99f6-42cb5b54d7b5" xlink:to="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_DermatologicMember_f3cb8f96-192d-4340-854b-5ddea67b14e5" xlink:href="cstl-20220630.xsd#cstl_DermatologicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:to="loc_cstl_DermatologicMember_f3cb8f96-192d-4340-854b-5ddea67b14e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_ad4883e4-513f-4855-b6b2-252e56167253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfca25c2-b85a-4263-825b-2fb1ce552732" xlink:to="loc_us-gaap_ServiceOtherMember_ad4883e4-513f-4855-b6b2-252e56167253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_75b03ef6-453e-4bc6-8f21-4e1c891d1383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd431527-dd77-4a3e-af33-4faad990bdc8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_75b03ef6-453e-4bc6-8f21-4e1c891d1383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a9ef0c4-2cbc-49f3-971c-b79021f44162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_75b03ef6-453e-4bc6-8f21-4e1c891d1383" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a9ef0c4-2cbc-49f3-971c-b79021f44162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#RevenueConcentrationofRiskbyRiskFactorDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c9e1f45b-c645-47e0-8a16-1c17898feb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c9e1f45b-c645-47e0-8a16-1c17898feb1c" xlink:to="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d4435cc8-a0d5-436e-a40b-4732eff184c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MedicareMember_7a742e0a-3bfd-4464-9d8f-7fb148d3c1c8" xlink:href="cstl-20220630.xsd#cstl_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:to="loc_cstl_MedicareMember_7a742e0a-3bfd-4464-9d8f-7fb148d3c1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MedicareAdvantagePlansMember_f843d579-6e16-42f1-be9c-fcaf607ffb08" xlink:href="cstl-20220630.xsd#cstl_MedicareAdvantagePlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:to="loc_cstl_MedicareAdvantagePlansMember_f843d579-6e16-42f1-be9c-fcaf607ffb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BlueCrossBlueShieldPlansMember_42ef9939-9de0-4df6-92d0-affb69edf1c0" xlink:href="cstl-20220630.xsd#cstl_BlueCrossBlueShieldPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95be1a2e-445a-4f75-a9a7-78f4c634e20a" xlink:to="loc_cstl_BlueCrossBlueShieldPlansMember_42ef9939-9de0-4df6-92d0-affb69edf1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_430f33ce-e60a-45bf-aa1b-b5ff30a2ceff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_1eb291a0-f7c1-4e1e-9cc8-0f58e695733b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_1eb291a0-f7c1-4e1e-9cc8-0f58e695733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccountsReceivableCurrentMember_41e09fa4-4b7b-4105-aa4f-6737069e43a0" xlink:href="cstl-20220630.xsd#cstl_AccountsReceivableCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:to="loc_cstl_AccountsReceivableCurrentMember_41e09fa4-4b7b-4105-aa4f-6737069e43a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccountsReceivableNoncurrentMember_06d11c56-6cf3-4dc2-a3a7-f8dd0740fd19" xlink:href="cstl-20220630.xsd#cstl_AccountsReceivableNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2829156-28c1-4f88-a0fe-d6231a1017e6" xlink:to="loc_cstl_AccountsReceivableNoncurrentMember_06d11c56-6cf3-4dc2-a3a7-f8dd0740fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a6cf4e9e-5445-467b-b132-f461645dbe14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0779277f-5ee6-46eb-86b3-07a07739a1bf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a6cf4e9e-5445-467b-b132-f461645dbe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ThirdPartyPayorConcentrationRiskMember_f3ca8f6d-85c4-4333-a47c-afb51356b99e" xlink:href="cstl-20220630.xsd#cstl_ThirdPartyPayorConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a6cf4e9e-5445-467b-b132-f461645dbe14" xlink:to="loc_cstl_ThirdPartyPayorConcentrationRiskMember_f3ca8f6d-85c4-4333-a47c-afb51356b99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_1c8fb64e-8834-45c6-939e-7405c6b3ba76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_55bf09b1-ac1d-4feb-82ae-565bf5b72c05" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_1c8fb64e-8834-45c6-939e-7405c6b3ba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_51c7a786-19c5-4f66-a00c-047bbba90de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_1c8fb64e-8834-45c6-939e-7405c6b3ba76" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_51c7a786-19c5-4f66-a00c-047bbba90de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LossPerShare" xlink:type="simple" xlink:href="cstl-20220630.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_88c4dfba-0e2b-48a2-a854-bbd8d2f65d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_347d1caf-593d-4425-95d9-610aba3a27fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_88c4dfba-0e2b-48a2-a854-bbd8d2f65d75" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_347d1caf-593d-4425-95d9-610aba3a27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LossPerShareTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#LossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/LossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6318765d-1c41-4283-876f-8df49ca8c079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4cddd6f3-5367-4bf8-bf57-9410ef85809a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6318765d-1c41-4283-876f-8df49ca8c079" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4cddd6f3-5367-4bf8-bf57-9410ef85809a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_786edcf5-1027-4750-97d5-c22d19c6970f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_786edcf5-1027-4750-97d5-c22d19c6970f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d46de277-787e-49f4-acb5-dc19b08d382b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_783b6da4-7238-42a4-b5d8-3c1a32139f77" xlink:href="cstl-20220630.xsd#cstl_StockOptionsAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:to="loc_cstl_StockOptionsAndRestrictedStockUnitsRSUsMember_783b6da4-7238-42a4-b5d8-3c1a32139f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_499de9d6-b00e-451a-8e2e-1c959596a244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b073fc96-a8a3-49ee-8674-d4b9c41119f6" xlink:to="loc_us-gaap_EmployeeStockMember_499de9d6-b00e-451a-8e2e-1c959596a244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c56fc4de-ef0d-4dcb-add7-678fa9c58fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_08a0147a-4cdf-4871-98aa-dd412d438a46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c56fc4de-ef0d-4dcb-add7-678fa9c58fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b2c37d43-5b8f-4be5-aaeb-35f6e1a81d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c56fc4de-ef0d-4dcb-add7-678fa9c58fe9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b2c37d43-5b8f-4be5-aaeb-35f6e1a81d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/Acquisitions" xlink:type="simple" xlink:href="cstl-20220630.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f46e1596-647e-4c37-8431-a32f34fb0c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_2035f1f5-af01-45be-8426-123b3ff02eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f46e1596-647e-4c37-8431-a32f34fb0c6f" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_2035f1f5-af01-45be-8426-123b3ff02eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1ebbcdea-5a6e-4b4d-8876-725f860d105c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f46e1596-647e-4c37-8431-a32f34fb0c6f" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1ebbcdea-5a6e-4b4d-8876-725f860d105c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fee240ab-d287-42ca-92da-0119e167ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3d21a652-cd90-4e17-b574-20916f2b8191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fee240ab-d287-42ca-92da-0119e167ccdc" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3d21a652-cd90-4e17-b574-20916f2b8191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_70f7c112-0ddf-4c32-bee4-122e9fd84b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fee240ab-d287-42ca-92da-0119e167ccdc" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_70f7c112-0ddf-4c32-bee4-122e9fd84b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6585966d-ac9c-4a2f-8faa-40bae45282ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fee240ab-d287-42ca-92da-0119e167ccdc" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6585966d-ac9c-4a2f-8faa-40bae45282ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8f547b87-cc14-45af-a726-8f6006f79d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8f547b87-cc14-45af-a726-8f6006f79d07" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16ee83c2-aed8-4077-a301-9f40e9f5e71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36c94c99-2917-4367-8c97-ab90566d3d99" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16ee83c2-aed8-4077-a301-9f40e9f5e71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_f5ed17ac-f3ef-42d7-af1f-2f3d03a6da64" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16ee83c2-aed8-4077-a301-9f40e9f5e71f" xlink:to="loc_cstl_AltheaDxIncMember_f5ed17ac-f3ef-42d7-af1f-2f3d03a6da64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_23c27336-0588-4750-92f3-1ff26dec4c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9db4a460-498a-469f-a3da-3b2523dce11c" xlink:to="loc_us-gaap_EquityComponentDomain_23c27336-0588-4750-92f3-1ff26dec4c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a8f5d622-1936-409f-a9a7-c7a81ac80b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_23c27336-0588-4750-92f3-1ff26dec4c5f" xlink:to="loc_us-gaap_CommonStockMember_a8f5d622-1936-409f-a9a7-c7a81ac80b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94796909-927d-4b83-b1a0-eae5a953df1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_04591525-4d56-49fb-a31d-f91144aa88ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94796909-927d-4b83-b1a0-eae5a953df1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b20fa873-2ba7-49a9-93a7-6434d15599a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94796909-927d-4b83-b1a0-eae5a953df1e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b20fa873-2ba7-49a9-93a7-6434d15599a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1834f5fd-0c88-4c85-af98-86e3ab6579ca" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_MyriadMyPathLLCMember_18ebaa1f-1779-4ed2-b94a-78b6486319a6" xlink:href="cstl-20220630.xsd#cstl_MyriadMyPathLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:to="loc_cstl_MyriadMyPathLLCMember_18ebaa1f-1779-4ed2-b94a-78b6486319a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember_08aec8f5-e929-4639-87d0-7d06bc7854e6" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ea356385-0708-477b-a537-694b1c082ef6" xlink:to="loc_cstl_CernosticsIncMember_08aec8f5-e929-4639-87d0-7d06bc7854e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_21b783d0-61aa-4721-9d80-65a098ce8cb0" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_7f21a246-3f41-45b1-af39-1ff8d17a5170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_7f21a246-3f41-45b1-af39-1ff8d17a5170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_IncomeTaxAdjustmentMember_fcb98653-5887-493d-842f-10944952281b" xlink:href="cstl-20220630.xsd#cstl_IncomeTaxAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_36d59c2a-959f-4f27-bc79-b1d26b7e6dfb" xlink:to="loc_cstl_IncomeTaxAdjustmentMember_fcb98653-5887-493d-842f-10944952281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_50e1a3b0-2cb6-46fe-9129-8903a38a4372" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_5c123a3a-d399-402c-a698-f2a83294ab9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_5c123a3a-d399-402c-a698-f2a83294ab9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_46b7aff2-27bc-4e25-bc5b-bf10299138a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_46b7aff2-27bc-4e25-bc5b-bf10299138a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f5c08c21-4d15-4eb5-9562-45aaafece550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f5c08c21-4d15-4eb5-9562-45aaafece550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_ProceedsFromPreviousAssetAcquisition_79ddd8ad-8e87-4998-a90d-6da3bb49e8bf" xlink:href="cstl-20220630.xsd#cstl_ProceedsFromPreviousAssetAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_ProceedsFromPreviousAssetAcquisition_79ddd8ad-8e87-4998-a90d-6da3bb49e8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1c166964-a3ce-4eef-b306-43e6bd423707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1c166964-a3ce-4eef-b306-43e6bd423707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fdd43196-5823-43e1-91b3-6f91718acb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_fdd43196-5823-43e1-91b3-6f91718acb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_6b29a9c2-8a25-4eef-8883-c4ef8fb46352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_6b29a9c2-8a25-4eef-8883-c4ef8fb46352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7066f268-8d01-411c-addd-9a420a5ba0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_SharePrice_7066f268-8d01-411c-addd-9a420a5ba0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5be0e44a-63d7-4532-8dea-d0e9c6488a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5be0e44a-63d7-4532-8dea-d0e9c6488a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_b359bce8-9303-4cb1-a545-812ce959bc8e" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash_b359bce8-9303-4cb1-a545-812ce959bc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_683825c6-549a-4a5d-858d-6830b5cb2a64" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock_683825c6-549a-4a5d-858d-6830b5cb2a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_816c1d3e-d869-46e3-9c8a-4d7cf72240e9" xlink:href="cstl-20220630.xsd#cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays_816c1d3e-d869-46e3-9c8a-4d7cf72240e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_542bf3be-2792-4911-9c74-46c64986698f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_542bf3be-2792-4911-9c74-46c64986698f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_12a7d924-5823-4759-a505-f5a3f204726a" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued_12a7d924-5823-4759-a505-f5a3f204726a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6581685d-5f80-4878-a585-b0dbf0ac1330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6581685d-5f80-4878-a585-b0dbf0ac1330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ee5f9428-130e-444a-9453-e847a7309873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7ce263ac-7bf3-421e-84da-4ea313d42ab6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ee5f9428-130e-444a-9453-e847a7309873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsAcquisitionofconsiderationtransferredDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aeaa035e-f71b-4c5b-bfc3-20fabe54d8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_aeaa035e-f71b-4c5b-bfc3-20fabe54d8a9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da7db6d-4122-42ad-b24b-9c92b965beed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_546fca38-8949-42f5-917b-b09a34b66d22" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da7db6d-4122-42ad-b24b-9c92b965beed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_ab3a782c-7d6f-4c70-b4fc-02bcfbb9aca7" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da7db6d-4122-42ad-b24b-9c92b965beed" xlink:to="loc_cstl_AltheaDxIncMember_ab3a782c-7d6f-4c70-b4fc-02bcfbb9aca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5ba03058-3208-4e0b-bb5c-ea8fe9936a05" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_d4d5ca5b-39bb-4a18-8e19-a7f20c305ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_d4d5ca5b-39bb-4a18-8e19-a7f20c305ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_dfdd29e2-99d4-43bb-88f8-75335fa0cae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_dfdd29e2-99d4-43bb-88f8-75335fa0cae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5d44a9f7-6fbb-4b1f-9f50-4245e8417179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5d44a9f7-6fbb-4b1f-9f50-4245e8417179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e0366e68-8c9d-4b07-962b-8fd44c7c8492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e0366e68-8c9d-4b07-962b-8fd44c7c8492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8ace582b-77cd-40f1-b195-1a2a2d3d5f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f96f1-7d90-4c3f-a59e-a51855ac1272" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8ace582b-77cd-40f1-b195-1a2a2d3d5f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ee93f78-f1db-49af-9911-75a0203c6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ee93f78-f1db-49af-9911-75a0203c6dc3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0825c352-30b0-4973-a6e5-6eb5106c7ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1cfd3924-faad-4a68-a886-f40fe0cac1b0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0825c352-30b0-4973-a6e5-6eb5106c7ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_828d05aa-cd39-429d-8cc1-11ca8cd31f1e" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0825c352-30b0-4973-a6e5-6eb5106c7ad9" xlink:to="loc_cstl_AltheaDxIncMember_828d05aa-cd39-429d-8cc1-11ca8cd31f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89761097-dd71-4b09-81fb-bd6c66d43446" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_569fd8cc-f6c8-41f3-89e1-6454a4050820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_569fd8cc-f6c8-41f3-89e1-6454a4050820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d2dc1ce-7b3d-4517-8b3d-960d1fe22966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1d2dc1ce-7b3d-4517-8b3d-960d1fe22966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eb707f84-c605-4878-8c36-c86deeeb15da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eb707f84-c605-4878-8c36-c86deeeb15da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_87bdeeed-b432-4061-a111-b115c3bb38bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_87bdeeed-b432-4061-a111-b115c3bb38bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a81053cb-ea02-46e7-9d92-35c68fcfc5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a81053cb-ea02-46e7-9d92-35c68fcfc5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b5acda19-c0bd-4a58-9397-6ab3591c501e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b5acda19-c0bd-4a58-9397-6ab3591c501e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a6aa46f3-80d8-4397-ae4f-310671f5fa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a6aa46f3-80d8-4397-ae4f-310671f5fa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_33ec08a5-fea9-4259-b749-ed5ff6f6600d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_33ec08a5-fea9-4259-b749-ed5ff6f6600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_ff96f8d5-2eb5-41e4-9671-d3f99cd2664c" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation_ff96f8d5-2eb5-41e4-9671-d3f99cd2664c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_7f01bc02-6360-42a9-b593-1b8ca5686a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_7f01bc02-6360-42a9-b593-1b8ca5686a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee255a01-ef3e-428e-83d9-1a9721c8193f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee255a01-ef3e-428e-83d9-1a9721c8193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6f3ce1bf-b6a6-438e-9dc5-a9f414995292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6f3ce1bf-b6a6-438e-9dc5-a9f414995292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c30bae06-05c5-48d4-baea-b887b85abdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c30bae06-05c5-48d4-baea-b887b85abdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_239dad33-4cd7-46cb-b9b4-ad661bd48793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_Goodwill_239dad33-4cd7-46cb-b9b4-ad661bd48793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0823335a-12a1-4e4d-b661-54a0adce0cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_393e7a53-8aa3-4845-bd4a-5e8691784263" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0823335a-12a1-4e4d-b661-54a0adce0cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cd948067-8dc6-4f36-9c5c-de87f108fc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cd948067-8dc6-4f36-9c5c-de87f108fc8e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_927a57b5-8766-46e8-b59e-ee08733fb701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_117b3f98-0f7d-4c7e-b1b6-b6664a162ff7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_927a57b5-8766-46e8-b59e-ee08733fb701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_1af633c1-72b6-447e-824d-237d24d97c2a" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_927a57b5-8766-46e8-b59e-ee08733fb701" xlink:to="loc_cstl_AltheaDxIncMember_1af633c1-72b6-447e-824d-237d24d97c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1579331-ca6a-494f-9ab8-f4e18738298e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9d2137ea-e495-4cbe-90c1-7aa0629364df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_9d2137ea-e495-4cbe-90c1-7aa0629364df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_47540580-c2b6-4284-bb60-4473d0e04bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b870cab0-b265-4997-9391-91c31994ac0d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_47540580-c2b6-4284-bb60-4473d0e04bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8c8061a8-ecd1-4310-9bf9-56571d30d554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c3bfeaf0-4d90-4703-b866-3b2e4e863495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8c8061a8-ecd1-4310-9bf9-56571d30d554" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c3bfeaf0-4d90-4703-b866-3b2e4e863495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7713c003-991a-4433-b244-9bcd4847c63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e05acd16-019d-486e-9558-4a215dd44fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7713c003-991a-4433-b244-9bcd4847c63d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e05acd16-019d-486e-9558-4a215dd44fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNetPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eb5e3f4d-cb9d-4efd-8815-86c40adc9f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eb5e3f4d-cb9d-4efd-8815-86c40adc9f45" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_babf2dc2-b8b8-4217-837d-d735beea6cd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_5bc23c25-f345-4f83-b6d3-dbd3bd8ade64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_EquipmentMember_5bc23c25-f345-4f83-b6d3-dbd3bd8ade64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7a7a392d-952e-4d92-b115-988136c31d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7a7a392d-952e-4d92-b115-988136c31d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_16ca3920-1bd7-4f9d-b295-0446a2743f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_ComputerEquipmentMember_16ca3920-1bd7-4f9d-b295-0446a2743f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_45a5d3d3-4cf7-498b-88ee-9aa2b7f4b87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_45a5d3d3-4cf7-498b-88ee-9aa2b7f4b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_5092e69f-cab2-4ce2-ad3a-923dbfdf21eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1a2821c1-fdea-467b-8922-e96d6d71d3dc" xlink:to="loc_us-gaap_ConstructionInProgressMember_5092e69f-cab2-4ce2-ad3a-923dbfdf21eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8e010216-da02-4321-b905-209774b90201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_60718945-a029-47be-98a7-1c4d8abd061f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_60718945-a029-47be-98a7-1c4d8abd061f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0b0babd7-bf2f-4dc7-b2dd-df46d984e140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0b0babd7-bf2f-4dc7-b2dd-df46d984e140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1e88ba23-4c65-492f-851c-5908e6a1b989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_1e88ba23-4c65-492f-851c-5908e6a1b989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_be561971-bb65-4787-ad25-fbfa28db8d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_be561971-bb65-4787-ad25-fbfa28db8d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_907d54cd-08a9-48b0-917f-61df6d5dbbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_683470f5-1f8b-48a3-b6dc-473966d1c3b1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_907d54cd-08a9-48b0-917f-61df6d5dbbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#PropertyandEquipmentNetDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ee0f08af-e6f2-406c-85fe-703c8fb17723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ee0f08af-e6f2-406c-85fe-703c8fb17723" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bcc0997d-0468-4d82-965b-a2d276a864b6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_db2e154f-225f-48c8-bbff-f374982bd40f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:to="loc_us-gaap_CostOfSalesMember_db2e154f-225f-48c8-bbff-f374982bd40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0447b909-0978-4c85-8249-59a71bf82ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0447b909-0978-4c85-8249-59a71bf82ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2ed263d5-d75a-456b-b40e-e77aaaf49d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33abfdd0-205e-48b2-8518-52c2f340e333" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2ed263d5-d75a-456b-b40e-e77aaaf49d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d0755ad-38ad-446c-99fd-4000bf4e380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3dff3018-96e5-43f5-a974-6e1d854776b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d0755ad-38ad-446c-99fd-4000bf4e380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_90f1d054-bde8-4ccd-9370-33f368de0085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3d0755ad-38ad-446c-99fd-4000bf4e380c" xlink:to="loc_us-gaap_Depreciation_90f1d054-bde8-4ccd-9370-33f368de0085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ecd9b7af-2a09-4c20-b7be-bfda67ae11df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_15f55544-58fd-4161-8b08-83aeb0bc3a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ecd9b7af-2a09-4c20-b7be-bfda67ae11df" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_15f55544-58fd-4161-8b08-83aeb0bc3a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_70744d4e-2694-4cbc-b31a-fc7d3a2ffae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_2c9b10cf-a05e-42eb-8610-41041762220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_70744d4e-2694-4cbc-b31a-fc7d3a2ffae4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_2c9b10cf-a05e-42eb-8610-41041762220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_68dc8f99-084c-4e26-b0ae-4b2fbe24c0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_70744d4e-2694-4cbc-b31a-fc7d3a2ffae4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_68dc8f99-084c-4e26-b0ae-4b2fbe24c0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_66303d42-a83a-4f02-9e7a-904238a2ee32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_70744d4e-2694-4cbc-b31a-fc7d3a2ffae4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_66303d42-a83a-4f02-9e7a-904238a2ee32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_016dc38d-cde0-4102-a879-9b08dc719830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_621c8b96-2ca3-44dd-9461-35bbfe350315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_016dc38d-cde0-4102-a879-9b08dc719830" xlink:to="loc_us-gaap_GoodwillRollForward_621c8b96-2ca3-44dd-9461-35bbfe350315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3b566938-47c1-4ca6-af44-f80745fcea83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_621c8b96-2ca3-44dd-9461-35bbfe350315" xlink:to="loc_us-gaap_Goodwill_3b566938-47c1-4ca6-af44-f80745fcea83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_bf20e36e-ded3-48eb-968a-5a99686a77d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_621c8b96-2ca3-44dd-9461-35bbfe350315" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_bf20e36e-ded3-48eb-968a-5a99686a77d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_58a09b39-62d5-4691-b97e-4c25f0e16d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_621c8b96-2ca3-44dd-9461-35bbfe350315" xlink:to="loc_us-gaap_Goodwill_58a09b39-62d5-4691-b97e-4c25f0e16d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76d3327f-c543-4ffc-8dd5-cf0be6d567d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4d8bd237-f853-421f-96d9-0983e7caa1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76d3327f-c543-4ffc-8dd5-cf0be6d567d6" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4d8bd237-f853-421f-96d9-0983e7caa1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_25b60598-a40a-4706-8e32-bd718c096e13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76d3327f-c543-4ffc-8dd5-cf0be6d567d6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_25b60598-a40a-4706-8e32-bd718c096e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c449290d-6b41-423d-91af-b4337dbacf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c449290d-6b41-423d-91af-b4337dbacf9d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_894a2fcd-17a2-4399-9729-ecd878935bef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4638446b-ac0a-4828-9da0-e93563121900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4638446b-ac0a-4828-9da0-e93563121900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssembledWorkforceMember_28e96ef1-3201-4f4a-bfab-f5ae6ac52cd2" xlink:href="cstl-20220630.xsd#cstl_AssembledWorkforceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4f84a572-8aa6-45b4-92d0-897e1344da5e" xlink:to="loc_cstl_AssembledWorkforceMember_28e96ef1-3201-4f4a-bfab-f5ae6ac52cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8dc53fdc-fb1a-43bb-9055-27df7cee3303" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e5b71324-f1d1-4e66-baef-53ec24d2e7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e5b71324-f1d1-4e66-baef-53ec24d2e7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3af2e72b-3fcf-46cc-8f14-0dd42f74683e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3af2e72b-3fcf-46cc-8f14-0dd42f74683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2de323c8-8161-4e0b-99c4-9c50e4af3a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2de323c8-8161-4e0b-99c4-9c50e4af3a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b8fd622a-2a2a-46c2-a19b-3d21e32aeded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3dc15836-b3e7-4883-9e6d-aab3caa6839c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_b8fd622a-2a2a-46c2-a19b-3d21e32aeded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_56117170-c664-47dc-8e7d-a704a65f0d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_56117170-c664-47dc-8e7d-a704a65f0d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4e674ec6-a7c6-4a0d-bd32-a404dd9b1654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4e674ec6-a7c6-4a0d-bd32-a404dd9b1654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0afd698e-cad1-4b04-8c3a-a44dcff3bc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0afd698e-cad1-4b04-8c3a-a44dcff3bc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c05aba6d-2cb7-47f4-919a-ade33fd311aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c05aba6d-2cb7-47f4-919a-ade33fd311aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_818d2dee-e310-42f0-bf5d-4f157e653cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_818d2dee-e310-42f0-bf5d-4f157e653cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_99201515-16f2-43b4-a7ff-d3bf89963e69" xlink:href="cstl-20220630.xsd#cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_99201515-16f2-43b4-a7ff-d3bf89963e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_332638c0-7fc3-46bc-8af1-e3d01b773468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f0263ecd-c030-4cd2-906a-be0bb720b3a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_332638c0-7fc3-46bc-8af1-e3d01b773468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities" xlink:type="simple" xlink:href="cstl-20220630.xsd#OtherAccruedandCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_852d3938-6390-4c94-9662-007128968a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_aea4aab2-dd13-4d42-9705-73443f138215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_852d3938-6390-4c94-9662-007128968a28" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_aea4aab2-dd13-4d42-9705-73443f138215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#OtherAccruedandCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bb324d45-b756-4d9b-8a91-e579731298d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_925138c6-f9cd-46d0-8435-db533c001efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bb324d45-b756-4d9b-8a91-e579731298d4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_925138c6-f9cd-46d0-8435-db533c001efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#OtherAccruedandCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a1129d87-2316-4590-996a-5e670185a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a1129d87-2316-4590-996a-5e670185a2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccruedClinicalStudiesCurrent_8b688af1-5768-4d60-a476-dfef60a55939" xlink:href="cstl-20220630.xsd#cstl_AccruedClinicalStudiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_cstl_AccruedClinicalStudiesCurrent_8b688af1-5768-4d60-a476-dfef60a55939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_86d947c4-0c6a-4d5f-aa2c-322a2e0214ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_86d947c4-0c6a-4d5f-aa2c-322a2e0214ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_112bd01e-fb0e-4cd1-9649-3322ce756d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_112bd01e-fb0e-4cd1-9649-3322ce756d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AccruedFixedAssetPurchases_0157ee63-4a59-435e-9377-3f4f5ede011e" xlink:href="cstl-20220630.xsd#cstl_AccruedFixedAssetPurchases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_cstl_AccruedFixedAssetPurchases_0157ee63-4a59-435e-9377-3f4f5ede011e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_BusinessCombinationConsiderationPayableCurrent_1fd00cbf-0458-42c4-952d-1594030194e8" xlink:href="cstl-20220630.xsd#cstl_BusinessCombinationConsiderationPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_cstl_BusinessCombinationConsiderationPayableCurrent_1fd00cbf-0458-42c4-952d-1594030194e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_b6a3a5f1-53d2-43e7-9800-48a586c3806e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_b6a3a5f1-53d2-43e7-9800-48a586c3806e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_dde977ee-a863-48ee-ba5f-6b470562c7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_dde977ee-a863-48ee-ba5f-6b470562c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7cfb8615-435a-40b6-843a-d6a36ae36f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_60a20b21-8e69-4d91-811d-c5576f62a3c3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7cfb8615-435a-40b6-843a-d6a36ae36f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/Leases" xlink:type="simple" xlink:href="cstl-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_532778f0-a853-4af3-8f14-27e93d60571c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_394102b8-2643-4371-9d89-c5425269e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_532778f0-a853-4af3-8f14-27e93d60571c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_394102b8-2643-4371-9d89-c5425269e0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LeasesTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b13867f7-17b7-4d29-bba9-74bcd014fb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_62046de5-54cd-4fd1-86bd-5585e324b247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b13867f7-17b7-4d29-bba9-74bcd014fb60" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_62046de5-54cd-4fd1-86bd-5585e324b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#LeasesAssetsAndLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_09ca5745-3b34-4953-85f4-4dfe6ca75fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09ca5745-3b34-4953-85f4-4dfe6ca75fa8" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_f0054aa2-d517-43c4-9fcf-2585115c50a4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_806166c4-4f5d-4626-84a0-77df602c2060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_806166c4-4f5d-4626-84a0-77df602c2060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_f08c13ba-185e-4b86-ba90-113a97b8edfc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dc9c2e89-0057-4098-bd21-6485b3c72175" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_f08c13ba-185e-4b86-ba90-113a97b8edfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_24080500-73eb-4c1c-b64f-c9b17d6ea20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_17abf0f6-9f5d-481e-b61e-640eb2662e21" xlink:to="loc_us-gaap_TypeOfAdoptionMember_24080500-73eb-4c1c-b64f-c9b17d6ea20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_88603de8-b9a3-47d8-b873-6621954ab7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_24080500-73eb-4c1c-b64f-c9b17d6ea20b" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_88603de8-b9a3-47d8-b873-6621954ab7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8446ccdb-cd52-40c0-aa06-de8d40e51f35" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c9c29df-428d-4cad-b352-90f91e66dcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c9c29df-428d-4cad-b352-90f91e66dcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7766b1b1-7d53-4783-9836-ca5505b99865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_OperatingLeaseLiability_7766b1b1-7d53-4783-9836-ca5505b99865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_b64933a9-5ff4-497f-b946-3564559b03c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2d15c510-e35d-49ad-844f-adfb668db053" xlink:to="loc_us-gaap_OtherLiabilities_b64933a9-5ff4-497f-b946-3564559b03c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_84452fa9-a733-4e2a-89f3-a326c0ebdead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_84452fa9-a733-4e2a-89f3-a326c0ebdead" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b775c9bb-ee21-419a-bd3c-4d39e7ea0d1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a1670a38-e8fb-4ea4-87b7-829809809d03" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b775c9bb-ee21-419a-bd3c-4d39e7ea0d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ea69e2f9-bf38-47e9-8cc2-ac3759f4cf7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b775c9bb-ee21-419a-bd3c-4d39e7ea0d1f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ea69e2f9-bf38-47e9-8cc2-ac3759f4cf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ffdfcd00-4d2d-4b55-bf65-5e2193ad62cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_8b1f5fca-36a1-46f0-9e0e-4fe6759da9f4" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ffdfcd00-4d2d-4b55-bf65-5e2193ad62cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ffdfcd00-4d2d-4b55-bf65-5e2193ad62cd" xlink:to="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseFirstSixMonthsMember_790f3468-a7c8-4246-9f3f-30d4a5973426" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseFirstSixMonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:to="loc_cstl_PittsburghLeaseFirstSixMonthsMember_790f3468-a7c8-4246-9f3f-30d4a5973426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_PittsburghLeaseAfterSixMonthsMember_f2df16c0-0d8c-4618-85a7-598da948df6e" xlink:href="cstl-20220630.xsd#cstl_PittsburghLeaseAfterSixMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cstl_PittsburghLeaseMember_83a7335d-aad8-4d76-8c50-11793b5a9376" xlink:to="loc_cstl_PittsburghLeaseAfterSixMonthsMember_f2df16c0-0d8c-4618-85a7-598da948df6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_463e3ac4-a87d-4289-9ebe-a089b2e15efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_157b7ceb-eed6-4057-90a5-e09eaa1e30b8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_463e3ac4-a87d-4289-9ebe-a089b2e15efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_3c848364-1f72-4acc-9b2d-35fb1595da44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_463e3ac4-a87d-4289-9ebe-a089b2e15efb" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_3c848364-1f72-4acc-9b2d-35fb1595da44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_72307eb6-77b2-4042-8225-7876b3d365ee" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06158c39-51c3-4d50-9789-f5cf3ba98ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_06158c39-51c3-4d50-9789-f5cf3ba98ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_d497fdd1-5d58-401b-b6ee-426fcea2826c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_d497fdd1-5d58-401b-b6ee-426fcea2826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a50ab5b-87b0-49df-94a7-04070d8843d2" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount_2a50ab5b-87b0-49df-94a7-04070d8843d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9855cefd-75d0-4191-9eda-895542f780f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9855cefd-75d0-4191-9eda-895542f780f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseBaseRent_356599ff-4edc-42c3-8b47-2b6d9f13f485" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseBaseRent_356599ff-4edc-42c3-8b47-2b6d9f13f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseMaximumBaseRent_ad323329-3971-48c8-b454-e05d17d8a098" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseMaximumBaseRent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseMaximumBaseRent_ad323329-3971-48c8-b454-e05d17d8a098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_5154deeb-1f04-4e63-95fb-61d62a927da4" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseNumberOfOptionsToRenew"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew_5154deeb-1f04-4e63-95fb-61d62a927da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_6fa9f59e-bcdc-42a7-bdd1-389835552568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_TenantImprovements_6fa9f59e-bcdc-42a7-bdd1-389835552568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseOptionToTerminateTerm_88829098-5397-4ba5-8044-69ee441d7efa" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseOptionToTerminateTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseOptionToTerminateTerm_88829098-5397-4ba5-8044-69ee441d7efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_LesseeOperatingLeaseEarlyTerminationFee_fa5cafc8-323e-417f-a18f-c61f0d35ac47" xlink:href="cstl-20220630.xsd#cstl_LesseeOperatingLeaseEarlyTerminationFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_cstl_LesseeOperatingLeaseEarlyTerminationFee_fa5cafc8-323e-417f-a18f-c61f0d35ac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a0a72fab-ae70-4fed-97aa-8858e0d0d52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f46723f0-1c4e-4d79-99c8-2db8c3ec0a8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a0a72fab-ae70-4fed-97aa-8858e0d0d52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ad12b9af-a68d-41c2-a349-22ba06941567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5595b093-efec-4570-83de-fcabfbd81b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ad12b9af-a68d-41c2-a349-22ba06941567" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5595b093-efec-4570-83de-fcabfbd81b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ff5fbe0-4cac-49cd-a490-49ccbe897e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_044160a9-8652-4191-87d9-f0919aada647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ff5fbe0-4cac-49cd-a490-49ccbe897e75" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_044160a9-8652-4191-87d9-f0919aada647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d178fa2c-e085-4fb7-9396-7d57f48ebf93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ff5fbe0-4cac-49cd-a490-49ccbe897e75" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d178fa2c-e085-4fb7-9396-7d57f48ebf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3c6126df-3f9f-403d-b908-af48f828cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3c6126df-3f9f-403d-b908-af48f828cd0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fffa3b5-13d4-458e-ac9f-83d638cad29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_473893f8-8c5b-468c-a505-3732ea419371" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fffa3b5-13d4-458e-ac9f-83d638cad29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cd61124c-a239-4cd9-b8f9-2ad5b58e50dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fffa3b5-13d4-458e-ac9f-83d638cad29c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cd61124c-a239-4cd9-b8f9-2ad5b58e50dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5302db97-6299-4fe1-ac69-dc95e35d986e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_557d609b-54ef-4924-af0b-950ffbc61ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_557d609b-54ef-4924-af0b-950ffbc61ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7b8e49b6-9723-4ebf-83b0-d9fae0d564cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7b8e49b6-9723-4ebf-83b0-d9fae0d564cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6a033941-f3d0-4ea2-8355-7590583608a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fa8db5e0-ddb3-4cbd-97f3-1b4cf364dde7" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6a033941-f3d0-4ea2-8355-7590583608a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbc7024d-eadd-49d9-9edc-b1ae065a83af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e64d4dd-220b-4440-9cf6-5566c6cd6e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5e64d4dd-220b-4440-9cf6-5566c6cd6e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_bd1e0892-9efd-4c05-a72b-7bf1cd53b6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d613523d-4046-4521-a997-1ba62ee70711" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_bd1e0892-9efd-4c05-a72b-7bf1cd53b6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_77bfc38b-3aa6-4305-9938-7dbae05e7ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_77bfc38b-3aa6-4305-9938-7dbae05e7ade" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_04fb4006-c3c3-45e5-8f6c-0d8ddaafbdff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e459deec-c54a-4dad-8cb7-a59ec611f16e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_04fb4006-c3c3-45e5-8f6c-0d8ddaafbdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember_5aa163a8-703e-4029-b15b-fdd592eb7876" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_04fb4006-c3c3-45e5-8f6c-0d8ddaafbdff" xlink:to="loc_cstl_CernosticsIncMember_5aa163a8-703e-4029-b15b-fdd592eb7876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5852ff90-b204-4ea6-9eaf-e92a29691fdd" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_35af7968-ec6e-41a5-980b-8ce05f2a5cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_35af7968-ec6e-41a5-980b-8ce05f2a5cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_b49c9419-2b07-4aa0-b8c6-4175a5e17a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_080c94ec-7266-4225-ba6c-781d087147a4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_b49c9419-2b07-4aa0-b8c6-4175a5e17a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_09f33b67-9c0a-45c6-95ee-2bf655b5662f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_618d689c-53ba-49c0-91bc-905a2f6cc8d2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_09f33b67-9c0a-45c6-95ee-2bf655b5662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_08d6c339-5bb0-4af0-abdc-4653077f1999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_09f33b67-9c0a-45c6-95ee-2bf655b5662f" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_08d6c339-5bb0-4af0-abdc-4653077f1999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17fdc4bf-acbe-479d-8da5-643c4ee7ecaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_72a7046b-6592-4bfa-bec1-b5d271b5e5c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17fdc4bf-acbe-479d-8da5-643c4ee7ecaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2a11ddbf-d294-4ef8-b76d-a143f3daf084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_17fdc4bf-acbe-479d-8da5-643c4ee7ecaa" xlink:to="loc_srt_ScenarioForecastMember_2a11ddbf-d294-4ef8-b76d-a143f3daf084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b33a6a-0309-4c0c-a855-5bf0348b90de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b42a5f6c-4b40-4205-b0ed-6f9d863f83dd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b33a6a-0309-4c0c-a855-5bf0348b90de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_3c3f8429-25d3-475d-b87c-611f6f09de51" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86b33a6a-0309-4c0c-a855-5bf0348b90de" xlink:to="loc_cstl_AltheaDxIncMember_3c3f8429-25d3-475d-b87c-611f6f09de51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_580f25d0-c1c5-407f-a1f9-49a6dbaed872" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0ed5dc8e-7692-49d2-bc34-62e2f0316b78" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0ed5dc8e-7692-49d2-bc34-62e2f0316b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_65dd7a13-7d9c-4d0e-a228-bde75a95b062" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares_65dd7a13-7d9c-4d0e-a228-bde75a95b062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_778bf78a-6783-4f68-98e6-30992acc1802" xlink:href="cstl-20220630.xsd#cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice_778bf78a-6783-4f68-98e6-30992acc1802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1f64bafe-e05c-464a-9392-51907cdfff2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1f64bafe-e05c-464a-9392-51907cdfff2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_246b181d-8c5e-4b6b-9e74-9ca486ff952d" xlink:href="cstl-20220630.xsd#cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_955ac8f1-b05c-4637-8183-8c1a21bae8f5" xlink:to="loc_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput_246b181d-8c5e-4b6b-9e74-9ca486ff952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f876e376-275e-425c-b38d-21ef59a035bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f876e376-275e-425c-b38d-21ef59a035bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_48098c43-4713-43d3-8286-19659a505585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f98d810c-585f-46b9-a307-922ce324d211" xlink:to="loc_us-gaap_AssetAcquisitionDomain_48098c43-4713-43d3-8286-19659a505585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_CernosticsIncMember_66a97eeb-0e64-41f8-941a-c4199cb2e8a3" xlink:href="cstl-20220630.xsd#cstl_CernosticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_48098c43-4713-43d3-8286-19659a505585" xlink:to="loc_cstl_CernosticsIncMember_66a97eeb-0e64-41f8-941a-c4199cb2e8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76daaed2-68d8-443b-bd00-9a5771fb2ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86b664ef-2281-4f55-abd9-ed5257372307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76daaed2-68d8-443b-bd00-9a5771fb2ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_b5bde9dd-5947-43b5-b875-6faf718bc6c0" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76daaed2-68d8-443b-bd00-9a5771fb2ba3" xlink:to="loc_cstl_AltheaDxIncMember_b5bde9dd-5947-43b5-b875-6faf718bc6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d8c4a89f-e6c4-4ccf-972d-4aa1cc5fcc36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6dc769b0-d324-480a-bd65-b87fcdbd630a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d8c4a89f-e6c4-4ccf-972d-4aa1cc5fcc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d8c4a89f-e6c4-4ccf-972d-4aa1cc5fcc36" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6356462-001d-47e4-bfc2-98e01fc6d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e6356462-001d-47e4-bfc2-98e01fc6d273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_254f4feb-669c-40b0-b9b2-6c76cccea154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_254f4feb-669c-40b0-b9b2-6c76cccea154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ced5bcdf-43f5-4b6e-b8f7-1d15028e4fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ced5bcdf-43f5-4b6e-b8f7-1d15028e4fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_abfe7d82-27c0-4de8-a0d1-cc74ef085a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77122c94-c05e-4800-a98f-3392820f7a5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_abfe7d82-27c0-4de8-a0d1-cc74ef085a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cstl-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_86ae1a11-000d-489f-b5bf-99ecd8a5553c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56ee2104-3f7d-4053-91cc-2e29dd481b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_86ae1a11-000d-489f-b5bf-99ecd8a5553c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56ee2104-3f7d-4053-91cc-2e29dd481b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_027314f0-60df-41a2-b800-1ad4c6ca4d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ee273183-6373-48b5-a69a-6d533d7e45d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_027314f0-60df-41a2-b800-1ad4c6ca4d63" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ee273183-6373-48b5-a69a-6d533d7e45d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8ed696-9198-445e-a479-51a1eb1bd8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3de3f0b0-2548-4ba9-9c79-e6524ea72269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8ed696-9198-445e-a479-51a1eb1bd8cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3de3f0b0-2548-4ba9-9c79-e6524ea72269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_21929e03-bce0-4c83-b745-7e6c22c6ada6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8ed696-9198-445e-a479-51a1eb1bd8cc" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_21929e03-bce0-4c83-b745-7e6c22c6ada6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_258eea6a-c504-4048-b882-89b4f1c0d9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8ed696-9198-445e-a479-51a1eb1bd8cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_258eea6a-c504-4048-b882-89b4f1c0d9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_87adcc1e-0ef6-4c71-af85-51670cd2b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8ed696-9198-445e-a479-51a1eb1bd8cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_87adcc1e-0ef6-4c71-af85-51670cd2b6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eab0557d-2661-409f-9103-779f2dd31aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af8ed696-9198-445e-a479-51a1eb1bd8cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eab0557d-2661-409f-9103-779f2dd31aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da9146fd-2f2c-476a-89e4-b7b0e6a14daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da9146fd-2f2c-476a-89e4-b7b0e6a14daa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:to="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7204fa79-16ad-413d-88a9-d29a3a5f845a" xlink:to="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_TwoThousandNineteenEquityIncentivePlanMember_48739080-d1ae-4bc2-ae39-a727a1e1455f" xlink:href="cstl-20220630.xsd#cstl_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:to="loc_cstl_TwoThousandNineteenEquityIncentivePlanMember_48739080-d1ae-4bc2-ae39-a727a1e1455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_EmployeeStockPurchasePlanMember_d4bb217a-2170-49f0-aa03-2faf079619f1" xlink:href="cstl-20220630.xsd#cstl_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33149b6f-7b5e-4c95-8f7c-d01844054d4c" xlink:to="loc_cstl_EmployeeStockPurchasePlanMember_d4bb217a-2170-49f0-aa03-2faf079619f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:to="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_13fb6cb3-3590-4005-a2c9-995267f9c37a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b3a051a4-e056-4f9a-a666-85a1399945f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:to="loc_us-gaap_EmployeeStockMember_b3a051a4-e056-4f9a-a666-85a1399945f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_527681c3-bb8f-4549-9014-ab99a574d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4224a55c-28e2-490e-b84f-c57b0e1fc4a5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_527681c3-bb8f-4549-9014-ab99a574d26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_161e30a6-b177-43d8-8b72-2b1cd4407b55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51e332c9-1480-4734-9f25-dd08b22ece62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_51e332c9-1480-4734-9f25-dd08b22ece62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_47343c6c-0829-4e0b-88f0-0e77b1594a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_47343c6c-0829-4e0b-88f0-0e77b1594a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5aa623c-097c-489e-aa8b-ff9fea3c57ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d5aa623c-097c-489e-aa8b-ff9fea3c57ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c1dfb0b-9fa7-450c-8498-ef99885410d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c1dfb0b-9fa7-450c-8498-ef99885410d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_85dde78e-bc34-465d-8de9-41819f5786c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_85dde78e-bc34-465d-8de9-41819f5786c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c87f7c0-74e4-446e-ad59-b3ce7eb0f10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_934a2c1b-00eb-4370-a1b7-8a1fedc7da29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7c87f7c0-74e4-446e-ad59-b3ce7eb0f10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bde2dbf-abdb-4d74-b2b3-0046fb27ad66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bde2dbf-abdb-4d74-b2b3-0046fb27ad66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c73d0dd6-eefb-4d83-b583-b8203c32d591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c73d0dd6-eefb-4d83-b583-b8203c32d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e2c5ac17-9315-4dfc-8448-be4c56b6f7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e2c5ac17-9315-4dfc-8448-be4c56b6f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4b5c4ab3-0b83-456c-8fbd-fa19ef1b521d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4b5c4ab3-0b83-456c-8fbd-fa19ef1b521d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8b9eb8ba-0aa6-46b8-9234-0e3d179f6827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8b9eb8ba-0aa6-46b8-9234-0e3d179f6827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbc13315-7e64-45a9-a6ca-ce32d32ea2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dbf9f361-2361-4d0c-bac8-237cf68af943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cbc13315-7e64-45a9-a6ca-ce32d32ea2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b9a43e3-39bf-4b4f-9237-680b61a722a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bde2dbf-abdb-4d74-b2b3-0046fb27ad66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b9a43e3-39bf-4b4f-9237-680b61a722a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bde2dbf-abdb-4d74-b2b3-0046fb27ad66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_297443ba-0ac2-441b-bee0-8efcb5671505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_297443ba-0ac2-441b-bee0-8efcb5671505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_72bb5279-a7c0-4820-8775-82d95cc2f7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_72bb5279-a7c0-4820-8775-82d95cc2f7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5236e434-cb7c-4956-858d-37a273142e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5236e434-cb7c-4956-858d-37a273142e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_94916998-98ed-4f4e-8bc0-984f97305e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_94916998-98ed-4f4e-8bc0-984f97305e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca2a645a-20c3-4204-be98-1bd54a23e060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ffae7e14-682f-4713-b931-49e3dc738ea2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca2a645a-20c3-4204-be98-1bd54a23e060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d342d553-b9d9-45ab-b803-6c210f9cac4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bde2dbf-abdb-4d74-b2b3-0046fb27ad66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d342d553-b9d9-45ab-b803-6c210f9cac4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_93fd931b-79b4-449f-bb81-aa8e35fe79f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bde2dbf-abdb-4d74-b2b3-0046fb27ad66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_93fd931b-79b4-449f-bb81-aa8e35fe79f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81fb6b32-3cc3-4031-8eab-a92616eb752e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_93fd931b-79b4-449f-bb81-aa8e35fe79f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81fb6b32-3cc3-4031-8eab-a92616eb752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e0e8759-3ba2-4b43-88ab-3ce039c7ec0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_93fd931b-79b4-449f-bb81-aa8e35fe79f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e0e8759-3ba2-4b43-88ab-3ce039c7ec0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e3c501b2-223c-4ae5-8a31-efa473a4fe11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_93fd931b-79b4-449f-bb81-aa8e35fe79f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e3c501b2-223c-4ae5-8a31-efa473a4fe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bfd0b603-5b97-4734-8f73-09f86a339f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_93fd931b-79b4-449f-bb81-aa8e35fe79f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bfd0b603-5b97-4734-8f73-09f86a339f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee8a4bff-9320-4b63-93c0-991eec71994e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee8a4bff-9320-4b63-93c0-991eec71994e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:to="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af451414-99d2-4df7-9fff-831856b515c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0ae5b8b1-0db9-4dea-9c73-ff105eb99b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af451414-99d2-4df7-9fff-831856b515c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ab37fd88-b6a8-4119-84ba-cd774cf3eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af451414-99d2-4df7-9fff-831856b515c7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ab37fd88-b6a8-4119-84ba-cd774cf3eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b20c85d-7c16-46e4-833c-decf9e03bdfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_a14c0a29-97b8-4b61-acde-a9de69c61c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_a14c0a29-97b8-4b61-acde-a9de69c61c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_cc095b72-62ff-49e5-88bc-0473c0ce82e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_cc095b72-62ff-49e5-88bc-0473c0ce82e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78f9b3fa-3e8f-4e7c-a794-4bffa2219b86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78f9b3fa-3e8f-4e7c-a794-4bffa2219b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_b5eb156b-c0c6-4eea-a458-2df44c860b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_b5eb156b-c0c6-4eea-a458-2df44c860b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_4fff0474-9421-4073-abbb-9e19f7f3f717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_76296e09-3c5c-46ca-8885-f972da3aa7ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_4fff0474-9421-4073-abbb-9e19f7f3f717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac02b668-1323-46d7-ba88-0eb715348229" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef6bd7b2-06ec-4fab-a060-7850666ea808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ef6bd7b2-06ec-4fab-a060-7850666ea808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d393e2a-d364-4894-a155-3ad9ed35f73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6d393e2a-d364-4894-a155-3ad9ed35f73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ec9c7b31-50a9-49f2-88b0-077ecc506f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ec9c7b31-50a9-49f2-88b0-077ecc506f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ad0fb33-1d7a-416b-b9f1-2b466c96c162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2ad0fb33-1d7a-416b-b9f1-2b466c96c162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3448871a-c7e5-4a75-954c-071816d3b919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2d65320-8bfc-4caf-b048-24adbfdde242" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3448871a-c7e5-4a75-954c-071816d3b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe509295-29bf-4af4-9880-81338547868d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe509295-29bf-4af4-9880-81338547868d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:to="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bb892b1-51d5-4cc1-94b0-03ac3e79db86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c703b02d-5772-4a7c-8e5e-95ec7add2864" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bb892b1-51d5-4cc1-94b0-03ac3e79db86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c8ebf1b1-dad9-4039-934a-4431546e0a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bb892b1-51d5-4cc1-94b0-03ac3e79db86" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c8ebf1b1-dad9-4039-934a-4431546e0a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:to="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a20175cb-55bc-40c9-835b-5672fe9e9243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1f165c9e-d3e4-4c90-af81-60da3f054bec" xlink:to="loc_us-gaap_PlanNameDomain_a20175cb-55bc-40c9-835b-5672fe9e9243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_EmployeeStockPurchasePlanMember_715ef502-5132-43bd-a998-627e49db71a5" xlink:href="cstl-20220630.xsd#cstl_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a20175cb-55bc-40c9-835b-5672fe9e9243" xlink:to="loc_cstl_EmployeeStockPurchasePlanMember_715ef502-5132-43bd-a998-627e49db71a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e187f38d-9e92-4adf-902f-ce11817709c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6afedf36-03d3-4283-9e07-e6363b37f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6afedf36-03d3-4283-9e07-e6363b37f5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37d4b825-aaf2-46e7-a3a4-532c1f88d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_37d4b825-aaf2-46e7-a3a4-532c1f88d7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14569b2b-0a3e-466a-8835-4c28be855e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14569b2b-0a3e-466a-8835-4c28be855e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8d5f03a3-96a7-4a67-be5e-8555f4d232b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8d5f03a3-96a7-4a67-be5e-8555f4d232b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5c331d91-46b4-49e6-ba2b-63b98aa12f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_5c331d91-46b4-49e6-ba2b-63b98aa12f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b39c8375-89dd-4746-9553-35469a5477e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fefc81fa-7662-4cca-a250-1ce5b2a9b086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b39c8375-89dd-4746-9553-35469a5477e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfbd3144-db6a-486e-bf5a-b7ff90c3ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfbd3144-db6a-486e-bf5a-b7ff90c3ea3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9bbaeb15-8969-487c-a334-892a8cebed90" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bb42ab62-4cec-480c-8dee-3c206780bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:to="loc_us-gaap_CostOfSalesMember_bb42ab62-4cec-480c-8dee-3c206780bfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_44d8d27e-c625-4f91-a69b-706ca54d26ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_44d8d27e-c625-4f91-a69b-706ca54d26ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_658f1311-846f-4ebb-8e42-90d253390696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_774d6da7-3769-4c0b-9f95-991987eafa12" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_658f1311-846f-4ebb-8e42-90d253390696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_103699d8-8e55-4cbd-9b78-5962d9f901d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80c5cc2c-9a4f-4e59-b92c-3405fbb5cd52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_103699d8-8e55-4cbd-9b78-5962d9f901d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_86d71c40-8e6d-4ab0-828c-70516224ae67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_103699d8-8e55-4cbd-9b78-5962d9f901d9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_86d71c40-8e6d-4ab0-828c-70516224ae67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cstl-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2bb697-4b08-4630-8a1f-b96bca7a33bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_26028a33-6576-4d8d-9c43-7b3bdca1a229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2bb697-4b08-4630-8a1f-b96bca7a33bb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_26028a33-6576-4d8d-9c43-7b3bdca1a229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.castlebiosciences.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="cstl-20220630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.castlebiosciences.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8ebc7ca1-1db6-47c1-ad6a-50332119da00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8ebc7ca1-1db6-47c1-ad6a-50332119da00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6ce937ff-ee43-4196-886b-7943fd3bef3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa0f9606-950b-402e-8194-57eaee04fbd7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6ce937ff-ee43-4196-886b-7943fd3bef3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cstl_AltheaDxIncMember_edef5c3b-95b3-4a6d-b1ac-a5487b56d567" xlink:href="cstl-20220630.xsd#cstl_AltheaDxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6ce937ff-ee43-4196-886b-7943fd3bef3f" xlink:to="loc_cstl_AltheaDxIncMember_edef5c3b-95b3-4a6d-b1ac-a5487b56d567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7f50fc52-0a24-4d3e-a392-1429c28b4896" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b89f8991-0851-45d4-97be-42e89efb4296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b89f8991-0851-45d4-97be-42e89efb4296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_16e8c7d0-7479-4bb7-8636-20a545421046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_041f334c-0c28-4f75-a125-e9bc022d54f5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_16e8c7d0-7479-4bb7-8636-20a545421046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264477904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CASTLE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0701774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 S. Friendswood Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Friendswood<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">788-9007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CSTL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,296,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001447362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265466816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 273,166<span></span>
</td>
<td class="nump">$ 329,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">22,606<span></span>
</td>
<td class="nump">17,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">3,365<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,775<span></span>
</td>
<td class="nump">4,807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">304,912<span></span>
</td>
<td class="nump">353,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Long-term accounts receivable, net</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,203<span></span>
</td>
<td class="nump">9,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">7,004<span></span>
</td>
<td class="nump">7,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangible assets, net</a></td>
<td class="nump">132,671<span></span>
</td>
<td class="nump">88,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets &#8211; long-term</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">458,380<span></span>
</td>
<td class="nump">462,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">14,850<span></span>
</td>
<td class="nump">15,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued and current liabilities</a></td>
<td class="nump">8,177<span></span>
</td>
<td class="nump">5,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,519<span></span>
</td>
<td class="nump">24,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Noncurrent portion of contingent consideration</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">18,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">6,480<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,720<span></span>
</td>
<td class="nump">50,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value per share; 200,000,000 shares authorized as of June&#160;30, 2022 and December&#160;31, 2021; 26,292,299 and 25,378,520 shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">541,672<span></span>
</td>
<td class="nump">505,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(120,038)<span></span>
</td>
<td class="num">(93,767)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">421,660<span></span>
</td>
<td class="nump">411,740<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 458,380<span></span>
</td>
<td class="nump">$ 462,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265369696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,292,299<span></span>
</td>
<td class="nump">25,378,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,292,299<span></span>
</td>
<td class="nump">25,378,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718263529952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">NET REVENUES</a></td>
<td class="nump">$ 34,838<span></span>
</td>
<td class="nump">$ 22,758<span></span>
</td>
<td class="nump">$ 61,690<span></span>
</td>
<td class="nump">$ 45,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract', window );"><strong>OPERATING EXPENSES AND OTHER OPERATING INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales (exclusive of amortization of acquired intangible assets)</a></td>
<td class="nump">7,686<span></span>
</td>
<td class="nump">3,697<span></span>
</td>
<td class="nump">13,630<span></span>
</td>
<td class="nump">6,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">11,926<span></span>
</td>
<td class="nump">6,793<span></span>
</td>
<td class="nump">22,687<span></span>
</td>
<td class="nump">12,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">37,498<span></span>
</td>
<td class="nump">20,822<span></span>
</td>
<td class="nump">67,951<span></span>
</td>
<td class="nump">38,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">2,097<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(20,398)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,836)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_OperatingExpensesNetOfOtherOperatingIncome', window );">Total operating expenses, net</a></td>
<td class="nump">38,809<span></span>
</td>
<td class="nump">31,568<span></span>
</td>
<td class="nump">90,177<span></span>
</td>
<td class="nump">58,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(3,971)<span></span>
</td>
<td class="num">(8,810)<span></span>
</td>
<td class="num">(28,487)<span></span>
</td>
<td class="num">(13,094)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(3,605)<span></span>
</td>
<td class="num">(8,786)<span></span>
</td>
<td class="num">(28,094)<span></span>
</td>
<td class="num">(13,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(1,957)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(1,823)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(1,648)<span></span>
</td>
<td class="num">(8,791)<span></span>
</td>
<td class="num">(26,271)<span></span>
</td>
<td class="num">(13,071)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (1,648)<span></span>
</td>
<td class="num">$ (8,791)<span></span>
</td>
<td class="num">$ (26,271)<span></span>
</td>
<td class="num">$ (13,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">26,064<span></span>
</td>
<td class="nump">25,091<span></span>
</td>
<td class="nump">25,746<span></span>
</td>
<td class="nump">25,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">26,064<span></span>
</td>
<td class="nump">25,091<span></span>
</td>
<td class="nump">25,746<span></span>
</td>
<td class="nump">25,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_OperatingExpensesAndOtherOperatingIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Expenses And Other Operating Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_OperatingExpensesAndOtherOperatingIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_OperatingExpensesNetOfOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Expenses, Net Of Other Operating Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_OperatingExpensesNetOfOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261087456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Effect of Adoption</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Effect of Adoption</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,812,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 415,691<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 478,162<span></span>
</td>
<td class="num">$ (62,496)<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock compensation expense</a></td>
<td class="nump">4,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, adjustment to offering costs</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(4,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,054,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 418,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">485,338<span></span>
</td>
<td class="num">(66,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Effect of Adoption<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,812,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 415,691<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">478,162<span></span>
</td>
<td class="num">(62,496)<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(13,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,164,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">415,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">491,458<span></span>
</td>
<td class="num">(75,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,054,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">418,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">485,338<span></span>
</td>
<td class="num">(66,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock compensation expense</a></td>
<td class="nump">4,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(8,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,164,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">415,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">491,458<span></span>
</td>
<td class="num">(75,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,378,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">411,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">505,482<span></span>
</td>
<td class="num">(93,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock compensation expense</a></td>
<td class="nump">8,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vested restricted stock units and payment of employees&#8217; taxes</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(24,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,485,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">397,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">515,701<span></span>
</td>
<td class="num">(118,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,378,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 411,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">505,482<span></span>
</td>
<td class="num">(93,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="nump">98,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (26,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,292,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">421,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">541,672<span></span>
</td>
<td class="num">(120,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,485,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">397,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">515,701<span></span>
</td>
<td class="num">(118,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock compensation expense</a></td>
<td class="nump">8,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock from vested restricted stock units and payment of employees&#8217; taxes</a></td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in acquisition of business (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">763,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in acquisition of business</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">17,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(1,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,292,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 421,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 541,672<span></span>
</td>
<td class="num">$ (120,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264222480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,271)<span></span>
</td>
<td class="num">$ (13,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,779<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">17,202<span></span>
</td>
<td class="nump">9,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(17,836)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1,839)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,628)<span></span>
</td>
<td class="num">(5,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(707)<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,066)<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease assets</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">504<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">302<span></span>
</td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(445)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(1,013)<span></span>
</td>
<td class="num">(523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Medicare advance payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,431)<span></span>
</td>
<td class="num">(10,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,807)<span></span>
</td>
<td class="num">(1,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_ProceedsFromPreviousAssetAcquisition', window );">Asset acquisition</a></td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash and cash equivalents acquired</a></td>
<td class="num">(26,661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(27,913)<span></span>
</td>
<td class="num">(34,845)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employees&#8217; taxes on vested restricted stock units</a></td>
<td class="num">(88)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from contributions to the employee stock purchase plan</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Repayment of principal portion of finance lease liabilities</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,877<span></span>
</td>
<td class="nump">3,401<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(56,467)<span></span>
</td>
<td class="num">(41,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">329,633<span></span>
</td>
<td class="nump">409,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">273,166<span></span>
</td>
<td class="nump">368,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued purchases of property and equipment</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in acquisition of business</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationNoncashContingentConsiderationGiven', window );">Contingent consideration in acquisition of business</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Consideration payable in acquisition of business</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationNoncashContingentConsiderationGiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Noncash Contingent Consideration Given</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationNoncashContingentConsiderationGiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_ProceedsFromPreviousAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Previous Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_ProceedsFromPreviousAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265880896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Castle Biosciences, Inc. (the &#8216;&#8216;Company,&#8217;&#8217; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve health outcomes. We are based in Friendswood, Texas (a suburb of Houston, Texas) and our laboratory operations are conducted at our facilities located in Phoenix, Arizona, Pittsburgh, Pennsylvania and San Diego, California.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 Pandemic</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the COVID-19 pandemic began in March 2020, we have maintained uninterrupted business operations with no interruption in turnaround times for delivery of test reports, but we have experienced declines in test report volume in certain periods, which we believe is linked to delays and/or cancellations in patient visits in response to COVID-19, resulting in reduced diagnostic biopsies and thus reduced diagnoses of cutaneous melanoma and test reports attributable to our lead product, DecisionDx&#174;-Melanoma, a test for cutaneous melanoma. The extent to which COVID-19 may further impact our business, consolidated results of operations, consolidated financial condition and consolidated cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718269974016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8216;&#8216;U.S. GAAP&#8217;&#8217;). All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated balance sheet as of&#160;June&#160;30, 2022; the condensed consolidated statements of operations and comprehensive loss, the condensed consolidated statements of stockholders&#8217; equity for the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021; and the condensed consolidated statements of cash flows for the&#160;six&#160;months ended&#160;June&#160;30, 2022&#160;and&#160;2021&#160;are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of our consolidated financial position as of&#160;June&#160;30, 2022, the results of our consolidated operations for the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021 and our consolidated cash flows for the&#160;six&#160;months ended&#160;June&#160;30, 2022&#160;and&#160;2021. The financial data and other information disclosed in these notes related to the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021&#160;are also unaudited. The results for the three and six months ended June&#160;30, 2022&#160;are not necessarily indicative of results to be expected for the year ending&#160;December&#160;31, 2022, any other interim periods, or any future year or period. The balance sheet as of&#160;December&#160;31, 2021&#160;included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the unaudited interim consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the Securities and Exchange Commission on February 28, 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents including Concentrations of Credit Risk</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), that are primarily invested in short-term U.S. government obligations. Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;) Accounting Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8216;&#8216;ASC 606&#8217;&#8217;). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration. See Note 3 for further details.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as noncurrent assets. The estimated timing of payment utilized as a basis for classification as noncurrent is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers&#8217; financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of June&#160;30, 2022, and December&#160;31, 2021. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. In accordance with ASC Topic 350,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that it may be impaired. We perform annual impairment reviews of our goodwill balance during the fourth quarter of each year. We may perform a qualitative assessment to determine if it is necessary to perform a quantitative impairment test. If we determine that a quantitative impairment test is necessary, we apply the guidance in Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, by comparing the fair value of the reporting unit to its carrying value, including the goodwill. If the carrying value exceeds the fair value, we recognize an impairment loss for the amount by which the carrying value exceeds fair value, up to the total amount of goodwill allocated to the reporting unit. We did not incur any goodwill impairment losses in any of the periods presented.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess acquisitions under ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (&#8220;ASC 805&#8221;) to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, in accordance with ASC 805, contingent consideration is recorded at fair value as of the acquisition date and classified as liabilities or equity based on applicable U.S. GAAP. For contingent consideration classified as liabilities, we remeasure the contingent consideration at fair value each period with changes in fair value recorded in the statements of operations and comprehensive loss each period.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration in transactions that are not business combinations, we apply applicable U.S. GAAP. With respect to the additional consideration that may be payable in connection with the acquisitions of Cernostics, Inc. (&#8220;Cernostics&#8221;), an asset acquisition we completed on December 3, 2021, we account for the contingent consideration as a liability in accordance with ASC Topic 480,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is classified as current or noncurrent in our condensed consolidated balance sheets based on the contractual timing of future settlement. For additional information on contingent consideration, see Notes 5 and 10.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Compensation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. Our board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of June&#160;30, 2022 and December&#160;31, 2021, we accrued $9,835,000 and $12,071,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the condensed consolidated balance sheets based on the expected timing of payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss was the same as our reported net loss for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265988032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to our DecisionDx&#174;-Melanoma test for cutaneous melanoma. We also provide a test for uveal melanoma, DecisionDx&#174;-UM, a test for patients with cutaneous squamous cell carcinoma, DecisionDx&#174;-SCC, two tests for use in patients with suspicious pigmented lesions, MyPath&#174; Melanoma and DiffDx&#174;-Melanoma, and a test for patients diagnosed with Barrett&#8217;s esophagus (&#8220;BE&#8221;), the TissueCypher&#174; Barrett&#8217;s Esophagus Assay. We also began offering a pharmacogenomics (&#8220;PGx&#8221;) testing service focused on mental health, IDgenetix&#174;, following a business combination completed in April 2022. Information on the disaggregation of revenues is included below. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a positive coverage policy, with or without a contractually committed reimbursement rate, with a commercial carrier or governmental program, our diagnostic tests may or may not be paid by these entities. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare claims that are covered by policy under a Local Coverage Determination (&#8220;LCD&#8221;) or otherwise are generally paid at a rate established on Medicare&#8217;s Clinical Laboratory Fee Schedule or by the respective Medicare contractor within 30 </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD or other coverage commencement date or are not covered but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed &#8216;&#8216;redetermination&#8217;&#8217;), second (termed &#8216;&#8216;reconsideration&#8217;&#8217;) or third level of appeal (de novo hearing with an Administrative Law Judge (&#8220;ALJ&#8221;)). A successful appeal at any of these levels may result in prompt payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of LCD coverage, contractually established reimbursements rates or other coverage, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the &#8216;&#8216;most likely amount&#8217;&#8217; method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Variable consideration for Medicare claims that are not covered by an LCD or otherwise, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the three months ended June 30, 2022 and 2021 were $578,000 and $(166,000), respectively, of net positive (negative) revenue adjustments associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Such amounts of variable consideration for the six months ended June 30, 2022 and 2021 were $(300,000) and $5,092,000, respectively, of net (negative) positive revenue adjustments. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of our contracts. Contract balances consisted solely of accounts receivable (both current and noncurrent) as of June&#160;30, 2022 and December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the disaggregation of revenue by type (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payor Concentration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our diagnostic and prognostic tests.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(current)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(noncurrent)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlueCross BlueShield plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265810864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per Share <div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or purchases under the 2019 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we reported a net loss for all periods presented, all potentially dilutive securities are antidilutive and are excluded from the computation of diluted loss per share for such periods.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the three and six months ended June&#160;30, 2022 and 2021 because to do so would be antidilutive (in thousands): </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units (&#8220;RSUs&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the acquisitions of Cernostics and AltheaDx, Inc. (&#8220;AltheaDx&#8221;), we may issue, or may be required to issue, shares of our common stock to satisfy our contingent consideration obligations, pending the outcome of certain commercial and regulatory milestones, as required by the respective definitive agreements. See Notes 5 and 10 for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718269597024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Myriad myPath, LLC</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City, for a cash purchase price of $32,500,000. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the developed technology, and therefore the transaction represents an asset acquisition rather than a business combination.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cernostics, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, we completed the acquisition of Cernostics, which offers the TissueCypher Barrett&#8217;s Esophagus Assay for patients with BE, for total consideration of $49,019,000, consisting of cash consideration of $30,732,000 and contingent consideration with an acquisition date fair value of $18,287,000. In connection with the acquisition, we recorded a receivable as of the acquisition date for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital. During the three months ended June 30, 2022, we received cash of $547,000 in settlement of this receivable. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AltheaDx, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, we completed the acquisition of 100% of the equity interests in AltheaDx. AltheaDx offers the IDgenetix test, a PGx test focused on mental health. We believe this acquisition enables us to expand upon our existing portfolio of testing solutions in support of our growth strategy. We have concluded that the transaction represents a business combination under ASC 805. The financial results of AltheaDx have been included in our unaudited condensed consolidated financial statements since the date of the acquisition. The amount of revenue from AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was not material. The loss attributable to AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was approximately $3,383,000. This amount does not reflect transaction costs from the acquisition or the effects of the valuation allowance reduction discussed in Note 13. Transaction costs associated with the acquisition were $1,711,000 for both the three and six months ended June 30, 2022 and were recognized as expenses in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock (763,887 shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the common stock issued was measured using the April 26, 2022 closing price of $22.40 per share, as reported by the Nasdaq Global Market.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the contingent consideration, we may be required to pay up to $75.0 million in cash and common stock in connection with the achievement of certain milestones based on 2022, 2023 and 2024 performance and expanded Medicare coverage for the IDgenetix test (the &#8220;AltheaDx Earnout Payments&#8221;). Upon achievement of each relevant milestone event, each milestone will be paid 50% in cash and 50% in shares of our common stock based on a price per share equal to the volume-weighted-average price of our common stock for the 20 trading days as of the applicable milestone determination date. In accordance with the terms of the definitive agreement governing the acquisition of AltheaDx, the maximum number of shares of our common stock issuable to former AltheaDx security holders may not exceed 1,271,718 shares. Therefore, taking into consideration the number of shares already issued at closing, a maximum of 507,831 additional shares of our common stock remain issuable with respect to the AltheaDx Earnout Payments. In the event a number of shares in excess of 507,831 would otherwise be issuable in connection with the AltheaDx Earnout Payments, we will issue shares up to the maximum number permitted and pay cash for the remaining portion of the obligation. See Note 10 for additional information on the measurement of the contingent consideration. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset is comprised of developed technology with an estimated useful life of 15 years and is being amortized on a straight-line basis. The goodwill, which is not expected to be deductible for income tax purposes, was primarily attributable to potential future growth opportunities and the organized workforce.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our calculations of the consideration transferred and the purchase price allocation for the acquisition of AltheaDx are based on a preliminary valuation and are subject to revision as the valuation is finalized and additional information about the fair value of the assets and liabilities becomes available. The primary areas that are not yet finalized are income taxes, intangible assets, contingent consideration and the resulting goodwill. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information for the three and six months ended June 30, 2022 and 2021 combines our historical financial results and the results of AltheaDx, assuming that the companies were combined as of January 1, 2021, and includes adjustments for amortization expense from the acquired intangible assets and additional stock-based compensation expense. Nonrecurring pro forma adjustments consist of acquisition-related transaction costs of $1,711,000 and an income tax benefit of $1,769,000, both assumed to have been recognized during the six months ended June 30, 2021 and therefore removed from the three and six months ended June 30, 2022. The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro Forma Data</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derek J. Maetzold, our President and Chief Executive Officer, and a member of our board of directors, and Daniel M. Bradbury, the Chairperson of our board of directors, each served on the board of directors of AltheaDx until the acquisition of AltheaDx was completed, were direct or indirect beneficial owners of AltheaDx securities and received consideration in the </span></div>transaction. Further, Frank Stokes, our Chief Financial Officer; Tobin W. Juvenal, our Chief Commercial Officer; Kristen Oelschlager, our Chief Operating Officer and certain immediate family members of Mr. Maetzold and Ms. Oelschlager were direct or indirect beneficial owners of AltheaDx securities and received consideration in the transaction. These individuals may receive additional consideration in the form of AltheaDx Earnout Payments if the relevant commercial and regulatory milestone events occur. Our entry into the definitive agreement to acquire AltheaDx was approved by our board of directors based upon the unanimous recommendation of a special transaction committee comprised entirely of independent members of our board of directors without any financial interest in AltheaDx or any conflict of interest with respect to the acquisition of AltheaDx.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Myriad myPath, LLC</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City, for a cash purchase price of $32,500,000. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the developed technology, and therefore the transaction represents an asset acquisition rather than a business combination.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cernostics, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, we completed the acquisition of Cernostics, which offers the TissueCypher Barrett&#8217;s Esophagus Assay for patients with BE, for total consideration of $49,019,000, consisting of cash consideration of $30,732,000 and contingent consideration with an acquisition date fair value of $18,287,000. In connection with the acquisition, we recorded a receivable as of the acquisition date for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital. During the three months ended June 30, 2022, we received cash of $547,000 in settlement of this receivable. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AltheaDx, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2022, we completed the acquisition of 100% of the equity interests in AltheaDx. AltheaDx offers the IDgenetix test, a PGx test focused on mental health. We believe this acquisition enables us to expand upon our existing portfolio of testing solutions in support of our growth strategy. We have concluded that the transaction represents a business combination under ASC 805. The financial results of AltheaDx have been included in our unaudited condensed consolidated financial statements since the date of the acquisition. The amount of revenue from AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was not material. The loss attributable to AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was approximately $3,383,000. This amount does not reflect transaction costs from the acquisition or the effects of the valuation allowance reduction discussed in Note 13. Transaction costs associated with the acquisition were $1,711,000 for both the three and six months ended June 30, 2022 and were recognized as expenses in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock (763,887 shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the common stock issued was measured using the April 26, 2022 closing price of $22.40 per share, as reported by the Nasdaq Global Market.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the contingent consideration, we may be required to pay up to $75.0 million in cash and common stock in connection with the achievement of certain milestones based on 2022, 2023 and 2024 performance and expanded Medicare coverage for the IDgenetix test (the &#8220;AltheaDx Earnout Payments&#8221;). Upon achievement of each relevant milestone event, each milestone will be paid 50% in cash and 50% in shares of our common stock based on a price per share equal to the volume-weighted-average price of our common stock for the 20 trading days as of the applicable milestone determination date. In accordance with the terms of the definitive agreement governing the acquisition of AltheaDx, the maximum number of shares of our common stock issuable to former AltheaDx security holders may not exceed 1,271,718 shares. Therefore, taking into consideration the number of shares already issued at closing, a maximum of 507,831 additional shares of our common stock remain issuable with respect to the AltheaDx Earnout Payments. In the event a number of shares in excess of 507,831 would otherwise be issuable in connection with the AltheaDx Earnout Payments, we will issue shares up to the maximum number permitted and pay cash for the remaining portion of the obligation. See Note 10 for additional information on the measurement of the contingent consideration. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset is comprised of developed technology with an estimated useful life of 15 years and is being amortized on a straight-line basis. The goodwill, which is not expected to be deductible for income tax purposes, was primarily attributable to potential future growth opportunities and the organized workforce.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our calculations of the consideration transferred and the purchase price allocation for the acquisition of AltheaDx are based on a preliminary valuation and are subject to revision as the valuation is finalized and additional information about the fair value of the assets and liabilities becomes available. The primary areas that are not yet finalized are income taxes, intangible assets, contingent consideration and the resulting goodwill. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Pro Forma Financial Information</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information for the three and six months ended June 30, 2022 and 2021 combines our historical financial results and the results of AltheaDx, assuming that the companies were combined as of January 1, 2021, and includes adjustments for amortization expense from the acquired intangible assets and additional stock-based compensation expense. Nonrecurring pro forma adjustments consist of acquisition-related transaction costs of $1,711,000 and an income tax benefit of $1,769,000, both assumed to have been recognized during the six months ended June 30, 2021 and therefore removed from the three and six months ended June 30, 2022. The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro Forma Data</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transaction</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derek J. Maetzold, our President and Chief Executive Officer, and a member of our board of directors, and Daniel M. Bradbury, the Chairperson of our board of directors, each served on the board of directors of AltheaDx until the acquisition of AltheaDx was completed, were direct or indirect beneficial owners of AltheaDx securities and received consideration in the </span></div>transaction. Further, Frank Stokes, our Chief Financial Officer; Tobin W. Juvenal, our Chief Commercial Officer; Kristen Oelschlager, our Chief Operating Officer and certain immediate family members of Mr. Maetzold and Ms. Oelschlager were direct or indirect beneficial owners of AltheaDx securities and received consideration in the transaction. These individuals may receive additional consideration in the form of AltheaDx Earnout Payments if the relevant commercial and regulatory milestone events occur. Our entry into the definitive agreement to acquire AltheaDx was approved by our board of directors based upon the unanimous recommendation of a special transaction committee comprised entirely of independent members of our board of directors without any financial interest in AltheaDx or any conflict of interest with respect to the acquisition of AltheaDx.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265870640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes lab equipment under a finance lease of $369 thousand and accumulated depreciation of $66 thousand.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was recorded in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265910464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets, Net</a></td>
<td class="text">Goodwill and Other Intangible Assets, Net<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on the change in carrying value of our goodwill is presented below (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AltheaDx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accumulated impairments of goodwill as of June 30, 2022 or December 31, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets, Net</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other intangible assets, net consists of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,922&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future aggregate amortization expense as of June&#160;30, 2022 is as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder of year)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense of intangible assets was $2.1 million and $3.7 million for the three and six months ended June&#160;30, 2022, respectively. Amortization expense of intangible assets was $0.3 million for each of the three and six months ended June&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265854240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued and Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Accrued and Current Liabilities</a></td>
<td class="text">Other Accrued and Current Liabilities<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued service fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued fixed asset purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration payable for business acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265795744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption of ASC 842</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we adopted ASU No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842), and ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the modified retrospective approach with an effective date of January 1, 2021. The adoption had no effect on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2021. Net cash (used in) provided by operating activities, investing activities or financing activities for the six months ended June 30, 2021 were also unchanged, but the presentation of certain prior period amounts within the operating activities section of the condensed consolidated statements of cash flows has been retrospectively adjusted to give effect to the adoption of ASC 842. The changes are set forth in the table below (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Before Adoption of ASC 842</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Adoption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After Adoption of ASC 842</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effect on Condensed Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the condensed consolidated statement of stockholders&#8217; equity for the three and six months ended June 30, 2021 has been retrospectively adjusted to reflect a credit to accumulated deficit of $21,000 in connection with the adoption of ASC 842 effective January 1, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Amendment</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2022, we amended one of our operating leases to expand rentable space in Phoenix, Arizona. We intend to use the additional space for general office and laboratory use. The term of the amended lease will begin upon the completion of certain leasehold improvements by the Phoenix landlord (the &#8220;Phoenix Commencement Date&#8221;) and continue for an initial term of 10.3 years from the Phoenix Commencement Date. Total undiscounted future minimum payment obligations as of June&#160;30, 2022 associated with the lease amendment totaled approximately $1.4&#160;million. As of June&#160;30, 2022, we have not recorded the lease amendment on our condensed consolidated balance sheet because we do not have possession or control of the underlying asset.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pittsburgh Lease</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we entered into a lease agreement (the &#8220;Pittsburgh Lease&#8221;) for the lease of certain office space in Pittsburgh, Pennsylvania. We intend to use such space for general office and laboratory use. The term of the Pittsburgh Lease will begin upon the completion of certain leasehold improvements by the landlord (the &#8220;Pittsburgh Commencement Date&#8221;) and continue for an initial period of 10.5 years from the Pittsburgh Commencement Date. During the first six months of the lease term, we are required to remit base rent of $37,800 for the period. Beginning with month seven, the base rent will be $0.6&#160;million per year with annual increases ultimately resulting in base rent obligations totaling $1.5&#160;million per year. The landlord under the Pittsburgh Lease has agreed to contribute up to $2.5&#160;million towards the cost of the leasehold improvements and we will be responsible for any costs exceeding this amount. The Pittsburgh Lease also provides us a one-time option that would terminate the lease effective at the end of the 90th month following the Pittsburgh Commencement Date, subject to certain conditions. If exercised, we would pay an early termination fee of $2.3&#160;million, subject to adjustment in the event the Pittsburgh Lease is amended to adjust the base rent. The Pittsburgh Lease provides us one five-year renewal option and also provides us a right of first refusal with respect to the lease of certain additional space in the same building. As of June&#160;30, 2022, we have not recorded the Pittsburgh Lease on our condensed consolidated balance sheet because we do not have possession or control of the underlying asset.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265931072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information, by level within the fair value hierarchy, of our financial assets and financial liabilities that are accounted for at fair value on a recurring basis as of&#160;June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Classified as &#8220;Cash and cash equivalents&#8221; in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Current portion, if any, classified as &#8220;Other accrued and current liabilities&#8221; in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Cernostics, we have recorded a contingent consideration liability for the additional consideration of up to $50.0 million that may become payable based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 (&#8220;Cernostics Earnout Payments&#8221;). The Cernostics Earnout Payments may be settled in cash or shares of our common stock, at our sole discretion. The portion of any Cernostics Earnout Payments that may be settled in shares of our common stock is subject to certain limitations and the aggregate number of shares that may be issued for the Cernostics Earnout Payments may not exceed 5,034,653 shares. Any Cernostics Earnout Payments in shares of our common stock will be based on the volume weighted-average price of our common stock for the 15 trading days ending December 30, 2022. If the settlement were to occur as of June&#160;30, 2022, we would make no Cernostics Earnout Payments based on the achievement of the performance conditions to date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of AltheaDx, we have also recorded a contingent consideration liability for the additional consideration of up to $75.0 million that may become payable based on the achievement of certain commercial milestones relating to the years ending December 31, 2022, 2023, and 2024, as discussed further in Note 5. If the settlement were to occur as of June 30, 2022, we would make no AltheaDx Earnout Payments based on the achievement of the performance conditions to date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis for the Cernostics Earnout Payments uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate, which were 40.0% and 20.2%, respectively, as of June&#160;30, 2022, and 20.0% and 16.1%, respectively, as of December 31, 2021. The assumptions for expected volatility of the financial metrics used in the analysis for the AltheaDx Earnout Payments was 36.0% as of June&#160;30, 2022. The risk-adjusted discount rate for years 2022, 2023, and 2024 were 6.3%, 7.4% and 7.5%, respectively. The contingent consideration liability is remeasured at fair value at </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each reporting period taking into account any updated assumptions or changes in circumstances. Any changes in the fair value are recorded as gains or losses in our condensed consolidated statement of operations and comprehensive loss. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs as of June&#160;30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cernostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AltheaDx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AltheaDx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,949&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265923872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265795744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock-Based Compensation</a></td>
<td class="text">Stock Incentive Plans and Stock-Based Compensation<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plans</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, an additional 1,268,926 shares became available under our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) pursuant to an automatic annual increase. As of June&#160;30, 2022, 586,155 shares remained available for grant under the 2019 Plan.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under our stock plans for the six months ended June&#160;30, 2022 is set forth below:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599,766&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity for the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679,954</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides for certain automatic increases in the number of shares of common stock reserved for issuance, which resulted in an additional 253,785 shares becoming available under the ESPP effective January 1, 2022. During the six months ended June&#160;30, 2022, we issued 42,332 of common stock pursuant to scheduled purchases under the ESPP. As of June&#160;30, 2022, 850,919 shares remained available for issuance under the ESPP.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Fair Value - Summary of Assumptions</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. The following table sets forth the assumptions used to determine the fair value of stock options:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.34% - 71.58%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.94% - 67.98%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54% - 2.91%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51% - 1.09%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.98% - 66.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.43% - 86.50%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 1.30%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07% - 0.13%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our common stock is also an assumption used to determine the fair value of stock options and purchase rights under the ESPP. The fair value of our common stock is the closing price per share, as reported by the Nasdaq Global Market, on the date of grant or other relevant determination date.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the ESPP purchase right and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the closing price of our common stock on the date of grant to determine the fair value of RSUs.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options, RSUs and the ESPP is included in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>For the six months ended June 30, 2022 and 2021, the weighted-average grant date fair value of options granted was $14.07 and $41.35 per option, respectively, and the weighted-average grant date fair value of the purchase rights granted under the ESPP was $19.91 and $39.26 per share, respectively. As of June&#160;30, 2022, the total unrecognized compensation cost related to outstanding awards was $99,493,000, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.0 years. The total unrecognized compensation cost will be adjusted for forfeitures in future periods as they occur.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265965568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of AltheaDx, we recorded $1,819,000 in deferred tax liabilities based on our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary allocation of the fair values of assets acquired and liabilities assumed. As a result of these additional deferred tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we determined that $1,769,000 of our existing valuation allowance on deferred tax assets should be reduced, which was reflected in our income tax benefit on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 as a discrete item.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264087888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Our unaudited condensed consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8216;&#8216;U.S. GAAP&#8217;&#8217;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), that are primarily invested in short-term U.S. government obligations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized in accordance with Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;) Accounting Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span>(&#8216;&#8216;ASC 606&#8217;&#8217;). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as noncurrent assets. The estimated timing of payment utilized as a basis for classification as noncurrent is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for Credit Losses</a></td>
<td class="text">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers&#8217; financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of June&#160;30, 2022, and December&#160;31, 2021. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. In accordance with ASC Topic 350,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles&#8212;Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that it may be impaired. We perform annual impairment reviews of our goodwill balance during the fourth quarter of each year. We may perform a qualitative assessment to determine if it is necessary to perform a quantitative impairment test. If we determine that a quantitative impairment test is necessary, we apply the guidance in Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, by comparing the fair value of the reporting unit to its carrying value, including the goodwill. If the carrying value exceeds the fair value, we recognize an impairment loss for the amount by which the carrying value exceeds fair value, up to the total amount of goodwill allocated to the reporting unit. We did not incur any goodwill impairment losses in any of the periods presented.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock', window );">Acquisitions, Contingent Consideration</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess acquisitions under ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (&#8220;ASC 805&#8221;) to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual </span><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a business combination, in accordance with ASC 805, contingent consideration is recorded at fair value as of the acquisition date and classified as liabilities or equity based on applicable U.S. GAAP. For contingent consideration classified as liabilities, we remeasure the contingent consideration at fair value each period with changes in fair value recorded in the statements of operations and comprehensive loss each period.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration in transactions that are not business combinations, we apply applicable U.S. GAAP. With respect to the additional consideration that may be payable in connection with the acquisitions of Cernostics, Inc. (&#8220;Cernostics&#8221;), an asset acquisition we completed on December 3, 2021, we account for the contingent consideration as a liability in accordance with ASC Topic 480,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is classified as current or noncurrent in our condensed consolidated balance sheets based on the contractual timing of future settlement. For additional information on contingent consideration, see Notes 5 and 10.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accrued Compensation</a></td>
<td class="text">We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. Our board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of June&#160;30, 2022 and December&#160;31, 2021, we accrued $9,835,000 and $12,071,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the condensed consolidated balance sheets based on the expected timing of payment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination And Asset Acquisitions, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265787984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedules of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the disaggregation of revenue by type (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermatologic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,690&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(current)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(noncurrent)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BlueCross BlueShield plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265878000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the three and six months ended June&#160;30, 2022 and 2021 because to do so would be antidilutive (in thousands): </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units (&#8220;RSUs&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718269972784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.766%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock (763,887 shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">April 26, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued and current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net identifiable assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Unaudited Pro forma Financial Information and Net Income</a></td>
<td class="text">The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro Forma Data</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,289)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265965568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,203&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes lab equipment under a finance lease of $369 thousand and accumulated depreciation of $66 thousand.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was recorded in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264467472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Our Goodwill</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on the change in carrying value of our goodwill is presented below (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AltheaDx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other intangible assets, net consists of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,639)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.940%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Remaining Life (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled workforce</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,922&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future aggregate amortization expense as of June&#160;30, 2022 is as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder of year)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265852240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued and Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued service fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued fixed asset purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration payable for business acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265910464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of Adoption of Accounting Standards Update</a></td>
<td class="text">The changes are set forth in the table below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Before Adoption of ASC 842</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of Adoption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">After Adoption of ASC 842</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Effect on Condensed Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265992304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information, by level within the fair value hierarchy, of our financial assets and financial liabilities that are accounted for at fair value on a recurring basis as of&#160;June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Items (Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Classified as &#8220;Cash and cash equivalents&#8221; in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Current portion, if any, classified as &#8220;Other accrued and current liabilities&#8221; in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs as of June&#160;30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cernostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AltheaDx</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AltheaDx</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,949&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264380000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement on Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under our stock plans for the six months ended June&#160;30, 2022 is set forth below:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599,766&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement on Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity for the six months ended June&#160;30, 2022:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,679,954</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text">The following table sets forth the assumptions used to determine the fair value of stock options:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.34% - 71.58%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.94% - 67.98%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54% - 2.91%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51% - 1.09%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, ESPP, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.98% - 66.75%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.43% - 86.50%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 1.30%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.07% - 0.13%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options, RSUs and the ESPP is included in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization of acquired intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264093200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued bonuses</a></td>
<td class="nump">9,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,071,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718263509344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_ContractWithCustomerCustomerPaymentTerms', window );">Number of days contract with customer is generally paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Variable consideration adjustments included in revenue</a></td>
<td class="nump">$ 578<span></span>
</td>
<td class="num">$ (166)<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="nump">$ 5,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_ContractWithCustomerCustomerPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Customer, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_ContractWithCustomerCustomerPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264118496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 34,838<span></span>
</td>
<td class="nump">$ 22,758<span></span>
</td>
<td class="nump">$ 61,690<span></span>
</td>
<td class="nump">$ 45,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cstl_DermatologicMember', window );">Dermatologic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">31,897<span></span>
</td>
<td class="nump">20,378<span></span>
</td>
<td class="nump">56,236<span></span>
</td>
<td class="nump">41,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 2,941<span></span>
</td>
<td class="nump">$ 2,380<span></span>
</td>
<td class="nump">$ 5,454<span></span>
</td>
<td class="nump">$ 4,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cstl_DermatologicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cstl_DermatologicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261452448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Concentration of Risk, by Risk Factor (Details) - Third-Party Payor Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_MedicareMember', window );">Medicare | Percentage of Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_MedicareMember', window );">Medicare | Percentage of Accounts Receivable (current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_MedicareMember', window );">Medicare | Percentage of Accounts Receivable (noncurrent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_MedicareAdvantagePlansMember', window );">Medicare Advantage plans | Percentage of Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_MedicareAdvantagePlansMember', window );">Medicare Advantage plans | Percentage of Accounts Receivable (current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_MedicareAdvantagePlansMember', window );">Medicare Advantage plans | Percentage of Accounts Receivable (noncurrent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_BlueCrossBlueShieldPlansMember', window );">BlueCross BlueShield plans | Percentage of Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_BlueCrossBlueShieldPlansMember', window );">BlueCross BlueShield plans | Percentage of Accounts Receivable (current)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cstl_BlueCrossBlueShieldPlansMember', window );">BlueCross BlueShield plans | Percentage of Accounts Receivable (noncurrent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cstl_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cstl_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=cstl_ThirdPartyPayorConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=cstl_ThirdPartyPayorConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cstl_AccountsReceivableCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cstl_AccountsReceivableCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cstl_AccountsReceivableNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cstl_AccountsReceivableNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cstl_MedicareAdvantagePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cstl_MedicareAdvantagePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cstl_BlueCrossBlueShieldPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cstl_BlueCrossBlueShieldPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718263582736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">5,085<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">3,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cstl_StockOptionsAndRestrictedStockUnitsRSUsMember', window );">Stock options and restricted stock units (&#8220;RSUs&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">4,974<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">4,828<span></span>
</td>
<td class="nump">3,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cstl_StockOptionsAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cstl_StockOptionsAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718262669488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 26, 2022 </div>
<div>USD ($) </div>
<div>tradingDay </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_ProceedsFromPreviousAssetAcquisition', window );">Cash received from settlement of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,957<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">1,823<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cstl_MyriadMyPathLLCMember', window );">Myriad myPath, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember', window );">Cernostics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Consideration transferred, contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_ProceedsFromPreviousAssetAcquisition', window );">Cash received from settlement of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interest acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Loss from acquisition date</a></td>
<td class="nump">$ 3,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Transaction costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Additional consideration payable based on achievement of certain commercial milestones</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash', window );">Contingent consideration paid in cash (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock', window );">Contingent consideration paid in common stock (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, number of shares issued or issuable in transaction (in shares) | shares</a></td>
<td class="nump">763,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc | Acquisition-related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Transaction costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc | Income Tax Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays', window );">Common stock, share price, volume-weighted average price, number of trading days | tradingDay</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, number of shares issued or issuable in transaction (in shares) | shares</a></td>
<td class="nump">1,271,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued', window );">Consideration transferred, number of remaining shares authorized to be issued (in shares) | shares</a></td>
<td class="nump">507,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Number Of Remaining Shares Authorized To Be Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Share Price, Volume-Weighted Average Price, Number Of Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_ProceedsFromPreviousAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Previous Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_ProceedsFromPreviousAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cstl_MyriadMyPathLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cstl_MyriadMyPathLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=cstl_IncomeTaxAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=cstl_IncomeTaxAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718263492032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Acquisition of consideration transferred (Details) - AltheaDx, Inc<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 26, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 30,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Common stock</a></td>
<td class="nump">17,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total</a></td>
<td class="nump">$ 49,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, number of shares issued or issuable in transaction (in shares) | shares</a></td>
<td class="nump">763,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718262614208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 10,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets &#8211; long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other accrued and current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net identifiable assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261311472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Schedule of Unaudited Pro forma Financial Information and Net Income (Details) - AltheaDx, Inc - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenues</a></td>
<td class="nump">$ 35,392<span></span>
</td>
<td class="nump">$ 22,840<span></span>
</td>
<td class="nump">$ 62,670<span></span>
</td>
<td class="nump">$ 45,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,289)<span></span>
</td>
<td class="num">$ (11,267)<span></span>
</td>
<td class="num">$ (32,680)<span></span>
</td>
<td class="num">$ (17,479)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264176064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">$ 17,883<span></span>
</td>
<td class="nump">$ 12,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less accumulated depreciation</a></td>
<td class="num">(6,680)<span></span>
</td>
<td class="num">(3,042)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">11,203<span></span>
</td>
<td class="nump">9,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">6,778<span></span>
</td>
<td class="nump">3,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease, right-of-use asset, before accumulated amortization</a></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease, right-of-use asset, accumulated amortization</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">4,965<span></span>
</td>
<td class="nump">5,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">4,014<span></span>
</td>
<td class="nump">2,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">1,423<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total</a></td>
<td class="nump">$ 703<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264121888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Depreciation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales (exclusive of amortization of acquired intangible assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264128832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net - Schedule of Change in Carrying Value of Our Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of AltheaDx</a></td>
<td class="nump">10,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 10,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264123712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill accumulated impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 2,097,000<span></span>
</td>
<td class="nump">$ 256,000<span></span>
</td>
<td class="nump">$ 3,745,000<span></span>
</td>
<td class="nump">$ 256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261096688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">$ 127,881<span></span>
</td>
<td class="nump">$ 90,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5,704)<span></span>
</td>
<td class="num">(1,958)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">122,177<span></span>
</td>
<td class="nump">88,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">127,318<span></span>
</td>
<td class="nump">90,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5,639)<span></span>
</td>
<td class="num">(1,949)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 121,679<span></span>
</td>
<td class="nump">$ 88,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted-Average Remaining Life (in years)</a></td>
<td class="text">13 years 8 months 12 days<span></span>
</td>
<td class="text">13 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cstl_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted-Average Remaining Life (in years)</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cstl_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cstl_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261084016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (remainder of year)</a></td>
<td class="nump">$ 4,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">9,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">9,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">9,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">9,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">80,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 122,177<span></span>
</td>
<td class="nump">$ 88,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264117200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued and Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued service fees</a></td>
<td class="nump">$ 3,163<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AccruedClinicalStudiesCurrent', window );">Clinical studies</a></td>
<td class="nump">2,165<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll-related liabilities</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee stock purchase plan contributions</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AccruedFixedAssetPurchases', window );">Accrued fixed asset purchases</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_BusinessCombinationConsiderationPayableCurrent', window );">Consideration payable for business acquisition</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,177<span></span>
</td>
<td class="nump">$ 5,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_AccruedClinicalStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Studies, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_AccruedClinicalStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_AccruedFixedAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Fixed Asset Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_AccruedFixedAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_BusinessCombinationConsiderationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_BusinessCombinationConsiderationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264183440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Assets And Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 7,004<span></span>
</td>
<td class="nump">$ 7,383<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Effect of Adoption | Effect of Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember', window );">After Adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261252944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Adjustment to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (120,038,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (93,767,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lessee, operating lease, lease not yet commenced, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseMember', window );">Pittsburgh Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseMaximumBaseRent', window );">Operating lease, maximum base rent</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew', window );">Lessee, operating lease, number of options to renew | claim</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Leasehold improvements to be contributed by landlord</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseOptionToTerminateTerm', window );">Number of months to terminate lease after commencement</a></td>
<td class="text">90 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseEarlyTerminationFee', window );">Early termination fee</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseFirstSixMonthsMember', window );">Pittsburgh Lease, First Six Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseBaseRent', window );">Operating lease, base rent</a></td>
<td class="nump">$ 37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseAfterSixMonthsMember', window );">Pittsburgh Lease, After First Six Months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_LesseeOperatingLeaseBaseRent', window );">Operating lease, base rent</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Effect of Adoption | Effect of Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Adjustment to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_LesseeOperatingLeaseEarlyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Early Termination Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_LesseeOperatingLeaseEarlyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_LesseeOperatingLeaseMaximumBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Maximum Base Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_LesseeOperatingLeaseMaximumBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_LesseeOperatingLeaseNumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Options To Renew</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_LesseeOperatingLeaseNumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_LesseeOperatingLeaseOptionToTerminateTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_LesseeOperatingLeaseOptionToTerminateTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseFirstSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseFirstSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseAfterSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cstl_PittsburghLeaseAfterSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264186496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 266,803<span></span>
</td>
<td class="nump">$ 327,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">18,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Items (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">266,803<span></span>
</td>
<td class="nump">327,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 1,979<span></span>
</td>
<td class="nump">$ 18,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261212400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>tradingDay </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration in acquisition of business</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected stock price volatility | Valuation, Income Approach | AltheaDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput', window );">Asset acquisition, contingent consideration, liability, measurement input</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Valuation, Income Approach | Forecast | AltheaDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput', window );">Asset acquisition, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember', window );">Cernostics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Additional consideration payable based on achievement of certain commercial milestones</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares', window );">Maximum number of shares payable in earnout payment (in shares) | shares</a></td>
<td class="nump">5,034,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice', window );">Number of trading days to determine volume weighted-average price of common stock | tradingDay</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember', window );">Cernostics, Inc. | Expected stock price volatility | Valuation, Income Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput', window );">Asset acquisition, contingent consideration, liability, measurement input</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember', window );">Cernostics, Inc. | Measurement Input, Discount Rate | Valuation, Income Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput', window );">Asset acquisition, contingent consideration, liability, measurement input</a></td>
<td class="nump">20.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition, Contingent Consideration, Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisitions, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisitions, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cstl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718263592064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 18,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Acquisition of AltheaDx</a></td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(17,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember', window );">AltheaDx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Acquisition of AltheaDx</a></td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">1,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember', window );">Cernostics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">18,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Acquisition of AltheaDx</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(18,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=cstl_CernosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265538000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.07<span></span>
</td>
<td class="nump">$ 41.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cstl_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized for issuance (in shares)</a></td>
<td class="nump">1,268,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.91<span></span>
</td>
<td class="nump">$ 39.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares authorized for issuance (in shares)</a></td>
<td class="nump">253,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cstl_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cstl_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264071856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation - Activity Under Stock Incentive Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,586,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">231,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(98,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(140,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,578,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, number of options (in shares)</a></td>
<td class="nump">1,599,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 34.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">22.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">5.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in dollars per share)</a></td>
<td class="nump">35.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">34.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 26.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Option Activity, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 12,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 10,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261209280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning Balance (in shares) | shares</a></td>
<td class="nump">1,050,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares) | shares</a></td>
<td class="nump">705,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(11,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited/Cancelled (in shares) | shares</a></td>
<td class="num">(64,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ending Balance (in shares) | shares</a></td>
<td class="nump">1,679,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value at beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 44.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">23.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">69.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited / Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">35.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value at ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718261135024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">62.98%<span></span>
</td>
<td class="nump">68.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">66.75%<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected term (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">68.34%<span></span>
</td>
<td class="nump">66.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">71.58%<span></span>
</td>
<td class="nump">67.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">1.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cstl_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718264188560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,783<span></span>
</td>
<td class="nump">$ 4,766<span></span>
</td>
<td class="nump">$ 17,202<span></span>
</td>
<td class="nump">$ 9,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales (exclusive of amortization of acquired intangible assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,831<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">3,659<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,055<span></span>
</td>
<td class="nump">$ 3,278<span></span>
</td>
<td class="nump">$ 11,793<span></span>
</td>
<td class="nump">$ 6,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140718265583712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - AltheaDx, Inc - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of existing valuation allowance on deferred tax assets</a></td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cstl_AltheaDxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>cstl-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cstl="http://www.castlebiosciences.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cstl-20220630.xsd" xlink:type="simple"/>
    <context id="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b225592077a49468f91c5a7a8070c8d_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i43af39ae2b5a4502ad42c6b29becf672_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf13288bff8d454995f61e624f289d17_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if579dae83b8c4e9985cc1382db6773cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie43334b369424f43a0a7ff7c5379bfab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46c2daf116a748ca9d99a88a918f8a7a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97c57848b43a4b04908a15f751f228eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55427030f29b4ec8919acde7614ce80a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i05142cc79cab4fe39aed0b747ac5ab72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7a028b432814c468151325be76f2288_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i96d79afbe3db4e63a8376b96ad2c2a19_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4e07a9c7b20e45d8a34bc3494233bad0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2db3849ecf344540b631208a8486e731_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8aef283682a0409391f3889a859516ee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifcf5f2d1d61c4399a85c38536d1b5870_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i10d8bc5806cc42a1a590de3ddefa542e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if45b15080c9a490e9b40a981b88c2ab4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i00a350df83e449a7bfb41c9fa0e438df_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief70ba11123c4a588f9021f36a8018f2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4716841dad0e4b91aa853fdde46b4497_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ddcfe5a62234411adef323f129a9431_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i876c6b7aacd34ac085dd8fed79a56ddc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie6ba51b1cf454b719b762b76d13bee4f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia4b43ea83fdf47bdaaabf1e474427f66_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2c649fe497204cb2a717f0ed7d84eb66_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idcb16faf4fb149658bbba1601aa0bbc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50aac6883ff6400fa2cae1a080701556_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61d01d11a47442dd85ecf3c5da42e59c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie414d3b9f48f4a62b15be9a778052e3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64651995ef994fb784afda58278f15c2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80d23ca5218f4f239df0df99e61be5fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff9ba1ac9bdc4a2f8c18d78ab64539ae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a71817e0bcd412b9689d66aaaede50c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i519d138276e44889b2be7e9e5bda9d96_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i652198504ae942f4b9eb116281a3e9fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie63ac35e1982419cab5b0e55ac7a9ec0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7cb246820c6d498e90a506f4b515e485_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if188768c20ab47cdb0dff4b33bd0c0ff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i34f5ad41aeed41b08758233329facba3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5404bc6eaf484be4813006a731482c19_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id85254eabd1f425ca0d60cbd627df78d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idb5cf2e6b2e24c06be4b1939e1daf492_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5fa26bc228544c24a0666ef5b1bd5976_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f9947a18f7d40039c6b420a80007dba_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia03e51765e914b8a9011d48a1ca77348_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cstl:DermatologicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8336c818a9d24de1b01f985248828ffd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i131a7e641770456ba0f7359e16012f93_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i743fbc9ec6194ca792d7d9caf96f471a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id0183c80be36439e982930171a859a72_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia301a48e31e3464b850d1a0710a2fb2e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icb4d6409a095497989a2cb7fb57c9812_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05824dd7aebb44438f53e1deb76ad500_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94472029ae74477fb2fffb4ece2766a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i323f1187bec8480581a9940120e35818_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4fb78aa5b5c14c7cad3c10b3fed78ccd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia8aeb153e06f4174a607042caec7e398_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8f647f897a49453e97a9bc858216da0d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia8647297e768439fa24eb3a61573953f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifdf616ceceff4a9789bd794cf9f29b01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i202ecb6dff6b4729b49d234fb2bef137_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8ef15e282314f3d8fec2981a454d8a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:MedicareAdvantagePlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id36b4a825e7f469b8fd2f597b3af8390_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfdb2a1c4c384d149ee8bca6e20af292_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee1f44ce249142beac6ca7381822ec8b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7cc96b39f3484f47995755bc11a69ddc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0135a04774dc4b219792a238d8bafb56_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic4caeb8a1e254252b6c25709ec4ec9d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cstl:BlueCrossBlueShieldPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cstl:AccountsReceivableNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">cstl:ThirdPartyPayorConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3851b8892a64a6bb5ee4d6a59a6d586_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic1e593f0419b463ab2feaebd198a1f36_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c32637b65384bdb811ce3fde43efe9c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id0fa44c09bb549a8bab2bb18b6137f27_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cstl:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae420fb56f4e41199cef237838e485c7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec43d4abf35e401b9ee6ac4b9e162d95_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id190812a859648c4aa204468be09784d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0e027d558f18441ebd34443aff9c0b0e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d5c289e6d474738890e1b72e04b9576_D20210528-20210528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:MyriadMyPathLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-28</startDate>
            <endDate>2021-05-28</endDate>
        </period>
    </context>
    <context id="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i36d6bf4b13ce4a24ae2fea8c910f9894_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i140b75ca6fb545eca7808706ff716d73_I20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4208ab3203fb45e2b40efa980b003a60_I20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-26</instant>
        </period>
    </context>
    <context id="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="idc558f1bcfcf460c9f62c48b28e4c8cd_D20220426-20220426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="iba6c475c71e34bab977bbfc04f289e75_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i342fb6e319104d52a2a096369c394d0a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">cstl:IncomeTaxAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i18246336ddbc4d7d82e4f43fbb8713f5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5a6d97ebe2b4ac8ac03f0f597e399e8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19966e00f06e4894824f928b10bfb6ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if3cbac6e564649baabb13f60dd0dd0e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5070d2dd0947412eb17de036ae48867f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id512a2f4079a4e7f8d0d10261566c191_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20d1fba04ed24847a7ae1ad277983eb2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7c244a39341a448791b5db69d1b41724_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia64acefec6184784b9890c8d9573b5ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibbd539bbaa4f45da97e6726e6d501957_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd2fa89ae0cb4fa7942493ffe73929b4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie55d01cabd3e4dfd8fc8d7634ccc3e6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01f3cc6a21d0455faa3a247ed3871fc2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i695763ce94f847ecb79699e832614ae4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5660ce4bef94584b72a1722257e6ddd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1cf326b10a224bb6a24085924905410c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib90b080f71e6434ea6c9ba3acadadcef_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibcfa896825f1413cb48c6b0e5e4b5954_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1f7c25b470c347d698685f93340964f3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3700a82a151f4c0a8bda6c74f43fe33d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb27d09e15f1493bafb7c9641c3f51aa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6d2f11e2e9a840b5a7a47d3f927f7647_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id95b5f253eb44af8b25296728af91542_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53b3a400ca564d61a070f1edf776917a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i901262209e794dce8a44fee61a9bfe50_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie686513e9d7f42f78dcefb7c17ec2bc3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2da820ae08bd4d858fbbc2c1c5bb1868_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4cd64260f474238bc48f5f8fbf709cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8dca6d7270d44eda30a928ed849ac36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i697af5026be14ac08242de05f2632427_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cstl:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1494102bc084aa0a7b78f886f46a23c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia0a424bc53f249fd89099cba54892a4c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i50e94943a8f84b59ae78cc37b86399dd_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if08210db194a470bb8c79782f96d1583_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ib08a4fbd714c45cdbc0c0ef66a81837b_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseFirstSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="id35ad05f10784973b277cc9339184bd2_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseAfterSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i1f9e74951a454794934048985403ea08_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cstl:PittsburghLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ibb8ceb3988914d2f9c2a79143d8fb4b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i21125ac2093648aea31470a65bc3c38d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i104f7bbc8cb7403d8a1ec5e1df30fa49_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6324a446c6ed44dcb012258eeb725d85_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ide11ef39260549e8a2e5914ad0f0afcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8ff935b4508458d896d72b6072dda6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fb402740817463da336bf3ad4500350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i684e2cbe0aee4089866a63e63228dd12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i028a35f4072e424b80f6c2c0e7c85713_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib99692ae97b9426581ef0e9d0e18336f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i02b6b0adf1ed4564ab66d5e6c116b521_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i02dfd58348864c25bf52e8044eb44e80_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64336bd6bad643a38e66641fec94637b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if05f1698a24e4537b9b6e321a862849e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab51d3dc6bd949c99033fd013c8820dd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3d374e88975f4250b70acfc62ee7b455_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i683d8e181278402690a483021f8294d6_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i3f8aa2919a654f9fb404a6244f4977b1_D20240101-20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="if2b51146ced54358bef8f0e24c5ad59a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec0ab012cf684932bc3842b6be81dc6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cstl:AltheaDxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30a1bb97eb834ce49721240374fb0bcd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">cstl:CernosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iedeeba3b13c34684a6126c12757e02db_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i4e3ed91cdcfc41dfa12bd21a3ade3077_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id49668ed558840d8a0b90ca6b883101e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4165eb4a39cb4beb89cc3cbf69e6654d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7805af27e10c4b63a1bc23dc07855219_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i11a61c8eb4b741ceae0ea9615e6fd60b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6684a747cbc242f286866f7a3ae50ae7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447362</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cstl:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tradingday">
        <measure>cstl:tradingDay</measure>
    </unit>
    <unit id="claim">
        <measure>cstl:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8yLTEtMS0xLTk3Mjcy_c0e85284-916e-4f02-8708-db6c0bee2ec7">0001447362</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8zLTEtMS0xLTk3Mjcy_6af2283e-cc45-4feb-ae02-30946ed9d030">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8xMy0xLTEtMS05NzI3Mg_2b958efe-726a-44b5-95cc-e01b5eb6d614">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8xNC0xLTEtMS05NzI3Mg_af7d814b-1635-4153-b03e-e5858bfc5578">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80L2ZyYWc6ZTA4ZTgyNTUzZDc5NDNmYjhlYmExNzgwZTYyYjkzOTIvdGFibGU6OWRkODAwMjlhYzI1NDBlNmIzNzZhYTZhMGY4ZTU2MjYvdGFibGVyYW5nZTo5ZGQ4MDAyOWFjMjU0MGU2YjM3NmFhNmEwZjhlNTYyNl8xNS0xLTEtMS05NzI3Mg_c178f4e1-8978-40f6-905c-593081027b8e">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0wLTEtMS05NzI3Mg_042c296b-db1d-4ee0-a8b1-7a689239030a">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:DocumentType
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTcw_9bf14b77-32fc-4e1f-b585-73b1a90b2afe">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NjNhNTU5NGU5MTgwNGI2YjgxNDNlMWVmNDU4ZDA1ZTQvdGFibGVyYW5nZTo2M2E1NTk0ZTkxODA0YjZiODE0M2UxZWY0NThkMDVlNF8xLTAtMS0xLTk3Mjcy_aee8fdac-7283-472f-b350-e6289fe74c4c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xMjg_ae8aecf7-b919-4dea-bc92-d29a024e7daa">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NTZhYjIxZWIwZmMzNDY3MDkyYjdhYjkxODc0MzRlYzUvdGFibGVyYW5nZTo1NmFiMjFlYjBmYzM0NjcwOTJiN2FiOTE4NzQzNGVjNV8wLTAtMS0xLTk3Mjcy_070e346c-4263-42bd-9665-1ed7b6d7f185">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY3_bc5f93fc-86ff-4f6b-9a8f-652f8b984f3f">001-38984</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTYy_b6b4bcf8-0f54-415f-9237-57a0c4c5d79f">CASTLE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8wLTAtMS0xLTk3Mjcy_c5835997-bf6d-4bf0-9fe6-3cdf4250096e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8wLTItMS0xLTk3Mjcy_72003507-91ad-4199-babd-ee0cdcca6554">77-0701774</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfNQ_3ee413d9-38a8-486d-b6fd-a561f59a373b">505 S. Friendswood Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfOQ_15eb5ee6-2b2e-4272-9385-32fa02fa2587">Suite 401</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfMTM_a6f64b2d-e595-47ad-a4bf-50d6ccb9d9d8">Friendswood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTAtMS0xLTk3MjcyL3RleHRyZWdpb246OTI2YmZjMzQ2ZmI3NDNiYzllOTJhYmViZDIxYzNkNTlfMTc_297d899e-a468-4730-aa3a-fdc0747ddbd5">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6NGZiNzM0OWE3ZjUyNGRmNGJlNjgxYTdjYjZjMjhhZjAvdGFibGVyYW5nZTo0ZmI3MzQ5YTdmNTI0ZGY0YmU2ODFhN2NiNmMyOGFmMF8zLTItMS0xLTk3Mjcy_d191aec4-cf71-474b-b79f-9315b0add5d5">77546</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY4_0cee9395-5c61-430a-b9e6-c65cc37a2a28">866</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTcx_511bf817-385e-48aa-bd08-e0137fb0a1cd">788-9007</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6ZTY2YTVkZjhiZDg3NDcxZDhjZGQ0MTdlMTJlMjA1YzUvdGFibGVyYW5nZTplNjZhNWRmOGJkODc0NzFkOGNkZDQxN2UxMmUyMDVjNV8xLTAtMS0xLTk3Mjcy_d78b2586-8dd7-4157-b683-20bff8ee87f9">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6ZTY2YTVkZjhiZDg3NDcxZDhjZGQ0MTdlMTJlMjA1YzUvdGFibGVyYW5nZTplNjZhNWRmOGJkODc0NzFkOGNkZDQxN2UxMmUyMDVjNV8xLTEtMS0xLTk3Mjcy_651ed6a1-b23f-49b4-9a5d-2e216ad73428">CSTL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6ZTY2YTVkZjhiZDg3NDcxZDhjZGQ0MTdlMTJlMjA1YzUvdGFibGVyYW5nZTplNjZhNWRmOGJkODc0NzFkOGNkZDQxN2UxMmUyMDVjNV8xLTItMS0xLTk3Mjcy_5e8ed6b3-a37c-45ad-8199-cd206e9dc902">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY5_0722b2ac-10b6-4951-9b1d-84acfd377ad7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTYz_40bfd4eb-fe3f-4350-92b9-5a4e0e8f51ee">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6MmE0MzExN2E4OTMzNGExYmE4YTM0YzQ0M2I2MmMwYTcvdGFibGVyYW5nZToyYTQzMTE3YTg5MzM0YTFiYThhMzRjNDQzYjYyYzBhN18wLTAtMS0xLTk3Mjcy_bfc73090-30b9-4e4b-aed8-01aaccbad131">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6MmE0MzExN2E4OTMzNGExYmE4YTM0YzQ0M2I2MmMwYTcvdGFibGVyYW5nZToyYTQzMTE3YTg5MzM0YTFiYThhMzRjNDQzYjYyYzBhN18xLTMtMS0xLTk3Mjcy_565d0e32-5e0a-4c3b-a7d0-2512108f008f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGFibGU6MmE0MzExN2E4OTMzNGExYmE4YTM0YzQ0M2I2MmMwYTcvdGFibGVyYW5nZToyYTQzMTE3YTg5MzM0YTFiYThhMzRjNDQzYjYyYzBhN18yLTMtMS0xLTk3Mjcy_47c5cd41-8c16-4350-b0c5-12b0ccb86073">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xOTY2_f1e95109-b2e0-46e1-a5ed-55aea02b1aef">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5b225592077a49468f91c5a7a8070c8d_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xL2ZyYWc6NjFlNDg2NTNlNzlhNDk4YzgzYzU4OWQ3NDBiZWQyOTAvdGV4dHJlZ2lvbjo2MWU0ODY1M2U3OWE0OThjODNjNTg5ZDc0MGJlZDI5MF8xODgy_c4611986-412e-4349-95a8-be1946f0c755"
      unitRef="shares">26296968</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNC0xLTEtMS05NzI3Mg_5a9ba610-8fd0-4c38-bd4b-7a401a4f0b32"
      unitRef="usd">273166000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNC0zLTEtMS05NzI3Mg_93e48e6f-9883-45f4-8618-d1e2b54dbcae"
      unitRef="usd">329633000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNS0xLTEtMS05NzI3Mg_e02807cc-227e-4c95-91f0-a0406511be19"
      unitRef="usd">22606000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNS0zLTEtMS05NzI3Mg_61b08a96-6d05-4552-afe4-18e53a380f7b"
      unitRef="usd">17282000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNi0xLTEtMS05NzI3Mg_f2765371-3718-4105-be71-06904369fecc"
      unitRef="usd">3365000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNi0zLTEtMS05NzI3Mg_c2c006e4-768c-4dcd-b246-672d702cd177"
      unitRef="usd">2021000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNy0xLTEtMS05NzI3Mg_c62b7833-0ca6-4b55-b312-e1ab3ef39ad1"
      unitRef="usd">5775000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfNy0zLTEtMS05NzI3Mg_c4bf6b28-7efb-48d0-bd8e-e07e12c3d775"
      unitRef="usd">4807000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOC0xLTEtMS05NzI3Mg_2ce1ebe6-3bf6-4b29-b952-d990e9c0ae59"
      unitRef="usd">304912000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOC0zLTEtMS05NzI3Mg_6fc0728d-3e38-4414-9823-64b4f2c40629"
      unitRef="usd">353743000</us-gaap:AssetsCurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOS0xLTEtMS05NzI3Mg_9d89f6c3-9001-429c-901c-6c0f93b02d21"
      unitRef="usd">1367000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfOS0zLTEtMS05NzI3Mg_6720efeb-8979-47e7-a7cf-51f6462a014d"
      unitRef="usd">1308000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTAtMS0xLTEtOTcyNzI_77e454c7-ccdf-432f-b634-2a3676b5066f"
      unitRef="usd">11203000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTAtMy0xLTEtOTcyNzI_aa08942b-c18c-4c25-badd-eb9db4ed66f0"
      unitRef="usd">9501000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTEtMS0xLTEtOTcyNzI_d6459cf7-e983-4264-8caf-d45cb74ded40"
      unitRef="usd">7004000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTEtMy0xLTEtOTcyNzI_cf018f61-bf8b-4423-b1a2-f7d7381a823d"
      unitRef="usd">7383000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTItMS0xLTEtOTcyNzI_bf657902-9152-4eb7-abc3-fb4d45bd4ff7"
      unitRef="usd">132671000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTItMy0xLTEtOTcyNzI_7b20f49f-afcb-4d37-a9c6-5f13b6b6a0ca"
      unitRef="usd">88922000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTMtMS0xLTEtOTcyNzI_5137221c-b335-4402-9419-3a637d240f5a"
      unitRef="usd">1223000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTMtMy0xLTEtOTcyNzI_6d37f8e2-a401-4970-975c-c9708d7d6ea6"
      unitRef="usd">1715000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTQtMS0xLTEtOTcyNzI_e4dd1edc-e4ba-4b04-a607-b53fba894ee3"
      unitRef="usd">458380000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTQtMy0xLTEtOTcyNzI_1781c4d9-736e-4dd5-8206-605e86ac1b13"
      unitRef="usd">462572000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTgtMS0xLTEtOTcyNzI_f8435c35-2dad-4c87-9c1f-086a64a74192"
      unitRef="usd">3281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTgtMy0xLTEtOTcyNzI_baec6d76-1f84-47f1-b94f-e57e573e9ac0"
      unitRef="usd">2546000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTktMS0xLTEtOTcyNzI_34a6cd0a-40d4-4984-a4ae-a2dcfa28eecc"
      unitRef="usd">14850000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMTktMy0xLTEtOTcyNzI_476648f6-0115-4253-896d-56374e04e665"
      unitRef="usd">15483000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjEtMS0xLTEtOTcyNzI_aad8f9c7-1a0d-405f-8029-3f437b786e96"
      unitRef="usd">1211000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjEtMy0xLTEtOTcyNzI_ee361b75-6eaf-4a8a-8d62-65af6edc3a3a"
      unitRef="usd">1179000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjItMS0xLTEtOTcyNzI_2ebcd722-83dc-42b1-8396-9280a6b29516"
      unitRef="usd">8177000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjItMy0xLTEtOTcyNzI_89c9df84-eb8b-478b-bd5f-c9496d193175"
      unitRef="usd">5678000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjMtMS0xLTEtOTcyNzI_ead25bba-f765-4cd8-b083-034d126edf44"
      unitRef="usd">27519000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjMtMy0xLTEtOTcyNzI_0e4db1fe-451d-4b40-90e0-17d542a005a6"
      unitRef="usd">24886000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjQtMS0xLTEtOTcyNzI_14e2d15d-4d74-4ec0-9c65-709c01c3113e"
      unitRef="usd">1949000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjQtMy0xLTEtOTcyNzI_d0508281-e40e-4763-ab35-91ba383d1291"
      unitRef="usd">18287000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjUtMS0xLTEtOTcyNzI_0bf418a4-b36a-449a-8da6-ddcbbfd459f6"
      unitRef="usd">6480000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjUtMy0xLTEtOTcyNzI_034e2cb6-eba3-46d5-a5e3-a0601bb9204d"
      unitRef="usd">6900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjYtMS0xLTEtOTcyNzI_f2146d19-7388-493f-91cb-021bef6302ac"
      unitRef="usd">614000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjYtMy0xLTEtOTcyNzI_ee6e1f4f-2ac8-43d7-847d-68aacbf987ce"
      unitRef="usd">635000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjctMS0xLTEtOTcyNzI_246a92df-9a95-47c6-94b7-2058c8cc7c2b"
      unitRef="usd">158000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjctMy0xLTEtOTcyNzI_81d5e07c-479f-4a60-98d6-bcd457a9572a"
      unitRef="usd">124000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjgtMS0xLTEtOTcyNzI_bca5ffed-5c93-41c0-b1c7-159622c1639c"
      unitRef="usd">36720000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjgtMy0xLTEtOTcyNzI_a0a2bf21-7ed6-4832-897b-b63ba4c3bde0"
      unitRef="usd">50832000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjktMS0xLTEtOTcyNzI_11b6ba62-7f4e-4f6a-87ba-c11d5c6c4835"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMjktMy0xLTEtOTcyNzI_8cd207af-34cd-407e-ae2f-8e33413d1c8f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN18yMQ_1a34b340-f152-43be-b3ae-2bcbe24d5006"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN18yMQ_51e5f927-ac3e-4392-9dc7-e9290a0abc7b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN180NQ_8e094fe9-1dd7-4f1c-aec0-d60bc5dd2169"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN180NQ_ef79770a-01da-46ae-a130-6009c908e6ad"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_513abd1e-909b-49a1-b570-62bb0ac7b876"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_532adf0c-dcb6-4e21-bb7a-8c18e617d71f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_96693a7a-0ad3-4c3b-a129-c603c4690479"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjo2ZDM4OWFlODEwMDI0OGJjYjgwYmQ3NzZjN2FkZmNjN184Mw_d0e0b7a6-c928-494b-90d0-cab65edbbb9f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMS0xLTEtOTcyNzI_b1afeb71-3c87-4669-8445-0d2b2c556a97"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzEtMy0xLTEtOTcyNzI_1cc20e3a-5d7c-4402-9811-42027b75a204"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV8xOA_15576ab2-0d2f-44e7-ada0-a7620748d9dc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV8xOA_9dca0291-8efd-4c88-94a4-bb5c35be0632"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV80Mg_13ace84f-58df-48db-8596-c7254d244429"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV80Mg_fe35eedb-009b-48d1-aef3-b75eae83fb53"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84MA_61e41eb1-6f57-4446-bead-9dd1c00b7836"
      unitRef="shares">26292299</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84MA_aade4747-24be-412f-abb5-ee36356172f8"
      unitRef="shares">26292299</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84Nw_b2f6765d-d85d-45c8-bee1-234811dd9f18"
      unitRef="shares">25378520</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMC0xLTEtOTcyNzIvdGV4dHJlZ2lvbjpjOGZiNGE1YWUyY2Q0MmRhODdmZTk4NzQ2NjIyOTQ5ZV84Nw_b84c6020-9295-42c1-a348-398f12164f21"
      unitRef="shares">25378520</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMS0xLTEtOTcyNzI_c478d4fd-b003-44c5-974a-76e38cf79784"
      unitRef="usd">26000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzItMy0xLTEtOTcyNzI_63882a3c-18e1-476a-8771-b3f8a2fce092"
      unitRef="usd">25000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzMtMS0xLTEtOTcyNzI_a096fc63-de9f-493b-aa3d-f5e6e69f962c"
      unitRef="usd">541672000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzMtMy0xLTEtOTcyNzI_bbffb025-f330-4857-8945-4014b75f3ae0"
      unitRef="usd">505482000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzQtMS0xLTEtOTcyNzI_a4c13c75-3061-4f68-b958-fea3ca0af839"
      unitRef="usd">-120038000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzQtMy0xLTEtOTcyNzI_963819d3-1581-48a3-b6d8-a783f202fd62"
      unitRef="usd">-93767000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzUtMS0xLTEtOTcyNzI_8f746c26-5cec-490b-94dd-36884d9a1ba9"
      unitRef="usd">421660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzUtMy0xLTEtOTcyNzI_5d0a5889-b3b4-4576-8e1b-10c483985708"
      unitRef="usd">411740000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzYtMS0xLTEtOTcyNzI_b8b82b22-f65e-4575-8dc1-8445fe50c603"
      unitRef="usd">458380000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNi9mcmFnOmE2ZTU1NDgwNjRiYzRjZWRiYTU5YzQ2YjU3YzhmZGRiL3RhYmxlOjMxZmFlM2EzNjQ3NjQ1YzNhYjczYzgwYWNlNDJiNGM3L3RhYmxlcmFuZ2U6MzFmYWUzYTM2NDc2NDVjM2FiNzNjODBhY2U0MmI0YzdfMzYtMy0xLTEtOTcyNzI_5d9616de-e21d-4fb9-9aed-cbce3814022e"
      unitRef="usd">462572000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi0xLTEtMS05NzI3Mg_4b31ec70-41bb-4edf-bfeb-195dbdc6f258"
      unitRef="usd">34838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi0zLTEtMS05NzI3Mg_028748cc-c257-4330-b404-54ccc57fa2fe"
      unitRef="usd">22758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi01LTEtMS05NzI3Mg_b25e576e-f52d-4061-9ebb-5b3ef0c567c3"
      unitRef="usd">61690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMi03LTEtMS05NzI3Mg_1810e0c7-70c5-454d-ac2c-f7e4f60c1108"
      unitRef="usd">45571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC0xLTEtMS05NzI3Mg_25c1bf50-7573-416d-a0e3-2f8ad5f470d2"
      unitRef="usd">7686000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC0zLTEtMS05NzI3Mg_0e10c08e-15d1-4a6c-84fd-1cfc4d7cfaaa"
      unitRef="usd">3697000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC01LTEtMS05NzI3Mg_0f9014b2-ca0e-4812-adc6-7498199b2bf3"
      unitRef="usd">13630000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNC03LTEtMS05NzI3Mg_8eff2236-6027-4663-bcbe-cf19999f76ee"
      unitRef="usd">6725000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS0xLTEtMS05NzI3Mg_d513c3f0-68ae-4f0b-9e42-612722491a69"
      unitRef="usd">11926000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS0zLTEtMS05NzI3Mg_143041e2-9c2f-4a9a-9983-0121526d6179"
      unitRef="usd">6793000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS01LTEtMS05NzI3Mg_9ee040a1-6973-46b0-baca-9f6fc3704ab6"
      unitRef="usd">22687000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNS03LTEtMS05NzI3Mg_49167a39-930c-4ebf-8c34-2844d7dbea3e"
      unitRef="usd">12701000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi0xLTEtMS05NzI3Mg_9c5a3408-876e-4d81-ac79-eedf5df478b8"
      unitRef="usd">37498000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi0zLTEtMS05NzI3Mg_c427f26c-a906-4cfb-8423-01cc09808ea2"
      unitRef="usd">20822000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi01LTEtMS05NzI3Mg_e94f1798-41f1-4664-b14e-e8126930e66f"
      unitRef="usd">67951000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNi03LTEtMS05NzI3Mg_14dcbc54-15e5-409b-ae6f-49aba3ac2b14"
      unitRef="usd">38983000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy0xLTEtMS05NzI3Mg_664e9b77-7ae5-41d6-a67c-655c6d33a54a"
      unitRef="usd">2097000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy0zLTEtMS05NzI3Mg_e415479d-6baa-4363-b70a-eb061f19ef60"
      unitRef="usd">256000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy01LTEtMS05NzI3Mg_35137fbc-bdc4-4f98-be15-4b237a17be0f"
      unitRef="usd">3745000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfNy03LTEtMS05NzI3Mg_7e0419e8-4500-4881-bd4b-894477a22030"
      unitRef="usd">256000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC0xLTEtMS05NzI3Mg_096cdceb-29a2-4e02-b1f4-c1b35f59d25e"
      unitRef="usd">-20398000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC0zLTEtMS05NzI3Mg_6b6f1ca3-00fa-45c6-b0cb-15676e923a5c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC01LTEtMS05NzU3NQ_96bcbcc1-cb6d-4440-95b9-e0fbd17315a1"
      unitRef="usd">-17836000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfOC03LTEtMS05NzU3NQ_7ade91f0-9f99-4a0f-a876-230c4bff479b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cstl:OperatingExpensesNetOfOtherOperatingIncome
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtMS0xLTEtOTcyNzI_26d5de2b-233f-4c03-9c3e-c7320bc54168"
      unitRef="usd">38809000</cstl:OperatingExpensesNetOfOtherOperatingIncome>
    <cstl:OperatingExpensesNetOfOtherOperatingIncome
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtMy0xLTEtOTcyNzI_4c6a694c-4516-4764-bba3-defc9f634f03"
      unitRef="usd">31568000</cstl:OperatingExpensesNetOfOtherOperatingIncome>
    <cstl:OperatingExpensesNetOfOtherOperatingIncome
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtNS0xLTEtOTcyNzI_29b07c1f-b800-4a18-804f-f9b41cc42b89"
      unitRef="usd">90177000</cstl:OperatingExpensesNetOfOtherOperatingIncome>
    <cstl:OperatingExpensesNetOfOtherOperatingIncome
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTAtNy0xLTEtOTcyNzI_c6bd860c-4515-4a7f-8f86-cf21496abf89"
      unitRef="usd">58665000</cstl:OperatingExpensesNetOfOtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtMS0xLTEtOTcyNzI_84a58e22-f948-4c95-9095-9c8eb4a2a0ad"
      unitRef="usd">-3971000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtMy0xLTEtOTcyNzI_67f90dc1-c7d3-4396-bfa1-bcd250f4d7f2"
      unitRef="usd">-8810000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtNS0xLTEtOTcyNzI_fe0ae596-3a7c-4ed5-bf4a-596e0da9b23b"
      unitRef="usd">-28487000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTEtNy0xLTEtOTcyNzI_8753ed63-1ed6-451c-a54d-0cc4bc2f9151"
      unitRef="usd">-13094000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItMS0xLTEtOTcyNzI_f85e04bb-aab6-4e2a-8d7c-fbf4493ee181"
      unitRef="usd">370000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItMy0xLTEtOTcyNzI_57c133ac-ef16-46eb-974d-e7e02c5aab0e"
      unitRef="usd">24000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItNS0xLTEtOTcyNzI_8f99110e-f32b-491f-b95d-5b2bb44b4b41"
      unitRef="usd">400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTItNy0xLTEtOTcyNzI_e3ae1e92-58e4-45fd-bea9-54a2f05923fc"
      unitRef="usd">28000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtMS0xLTEtOTcyNzI_106bf60d-ff7d-4a89-931c-f5b320757ff8"
      unitRef="usd">4000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtMy0xLTEtOTcyNzI_9ea9c228-e8ea-4450-8831-9991cf0b1901"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtNS0xLTEtOTcyNzI_a64294b6-6af7-4f03-a90d-f5b7cc33270e"
      unitRef="usd">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTMtNy0xLTEtOTcyNzI_e0f23689-9ca7-4796-b5d9-a9330983fa25"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtMS0xLTEtOTcyNzI_21315e98-c99f-4fae-ad42-31923b4f93de"
      unitRef="usd">-3605000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtMy0xLTEtOTcyNzI_ed4227ba-b004-450a-8db8-705adf0890c7"
      unitRef="usd">-8786000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtNS0xLTEtOTcyNzI_af8b1d65-c09f-4eed-9e3d-458dac4f3607"
      unitRef="usd">-28094000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTYtNy0xLTEtOTcyNzI_34652534-5be6-4206-92b5-35d964b5b3dc"
      unitRef="usd">-13066000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctMS0xLTEtOTcyNzI_d12fbbfc-efb4-461c-abbf-ce71e0151354"
      unitRef="usd">-1957000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctMy0xLTEtOTcyNzI_3b993e39-0683-4645-b139-8d212512568a"
      unitRef="usd">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctNS0xLTEtOTcyNzI_2862abae-3f8b-4490-a9ed-8a8ccfef42ca"
      unitRef="usd">-1823000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTctNy0xLTEtOTcyNzI_ecd9f29b-ed41-423f-b414-4699cd64ca5a"
      unitRef="usd">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMS0xLTEtOTcyNzI_e7b3e940-a1f9-4de0-b7c1-4a4bb4c514d5"
      unitRef="usd">-1648000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMS0xLTEtOTcyNzI_e9fa4b2d-c919-4d95-9303-da8b66cfd5b8"
      unitRef="usd">-1648000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMy0xLTEtOTcyNzI_544fc713-4277-4f49-928e-f3ef43dfed6b"
      unitRef="usd">-8791000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtMy0xLTEtOTcyNzI_fa7a3668-2fcc-4f16-8d38-4d6cd03121b7"
      unitRef="usd">-8791000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNS0xLTEtOTcyNzI_0b4df884-efd3-49b9-8260-74187429688d"
      unitRef="usd">-26271000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNS0xLTEtOTcyNzI_a02a867e-c8b7-44d5-bf44-ed66de306644"
      unitRef="usd">-26271000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNy0xLTEtOTcyNzI_4e5528ad-9830-4ea5-8105-120f4a61a27a"
      unitRef="usd">-13071000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMTgtNy0xLTEtOTcyNzI_743f789d-cc22-4253-89b5-72653e04d48e"
      unitRef="usd">-13071000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMS0xLTEtOTcyNzI_75724a60-75e6-4a85-a9d5-dc899e2a9fb5"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMS0xLTEtOTcyNzI_934df12d-3101-4444-9188-1cd0c3a5a91c"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMy0xLTEtOTcyNzI_005b3bf2-c88f-432b-a40e-9b95a6dcfa45"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtMy0xLTEtOTcyNzI_b497d8f4-e973-4380-9574-acd29b5ad046"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNS0xLTEtOTcyNzI_01c84a81-8a75-4510-a72e-381cac8849ad"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNS0xLTEtOTcyNzI_f9a29728-d2e5-4790-96ee-f89b4d7d653f"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNy0xLTEtOTcyNzI_1bdd3a6e-b40a-413b-864f-e5b45dd68023"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjQtNy0xLTEtOTcyNzI_f576ae70-5dbc-4dcd-a5ea-e335b76d11ff"
      unitRef="usdPerShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMS0xLTEtOTcyNzI_d60c3cd4-64e5-4b75-a937-10e7ada581f0"
      unitRef="shares">26064000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMS0xLTEtOTcyNzI_e7f2c821-3ba3-4351-ae19-f6c185e19abb"
      unitRef="shares">26064000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMy0xLTEtOTcyNzI_a5205ade-0b25-476a-bf3f-b6b13d37fb56"
      unitRef="shares">25091000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtMy0xLTEtOTcyNzI_e2ea7f3f-61a0-4cac-a2ad-4d9bb674dee1"
      unitRef="shares">25091000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNS0xLTEtOTcyNzI_4ab02432-4c67-4a25-8d0c-19b3083db651"
      unitRef="shares">25746000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNS0xLTEtOTcyNzI_a0903c81-9cef-4801-9c0c-fc387429df19"
      unitRef="shares">25746000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNy0xLTEtOTcyNzI_9dc071d1-a6a6-4552-ba1f-de60fffad1a2"
      unitRef="shares">25002000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xOS9mcmFnOjE1ZGQ0YTQ1NjE2MDRkMzBiNzViNzQ0NThkMTlkNDA5L3RhYmxlOjM2OWEwZWMwMDcxNjRiYjZiYWI4ZWU4MmE2ODkwOTk5L3RhYmxlcmFuZ2U6MzY5YTBlYzAwNzE2NGJiNmJhYjhlZTgyYTY4OTA5OTlfMjgtNy0xLTEtOTcyNzI_f49e0768-d172-4583-b519-40b6793249bd"
      unitRef="shares">25002000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="if579dae83b8c4e9985cc1382db6773cc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0yLTEtMS05NzI3Mg_e00b0827-8114-4128-8aaa-f54048b1f870"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if579dae83b8c4e9985cc1382db6773cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi00LTEtMS05NzI3Mg_480c88e0-2ac3-4c4f-9429-c45918e71715"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie43334b369424f43a0a7ff7c5379bfab_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi02LTEtMS05NzI3Mg_356bd882-765d-409a-b801-d4b41d30e948"
      unitRef="shares">24812487</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie43334b369424f43a0a7ff7c5379bfab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi04LTEtMS05NzI3Mg_20a3c5f1-5ebd-4107-a757-86a9f48dfaeb"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46c2daf116a748ca9d99a88a918f8a7a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0xMC0xLTEtOTcyNzI_b2654ba6-7427-48cd-b775-023933a63cd9"
      unitRef="usd">478162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97c57848b43a4b04908a15f751f228eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0xMi0xLTEtOTcyNzI_a941cafe-8331-45e5-888f-38d3747dbeae"
      unitRef="usd">-62496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55427030f29b4ec8919acde7614ce80a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMi0xNC0xLTEtOTcyNzI_00ac9ae1-cf0a-4b40-a93d-4e9ac83a08b6"
      unitRef="usd">415691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05142cc79cab4fe39aed0b747ac5ab72_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0xMi0xLTEtOTcyNzI_e37c3b06-a5c6-4d23-8290-f62260fdb4e5"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id7a028b432814c468151325be76f2288_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMy0xNC0xLTEtOTcyNzI_0d33faa0-c0c2-4094-9afd-40b537707de1"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNC0xMC0xLTEtOTcyNzI_63fe4cba-41a9-4674-aac1-bee578cc5b8f"
      unitRef="usd">4913000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNC0xNC0xLTEtOTcyNzI_3260e772-1989-4da5-8500-73719ece9173"
      unitRef="usd">4913000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i96d79afbe3db4e63a8376b96ad2c2a19_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNS02LTEtMS05NzI3Mg_07f075e6-15e4-4c3f-98c4-7bfd8c978704"
      unitRef="shares">171315</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNS0xMC0xLTEtOTcyNzI_629a52b9-c64c-455c-8d1e-1456ee24918c"
      unitRef="usd">991000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNS0xNC0xLTEtOTcyNzI_27c527d2-6723-4d9a-84d0-078387afb898"
      unitRef="usd">991000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i96d79afbe3db4e63a8376b96ad2c2a19_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNi02LTEtMS05NzI3Mg_cdf8d869-42d8-478f-9178-c850207e5f78"
      unitRef="shares">70711</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNi0xMC0xLTEtOTcyNzI_0f43c89c-4f80-4163-a0ad-f59058d2207c"
      unitRef="usd">1233000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNi0xNC0xLTEtOTcyNzI_43e139c0-768c-45e3-a22d-b12063b0312c"
      unitRef="usd">1233000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifad442a5ece94a9fb3c34ba88cf0280b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNy0xMC0xLTEtOTcyNzI_86fc4266-9c20-4cf7-ac17-92734a21133a"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfNy0xNC0xLTEtOTcyNzI_36c6f21d-7480-4a53-82b8-f0e86d8fa21d"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i4e07a9c7b20e45d8a34bc3494233bad0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOC0xMi0xLTEtOTcyNzI_09a8fdd9-f245-4fbf-885a-507212244d20"
      unitRef="usd">-4280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOC0xNC0xLTEtOTcyNzI_696d0397-d3cb-4823-b356-579543155ab1"
      unitRef="usd">-4280000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2db3849ecf344540b631208a8486e731_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0yLTEtMS05NzI3Mg_3f048d14-ba30-4e11-966b-4451c7479306"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2db3849ecf344540b631208a8486e731_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS00LTEtMS05NzI3Mg_76723820-470f-49a7-abcd-913fb64199f6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8aef283682a0409391f3889a859516ee_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS02LTEtMS05NzI3Mg_a4a64d56-e8c1-4e2d-a669-95340fec2e2a"
      unitRef="shares">25054513</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8aef283682a0409391f3889a859516ee_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS04LTEtMS05NzI3Mg_119b8e6d-2145-46d6-884c-bd48c7b95f78"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifcf5f2d1d61c4399a85c38536d1b5870_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0xMC0xLTEtOTcyNzI_b6defd01-42c6-4314-8525-1fb83a68f84c"
      unitRef="usd">485338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i10d8bc5806cc42a1a590de3ddefa542e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0xMi0xLTEtOTcyNzI_7456ca07-d8ea-4c86-a968-b3a2ee25f24a"
      unitRef="usd">-66755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if45b15080c9a490e9b40a981b88c2ab4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfOS0xNC0xLTEtOTcyNzI_30ac6357-96d8-4e1f-88fa-2fb12a3afb17"
      unitRef="usd">418608000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i00a350df83e449a7bfb41c9fa0e438df_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTAtMTAtMS0xLTk3Mjcy_c128e399-0416-4a38-9284-40acfa225461"
      unitRef="usd">4766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTAtMTQtMS0xLTk3Mjcy_4f02f117-0a14-49ac-a390-d620896d3d98"
      unitRef="usd">4766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief70ba11123c4a588f9021f36a8018f2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTEtNi0xLTEtOTcyNzI_8919ece4-cb44-49c4-b8d5-66869d9e269e"
      unitRef="shares">109540</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i00a350df83e449a7bfb41c9fa0e438df_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTEtMTAtMS0xLTk3Mjcy_d1db7c8e-1b19-4250-b7b7-70b5800f0e6a"
      unitRef="usd">1354000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTEtMTQtMS0xLTk3Mjcy_01aa73fe-d20e-4f02-b190-0baf31bfe4fc"
      unitRef="usd">1354000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="i4716841dad0e4b91aa853fdde46b4497_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTItMTItMS0xLTk3Mjcy_013f76af-ad4a-4032-a6eb-5c11b3d3a73f"
      unitRef="usd">-8791000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTItMTQtMS0xLTk3Mjcy_8a60d10e-f8f7-4275-935b-20b2ae6f44dc"
      unitRef="usd">-8791000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3ddcfe5a62234411adef323f129a9431_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMi0xLTEtOTcyNzI_789256f9-ef3a-4bb8-80e5-59680d52ccb0"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ddcfe5a62234411adef323f129a9431_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtNC0xLTEtOTcyNzI_39f0b03f-6d33-4351-9d83-52f2d7ba8239"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i876c6b7aacd34ac085dd8fed79a56ddc_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtNi0xLTEtOTcyNzI_650625df-e319-4e65-8ff2-dda4f8e07814"
      unitRef="shares">25164053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i876c6b7aacd34ac085dd8fed79a56ddc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtOC0xLTEtOTcyNzI_5505d753-20bb-4723-a962-476351b970ef"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6ba51b1cf454b719b762b76d13bee4f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMTAtMS0xLTk3Mjcy_1d4ade1b-96dd-424a-9473-3b78b9f5a781"
      unitRef="usd">491458000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4b43ea83fdf47bdaaabf1e474427f66_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMTItMS0xLTk3Mjcy_a5fcf826-42b8-4331-a5e3-a13663af2b98"
      unitRef="usd">-75546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMTMtMTQtMS0xLTk3Mjcy_d54bbad3-2f76-4776-863f-5de3b0bf4bcb"
      unitRef="usd">415937000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="idcb16faf4fb149658bbba1601aa0bbc7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMi0xLTEtOTcyNzI_07914f1c-bf60-4b02-bf5b-dbec370cf930"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idcb16faf4fb149658bbba1601aa0bbc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtNC0xLTEtOTcyNzI_8116cf76-1106-48ee-be50-66e9af0d888c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i50aac6883ff6400fa2cae1a080701556_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtNi0xLTEtOTcyNzI_0bee92be-5c22-4938-a06b-2172a9317187"
      unitRef="shares">25378520</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i50aac6883ff6400fa2cae1a080701556_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtOC0xLTEtOTcyNzI_f3eeb0ae-8618-4f78-abf3-aba3f3ac592b"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61d01d11a47442dd85ecf3c5da42e59c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMTAtMS0xLTk3Mjcy_7f073a84-9708-4d29-b7bd-d164628a2b82"
      unitRef="usd">505482000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie414d3b9f48f4a62b15be9a778052e3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMTItMS0xLTk3Mjcy_f57015e4-05f4-4d0a-9756-52c8e85cf852"
      unitRef="usd">-93767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjAtMTQtMS0xLTk3Mjcy_73e368b8-bd01-41dc-9768-ae31fd828753"
      unitRef="usd">411740000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjEtMTAtMS0xLTk3Mjcy_0b21c99d-b67a-4c8a-b6df-28e560552e70"
      unitRef="usd">8419000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjEtMTQtMS0xLTk3Mjcy_07add295-7882-470b-abbe-e6af29ab5637"
      unitRef="usd">8419000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjItNi0xLTEtOTcyNzI_4c861954-ffb6-40c1-9ae2-d96e9ea55251"
      unitRef="shares">62102</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjItMTAtMS0xLTk3Mjcy_3d21cb06-41d4-4be8-ae23-7caafc8f35f0"
      unitRef="usd">399000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjItMTQtMS0xLTk3Mjcy_34698128-1122-4426-8dce-34f43ec01a15"
      unitRef="usd">399000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjMtNi0xLTEtOTcyNzI_16e66d74-97b7-49b9-be4b-a2077d74f3a4"
      unitRef="shares">2466</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjMtMTAtMS0xLTk3Mjcy_1dcd0006-2160-4417-b922-71122551cdfe"
      unitRef="usd">-56000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjMtMTQtMS0xLTk3Mjcy_061575ee-cb31-4b60-838e-34b5c8b4f3d3"
      unitRef="usd">-56000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i38ff2b4382414415a2e958ab29aca692_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjQtNi0xLTEtOTcyNzI_1f19ac4b-14f3-49a1-aa66-5aec8a8588b4"
      unitRef="shares">42332</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i64651995ef994fb784afda58278f15c2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjQtMTAtMS0xLTk3Mjcy_2247abd0-ddf1-4d50-98a6-3f42900a0ca5"
      unitRef="usd">1457000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjQtMTQtMS0xLTk3Mjcy_50cee72d-48b2-48a7-bcbc-977990848942"
      unitRef="usd">1457000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i80d23ca5218f4f239df0df99e61be5fb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjUtMTItMS0xLTk3Mjcy_50e87af4-ea9f-4fc4-98d2-3e08034f467b"
      unitRef="usd">-24623000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia11bb88f5a0f4efc90dee4ae50d5a190_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjUtMTQtMS0xLTk3Mjcy_af3fbde9-b162-4f63-bb95-6fe20caa7951"
      unitRef="usd">-24623000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iff9ba1ac9bdc4a2f8c18d78ab64539ae_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMi0xLTEtOTcyNzI_8d6606ec-ed4f-404f-81da-84c2e6c5fe8e"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iff9ba1ac9bdc4a2f8c18d78ab64539ae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtNC0xLTEtOTcyNzI_ae6f01a3-c563-4857-9f8b-fd6aaf3e0ec7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5a71817e0bcd412b9689d66aaaede50c_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtNi0xLTEtOTcyNzI_9ac70376-523a-4a1f-b063-181cbc5821d6"
      unitRef="shares">25485420</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5a71817e0bcd412b9689d66aaaede50c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtOC0xLTEtOTcyNzI_97555af7-772d-4a21-84b0-abd3b96c77c8"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i519d138276e44889b2be7e9e5bda9d96_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMTAtMS0xLTk3Mjcy_647e35aa-8bd8-4ebd-8710-c9de45c4eeff"
      unitRef="usd">515701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i652198504ae942f4b9eb116281a3e9fc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMTItMS0xLTk3Mjcy_01cd3d4b-25f3-4d81-a27b-439242d0b6cd"
      unitRef="usd">-118390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie63ac35e1982419cab5b0e55ac7a9ec0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjYtMTQtMS0xLTk3Mjcy_7a8f1436-33f9-454c-8f2f-eb7367865701"
      unitRef="usd">397336000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjctMTAtMS0xLTk3NjU1_74921d30-de7b-4402-a5e2-7e369eeda2fe"
      unitRef="usd">8783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjctMTQtMS0xLTk3Mjcy_b8bb2060-cf8f-4b98-a5cd-67fb0af370d4"
      unitRef="usd">8783000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjgtNi0xLTEtOTc2NTU_68854356-3704-4571-8a47-2d146209fe2e"
      unitRef="shares">36634</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjgtMTAtMS0xLTk3NjU1_b71a1a48-4e82-4880-9831-6d642c1350c7"
      unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjgtMTQtMS0xLTk3Mjcy_d4d28267-feb4-4b12-b05f-296f1892c1c2"
      unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktNi0xLTEtOTc5MTI_4b0d3daa-26a7-4331-a80d-f87a80cb04a4"
      unitRef="shares">6358</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTAtMS0xLTk3OTEy_3bdeffc5-f0e7-4d09-a847-28db13e4e67d"
      unitRef="usd">-32000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTQtMS0xLTk3OTEy_6a54cf20-39ad-4103-8cbf-2462f68f8909"
      unitRef="usd">-32000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtNi0xLTEtMTA1NDU4_33c57653-d052-4616-a1fb-6abb60077f32"
      unitRef="shares">763887</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i4932efe78e004a3c86a8dbf8adb270ed_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtOC0xLTEtMTA1NDU4_a655673f-14f7-4d0d-956f-367d99fa68f8"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i991b6ac6b0534481b3f14bc0619076c2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTAtMS0xLTEwNTQ1OA_6f452276-245d-4c92-b5b4-690cf372bc48"
      unitRef="usd">17110000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTQtMS0xLTEwNTQ1OA_21fbd1e7-cfda-4540-b023-d3e6e6000d6e"
      unitRef="usd">17111000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NetIncomeLoss
      contextRef="i7cb246820c6d498e90a506f4b515e485_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTItMS0xLTk3NjU1_4c7cecf3-6a3f-4642-9c2a-2b85926688af"
      unitRef="usd">-1648000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMjktMTQtMS0xLTk3Mjcy_2c7a6740-d6d2-4781-8987-48dc07f9e7c4"
      unitRef="usd">-1648000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if188768c20ab47cdb0dff4b33bd0c0ff_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMi0xLTEtOTcyNzI_85c274f0-ee7f-448b-81b8-733ba83f8c75"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if188768c20ab47cdb0dff4b33bd0c0ff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtNC0xLTEtOTcyNzI_2f109050-db07-4100-a7da-2d199c5a83ff"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i34f5ad41aeed41b08758233329facba3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtNi0xLTEtOTcyNzI_3ad7a3ee-6937-4522-b6af-1fabae811afd"
      unitRef="shares">26292299</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i34f5ad41aeed41b08758233329facba3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtOC0xLTEtOTcyNzI_d4d26cad-3c57-4e85-9b17-9f669df285d3"
      unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5404bc6eaf484be4813006a731482c19_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTAtMS0xLTk3Mjcy_635c2b34-976e-4265-8688-932060e6307f"
      unitRef="usd">541672000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id85254eabd1f425ca0d60cbd627df78d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTItMS0xLTk3Mjcy_8aca9967-b8a8-4aa7-9f23-281564652b6b"
      unitRef="usd">-120038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yMi9mcmFnOmUzZDRlNzJlMzljMTRkYWY5MWU1MWYxMWM1MWRiYmRhL3RhYmxlOmUzMmZjN2M5MWE0ZDQ4NmJiYzgyY2IzY2I2ZTViYzYwL3RhYmxlcmFuZ2U6ZTMyZmM3YzkxYTRkNDg2YmJjODJjYjNjYjZlNWJjNjBfMzAtMTQtMS0xLTk3Mjcy_ad8c5b13-b457-4c48-8d69-c9a669acaacf"
      unitRef="usd">421660000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMy0xLTEtMS05NzI3Mg_67a7a12e-79d4-4ad3-97eb-698b2b4c37f2"
      unitRef="usd">-26271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMy0zLTEtMS05NzI3Mg_4cb8ff34-57fc-46c1-8c12-9fa3e287c1e8"
      unitRef="usd">-13071000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNS0xLTEtMS05NzI3Mg_e2bff59f-ae74-4dd2-9938-b0fe8761b3cb"
      unitRef="usd">4779000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNS0zLTEtMS05NzI3Mg_e571fcbc-ebee-46c3-afac-c2f12fd2dd31"
      unitRef="usd">867000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNi0xLTEtMS05NzI3Mg_cfe4f5d6-dd9f-42bb-a71a-c55d29e90a84"
      unitRef="usd">17202000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNi0zLTEtMS05NzI3Mg_5691de0c-ea66-4a7f-8d7f-c55896a10f1d"
      unitRef="usd">9679000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNy0xLTEtMS05NzI3Mg_9934f143-ee5a-4f24-b24a-670e7606ef74"
      unitRef="usd">-17836000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNy0zLTEtMS05NzI3Mg_5a4a08ab-6cea-4db0-82f1-ea721f467e5f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOC0xLTEtMS05NzI3Mg_b65e7b41-5cc1-4491-bbce-71ed8655542a"
      unitRef="usd">-1839000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOC0zLTEtMS05NzI3Mg_4773536f-7862-4d48-b975-89af2d975fd9"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOS0xLTEtMS05NzI3Mg_255b6577-ab19-45f2-b3a6-0a2d5b8347f9"
      unitRef="usd">-39000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfOS0zLTEtMS05NzI3Mg_ee360257-1927-4e10-a996-91bd2b0cd0b6"
      unitRef="usd">-69000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTEtMS0xLTEtOTcyNzI_e5670441-4da8-4144-afc3-c02a2923f7f8"
      unitRef="usd">5628000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTEtMy0xLTEtOTcyNzI_a4966459-5726-4de3-9625-e3baa8503c21"
      unitRef="usd">5275000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTItMS0xLTEtOTcyNzI_6ef08f6d-35b5-463e-9264-5b6b5bd4dc9f"
      unitRef="usd">707000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTItMy0xLTEtOTcyNzI_a7b627fc-ae95-478b-bfa2-a7799ae9399b"
      unitRef="usd">-1347000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTMtMS0xLTEtOTcyNzI_ce61e9b3-b736-410e-bf10-d85874ed78de"
      unitRef="usd">1066000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTMtMy0xLTEtOTcyNzI_41b6960e-f544-4f40-a489-7f4d04bb1b14"
      unitRef="usd">-223000</us-gaap:IncreaseDecreaseInInventories>
    <cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTQtMS0xLTEtOTcyNzI_d823ee5d-5375-4a2d-8875-37ed70c0023b"
      unitRef="usd">-437000</cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTQtMy0xLTEtOTcyNzI_3170d97f-6baf-43cd-8004-c552bfa40a2f"
      unitRef="usd">-462000</cstl:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTUtMS0xLTEtOTcyNzI_c9986162-0583-42f5-9444-d171582c0387"
      unitRef="usd">-504000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTUtMy0xLTEtOTcyNzI_f7a71820-af60-4159-97f8-561c955075ae"
      unitRef="usd">95000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTYtMS0xLTEtOTcyNzI_02676e2b-e326-4c29-a986-66c71f56f530"
      unitRef="usd">302000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTYtMy0xLTEtOTcyNzI_7f34ebd1-9169-40d9-9ecd-f198cac3b3a6"
      unitRef="usd">-683000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTctMS0xLTEtOTcyNzI_0191f0a8-909d-46e6-a326-bd5ec7efbad6"
      unitRef="usd">-445000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTctMy0xLTEtOTcyNzI_4c9a69dd-7302-4fd2-8d31-1faf71b7f586"
      unitRef="usd">-590000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTgtMS0xLTEtOTcyNzI_e5c2a3c6-5b86-4f5d-88e1-f4b7aae91306"
      unitRef="usd">-1013000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTgtMy0xLTEtOTcyNzI_96b16571-8b41-47d6-8a40-0db6f4c59ca2"
      unitRef="usd">-523000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTktMS0xLTEtOTcyNzI_311a9584-3af8-4f0f-950a-42be23c28f93"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMTktMy0xLTEtOTcyNzI_ba278d07-56d7-4bfb-a58c-b08878d0357d"
      unitRef="usd">-2173000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjAtMS0xLTEtOTcyNzI_f6bb1682-6dee-41b9-b8d6-2be5b66607d4"
      unitRef="usd">1111000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjAtMy0xLTEtOTcyNzI_c89d3ef9-ed85-402e-9488-53eecca9d847"
      unitRef="usd">-306000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjItMS0xLTEtOTcyNzI_cdb12ef2-45d2-4ec9-beeb-97eecd28e4c1"
      unitRef="usd">-30431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjItMy0xLTEtOTcyNzI_29d7b6a8-d9d2-43a2-9fb6-0ca268d096ca"
      unitRef="usd">-10069000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjUtMS0xLTEtOTcyNzI_d4e886b0-b279-485e-9900-9fd8c9eb2f6c"
      unitRef="usd">1807000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjUtMy0xLTEtOTcyNzI_b0158045-9864-401b-b2ff-33737eb12cfd"
      unitRef="usd">1663000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cstl:ProceedsFromPreviousAssetAcquisition
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjYtMS0xLTEtOTcyNzI_6153c873-5a64-4d70-ae8c-97e911807458"
      unitRef="usd">547000</cstl:ProceedsFromPreviousAssetAcquisition>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjYtMy0xLTEtOTcyNzI_0e443d74-bf7f-45db-b923-2f492c5ed471"
      unitRef="usd">33184000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMS0xLTEtMTA2MjY4_85a66587-300e-4db8-9bf0-ad6ee83d6a19"
      unitRef="usd">26661000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMy0xLTEtMTA2MjY4_962f01cd-a691-4e47-b127-c6dc352a8456"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMS0xLTEtOTcyNzI_9de5f30b-ac40-4637-abfa-a7a3f3ccf75c"
      unitRef="usd">8000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjctMy0xLTEtOTcyNzI_3db74641-a090-42bb-8800-7bb0c0ae75dc"
      unitRef="usd">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjktMS0xLTEtOTcyNzI_283746ef-ed99-4160-b879-81c0ee73c966"
      unitRef="usd">-27913000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMjktMy0xLTEtOTcyNzI_c9fc976f-9f74-4154-96b7-6ea41416ad7a"
      unitRef="usd">-34845000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzItMS0xLTEtOTcyNzI_d05adcb6-fbd9-4d2e-b7d1-5474919b394d"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzItMy0xLTEtOTcyNzI_d407568f-1176-4c65-a18f-e30c11b8a907"
      unitRef="usd">336000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzMtMS0xLTEtOTcyNzI_f832cc86-686e-4214-bc9b-c718948795bb"
      unitRef="usd">509000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzMtMy0xLTEtOTcyNzI_d8d4f580-861a-4b4b-be78-5bffdbf5ece8"
      unitRef="usd">2345000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzQtMS0xLTEtOTcyNzI_32640bcc-aa89-4ddf-a2b2-9e6e0e536e69"
      unitRef="usd">88000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzQtMy0xLTEtOTcyNzI_dadea61f-ef32-493a-ad29-0b16e093bf8d"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzUtMS0xLTEtOTcyNzI_d291aeb1-450a-407d-bd93-4a3928f5cfaf"
      unitRef="usd">1511000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzUtMy0xLTEtOTcyNzI_94a1cfaf-7143-4c71-b0da-25d5848d05f6"
      unitRef="usd">1392000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzYtMS0xLTEtOTcyNzI_6541188f-353f-4fb5-b686-7b26f3ba8672"
      unitRef="usd">55000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzYtMy0xLTEtOTcyNzI_524033cd-c515-4ad2-a2a6-59d7ef593d95"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzctMS0xLTEtOTcyNzI_df73183f-ffb5-4cd6-bddc-1cee85b3d86d"
      unitRef="usd">1877000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzctMy0xLTEtOTcyNzI_7f14eba5-3aed-4333-bda5-ee609c242f3e"
      unitRef="usd">3401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzktMS0xLTEtOTcyNzI_66f0956e-8710-40f0-83c9-cef4772c0af5"
      unitRef="usd">-56467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfMzktMy0xLTEtOTcyNzI_bec5eb88-7b36-4f47-8c92-f5c0d802d81b"
      unitRef="usd">-41513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDAtMS0xLTEtOTcyNzI_c1c3253a-aa42-4c9d-8066-33dccc5c6335"
      unitRef="usd">329633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55427030f29b4ec8919acde7614ce80a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDAtMy0xLTEtOTcyNzI_83896cf6-06a9-4296-877c-88d1df8796e1"
      unitRef="usd">409852000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDEtMS0xLTEtOTcyNzI_1155b617-e06e-4625-85e5-6809d7ca497f"
      unitRef="usd">273166000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDEtMy0xLTEtOTcyNzI_cfe0a41f-ab2e-41ec-8051-d8c9b125b099"
      unitRef="usd">368339000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDQtMS0xLTEtOTcyNzI_b71e153e-a56c-44d2-a826-58852d61e264"
      unitRef="usd">696000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDQtMy0xLTEtOTcyNzI_a1f9c588-ac29-4154-81f4-a05823303e8f"
      unitRef="usd">3000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDYtMS0xLTEtMTA2Mjk4_b1044b6a-9570-4539-9cfc-d7544f24f17a"
      unitRef="usd">17111000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDYtMy0xLTEtMTA2MzAx_cc42ffa8-4ad6-4e5e-beaa-fa5044d9f36d"
      unitRef="usd">0</us-gaap:StockIssued1>
    <cstl:BusinessCombinationNoncashContingentConsiderationGiven
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDctMS0xLTEtMTA2OTcw_badbb260-f81f-43e6-a75a-1b14467a0f27"
      unitRef="usd">1528000</cstl:BusinessCombinationNoncashContingentConsiderationGiven>
    <cstl:BusinessCombinationNoncashContingentConsiderationGiven
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDctMy0xLTEtMTA2OTcw_d3408903-618b-4bc3-b9b3-cb7d26e933d2"
      unitRef="usd">0</cstl:BusinessCombinationNoncashContingentConsiderationGiven>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDgtMS0xLTEtMTA2OTcw_ad7d8e4d-8782-4da7-b5f9-9485ad68d0fc"
      unitRef="usd">313000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8yNS9mcmFnOmFmZjMzZjBlODFjZjRhYmViYTlkMzNjNGY1ZjZkYzdmL3RhYmxlOmVkOGE1YTQ0OWZmNjQ1MmQ4NzA1YmM5MDZjNmExMzA1L3RhYmxlcmFuZ2U6ZWQ4YTVhNDQ5ZmY2NDUyZDg3MDViYzkwNmM2YTEzMDVfNDgtMy0xLTEtMTA2OTcw_729c4583-194b-486d-8007-b93bdffc1540"
      unitRef="usd">0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zMS9mcmFnOjE1MGEzZmEyNmYxZjRiODQ5NWQ0YjFhZTEyMzNhYWU0L3RleHRyZWdpb246MTUwYTNmYTI2ZjFmNGI4NDk1ZDRiMWFlMTIzM2FhZTRfMTI4OA_b1460e9a-f4f4-431c-bea0-c0baf4d2f8af">Organization and Description of Business&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Castle Biosciences, Inc. (the &#x2018;&#x2018;Company,&#x2019;&#x2019; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve health outcomes. We are based in Friendswood, Texas (a suburb of Houston, Texas) and our laboratory operations are conducted at our facilities located in Phoenix, Arizona, Pittsburgh, Pennsylvania and San Diego, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impact of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the COVID-19 pandemic began in March 2020, we have maintained uninterrupted business operations with no interruption in turnaround times for delivery of test reports, but we have experienced declines in test report volume in certain periods, which we believe is linked to delays and/or cancellations in patient visits in response to COVID-19, resulting in reduced diagnostic biopsies and thus reduced diagnoses of cutaneous melanoma and test reports attributable to our lead product, DecisionDx&#xae;-Melanoma, a test for cutaneous melanoma. The extent to which COVID-19 may further impact our business, consolidated results of operations, consolidated financial condition and consolidated cash flows will depend on future developments, which are highly uncertain and cannot be predicted with confidence.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTE0MQ_0837339e-5764-4f54-ba49-972bbdf28a2d">Summary of Significant Accounting Policies&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unaudited condensed consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x2018;&#x2018;U.S. GAAP&#x2019;&#x2019;). All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated balance sheet as of&#160;June&#160;30, 2022; the condensed consolidated statements of operations and comprehensive loss, the condensed consolidated statements of stockholders&#x2019; equity for the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021; and the condensed consolidated statements of cash flows for the&#160;six&#160;months ended&#160;June&#160;30, 2022&#160;and&#160;2021&#160;are unaudited. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of our consolidated financial position as of&#160;June&#160;30, 2022, the results of our consolidated operations for the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021 and our consolidated cash flows for the&#160;six&#160;months ended&#160;June&#160;30, 2022&#160;and&#160;2021. The financial data and other information disclosed in these notes related to the three and six months ended&#160;June&#160;30, 2022&#160;and&#160;2021&#160;are also unaudited. The results for the three and six months ended June&#160;30, 2022&#160;are not necessarily indicative of results to be expected for the year ending&#160;December&#160;31, 2022, any other interim periods, or any future year or period. The balance sheet as of&#160;December&#160;31, 2021&#160;included herein was derived from the audited financial statements as of that date. Certain disclosures have been condensed or omitted from the unaudited interim consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021 filed with the Securities and Exchange Commission on February 28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents including Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;), that are primarily invested in short-term U.S. government obligations. Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized in accordance with Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;) Accounting Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x2018;&#x2018;ASC 606&#x2019;&#x2019;). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration. See Note 3 for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as noncurrent assets. The estimated timing of payment utilized as a basis for classification as noncurrent is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers&#x2019; financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of June&#160;30, 2022, and December&#160;31, 2021. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. In accordance with ASC Topic 350,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that it may be impaired. We perform annual impairment reviews of our goodwill balance during the fourth quarter of each year. We may perform a qualitative assessment to determine if it is necessary to perform a quantitative impairment test. If we determine that a quantitative impairment test is necessary, we apply the guidance in Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, by comparing the fair value of the reporting unit to its carrying value, including the goodwill. If the carrying value exceeds the fair value, we recognize an impairment loss for the amount by which the carrying value exceeds fair value, up to the total amount of goodwill allocated to the reporting unit. We did not incur any goodwill impairment losses in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess acquisitions under ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (&#x201c;ASC 805&#x201d;) to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, in accordance with ASC 805, contingent consideration is recorded at fair value as of the acquisition date and classified as liabilities or equity based on applicable U.S. GAAP. For contingent consideration classified as liabilities, we remeasure the contingent consideration at fair value each period with changes in fair value recorded in the statements of operations and comprehensive loss each period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration in transactions that are not business combinations, we apply applicable U.S. GAAP. With respect to the additional consideration that may be payable in connection with the acquisitions of Cernostics, Inc. (&#x201c;Cernostics&#x201d;), an asset acquisition we completed on December 3, 2021, we account for the contingent consideration as a liability in accordance with ASC Topic 480,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration is classified as current or noncurrent in our condensed consolidated balance sheets based on the contractual timing of future settlement. For additional information on contingent consideration, see Notes 5 and 10.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. Our board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of June&#160;30, 2022 and December&#160;31, 2021, we accrued $9,835,000 and $12,071,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the condensed consolidated balance sheets based on the expected timing of payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive loss was the same as our reported net loss for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyMg_1e717b88-88e8-4f53-97bd-e83b4de47c99">Our unaudited condensed consolidated financial statements include the accounts of Castle Biosciences, Inc. and our wholly owned subsidiaries and have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x2018;&#x2018;U.S. GAAP&#x2019;&#x2019;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyNQ_32267c9f-ebe2-407d-b003-c46e0dc51a44">All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzMw_bc2f7308-b9bc-4bbd-aebf-cd1c73d864ab">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets, the valuation of contingent consideration and other contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzOA_bd256b83-ebd5-461e-83cf-b6df18c41291">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less. Our cash equivalents consist of money market funds, which are not insured by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;), that are primarily invested in short-term U.S. government obligations.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTExOQ_ddd872e8-a03a-4b5f-a148-e4bcc569f215">Cash deposits at financial institutions may exceed the amount of insurance provided by the FDIC. Management believes that we are not exposed to significant credit risk on our cash deposits due to the financial position of the institutions in which deposits are held. We have not experienced any losses on our cash or cash equivalents.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyOQ_7a0b49a9-8b88-478f-ad07-933fda2082b0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized in accordance with Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;) Accounting Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;(&#x2018;&#x2018;ASC 606&#x2019;&#x2019;). In accordance with ASC 606, we follow a five-step process to recognize revenues: (1) identify the contract with the customer, (2) identify the performance obligations, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations and (5) recognize revenues when the performance obligations are satisfied. We have determined that we have a contract with the patient when the treating clinician orders the test. Our contracts generally contain a single performance obligation, which is the delivery of the test report, and we satisfy our performance obligation at a point in time upon the delivery of the test report to the treating physician, at which point we can bill for the report. The amount of revenue recognized reflects the amount of consideration to which we expect to be entitled, or the transaction price, and considers the effects of variable consideration.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyMA_c95fef6e-5eb7-40d8-8ac1-323c98e6d9c5">We classify accounts receivable balances that are expected to be paid more than one year from the consolidated balance sheet date as noncurrent assets. The estimated timing of payment utilized as a basis for classification as noncurrent is determined by analyses of historical payor-specific payment experience, adjusted for known factors that are expected to change the timing of future payments.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzMA_e7c86523-1a23-4fd3-aa83-baeb363778db">We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of customers&#x2019; financial condition and generally do not require collateral. Historically, our credit losses have not been significant. The allowance for credit losses was zero as of June&#160;30, 2022, and December&#160;31, 2021. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNjg1Ng_621e940a-27d9-431b-b9de-f64c1b5aae2c"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNjg1Ng_98778528-98ad-4a0f-9b44-8284761a183e"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNjU5NzA2OTc4NzEzMQ_e4703278-89d5-4b6e-9b68-3038c5d5b5a9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. In accordance with ASC Topic 350,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles&#x2014;Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, our goodwill is not amortized but is tested for impairment on an annual basis or whenever events or changes in circumstances indicate that it may be impaired. We perform annual impairment reviews of our goodwill balance during the fourth quarter of each year. We may perform a qualitative assessment to determine if it is necessary to perform a quantitative impairment test. If we determine that a quantitative impairment test is necessary, we apply the guidance in Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, by comparing the fair value of the reporting unit to its carrying value, including the goodwill. If the carrying value exceeds the fair value, we recognize an impairment loss for the amount by which the carrying value exceeds fair value, up to the total amount of goodwill allocated to the reporting unit. We did not incur any goodwill impairment losses in any of the periods presented.&lt;/span&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_0302bc45-b05f-419d-bed7-38b0c0aeb383"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_7b66858e-d23f-4817-b968-6c786e7ec452"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_d567d600-23cc-4719-b7bf-39ba3371ffea"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfNDM5ODA0NjUzNDc2NA_ec4d5509-1961-4ddd-9680-7ad474b0964b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <cstl:BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEzMg_437abe9d-f465-4cb7-ab54-62638240dd0a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess acquisitions under ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (&#x201c;ASC 805&#x201d;) to determine whether a transaction represents the acquisition of assets or a business combination. Under this guidance, we apply a two-step model. The first step involves a screening test where we evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single asset or a group of similar assets. If the screening test is met, we account for the set as an asset acquisition. If the screening test is not met, we apply the second step of the model to determine if the set meets the definition of a business based on the guidance in ASC 805. If so, the transaction is treated as a business combination. Otherwise, it is treated as an asset acquisition. Asset acquisitions are accounted for by allocating the cost of the acquisition, including transaction costs, to the individual assets acquired and liabilities assumed on a relative fair value basis without recognition of goodwill. Business combinations are accounted for using the acquisition method. Under the acquisition method, goodwill is measured as a residual &lt;/span&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amount equal to the fair value of the consideration transferred less the net recognized fair value of the identifiable assets acquired and the liabilities assumed, as of the acquisition date, and transaction costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of business combinations or asset acquisitions, we may be required to pay additional consideration if specified future events occur or if certain conditions are met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a business combination, in accordance with ASC 805, contingent consideration is recorded at fair value as of the acquisition date and classified as liabilities or equity based on applicable U.S. GAAP. For contingent consideration classified as liabilities, we remeasure the contingent consideration at fair value each period with changes in fair value recorded in the statements of operations and comprehensive loss each period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration in transactions that are not business combinations, we apply applicable U.S. GAAP. With respect to the additional consideration that may be payable in connection with the acquisitions of Cernostics, Inc. (&#x201c;Cernostics&#x201d;), an asset acquisition we completed on December 3, 2021, we account for the contingent consideration as a liability in accordance with ASC Topic 480,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;), under the guidance for obligations that must or may be settled by issuance of a variable number of shares. In accordance with ASC 480, we record the contingent consideration initially and subsequently at fair value with changes in fair value recorded in the statements of operations and comprehensive loss each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration is classified as current or noncurrent in our condensed consolidated balance sheets based on the contractual timing of future settlement. For additional information on contingent consideration, see Notes 5 and 10.&lt;/span&gt;&lt;/div&gt;</cstl:BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTEyMw_4aa71561-cf42-4827-bedb-b50363571c87">We accrue for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by our board of directors, compensation levels of eligible individuals, and target bonus percentage levels. Our board of directors reviews and evaluates the performance against these objectives and ultimately determines what discretionary payments are made. We also accrue for liabilities under employee sales incentive bonus plans with accruals based on performance achieved to date compared to established targets. As of June&#160;30, 2022 and December&#160;31, 2021, we accrued $9,835,000 and $12,071,000, respectively, for liabilities associated with these bonus plans. These amounts are classified as current or noncurrent accrued liabilities in the condensed consolidated balance sheets based on the expected timing of payment.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfODYzMg_926c0c2f-d482-4158-acdb-e4ffbdbacf91"
      unitRef="usd">9835000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfODYzOQ_b15a9e9e-b9c6-481e-8932-b28f0002b21e"
      unitRef="usd">12071000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNC9mcmFnOmU3ZTY4NDY2MzU5ZjRjOTFiZjE5MWZiYTg0Njk1ZjBkL3RleHRyZWdpb246ZTdlNjg0NjYzNTlmNGM5MWJmMTkxZmJhODQ2OTVmMGRfOTE0MA_487c3f6e-80c4-49e1-92d1-a9a5f8336def">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNzQzMA_794166e5-0cd1-4e11-b214-5a129a05e499">Revenue&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;All of our revenues from contracts with customers are associated with the provision of diagnostic and prognostic testing services. Most of our revenues are attributable to our DecisionDx&#xae;-Melanoma test for cutaneous melanoma. We also provide a test for uveal melanoma, DecisionDx&#xae;-UM, a test for patients with cutaneous squamous cell carcinoma, DecisionDx&#xae;-SCC, two tests for use in patients with suspicious pigmented lesions, MyPath&#xae; Melanoma and DiffDx&#xae;-Melanoma, and a test for patients diagnosed with Barrett&#x2019;s esophagus (&#x201c;BE&#x201d;), the TissueCypher&#xae; Barrett&#x2019;s Esophagus Assay. We also began offering a pharmacogenomics (&#x201c;PGx&#x201d;) testing service focused on mental health, IDgenetix&#xae;, following a business combination completed in April 2022. Information on the disaggregation of revenues is included below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once we satisfy our performance obligations and bill for the service, the timing of the collection of payments may vary based on the payment practices of the third-party payor and the existence of contractually established reimbursement rates. Most of the payments for our services are made by third-party payors, including Medicare and commercial health insurance carriers. Certain contracts contain a contractual commitment of a reimbursement rate that differs from our list prices. However, absent a positive coverage policy, with or without a contractually committed reimbursement rate, with a commercial carrier or governmental program, our diagnostic tests may or may not be paid by these entities. In addition, patients do not enter into direct agreements with us that commit them to pay any portion of the cost of the tests in the event that their insurance provider declines to reimburse us. We may pursue, on a case-by-case basis, reimbursement from such patients in the form of co-payments and co-insurance, in accordance with the contractual obligations that we have with the insurance carrier or health plan. These situations may result in a delay in the collection of payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare claims that are covered by policy under a Local Coverage Determination (&#x201c;LCD&#x201d;) or otherwise are generally paid at a rate established on Medicare&#x2019;s Clinical Laboratory Fee Schedule or by the respective Medicare contractor within 30 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;days from receipt. Medicare claims that were either submitted to Medicare prior to the LCD or other coverage commencement date or are not covered but meet the definition of being medically reasonable and necessary pursuant to the controlling Section 1862(a)(1)(A) of the Social Security Act are generally appealed and may ultimately be paid at the first (termed &#x2018;&#x2018;redetermination&#x2019;&#x2019;), second (termed &#x2018;&#x2018;reconsideration&#x2019;&#x2019;) or third level of appeal (de novo hearing with an Administrative Law Judge (&#x201c;ALJ&#x201d;)). A successful appeal at any of these levels may result in prompt payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of LCD coverage, contractually established reimbursements rates or other coverage, we have concluded that our contracts include variable consideration because the amounts paid by Medicare or commercial health insurance carriers may be paid at less than our standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration attributable to these price concessions is measured at the expected value using the &#x2018;&#x2018;most likely amount&#x2019;&#x2019; method under ASC 606. The amounts are determined by historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties. Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. Variable consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in the absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Variable consideration for Medicare claims that are not covered by an LCD or otherwise, including those claims undergoing appeal, is deemed to be fully constrained due to factors outside our influence (e.g., judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time. Variable consideration is evaluated each reporting period and adjustments are recorded as increases or decreases in revenues. Included in revenues for the three months ended June 30, 2022 and 2021 were $578,000 and $(166,000), respectively, of net positive (negative) revenue adjustments associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. Such amounts of variable consideration for the six months ended June 30, 2022 and 2021 were $(300,000) and $5,092,000, respectively, of net (negative) positive revenue adjustments. These amounts include (i) adjustments for actual collections versus estimated amounts and (ii) cash collections and the related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of our contracts. Contract balances consisted solely of accounts receivable (both current and noncurrent) as of June&#160;30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the disaggregation of revenue by type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dermatologic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Payor Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our diagnostic and prognostic tests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(current)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(noncurrent)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BlueCross BlueShield plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <cstl:ContractWithCustomerCustomerPaymentTerms
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfMjI2NA_92b7627c-8778-4d78-8377-d8fd44b57636">P30D</cstl:ContractWithCustomerCustomerPaymentTerms>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNDg3NQ_53fbf0ed-0dba-40b4-934e-c1b81ac524a1"
      unitRef="usd">578000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNDg4Mg_4a77f1b8-d97f-4eef-89b1-6e66012f7e86"
      unitRef="usd">-166000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfMTA5OTUxMTYzNjYwOA_49badc8d-670f-49fd-ad77-33f14a4d667c"
      unitRef="usd">-300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfMTA5OTUxMTYzNjYyMQ_d4d9e85a-2155-45a5-8501-a845df80e110"
      unitRef="usd">5092000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNzQzMQ_05874ef0-9971-420c-9c36-2401fafebbff">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the disaggregation of revenue by type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dermatologic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb5cf2e6b2e24c06be4b1939e1daf492_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0xLTEtMS05ODAyOQ_125570a3-dddc-459c-9121-4a433bf56a17"
      unitRef="usd">31897000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fa26bc228544c24a0666ef5b1bd5976_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0zLTEtMS05ODAyOQ_b6f919ef-b297-4b42-ae76-d99184e19216"
      unitRef="usd">20378000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f9947a18f7d40039c6b420a80007dba_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0xLTEtMS05NzI3Mg_0619c80f-4add-4144-87a2-f4050c17a1d3"
      unitRef="usd">56236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia03e51765e914b8a9011d48a1ca77348_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMi0zLTEtMS05NzI3Mg_231e7ed3-e853-4525-8728-4bc885516af1"
      unitRef="usd">41288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8336c818a9d24de1b01f985248828ffd_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0xLTEtMS05ODAyOQ_3a7e138f-a53d-4d01-9f10-784cc56d76c1"
      unitRef="usd">2941000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i131a7e641770456ba0f7359e16012f93_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0zLTEtMS05ODAyOQ_82a7f983-134e-4dc2-a511-21ec30c3567b"
      unitRef="usd">2380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i743fbc9ec6194ca792d7d9caf96f471a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0xLTEtMS05NzI3Mg_2b51ba1d-cd45-4ec1-b661-60c36a79e2be"
      unitRef="usd">5454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0183c80be36439e982930171a859a72_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfMy0zLTEtMS05NzI3Mg_c7cb25c7-f52a-4c8f-bf10-a463b2ae1e28"
      unitRef="usd">4283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0xLTEtMS05ODAyOQ_e7959d99-9ba6-4008-89a6-59d49985bf06"
      unitRef="usd">34838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0zLTEtMS05ODAyOQ_ccc6111a-77cc-4822-b23b-2d283633c0aa"
      unitRef="usd">22758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0xLTEtMS05NzI3Mg_091d6816-cb12-4151-9cb6-70af51bcc5e6"
      unitRef="usd">61690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjNjMzBmNmM5NmRmODRlMmRhNzBhNzNhZDcxOWY5N2M0L3RhYmxlcmFuZ2U6M2MzMGY2Yzk2ZGY4NGUyZGE3MGE3M2FkNzE5Zjk3YzRfNC0zLTEtMS05NzI3Mg_8e7606fd-f109-4603-8078-38434526ac9e"
      unitRef="usd">45571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RleHRyZWdpb246MTNmOGY4ZTU1YzdiNGI0OWFjODIxNWFmYjgxODc4M2JfNzQzMg_373c35e3-04c9-4762-8b73-67a2ba9cce0c">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(current)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(noncurrent)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BlueCross BlueShield plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia301a48e31e3464b850d1a0710a2fb2e_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy0xLTEtMS05NzI3Mg_fb4f5e1e-0ee6-4640-811f-3862362f4603"
      unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb4d6409a095497989a2cb7fb57c9812_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy0zLTEtMS05NzI3Mg_ec1f3e25-40a9-4a13-aa7b-c6c3b636bd7f"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05824dd7aebb44438f53e1deb76ad500_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy01LTEtMS05NzI3Mg_75bcde44-de3d-40f9-ae22-df3969ae7b34"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i94472029ae74477fb2fffb4ece2766a6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy03LTEtMS05NzI3Mg_f208846f-7dd8-4c28-8324-9f02700c5336"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i323f1187bec8480581a9940120e35818_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy05LTEtMS05NzI3Mg_c7d9ec0c-1b62-4553-8acf-96ec82253c06"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4fb78aa5b5c14c7cad3c10b3fed78ccd_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfMy0xMS0xLTEtOTcyNzI_d11a4f04-86b1-4c35-8907-9fbdbcd5cfb6"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8aeb153e06f4174a607042caec7e398_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC0xLTEtMS05NzI3Mg_1e631a25-b48f-4fc7-b4b9-90ec76e6405d"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8f647f897a49453e97a9bc858216da0d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC0zLTEtMS05NzI3Mg_679ad0ba-8aeb-4884-bf7b-adc138441093"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8647297e768439fa24eb3a61573953f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC01LTEtMS05NzI3Mg_a9ee5a5b-c910-4b70-9f8b-a2880976084e"
      unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifdf616ceceff4a9789bd794cf9f29b01_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC03LTEtMS05NzI3Mg_133a0b20-4ffe-451e-974e-9a4cf3826706"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i202ecb6dff6b4729b49d234fb2bef137_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC05LTEtMS05NzI3Mg_82180988-d481-4dd3-8fce-63f3ca971d2e"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if8ef15e282314f3d8fec2981a454d8a4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNC0xMS0xLTEtOTcyNzI_d5815891-3042-4efe-b474-c7522024f4a8"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id36b4a825e7f469b8fd2f597b3af8390_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS0xLTEtMS05NzI3Mg_90f1be8f-301f-404a-a5fe-6d61832e562b"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibfdb2a1c4c384d149ee8bca6e20af292_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS0zLTEtMS05NzI3Mg_15523fb2-1087-4590-9478-e6fa10708592"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iee1f44ce249142beac6ca7381822ec8b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS01LTEtMS05NzI3Mg_2a167c24-7100-4c76-99c4-d248b4c6c722"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7cc96b39f3484f47995755bc11a69ddc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS03LTEtMS05NzI3Mg_52218c30-cc2f-453c-ae6b-b8bc69dfe1be"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0135a04774dc4b219792a238d8bafb56_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS05LTEtMS05NzI3Mg_dcde8ddb-e182-4431-b7e1-9a754eb3bbee"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic4caeb8a1e254252b6c25709ec4ec9d4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8zNy9mcmFnOjEzZjhmOGU1NWM3YjRiNDlhYzgyMTVhZmI4MTg3ODNiL3RhYmxlOjYyMjRhZDlmNWVmYjQxY2VhNTc1ZGYzMDkyY2UxOGViL3RhYmxlcmFuZ2U6NjIyNGFkOWY1ZWZiNDFjZWE1NzVkZjMwOTJjZTE4ZWJfNS0xMS0xLTEtOTcyNzI_9e63b909-5c09-42b3-9079-dfea3465312e"
      unitRef="number">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RleHRyZWdpb246ZmQyNThhZjMyNzU2NDQzODk2YzNkNDFkYjI5MDVhZjVfMTM1MQ_d0a89ab4-109b-419c-aef8-014a6005d84d">Loss Per Share &lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or purchases under the 2019 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. However, potentially dilutive shares are excluded from the computation of diluted loss per share when their effect is antidilutive.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because we reported a net loss for all periods presented, all potentially dilutive securities are antidilutive and are excluded from the computation of diluted loss per share for such periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the three and six months ended June&#160;30, 2022 and 2021 because to do so would be antidilutive (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in connection with the acquisitions of Cernostics and AltheaDx, Inc. (&#x201c;AltheaDx&#x201d;), we may issue, or may be required to issue, shares of our common stock to satisfy our contingent consideration obligations, pending the outcome of certain commercial and regulatory milestones, as required by the respective definitive agreements. See Notes 5 and 10 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RleHRyZWdpb246ZmQyNThhZjMyNzU2NDQzODk2YzNkNDFkYjI5MDVhZjVfMTM1Ng_469af7c7-bdb0-4573-a4a4-49e9919bd1ad">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in our calculation of diluted loss per share for the three and six months ended June&#160;30, 2022 and 2021 because to do so would be antidilutive (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3851b8892a64a6bb5ee4d6a59a6d586_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi0xLTEtMS05NzI3Mg_79c982bf-f027-406d-9fac-ea1dde09bca2"
      unitRef="shares">4974000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic1e593f0419b463ab2feaebd198a1f36_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi0zLTEtMS05NzI3Mg_2b8aecf6-d371-4cd5-9ab2-d4a6803c921d"
      unitRef="shares">3374000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c32637b65384bdb811ce3fde43efe9c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi01LTEtMS05NzI3Mg_98fdcdc9-b096-4c06-bd02-e5b932564d2a"
      unitRef="shares">4828000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id0fa44c09bb549a8bab2bb18b6137f27_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMi03LTEtMS05NzI3Mg_7f4df2f8-07a9-43fe-9fb2-46aec77505d7"
      unitRef="shares">3417000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iae420fb56f4e41199cef237838e485c7_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy0xLTEtMS05NzI3Mg_f1c002ce-552b-4122-8e26-682cb1a3aa7d"
      unitRef="shares">111000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec43d4abf35e401b9ee6ac4b9e162d95_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy0zLTEtMS05NzI3Mg_cb4fd98a-bbfa-4775-aa16-f6bee7c7760f"
      unitRef="shares">56000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id190812a859648c4aa204468be09784d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy01LTEtMS05NzI3Mg_0c081f8b-a61b-4488-98e3-683addc662e5"
      unitRef="shares">101000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0e027d558f18441ebd34443aff9c0b0e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfMy03LTEtMS05NzI3Mg_a25fadc9-6993-4495-a1b4-f09efe3e0ba1"
      unitRef="shares">66000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC0xLTEtMS05NzI3Mg_0a019e18-c599-4eec-a97f-68fa0b7b2be5"
      unitRef="shares">5085000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC0zLTEtMS05NzI3Mg_f61fdf73-a198-4739-b139-271358d3be88"
      unitRef="shares">3430000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC01LTEtMS05NzI3Mg_3d5d11c8-6e59-4f07-9925-8067f7636c7f"
      unitRef="shares">4929000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80MC9mcmFnOmZkMjU4YWYzMjc1NjQ0Mzg5NmMzZDQxZGIyOTA1YWY1L3RhYmxlOmQ3ZjYyMWY2ZGMxNTRhZDBiNjcwMmI3NjZkZjFjZWQ0L3RhYmxlcmFuZ2U6ZDdmNjIxZjZkYzE1NGFkMGI2NzAyYjc2NmRmMWNlZDRfNC03LTEtMS05NzI3Mg_bdc7c490-ef25-4b97-9a43-a1a2e80bfb99"
      unitRef="shares">3483000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzcyOTcx_7ea423d0-3c4c-4afc-b690-40e212e153ae">Acquisitions&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Myriad myPath, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City, for a cash purchase price of $32,500,000. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the developed technology, and therefore the transaction represents an asset acquisition rather than a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cernostics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, we completed the acquisition of Cernostics, which offers the TissueCypher Barrett&#x2019;s Esophagus Assay for patients with BE, for total consideration of $49,019,000, consisting of cash consideration of $30,732,000 and contingent consideration with an acquisition date fair value of $18,287,000. In connection with the acquisition, we recorded a receivable as of the acquisition date for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital. During the three months ended June 30, 2022, we received cash of $547,000 in settlement of this receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AltheaDx, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2022, we completed the acquisition of 100% of the equity interests in AltheaDx. AltheaDx offers the IDgenetix test, a PGx test focused on mental health. We believe this acquisition enables us to expand upon our existing portfolio of testing solutions in support of our growth strategy. We have concluded that the transaction represents a business combination under ASC 805. The financial results of AltheaDx have been included in our unaudited condensed consolidated financial statements since the date of the acquisition. The amount of revenue from AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was not material. The loss attributable to AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was approximately $3,383,000. This amount does not reflect transaction costs from the acquisition or the effects of the valuation allowance reduction discussed in Note 13. Transaction costs associated with the acquisition were $1,711,000 for both the three and six months ended June 30, 2022 and were recognized as expenses in the unaudited condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.766%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock (763,887 shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the common stock issued was measured using the April 26, 2022 closing price of $22.40 per share, as reported by the Nasdaq Global Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the contingent consideration, we may be required to pay up to $75.0 million in cash and common stock in connection with the achievement of certain milestones based on 2022, 2023 and 2024 performance and expanded Medicare coverage for the IDgenetix test (the &#x201c;AltheaDx Earnout Payments&#x201d;). Upon achievement of each relevant milestone event, each milestone will be paid 50% in cash and 50% in shares of our common stock based on a price per share equal to the volume-weighted-average price of our common stock for the 20 trading days as of the applicable milestone determination date. In accordance with the terms of the definitive agreement governing the acquisition of AltheaDx, the maximum number of shares of our common stock issuable to former AltheaDx security holders may not exceed 1,271,718 shares. Therefore, taking into consideration the number of shares already issued at closing, a maximum of 507,831 additional shares of our common stock remain issuable with respect to the AltheaDx Earnout Payments. In the event a number of shares in excess of 507,831 would otherwise be issuable in connection with the AltheaDx Earnout Payments, we will issue shares up to the maximum number permitted and pay cash for the remaining portion of the obligation. See Note 10 for additional information on the measurement of the contingent consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset is comprised of developed technology with an estimated useful life of 15 years and is being amortized on a straight-line basis. The goodwill, which is not expected to be deductible for income tax purposes, was primarily attributable to potential future growth opportunities and the organized workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our calculations of the consideration transferred and the purchase price allocation for the acquisition of AltheaDx are based on a preliminary valuation and are subject to revision as the valuation is finalized and additional information about the fair value of the assets and liabilities becomes available. The primary areas that are not yet finalized are income taxes, intangible assets, contingent consideration and the resulting goodwill. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited Pro Forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information for the three and six months ended June 30, 2022 and 2021 combines our historical financial results and the results of AltheaDx, assuming that the companies were combined as of January 1, 2021, and includes adjustments for amortization expense from the acquired intangible assets and additional stock-based compensation expense. Nonrecurring pro forma adjustments consist of acquisition-related transaction costs of $1,711,000 and an income tax benefit of $1,769,000, both assumed to have been recognized during the six months ended June 30, 2021 and therefore removed from the three and six months ended June 30, 2022. The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pro Forma Data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derek J. Maetzold, our President and Chief Executive Officer, and a member of our board of directors, and Daniel M. Bradbury, the Chairperson of our board of directors, each served on the board of directors of AltheaDx until the acquisition of AltheaDx was completed, were direct or indirect beneficial owners of AltheaDx securities and received consideration in the &lt;/span&gt;&lt;/div&gt;transaction. Further, Frank Stokes, our Chief Financial Officer; Tobin W. Juvenal, our Chief Commercial Officer; Kristen Oelschlager, our Chief Operating Officer and certain immediate family members of Mr. Maetzold and Ms. Oelschlager were direct or indirect beneficial owners of AltheaDx securities and received consideration in the transaction. These individuals may receive additional consideration in the form of AltheaDx Earnout Payments if the relevant commercial and regulatory milestone events occur. Our entry into the definitive agreement to acquire AltheaDx was approved by our board of directors based upon the unanimous recommendation of a special transaction committee comprised entirely of independent members of our board of directors without any financial interest in AltheaDx or any conflict of interest with respect to the acquisition of AltheaDx.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzcyOTcx_92550b21-9420-4e77-ac4e-0e4036548958">Acquisitions&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Myriad myPath, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2021, we completed the acquisition of all of the equity of Myriad myPath, LLC, a laboratory in Salt Lake City, for a cash purchase price of $32,500,000. Based on the guidance in ASC 805, we concluded that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset, the developed technology, and therefore the transaction represents an asset acquisition rather than a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cernostics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, we completed the acquisition of Cernostics, which offers the TissueCypher Barrett&#x2019;s Esophagus Assay for patients with BE, for total consideration of $49,019,000, consisting of cash consideration of $30,732,000 and contingent consideration with an acquisition date fair value of $18,287,000. In connection with the acquisition, we recorded a receivable as of the acquisition date for the post-closing purchase price adjustment, representing the difference between actual and estimated cash and working capital. During the three months ended June 30, 2022, we received cash of $547,000 in settlement of this receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AltheaDx, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 26, 2022, we completed the acquisition of 100% of the equity interests in AltheaDx. AltheaDx offers the IDgenetix test, a PGx test focused on mental health. We believe this acquisition enables us to expand upon our existing portfolio of testing solutions in support of our growth strategy. We have concluded that the transaction represents a business combination under ASC 805. The financial results of AltheaDx have been included in our unaudited condensed consolidated financial statements since the date of the acquisition. The amount of revenue from AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was not material. The loss attributable to AltheaDx included in the unaudited consolidated statements of operations from the acquisition date was approximately $3,383,000. This amount does not reflect transaction costs from the acquisition or the effects of the valuation allowance reduction discussed in Note 13. Transaction costs associated with the acquisition were $1,711,000 for both the three and six months ended June 30, 2022 and were recognized as expenses in the unaudited condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.766%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock (763,887 shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the common stock issued was measured using the April 26, 2022 closing price of $22.40 per share, as reported by the Nasdaq Global Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the contingent consideration, we may be required to pay up to $75.0 million in cash and common stock in connection with the achievement of certain milestones based on 2022, 2023 and 2024 performance and expanded Medicare coverage for the IDgenetix test (the &#x201c;AltheaDx Earnout Payments&#x201d;). Upon achievement of each relevant milestone event, each milestone will be paid 50% in cash and 50% in shares of our common stock based on a price per share equal to the volume-weighted-average price of our common stock for the 20 trading days as of the applicable milestone determination date. In accordance with the terms of the definitive agreement governing the acquisition of AltheaDx, the maximum number of shares of our common stock issuable to former AltheaDx security holders may not exceed 1,271,718 shares. Therefore, taking into consideration the number of shares already issued at closing, a maximum of 507,831 additional shares of our common stock remain issuable with respect to the AltheaDx Earnout Payments. In the event a number of shares in excess of 507,831 would otherwise be issuable in connection with the AltheaDx Earnout Payments, we will issue shares up to the maximum number permitted and pay cash for the remaining portion of the obligation. See Note 10 for additional information on the measurement of the contingent consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset is comprised of developed technology with an estimated useful life of 15 years and is being amortized on a straight-line basis. The goodwill, which is not expected to be deductible for income tax purposes, was primarily attributable to potential future growth opportunities and the organized workforce.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our calculations of the consideration transferred and the purchase price allocation for the acquisition of AltheaDx are based on a preliminary valuation and are subject to revision as the valuation is finalized and additional information about the fair value of the assets and liabilities becomes available. The primary areas that are not yet finalized are income taxes, intangible assets, contingent consideration and the resulting goodwill. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited Pro Forma Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information for the three and six months ended June 30, 2022 and 2021 combines our historical financial results and the results of AltheaDx, assuming that the companies were combined as of January 1, 2021, and includes adjustments for amortization expense from the acquired intangible assets and additional stock-based compensation expense. Nonrecurring pro forma adjustments consist of acquisition-related transaction costs of $1,711,000 and an income tax benefit of $1,769,000, both assumed to have been recognized during the six months ended June 30, 2021 and therefore removed from the three and six months ended June 30, 2022. The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pro Forma Data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derek J. Maetzold, our President and Chief Executive Officer, and a member of our board of directors, and Daniel M. Bradbury, the Chairperson of our board of directors, each served on the board of directors of AltheaDx until the acquisition of AltheaDx was completed, were direct or indirect beneficial owners of AltheaDx securities and received consideration in the &lt;/span&gt;&lt;/div&gt;transaction. Further, Frank Stokes, our Chief Financial Officer; Tobin W. Juvenal, our Chief Commercial Officer; Kristen Oelschlager, our Chief Operating Officer and certain immediate family members of Mr. Maetzold and Ms. Oelschlager were direct or indirect beneficial owners of AltheaDx securities and received consideration in the transaction. These individuals may receive additional consideration in the form of AltheaDx Earnout Payments if the relevant commercial and regulatory milestone events occur. Our entry into the definitive agreement to acquire AltheaDx was approved by our board of directors based upon the unanimous recommendation of a special transaction committee comprised entirely of independent members of our board of directors without any financial interest in AltheaDx or any conflict of interest with respect to the acquisition of AltheaDx.</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i2d5c289e6d474738890e1b72e04b9576_D20210528-20210528"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4MzQw_257ef41c-e348-42d1-acea-c5ceecb7a2f7"
      unitRef="usd">32500000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4MzUz_cccb504b-1fd2-45b7-835f-23d600cd0a4c"
      unitRef="usd">49019000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4MzY2_afc379b2-5092-49de-abff-2f8d639fe6d0"
      unitRef="usd">30732000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="ie0c7e2d6c9b34ae1b01901595569327d_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4Mzc5_bb94f97c-68ec-49e3-a62f-4a04a16b6def"
      unitRef="usd">18287000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <cstl:ProceedsFromPreviousAssetAcquisition
      contextRef="i36d6bf4b13ce4a24ae2fea8c910f9894_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4Mzky_72d6ec98-7db9-4271-b9aa-d0bc00f03a8e"
      unitRef="usd">547000</cstl:ProceedsFromPreviousAssetAcquisition>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODExODY2_9625df9b-3380-44b2-9ff6-963f81f33622"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8xMDk5NTExNjczNDM0_2523b039-49c2-41a4-b46c-51257eab71d1"
      unitRef="usd">3383000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
      contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjk4OTEw_9fccb104-4f4b-4598-a1bc-eab5f51eaf1f"
      unitRef="usd">1711000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
      contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjk4OTEw_f2ec3d9c-aa13-40dd-a0ac-ca25d251df33"
      unitRef="usd">1711000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDE1_eb427069-4173-4b33-932f-ff8d529e5d00">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary acquisition-date fair value of the consideration transferred consisted of the following (in thousands, except shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.766%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock (763,887 shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8xLTItMS0xLTExMTU2NA_d6736b3c-f36a-47c1-9831-35e2bb83445a"
      unitRef="usd">30510000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8yLTAtMS0xLTExMTU2Ni90ZXh0cmVnaW9uOjE2NDVmMzFjNjA3OTQxYjhiM2JiNWY0OWFmYTI1ZGVjXzQzOTgwNDY1MTExNTQ_5a0d71f0-964c-45c2-98b5-e852530f652b"
      unitRef="shares">763887</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8yLTItMS0xLTExMTU2NA_f30cc81a-bd9c-41c0-80b9-bcb171f8fc8f"
      unitRef="usd">17111000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml8zLTItMS0xLTExMTU2NA_277d1897-0310-44a3-880c-bfb822663cc8"
      unitRef="usd">1528000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6NGM4YTA0OGFhMzAyNGYyODkzZDlhOTZhMTI2MTAwODIvdGFibGVyYW5nZTo0YzhhMDQ4YWEzMDI0ZjI4OTNkOWE5NmExMjYxMDA4Ml80LTItMS0xLTExMTU2NA_cdfdcca8-1b1d-4955-a068-c354c585c114"
      unitRef="usd">49149000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SharePrice
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODEyODc5_d9b0f2ad-1528-4705-946f-37562121f158"
      unitRef="usdPerShare">22.40</us-gaap:SharePrice>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDEx_1abfb321-e782-4218-b256-fc26b4889069"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <cstl:BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDE4_4ba03927-4b6d-4b55-854a-a844942cc9f1"
      unitRef="number">0.50</cstl:BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash>
    <cstl:BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock
      contextRef="i62417c66f9e8412cb78339018fd81c48_D20220426-20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDIy_30729379-3b88-4157-9558-9a6ade798661"
      unitRef="number">0.50</cstl:BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock>
    <cstl:CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays
      contextRef="i4208ab3203fb45e2b40efa980b003a60_I20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzcyOTc0_c5f4b8ea-52cc-4bfe-9240-bc47589bb802"
      unitRef="tradingday">20</cstl:CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDE3_99b23838-795b-40d1-a4ac-1972b56bb77f"
      unitRef="shares">1271718</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <cstl:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued
      contextRef="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDI4_a2808c38-b74c-4185-8d7e-0b6da8b8d702"
      unitRef="shares">507831</cstl:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued>
    <cstl:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued
      contextRef="ia033fd51565e4fb29de17430d22c0d57_D20220426-20220426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDM3_0b3b87f0-68ea-46a8-9e53-e3853da5e32a"
      unitRef="shares">507831</cstl:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5NzczNjQw_2b173848-8767-4828-bfd4-8928c673fe1c">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary allocation of the fair values of assets acquired and liabilities assumed in the acquisition of AltheaDx at the date of acquisition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;April 26, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xLTItMS0xLTEwMzMxNQ_d2fc2510-5749-4603-9243-e872765eade5"
      unitRef="usd">3536000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8yLTItMS0xLTEwMzMxNQ_207c002a-11b4-423a-a34e-f90dcc51b166"
      unitRef="usd">302000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8zLTItMS0xLTEwNzMyOA_df77b561-632d-4a7a-ad4e-7485267cab75"
      unitRef="usd">279000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8zLTItMS0xLTEwMzMxNQ_fb8348c2-6dcd-4e55-a5a8-3f9adc1a6ddb"
      unitRef="usd">262000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl80LTItMS0xLTEwMzMxNQ_66d9fead-3b73-48b5-a02d-1b219bd1bf00"
      unitRef="usd">314000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl81LTItMS0xLTEwMzMxNQ_e8485f0a-36d9-4282-ade6-1127f16a5c28"
      unitRef="usd">37000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl83LTItMS0xLTEwNzMyOA_795e8e7f-6f25-4562-a622-5393732ccb26"
      unitRef="usd">12000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl82LTItMS0xLTEwMzMxNQ_74bd5e6e-c8e3-469c-badd-fde9dbaf09e6"
      unitRef="usd">231000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <cstl:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl83LTItMS0xLTEwMzMxNQ_436e54fb-5a23-43a5-98d9-5bc047282e70"
      unitRef="usd">380000</cstl:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl84LTItMS0xLTEwMzMxNQ_2092efef-730d-4c8f-b706-d3f896f9a8a0"
      unitRef="usd">532000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xMy0yLTEtMS0xMTM3MTI_181018fd-e89f-4b21-b042-317ae29dc027"
      unitRef="usd">1819000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xNC0yLTEtMS0xMTQzMTI_abf9c856-2463-4789-b587-f649804f186e"
      unitRef="usd">88000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xMS0yLTEtMS0xMDMzMTU_91438950-5a87-4bbd-ba02-01276dd6762a"
      unitRef="usd">38655000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xNS0yLTEtMS0xMDczMjg_943f7810-6cd8-4ad5-b752-c7cc965ff152"
      unitRef="usd">10494000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjA4ODU1NjBmMzI2NGRkYzg2NDA3OTkzYjMyYmQ0Y2IvdGFibGVyYW5nZToyMDg4NTU2MGYzMjY0ZGRjODY0MDc5OTNiMzJiZDRjYl8xNi0yLTEtMS0xMDczMjg_a60542e8-a087-40cb-8a8b-8e0a5f0e1557"
      unitRef="usd">49149000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="idc558f1bcfcf460c9f62c48b28e4c8cd_D20220426-20220426"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8yMTk5MDIzMjYyNDgx_3c53addf-28e7-4805-9ea0-37c05eba890b">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
      contextRef="iba6c475c71e34bab977bbfc04f289e75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8xMjY0NDM4Mzc2NjYxNQ_2d7d4468-7a93-4a0d-9e77-5655e3c4ebdf"
      unitRef="usd">1711000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i342fb6e319104d52a2a096369c394d0a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl8xMjY0NDM4Mzc2NjYyNw_cf64a4d4-19f4-45a8-9e3d-6c809fcf86f5"
      unitRef="usd">-1769000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGV4dHJlZ2lvbjozMGRiZjMzMDdjNGQ0Mzk0YmZkMGEzNjg4OWQyYTkwNl82NTk3MDY5ODA4NDQ1_81135d1c-440a-426a-9a49-b256ab1c99a2">The following unaudited pro forma financial information (in thousands) is for informational purposes only and is not necessarily indicative of (i) the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2021 or (ii) the results of operations that are expected in future periods:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pro Forma Data&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTItMS0xLTExMjc0Nw_1fd11a32-6b1c-43e0-a540-3fa45c6af9d8"
      unitRef="usd">35392000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i18246336ddbc4d7d82e4f43fbb8713f5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTQtMS0xLTExMjc2Ng_7436abee-b71f-4403-8ac7-40d0696993fd"
      unitRef="usd">22840000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTItMS0xLTExMTU5MA_7e7e9334-f5fa-4c6a-8a43-f9aed0189180"
      unitRef="usd">62670000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ie5a6d97ebe2b4ac8ac03f0f597e399e8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8yLTQtMS0xLTExMTU5Mg_68dc503c-21ff-41f6-ab63-783802763e14"
      unitRef="usd">45676000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTItMS0xLTExMjc0Nw_96cf722c-32ff-4f0f-946c-4c94240f783c"
      unitRef="usd">-4289000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i18246336ddbc4d7d82e4f43fbb8713f5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTQtMS0xLTExMjc2Ng_6de1966b-333e-44a3-b9c4-6115a0b8af05"
      unitRef="usd">-11267000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTItMS0xLTExMTU5MA_50fc75b6-816f-4231-8f98-8a40496dc482"
      unitRef="usd">-32680000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ie5a6d97ebe2b4ac8ac03f0f597e399e8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xMzg1L2ZyYWc6MzBkYmYzMzA3YzRkNDM5NGJmZDBhMzY4ODlkMmE5MDYvdGFibGU6MjEzNzRhYmIxYzBkNGIxY2ExOGI0Nzg1NDNhNzdmNTQvdGFibGVyYW5nZToyMTM3NGFiYjFjMGQ0YjFjYTE4YjQ3ODU0M2E3N2Y1NF8zLTQtMS0xLTExMTU5Mg_1680a610-c94b-4162-8c34-95461574ef2b"
      unitRef="usd">-17479000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMzY5_30ed5562-413f-4dd1-b189-1bf5e52641a9">Property and Equipment, Net&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Includes lab equipment under a finance lease of $369 thousand and accumulated depreciation of $66 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was recorded in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales (exclusive of amortization of acquired intangible assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMzcw_6b6505f3-984f-4e4f-877b-6100c0b89356">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Includes lab equipment under a finance lease of $369 thousand and accumulated depreciation of $66 thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was recorded in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales (exclusive of amortization of acquired intangible assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i19966e00f06e4894824f928b10bfb6ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0xLTEtMS0xMDg1MDQ_e37f745b-9dcf-4f02-8240-3f313b564dcc"
      unitRef="usd">6778000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if3cbac6e564649baabb13f60dd0dd0e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0zLTEtMS0xMDg1MTE_e98a06a4-1c1d-458c-9097-dff2dd733d4a"
      unitRef="usd">3727000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i5070d2dd0947412eb17de036ae48867f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0xLTEtMS05NzI3Mg_f4c115e3-6df4-4457-aa41-2cd3adb913a4"
      unitRef="usd">4965000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id512a2f4079a4e7f8d0d10261566c191_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMS0zLTEtMS05NzI3Mg_38f279e8-8b1c-4056-9634-55e26dc11d8b"
      unitRef="usd">5044000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i20d1fba04ed24847a7ae1ad277983eb2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMy0xLTEtMS05NzI3Mg_97c42c35-2edc-4f74-a56f-5db43182534f"
      unitRef="usd">4014000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7c244a39341a448791b5db69d1b41724_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfMy0zLTEtMS05NzI3Mg_2b7474e1-0fa3-44a8-9af0-6fd6e7c42707"
      unitRef="usd">2457000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ia64acefec6184784b9890c8d9573b5ac_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNC0xLTEtMS05NzI3Mg_e63e4bde-5ce4-4541-af6b-03b5f731d0e2"
      unitRef="usd">1423000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ibbd539bbaa4f45da97e6726e6d501957_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNC0zLTEtMS05NzI3Mg_58ffb319-72c3-47d9-b3e1-769b917fbf3c"
      unitRef="usd">1288000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ifd2fa89ae0cb4fa7942493ffe73929b4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNS0xLTEtMS05NzI3Mg_75ec259a-4a27-46eb-a11c-b8338be19f8f"
      unitRef="usd">703000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie55d01cabd3e4dfd8fc8d7634ccc3e6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNS0zLTEtMS05NzI3Mg_967595be-cd07-44cb-84dd-7e1223605512"
      unitRef="usd">27000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNi0xLTEtMS05NzI3Mg_d6637215-8357-439d-a508-109e4bff9a6e"
      unitRef="usd">17883000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNi0zLTEtMS05NzI3Mg_8e25613b-ea67-40a2-ad1a-cddba69b42c4"
      unitRef="usd">12543000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNy0xLTEtMS05NzI3Mg_cadfea3a-b7b2-4e07-8142-02b358d1c7b3"
      unitRef="usd">6680000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfNy0zLTEtMS05NzI3Mg_71ab1713-3347-4393-9f37-e7cd82e4d21a"
      unitRef="usd">3042000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfOC0xLTEtMS05NzI3Mg_8b49c6dc-5e20-45da-8ac6-2b8325b90857"
      unitRef="usd">11203000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOmY0ZjQzYTdkNTkxMTQ2YjY5YjE5YzQyYzE4ZGI4NTI4L3RhYmxlcmFuZ2U6ZjRmNDNhN2Q1OTExNDZiNjliMTljNDJjMThkYjg1MjhfOC0zLTEtMS05NzI3Mg_21020a64-8949-480f-80f0-09b5e141d6da"
      unitRef="usd">9501000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i19966e00f06e4894824f928b10bfb6ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMTYz_b502a108-f34f-4cfd-82e8-20a849425543"
      unitRef="usd">369000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i19966e00f06e4894824f928b10bfb6ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RleHRyZWdpb246ZmRlNTEwMjNhODJkNDYxYjliZThkZmFjMWQyMTI2ODZfMjA3_93413d97-6442-458c-bdd6-3cdfce16edd7"
      unitRef="usd">66000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:Depreciation
      contextRef="i01f3cc6a21d0455faa3a247ed3871fc2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi0xLTEtMS05NzI3Mg_6fa95dbb-6649-44b0-8930-d0d83bd3f3a2"
      unitRef="usd">185000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i695763ce94f847ecb79699e832614ae4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi0zLTEtMS05NzI3Mg_f95cc78a-df9a-4dbc-bbfa-eca8df0643fc"
      unitRef="usd">111000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie5660ce4bef94584b72a1722257e6ddd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi01LTEtMS05NzI3Mg_6a1904b5-a108-4583-ae09-cc9ba66dd925"
      unitRef="usd">354000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1cf326b10a224bb6a24085924905410c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMi03LTEtMS05NzI3Mg_aa9ebdab-a26a-40a9-8daa-988aeee01d5c"
      unitRef="usd">213000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib90b080f71e6434ea6c9ba3acadadcef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy0xLTEtMS05NzI3Mg_bbf463fa-b15c-4792-a93d-2843e3556bae"
      unitRef="usd">80000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibcfa896825f1413cb48c6b0e5e4b5954_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy0zLTEtMS05NzI3Mg_dd0b8b9f-9d88-4ae6-a56e-f0fe6b54d207"
      unitRef="usd">64000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1f7c25b470c347d698685f93340964f3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy01LTEtMS05NzI3Mg_ec6d7fc2-74e9-4464-87fa-2099af8625d0"
      unitRef="usd">170000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3700a82a151f4c0a8bda6c74f43fe33d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfMy03LTEtMS05NzI3Mg_d404a634-e88f-474e-b419-7990dbaf3f27"
      unitRef="usd">108000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ieb27d09e15f1493bafb7c9641c3f51aa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC0xLTEtMS05NzI3Mg_b7970fd2-1d83-4cf8-924c-f9a43e49f366"
      unitRef="usd">266000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6d2f11e2e9a840b5a7a47d3f927f7647_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC0zLTEtMS05NzI3Mg_3a423808-bc7f-4454-9039-7d493ba89aba"
      unitRef="usd">203000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id95b5f253eb44af8b25296728af91542_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC01LTEtMS05NzI3Mg_b20a1187-dca0-4f9f-85a5-c0d1f8c0826e"
      unitRef="usd">510000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i53b3a400ca564d61a070f1edf776917a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNC03LTEtMS05NzI3Mg_8c279322-f7b6-43b4-9ca5-727c5f0e62b5"
      unitRef="usd">290000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS0xLTEtMS05NzI3Mg_53c5df43-506f-4e55-99d6-54921617a754"
      unitRef="usd">531000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS0zLTEtMS05NzI3Mg_b20af53d-749f-4925-902b-edbe4b5b9ff4"
      unitRef="usd">378000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS01LTEtMS05NzI3Mg_24085432-3f21-4961-ac65-52dc7912ad8e"
      unitRef="usd">1034000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80My9mcmFnOmZkZTUxMDIzYTgyZDQ2MWI5YmU4ZGZhYzFkMjEyNjg2L3RhYmxlOjY4NTA2Y2I5YjAzYTRjYWQ5YzM4ZGEzNTdkZGYxYTAwL3RhYmxlcmFuZ2U6Njg1MDZjYjliMDNhNGNhZDljMzhkYTM1N2RkZjFhMDBfNS03LTEtMS05NzI3Mg_fa451287-3cf4-4682-8e17-87ffd8545b58"
      unitRef="usd">611000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMzU1_12b55e97-89d0-4a30-8ccd-0f39857023d6">Goodwill and Other Intangible Assets, Net&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on the change in carrying value of our goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of AltheaDx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no accumulated impairments of goodwill as of June 30, 2022 or December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other intangible assets, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future aggregate amortization expense as of June&#160;30, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remainder of year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets was $2.1 million and $3.7 million for the three and six months ended June&#160;30, 2022, respectively. Amortization expense of intangible assets was $0.3 million for each of the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfNjU5NzA2OTc2OTEyNA_69bd5009-ec1b-4cad-aa6a-b39f9ba7899d">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information on the change in carrying value of our goodwill is presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of AltheaDx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjUwMTJjYzE4NThmZTQ1NjVhNzc1ZTY0NjI3MzE2YzYxL3RhYmxlcmFuZ2U6NTAxMmNjMTg1OGZlNDU2NWE3NzVlNjQ2MjczMTZjNjFfMS0yLTEtMS0xMDU4NjU_4e774824-9193-47cb-945c-6bcf0264182d"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjUwMTJjYzE4NThmZTQ1NjVhNzc1ZTY0NjI3MzE2YzYxL3RhYmxlcmFuZ2U6NTAxMmNjMTg1OGZlNDU2NWE3NzVlNjQ2MjczMTZjNjFfMi0yLTEtMS0xMDU5Nzg_46155c1c-1abc-48a6-956c-a069772298d4"
      unitRef="usd">10494000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjUwMTJjYzE4NThmZTQ1NjVhNzc1ZTY0NjI3MzE2YzYxL3RhYmxlcmFuZ2U6NTAxMmNjMTg1OGZlNDU2NWE3NzVlNjQ2MjczMTZjNjFfNC0yLTEtMS0xMDU5Nzg_e508b178-0692-4523-860a-e72b5042f1e6"
      unitRef="usd">10494000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfNjU5NzA2OTc2OTEyNg_22d9bfb8-be1a-4d54-baef-6f26570bf43a"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfNjU5NzA2OTc2OTEyNg_d4511802-060c-4658-a7cf-ebf30cf1b41c"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMzU2_7f5b73d9-4507-4b93-91fe-ca3bb8c2a296">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other intangible assets, net consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled workforce&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10.8pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i901262209e794dce8a44fee61a9bfe50_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi0xLTEtMS05NzI3Mg_5f1015fe-99d4-4569-9604-2da683753e40"
      unitRef="usd">127318000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i901262209e794dce8a44fee61a9bfe50_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi0zLTEtMS05NzI3Mg_34250057-0939-49fc-b338-bb6ed15c5aeb"
      unitRef="usd">5639000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i901262209e794dce8a44fee61a9bfe50_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi01LTEtMS05NzI3Mg_ae31c3f5-0746-43c2-87ad-305b20d8aafb"
      unitRef="usd">121679000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ie686513e9d7f42f78dcefb7c17ec2bc3_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMi03LTEtMS05NzI3Mg_e959ce42-7a3a-45f7-872d-4cecf2c0417a">P13Y8M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy0xLTEtMS05NzI3Mg_1c317839-fd6d-425f-8d87-71c0bb430577"
      unitRef="usd">563000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy0zLTEtMS05NzI3Mg_911d4efd-699f-49e2-982d-f742b704d338"
      unitRef="usd">65000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a0b2e6817e64ce5a697af34a2c5cc31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy01LTEtMS05NzI3Mg_9644956d-2aa5-424a-b6e5-6816ea771f7f"
      unitRef="usd">498000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i2da820ae08bd4d858fbbc2c1c5bb1868_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfMy03LTEtMS05NzI3Mg_c2c79a57-30e3-4948-b23d-a8e4db27e112">P4Y4M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfNC0xLTEtMS05NzI3Mg_a1ae60cc-e865-4ccb-ab28-443e7a84cd76"
      unitRef="usd">127881000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfNC0zLTEtMS05NzI3Mg_47da4849-efad-4f01-a434-b607803ded92"
      unitRef="usd">5704000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmQyYTJiOTk1MTI3YTRkYWU5NTE0OTJmODFjOWQ3YjU0L3RhYmxlcmFuZ2U6ZDJhMmI5OTUxMjdhNGRhZTk1MTQ5MmY4MWM5ZDdiNTRfNC01LTEtMS05NzI3Mg_fca3954b-3639-41ba-afa1-20feaace9905"
      unitRef="usd">122177000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia4cd64260f474238bc48f5f8fbf709cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi0xLTEtMS05NzI3Mg_c61f09e6-5dd1-4d25-af57-7e1bf4572750"
      unitRef="usd">90317000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia4cd64260f474238bc48f5f8fbf709cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi0zLTEtMS05NzI3Mg_b3d7e94e-fc28-4f07-a3e6-2da405079992"
      unitRef="usd">1949000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia4cd64260f474238bc48f5f8fbf709cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi01LTEtMS05NzI3Mg_cfed44bf-0a9f-40a3-a85a-609c0c773012"
      unitRef="usd">88368000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ia8dca6d7270d44eda30a928ed849ac36_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMi03LTEtMS05NzI3Mg_76881b9c-6ea4-44c9-bd5d-8bdeee8c984d">P13Y2M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy0xLTEtMS05NzI3Mg_25bb62d3-3f98-4ded-8a06-ea39667da28b"
      unitRef="usd">563000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy0zLTEtMS05NzI3Mg_dc94d809-edc7-4e50-8ba2-225d1de84ad1"
      unitRef="usd">9000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0b98b2ee42ea434a9f7b1a6c15cc04c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy01LTEtMS05NzI3Mg_19d2ba41-a755-4e18-a4ac-51ac14d5f62f"
      unitRef="usd">554000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i697af5026be14ac08242de05f2632427_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfMy03LTEtMS05NzI3Mg_a33874f3-1ee5-4f9d-9d05-5076c6ac2458">P4Y10M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfNC0xLTEtMS05NzI3Mg_f8dd4477-3a67-4ccb-b186-bf36a0a3fbf5"
      unitRef="usd">90880000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfNC0zLTEtMS05NzI3Mg_fdc02c8e-0066-412e-b5ad-ad75b63e35b2"
      unitRef="usd">1958000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOjEzYTNkZjk5ZDVhODRhY2Y5ZGVjZGNlZjU1MzZlZjExL3RhYmxlcmFuZ2U6MTNhM2RmOTlkNWE4NGFjZjlkZWNkY2VmNTUzNmVmMTFfNC01LTEtMS05NzI3Mg_df5cc6b7-444c-4a01-b167-f84732f1d34c"
      unitRef="usd">88922000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMzU3_909abfb6-cf7d-4bc9-85b6-a1195a971310">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future aggregate amortization expense as of June&#160;30, 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remainder of year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfMS0yLTEtMS05NzI3Mg_d57fa1a8-8e8a-4b89-9c12-4d2d1dc5d4fd"
      unitRef="usd">4611000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfMi0yLTEtMS05NzI3Mg_61533ec7-77f2-4bed-86b4-32434a01369f"
      unitRef="usd">9147000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfMy0yLTEtMS05NzI3Mg_16f66151-51c5-421a-bd0f-37aa3b9eb2e1"
      unitRef="usd">9172000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNC0yLTEtMS05NzI3Mg_5cf55d40-b05e-42a5-b25e-278f9ecf95a2"
      unitRef="usd">9147000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNS0yLTEtMS05NzI3Mg_645a4943-00b8-4f62-b637-19cfef87f548"
      unitRef="usd">9137000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <cstl:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNi0yLTEtMS05NzI3Mg_34ab2a65-8f66-4be7-b8c5-53094f1c5eb8"
      unitRef="usd">80963000</cstl:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RhYmxlOmI5M2IxMzdhZDA3NDQzMTE4ODE5MzhjYjRlMzQ5OTZiL3RhYmxlcmFuZ2U6YjkzYjEzN2FkMDc0NDMxMTg4MTkzOGNiNGUzNDk5NmJfNy0yLTEtMS05NzI3Mg_558090a5-bc34-4556-b8d0-0e4fc5f67005"
      unitRef="usd">122177000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMjQz_b99a1b7e-6d34-4009-be8f-3339086a71ef"
      unitRef="usd">2100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMjE5OTAyMzI1NjMxOQ_97a48537-5e36-42de-bd03-9635a1c5333a"
      unitRef="usd">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMTA5OTUxMTYyODUwMA_6123d1c1-87e0-4eeb-be89-72ee4625a4c5"
      unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80Ni9mcmFnOmE3MjhhNjJlOTY5NjQ3MGZhYmQyYjQwOTU2ZTY5NjhjL3RleHRyZWdpb246YTcyOGE2MmU5Njk2NDcwZmFiZDJiNDA5NTZlNjk2OGNfMTA5OTUxMTYyODUwMA_b905310e-fb38-4a0a-81cb-253327ce7d9b"
      unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RleHRyZWdpb246ZTZjYjZhM2NiMzUwNGFlOWE4OTE1NTliNGI0ODYwZWFfMTE1_f0f8a6e9-a24b-4e50-83bc-bc898d795674">Other Accrued and Current Liabilities&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued service fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued fixed asset purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration payable for business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RleHRyZWdpb246ZTZjYjZhM2NiMzUwNGFlOWE4OTE1NTliNGI0ODYwZWFfMTE2_7a76810c-57c9-411f-bb6c-0845f7fd07f7">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued service fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued fixed asset purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration payable for business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMS0xLTEtMS05NzI3Mg_fa7f2907-99ce-430c-a507-1470dec617ab"
      unitRef="usd">3163000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMS0zLTEtMS05NzI3Mg_4a2a1194-5771-4100-94a5-540f73b16520"
      unitRef="usd">1905000</us-gaap:AccruedProfessionalFeesCurrent>
    <cstl:AccruedClinicalStudiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMi0xLTEtMS05NzI3Mg_1117f77d-57b6-4404-b304-8002f1789998"
      unitRef="usd">2165000</cstl:AccruedClinicalStudiesCurrent>
    <cstl:AccruedClinicalStudiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMi0zLTEtMS05NzI3Mg_fb4ee100-32d9-42e6-af84-3a32261e882f"
      unitRef="usd">1655000</cstl:AccruedClinicalStudiesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMy0xLTEtMS05NzI3Mg_bddfa37b-87b5-46f9-9846-3d75e6d9a1eb"
      unitRef="usd">848000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfMy0zLTEtMS05NzI3Mg_09208719-ec7d-431d-9cb4-6c65a80b470d"
      unitRef="usd">695000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNC0xLTEtMS05NzI3Mg_8eb199de-e9d8-42a1-bdfd-b8ae86f72ced"
      unitRef="usd">815000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNC0zLTEtMS05NzI3Mg_56eaf3d1-65e5-44ee-beae-0e88ebf82213"
      unitRef="usd">760000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <cstl:AccruedFixedAssetPurchases
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0xLTEtMS0xMDkxMjI_e803ee35-51c0-4cac-b33c-86c29cf334ba"
      unitRef="usd">469000</cstl:AccruedFixedAssetPurchases>
    <cstl:AccruedFixedAssetPurchases
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0zLTEtMS0xMDkxMjI_014a2194-a40b-4cc5-8a26-e3a5927cecfa"
      unitRef="usd">10000</cstl:AccruedFixedAssetPurchases>
    <cstl:BusinessCombinationConsiderationPayableCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0xLTEtMS0xMTI0NTk_81b3d1d8-cfe4-434d-add8-5e10eda99683"
      unitRef="usd">313000</cstl:BusinessCombinationConsiderationPayableCurrent>
    <cstl:BusinessCombinationConsiderationPayableCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0zLTEtMS0xMTI0NjY_1b98e013-3ed4-4eb2-874e-df4b45f4b457"
      unitRef="usd">0</cstl:BusinessCombinationConsiderationPayableCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNy0xLTEtMS0xMTI1MTk_03644f77-7aac-4dee-9e1f-05ebe74db7db"
      unitRef="usd">215000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNy0zLTEtMS0xMTI1MTk_6bc1a4ba-700d-48c7-bb26-e2e026f08c1d"
      unitRef="usd">141000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0xLTEtMS05NzI3Mg_958bec7f-b617-4f15-b8cc-a9fc219e23d0"
      unitRef="usd">189000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNS0zLTEtMS05NzI3Mg_ffc33c8a-c105-4901-b982-270627b6a8b4"
      unitRef="usd">512000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0xLTEtMS05NzI3Mg_0d50710f-6e0b-4138-919d-f87647c8ae5d"
      unitRef="usd">8177000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV80OS9mcmFnOmU2Y2I2YTNjYjM1MDRhZTlhODkxNTU5YjRiNDg2MGVhL3RhYmxlOjFjYTM4YzJlZjIzMjQ3NWJiZDUzYzcwZGQ3YjJhOGZmL3RhYmxlcmFuZ2U6MWNhMzhjMmVmMjMyNDc1YmJkNTNjNzBkZDdiMmE4ZmZfNi0zLTEtMS05NzI3Mg_57cc06ef-6d28-497d-8a36-f7ebd2f53c11"
      unitRef="usd">5678000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTg5Ng_c10548b8-480d-4330-a9cb-b24dfe609fc0">Leases&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adoption of ASC 842&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2021, we adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842), and ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) using the modified retrospective approach with an effective date of January 1, 2021. The adoption had no effect on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2021. Net cash (used in) provided by operating activities, investing activities or financing activities for the six months ended June 30, 2021 were also unchanged, but the presentation of certain prior period amounts within the operating activities section of the condensed consolidated statements of cash flows has been retrospectively adjusted to give effect to the adoption of ASC 842. The changes are set forth in the table below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Before Adoption of ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effect of Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;After Adoption of ASC 842&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Effect on Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OPERATING ACTIVITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the condensed consolidated statement of stockholders&#x2019; equity for the three and six months ended June 30, 2021 has been retrospectively adjusted to reflect a credit to accumulated deficit of $21,000 in connection with the adoption of ASC 842 effective January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Amendment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 11, 2022, we amended one of our operating leases to expand rentable space in Phoenix, Arizona. We intend to use the additional space for general office and laboratory use. The term of the amended lease will begin upon the completion of certain leasehold improvements by the Phoenix landlord (the &#x201c;Phoenix Commencement Date&#x201d;) and continue for an initial term of 10.3 years from the Phoenix Commencement Date. Total undiscounted future minimum payment obligations as of June&#160;30, 2022 associated with the lease amendment totaled approximately $1.4&#160;million. As of June&#160;30, 2022, we have not recorded the lease amendment on our condensed consolidated balance sheet because we do not have possession or control of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pittsburgh Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we entered into a lease agreement (the &#x201c;Pittsburgh Lease&#x201d;) for the lease of certain office space in Pittsburgh, Pennsylvania. We intend to use such space for general office and laboratory use. The term of the Pittsburgh Lease will begin upon the completion of certain leasehold improvements by the landlord (the &#x201c;Pittsburgh Commencement Date&#x201d;) and continue for an initial period of 10.5 years from the Pittsburgh Commencement Date. During the first six months of the lease term, we are required to remit base rent of $37,800 for the period. Beginning with month seven, the base rent will be $0.6&#160;million per year with annual increases ultimately resulting in base rent obligations totaling $1.5&#160;million per year. The landlord under the Pittsburgh Lease has agreed to contribute up to $2.5&#160;million towards the cost of the leasehold improvements and we will be responsible for any costs exceeding this amount. The Pittsburgh Lease also provides us a one-time option that would terminate the lease effective at the end of the 90th month following the Pittsburgh Commencement Date, subject to certain conditions. If exercised, we would pay an early termination fee of $2.3&#160;million, subject to adjustment in the event the Pittsburgh Lease is amended to adjust the base rent. The Pittsburgh Lease provides us one five-year renewal option and also provides us a right of first refusal with respect to the lease of certain additional space in the same building. As of June&#160;30, 2022, we have not recorded the Pittsburgh Lease on our condensed consolidated balance sheet because we do not have possession or control of the underlying asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTg5Nw_09ab88fb-db53-4395-8c1d-71176876b7b2">The changes are set forth in the table below (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Before Adoption of ASC 842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effect of Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;After Adoption of ASC 842&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Effect on Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OPERATING ACTIVITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNS0xLTEtMS05NzI3Mg_cb0662dc-cf13-4f11-82db-350827da1c87"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib1494102bc084aa0a7b78f886f46a23c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNS0zLTEtMS05NzI3Mg_76a32381-8331-4172-8dcc-af19a7177078"
      unitRef="usd">462000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia0a424bc53f249fd89099cba54892a4c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNS01LTEtMS05NzI3Mg_67c43214-b04f-42ff-bb7b-09aa6f9853b5"
      unitRef="usd">462000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNi0xLTEtMS05NzI3Mg_4140c293-33be-4fcc-93cb-15fb8fd6c988"
      unitRef="usd">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib1494102bc084aa0a7b78f886f46a23c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNi0zLTEtMS05NzI3Mg_e33003a9-9542-4460-b5f3-a56a67d38ef9"
      unitRef="usd">590000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia0a424bc53f249fd89099cba54892a4c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNi01LTEtMS05NzI3Mg_46a947fd-2b45-4ee4-afa1-12fe30b6a2de"
      unitRef="usd">590000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherLiabilities
      contextRef="i2c649fe497204cb2a717f0ed7d84eb66_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNy0xLTEtMS05NzI3Mg_bc3335ff-88ef-449f-b6b6-6867aac5a20d"
      unitRef="usd">128000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="ib1494102bc084aa0a7b78f886f46a23c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNy0zLTEtMS05NzI3Mg_c671473d-8b6e-4d70-9ba3-eb0d167972e0"
      unitRef="usd">-128000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="ia0a424bc53f249fd89099cba54892a4c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RhYmxlOjFlMWVmNDViNWVkNTQ0NmQ5YWY0YTI1MzBmYTI0OGIzL3RhYmxlcmFuZ2U6MWUxZWY0NWI1ZWQ1NDQ2ZDlhZjRhMjUzMGZhMjQ4YjNfNy01LTEtMS05NzI3Mg_544c01f1-0ae0-4106-a62b-99251bab4b26"
      unitRef="usd">0</us-gaap:OtherLiabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i50e94943a8f84b59ae78cc37b86399dd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTA4NQ_1cd23400-e8e9-4b04-a4de-e5951aadfea8"
      unitRef="usd">21000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="if08210db194a470bb8c79782f96d1583_I20220311"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTU0NQ_d4d16a36-ae72-48eb-a834-ed12ae98ef47">P10Y3M18D</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <cstl:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfMTcxNw_158f9e90-bc87-480b-9e7e-197c52ef6a6f"
      unitRef="usd">1400000</cstl:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjczMg_c9048e30-d749-4ded-96bc-d576c97cf309">P10Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cstl:LesseeOperatingLeaseBaseRent
      contextRef="ib08a4fbd714c45cdbc0c0ef66a81837b_D20220401-20220401"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjczNA_0fbfe551-620a-429a-b27a-6080714e4762"
      unitRef="usd">37800</cstl:LesseeOperatingLeaseBaseRent>
    <cstl:LesseeOperatingLeaseBaseRent
      contextRef="id35ad05f10784973b277cc9339184bd2_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc4NQ_5c50134a-5b95-433d-932f-d6f9c8bc2b52"
      unitRef="usd">600000</cstl:LesseeOperatingLeaseBaseRent>
    <cstl:LesseeOperatingLeaseMaximumBaseRent
      contextRef="i1f9e74951a454794934048985403ea08_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc0Mw_faeb4415-700a-4d8a-a762-18449b1e1b6b"
      unitRef="usd">1500000</cstl:LesseeOperatingLeaseMaximumBaseRent>
    <us-gaap:TenantImprovements
      contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc1Nw_5ef4bcf3-a834-4e54-960b-f3a0a18eee4d"
      unitRef="usd">2500000</us-gaap:TenantImprovements>
    <cstl:LesseeOperatingLeaseNumberOfOptionsToRenew
      contextRef="i1f9e74951a454794934048985403ea08_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc5OA_2b8e727f-7790-41c1-82e5-ed1b36d93ba8"
      unitRef="claim">1</cstl:LesseeOperatingLeaseNumberOfOptionsToRenew>
    <cstl:LesseeOperatingLeaseOptionToTerminateTerm
      contextRef="i1f9e74951a454794934048985403ea08_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjgwOQ_c4429703-0c1a-42aa-bef4-234cd89dd4b3">P90M</cstl:LesseeOperatingLeaseOptionToTerminateTerm>
    <cstl:LesseeOperatingLeaseEarlyTerminationFee
      contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3Mjc3MQ_1e8d07db-448e-4357-ba81-43d8f3cd7600"
      unitRef="usd">2300000</cstl:LesseeOperatingLeaseEarlyTerminationFee>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6189c92d6a1a43a9b30ddec4f64e4dab_I20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81Mi9mcmFnOmE3ZDJhNTVmOTdhZTQ5YWFiMzJiODE1ZGYyMGQzY2VhL3RleHRyZWdpb246YTdkMmE1NWY5N2FlNDlhYWIzMmI4MTVkZjIwZDNjZWFfNjU5NzA2OTc3MjgxMg_885537ce-1f68-4df2-a53b-ed4bd2bef245">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjM3NA_b9893214-23fa-4430-ad70-6a21696464b5">Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information, by level within the fair value hierarchy, of our financial assets and financial liabilities that are accounted for at fair value on a recurring basis as of&#160;June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Items (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Items (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Classified as &#x201c;Cash and cash equivalents&#x201d; in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Current portion, if any, classified as &#x201c;Other accrued and current liabilities&#x201d; in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Cernostics, we have recorded a contingent consideration liability for the additional consideration of up to $50.0 million that may become payable based on the achievement of certain commercial milestones relating to the year ending December 31, 2022 (&#x201c;Cernostics Earnout Payments&#x201d;). The Cernostics Earnout Payments may be settled in cash or shares of our common stock, at our sole discretion. The portion of any Cernostics Earnout Payments that may be settled in shares of our common stock is subject to certain limitations and the aggregate number of shares that may be issued for the Cernostics Earnout Payments may not exceed 5,034,653 shares. Any Cernostics Earnout Payments in shares of our common stock will be based on the volume weighted-average price of our common stock for the 15 trading days ending December 30, 2022. If the settlement were to occur as of June&#160;30, 2022, we would make no Cernostics Earnout Payments based on the achievement of the performance conditions to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of AltheaDx, we have also recorded a contingent consideration liability for the additional consideration of up to $75.0 million that may become payable based on the achievement of certain commercial milestones relating to the years ending December 31, 2022, 2023, and 2024, as discussed further in Note 5. If the settlement were to occur as of June 30, 2022, we would make no AltheaDx Earnout Payments based on the achievement of the performance conditions to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is classified as a Level 3 fair value measurement due to the use of significant unobservable inputs and a Monte Carlo simulation to determine its fair value. The Monte Carlo simulation uses projections of the commercial milestones for the applicable period as well as the corresponding targets and approximate timing of payment based on the terms of the arrangement. The analysis for the Cernostics Earnout Payments uses assumptions for expected volatility of the financial metrics and a risk-adjusted discount rate, which were 40.0% and 20.2%, respectively, as of June&#160;30, 2022, and 20.0% and 16.1%, respectively, as of December 31, 2021. The assumptions for expected volatility of the financial metrics used in the analysis for the AltheaDx Earnout Payments was 36.0% as of June&#160;30, 2022. The risk-adjusted discount rate for years 2022, 2023, and 2024 were 6.3%, 7.4% and 7.5%, respectively. The contingent consideration liability is remeasured at fair value at &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each reporting period taking into account any updated assumptions or changes in circumstances. Any changes in the fair value are recorded as gains or losses in our condensed consolidated statement of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs as of June&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cernostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AltheaDx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of AltheaDx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjM3NQ_f680dee7-4cbf-418b-b50b-6d4ee45d5852">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides information, by level within the fair value hierarchy, of our financial assets and financial liabilities that are accounted for at fair value on a recurring basis as of&#160;June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Items (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Items (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Classified as &#x201c;Cash and cash equivalents&#x201d; in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Current portion, if any, classified as &#x201c;Other accrued and current liabilities&#x201d; in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibb8ceb3988914d2f9c2a79143d8fb4b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy0xLTEtMS05NzI3Mg_940967af-6ca2-437a-8dc6-503ef8f2b67e"
      unitRef="usd">266803000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i21125ac2093648aea31470a65bc3c38d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy0zLTEtMS05NzI3Mg_ebe08de6-ab78-464f-8b15-8d2d756fa471"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i104f7bbc8cb7403d8a1ec5e1df30fa49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy01LTEtMS05NzI3Mg_41f4bd2a-7ddc-47eb-94e8-df52c96b47fb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6324a446c6ed44dcb012258eeb725d85_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfMy03LTEtMS05NzI3Mg_80439928-c1af-407f-a3f5-96326b45bf34"
      unitRef="usd">266803000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="ibb8ceb3988914d2f9c2a79143d8fb4b7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS0xLTEtMS05NzI3Mg_cb2fef24-c344-4329-8abf-40d6ca7e8a9a"
      unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="i21125ac2093648aea31470a65bc3c38d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS0zLTEtMS05NzI3Mg_4a7e09ce-bc2b-48d5-962c-05bb99e60a4d"
      unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="i104f7bbc8cb7403d8a1ec5e1df30fa49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS01LTEtMS05NzI3Mg_e5b4a821-7e8d-41f2-928d-f4f973f0fad9"
      unitRef="usd">1979000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="i6324a446c6ed44dcb012258eeb725d85_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOmU4NzlhZTk3ZWI3MjQ4ODI4MjlmYTJjZGFjNDQ0MWU2L3RhYmxlcmFuZ2U6ZTg3OWFlOTdlYjcyNDg4MjgyOWZhMmNkYWM0NDQxZTZfNS03LTEtMS05NzI3Mg_3682ba9c-bd7c-41a6-9d1f-d50f9c076e54"
      unitRef="usd">1979000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ide11ef39260549e8a2e5914ad0f0afcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy0xLTEtMS05NzI3Mg_28bff3f5-5c64-43e1-9e3a-59d89e61cedb"
      unitRef="usd">327721000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8ff935b4508458d896d72b6072dda6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy0zLTEtMS05NzI3Mg_731fd8a3-6f5e-496d-9e67-565f16ce1ae4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6fb402740817463da336bf3ad4500350_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy01LTEtMS05NzI3Mg_b6a18a57-3682-4d5a-b092-bbdba6eb5dc7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i684e2cbe0aee4089866a63e63228dd12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfMy03LTEtMS05NzI3Mg_afda9244-3768-490f-969c-cce82b665125"
      unitRef="usd">327721000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="ide11ef39260549e8a2e5914ad0f0afcf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS0xLTEtMS05NzI3Mg_f1489515-f728-40da-a56c-1d4990bf2d97"
      unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="if8ff935b4508458d896d72b6072dda6d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS0zLTEtMS05NzI3Mg_90988484-586f-4536-ba44-a27954db454a"
      unitRef="usd">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="i6fb402740817463da336bf3ad4500350_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS01LTEtMS05NzI3Mg_dd159ebb-3538-47aa-bbac-02bd19ec7b72"
      unitRef="usd">18287000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="i684e2cbe0aee4089866a63e63228dd12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjYyMTA1MWNiMTQ2ZTQ3YjA4YTkwNjg2MzJkZDY4M2Q0L3RhYmxlcmFuZ2U6NjIxMDUxY2IxNDZlNDdiMDhhOTA2ODYzMmRkNjgzZDRfNS03LTEtMS05NzI3Mg_e35a76d3-a43f-4f43-8d2e-30d4647d7e53"
      unitRef="usd">18287000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <cstl:AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjM5OQ_b8387e0d-31c8-4df4-a139-67c82b995ae7"
      unitRef="usd">50000000</cstl:AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <cstl:AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares
      contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjQwNg_e30ed576-eff4-4cc1-b7a8-29dc093ded87"
      unitRef="shares">5034653</cstl:AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares>
    <cstl:AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice
      contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjQxMQ_6a39714e-827f-4c18-9e72-e913d915fa0e"
      unitRef="tradingday">15</cstl:AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib99692ae97b9426581ef0e9d0e18336f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjE5OTAyMzI2MjM4MA_4823b8f8-db0b-42d7-83ac-94fb84a72416"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="i02b6b0adf1ed4564ab66d5e6c116b521_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc0OA_47b380e2-b45a-4ba5-82a6-82c2bce668a2"
      unitRef="number">0.400</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="i02dfd58348864c25bf52e8044eb44e80_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc1Mw_2215c52f-33c0-448f-a9a9-380333b95311"
      unitRef="number">0.202</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="i64336bd6bad643a38e66641fec94637b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc2MQ_b79d0202-a8d1-4f65-bea9-70ee645964b5"
      unitRef="number">0.200</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="if05f1698a24e4537b9b6e321a862849e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzc2OQ_4fd7955a-c278-48b3-92cb-559c4f4ae8d2"
      unitRef="number">0.161</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="iab51d3dc6bd949c99033fd013c8820dd_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzMzk5OA_23e1f0e4-19ea-4484-a5c2-5f227991067b"
      unitRef="number">0.360</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="i3d374e88975f4250b70acfc62ee7b455_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzNTcwMg_fabc4e74-4c7a-4cda-8154-bcdcac71001f"
      unitRef="number">0.063</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="i683d8e181278402690a483021f8294d6_D20230101-20231231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzNTcwNw_ce1b5525-01b8-48a9-b8ca-71a064fa4acf"
      unitRef="number">0.074</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput
      contextRef="i3f8aa2919a654f9fb404a6244f4977b1_D20240101-20241231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMTA5OTUxMTYzNTcxNg_77464cd9-e090-4bf1-89da-eabfa07c22a9"
      unitRef="number">0.075</cstl:AcquisitionContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RleHRyZWdpb246MTljNWQ0ODM1MzYyNGQ1MjgzOTRhOGRiOWE2M2JhYjNfMjM3Mw_437a8385-ca0f-454a-bb01-8ad2f23a735c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table discloses the summary of changes in the contingent consideration liability measured at fair value using Level 3 inputs as of June&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cernostics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;AltheaDx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of AltheaDx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if2b51146ced54358bef8f0e24c5ad59a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMS0yLTEtMS05NzI3Mg_2d5cc0e8-8822-4636-a528-1bff03958b6c"
      unitRef="usd">18287000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iec0ab012cf684932bc3842b6be81dc6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMS00LTEtMS0xMDM2NjA_47956f86-1598-4930-9095-2b91a2e9bf83"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMS02LTEtMS0xMDM2Njc_8863d054-58d5-43fb-b8ac-1495f3533b0e"
      unitRef="usd">18287000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i30a1bb97eb834ce49721240374fb0bcd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMi0yLTEtMS05NzI3Mg_385855f1-4f74-4207-b9ee-954963e6423f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMi00LTEtMS0xMDM2NjA_4c1e74a2-6643-4b57-90be-40207cad1f23"
      unitRef="usd">1528000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMi02LTEtMS0xMDM2Njc_d118c17a-de06-49e6-afcc-ef3b4b8a4120"
      unitRef="usd">1528000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i30a1bb97eb834ce49721240374fb0bcd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMy0yLTEtMS05NzI3Mg_da55a4e3-7e82-4e9f-9718-1d4c7032043a"
      unitRef="usd">-18257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMy00LTEtMS0xMDM2NjA_bb582042-f129-4227-a448-6958b0b6b00f"
      unitRef="usd">421000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfMy02LTEtMS0xMDM2Njc_cde43905-e0e1-442e-bdca-d97acad10c42"
      unitRef="usd">-17836000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i028a35f4072e424b80f6c2c0e7c85713_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfNC0yLTEtMS05NzI3Mg_72fbcf00-6cf0-4867-adee-ee20f70c47f0"
      unitRef="usd">30000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib99692ae97b9426581ef0e9d0e18336f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfNC00LTEtMS0xMDM2NjA_19ba3b63-db64-4160-b3c7-f2e1434ed615"
      unitRef="usd">1949000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81NS9mcmFnOjE5YzVkNDgzNTM2MjRkNTI4Mzk0YThkYjlhNjNiYWIzL3RhYmxlOjdlMTJkYWEwMzg2ODQxMmU5YWJlMDhlNDdlMGVhOWQxL3RhYmxlcmFuZ2U6N2UxMmRhYTAzODY4NDEyZTlhYmUwOGU0N2UwZWE5ZDFfNC02LTEtMS0xMDM2Njc_a57add8f-199c-4981-bd40-221e6c06078f"
      unitRef="usd">1979000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV81OC9mcmFnOjllZTM3NWQ3MTE0NzQyYjM4NjNkNDI3MzkyYTM3Yjg1L3RleHRyZWdpb246OWVlMzc1ZDcxMTQ3NDJiMzg2M2Q0MjczOTJhMzdiODVfMzQ5_32204fb9-6f0c-4ad5-85e0-f74aa4cc70fd">Commitments and Contingencies From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMg_80878a23-780d-4d3e-b0ec-bdb36d7eb6a5">Stock Incentive Plans and Stock-Based Compensation&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, an additional 1,268,926 shares became available under our 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) pursuant to an automatic annual increase. As of June&#160;30, 2022, 586,155 shares remained available for grant under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under our stock plans for the six months ended June&#160;30, 2022 is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU activity for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679,954&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP provides for certain automatic increases in the number of shares of common stock reserved for issuance, which resulted in an additional 253,785 shares becoming available under the ESPP effective January 1, 2022. During the six months ended June&#160;30, 2022, we issued 42,332 of common stock pursuant to scheduled purchases under the ESPP. As of June&#160;30, 2022, 850,919 shares remained available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Determining Fair Value - Summary of Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes option pricing model to estimate the fair value of each option grant on the date of grant or any other measurement date. The following table sets forth the assumptions used to determine the fair value of stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.34% - 71.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.94% - 67.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54% - 2.91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51% - 1.09%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.98% - 66.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.43% - 86.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 1.30%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.07% - 0.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our common stock is also an assumption used to determine the fair value of stock options and purchase rights under the ESPP. The fair value of our common stock is the closing price per share, as reported by the Nasdaq Global Market, on the date of grant or other relevant determination date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Previously, because of the limited period of time our stock had been traded in an active market, we calculated expected volatility by using the historical stock prices of a group of similar companies looking back over the estimated life of the option or the ESPP purchase right and averaging the volatilities of these companies. In the third quarter of 2021, we adjusted this calculation to include our own stock price on a relative basis to the peer group in the calculation of expected volatility, as our common stock has now been traded in an active market for more than two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the closing price of our common stock on the date of grant to determine the fair value of RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options, RSUs and the ESPP is included in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales (exclusive of amortization of acquired intangible assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the six months ended June 30, 2022 and 2021, the weighted-average grant date fair value of options granted was $14.07 and $41.35 per option, respectively, and the weighted-average grant date fair value of the purchase rights granted under the ESPP was $19.91 and $39.26 per share, respectively. As of June&#160;30, 2022, the total unrecognized compensation cost related to outstanding awards was $99,493,000, which is expected to be recognized on a straight-line basis over a weighted-average period of 3.0 years. The total unrecognized compensation cost will be adjusted for forfeitures in future periods as they occur.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="iedeeba3b13c34684a6126c12757e02db_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMTIz_c33a6263-f539-41f7-a3df-b3e35962a615"
      unitRef="shares">1268926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4e3ed91cdcfc41dfa12bd21a3ade3077_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjU3_ef50f65d-a376-4f9e-a2f6-b35d4f06a41e"
      unitRef="shares">586155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMw_33039886-3f83-4f8c-ae9e-c3a76b0952dc">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under our stock plans for the six months ended June&#160;30, 2022 is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfMi0yLTEtMS05NzI3Mg_050ba082-71ce-4517-918a-8df337d34a42"
      unitRef="shares">3586688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i34a7685d73ad478787bdd4c9c2c2eb52_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfMi00LTEtMS05NzI3Mg_0b8e2e2b-07bf-4e41-998d-5741f9ae09cb"
      unitRef="usdPerShare">34.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNC0yLTEtMS05NzI3Mg_17041232-941f-4fa7-aa04-b81356175c79"
      unitRef="shares">231376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNC00LTEtMS05NzI3Mg_16255d20-77e6-4828-bd70-c8364ec26915"
      unitRef="usdPerShare">22.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNS0yLTEtMS05NzI3Mg_530a64b1-177a-44c2-9f4a-a41034d51efd"
      unitRef="shares">98953</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNS00LTEtMS05NzI3Mg_d3584943-9953-46ff-9a16-1abd025652e9"
      unitRef="usdPerShare">5.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNi0yLTEtMS05NzI3Mg_4ae14122-a8d6-47f7-b1c3-0c3ee5ef8a39"
      unitRef="shares">140468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNi00LTEtMS05NzI3Mg_9928c285-7afe-439b-bf98-2c68cd8f9f54"
      unitRef="usdPerShare">35.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy0yLTEtMS05NzI3Mg_06191fae-d532-49e2-be10-03e5b3d7f401"
      unitRef="shares">3578643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy00LTEtMS05NzI3Mg_2a8705c9-d817-4361-91d6-29a4f55cc057"
      unitRef="usdPerShare">34.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy02LTEtMS05NzI3Mg_3bf3d4e1-3735-4f11-bd5e-3bb995c579ef">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfNy04LTEtMS05NzI3Mg_633b52ac-c35c-4241-9a1d-cb99a4e2294c"
      unitRef="usd">12314000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC0yLTEtMS05NzI3Mg_da66b5b8-9bdb-416f-b0f6-a9b9dbd81daa"
      unitRef="shares">1599766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC00LTEtMS05NzI3Mg_e1b3f086-944b-4ea2-b373-9a11d4668c91"
      unitRef="usdPerShare">26.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC02LTEtMS05NzI3Mg_8228203b-e7de-47a0-98cb-9f99f1ece1f5">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmI4Y2Q3NzUwNTQ3MTQ0MmVhOWFhZmQ3NjQxNDhiNmFhL3RhYmxlcmFuZ2U6YjhjZDc3NTA1NDcxNDQyZWE5YWFmZDc2NDE0OGI2YWFfOC04LTEtMS05NzI3Mg_ad62da32-44c6-417b-9f2f-2c693aa56520"
      unitRef="usd">10253000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMQ_82e2e4f8-1512-4beb-b081-c654038722a2">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU activity for the six months ended June&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,679,954&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="id49668ed558840d8a0b90ca6b883101e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMS0xLTEtMS05NzI3Mg_06e94292-5ad5-4d9c-80a8-a3c45ec14fd5"
      unitRef="shares">1050174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id49668ed558840d8a0b90ca6b883101e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMS0zLTEtMS05NzI3Mg_8ad5388a-2d88-4eed-9423-ed52feebb510"
      unitRef="usdPerShare">44.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMi0xLTEtMS05NzI3Mg_922992f6-a20f-427c-a099-8622beda61ba"
      unitRef="shares">705430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMi0zLTEtMS05NzI3Mg_0c9ea49a-6088-4543-9c4b-85fc7d8f2024"
      unitRef="usdPerShare">23.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMy0xLTEtMS05NzI3Mg_5a2740ac-276a-4356-a8d4-956298ab1ad9"
      unitRef="shares">11475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfMy0zLTEtMS05NzI3Mg_79aa9022-2dbb-4f6f-b9fa-98e5f55f026b"
      unitRef="usdPerShare">69.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNC0xLTEtMS05NzI3Mg_42c9ec20-dc25-4322-a830-4bdc80a4eea6"
      unitRef="shares">64175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0d17cc44838d4c4c9bdddfaefab3c206_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNC0zLTEtMS05NzI3Mg_1c247027-2de1-4f9b-8b7e-888add3578f9"
      unitRef="usdPerShare">35.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i4165eb4a39cb4beb89cc3cbf69e6654d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNS0xLTEtMS05NzI3Mg_95c7dff1-e841-471b-bd4e-9b815a68a227"
      unitRef="shares">1679954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4165eb4a39cb4beb89cc3cbf69e6654d_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmJiM2ZhMTM4MzRiNDQ0MDg5OTdjMDVmZjRjZDlkOTQxL3RhYmxlcmFuZ2U6YmIzZmExMzgzNGI0NDQwODk5N2MwNWZmNGNkOWQ5NDFfNS0zLTEtMS05NzI3Mg_53ff0b86-976b-4bce-add5-6b31e8e768af"
      unitRef="usdPerShare">35.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i7805af27e10c4b63a1bc23dc07855219_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfNjk5_1350180a-6f45-4c71-ac31-0357d074980e"
      unitRef="shares">253785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i11a61c8eb4b741ceae0ea9615e6fd60b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfODEx_2bbf3027-4982-45cf-98c6-ab6d2d5f2e7c"
      unitRef="shares">42332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6684a747cbc242f286866f7a3ae50ae7_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfODg4_986f3a4b-03f6-4087-8030-e30e6f69f263"
      unitRef="shares">850919</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzNQ_ccb254b1-630b-44d4-8f5e-76581ec7cdac">The following table sets forth the assumptions used to determine the fair value of stock options:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.34% - 71.58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.94% - 67.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54% - 2.91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51% - 1.09%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMi0xLTEtMS05NzI3Mg_5c092225-f8e3-4c88-afb6-be5cc3e99b32">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMi0zLTEtMS05NzI3Mg_9e1221d3-85c2-408f-9962-d36cdaaa84f9">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjk5MzE2NzAzMzA2NDQ1MWNiNGNkNzFjYmJjNTRkMGJiXzQ_6b332243-0add-44d4-b2cd-c6cd6ded4182"
      unitRef="number">0.6834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjk5MzE2NzAzMzA2NDQ1MWNiNGNkNzFjYmJjNTRkMGJiXzk_90660bb2-3afc-4f96-9dee-9e23baf13386"
      unitRef="number">0.7158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmNkMzY1MGFjMzJlZjQ5ZmY5YTI3YjFmMzgyYWQzNmI4XzQ_c38e501f-f286-487f-817e-32c067bb4efd"
      unitRef="number">0.6694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmNkMzY1MGFjMzJlZjQ5ZmY5YTI3YjFmMzgyYWQzNmI4Xzk_baba71e4-ceb7-4fdd-8d27-50b5c82940d9"
      unitRef="number">0.6798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjVlOTFhN2U3NDY1YTQ2OWE5ZmVjNjRiYWNhNTcwMzU5XzQ_7a74c666-dd51-4461-a3ab-3d0c8efc6a5f"
      unitRef="number">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjVlOTFhN2U3NDY1YTQ2OWE5ZmVjNjRiYWNhNTcwMzU5Xzk_729b5f90-2922-4979-93aa-38240300f738"
      unitRef="number">0.0291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjE0NzUyNWE3YWNiMTQwZWE5MjU1ZmI4YWI2ZDJkMjFiXzQ_2b3b71f2-54a3-4bee-8a0c-cce9089b4b01"
      unitRef="number">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjE0NzUyNWE3YWNiMTQwZWE5MjU1ZmI4YWI2ZDJkMjFiXzk_41874965-446c-439b-af5d-dbdf79246505"
      unitRef="number">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNS0xLTEtMS05NzI3Mg_ee46c70c-6b4a-4378-ac8e-67f637350bf8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmYyZWJkMzNlMWE1NTRhZDM4N2QzMjAzYTlkNjc0MDdiL3RhYmxlcmFuZ2U6ZjJlYmQzM2UxYTU1NGFkMzg3ZDMyMDNhOWQ2NzQwN2JfNS0zLTEtMS05NzI3Mg_8db0b5f7-9423-432b-ba1d-7431b344fa77"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzNg_ea03fdc0-16ee-4989-bda3-08683fe47cb9">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth assumptions used to determine the fair value of the purchase rights issued under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.007%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.98% - 66.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.43% - 86.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 1.30%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.07% - 0.13%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMi0xLTEtMS05NzI3Mg_f47d50dc-1bed-41c2-b425-88f43cf47803">P1Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMi0zLTEtMS05NzI3Mg_8e01065f-d415-4fc8-8d78-932ec9e6b767">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmI1ZmMwNTMwMjExODQ2MWI5MWQ0Zjk0M2VkNThlMzcwXzQ_c2cc72dd-7fae-4224-81c6-4bb6339ce725"
      unitRef="number">0.6298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmI1ZmMwNTMwMjExODQ2MWI5MWQ0Zjk0M2VkNThlMzcwXzk_00cb99b1-8596-4883-bbd2-5fab2ac97243"
      unitRef="number">0.6675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmQ5OWM1MTE1NDA4YjQ2YjdiZmU2MDU1YjAwNDE1YWNkXzQ_72f0a011-996b-48b3-8cd1-6794f646d7a8"
      unitRef="number">0.6843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfMy0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmQ5OWM1MTE1NDA4YjQ2YjdiZmU2MDU1YjAwNDE1YWNkXzk_66355d15-95c6-459b-8fc4-51ce3df7ed57"
      unitRef="number">0.8650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjAwNDczZDFiNWYxZTQzYjE4YWYxZTA5MWZkNTM4ZTYyXzQ_98c9e6f1-e56c-4f08-b965-dae27bd62858"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0xLTEtMS05NzI3Mi90ZXh0cmVnaW9uOjAwNDczZDFiNWYxZTQzYjE4YWYxZTA5MWZkNTM4ZTYyXzk_285ada11-d712-4428-a110-d8cccb2db4cf"
      unitRef="number">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmUyYmFhNjE3NjNhMDQxNmViYmNmNjI4MDhhZWJlOWFjXzQ_a1c4a227-0205-4383-8b6f-f8b88c790ac0"
      unitRef="number">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNC0zLTEtMS05NzI3Mi90ZXh0cmVnaW9uOmUyYmFhNjE3NjNhMDQxNmViYmNmNjI4MDhhZWJlOWFjXzk_945500b5-9e53-4e4a-b2ce-5764239579f3"
      unitRef="number">0.0013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNS0xLTEtMS05NzI3Mg_03851f15-ab46-40da-8da8-0f1b7eae1f66"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOmQwZjk4MTM5MTVmYjQxODk4MTg0YzUxNDRiMWUyNjQwL3RhYmxlcmFuZ2U6ZDBmOTgxMzkxNWZiNDE4OTgxODRjNTE0NGIxZTI2NDBfNS0zLTEtMS05NzI3Mg_a1bd96d6-53e9-466a-b96e-0ef1ec704de3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzNA_62a5bdc4-0f4d-4534-9d25-47709d609415">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options, RSUs and the ESPP is included in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales (exclusive of amortization of acquired intangible assets)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01f3cc6a21d0455faa3a247ed3871fc2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi0xLTEtMS05NzI3Mg_91bf37e5-8342-4b8d-816a-d8a5559bf94b"
      unitRef="usd">897000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i695763ce94f847ecb79699e832614ae4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi0zLTEtMS05NzI3Mg_6de08957-ddd4-47bd-99be-ac6ebcc48dac"
      unitRef="usd">415000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5660ce4bef94584b72a1722257e6ddd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi01LTEtMS05NzI3Mg_45137ba9-e6a2-4b38-af54-9c2b3735a3c7"
      unitRef="usd">1750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1cf326b10a224bb6a24085924905410c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMi03LTEtMS05NzI3Mg_34975c32-ffa9-4ee4-adf1-cfc60b481bed"
      unitRef="usd">925000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib90b080f71e6434ea6c9ba3acadadcef_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy0xLTEtMS05NzI3Mg_dd758946-9f40-4fe2-ab18-2bc8efe14569"
      unitRef="usd">1831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibcfa896825f1413cb48c6b0e5e4b5954_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy0zLTEtMS05NzI3Mg_66cb1cb4-2f3d-4764-b7b1-d5d4dd588d4f"
      unitRef="usd">1073000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f7c25b470c347d698685f93340964f3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy01LTEtMS05NzI3Mg_06d922d9-17e5-4724-81b6-9d1959b9a4ba"
      unitRef="usd">3659000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3700a82a151f4c0a8bda6c74f43fe33d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfMy03LTEtMS05NzI3Mg_8c1ec7d0-6114-490c-88ba-e148c67a5711"
      unitRef="usd">2131000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb27d09e15f1493bafb7c9641c3f51aa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC0xLTEtMS05NzI3Mg_72977626-4248-4ec6-bb3d-bb08894b63bf"
      unitRef="usd">6055000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d2f11e2e9a840b5a7a47d3f927f7647_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC0zLTEtMS05NzI3Mg_4e705788-366a-495c-a65b-fb639543a37c"
      unitRef="usd">3278000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id95b5f253eb44af8b25296728af91542_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC01LTEtMS05NzI3Mg_48890376-0119-4a6e-998b-30a7acb8afe9"
      unitRef="usd">11793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53b3a400ca564d61a070f1edf776917a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNC03LTEtMS05NzI3Mg_3809dae0-259b-4950-92e9-071962270c79"
      unitRef="usd">6623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf13288bff8d454995f61e624f289d17_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS0xLTEtMS05NzI3Mg_1488b25e-830b-4675-95c2-2eeaf3ce4b76"
      unitRef="usd">8783000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i144953382d8b47ff8b198e4c4bce9086_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS0zLTEtMS05NzI3Mg_3cb3fa1d-11ab-4a30-9aeb-38235ddd55dd"
      unitRef="usd">4766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS01LTEtMS05NzI3Mg_f357d2c9-8c5e-4400-bdae-5b381e0597f6"
      unitRef="usd">17202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9e0f06ad66644c878292a8eaa3373e37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RhYmxlOjA1MDQ1NTM4YzRiMTRhMzI4NjQ0ZTJlNGU3YzUxNDdlL3RhYmxlcmFuZ2U6MDUwNDU1MzhjNGIxNGEzMjg2NDRlMmU0ZTdjNTE0N2VfNS03LTEtMS05NzI3Mg_fe8c6e28-c005-4561-9901-79e37c2e58dc"
      unitRef="usd">9679000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i34cc9a7509d048d2b5c360336e79561e_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjY2Mw_189d78c8-aa18-4092-bc9b-45e98c6a86e7"
      unitRef="usdPerShare">14.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if68633edb0424ccdae1cb02848e2d1bb_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjY3MA_7b538fd6-10ab-4bbf-9e80-95804ae8cb21"
      unitRef="usdPerShare">41.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjc5Ng_7662c63c-2488-4dd4-9570-024eba17f0c4"
      unitRef="usdPerShare">19.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie2bc1a51fe8d4438bffd2b15c805045c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjgwMw_6bd17255-0c12-4ed9-925d-7e9547ff68d2"
      unitRef="usdPerShare">39.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i43af39ae2b5a4502ad42c6b29becf672_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMjkxNg_df40f035-2713-4d7a-badf-61e4bebff14a"
      unitRef="usd">99493000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV82MS9mcmFnOmVhZDA2ZGY4MGVmMzQ4NTA5NjMxYzg0NWFhM2QzMWE3L3RleHRyZWdpb246ZWFkMDZkZjgwZWYzNDg1MDk2MzFjODQ1YWEzZDMxYTdfMzEzMA_e54ce461-4b2a-4dd8-a91b-64d81c4f7ae6">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl82NTk3MDY5NzY4NTkz_0cab010f-1dee-4c5b-881b-d4270fcc9cf3">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of AltheaDx, we recorded $1,819,000 in deferred tax liabilities based on our &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;preliminary allocation of the fair values of assets acquired and liabilities assumed. As a result of these additional deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we determined that $1,769,000 of our existing valuation allowance on deferred tax assets should be reduced, which was reflected in our income tax benefit on the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 as a discrete item.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i140b75ca6fb545eca7808706ff716d73_I20220426"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl8xMjY0NDM4MzcyMTM2Ng_efa6077b-6c96-45ff-a41c-7fa2872d7351"
      unitRef="usd">1819000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i69c23aa5f3c441ffb833f0742c2320c3_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl8xMjY0NDM4MzcyMTQ2MQ_06997d0f-6220-43bb-91b9-ef694c6d4a49"
      unitRef="usd">-1769000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZWQ3M2NlODhiMzQxMTg5NjVmMzZmNjZjMjk4YWUxL3NlYzo4NWVkNzNjZTg4YjM0MTE4OTY1ZjM2ZjY2YzI5OGFlMV8xNTc0L2ZyYWc6NTEwM2MzNmNmMmIzNGNlNmI1NGNmNDM2NWEzODVlNmIvdGV4dHJlZ2lvbjo1MTAzYzM2Y2YyYjM0Y2U2YjU0Y2Y0MzY1YTM4NWU2Yl8xMjY0NDM4MzcyMTQ2MQ_d2a67117-e2bc-4781-9879-25f0fce5b6a9"
      unitRef="usd">-1769000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MD, \8&P\7*D8=T<''AI?D;-;<';/[)F2P1*2K0#'VQ'76K P,38D&E81L%<
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MJ*>J LQZWVCZ5;TXQS8$A"'I +6MQB'L*5D$6Q*"7JC7&BA5/+\#*=.<["F
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M=J:WY<Q/":NANG.*/,?S*N##W? 1!!KNIG"W#+>U^R(%7I$"+^6K;^&;*JQ
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M^DN>:JS3(9.U5,6R#H89+--\^Y\_UT+L!4 >/(#5 <P,\(X$N'6 ^]H1O#K
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ME$1W)#67D[WW$]634WD[[@LH^P):LS.)XV(KZBXO+)CLHKM4.SGW7HZ&CQ_
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M965T."YX;6R]6VUSVSB2_BLL[]964B7+LIUDLGFKLIUDUWL[.ZEXLO/AZCY
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M+  -HER1M8>D2H[?J*]P_70NL:T\NJ2UY"CV'+584.:5U$::HFS>)+"$]3I
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MC43=L#]TZQFH2L,"D7:M4*D;2ZA]1?[7AKXQM<Z/##FYTP&:; $>>N>&[BB
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MW/*(X6B.]:MV=GR$2AP>C%H0V,,,ETD"V].M4!>J5DG8FV<LA D[9^9]QUX
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M+]A88/EXP^;@HOS4M/>VYMELX5$!=,O^1!Z\H;L>AM-2W <!Z#6#3O$@C8Z
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M"?*$3I4; B#.O]"!5_'>ZD7MY2)7PAL><*]27N3^&3Z\FMZ<?5:Y+$TA6;
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MC<U8S;9F]N'7SWXV#DRQEIO>Z!?@IK!%X%=@^:'XG0,&N-51$)F*K@.])ZL
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M3<<OSQ)AXX,M;KQIPR-I;3R>7&&))"*F+(#[C8$K_88-#*_FQ3]02P,$%
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M'P+DO'".]T9(,/X'+'\!4$L#!!0    ( 'J("%6O&D8Z*@@  'P4   9
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*U8:6_C.!+]*X1G,D@#BJS#DNUT
M$B#77,#L!,ET]X?%?J EVN9&$M4DY23SZ_<5=<3.V8W9#XE%J5C'JZK'DH[N
ME+XU:R$LNR^+RAR/UM;6A^.QR=:BY,97M:CP9*ETR2V6>C4VM18\=YO*8AP%
M03HNN:Q&)T?NWI4^.5*-+60EKC0S35ER_7 F"G5W/ I'_8UKN5I;NC$^.:KY
M2MP(^ZF^TEB-!RVY+$5EI*J8%LOCT6EX>#8A>2?P68H[LW7-*)*%4K>T^"T_
M'@7DD"A$9DD#Q\]&G(NB($5PXVNG<S28I(W;U[WVGUWLB&7!C3A7Q1>9V_7Q
M:#9BN5CRIK#7ZNY7T<63D+Y,%<;]9W>M; *+66.L*KO-6)>R:G_Y?8?#UH99
M\,J&J-L0.;];0\[+"V[YR9%6=TR3-+31A0O5[89SLJ*DW%B-IQ+[[,F-5=DM
M^ZW*1$7PL*N"5X;Q*F?NR<$9(L[9N2I1!883D$=C"[NT>YQU-LY:&]$K-E+V
MAZKLVK#+*A?Y[OXQ_!V<CGJGSZ(W%?[>5#Z+ X]%012]H2\>0(B=OO@U$-9<
MBR[4*_Z FK/L5&M>K82[_O?IPEB- OK/2\&WNB<OZZ:F.C0US\3Q"%UCA-Z(
MT<E//X1I\/$-SR>#YY.WM/^?TO>FC9<C^'[#[.4ME\NE<)W)?N=5 UY@89M7
M#]H8SW-)FWF!VU$Z\^91R@RER["%R'@I&-]P6?!%(5B#\M),-1K[PSF[_-I(
M^_#$(-NW:\%^^F$61<%')T9WW3K\^('5C38-1\JM<N8;]!^\S[" <P6350;J
M,\)GIX:I)4,EBJ$2/9;,4B],DMY#+8@6@<.CCZ!1MM)DH?66O!G<\#N,_JPI
M9M.M5/W(7Q308YC&/:\=CJ28E!EYS\JVW02UVZZ+3!IF0/60MFL@"$X^9%\<
M=8G\X'0C-)CXB1>7]T)GT@AV[<*1U8J=KE9:K+@5[(S#>H8L.#@N1";*!;R+
MVR2&+/8(DW0V8S^R>.)/$_8+10^_(LC$TQ3WH\@/HL%,SO;GR',2?\"CQ \3
M!OI="HD]XW.R510D$TX";Y+.2"A._$G\Q)/=J.'%=.:ED&J]"-G4G^,ZC+PX
MG/2F78*X?;(W])+YW)NFSM/4G\^Q-Z*]@1<E,4 !-<B,(FIA^U1):]A?:\IU
M 7P)+^M4MP>?_!N50=F[OOGTF-1O2]_A:^;^;*RQZ#XR]BR=#G%V0>GZF4O-
M/O.B>3]SH1<D@1=.)XAU,O'C<,C<-$B\21P0'K$_#]AG^.12$GJ3:4(92>=^
MDKZ<MW0"G4F7MEGX9MI"+YW.40J33AH]7=:%>A!]B5XU.ENC'=O6)LPO;ZZN
M6*W51N:B;8I,:(NRW>KEOHD-KASH5>-"A_VN<7&5J1)YZ%JLH[W<*92&*"(3
M'KM;RVQ-#S$"X"$9V:$LU(<WG25;A*5*RM!3RK*]X^(U,O391:-=);U;(W!+
M.!_Q8(+ZCJ-GX6RS'(UY>4.IJ3LPS1.O7N&Z&:IC#N)ZF^MZL)[IO!!6Z+*E
MDZVJ/& W[7A(%D^QN>Q8Z M4(-&DX*S@.&%NLK4J*%<M/=;H"M)5JEP4%!B*
M4I94\[1E218VS@+T"HZT=?M:,E9M(>0D#X'NID8^X0B>:%:B8AK=S@,DYK_<
MXL*:CEQ)']\*H"%J@U]Y%_A+CIDMPC>'[ :)WAZ=VJYPW=GWMKBOA6,#4LKV
M'P37Y@-H<\92T%KWK,LZ$!)LHPHT04&<D\[\>+('R*>AG\SV6 IV<^L4[(CU
MM32W!TN-;I/H>R39,DT 0=J)1?X\W&.!GX2T"OU@OL<N)'4>QH '*8K<';1A
M]''O\>(=U+X7,;K3%R[31'RF+_[=BOL':(9^C+_H?3PC!]L! 3E-]@C?24SK
M6>HGP>MX!GX:M C& >$93&D5^&'\K7CN0$)GRTZ[X\SGA6D'F@'>[Z]'-]T]
MQ?II6W^;.R2?%<I0";0PUM#BF,2CDT"+&M4 _Q8/3O9?W.3\*_NE4 O0ZA]<
MWPKKO=JT;<-JO/EMZ$X?8#N%MKU[I<5&JL84#YZ;(XE:NFHJ9$EG%GDD5>[N
MXBUT:]Y:<_@E!(QKGC_2?LO;9><;.#CC1=:@." RU-56M2"TQO24OI;0#2 0
MW59Q.=KE"$PUM4L'7"NX@[/FE<3S J^[I&/!*4^;+A4]]>4(9CD$UA&>VCIO
M=K/I$LQ=*_1^#?[*UAG<@_1@W\=T[>3L6NJ<?<619=N#E-K*H<#S_S9N/("(
M&3 A1U![.(F+)F_!57?53F/1R$M)Y Y7O'E3W:BVX870'2K=";ZMEPC^.=ZN
MKI[5(H)G%5ZYWLFG.\I*I2E0/+-WBCEN\+>/I=V"?JGR7RS8=UH04Z+Q7W^I
M(DZJ3#</'2R<0+8M(#H!AV3;\3M=[3D++O5#64C39R;O <9T:=WAY\I H3GX
M(RF002W6]*D&D $&0V"W+&_8OE.!9H.H^7 (BB *W&'B-ZCY\>I<@3"I"S@=
M^_OB'AXZ@]0D2(Z5?P\%P#.\_&GG/L;BE723O:%SAB;/V7Q*0RU>+3#&>].$
M1MEYE-!PC:QB-J"@<K'!ZU'M#OS0F\5N(I[&>)=(DSF+O!!W;C#4(N4>6XD*
MB!1M!^4TUM ' U=!*>;H!+NBZ8QA0I[.8]Q*HYC]I6S?[F\E#NYBB*0WETGW
M%A)./0!"/M-\S%[ZC##>^B)4"KURW[W0?JJI;/MQ:+@[?%H[;;\H/8JWW^7
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M*7?.9:T(+[S];G2L%]EI!AHWJK7QD^_>XY#/2^&KO*7T"UWO.YME4+44?3.
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M.KJ:/;^>G=,"?N,/HQ]\\CDC4>;6?J8O[XI71U/B2)<Z#T1"X=^]OM%E293
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M6MX[A^]?M>@G>)?,:S?.+AVW0G'"VP[A$$1T'BRW*39TM"8!0P:?\P$,7<9
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MI&P?O':B1=4\,ANAZ49MQ(R^$5 :!=K?"J&/$^.@_^J8_0=02P,$%     @
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M\($SI8^P1&208 IOOVUK(F*-PYVLT/>*<)ID;A@=P#&DOAMG!Y!@)MM]@I4
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M]0'J>*R#L<B4?9)5I=OK.R0NE19Y#48/<L:K-WVH\[ !0)YV@%\#_*> [C.
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M]&LA.W)@"B#75Y2*_4 9Z'K\Y!=02P,$%     @ >H@(55 .;6;M!   &28
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M*N1A6C<+!'/$E(&<WU$JCAVU0']'L_H74$L#!!0    ( 'J("%4"^]K<<@D
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MY;;UZ@V98U] :2Z4YD%I/I060&DABJ9+L'4ZG/$'=+]0AP-*<Z$T#TKSH;0
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MHH>E!:V7AB]DNQ.JP5XM4K3%3UA\2Q^9/+,KE9#$..&$)H#AS=*ZA3>^ZZB
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MYE'=ZPEP[:#V%XS)[4('J#]THM]02P,$%     @ >H@(5=TM*^LK!   .Q4
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M.?V.Q#(=5NFPGV[+DC1U04U=4(4W^4Y=KL RQ5)ROP!_?9#AX+T@&?];)_6
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MF J0US>4BN<3M7_6[)=&_P)02P,$%     @ >H@(56&U?4?T P  H10  !D
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M+9G738=I)E:M?%7/E:4>X8=T?#EJ%T#["Z7L=N((VC:?_@902P,$%     @
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M^FICO.QQRH%DN;F3YTRJ&]X\)JHM!*X#U/L%8W(ST )UHQG\ U!+ P04
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M@2D#^7Q.J=@.U O:+R&3;U!+ P04    " !ZB A5:K'L6N\"  #,"0  &0
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M..E1N0?'N;E+?27BFE82,=AHF7<2ZZ1$>SUI&XK7]H1?<Z7O"_:QT%<Z$"9
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MUS 6,^TNP/E2*7M8. 'UH#W[!U!+ P04    " !ZB A5[USJCWD#  !E"P
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MAP-S^CW"%%\=OA*^HNK F<!20:I1JX8H+P[R14.RW)R%%TRJD[6Y7 .)@>L
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MAYX]U)>R+B^=Z#:[%Y%YT;TQ6+5U?09U"S.SLMI__K/_=.G#?U!+ P04
M" !ZB A5##^0_.4!  !_(0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSS=H[3L- %(7AK41> )/[F/!00D5#B]B %28/D<269Q#)[HE"$8Y%08/F
M5-;8\O7?^)-E>_Z2=FW9=H>\V?9Y<MSO#GG1;$KI'T+(RTW:M_FFZ]/A?&35
M#?NVG)?#.O3M\KU=IZ#3Z2P,/V<TC_.?,R>OIS[]96*W6FV7Z:E;?NS3H?PR
M.'QVPWO>I%2:R6L[K%-9-.&XN^[.X;*1F_/D9O+\MFB&YS=I0NT@A2"M'V00
M9/6#'(*\?E"$H%@_: 9!L_I!MQ!T6S_H#H+NZ@?=0]!]_2"9HHQ3@J01U@1:
M"W(M!%X+@BT$8@N2+01F"Z(M!&H+LBT$;@O"+01R"](M!'8+XBT$>BOJK01Z
M*^JM!'KKZ&&;0&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
M;T.]C4!O0[V-0&]#O8U ;QN]+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\C
MT-M0;R/0VU%O)]#;46\GT-M1;R?0VU%O)]#;1R^["?1VU-L)]';4VPGT=M3;
M"?1VU-L)]';4VPGTCJAW)- [HMZ10.^(>D<"O2/J'0GTCJAW)- [CCY6$N@=
M4>_XGWKG<MJE?.WY7N/U_Y/J<CXW72]_67[O'-WC%YP#_&_Q^ 502P,$%
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M^>TUK779'/)9][G$Y!-02P$"% ,4    " !ZB A5!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( 'J(
M"%7WH<TK[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( 'J("%697)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ >H@(5>(HS7/L
M!0  PA\  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( 'J("%47P4[)9 8  /$:   8              "
M@2\.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !ZB A5
MA<=*Z0D#  !A"@  &               @(')%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ >H@(5=-I^:9%!@  C!H  !@
M     ("!"!@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M 'J("%4:D^,0.@T  !20   8              " @8,>  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " !ZB A54FBCS.T'  !S(P  &
M            @('S*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ >H@(53,E)D(!!0  N0H  !@              ("!%C0  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( 'J("%7PB==HX1$  $HU
M   8              " @4TY  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " !ZB A5ZB!LU? ,  #[(   &               @(%D2P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ >H@(5;5##+3I
M!   00L  !D              ("!BE@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " !ZB A5^N5P$CX-  #0/@  &0
M@(&J70  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( 'J(
M"%5XFRA9X ,  '8(   9              " @1]K  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ >H@(570KJ_ X!   BPH  !D
M         ("!-F\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " !ZB A5D/62UOP"  "/!@  &0              @(&E<P  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( 'J("%4UH=EIBP<  .P3
M   9              " @=AV  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ >H@(5:0UH,YO!P  BA4  !D              ("!FGX
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !ZB A5E4(&
M;;0"   /!@  &0              @(% A@  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( 'J("%6O&D8Z*@@  'P4   9
M  " @2N)  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M>H@(52#^86D2 P  P 8  !D              ("!C)$  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " !ZB A51A9EOW@/  #2+@  &0
M            @('5E   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( 'J("%5?0,UQH0,  ($(   9              " @82D  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ >H@(57-%<F@T P
MRP8  !D              ("!7*@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " !ZB A5^>Z)[@<%  #J"P  &0              @(''
MJP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'J("%5Q
MCOW^\@,  '8(   9              " @06Q  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ >H@(52208@PI!   C0H  !D
M     ("!+K4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M" !ZB A5*.ZB)@P#  !L!@  &0              @(&.N0  >&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( 'J("%4=Z>E0ZP(  '0&   9
M              " @=&\  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!
M A0#%     @ >H@(550WLD=@!   F L  !D              ("!\[\  'AL
M+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !ZB A5JY&%FNX%
M  "7#P  &0              @(&*Q   >&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;%!+ 0(4 Q0    ( 'J("%4_(0#0 P,  )H+   9              "
M@:_*  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ >H@(
M52$/:0GN @  B@D  !D              ("!Z<T  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " !ZB A5K+8[/E0#  #O#P  &0
M        @($.T0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( 'J("%50#FUF[00  !DF   9              " @9G4  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ >H@(52([&,B@ P  KQ$
M !D              ("!O=D  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " !ZB A5 OO:W'()  !.7P  &0              @(&4W0
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( 'J("%5C"XNC
MI (  '0&   9              " @3WG  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ >H@(53XI*KBI!   .!D  !D
M ("!&.H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !Z
MB A5/ TF_?("  #T"   &0              @('X[@  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( 'J("%7=+2OK*P0  #L5   9
M          " @2'R  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#
M%     @ >H@(56&U?4?T P  H10  !D              ("!@_8  'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !ZB A5A7*[FXL"  #R
M!0  &0              @(&N^@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM
M;%!+ 0(4 Q0    ( 'J("%43@29;]0(  '0*   9              " @7#]
M  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ >H@(56MC
MZ^09!   %1$  !D              ("!G  ! 'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6Q02P$"% ,4    " !ZB A5:K'L6N\"  #,"0  &0
M    @('L! $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M 'J("%7UD9[P3@,  # *   9              " @1(( 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ >H@(58+:+%EL P  ^!,  !D
M             ("!EPL! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " !ZB A5"]BZ<J4%  !*+0  &0              @($Z#P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( 'J("%4#YEF<KP,
M .T0   9              " @185 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ >H@(53FWD>#S!0  S2P  !D              ("!
M_!@! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !ZB A5
M='LO&(D#  #W#0  &0              @($F'P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( 'J("%7+TR,)%04  -H>   9
M      " @>8B 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ >H@(53\)+F9 !   = \  !D              ("!,B@! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !ZB A5[USJCWD#  !E"P
M&0              @(&I+ $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( 'J("%6+?G2M*@0  %H1   9              " @5DP 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ >H@(5=[$A0<J
M!   B!4  !D              ("!NC0! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " !ZB A5WEP7?[<"   G"   &0
M@($;.0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( 'J(
M"%7P$;BU+@,  .X2   -              "  0D\ 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ >H@(59>*NQS     $P(   L              ( !8C\!
M %]R96QS+RYR96QS4$L! A0#%     @ >H@(58\!A Z%!   /B4   \
M         ( !2T ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'J("%4,
M/Y#\Y0$  '\A   :              "  ?U$ 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'J("%6/X;=ITP$  #8A   3
M      "  1I' 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $  =Q$
' !Y) 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Goodwill and Other Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Other Accrued and Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities</Role>
      <ShortName>Other Accrued and Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142112 - Disclosure - Stock Incentive Plans and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/Revenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/LossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/Acquisitions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Goodwill and Other Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Other Accrued and Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables</Role>
      <ShortName>Other Accrued and Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Stock Incentive Plans and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/RevenueNarrativeDetails</Role>
      <ShortName>Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenue - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenue - Concentration of Risk, by Risk Factor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails</Role>
      <ShortName>Revenue - Concentration of Risk, by Risk Factor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Acquisitions - Acquisition of consideration transferred (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails</Role>
      <ShortName>Acquisitions - Acquisition of consideration transferred (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Acquisitions - Schedule of Unaudited Pro forma Financial Information and Net Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails</Role>
      <ShortName>Acquisitions - Schedule of Unaudited Pro forma Financial Information and Net Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Property and Equipment, Net - Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment, Net - Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Goodwill and Other Intangible Assets, Net - Schedule of Change in Carrying Value of Our Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net - Schedule of Change in Carrying Value of Our Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Goodwill and Other Intangible Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets, Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets, Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Other Accrued and Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails</Role>
      <ShortName>Other Accrued and Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Leases - Assets And Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails</Role>
      <ShortName>Leases - Assets And Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Fair Value Measurements - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Activity Under Stock Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation - Activity Under Stock Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448426 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock Incentive Plans and Stock-Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cstl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.castlebiosciences.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.castlebiosciences.com/role/IncomeTaxes</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cstl-20220630.htm">cstl-20220630.htm</File>
    <File>cstl-20220630.xsd</File>
    <File>cstl-20220630_cal.xml</File>
    <File>cstl-20220630_def.xml</File>
    <File>cstl-20220630_lab.xml</File>
    <File>cstl-20220630_pre.xml</File>
    <File>exhibit311-q22022.htm</File>
    <File>exhibit312-q22022.htm</File>
    <File>exhibit321-q22022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="641">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cstl-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 170,
   "dts": {
    "calculationLink": {
     "local": [
      "cstl-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cstl-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cstl-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cstl-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cstl-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cstl-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 453,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 25,
   "keyStandard": 274,
   "memberCustom": 18,
   "memberStandard": 30,
   "nsprefix": "cstl",
   "nsuri": "http://www.castlebiosciences.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.castlebiosciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Loss Per Share",
     "role": "http://www.castlebiosciences.com/role/LossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Acquisitions",
     "role": "http://www.castlebiosciences.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Property and Equipment, Net",
     "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Goodwill and Other Intangible Assets, Net",
     "role": "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet",
     "shortName": "Goodwill and Other Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Other Accrued and Current Liabilities",
     "role": "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities",
     "shortName": "Other Accrued and Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Leases",
     "role": "http://www.castlebiosciences.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Fair Value Measurements",
     "role": "http://www.castlebiosciences.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.castlebiosciences.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142112 - Disclosure - Stock Incentive Plans and Stock-Based Compensation",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Income Taxes",
     "role": "http://www.castlebiosciences.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Revenue (Tables)",
     "role": "http://www.castlebiosciences.com/role/RevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Loss Per Share (Tables)",
     "role": "http://www.castlebiosciences.com/role/LossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.castlebiosciences.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Goodwill and Other Intangible Assets, Net (Tables)",
     "role": "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables",
     "shortName": "Goodwill and Other Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Other Accrued and Current Liabilities (Tables)",
     "role": "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables",
     "shortName": "Other Accrued and Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Leases (Tables)",
     "role": "http://www.castlebiosciences.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Stock Incentive Plans and Stock-Based Compensation (Tables)",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivable",
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cstl:ContractWithCustomerCustomerPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Revenue - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/RevenueNarrativeDetails",
     "shortName": "Revenue - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cstl:ContractWithCustomerCustomerPaymentTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenue - Disaggregation of Revenue (Details)",
     "role": "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails",
     "shortName": "Revenue - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idb5cf2e6b2e24c06be4b1939e1daf492_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ia301a48e31e3464b850d1a0710a2fb2e_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenue - Concentration of Risk, by Risk Factor (Details)",
     "role": "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails",
     "shortName": "Revenue - Concentration of Risk, by Risk Factor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ia301a48e31e3464b850d1a0710a2fb2e_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cstl:ProceedsFromPreviousAssetAcquisition",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i2d5c289e6d474738890e1b72e04b9576_D20210528-20210528",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i62417c66f9e8412cb78339018fd81c48_D20220426-20220426",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Acquisitions - Acquisition of consideration transferred (Details)",
     "role": "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
     "shortName": "Acquisitions - Acquisition of consideration transferred (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i62417c66f9e8412cb78339018fd81c48_D20220426-20220426",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i140b75ca6fb545eca7808706ff716d73_I20220426",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Acquisitions - Schedule of Unaudited Pro forma Financial Information and Net Income (Details)",
     "role": "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails",
     "shortName": "Acquisitions - Schedule of Unaudited Pro forma Financial Information and Net Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)",
     "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, Net - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Property and Equipment, Net - Depreciation Expense (Details)",
     "role": "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
     "shortName": "Property and Equipment, Net - Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Goodwill and Other Intangible Assets, Net - Schedule of Change in Carrying Value of Our Goodwill (Details)",
     "role": "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails",
     "shortName": "Goodwill and Other Intangible Assets, Net - Schedule of Change in Carrying Value of Our Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Goodwill and Other Intangible Assets, Net - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets (Details)",
     "role": "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "role": "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangible Assets, Net - Finite-Lived Intangible Assets, Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Other Accrued and Current Liabilities (Details)",
     "role": "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails",
     "shortName": "Other Accrued and Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Leases - Assets And Liabilities (Details)",
     "role": "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
     "shortName": "Leases - Assets And Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i2c649fe497204cb2a717f0ed7d84eb66_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "if08210db194a470bb8c79782f96d1583_I20220311",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i6324a446c6ed44dcb012258eeb725d85_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i6324a446c6ed44dcb012258eeb725d85_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ib99692ae97b9426581ef0e9d0e18336f_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ib99692ae97b9426581ef0e9d0e18336f_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "if579dae83b8c4e9985cc1382db6773cc_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ibfe55ff211ed4f38b0b5928664b7c47a_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Fair Value Measurements - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "role": "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
     "shortName": "Fair Value Measurements - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i43af39ae2b5a4502ad42c6b29becf672_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Activity Under Stock Incentive Plan (Details)",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation - Activity Under Stock Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i34a7685d73ad478787bdd4c9c2c2eb52_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "id49668ed558840d8a0b90ca6b883101e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "id49668ed558840d8a0b90ca6b883101e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation - Assumptions Used in Fair Value of Stock Options and ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i8ece9f0ad1c34bd381ae5c6e62573db7_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448426 - Disclosure - Stock Incentive Plans and Stock-Based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock Incentive Plans and Stock-Based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "idf13288bff8d454995f61e624f289d17_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i140b75ca6fb545eca7808706ff716d73_I20220426",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - Income Taxes (Details)",
     "role": "http://www.castlebiosciences.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "i00c6e09134294ab4b06e6607181aac2b_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Revenue",
     "role": "http://www.castlebiosciences.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cstl-20220630.htm",
      "contextRef": "ie465178e2cb24dd3ad4d7f48f145f590_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "cstl_AccountsReceivableCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Current [Member]",
        "label": "Accounts Receivable, Current [Member]",
        "terseLabel": "Percentage of Accounts Receivable (current)"
       }
      }
     },
     "localname": "AccountsReceivableCurrentMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_AccountsReceivableNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Noncurrent [Member]",
        "label": "Accounts Receivable, Noncurrent [Member]",
        "terseLabel": "Percentage of Accounts Receivable (noncurrent)"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_AccruedClinicalStudiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Studies, Current",
        "label": "Accrued Clinical Studies, Current",
        "terseLabel": "Clinical studies"
       }
      }
     },
     "localname": "AccruedClinicalStudiesCurrent",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_AccruedFixedAssetPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Fixed Asset Purchases",
        "label": "Accrued Fixed Asset Purchases",
        "terseLabel": "Accrued fixed asset purchases"
       }
      }
     },
     "localname": "AccruedFixedAssetPurchases",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_AcquisitionContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition, Contingent Consideration, Liability, Measurement Input",
        "label": "Acquisition, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Asset acquisition, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "AcquisitionContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cstl_AltheaDxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AltheaDx, Inc",
        "label": "AltheaDx, Inc [Member]",
        "terseLabel": "AltheaDx, Inc"
       }
      }
     },
     "localname": "AltheaDxIncMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assembled Workforce",
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "label": "Asset Acquisitions, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Additional consideration payable based on achievement of certain commercial milestones"
       }
      }
     },
     "localname": "AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisitions, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares",
        "label": "Asset Acquisitions, Contingent Consideration Arrangements, Range Of Outcomes, Value, High, Shares",
        "terseLabel": "Maximum number of shares payable in earnout payment (in shares)"
       }
      }
     },
     "localname": "AssetAcquisitionsContingentConsiderationArrangementsRangeOfOutcomesValueHighShares",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cstl_AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisitions, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price",
        "label": "Asset Acquisitions, Earnout Payments, Number Of Trading Days To Determine Volume Weighted-Average Price",
        "terseLabel": "Number of trading days to determine volume weighted-average price of common stock"
       }
      }
     },
     "localname": "AssetAcquisitionsEarnoutPaymentsNumberOfTradingDaysToDetermineVolumeWeightedAveragePrice",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cstl_BlueCrossBlueShieldPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BlueCross BlueShield Plans [Member]",
        "label": "BlueCross BlueShield Plans [Member]",
        "terseLabel": "BlueCross BlueShield plans"
       }
      }
     },
     "localname": "BlueCrossBlueShieldPlansMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination And Asset Acquisitions, Policy",
        "label": "Business Combination And Asset Acquisitions, Policy [Policy Text Block]",
        "terseLabel": "Acquisitions, Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionsPolicyPolicyTextBlock",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cstl_BusinessCombinationConsiderationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Payable, Current",
        "label": "Business Combination, Consideration Payable, Current",
        "verboseLabel": "Consideration payable for business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationPayableCurrent",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Cash",
        "label": "Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Cash",
        "terseLabel": "Contingent consideration paid in cash (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCash",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cstl_BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Common Stock",
        "label": "Business Combination, Consideration Transferred, Contingent Consideration, Percentage Paid In Common Stock",
        "terseLabel": "Contingent consideration paid in common stock (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredContingentConsiderationPercentagePaidInCommonStock",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cstl_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Number Of Remaining Shares Authorized To Be Issued",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Number Of Remaining Shares Authorized To Be Issued",
        "terseLabel": "Consideration transferred, number of remaining shares authorized to be issued (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableNumberOfRemainingSharesAuthorizedToBeIssued",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cstl_BusinessCombinationNoncashContingentConsiderationGiven": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Noncash Contingent Consideration Given",
        "label": "Business Combination, Noncash Contingent Consideration Given",
        "terseLabel": "Contingent consideration in acquisition of business"
       }
      }
     },
     "localname": "BusinessCombinationNoncashContingentConsiderationGiven",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Compensation",
        "negatedTerseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedCompensation",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_CernosticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cernostics, Inc.",
        "label": "Cernostics, Inc. [Member]",
        "terseLabel": "Cernostics, Inc."
       }
      }
     },
     "localname": "CernosticsIncMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Share Price, Volume-Weighted Average Price, Number Of Trading Days",
        "label": "Common Stock, Share Price, Volume-Weighted Average Price, Number Of Trading Days",
        "terseLabel": "Common stock, share price, volume-weighted average price, number of trading days"
       }
      }
     },
     "localname": "CommonStockSharePriceVolumeWeightedAveragePriceNumberOfTradingDays",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cstl_ContractWithCustomerCustomerPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Customer, Payment Terms",
        "label": "Contract With Customer Customer, Payment Terms",
        "terseLabel": "Number of days contract with customer is generally paid"
       }
      }
     },
     "localname": "ContractWithCustomerCustomerPaymentTerms",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cstl_DermatologicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermatologic",
        "label": "Dermatologic [Member]",
        "terseLabel": "Dermatologic"
       }
      }
     },
     "localname": "DermatologicMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_IncomeTaxAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Adjustment",
        "label": "Income Tax Adjustment [Member]",
        "terseLabel": "Income Tax Adjustment"
       }
      }
     },
     "localname": "IncomeTaxAdjustmentMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets",
        "negatedTerseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_LesseeOperatingLeaseBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Base Rent",
        "label": "Lessee, Operating Lease, Base Rent",
        "terseLabel": "Operating lease, base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRent",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_LesseeOperatingLeaseEarlyTerminationFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Early Termination Fee",
        "label": "Lessee, Operating Lease, Early Termination Fee",
        "terseLabel": "Early termination fee"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEarlyTerminationFee",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_LesseeOperatingLeaseMaximumBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Maximum Base Rent",
        "label": "Lessee, Operating Lease, Maximum Base Rent",
        "terseLabel": "Operating lease, maximum base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMaximumBaseRent",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_LesseeOperatingLeaseNumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Options To Renew",
        "label": "Lessee, Operating Lease, Number Of Options To Renew",
        "terseLabel": "Lessee, operating lease, number of options to renew"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfOptionsToRenew",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cstl_LesseeOperatingLeaseOptionToTerminateTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate, Term",
        "label": "Lessee, Operating Lease, Option To Terminate, Term",
        "terseLabel": "Number of months to terminate lease after commencement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateTerm",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cstl_MedicareAdvantagePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage Plans [Member]",
        "label": "Medicare Advantage Plans [Member]",
        "terseLabel": "Medicare Advantage plans"
       }
      }
     },
     "localname": "MedicareAdvantagePlansMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_MyriadMyPathLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myriad myPath, LLC",
        "label": "Myriad myPath, LLC [Member]",
        "terseLabel": "Myriad myPath, LLC"
       }
      }
     },
     "localname": "MyriadMyPathLLCMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_OperatingExpensesAndOtherOperatingIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Expenses And Other Operating Income",
        "label": "Operating Expenses And Other Operating Income [Abstract]",
        "terseLabel": "OPERATING EXPENSES AND OTHER OPERATING INCOME"
       }
      }
     },
     "localname": "OperatingExpensesAndOtherOperatingIncomeAbstract",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "cstl_OperatingExpensesNetOfOtherOperatingIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Expenses, Net Of Other Operating Income",
        "label": "Operating Expenses, Net Of Other Operating Income",
        "totalLabel": "Total operating expenses, net"
       }
      }
     },
     "localname": "OperatingExpensesNetOfOtherOperatingIncome",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_PittsburghLeaseAfterSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pittsburgh Lease, After Six Months",
        "label": "Pittsburgh Lease, After Six Months [Member]",
        "terseLabel": "Pittsburgh Lease, After First Six Months"
       }
      }
     },
     "localname": "PittsburghLeaseAfterSixMonthsMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_PittsburghLeaseFirstSixMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pittsburgh Lease, First Six Months",
        "label": "Pittsburgh Lease, First Six Months [Member]",
        "terseLabel": "Pittsburgh Lease, First Six Months"
       }
      }
     },
     "localname": "PittsburghLeaseFirstSixMonthsMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_PittsburghLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pittsburgh Lease",
        "label": "Pittsburgh Lease [Member]",
        "terseLabel": "Pittsburgh Lease"
       }
      }
     },
     "localname": "PittsburghLeaseMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_ProceedsFromPreviousAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Previous Asset Acquisition",
        "label": "Proceeds from Previous Asset Acquisition",
        "terseLabel": "Cash received from settlement of receivable",
        "verboseLabel": "Asset acquisition"
       }
      }
     },
     "localname": "ProceedsFromPreviousAssetAcquisition",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cstl_StockOptionsAndRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and Restricted Stock Units (\u201cRSUs\u201d)",
        "label": "Stock Options and Restricted Stock Units (\u201cRSUs\u201d) [Member]",
        "terseLabel": "Stock options and restricted stock units (\u201cRSUs\u201d)"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_ThirdPartyPayorConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third-Party Payor Concentration Risk [Member]",
        "label": "Third-Party Payor Concentration Risk [Member]",
        "terseLabel": "Third-Party Payor Concentration Risk"
       }
      }
     },
     "localname": "ThirdPartyPayorConcentrationRiskMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cstl_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Equity Incentive Plan",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.castlebiosciences.com/20220630",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r34",
      "r36",
      "r77",
      "r78",
      "r221",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r2",
      "r83",
      "r91",
      "r164",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r383",
      "r388",
      "r389",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "After Adoption of ASC 842"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r83",
      "r91",
      "r97",
      "r164",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r383",
      "r386",
      "r388",
      "r389",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Effect of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r83",
      "r91",
      "r97",
      "r164",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r383",
      "r386",
      "r388",
      "r389",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r83",
      "r91",
      "r97",
      "r164",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r383",
      "r386",
      "r388",
      "r389",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r144",
      "r206",
      "r207",
      "r247",
      "r249",
      "r456",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r144",
      "r206",
      "r207",
      "r247",
      "r249",
      "r456",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r35",
      "r36",
      "r77",
      "r78",
      "r221",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r92",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r92",
      "r97",
      "r205",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r92",
      "r97",
      "r205",
      "r266",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Effect of Adoption"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r84",
      "r85",
      "r86",
      "r87",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r353",
      "r354",
      "r355",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r423",
      "r427",
      "r428",
      "r429",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Other Accrued and Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r449"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetNoncurrent": {
     "auth_ref": [
      "r147",
      "r465",
      "r475"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "auth_ref": [
      "r466",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.",
        "label": "Accrued Bonuses",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee stock purchase plan contributions"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Payroll-related liabilities"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r11",
      "r29"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).",
        "label": "Acquisition-related Costs [Member]",
        "terseLabel": "Acquisition-related Costs"
       }
      }
     },
     "localname": "AcquisitionRelatedCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r449"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r312",
      "r313",
      "r314",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r84",
      "r85",
      "r86",
      "r87",
      "r97",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326",
      "r327",
      "r328",
      "r353",
      "r354",
      "r355",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r458",
      "r459",
      "r460",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r24",
      "r153",
      "r167",
      "r168",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r62",
      "r185",
      "r191"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Consideration transferred, contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r16",
      "r73",
      "r133",
      "r136",
      "r142",
      "r160",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r375",
      "r378",
      "r406",
      "r447",
      "r449",
      "r463",
      "r476"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r26",
      "r73",
      "r160",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r375",
      "r378",
      "r406",
      "r447",
      "r449"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r265",
      "r267",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r265",
      "r267",
      "r345",
      "r346",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business acquisition, number of shares issued or issuable in transaction (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails",
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Unaudited Pro forma Financial Information and Net Income"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r358",
      "r359",
      "r362"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r356",
      "r358",
      "r359",
      "r364"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r61",
      "r368"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Additional consideration payable based on achievement of certain commercial milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r357",
      "r360",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration in acquisition of business"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r357",
      "r361"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Noncurrent portion of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r351",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Loss from acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Other accrued and current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets \u2013 long-term"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.",
        "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed",
        "terseLabel": "Transaction costs expensed"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r79",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r12",
      "r64"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r59",
      "r64",
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r415"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r468",
      "r480"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r208",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value per share; 200,000,000 shares authorized as of June\u00a030, 2022 and December\u00a031, 2021; 26,292,299 and 25,378,520 shares issued and outstanding as of June\u00a030, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Accrued Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r38",
      "r40",
      "r41",
      "r47",
      "r470",
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r146",
      "r403",
      "r404",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r146",
      "r403",
      "r404",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r120",
      "r121",
      "r146",
      "r403",
      "r404",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r116",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r120",
      "r121",
      "r146",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r403",
      "r405",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r120",
      "r121",
      "r146",
      "r403",
      "r404",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Variable consideration adjustments included in revenue"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r49",
      "r73",
      "r160",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r406"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales (exclusive of amortization of acquired intangible assets)"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales (exclusive of amortization of acquired intangible assets)"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r62",
      "r74",
      "r324",
      "r331",
      "r332",
      "r333"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r62",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r62",
      "r131"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedules of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r270",
      "r271",
      "r306",
      "r307",
      "r309",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Incentive Plans and Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r48",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r98",
      "r100",
      "r102",
      "r103",
      "r104",
      "r108",
      "r109",
      "r389",
      "r390",
      "r471",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r48",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r100",
      "r102",
      "r103",
      "r104",
      "r108",
      "r109",
      "r389",
      "r390",
      "r471",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r42",
      "r43",
      "r44",
      "r80",
      "r81",
      "r82",
      "r85",
      "r94",
      "r96",
      "r113",
      "r164",
      "r227",
      "r228",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r388",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r446",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r392",
      "r393",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r393",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r395",
      "r396",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r222",
      "r257",
      "r258",
      "r263",
      "r264",
      "r393",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Items (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r257",
      "r258",
      "r263",
      "r264",
      "r393",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r393",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r397",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Acquisition of AltheaDx"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r451",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r400",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r434",
      "r439"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Repayment of principal portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r433",
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Finance lease, right-of-use asset, accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease, right-of-use asset, before accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r14",
      "r190"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (remainder of year)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r193",
      "r457",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r190",
      "r461"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r186",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r190",
      "r457"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails",
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted-Average Remaining Life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r13",
      "r170",
      "r172",
      "r179",
      "r183",
      "r449",
      "r462"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r173",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisition of AltheaDx"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r182",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r172",
      "r179",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill accumulated impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r62",
      "r171",
      "r176",
      "r182",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetScheduleofChangeinCarryingValueofOurGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach converting future amounts to single current discounted amount.",
        "label": "Valuation, Income Approach [Member]",
        "terseLabel": "Valuation, Income Approach"
       }
      }
     },
     "localname": "IncomeApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r44",
      "r50"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r199",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r320",
      "r321",
      "r323",
      "r329",
      "r334",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r76",
      "r95",
      "r96",
      "r132",
      "r319",
      "r330",
      "r335",
      "r486"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax (benefit) expense",
        "terseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r61",
      "r454"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Medicare advance payment"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r61",
      "r439"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r45",
      "r130",
      "r424",
      "r425",
      "r472"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r25",
      "r449"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r52",
      "r129"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r73",
      "r137",
      "r160",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r376",
      "r378",
      "r379",
      "r406",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r73",
      "r160",
      "r406",
      "r449",
      "r464",
      "r478"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r30",
      "r73",
      "r160",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r376",
      "r378",
      "r379",
      "r406",
      "r447",
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r60",
      "r63"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r37",
      "r39",
      "r44",
      "r46",
      "r63",
      "r73",
      "r84",
      "r89",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r101",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r160",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r390",
      "r406",
      "r469",
      "r483"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Axis]",
        "terseLabel": "Nonrecurring Adjustment [Axis]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Domain]",
        "terseLabel": "Nonrecurring Adjustment [Domain]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r135",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "negatedTerseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued and current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets \u2013 long-term"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Other Significant Noncash Transaction, Value of Consideration Given",
        "terseLabel": "Consideration payable in acquisition of business"
       }
      }
     },
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r209"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of common stock offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payment of employees\u2019 taxes on vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r54",
      "r363"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of business, net of cash and cash equivalents acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedLabel": "Asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r55",
      "r370",
      "r371",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of June\u00a030, 2022 and December\u00a031, 2021; no shares issued and outstanding as of June\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r311"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from contributions to the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r197",
      "r433",
      "r438"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r198",
      "r438"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r16",
      "r196",
      "r431"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r198",
      "r449",
      "r473",
      "r479"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r316",
      "r455",
      "r507"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r228",
      "r449",
      "r477",
      "r495",
      "r500"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Adjustment to accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r80",
      "r81",
      "r82",
      "r85",
      "r94",
      "r96",
      "r164",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r388",
      "r491",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r246",
      "r247",
      "r456"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "NET REVENUES",
        "verboseLabel": "Total net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r120",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Percentage of Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueConcentrationofRiskbyRiskFactorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r248",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/OtherAccruedandCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r345",
      "r346",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsAcquisitionofconsiderationtransferredDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/AcquisitionsScheduleofUnauditedProformaFinancialInformationandNetIncomeDetails",
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r186",
      "r189",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r186",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Our Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r88",
      "r91",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of Adoption of Accounting Standards Update"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r275",
      "r292",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement on Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, ESPP, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement on Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/GoodwillandOtherIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "cstl_OperatingExpensesNetOfOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/PropertyandEquipmentNetDepreciationExpenseDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceOtherMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.",
        "label": "Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/RevenueDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited / Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value at ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average grant date fair value at beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "verboseLabel": "Increase in number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Option Activity, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationNarrativeDetails",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Average expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationAssumptionsUsedinFairValueofStockOptionsandESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r70",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r33",
      "r42",
      "r43",
      "r44",
      "r80",
      "r81",
      "r82",
      "r85",
      "r94",
      "r96",
      "r113",
      "r164",
      "r227",
      "r228",
      "r312",
      "r313",
      "r314",
      "r327",
      "r328",
      "r388",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r446",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/AcquisitionsNarrativeDetails",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r113",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued in acquisition of business"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r17",
      "r18",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock in acquisition of business (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r17",
      "r18",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock from vested restricted stock units and payment of employees' taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r227",
      "r228",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.castlebiosciences.com/role/StockIncentivePlansandStockBasedCompensationActivityUnderStockIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r33",
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock in acquisition of business"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Public offering of common stock, adjustment to offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock from vested restricted stock units and payment of employees\u2019 taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r73",
      "r156",
      "r160",
      "r406",
      "r449"
     ],
     "calculation": {
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Leasehold improvements to be contributed by landlord"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r84",
      "r85",
      "r86",
      "r87",
      "r97",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326",
      "r327",
      "r328",
      "r353",
      "r354",
      "r355",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r422",
      "r423",
      "r427",
      "r428",
      "r429",
      "r430",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r458",
      "r459",
      "r460",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/LeasesAssetsAndLiabilitiesDetails",
      "http://www.castlebiosciences.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r114",
      "r115",
      "r117",
      "r118",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Reduction of existing valuation allowance on deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.castlebiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r510": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r511": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r512": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r513": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001447362-22-000137-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001447362-22-000137-xbrl.zip
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MJ;G 8<%L>+O(O;2(EAS!<BGXF!8Q C+U)F!G$5%,!>*QO1UW5PGR$8*<2>T
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M84%Z8Y96_QEVPG__)Q;H#XJ6:ZG?;QOW+%WCQ^GD]L[/^/(U0YH[!OWKLU?
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M_)KWO92S9_37.V@ KC#^9QA_?IO)O*,[K?"OG;.#3_X$A"&VFUMDOPW/.O]
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M[YVDZKNADW=[UP"I I^%D;1Z*<O_DUAIJ\!G["K)EU;K< VPH1B !%U;\*]
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MJVY7$]'N]A/&G?7'^_&.MUQVKCO'A<'4A87[LT4!D!;.NV"!:$. !43 XLC
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M\$1426(Q3 %SFH-&^8=3P3)###(^!PSK6QIKS7UDU@PZ4^-AVMHB0 T^CX(
M3X0 4R1&R*B1SZ?FTE-@5 NPT6"PSA..8K9<R<:F:BL\VP"@(,#:(L#R0G$*
M BP9 :8=&S$@$WC2>VIDKE'H>4( 9B#]*2!OM"74;FP2U6:WU HM$+"V$%"#
M4Z- P!-!P!0)4)+3X 4%G'YF=X8#D[OL(I<I'8D:<URU 4*:-1T"GE=OW=O5
M=#>IX3",QJU>I2"EQLBCU1C9[7].\YZC_";8="F) D%S0=#NC"<B*AX0LQ:,
ML0F" C&@?.(C,7$1IFD(6.%<BW3A-F0E<;FYZEI[ZD]1U[K4=8HQ<.DPI<9!
MB#D^0@0+6B;&$&1 Q/&DQ"CGZ<VRA:*MST9;:Z\<4K2U)FV=-O%5U!IC%"!2
M8H'I',6@N0=NB;6,V?1?VES3@BCJ^GS5M?;DF**N=:GKU.8:J DX: (\D9]D
MCD</-A@-G!D2$=>$1I<]<@W2UN<5.O #J_LBBZ(4^7A,NWLR]U<EB O$S $Q
M>S/F=H)W&P7R$*/TP(S*+8IP,K>YI01)GHVOQ A*GNSJZ.?3VME3ZEGR6>M1
MVREFH!,-<(0H"(FX 6,<@5(4@T[\WD64Q(AP$Q-:BP8W\ "^[+!UJNJTS6T$
M(YI9 <)$F;M>T]R*Q^<=5CI'*9'90U;#B7K1SP;NL$LPMLL.NQ2UG;:]4214
M9#KL3%);F>/AN-=)=RE%6M%H"&_B#EM*1CQ-R8CF#7A5KGQ>@1JW9YODT*66
M#0FKPT6L1FMLOH2%NL+<&3ZS!C%GRTL]^19JMC4>#WOV;&SL<3@<O#'#T!^7
M\+/Z]MP/L^4W,,4\: 5.ZYBHL@F0S!D"%&M"+8N:^I"S4 2:S:.[/UV>5WU6
MZ.!JG2%A>;DH!1(>$1*F:7C2?R*M 8M0/@)#.1S,*I"(&Q^1TLC)G)8BU2*U
M' LD/$M(6%YR2H&$QX.$&8=:AG8O.#B464(('G2@/H&#\L:Q2 6259[*8D'J
M!1.>)28L+UNE8,(C8L(43: )Z0FG#+@- EB"<M#$<J#<:\$LM]2[2>**6 6>
ML!Y1-)=ND-:_;.B'V!O_NT34/+GGX]!\N3A:>#412@&N^H#+S;@\/";1VICC
MYVVR;T3.N$O/P06) \(<4\X2<+4U+R>$*Z313QN#<X<>%U6=3U6G.8;5.C%$
M#4@HFE25<; X/56>8,+3_X4R&YL+5_@JNMK@W7?9'H6R^RY5I6=J>2I!C#4!
M:()=2$",P.C@01GE7 R1$6?R[JL(+;OOZFCTT\;GE-VW%E6=/@AP7D>B+03/
M<++P:03+<*;,6CLOF#.\8;OO.L0U=,.XJI_9,OU\DR>GPW"45GWO<[BUK.82
MZP(WSK_Q?Y9T\\V&WF:X,M*R+"6#EH'+GV8<&$%:&C1+Q E'#<P'!%:ZA-"&
M6<L<Q\SSQR[5<L>JV+Z.3Y/U457,3IMU62-+72,ZIM5 $N!IG-=(+BQ+$05O
ME!7"1<^MRC1;L-E4UB5ZZYMT?%=VQK(S/D8L4]D9EX=ZTZ5Q&(M.8IJ,%9D3
M?Y@&352NO1$BHSX&+^QC>XK+SMBL-1*--%0(!20ZE]8(%J \56F/%,XCB@FV
MD_ V/5MWO>R,96=<NYUQ>0[XLC,N#?6FW>[(,A^58A!BKC6OK09%! +)L)*,
M:*&4?^P*9&5G;-8:,8@8)60 IVQB3VQ2C3PM&2^$#Q1E?_W&)A%M<DM+DK(U
MEJUQ[;;&Y46V%A!\+!"<[CX;."?*>-"*(F#!<% 8<< $168$-D2:QS[N+/3I
MJ5>%9#1*I1/@.4* $4Y!:<M!$L%I0,PS%2;!SBNX-98T^U*_8+6N+!.[W(F]
MO.22&/&* ]<="76/S[@&?#2AFQ^<V>,PD_>QR#>44:[\* L:-+M,S,381;=8
MN]7S7M^'_O@EZ--F&8)5 9G3D,#PR Q#NV7-J.>JJ"O?.SX;![](L>=GZ@%X
M+G;^FS \R%*O-U"&W&G*=<RPG^9M=/F]K_):N[+:4+':?FRU_?5V)@A&<DF2
MS8Y \IRB:A0'HST'[Y36@1@=[0\"I9YZ'>Q,D*:LA 57@J8LR8QXH-G/PM+_
M0&.E #N/'#7<:.PV-M$+-)NJO+CUOD+NZ[)%->G>'K)%+1BQ4J!IZ= TY5I$
MB%MJ(P&G5 26NP09A@)HJ[D1WD7#'K9)/=I**&2ECG5@F99>109!R]P-7B'0
M7#(PSA-MN?&(B;Q%T=F$F[)%E2UJA;:H!4-'RA:U;&B:"1["3B7K"8,RDN<>
MU0B,) &HPLZD;8MI\X/@H:=>"66+JF,=1&V(ED2!)X'G NUIBQ(A0%3:)L%Y
MP6G<V,0O$"E;5-FBFG)O#]FB%@S:*%O4TJ%IBCUCF[</$< R9(!A:D$)%B%P
MR[CW0B%"'[1%/=I**%M4'>L@<BE,D BXMPZ8=QX,#P8"I=Q*X3&.,5M1O*E;
M5#G,7)/0AO(9*_0912N;'6+0:'+]1_4DI)THC<I\"I. @E%K<#8>C4T_W\<]
MH@NN9F?-NJE/)FO938XO9;0U$5'W[,2&X7ZLF-EH_YN@+EA:B;6NB\+-EJ[P
M CGJ/ /!LI?!RGQJ3R5@%*3QABL<45/7RX4Y-[-LRHI9YHH),A*G" 9J33XZ
MX1A,P!JB<%CQ],A86R6N(3';GF#1\F7-<T^5G6*9M7Z+YC^EYD^9^X:3W)4H
M +(D>Z2% 1MSG4)A,?541LM%4U=,X1:/OUX""4;F!2*P0<"<<6"(\;E EK5"
M,A\"3CL%;Z/[5/\H.\5SVBEJ;^M>=HHGU/SILTMF+"*,DJ3T0@(S:;M0'CG
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M./A6XR27-]GM7Q0VN6SX&_SV-1Y2,9/]ZLQD]"XD.C[JC<-!&'[NN? FS</
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M9PJ=60C=2D>R^@&,30$8QMJJ(#P0G%W%P@M0BCFPGBDGK9XDU9.Z2E86X"K
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MBMXEB&KO#ZU(0LX24.%2O /7H-:E.I:$AUR:*(L I)=BK1]$Z*\W#LU1/JU
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M2Z>75KGF77DPK$1WA(7!4&W8J"M"-$Z_:F%U_8C&*]>V>ENU%Z&:,S8Y*[^
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M_;V3WLGNY<O3WNENU#O]<+JW_:&_>_KAN'?Y$O[7._ZR;2[V/A]$/;8;UN]
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M32JK:<1M&.>")D+%81(*9I0UB>7I'0MN'3#>'!A7I$*B-N94L8AH(7,B<I/
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M#3(A[%9N05W!&JD=8'2 <6^!UY1'*A1)(C(C-*-IDC+%N,RD5KF.XD[">$#
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M'XV4)#Q/56:HBK-, S[&G?SWL_$1,T./ISXV"+CE#!U8.F'P=P/#F@[>]15
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M^#/)S[7*5;- X".7%7N!BQ=QQU40(A[GVK[;=9N;06\X&&%]MI$OY%VO>GM
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M).8Y)REW5&$)*T[A;8H]N_;LL$*^I4*^2S9?ZZNH;^RIJ*)AC*,DDD4<K#Q
M/LY0,C8&3+0A&J^L2[HJU:M$OKO'/"I,K##Q1SZ%L#(8%5VDCEL/1@,&3$P"
MWF+&1'WO5+(*$Y_#&LR8N+\G=? ",X\H['((MCJ)K),,*<TTIDJR2/C*.A>
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M#0U&.)&H8-%Q#KZ:HX(:J:BVR1#!:>57/Z&&SOK5CF)+B%8H>(L13R8A+:Q
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M6L84BTQ5<= GA,;9.&BR7!"J%6(^<<2EIDA'HG(:8 H FL()O;(N'UY7O03
M> VK\N2A&J-C4 ,__CT+;[L[*L5K3)!9"I86,2CFH]:.<4*TD2(QF:3TU&@;
MR1Z7*\O(3#K'B50RDZJUXC]7GGT!MLY5+=V^X!(J*7$'M?; =WJ#43^VX#9_
M=GK^Z)E5MM&>JNP6JQ\>'#0./W3@L_#]<,^LJL>?SG8./YTV6U_I;OG^P>$L
M"^Y.RY\UWV_1^O%7^/L1;=3\Z>[QN_9N[4.[4=L0C=9N)[_??-](]?.O9(]0
M)T0TH&$F8,0MPTA['Q!.S&BA,&5!C@$49#"&C6P16LF2)E@)*Q0/43M'/'CB
M((0Z6$;H2A$!!4]@\H?]$5@R[WN]<-KNC)/2FL.#V"]^K$8Q7HY5D*3AO/Q?
MYH:=T87Q8OUZ+%?'KKE4TG-+61*Y1$=;:XFP26D>A YF94FTI?S&/]I#  Y_
M"_V93O'<C#VB1GWQ!S&,.K&9IG=_JYK4.(3/G&_09LO#?["9;NQ)XX+ V*#H
MB4/<VX"LE18Y9I)Q5FECPJR>+(?D_91!>KL[]@M+IK8Q5[0_ $V.F3G:VW[_
M#';%XA_;&97,;KU1O]B?:G][4("A-,B$?*%PL=,[?9-<T)JO47T_$N!GXD&6
M3T(M_*"/O@SFQSF4?GWIZ=<_^)^VDWL3K!:UZ..Q P. D=7BEORJ3T?>\:J#
M 7=[^%?C[B^J,]94=Z]&1E/[>PSH//9[2^/YW]/XF7C^7T_KK0^'N455HW5P
MO-OZ1&!<!XUS3^"SN'$(7OKY%MQOY_N<Y]_:^%Z'T<.SD.9[,(YJ7VGCVQ9K
MG/\-AM(G6C_TY_76[F'C\%T"C_]LXOE_K]>^<C"@]GA4*C<_0888AKCR#ADN
M/)+.)TPE)YJ&3-RM*:'_?FP:CZ5+D")LR8%H(Y/V#MI3#M^-#MB&MO;]7OA>
MU4H^UQG0%.4V)A3,M5$?9N\O>)!>>!EG0B\"_MI7X ]\Q_T]+HD0GGA$K/.(
M:RN1$=(CBZ51BE*C \^5E:O<+!-!P9NR7J==,8K;DM\_DN5:'7(]TM2\FHUA
M45VYK[=Z*^R_/_8W-N>Q/PJL'>SC"+ ^MZ*C#&F)+8H*U@]SFDB4B\+^!:K+
M(QY\+7\DM'40^[$XS3\>72^W&^]N4LSMXQ.;#;5++1[';V4BO8^]P>"7_BI^
MF4J[N&#]_AZEP;CD-'*19#9OP9&S,2&9J!0*NP3+]@1!AVJ9'W>9 Q>$:$P!
M9C&8V%)H9)5/*+K$L$_$<>)7UKN].8B=;P%ZN?EK^V(ARF:8%^<=MOSUBLU8
M]/KS(="9-J+7G_E/T&T"03P?4ISTQN[V'_W8*1D^?IQ-_,_5PZ0)=N(?EU@'
MF#X:WGS)7"#]F6 V,[9>F9U+/P_Z/XX!]B-R_6B/D,VMZ/^PG5-[-ECYU]6=
M!#:-R9<K"G>???8;GS"E1WO"\=89<O_5<K7_*#M,YT_!F.S2C*4XZ&=@^Z]?
MIYTHV!K+HSB0_<V,B: 6__F77;_Q;._I)>WZ(_3-C2^MCUO%G]O-+YO;6XW-
MK2^KQ79C\^8FO\LR\ ; VY>BU2PVFXW:5N/+5BV_^M+\N%W;:,$O[[8;&XW-
M[8V/Q9<6O%'?:K2^%+]M3M,B?E_Z!_SM:V/C:VT;GN7WZ\#@VKR05YKG\?/L
MF>?(_7C7!C,H?H3M)\RF6)4X\%9S0NKG7^F>2L(I%@SX=%@A[@Q#AJ2(O&7.
M:4\M-?(%9H$T1_VB5TKB7(>^U:(;AV6O\/9@; _E')%Q[^^<&K*HC(_YD_Z7
ME /"V9K2;/'9&F3-D/NFCSQYU^IJL(^8M,-O-P</3=JAY(6FXMP<RJ^Z7+_<
MCLWO^[W!8"8/L>IZ?;<YO!1BNM*9MYK'N\WC98N\FK);3=FW\I<8T :,RN['
MXG,\MN!?@"I_;*=8&H]GT?9G^D"_KC/HZZ&\-FZ/ SHYC/Z@"W?=/WNDU+]7
M?3[\9DZ #294@O-NHC(\^*@MYRE&2:QQ*0I\VQ/@G_CWY6[[!DZ&\]]:']K-
MUA&IM[;93NOS$8P#O/TMW&Q].&[6WATV8>P[AU_Q[,GP;NW#0?T8QI%+, _#
M0>/]YX/=\GL^B?KQ#J]_JXO=6F@W6I^O:Y<M$L%$I)CIACCB0AID).:(!BLU
M4X)%GALB4+7*R(,Y-IXD)[)*\:Z@[E9/_=MR8=TEJWCCDE%<H=\"T6^.6)I3
M@;%0"!MF$#?)(\>81L[)&(CPPD:WLBY6)3-SV/=[!7L5[+U V%LNU ,?MD*X
M!2+<+!.0C:QL,H*PXIGVUU.DE0V(8>$H#MK:Y+)]1U:EFL>X5VS?W>4[[A7]
M6%K-O_[$5FHI"(LFG]/2I'1N]NJ4)RIZZOSU7>MNK>4749;+ELVXYH-<47]X
M-/]'&/5S#*92^-LH_"R_333"^,@I4I99<.A2IK:A 7$??:(><Z)L3GI:4S=R
M8;R5[M!9-H]!1D-QVNL?@13Z^[6P>A.%8-AB1P$E ! DR)*PTBB;&+?4"^\9
M65RTI]KP;Z__\SVB8;<G2H,WDX($K:<B(1VT0HIX[!R'?5\I<&GD@WOE5!TN
MESA>\03:>F.\HM+?N^CO;$C"$!)X3 %)4Q(>1XJ,AOT[*4Z=PCPPEOGIQ /B
M$97FONEMMG2Y*R6]BY+.>M5&9LYXV%^IM0(V66Z1DU$@6#<9K5(DJ;2RSLTR
M-:E=M*H^S!E86B6]UCNFP6J*;<3:!1ZTT,DY3SWQPCFBI:Z\XR55W%GO&!9-
M&2L48C@RV%VY1HZR@*R./#BJ(B$4%'>-+]8YOF4Z2/E[NQMB-POEFI[/$7[^
M_E0W)&0_2S']JSYEJ'@&%LHS4&69/!7L7M-BVQ(;)?8>12W!7O+>(>NH1IRS
MJ*SF/B@YSC+1^L'$VTO /U"1M50@NE3QH"= T2I_Y?%Q=398Q%6P7'.#8K(!
M\03^A^6,@S.*E<8LQ&!HSE]1>)[5Y;[Y*Q6@5H#Z.@%UN?"TRHQ9+';.QO"2
MM\P([A"3.?>/.(MLLCF DZ*U/AJ#1;9)Z2I1JK))%_8=UW!S55792UH[_*(*
MG5_48*NJ[.<I /QY>X"J,OOEEG96E=E59?:RS&-5F5U59E>5V<L6NW@ST0G+
M?9"<2IRXXI1IY[E.(NGDDL+&^]MVI*G.S)J'6^<[K<;1[N&1V*W]?="LP?MT
M1^R^__MP]WVCLWOXE< 8X=^M.<[N>JMQ4*>?CYNMSE'CVQ9OO'\'3](YVOW6
M.-JA?Q\W6E_/&\?PC*UWUU5F>TD2-E$B$0)!/%"!;!(*J4A<XD)1)?#*NL&K
MC"PX/+'< 8@*Z5X[TMWE8.L)H.[M'FP]'?C-'FPY%E0T/*+D<YI P@I9!EA(
M@^588&5,/M@BJX97A=D5[+T.V%LNU'L;QT]/AW"SQT\^Q<"Y2PC;7.>!+4-6
M"XLDK!_V2C&<,U&U7F7R3?'N5'795S5=!V]E &L?@[C$8!G("]4Q:&ZL9[+,
M/"?3S/.)RE>9Y\^O[[.9YTIJ39SQ2$;+$>?>(!=$0-J%&*/V1O-0UF73JBZ[
MJLN^0\&8,]K1&#F-.?4+-A/EB)6>".\Q]W)QL9YJO[^]_L_795/AG*2!(98,
M>#0A@NI;+%&TS$BI@J7:5779+U%9[U27_?C:^JKKLI].?V<C$L$;'C0V* :O
M$(\"P]9M*:)4!!*BYA9,IO6'1",JQ7W3N^RK*<M^.AV=]:F)"=193I!50H".
M$HTLMQX)8CWA021)$^RQ8IG:6U=EV?=WCDMN!(&I=)' .F--.0T1BT0E@Y>J
M<HZ75'%GG6/+F%8\,41B!,5-)B 3L$ "*^FE]90+G<NR3566795E5P4P2V 0
MW:__<)5B\GRP>TU9=M*P9EPIQ*Q4X[+L3&>"7&+28LN22Z),,=$:5Q4P%896
M&+K8:- 3@&B5O/+XL#H;*DK!8^IU1!A+B3BA$3EA [)!"2=99,*-DU?$_,EN
M595= 6H%J,MKE%9I,8O%SMD07DC">^G &N7<(VXQ 9,4C-.DN6(TD<"X+]-B
M#*652?J81=FSD9:G:??>^UF[]W>CX:@?+]LQ6]]/8G<0WWH?>+9GL+$N.8E\
M4@%QYPW28&P@2X@1UBC""'Z!?>!;!Q$&/01DS26)J5S_PN[O]^,^O'.E1K&(
M8UDH;-D4/K=?'N/!M =ST1[DOXT[Q0^J/O'EWS1?H_I^=?//4^#.Y"(+W)?+
M*+R^,G(G5ST66]T\X.)R_?HM2DSOL&'<O"_<(Z1^K\S,I3/'2]3XK5^> \'C
M9%C)9SQS/MIB9Z;*_*\R_Y^5R&_>OOH\58$FF&?9P=DICSI?O1]TO"WJ=/M[
M_3P<[-8V6*/VZ;R\5VU+U,\/#G<./W=@O*+9VFW/^D$[AT?G.^!'->B[HWK-
MXT:MGI^+UUM'YV"UM1OOP0^J'8G&\8<$_L_9K!\D5++$:J2CMF#/:8.,)S37
M@082O @\A95UOBK)@OE2'\G1>0MYRZ!Y[%Y;0Y6&M=3HUX#[MTYCYY]8A\$<
MO(4SR:<"OO8<\$DB&(M>(:42P)W+>=+2<<1HSKO#A$F35M;-*N$/KGI?8!;7
M6Z A =7B#[%\'P1OU\Q7!6^+@;=LR[5.>Q6J+0S5SN90C<@D =D($L3GAD'$
M(A=P0DQ9RYR)CD92HII:5%2[,MINC6JB,MI>*:H=]&.L<&U1N-;8G,,UX9,
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M^9E-=#<SX%H+ZI</\X+ZI BS)A1=?.L1LB:)>80^*4SS:K#T=@MVRZ8N-R;
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M8);+%.-=G<>'[J W"MY6'EWKQ^#>Q5CMJ;> *5;_M$>B#E@%ASC7$>Q_H1
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MXL4NU23Q#1&>5J\R?T;_#+[M[5C?WG]UP&2!M3\Z_>,=>$_O\NO5B='_\FX
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MF*_>&%UW#<,_+W>OU4D;2:)GWQTS\)W0<]%BXKICAY'.$C?6XRA._-!R/-?
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MXN]^XL]<$G^.:]I^Q$)=@&T.!IX=X*T=CAYR*\*!^LSF.&FJXZ_IVFT%8"L
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M&'KH!H;#1, CR\1;];KVZNQ!;2P*)7LZ6B'*L>!HO0YG':*F^\DP?'H\+?@
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MFG0/HQFN-:50"<4*#=J$76K#.2(T.7 4*1 HLF+(-4QBV69B_4PF&8/[D(Z
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MVE W6DRKIC 6!8'&+?)SQ/1 H/#%B" )X#3+\G,I_\%YJ83!R13DK :J#58
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M<HGA:7@)]EN6.4@?<G5!- '9*3D(^RE5_9JT>\"Y'K+1B.27BK;5,<8ZJ+)
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MH/!LWS3R?@&#BVAJ8FIU2O2#05^M*;O&S:!BD#2+139YK>,GC\T+X6VL8"&
M?S-_KSC@R=^^"!6_ZUH(A8.,#Z<QO&(O39*]2[TGABR#-VDLB[7>[ .;#+3J
MLZ[V16B1.(&-YTD"6\A.EA_1$B#K_ *_R:>%QOA_IFF93M(<?T+]\[U9D;)Z
MZ;\9T >;Y,5,@T=Z;*:!M*" '[V,7J,!H@<K+\+]+>\9Y <\CB_>2]E)EI?
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MTB3Z*A%4&5'&.1M.1;7P*!\*/@6R '36.A,QA!P]+G)8%GX)9)U/3P:2:%/
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MGF[(IAD?5(;E?>R/KG8\ +9I8!1/1\ 7Q"8GK)P4N<!](M9F&DI:  .QT63
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MQ57[E[(3Q4!-K@AGLHTJM&=S)$D"N"/>ZRBTI]"^;1Q\D-V8X5B &#XH35[
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MNED28%EET.)IL=#C7HLY7H"1MN3.P"^! T]$-72A!*^+487L.2M2IBXKP.>
M;J>E[.D\03K*9'<;&)"%;-\KJXHA#$6HNGH9LL@F13Z48[2I4V#%UUJ_GC:>
M4J7,>,CD7/P2S'UI\-:[K'?6J+:4IC+\< 16)[U";6]A<:Q B:A5/:/]5'5=
MF.I'NSJ5IC^" 8U.\/F4@[E4A<+3 FQ-\O_05QSG5)Q/M0/2\*SC,;A[V'*5
MEUZPG!<$1^V>SZM4)GCQ!<JP?>QLJ(O3X*A*B"W#=.&L]<RI<Y8.651/P3F'
M5U6S!CLK.T)::EK@LAFME Y$5;\8S=2M"K61+XME\^9E##6T)43DS^;2$4M;
M945HGC6<Z[I+$/RV'"?E5?Z.1/B"J)65 <.FH)T+Q+J40)T,EQ%#407HQA33
M&XB:@'&S\T*M45JJ<DGRA<025,HS=!!E&2L>7<T$57#:NG*MG;+9'H.L+, Q
M/)<70\@PXS0C0Y3"G;+^%"]/R>?R:IU7J41710 T([$AN& QU35$TS;KNU&:
M0:QYC+_>H48^:3D@YBK7O$55_=\0ZBT4QBJVE#645:<0B$R:!UEU E>C+II'
MI$YP-6(2J3G"\C\U(2H3R,L@0U <9'1? [JD]5C1-0=5I9Z ^DC497^DOJLM
M-J,0HQQ;%%;'C-=RZ*%![P[-Q)9-J>69EM!POG)>Q;QPM\TG>*34/J'#+,,&
MJ+W>JI6J5N3%$6+K5P5>^L  I@<''>U@(D::N=/M--^BO9,_J18EXPR _5$&
M/P#,GR16X#@ 'UC T#\^/,<3;E:.Y\:,CH*,QF2[M"J)4A/S4$!MFRQ:C%\5
M4OJ4-(F=R!K0C ,0*R(BOB$S8,[_K)JX?%&7_JW<$2*?[C1#R:A]YG"K<O;K
MA%)M3&UYGF0]23VI;;QN"^MMXT]-W=+]I;6FR_7OBYYB%?;%RQYDY)?4YF!6
MJN'=*8T#G-.RTA%Y4<GK><DR#;BD3MA1KDS*P7P,IVJCDSXUWEPP4\.+5+6N
M3'Q0,PPR$HF(>5><TM(J2U.5?8W22QEY546]<L4F8TAKN*QT1V5:4F:)(N;4
M4@#F54S]N.H 9+[630*H.7'> _U=0V;1E9Y0D;$L.*L?J0[8M#-DE7V$1?\G
M3'JM"T9GH]@&;?I:7_VXD; T9YBL@"W/!FV93&ATUFV63)"=ZJOM?[<R_\)5
M=U7Q$8[NI'GVV*Z(=69D0E,W75T6C5R[-/6TTW"#V#"-Z:/*Y<NG$VS+D$Z?
M(FM,*N5(_7*0^V2>*E.5#M2V6RR"O2ERKA<.P%6@/*D,>/6<M[F2DEM+-7WD
M!SRLC>"Q#8A)W9W'WA>YO$P-H+A9+(:$<]+8W>V\M=[24S18.4%=[7_@I6)Q
M;>2\9%B5^3#5MEZ*:L![.E]'W5FTE)N<OUJH'C9>%P<U!F?-S<PMI_&MTB/]
M>5%[TUKXM>2^LS#QG<D2KB5:19*7W:;G0A;(J 3Y^E+C9J?;/"(\_W39.KJA
M]I]F033OX+KY^48E>O,Z+R75JW8?JN@K8$DNDR4G3-[56-M_<WMRN16!CEK(
MAON$G0,_8;RJ<<>*K+$HT2!4=\-@>$4F/JHS/31D$%A;%#*X]9ZY;0L9'"\4
M/M;3K:^YDD^.CZ^J>QHW\U$4H;J>+ZZ#3+VZKK@>:[TWOT6:9L;!*X ^*4SP
MKHY7[M;Q2GQFW=7/VS?Y_/CZLJ;;9H/26)*EP:!_+$UP61DFNC+"<3[8J''!
MSZ+[717WQ]<588$ F"[4!LA'_C][7]KD-G)M^5<0_62'-(%B<U\DVQ'5)76/
MWK26)\EVS*<)D$RRT (!&DN5V+]^[I(;0'"M#61A(N99722!7&[>+<\]5WH%
MW'I<-MEESAS3D%S>=>4RP;[][&DDUG/ DRAF=,/47.*H4F=Z/>M<Z4(3WP31
M%?B):4V.M="9O@R1%<@$%%[@72_G"@Q($G>$+O-8"8;8:E;>$,KZ9"Z3);Q8
ME@@6=3X,U)H;O7/EJ<MTA)_7OMK5493N"^'1A8V'6CM)I5V2;9-S_E8>Q6Q,
M@1D"_ M&-<ODE3D:-TX9JY&IO3-)C#QX6_%B677E<'8N]+)CERMOI6@Z\-3#
M.+D]B6)PT,R.<F.2DJ6C?B()1%$,@94B29S<GA/ +E$*PJ,K6+HRB(JX HE#
M5-24N17AP(M^-R%*2PZ_<HHM(;8.O/#2C;L7M"$QQF&N[-6!?7"0B7\/0 R3
MKA5@X[8EYQ[6?',F0BU=K#+AO_Z CZTV 6OW0EO4WO.#Y/5J2%X%QO+DD+PG
M$C_->E+00DQ69E2',E>2?VF;<9,4M<8DYJQP5*96=6-,N^5V3)P,2,ZE^]HD
MI^<P?3R\)_EFQR;?H51U^/36'\(V+"OKK;[5[T%UC]WKIIS3*VV83JQU.)QC
M'+ZR'L][^ #K9E\3_W/5RV9N%U6PA8](4H]HN_'O:-#8L,",KOVEY#*QUECV
MB(HEW(;2/@7W)\E\YFDK:]&NO(.RJ>D814_0Q"=%AX?9'=7-KI50Y0PS#0P]
M.)5)+1F*PD#FUK; O%_B!"MW5V6 D0P>85G@B_KI3E=7NJJ;GRM\NE[)>]/(
M2VET1V02RY(&5GK#99I@SU"]=T*A.O+F1:&P$'EE<605 _8#"U,_BM21'$-5
MG,VNM+3FJ#$V;1M?7,.Y4A2\KMUJ.)$5G?Z"3Q/:C9LR\KFR;CZ2VLV$SZQ8
M[]07^=2VXI]V@*9ZS;+*,)?B,H7/<;.!B#!W&^*GT@!5G-6^@%#=>'7EA^F6
MT%I7A14UG14JQ\)VC60TCRS\^9MP4RM9; NAT;5$P(7_\B1B=5>L3TUS.-97
MTR_O9BU%1,(WZ1OPXH#PJ4A+1Z9/DIK)S@JP)L1-*;_K!8&L/Z7\JNEFD.3"
M16R6BU36?'T"GTR8R1.F_Z_R">52(A##!BNUB!)3Z*N>)6/&*ZZW3D4YB!/D
M$C#\;00/P@E$DPEE+0JP.XYTR=*&,G.8JGPU4O<%%+EO'K-*ITQ59\R"3>2*
M;Y.^D6U*T.P2?Z?B*4L8D6H5]"G-L?'MN:9RLL<)KPK\-T[9 O5*@GB%?+CU
M$[%>""N?0:(EV8*62X'EM)0)$PL6;*0@S0)R">31P?08I[ 4>"O*4ARIS!3-
M@HSNL5^*QKSA.G]DTSE?),24SI$4'<R63:&)2%YI?*'9%]T35YYP'HN);-AI
MT1A+]3%O(C>G=8+([ T^S<>LQ:^L)9.RB?&BD,:1J&1B5R_JGKQ^*(X;AJ9N
M+E9Z1)P.E(3/;WG]#,Y3,6=15TT2B'5B?>+[5P68O%?.9,5MAJWFX\6ONUK-
M8#S'Q]Q@G3F]I":4ASCD[T%S]NU@"DB.1'(8H^*B\I:I=D56!_:P[$XJ/U2+
M9IOF-D[EC=/ZQ9$4 -G*"E2;2N]M?"(I1?VD<G.4J&%2DI I)VG!">$,=C/@
MGING!RHO[)NF6LS) RE>WK(2R(CJV[[$G#\38*!<45F$C/&X.L7ELF25KG"-
M0R8K*62["H::Q&C6^0-)R:$9M,)ICKLNEVN5\FSK0WZJS2+D2ADJ(_VVGU7N
MD146::VAXDQ+H.Z)7<F<R('>_U7$*86OM"<OQ0]8X41"YD&+P[;^J:N;:+$Y
MV0PNR)Q2]DS5]*J""['SWG*2B_#8N>/%D-F,&)E!J#<"%SG*KN@*UVG8PW6V
MG>KYF*_#-91'\@<OC?C""[R8%/TX"C-",VK4%[T)Z:,O.$V PQ1APKL@.51?
MN8Y [11'V/C$L.>CV\+=]);\4IE>E&@$20XB>9E<K-Y9+DGE7N/!9JP7V*2$
M\@%Z(O:)X1R7$+(T#4QC1-=U5.MXC55B9I8QW<?D$BR*Q&NEAH>8.@F0H+YU
M$]1 OFI%@^NKKG$95^>COW6USP;D/3GM1:[WUN,*J$!FLQ2W.UW%7(LP'R!:
M'O ZO0^&-]0<X-)44+ME@H4?@W3@]0?:.>,-LY6^0>K_/0RTCBH0[JSH^961
MPSI3_=0-P5&!!-_@E6$/,4J>VA2^^3E@=DS>],"[ Q#G)&=JO&(*M1C@&L<:
MUDMKYV#E6G%A_I7VXTU%'F;B$JF@+##7Q%N"+*4K>9R\V4R29&AV)^FI6J3H
M>;IJW?A(7KI-[2M7_I?2AV76Z.2<!AMLR&6G]A\L<44!^2YT?14:T%MYDQW)
ME&D!U/=55C:E3'8$CU,51F4I-<)ZM-]<$>N*GYC*VKVKL^T*J*/>E&#[IOW?
M,Z/0$'R/H)+;?J!+\,6&L+TU+GP%9[:#.'T#%$\3D<LR.*GXE-)CQ#1[I7L
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M"NW?%>(^EZ;:!P5T6+][0"G>/:[,$P<R];FHS\7VW,SH (!T?2[J<_$<SL7
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MQ.&AYV&%KB-^3 1HDJ6($23@S44--:RAAA4=[#U##4_!"R[W]6I0Y.. (L]
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M?8/NF_A++Z^(<+PY]UUF@V@WZ=4W7CAANS7&6 :-22S\Q3B+$PZ0)AB/P?S
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MX."N27JIT[WN<'.V.*9\I:SN4)Z/=( ]O%6+XN_L["GGQ?B,'*C)* #=56Y
M;SF5=A FE21[2-H1MZ+F]<*Q!0$V%!#"=O207PTYU_2%L!5BY3Z%:.<SB(GS
M_KWKO ?WSVE=-EQU=_P%UMKYE9^OT#&^+(;X'V;B@T%]$7Q;)E$\K>;%_YR<
MM$%P,(T(EF\"6W)\<8518/R4;T45!1]YJ+@'N*^FCS QF=G!I]IV/]%8C;4
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M8]QO4(3DQA,Y"U(W>FD6P\:"E%$O3 4Y&X-+)),@V'DIJ;WTQ]S7SQ)$%E'
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M&%&\ .[\O\HG" <:@J,L544P[&RN_1ZSK0O02!F^1N9JQ8\E.:FRV;QA"*>
MI?]&_L\B NTG;Z1X"65 HS*JLDD$-^BY_'KE])M]#C_4BG.[9)#;!:5]8.V9
MF9Z*$CVIRPP]H%Q"K&I%S9NNEJSI2/4ZF(J>(]HT];XSBP<3[EB+0H$9E3?:
M+6_EI9=TOB6C/1I8GK^" D'X0TL#>VY<=:ME,EW18^25]Z1Y-66C9Z2EI%9D
M*DR4NI^O<7,C]5*F'TFH'8.B*9+1$PPYH6["BA5<7N+E 9FZ&3 %(?(2;ZT.
M!6P<[P NVH;CDE['43:'!Q?^KML-F;".>JTE!7>.FL#BMR7+#3=N4LNT,J1@
MYG,^5A!HX3%2ZT?7#)A>;SA?<:(;ANOGXTMYJZ3NVE5@%7+'1!;YE$K!:,W!
M,([YV% @G)L(:M<X >E4'=O,_G'C:Y0;Y3!I73WEZUL\^!1_LIP0M",G*Q(W
MG2B)L=[ -9DL/1L/O51$^$>8KZ\Z4=-5"OEHG&PM6PWB0=8F]9:ZV]D][I1F
MY2B:*EQD;^(-O M65[MQHK/2ZGC1X)=TB\S67[:DX)- !UY=R'#Z@0_YQIFC
M4Z/U]B3P?%7+0WF**+4]4E#,OU^]U=CV6S\1ZV7T\AFDO.81_IU@%U@*D5"X
MJYNWJZ(_L^;3K/RPVB?5>2D:\X9KSF@4;SRBK[2ZL,Z,YJR2WJ/4+Q0:3'G3
M4J/*"^J' ZX@8I"85%Z<?=NPP/! T^^:W$[3:D ^@E,=?V2<9DBDR'(O>E1)
M"H!$1E 1+I/[IGR6AG.)FH,].35!&!8M/]U%J]-FOP<G4ZX(W (@3KF(BH\0
M>S_*!2>]J5W(D*,1F!7X.A=R?F,/DW+RC.7ZI)"4D*'/@;(P$R0\U*L@(Y3R
M4;3\KE*;!3\V'^<6.[+@1+.$XQ2+%!.SA7)2LTAE>E#P\OT=\+YI@D;,#@^M
M&FVS/CK&4=^*RA9QYA'/"&8,6<P4*#_=BF>\E7>QY#?<&7%4&2_](1LLG9R'
M_I4FROI.3U9=VU$H:>O[4*@50F*2/<+X6_40]4M\RHM.J]%Q%LBUJ) K(8G_
M0K*L8!-G]*'QNZ-.8VB^FS#^8"VEK :3^#\<$.#T.I%#^N\L%$ZG2=]KNQO&
MT^XW.G_]KU:_^4:^B+0;?(*_Y@_6'[%YR+"RC::C'X7T,EXHT[34@HE94\G1
M*!4C98Y#7%J9PJ;('X,0>J!Q51E"+\4VUS.(+ULH:\-?1&63$W:K]0@V#D$U
MA#>Y*K1 2DV3IK+BJRB>@Z[\T]/ZT? 'SPQ529;R9'"#P1Y1W8[F+Z%*_!W4
ML,J4VE2U9'MSQ4O6)'0- "X1);;E.MF3-K;-5V$?*+N+L<>W1HNE '^+'HX_
MQB)AO./6#;/ O"2NBM2Y0]<<+[$D"I!G(B]T(ITNXWH5N^.7-6P$TTS9^4##
MA ^5?HD:ZY0ZID[0I-IW H&D-[#0X^9F0UU@*&HA+K;1!)K@4)"O5-)]@0OD
M;SRU^__\3MX2/N@+7GYYKH/-T"/XLI. 49E&MR&MB0Y5"?E.-R,R"&!S@RZ5
M%!K=RIE!L#)>I!U'[20HQ$%IPB.3:HI/MFA$9:T<Y/RX%<26!"7D^T7*'T#P
ME*GPNE#7F"01B'6J[L_&@IR8PJ:M^YW%WX'KC6Z:H!1/X,\H=X/;#Y*$B#NB
M)..+*/W,6_LHZX(^6193?E*I+[:+R@?%0?E;/%,IL>L'@!UL%#US>))#2_]8
M8^7 Z>:%W\A+,@*K/N$?*0_I&B0=NV"1>\1>#^L_P\%I65-'-DRBF:PO2JG2
M8W_9I,]Q."1\U,.X1I9H9$FK1I948"QGC"S9*GZ4@4/ )X:>8[&*5&.HB)KE
M%6'PDL6C /<[",:WR<UP;:['DNL8MDQK76X,W4CA;LZ"'6QLAV!*\_G>SF(2
MW.H0RN?:A91[H1"LMI <];(VYM[D.FBE)'J2<@ J]?.F'G7G$0<^CPZM3W?Y
M8Z_OW9:7S\G&C^^R[*1"\+>)OE$@QWV,R6QK+Q0/%>:P=)VS13INNR96]H^R
M290>A"%Y,?E\Z/:&4X;IX+0+B(!B^:#=5 ,_U\% 7DURXK\T>,.&?(D\^Z@K
ME-NX44,A#X,&Y:_[?68#4&-(NE1N*$KY-',Y1/><%"P9!-E.;!ZM&8C'V \Y
M%",'FUY,A@"!%!-_*2E9E<MI!J6=3\2Z(2_.Q#S%#GX@</ P[N5\=\'?Y[R?
M_2J+5S6_"/I]QXDAN]XH6J4GWU%^*&$1( +-1WQ\9:23A^>G14C\['Z"(B3I
MUQX!":]:;6I9A@$>X]W,/2!%PEM548$JISS,D_*F/).$F -E/;>5%]'9"]HP
ML)YYN@(S C=_"+5JVN0O,&^BA)7(-AA25GDU;(;#/'Q2-0'+\.JZBI)PH 6W
M2%:-%K$"8T-F1,5MN(H3Q9U+SI,$P+B@K_7]2UF'YESRG\Z; ;'QMT19<KZ"
M*[SUK%V:I0.IA458HM68"]#J?)=(#5;-3>T_0[+&5!A&2O029!J4/ME]RS)2
ME@?T4BH1'9R0,K!*Z[U?]9;]$L'_<%+GZ[LK5Z81X3"!8SJ.IK(SH;S< V]Y
MD05S5+!,4R5?R 6N,!GZI&QZ#>=2$2G[X1[" ^9=.2NVP<]#J+1,V-=81-UU
M(\)UX9&YKER1.3?AHOP=UQ]1=DL.-#'T 0W:_-S4HC!"_\.@W&'95CK;IO>!
MS=[&'](D9:62N2SC2_%<.-)PK@R<7',_Q5D@$E4'#\HXP5>JI)X"XN6.9"E$
M5*]D::-S?/8M_/36RD#G$/27Y1<&KJ*>-3F[S5DZFGL8W1+]\FHMEZO"RJF.
M$R78/A8W/KHE93)51=5P!(#88-GX%H<* S9<XFJ^+MILI5%%7I;R9:#;(]RU
MT-;"V 9W:$/Z1,KW8P;BA\I-@A%DQC*7*+'Q"3)38EDS6>!!8+(BLK44A[G?
M]O'MFOA!#45=JUZ#/6FL29%W"FMW"?@BA.*J/+=RQ,H@!>PPK;5TUJGEW 1,
MO:!6"WC/%:JX1MV@$^FOBL5VW^OC8R6DP4?8D^W\Y\9,-9,WGA\PD@%D.R^Y
M:QT]UKD]=#%*85A1R,Q!J/,5VD'A4ZR]WG3G;X<^^"B)B&!4"19"@SGD:)/#
M!7E]1=UC;T6<BS5TYBT/]W 5(D,6+*T?^(=!95C59HR6-?3/!/G3Z@8GCP C
MFH?4%F<0"N7$9&L1QIHX.%1W&RB9G/D_V(LC>CU).44'2-W<P&LRK&&F]"Q%
MUWXHRY3"'(A$TEJ1EZRRGB26#7+KZ!.,0RP/6\DM[&6<(C9%!2;JB-$<P @3
M:2 N_"9P^<: 7"-?,$LKU1P*FOPG15&4]R%_1B%$R^@L[#(NPM&<MI7YAI-F
M"):YG<]"C?7C/])*4[RL*P\U6!5C8JN@<QS=J(0T7=,9]1G)Q+;/#3470MB@
M9>."ZIXZD5T1I,%2.9P4W>Z%*ZE;#D8_E;V^_$7P'_P3?-L\\Z?,ELOWD;*2
MQJKSR'U%M9/RDT-?NPN1E:\FS$LBPVR]'%.4^B;_CGUW"D$(U:JK\P7?#2_1
M8P4/1#NYP<J1'"(;5J"*XG^@&_M>X;*I96R@W2HJK"G+!2B\I@K W U]:JV4
MG'1H\B5O5A@S([9 !G* 6(/?I&JV**^*:,]@)=.K]CU#+HDA1Y24-G<QW\YA
M#@-)YC!#BG"&%F\(NNP:;?5 ZM.&,]5R9B-J[DI9]T0*\IW:UP-%@L OV,C=
MW)TI/4!EEB@5Q=^6[2_F(W2!UJWPOG,[LH16F1NA8 <A0CG8&7+D 5.?RSSF
M_C.0Q0B* XBAY)[$3C  G$HP).\.@^WU*!=^HE/W&NLL@PEYLOS%'@7Y&GD_
MIMJ.&X1'3!F!G++G$%G+1=YDHT9T&$1'NT9T5& LSQ71P?<2Z/"139#],MF%
MF,TDRU .L\9* %,_(=_/1;'^O6[_I!MO'J#,T)G123A,-N(;UY2J4&&'U#5%
M*GJ*'63EH@IU#[()VD6PF*SS[C'1EJ".3)*,5T5;\VCIA[0FX6$O5A=$U/3#
MGZUH,=0-MA4ZV<:"\9IKRR-KGLF/F:PD.!-TK^2&F*TY-&KN,L1?)]-8Z\:E
MEK[4ENBX;K?IT*A7U:_+W6B@#GPF.\T6_']L-RS38EILJ2&9['%QD>8Q!S@U
M$;,T93,.DK#2L>  EN5#<\X=X:B)J2O'JG>/3+%/6I@P!@V[L.&X 7'Q3B54
M&V6;4HRMD:E:,(  %%^-E5 "NT,)T9+.LIAP!@JBSBATQ@HL V^B"NJR4GQW
M$;R6VWQ%INC%8P]V\.+3CT"LG$O&SK>;S;9NZIK_BNKO6H#__W_VWK6YC2/+
M%OTKB+G3-^R((EN2VVZ['>=$J"F[K6Z[K6O9XW,^%H$"6190A:D'*?C7W]QK
M/W)G5@&DW#,2.<:)$],6 =0C'SOW8^VUK"PN61LJ,KA=CJ97 7J$EZ=22Q?)
M3=[)L/BWHL2 #!&@)F8?=30%D^#J'G0$T)7IB8JP?M71I'K:)0HQ9:_MVD 6
MK]?PD%4C.1:\'N!*?G?D&3<2\30<PMCQ2M1VVSE1E52_D(X\C]WFJ?&9,6I#
M?W0M2C^3&=@ %)D,!"I*5EJB/793;JSFF>!VZ M<QAZTMY8147G+B:XV)SKI
M)\&Q72@#"54:^JKB^$[JH9)32 L$_]6/"@+6)GU0:ESIPYD/UA/5RDGMC]O$
M0JP0+LRI?[9P,ZPC_#%X$B*15$SG:O4_DT:?!\A&H:I_"<TKA[':&YSH-'2T
MI_JD"3X)D6DDT) ;3LPP!J1+5%T.:N[P!^II9F5LWF-13ZG<\ F? >E(VZCG
MJILXL:PNB!.F XF!@-I^-MQ.'$;&$C2,2:H'].R^%9/,)IN>&^U96:%(AB L
MOC=SQL-:FY5RQCIRA,H%4Q'?+FG'#>^-/"%WJNGVTQ/6+3KN&],EXV3,M&TM
M2EP0>]!#--YW&1_1VF)V0[+5F-CI@*<8;6 AS/Y&I!^SQO94_K"ACXQO_(4!
M--W&NT3SKPLT#"CMB;%AW[+E7AK94-KJXMR/]B\G"N[W1L&=ZG;,0&[5J='#
MXX50/;UX>_9=<,N:\%B%_^/KBXOP[WJ]3K[PW?Y5&4*,V5_\]%VQ^)'"R>IB
MO[N6L.#E"SI1AOHMZNN]]A]V# G<[L)'"%,=Y+"G#G[V7QE98*T'49-0SH<O
M3ROLO:TP]D0$O5S=2-K>0T75%)N;%!V&R+WJ>V;K'2)Z^MY55VY/T_D>I].=
M$.)S@!6IXIE;E\M8H[6PK5+O=Q<^'O:GZ?H@TY7TQ8*_BL]@8KIBEI(WE!6"
M@D*Q:-'Z8?^\*L/9W]8-SR6726CS1NHREX;DS@Q5N#\9W?<_[>B9)I2,JH9;
MR1X^GUL)IUEY[[.23@:CIK&7@B&-S>VHEZ*]_4O:4*=I>G\>BT3H&B6EZ+)@
MVZ2]0)Q2(K=#8$3^J+$+/+:H\7ND3\#)[?N!R7MC9))+R"#EQ"+O"Q##-?L(
M ;9([A3&O;\EF]6HM"-;06;<'7 R]>]W0CH1GT*8 DA,0Q24Y>6F[J\1YS"U
MZ&%>99^+TU;0/#MYFM4//JN%5,M[PQ(ADU+XA.NQ6;96R;QSLTC72\X' 32;
MN-?%?&:&4R*Q#?GDC+__5<,D3[PXTMJCBZ S5G*7[D^%8]YI94GR[C39#\Q$
MW(-E96H*5G5YU80+U,N8($,ODKL6]XJ[*YZF_OWN\UU+F#C6'\!<%S+'&Y+*
MKH5[,*$'7*=5\#(EJ77](EUU1=2-L!8$4Z+'08=GO51PCR^"?GD8:'J:^_^6
MT/XWDM2=]NC[W:.KT2D06PO"FK2H;X2?14@?#\_,[P^J_<D)JOT GN6#0[5/
M)N>WF)RLT<DY^V%V-)VX:S?!*"PEL6A\M1']DJ,TWR<1[KL9S@_ EGO*DG^H
M9<VR&L!DT,(TST97LBPG#]5X=.GQ'Q,I%]6H/ R#=<QV%+%[(!^ _#>D<$_6
M&6"^"+TO6% S[,K@X%_7N[B!%.>YJLE?6!7&UD7Z.@K2IF;S"..'1J9(53&V
MLE2\GV:#*E.$XA:YG- &3]/10$ADXIM[6>2>-'X\(%&)(<.5B89'7ML^+@BA
M9SC30AX2PCZL_,+93M8HDH>G% <Q6_1,IPC3 96*H:N7ID+K$N" HQ%7!:'*
M5?HDZA>QCD(&BJ.9H,<!CV'JSW?SM2!6&MDPK418PX1M>9A$.?=H@YJL9>'7
MEY5\'XRI'1WO #%U:6U5I#&<*)";$ T,#TWS<<TT];1O9$U*S.O#J2)C=:!'
M96I(2Y4H<(AYLIQ28?@KL71ST1S'->\NK$;7,1TAJB#$/-+3^4#G_'FSIPGJ
MQIUVD.#]PS8L!^7OE0.7#^C8>(+V)#FNA=L ,FMUJVH^#?(3Q&$PZ\3\]C.^
MB"PZW#"G'<RPHM0_D!F;G"^8ELLE=3\5_(F0!X>[_U$);&!?P5+&^X) Z[%[
MZHY=$FU\!M*.-C==_$1J0 !P,NBQ6TNJK2ONAMJ0EB<,7R%:GYQ!(%DUX^=T
M;17J@1U*,BJDT]9[W$O)/N1N,9S=,D!RE9C)T(.0=7=,\4K,?WH!^W5+^6G2
M<?L7%)K_]-@5FO\J":(':#A^ ZN:FEHOVDT'9>]T?\EKT+:0^5H5=RQR3[TT
M&FE?B0?P)^K#Z+^(<A)Q9;:H>J?D>H^ND>@[*1AXQA@F*&.]868J*ZDGI8,T
MFUE4]3KO52<\7_Q\380>MR+!P5=+!SI#;.>0;[K/BUBA^-M7KZR&M?A(.T+#
M\=]SR)@!PO$R&6K\8SX,$FCX7X/UK ;5 NT77_7M[KJ\&OO%\W 0[,TG3N'C
MB6B)$$8$P_0+D=SN)YK6![NDH@ON!_O8FCY??,T]AX7O23%!6>)Q/",[[C'J
MRMF=@6PR!U=MJ8NO9E6%OL]_=G1B#^+S\]F>XOESQ/^[3ETQ,V_2:K9W4BOI
ML9,V$ZK0$G.!&(>>G#ULCDC-\3Z*UI2+63(O<QBB*_IBLXU*W#&44%U(45&@
M;P>31^F0R5>=N*]R-X>-%]Q?8FWGC/"->RA]A")MHG->J#WR*A%[2TE])IK.
M\XZ--8+$)A#!#A\9)=HKL\O'+\]LDA(SS:/FZ9_%/TOO:HP*T]MC<)T/G\L/
MS@.C4JF*VYE6?#$DAUD\CQ%;/<!CYAT/]1]GN3&OT8BA*0*6YY+%)^W^;:0\
MS[^8=96EJ<RLD=.1:J* 9FT@]%UC$FCS3.KN>M^'/5,VWB5@?#JT6X7>J"/'
M.T0"$';*;Q?S*M-&4%+/I4,,9P(R$/ERU*M15^88%LJ6;A:?)?6O$?J&)]EZ
M-N#'ZZR\8DH!Z0=8=C5D*<7XZ1KB%LX0S%!W03!\*!8)=?-_S=(Z_^_)E#Z[
MUQ@L/ER:-@3U4WW;(YIYE/N8F3$YR"KJJ]T4S"Z"/VU:2NBZHU!V0]5'"7A0
MH_21V$(#ZS+7 XK4NFD:@@YVH6:\I_E@9@8Z]%1JY=1!^C[K ,J .L>$K!W=
M*=U>!PL\[S%S(."=3VT )1,R(/Z[H<0L=Z1VP8+098GJ67KFV=Q>UNVN)QN+
M97A958+ DLYHLR275<$9%K8U?VREY6E3K4ZPC/>XB,P&3.5_)JDMCY*3!8:M
MKW[ )%BB*XRD\#H(U9'W$S*;V87ULHFE!5U/US1WE)$C=N=>*EYR4;*OV65/
M:^=]&B!@ZR@]Z4X2*'9X9TO.'ZIC<%&; %E5^-1J8N%"(0!CV6@X@..6?!60
MR,>8D\S1:7H_S/0ZO:0PG3)?7'3V\0)JIK82<HQL@K<USSRQ(.O%FVKOZ&@G
M]F8+<0YCN"'ULW <>?:O>K,I)A1K#JQY4RZ7RO)"H8_"(_X(AI-R?U8.9R$R
MJ&+AP)QF/C^#5]0*XS4R5E*@XBA6/SGLO241F.2C7EVW55._+1;/N_K7M@EQ
M_.NP!E[4U55;+"Y((+CM&H*0O*J'H0^!S]5U^.^J:?K]YJ8,G^!.7Y-?M^IO
MVS;$T3^&D[G'S3&T)T!=!-3]Z02H>P#/<@+4/<X3H9KD(@^IVSK?4LF^1\@B
M$;2^J3;N$% F4Q.>SWC)9RK7*IOB\7#SPC*MNWE=(3%<=3>45XQIJ4.9(E*"
ME#P1:8B<L&X?9L51RJ3MAUW;5*+8IMIG.-ZM0<-/))W&':6&%\&4,W<M1S7-
MT&G/]$P40[VBP7EH]U45F3"+V?B$&;6(X7,]=AO@$ A5&A,U>J''!TWZ^AV4
MFZS*YR2;0/SKD@[S@DV@89!B$=/9Y@I2$CSTA&=9F3H+Z$^?/2G2_+&XI57,
M9M^C3S-F49Y^?O[I'T2NB&O@A^[\] OP\\6R8@6=DTSS:>9U;XG%- S-&X<P
MZ=/TQR8NPS3MXN$[)&)9@88Q%GXM\<)I])'#:WIS,< PFB.T[4@ @'_)%=3E
M&/9)18)B6TT'L?..-..D#K <MZ,H/VF*$&PSVU;*H)JNOZG8C4]#?8;2K"33
ML(2HSXY>1NK(8?&'?_8&6^!OK,8N+L<#N=7'!P?[/LI-J<A'+'93Y906 /B#
M'0H6P91"PO-=2<GD>E+F@5YAI72[?0C 2^IU97D?QS5\4W>C9*+3A+-9O<)I
MS%U6^U9J?4()?+YXOJ&Z:C"%QQ/8T8KN1M"Q@"L9Q*0J@Q.?TIXL9A47E2I-
M;0FJ88%.D5[<<%UU(_(T[$ 0US'M\)J-D(J%AH,$/^.Q![Y5LA=U%U8]51IQ
M&EBWH67)=:!)MI!9.+ERGJ9./:\:HPT$1\DK?0A+LB+TP%<0WE$):I$0)J:H
M;$PGZ3*PL#/&E[-PF&.+>.G1LR>"'K*S!2@*UCV;,A2#)=8=$W,CLG3Z3\X5
MQSB8BTB7,>>[@KQJ=5VQUGCD-6>UD U.D+87.LPXX7[$K&&COZ[7XGA&8T%G
M#J#O\F9TF6I328T%XJ[E\KKJO2I.I-@GWG=5$&&?(QD51]'E7 P=IT=WO/]$
M85@X'J_JG@^<1=7PE'V4Y33D[Q^K$F^JXRO5*K^W@7P@\X\C3LU2K$Q1QPM
M/%H5D#_DXIZ@Z VAA%"A:S*&I(58%*LG3!,SB&^P_?E0=57G.%$.]T$%]G!P
M7ZE"34*PHYIA#&Z8W-S=4X;'*1?;7KS1U@!Q-PU_&]<=P42VE_752$8'8 J[
MC)*E;]L5F-DY8YK)(L,^J\X6P#[8;&X:S.?%M^W(%"6<EW*>0%#!27$@;[:7
MG%D3$[+<Z=!Y0N!<Z[S4\>)8B><TBI[-C0CW$FRD@RG5&^;VZT/8W/"]L0M>
MS<#SB=OMALS[/CI_SIW(CDZ +2*MML697+,%RIEFC%*$MJQF2UP&H3QPB?CK
M3"-9^@)D#!EP/;G"Q*FB;TN#!HMOLQ;"=$#FQJ-PJGW5XM^?GG\1+.)F(ZZC
MQLEH"*B$8MH]HYRJ-!4_G;^FOA2*G[7+_ANQP&&(OAF#Z5J\YO"[-_F";[YY
MK9H%M%Z?[[JP')]^5HB77VMI^KKLMJHZ-@ZR-<*FNX(J,^&/:I9R@5@*[0B7
M^)W;'.)ZSY:\'[,RV8\SRUJ7)FMOH^]'K*'T5K5BH.R'\$35'LV  7*HI/@\
MOM_,>XLD'QN&.,4'AC,URGB1KJ3:DR@UEZ[-W/%5?Y>V KNXN3/[&_Q?7R1
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M-R/+?9K^BR)63*?<Z;M0=;.CO@5O!P!(I#_*917QO&214"X *BXOK0"ZJJ&
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M^DVJ7ET !CBWL4^8&T,U&<9/JJ77==B$E;H;9$6 I.TKYUW)_JK56/&&YVQ
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MEN6E"&0M0V3!^*?GP4G?T"'^IX(J;^ CH27>BPE[U;5#Q7I SXT5Q!;3<R@
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MH300?'-IT?1O08]BGWL"2VG4 2L,RC]IJQ4&* SAY?P %E%*V%$7MIWCOUB
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MVDZ.KL/Y@^;WSQ!/$"8D>8#"LU8 M$%5]9RU(NS(L%$_-NQ0I"^H-:0@G^D
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M#;^697WO=1].6%#O7NJ>>X"&9(CU)_,L>KJ$#'IQ5P%Z1UZS[+*A?+L@,4(
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M*,183**J53+W;(CR\2OR&Z,-A@MC_(L80CE*=P1%0U=QX_,VF 3)/>.(%S5
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M6 :D#4Y0C%RZ4V2*G1@A1V3CY#FP6NV^;*QP:=&ZUQ+<V_# -2#SX! @K([
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M_#)V*D9O<!-&:FE5YP>6#A1"?4_]RE2-$Z?WIH0,FX19V3DC[6MR"*TELN!
M398TFP7TL*'X<PNM//5P=I<X=D $8O@/ZG,;:L>(IVW"R>\!QYZ=(1Y48LUU
M!")!?=B42.1C(8O(EK3FWQ%<&NRE-D5WF*&%LGLEWR./W-?-+H!$Q5]7F/,S
M\,N&%&I%I.4N4W4?KUU]I<Q[9].OJ]YU>R&(F"?^7N1-S*X%Q,@]Q#V[/4A3
MX_!A_JODCK64)JLL=YG /,AK@1J4B6CY,9XY]]6'R#L #E-NF[;8%%3KF!CG
M0?VTGQ/GZ&,<M5M/:J\9E8J#NO-J=1Z9OA%%#2G&$$"UX(1=<81M[WSQ5GCU
M;B?X=&+*$_8;%\L5",F602#3,]ROY"QK $3L\.Q;[X(02397FO>/X<JPW:(\
MS3^F0AT5)JB+O*KEQU.9\VB9<U(8-HR(6FCUMNO$32GU2:/IW%22Q]7#R55+
M.19<7%37H%INJT8+I8C)>!&W?- 56C9GQPASGX/PZ4R%AIX2GZ+H)'R,L.VX
M$)PD#MN&EHTM=X'[ZGCRONADJ>HAR+-2^IH.&EK&_, B_9BQK;$WH,N8@ 9;
M*5_RZ94EQND'I>W3MZ68DSO:D9?CTC]!(&1WF*]\^(LQ8&HN4 +],)9=G/J5
M=<I.Z3+_QRR\?IBMP>XNI+S%J&0Y@B&.J69YB(TKD4IJ<?E>,&^BJT>8?R=]
M6]-D<V[;@,@"HTC-Z!1??NX3!6E!H;1B_\@XKYWD!M?EX];>EDL4I53$GMU]
M,9J%1XKGL?4T0S1FL'MRI]A(X>&F9(55*E?[I7M<O"=7DLC0?0G']P89@,1S
M[,D!94T#OM?3@4($LN2QL> KT<-ORPO2HJ]4?I,?)>.J/+AX[@,<1<)R?T4
MP:VT,]*#=Y>(1OMJR^(A[RNJV\=///O]8A='^;(3<RIR!J"2K9EHCFMXGSVN
M(S"<7WS,@^^\8+\[A]T8?6N)R)*:=T"4V.@DI+(+(#J?%ZPVC7DY) DBM-*E
M2;<P1?=MI /@H#O,5Q'*U>5=U 64\N^#.0Y8%S6/\Q$D6<90 I6*Y$UGTP(@
M#Q)0_3HC)V>$;G4EE+29QY&=TO,8+$?N/(M](];.Z(BD6)_+I<)Z= N)%_+9
M$X+IL0.1<6!B9LDY(3^'U&,)/M7"N>$D#*-P,%YS\C?EB O[+D=36I$4[;Q
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MYC=S-$UV]DVH60^*=>\U@6>7_B AND1-].2.RU0]MX/?'7,"2^@OJ9&2&7&
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M55R9PCWR5]M"Q>)57!'0CN99H$)P*%^_G[ !L>%;]<R(C05$G>)!P^]LZZN
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M;Q9./49;\6'9I 1X2)RF.%]*I8+SI[$+$B#=Z0!Y5&K)E!<]/>VD?,C"8.W
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M.14>^LS(DQ)/*-8A2@CQ-N RTH+Q5W&1\&46G\4M0E(_X7-:>R 3Y:RT4]8
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M"NEEKF(*7%],^P<9$[Z5(H+2@LR,RI-S=H4CO*$4+2$+$P%."M;CDGC#>"M
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M:34'A B>33Q7;&=8/B<-2D0^^@F;]6_>]]2< W6Z?=)M)WJ,ZTJA?=J9[L!
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M)DXLY F"(%?Q5>U?&[JD^,4>+&";-X&?D[IEFDYH*W7*)UU22HNN;U!DA-!
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M?)%S?C<*JLP&7UG@XX0.'9A#M3&@M(JHD[,;0"]S*D%QV:WAS=:'@B: X3(
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M^@K4V^'V*\4'">44@ ^L#JQEI%YDRTW!C0H IKTL1CP9;)_T;+,P!X96%^I
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MP+M0&2FJ(=*_7>J%':L$7(KI,MGN2O5H5,&9KRL(50/T1U69PJI"U<L5@JI
M]U5!*"BE)X)2FM&@E$XTGCV.P8SXU;>+W\C!_NGC5\OQF^,WC%]M#7YO6+SU
MYDC5<J1NB%0CM[3GBU2VZ/8 J6I-U5X,BE1#6%I$22R@+FYI-X*KL=:P)@>O
M),:NA$-7"F_<:6/!>A%"<_H@S\UQ#O((R+DY-L<O%!>)1KDC"K.+H,X>8^3V
M-^-BYXWVDF@B&FW-SIO%)O$<,X@>CU$(958@Z^Q]KD"VKT"(*I//N0HY+Q7"
M/FH:*HZRPGM$5+UD#2Q(8YTM'*A1[S)5TK4AS'M%.S"_%8GYY02E28)^:#0;
M$(#%GBZU@3$/,B(E_0V^-RJO^JJ*^*LK_;:P'(^.S#*^'2!JZ;<4I'^UEE+]
M3/QN1":7.<Z/&.>\/3HAI3\T%%D$9[!NYRZQ>X<":3RW)@G5"\*I!+T%9!(1
MW2H1X\(J($))><C_QR$6R8L_?8AH.41. B):5HC<TI7@%%-?<XAD@8A&K4B.
MD5/ B/8.,X)GM9M@J%^ +!4.H7XBA%B,!ZE)/V13;LH^_0K1R^JIPXNH1.[<
MF8< L'UTOX/1L-*_;WI=J<,I,J06#]9#+X!VS9B/^#41R$<_V*X@ [(MQT^S
MA$A$BR6+M>@F2$+O@.6B>P)?XUF/C"D$@G.&PRCI7;@]XE7R6X(&CV;D0?#,
MYC]SP>M*WZV7V73VM*1*R;.GR#5E#D;VDW6Z,]]L=/.93YSYIC498/5"X+,;
M3W_V+=<^73EHM6]S.4B4@Y;]@%SI9R$&W<9-+@:)8M"U^O;D#"3@OM?.)2!1
M N[]:/,S4 7&N0I!$UDY[X&=+'D+<?':=D'0*/JT6\'Y!2DDR(N"*8"AE,/]
MI(+^GN5/EO1(2&Z-UA>KB0D_@-IKEXP*9/7?6SPF E(8F-?4CAYPS]*[MG"F
M8W<4ZEYZGNM!]@\S2CZG=0_V:$-T-3$.>);*R]BGQJ[X!:-I0:Z?&2=E#ONJ
M6":P2BZLPD49O5,]^U&L_\W2KU#;:3";+_V:9OP9+G\YUDG@;Q+<E _^N',F
M+#A[1%I58-2T72^@9RY*(U%G"0D$.84>OP_)M,=#7O/' \I=]'W$G6V29O1+
M6I)KC=6M K+_A/:ZLZ"I1R89*/F_I$G&?=($]PL76L($%X.B7I =PJE37Y&@
M"V#B'HA3:ZSKJ%[_Y_+R\K_XF5P7D$0+J*,$45"<RY9YM7P* >"2!&^63T:%
M%).LK@B01_KB@5( #JTY5B"P.>>R+R9(.1M4;1.=<Y/!DA$<*6-WON!@ O_E
M;WU'^9**G)VQ*R52+QP*Y5)-W0KE4LW(*9=VWY8=4R[54R@V/E9NDSE"S,X_
M[AK??_3:9D9VE_K>#&'8WC':>"3NYD2!*Q4,HH6;'R12UXTB_Z(?O04,B4,(
M!D4S-F06T6%Q5HP:&&C!@3"25:QD)6Y$<064('X#$GPOIO1+^#QKX8UF#NW=
MFC5'E'7EF#A6#%E7ZUMG0R$U62UK6W^L5I/+U=K6'_LQ8Z#792WC&&SNC\%B
MP8?CE6#+V8]QR:3>6MG4>[-7PI=FP_S>;4LWG6]FL].^:[;-HM2Y:V[+49<+
MQCO<>CL2C"T-U9%VZF1DNT5WM5<G-E^-Q>.";ED9-\Y^\[?V.@XWRW?.[%ZI
MQI+[I+B*U*)+W)_2OV3IJV5[_YM-AIM \V-T](E)4&9UOBDUV4&2V<6E"_Q.
M<#")_B]TZ35'8_MA-7 3[[Q8$]E92)+4F =+YYNPPY;>36_-#><!PSTWG*=M
M.&\=:_H3^ A^VFYN,W.;N36;&1$L,(+,0*YD+L0-9' #YJ\.!K,%EL9<8R]3
M(CE23H<^Z.+.#YT.YGR)I)\O*?W9<$E_C+RGR9?_ U!+ P04    " !ZB A5
M_&'O(7 /  !?G0  $0   &-S=&PM,C R,C V,S N>'-D[5WK<^*V%O^^?X4N
M7V[OS+)@<#:/V6R'\.AF2@(WD&[[J2-L ;IK+"K)2>A??R79!H.QL UL:<W,
M3M98.B_]CHZ.'K8__?@V<\ +H@P3][9D?*B6 '(M8F-W<EMZ'G;*5Z4?/[][
M]^E?Y?*O=T]=T"*6-T,N!TV*($<V>,5\"K[:B'T#8TIFX"NAW_ ++)<_*Z(F
MF2\HGDPYJ%5KM<U2>E.S+B]KE]=6^?KRTBZ;U1HLCXQ1K7QAUZZ17;W^6*W;
M[R<W-KRRJN/Z5;EFP[JH-AZ+:O5Z^7IL7QJ6<6&@*E),W]@-LZ9H!H$PS&4W
M;^RV-.5\?E.IO+Z^?GBM?R!T4JE5JT;EUX?N0%4M!74=['Y;J_TVHDY8OUZ1
MQ2/(4%C=8MQ9JVY!<0>-,&$6%HV(V >+S"K2[NK'>C4DDTRQ1@QV&8>".JQO
M<UKFBSEBVVE$<4462SG5<M4HUXP2@)Q3//(XZA Z:Z$Q]!Q^6_+</SSHX#%&
MMD#901+'M0J18@[I!/%'.$-L#BV4Q<[/[P"0..#9G% .W!B/,60CI3NC7)&5
M@(]9EUB0*T>4-9FHJLR,U:\@AS/YJRQ_?7AC=JF27JK'RA,(YYDD1VE\Z<&=
M+!I$'-"XOKZNO$F/VJ[!5L]0]<ORLFS4RG4C@]@D%TLO6_PJAW2'T&'5F[+I
M$-+MJ</6;I/D"[LHU6^64@W%B"'KPX2\5&R$T_CA9G5YL<7SH.L2KNCEG>#>
M?([=,?%OB%NR_6["1GQ"XS JQ8+?%D]5_]U :E'B['#KRIR2.:(<(Q8-G(K!
ME*+Q;4F&SW(8-'YWX.B#T"2L$A.P[@FRN")(D--=61+22C!N2TP X""_;4[9
M\#E%60T7)$R$;@7TW]Y^"SI9[1<DEN?\,\RWT3BK^8($NSB']9)Z*,H!MF]+
M32*ROA*0]YZ?[E.,[TJV3Q6R#1FO-/I<%9F5^ ?*JTRQ#!35I\IFW0TN'D-V
MS_VLKC==/" .JF@(-WPC-=UZHVXE"VZ&K:AKV]YCJ_TX:+?$Q:#7O6\UANW6
M7:/;>&RV!U_:[>$@>\/O9JE!Q5"HU 04 ]&F*(0EY FB3$' %?ALS[!%VK@/
MJ3!OBC@6"A\!PW7^>D!E0,@#*/AA3<I_B@[P8"C^/K0?AX->I]=O/S6&]Z*T
M\2@J/?2?VE\$P?TO[6YO<*!.FT&>W@'JU:J9S@%6(D&O U9"@9 *UL0"*??L
M$2N$!L->\^<OO6ZK_31H__?Y?OC;X;U@BPP]\F:U>I$'^:B@?P-?U!GL%1#-
MQN!+I]O[>H2>OF*MA_:B6OV8!UK)'R@!!0*T1R?0Q7\J+:!KMQ"S*)[+7V1\
MYS'L(L8R0YF*J0;$FE$U##\#QLQR"/,H$C^B;('@"R*, 1F#D'6!X!MXLQFD
M"S(>X(F+QR(;<7G#LHCG<NQ.^L3! ISL *9DJX=0_MN$,& LT8JP!BO>(&1^
M!G&CM8\,9BI0:]5Z+=XOTX,J$N?@JD@Y<SH 'B&E0M$7U$(<8N=8.,?$Z/ V
MJZ:Y%]YEL)0'?@@D%@GZ)_2"7 ]EQC*DTT?8"T/-7]? "2B+U\9#.')R1,=U
M:EU[U^5J8ZPS!/3@!Y]# 9U[[\"5Q$<?F2[->'H1@G$..ZH=1-O R82B"?1S
M[_#V?CCMX*I'[<I,#%G^[0AK.< LNU=Q46P2 8/+:=C<F'T;+>3?#K0XH7NB
MF9*['M5K4ZVC):"Z)D*!*MB_!Z.%N@"^H$(BW"6,]1$=3"'-GB.L$6L3!3&7
MCN,CR8&@!XI!01L]9]*PA84V<S",>GRP6@>@B E$M!D;8N9@8\>38_8 61[%
M<@.X_68YGHUL>2ZN269SCP=QJ@VI*V8:2_*\4? (*FA#I2&BY<4.3RB#J"9@
MI0H(=?'/"4:TD5$UU"?J4P6,J0WK#P\SQ2V[.ZP1ZV-JW8@#&24O:)/GC*A;
M6.@CJEF/)Y)1)D6,IU'[]YZ5:9GI8]R%J79@DK$I^OPLVAB1:S*VQ UL(S]5
M%AFSR\:(4F0? L1,@O0 ?Q33[QT 1W[*P6E-'H@(/.//&.(^.*(YH&MW,1QA
M1PWXHLR;'0C]]&+TV%^*2?PN[)4L$ I3>W41<2"05WCHY;,3MN<@,GYVH6=C
MCNP^)6-"9["#7>A:&#KWKOH=;*4^(G[O"GP/$M4/(%[O*E=F]7J'JX0ZR!BQ
MU ((-8"2"Y:*@(@FRJ&$+L!7II!^U/</R2Y$4[1%B\[E20?1))D=(HF//OF]
M-N(C?,A)H;/D]5X"=<8E9UJLYZ;-D&O5>GS11X-1$1/FA.;==CMOP,TA0AM4
M:X9I5+/ FE1ZCIHK-%I(F"5&&2FE_39'+LL]P&:7H(=;#*.Q/4<]W%%1()!5
M2+!_(L1^Q8XC6JG'IXC>"TO<"19!SD]0\PR7:7AJA\Y:W8C/G4*N"E#%%ZP8
M!^ETT0;2%"V=<U!-SUD_P)KU^ I@:B2+.-RF:/C5G*0Y%64(NTU(Z0*[DU^@
MXXG;/8^&;/*&Z".IH8_C%Z81VP%*[RSK$R5?)X!=$&H%E%JR3"BVXGN.^EO1
MW7MM-(\,O7M\-(W8<G86]RCV>FH*/#I2&NJ*%K(W2X_H!2FDZOWBTC1BD[@L
M?N$K4%8:Q&N=G24S;!V/"Q0:,T)Y\"C"GA.&(ZNC=Z\KT]@CA=GE7N^!KQZ(
MZE?H*8EJSH9E44^MP3<]*I\CC:R-9W_69B='_73DVH@OY_N@!TR5&P1LHZOX
M9]16;9%S(I*6KW8:4J_6XVNQJ1 LXA1D9Y/G#>.I&6L#<MTPC;Q@%C"<=A%D
M>8[O^63:P%BO&?'-*Y^P< V<]Y1DE%@?PT04BRV*^>1%#%*^Y<&._=I.?>YC
MCCLYZL.2:1I)^*RV^S=V^8L;D/9>7TA@H\?HPC1BF=P2HV*O#W0@IFJ%[$&T
MAV@9N5V2'97M7/2CR$<COELG^00+=E%.1<<CYRBCXZ4?="[K\:E/ C9%'(6V
M-NSRIA_TU\^1!15MXC[),^L4NY,[R'#N4>OP&N@CZ)5IQ%*^)(>(EKP/A\#-
M@VZA.H"X8*D04!J=XW#8E'N/ENFXZJ&_-FMIX_1Y--5VRQ2]\=DE(X;HBPRI
M]^[<XZ*8N):@4I8=)UP<3B^M)YE5LQ8[L)$NB*2,'.]!5$^@% 7KFA;2+9MD
M-L-<-:Q<@"'J513"1?*LJNIX:1,^TS#BYW4BW/SEFRB_ B$TX,3Z=J\>!A:Q
ML^] 5[:NNBL\&]GR@38D[DEQV5]_DH6Y'L.:$=^K5XS DC]0 A2:JJ2L9("H
MD#.P6]L^9YJ?0X0V^S?K]?CZ7G:0BS@QR +%_F\UVD>8?J0VS=H!NGGAT\$L
M"#4L40?SQ;-K(QHG_!Y.DE(%O>M<F+78<9U<KA-J Y0Z6WF<G6H'HD^(<8HM
MCOSR9Z$$"]OU>WA4&OEZ=_IHUF*G?'*YTTJ5@%XIL_*RLROM" [RR43U0E'V
M+(JPNYP^DK&BZ/F%\G3_H-__+O$JGTIZA[LT:[%S/_GBUTH[(-63AU(CLUWY
MBD#%-E#2?V)!J'GVQ!VPJ[NCS;M[GC4[N )Z+[LR:['##+F\S"\:Q8N*?);,
M?_AU"-]RS*:BM/JY\+41/Y@</':KR(O9X'D[X!86VBYT435KL8WW://_TSW_
M4V7] US^[[6/=,E/= 6?XE,PR:\#_2XW9&9B8F[+SR6.";70@_@M/]<#1R)%
M@A:_+7$JW\PJ/R]V6TJN[\JSN2/Y32&_OOKXX,T<44SLH?I4D.W18,F*>8(Y
MYI[\]1,EWORVY%?'',U*P/^RT/)KA#<VF4'LWHLRR6CU$;*X-?ZK==D3LA!6
MR[[!"; =1NTB.P7;^I18"-FL0\FL3]$+)IY_4"7RIH"H@6/HL*6%Z8BSF.F7
MC: CO](G"D0_YBF-]^_,B"MZ)%VD,#U\8;T8TD;8];,]U][4WW\U]\+_.T1O
M_,X1HV%BD^S'](@>P4,I*5JF*PQ J#=7+XQQ)^H82QM21ZA*9X%5'802&R$U
M_6Y[_2\V\IAG6%0DXT=SC:7J088C'P/HC=5)T&61/PXDMD$6%J?:0^3.29"*
MJC?:]<7D%OU"'&^&OB+Y35QD-UZ$+1._Y-&3<:TW'E(H/[_;@@N6V#R'8)W!
M>S*T#W8YFB":;ER09X([^ WY/;SO46OJGXE-,%M'<JJ=84M(:T;?)S5<O4Y*
M/@W/%_>B!46&P]F]F)X*.UU;7DC30AB?D!R>!) *>];P^)10_">RA^0.^519
M(NQW4>?@L=F_PY3(G$$Y-""8WP_)$W+1:Z:XG,3B2.9FZ%V.B)6P]2:"Y(X\
M*U[Q%#*KY,?&Y(@@%PFCSV4UQL))?T.0=HA'$P'<BV?^^/*]T[!'XHI9W'2Y
M4<_7.OA/POSDG#0ONSW&X..&WVV=]DY],U4BE:&GKXA.-]]PE3%?,9\V/<9%
M<D3#__MP(2O+#%*75:1E<*3P%A*E,#:Z>BS&I&W;&$^#9Z:/?1F9G$)<C$^+
M9?_,-Z&.4YZ"A7>.AYJ4,"8O!E.,'%NML^JMVT5U"I;U,>=LY-')5$64#J:,
M#_#;@^AVTQWFI2(]!1L?1#"W1$ZF-V>SUBEH'EE@2!CKPC..B\@Y2'6"43-A
MV8/G$1M%,)%[& >8OHAQ(;(VEWO:L<GF5&=S&_TP4Z<])6?/, U,<-R^[T)R
MB0%BD4]'EB0.,?G,(_4D.LRVW-%/,88D7,!#\B)3]IG X:_/P[9 *H]S3URY
M '!ORXW2,8;+5WZ$KU5N;'N'<["\LWZ2-KTK'5;NWR0"J5EJOB1B.^DI1*?8
M@G]"-&A0*E\FI@ZG/\FKWKCG<;DJS-01CB]X,O47I9)'Z".(.L[*ZEY+7?YB
M%>&_(2Y#IMS9E8L=7L9)L([-J7:8X2L93HDG#XL\BI#!$7+#E<W(61)]S\G&
MXQ2Z4)AA-^P7Z(^7N^=0>IJ3L&I!,;0?%GW(I]UN<X<YVRN?@AW+HQ0-^W\>
M4T_7Z&W1$)R"/8>,HM\E5)]PN)IB:O<AY<)O%X2N?7]0?G)P1Z!*27T*3M.>
MS1VR0$AE[^%.WNY8O)/L%&P[PDP'LN2N<2QQA\YD\DRHPNS<P:X8G9P!]VR1
MNN]:<-A!=:J]/Q;CY(?QB,>#Y7>V92=_2%HB(9'30LT)@/1!]6 "_^KS!4TD
M#!%L+;9S#W1KU5,((]MR\ ?XAF?>+-<F5HSV5/>R8N=_&L$;1C=._S0"VY.0
MS<[G6 <5N'P(/H7E+20_%$0<,L$[O'9;S5-P6M&B5#I;"_G_W[OK3O@DHT5O
M_,R"M9E$#\[.Z*_?AE9G?)DU13/X^=W_ 5!+ P04    " !ZB A5KA%BZB@;
M  !=%P$ %0   &-S=&PM,C R,C V,S!?8V%L+GAM;.U=6W-329)^[U_A95\W
MF[I?.J9[PH"9)H+&!+BG9Y\4=05%RQ*C"^#Y]9MU+(%L2[8N=>1C;T<0QI9E
MG2\KO\K*S,K*^MO?OYX/CCZG\:0_&O[\A/Y(GARE81C%_O##ST]^/WL)YLG?
M?_GAA[_]%\"_GKU[??1B%&;G:3@]>CY.;IKBT9?^]./1'S%-_CS*X]'YT1^C
M\9_]SP[@E^:/GH\^78S['SY.CQAA[/IOQS^QH#73-H#5.H(@S(&GGH&,S*9(
MK"(\_L^'GZ(S@61N@$7'\6TYX]LX!YNCIH%*FDAJ/G30'_[Y4_GBW20=H7##
M2?/CST\^3J>??GKZ],N7+S]^]>/!CZ/QAZ>,$/YT\>XG\[=_O?'^+[QY-[76
M/FU^^^VMD_ZJ-^+'TJ?_^NWU^_ QG3OH#R=3-PSE 9/^3Y/FQ=>CX*;-F-^)
MZVCM.\I/L'@;E)> ,N#TQZ^3^.27'XZ.+H=C/!JD=RD?E?]_?_?JRB.#FTP'
MR?='D]!'Q:?)CV%T_K2\\^GSTS<O3MZ\/WF!W[P_??WJQ?'9R8MGQZ^/WSP_
M>?_KR<G9>Q2H><#TXE/Z^<FD?_YID!:O?1RG_/.3@)\.1?-$<5)@_?<&G_KT
M._3@!F$V:$;J-?X\_^P"KRTITM=I&L9T.7X+&(-1N/*F0='>:+SXRX'S:="\
MVIM-X(-SGWJO^\[W!_UI/TUZQ@LB3$X0.4T@!-'@>(B@25#4B4RI\5>'K8@V
M0=D:=6<W\8W.YY_]M(SGTS283A:O-"/<C.Z*QU\.9Q5)GL_&8YS[/9L5E<Y1
M$$:A0-9*\%&H,CDILS%$IV)[ LU17)5KB2C'XW T&L<T1GOVY.A+*M9G;MHN
M(;EQN,&@JQ-K_HZGD]GY>?.9T)^F\\7?%SM71]O34=6QOE0I@M]7Y\]FD_XP
M32;/1^>^/VQ&X/EH.,5% 2'A=Y,^#N]\5EXBOG@S&H8Y9$.(\C:CW"(9$-)J
M\(PK0*L8$Q?)2RLKTV,OP)LPB3TP)AU.@]5(=_JI033\\#KA<K8*EI)$<F\8
M4)\=B"P8>*L#9)&S4EX+[5UE8MT):A/R\ =&GKJ:J$>0Z<<T7I)Q"8\0AHA@
M!8A@)/J'$:TD1];*X(6(3IKH6&UFK$6S"27$0Z-$G;&OQH47*2=\?'R%P<IY
M.G-?E[&E:2^AK)9[ 4$1!!61JCYR"<PZP;4Q7.A4F1!W0-J$%?*!L:*F%JI1
MX_UT%/[\.!K@B$Y._CU#P]5C5N5@G03E*9HK?#08? 5H#HYI:CTWMC(;;J+8
M5ZZWX_EH-Q_]3S>8I=/9M(26)5KO96*ICIY#%"&7-1LC:6DC)((Q,G$" VI5
M6<;;$77)0=^3$]=Y7U$5U6B/GM[Y:+@:$//:LF@L&"L#"(^RNA@\<+3.@;&<
M)>.5N7$+G"[YVY6)44L)U5AQ'&._#(,;O'5]M-//W:?^U UZD;BL6&00++$@
MF+3@&-I_Q6RR/ADE8J[,B#50NN1 5V9#C<&OQH1W:>HP)(PG;CQ$.DZ.0YB=
MEZ%.$9?Q?NA/>]E:D8W6H%16Z,XA0J<EA9QDSI:D3&/M9?)N5%WRIBOSH[)*
MJE%E11I*R&0=%0*X, 8].8;&"Q<S<"9*IK-/^-*!4WX[&,,01K/A=/+673@_
M2 O9O,9P)3 )A#HTS)QE0(5:4$)*DJP-Z*?6MH4KD73)8]J3 S=,X?Y#7XW>
M)^>?!J.+E-ZE9JJMD%0J)@/E"@+7!(0)M&PW><A>8_CBK?75H\<[077):ZI,
MCKH*:3LA^2TS3]#$^USVW"1*3+5 [MH 6@4,F0/!<+IZSNE61%WRI"HSI*(J
MZJ8CT:Z-9RLIJV7P,BD"U(945FX-1CN&/UH5<HY"J-KQ^.V(NN1(U:9'/574
MB[PFDS2=]+S(A!D4AF8T7\(+"UY*!=PZS[DC,>K:>Z673ZZ#?S&$E,5( Q%
M>,0A=$&"]2[B=]%+C6ZID-5]I&4 77*-=M#L#7=HY\&MQ\^Y1_8NA=3_7)RR
M-VFZE-8G3'C-2EK?LA)YA(#B>0N,9NT$-8[)VIMM=T#JD@=4@P,5%5"-%6_'
M(UQJIQ=O!VXX/1[&$N5^*@5?)9U/+0^!.73 $CI@HNP-6^X,Q.0$]RD0HVI3
MXC8\7?)W*O"AVM!7]G :R99XR1P34>'RJ;5 &Z5) L^R1E[*)+P1PJC:Y4PK
M@73)GZF@_OT'NYK>7PVG;OBACQ9ICB=-7PW#8%;2V/\8C>*7_F" (9EWGD4#
M01N4U1D.-EH+ABD>?<A&,EJ9!IO@ZM(V:P565%=%2]'QNS*<I_GWR27.GI7,
MFHQ 9,KHS;/@P 3\T5%IK4W*4U&;';<"VH06ZN'0HM[@MY$TQL5K1:8\":TB
MFC,$9!S*RS' \TZ BE1F(U+,O/;NPEV8*LK<4]E2YH,"'9S$22@%.!L\9&(M
M<S)$Q5H4KTOQ454FW%(BN]605]UG[T^+7U:D^U94&0J@P$)0)G((L>2AE'3@
MF"<0A,:56QBF16AAGWT-G"[%2ZURHI9*VBQ!2LXQ(Z-&!UX6^2(M#KR"X*6+
M02B;?>T$REWVKC,9XOJ,V%,!E9. BSQ/RB2FX!-0$BTZ\YF"UPG799V",S'1
M4#U^OB6)MH/I<Y./98+A?V50/[M!,^6FS]UX?(%3KBEYZ1E)2 I)XSS+*&76
M":P("4P6FM'H#-6U%\*-@'5IB=R=%S=L7W6=M)MA_+;SBT%)5#R4PWSXQ=+&
M1Q5@B4XE[\^5U(=(+W9P=[4>.:IIH&)JX3,^>S2^*$DM+A4GVE%@EI6UV5BP
M5I>(Q6<4C5.M:Q\46GY^EU;#>CK?>80KYI#3)]>/)U\_I2&&I,.XE-KZ)J$,
MQ$0E(44?04AOP$2:D8$V14:B2J'V]-\ 5O=2BC4845L?UXCRMZ?71^LU_MS.
M\>/W9_CUMY,W9^]/7YZ^/7EW?/8*?WO\!M_TV]MW)[_B'[SZY\GKT_?USB9O
M\<CV#R[O*G^E4\V7V<?1>7H]FDQZ/#EC<DP@LT+.J'(HWR![B/=16"&4J[Z$
M7P&P_UJT^*3CZ73<][-I62'/1F]=,R6B*:4'@H L0:.( N./$"@D;8*WF1K-
M:Q?-WXZH2P[L[DRXN5Y5TT)%+V5^GFEN,Y^E8<K]::\\T6;F@)MR(EN7:EPA
M(W J@[:)9Y)K%W.L@;*EOPH/B@S[#7QE%JQE)J[&*4D,I[PO^[+6XW>X6I::
MQ.!-LB2:VD<HMK$/>^SH+"F3*:>\%1%BTK9L/GNP4FC0*9&0&-&RNI^V D:7
M+%]%5JS=U=E1 56CM$F34+U$\FHX36-\I2="5H2%" 8?C]))G-N22W!&":^L
MYM36SF*NP]*EB+U%3E111<W*@.;I<_/<DXP2P3 8<8*6 [[*@&<6+;3RR2:M
M-*EN'JY!V#*(;W<A;)4'NX]\_3W_)0,E2REM0-],Q[+<.Y'+TBR !Z&)#-;8
MZ@6N=ZX0VTOV+GU.PUEZB2HM^T=C%Z9_]*<?G\\F4WS"^.3KO.:B1,WX+Z*+
MTB-,^EPFGV4FX\ G@9-/>I!:Q*0$MTK43N?O +-+:^>^_+EY@*Y=K>T]<4J.
MX;O4\[E;BGA.<Y.$N38@O9B)3\P',*79G2 J@*-4 PM:.D2=);]66W<SB['E
M,SL52=0B2)OC?G!2$&4%HK- 8L00.$6/ 54.$+W*@ON@(B>MDF)[<[IY^ZGC
M\=CAJ\WF_?./Y=M7P^/SLFMQFN_J6$5[W*'_:\M)GTAP:$SI0R1<!)4X#Y0*
M8ZH?2SV0:%TPVVT2=?>&98=C3+UZD#08E(+--$1 @^-A/([G_6%_,BWP/J>%
M3^<=+D&11V!*%O_0:+ X<I"2X2%J[4CUZ&HS9%V(M0Y)QA;T5;'^;((BSSV?
M'A64\&0B$*?*!E_BX!7ED&W6Q!#G%*U=9WL%0!?V4 _)C-U'OV(CCTG"CRE5
M'R\0QV#4'!)9<!)C3!\#0R 83P)&B 8L18I2*I4*AFFC:A/B5D!=V%(])$'J
M::=>'<[Y:#SM_Z<9H=-\_41!3SE;BB$=4"<5^KXD 5HR"BQC1.0CT\K5;G9P
M.Z(N'.$X)&4JZJ<C6_//C]__^O+UZ1_M[,)___3#;KBOD:K2WGJIX+M6Q8>V
M9#KNAVF*\RJ_JR\LO?-M&O='I0WCN)P'>9$N__]V4NCD:V@<Y7=NFDYR3F':
M,\I+@5$M1,)+1WT6P7)<OU2(,FG\1?T#W8>5<%^K62KE$,+;\>@SQA'QV<7O
MD]+H\MO$/P[H"EZ>0Y!*6$K0EG-2NMA8J\!%[R#23$NOY"RK-Q#:'%T7 LD'
MP/'K1KDE]5=;U-?@N]PNNHHO)Q]XJ9S/O-1V41K!\\R!!$V4PA@E<W,8>JY
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M*#:J]'7_\\T2GCW\KSH/KNJ2M3 6E;RT6QY;?'A'@I1&..".E="5.[!)&<#
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MV1AC\"PW+PVXBY[^(Q6-4' S8Z21T#O)$UJB[=R!TCH6YB.'D'BN%3"1]NJ
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MS&\G];_SJNT%%W..%[\=:"5(=A%!6"] >4Y>>[**&"*+PCMCO&M='MV&\D<
MQ3VJ\A9$[G9)L<$6?BMO1Z.\S-Q[K&JA]7;.Y='9['@\F;OQXV>XX)F+8+,7
M:A%TLMJ3!<(T%!UD$4Q984+K<[HA_8\ Q ]%^[<@?N>[F8L0_J]5;?AZ^ 7)
M])B1^S8D1LZ3'9:.D]^G6,Y.7@\+#HRF(\21,:*+8S4]WA'Q3D-D.186$I>R
M^7WP#O0^ JCVKK9;,+?S=<VK48T*? Q?%\')9S@B7<P&B+IX)1QP69/]:IC
M*RT!G;+!2N9=\[C/"E(>$5):"/L6$.Q\V7%9J7,+Z]-GWZY\MVCTPI '&5D=
M8%E[-A0$SX4'YYD,M1)'VM:W%YO2V%<]8'<AY2Z5<BA5?+>P-B]OD"9YE;P'
MX;FMK<DMN.0MA.B9-B;+[%N7I*\@9?_5<UVH_WZ786,U=) C=QM9BYOCBX'E
M:Q#847';O<3MI[JMB2K7@,?N>M@+8+A!=+(VE,/L0#%+-$I&KFVI$9:BT?(>
M A1] .6>XK3]X&03\3=OZ7@R.\;PXBM981<M@C1F;NEX+A(+'<^9J"F\@"@R
MTZ9I\KIA^1N//@BC=1?9CYL)KHO>%[,PF]LAY]Y_K:(<C^I=YQS!/D<5E"%O
MRM< JO&%^,QU@H700N:$G+<NR+B3H!_"@FBGD@X:>B[1=#%480VB.K(=;B5H
M/_9"0\4MUQ VDWH'EL+MQ G:'JV4!IAVKD8 &7C:TX"7(DS&I))N;1WT"(5[
M+(*^D;")L#MIV?G]TNYBH*\K=1JL .Z)*L4JBW7*2K+!\9 <B\L-G1LTZEPB
MHG_#H8%R;G3EW$6R'=@+=T1FGWW[+?QC/'E^$J;G.&=*>ZYK6F;6IC96B(1S
MGJ%XSI4*P;F$C4&P 7D_A"W1E;HZ**>Y@]1+0J_4Y*]#;D<VQX:D[L<:Z4SU
MZT.LF=XZ.+,V)=LKZXUGGO9NFT%%)R'6 1H84 >O92Z\Q\VL/YC=8^D<*LHV
M45<'Z'J!7_!D_!GS1TS'H_')^-.W]_7>\J+Y2Q2L!&<EB!AJZ6(@0NM8!J-D
MK6/5WH?6=X+WD-2_M=2I2L?=Z:.'Q@?SY<*=5$67#"Q5NS$Y#:%X!\Z@#-%H
MZ]-:DW8W24.XA8X?PD[:60$=E'\NTW01>UR#JJZ:$-Y*T9Y:#^ZLL7L@L(.X
M>^AQL: .@]1&$DW,LNI;6CI2M:1]RZO($W,"V_<'[!$$]W4%[ D#FTBY^>SM
M;Y-AR+]]>Q=FQZ]?/[^8W^8PAL +<&L]*,P"HE<!K(M&.2.Y#TMZ7S6R^;;'
M[Z$#6P/!CYM*K?74N^<X&8VGLV&:7M[],!<PN:(!O:B9ZI(.*YL9T/^;F*S3
M:GEZYJKZ@9L/?_@ZW%5B'>S";\:C2>T/.!F./AWE?YQ-9S7(.]]V!(_622+%
M\!"(3<'K='?Z5@?FR;%Q*;9.&EU-S0]ALS521@<=#VZG["(<O 9M'=EO=]&U
M'RNNE0[7@L8."NAM+_F>!)2U3R* U[Z *L(";6^>'-XL3+1H<FG=-K]_<-QC
MW>T#&YO(O0LK_W)_?(\G85:K*J??@Q2V"!Z$,B"+XG6&-"?+EDY 7HJK.22:
MVT[J$E81U+^)T4YWMQ4>-!%\:[OQ>Z+[);\7F4,I>F>T!.WF[<]D!J<$&;?,
M*^6U$(['M:S'E:]X! IN*,,]-F*^\O6XI*OU6[/+^JU&39HW>E=7#9RW9WBI
MN;,S022? Y-)J23(0R"@2"N="R$FO-[<>:.W=MCXN: KWA1.;HUGH)(LY#)Y
MI'^XTSHD+IK7A/3:^/GB93C]ZV0\K1,8LDY!1Y ^1E"!.W#(/03:>%F23&-J
M?;#=1]-!9)UNAXA[VS[O(OX.+C\:EJ@.<LE9>!3@?:Z32HD?YXH#JZ74); 4
ML/4$@X;D/R+0[4NI'59"K,'*ZV&(PY-AG1Y!-L?9O#FVSDH%7RR84E=7Y 5\
MT21/H30ZQ2VW7=5?;4?QCXG"75770:[U!M3S 3)I#-9>>63N$*W,@C>"5DHA
M)I)-3OD>NF"NI._'!-5F:NFG1_4V#4Q<2*@=D6UM(BX8"2YRKX&\XB"RS+K(
MKAH&/ZI>-"U@UZ,J.TAJV/R&()+OQK0#*>KU$;((,>H$&.I45R]-8*VA]R#K
MXW>!5J=*.?3Z>*U,24'2#NV5IZ.]:/#<$D/,!ZFB,5GTX&P_K%N[3=2_9GW\
M)FK82[GS.@0^U<=OK,J-ZYZWT<-> .-RL#D:.F2Y$'7 8X8H5 2?O(C>Z(@U
M2OD8@+)E?7RW.-E$_-W7QX<H@W4BT?%L"AW/ED%4)0$3,9%SZ4,*ZTU7?1#U
M\1O)_N[Z^$T$MS(XV<,-S3QO_:)_61A=C2?0[\Y.V]W/K/^FSFYGMF1VZ6Z&
M:TG*-4%;U+7\(R9IDY2>Y>2"0378\IT=WLQ(+]$&+<&%.@C6*0TQJP :G:&]
MRREANNKAW\7-S"VAC,N9'*\R6=W#,@S?RS(NI']TF_1KWW'Z1?5)OX23>N$P
MT,:7[%*"8A+9B;R0W#QR,(KTK9AF3K2^U^F6HX/8:[=#XQI1K'VIOI\[I>VY
MJ\'@T>S\D_04)";I+Z<#GD5./"'8*'.=XFS!U:^\89D7%,*;KN;S=LG7$\B[
M@T$_UU-;\_AJ](4^/YY\&V"TS!:G(!FFSYNINB0-)&<R(D:N<^OBLTX8>0)S
M0T7W<\?59H6^F^#G,,R+]K#T^;?D64P6<ZZ=C94Y\DJ4)/^$&0Z!\QH)YSK)
M&*6+K=-K]\+H$_I[!$J'UW<MF'XW&7_&R>S;NY- K)];:Y]K8'T0'&=:I@@8
MF*@#,RSX[ 5(G8PKJ20=>LA0:,_8$_H[!$(_\VYW.."N=Q28+^J/QV'TU_$X
M_S$\.1E$'5(.W$-B,=?A0W58EK=@0AV>Q9-FS1MZ],K@$_I[ $8_XW*W9G;.
MW)OQ>3[3Q8$W""8$9:I'SFKWTLI;0%5 <F8L+S6E[I#W^UN9>D)[1P#H8&AN
M!Z;<U5^D-#X;D5T7OLTOJZ7$Q%S04##46R;M(5KE ;,NQ11C&.OJ&JX7!I^0
MWP,P&DX77C66:6M.B:_)62U8.ZT>S/Q9@U)S@5S6(#"25\]1@:>E#5D6[U,6
MQJBEQLWK3]]J2>@C ._!Z;/A@.%^%N;\D!K8PGA,Y'<865OC"EJ347L)/+H4
MM'$F\!Y*-UJS]0@ ?J@@:#BWN L67^!Y#OC'\/7*+P>(0NO .&"12!PZ!">S
M!QZ\%3PY[F574S.ZX^H)Y5U!H.78XRY8O/0M;JQE<C 2\E@@FF#(RR V?4X:
M@B^**^^UZ*,BI0/.GM#>)12Z',G<A$V<#9)D,2"K+=U3O33+"NC[ -$Y&YT.
M,9=#OATE%IXPW$2Y+:<U7_#S/1 II,\A2Y)'RK8.BXX0?500LC&<Q..L;YUL
M]@B#QUN)LXN9Q%OB](+^E7AE3D@I=0 N @>%*M,V:SAH%5C("5G*!^(XW<?*
M(T+=(2B[BR''&]<*.6\-9]Y"SI;7 E@/CA=:>MDD8[*22K5.DGN0]7N[@*U3
MI1QZ_1Y/)<LZ:KZ$4*_KC(/@G(&B6*'E$!)OWGCSH=?O;:3^->OW-E'#?L:5
MKD'@4_W>QJK<?&[I%GK8"V#HJ-5):@'D#]19;59",*C!8-2<F61#[F-P]N'6
M[W6+DTW$WWW]GA,N,QT")&(9E/ 97$H<.$_!T<_XC?$_#[E^;R/9WUV_MXG@
M]EB_=W&&CLOOHW"6A[-YGEP93T[#KV2_C](PG+P:S;^OGP^C:HV?]Y5L5-?7
M@(*NZOU:"V>I#C#ZS&O_]BPSJB)TR,&4;&-)/CIMRZ Q+1W6!T9G:>.C-1.%
MT;1PR,;RTG/P/$GNO0JILV23+NL#KRJ I/UKE>Y[_(*C,QSX++BT& "5)Y83
MV:R>T0*W(3 CO#0J]S &?IFL@]A5M\/%&D?E3DKHL-SN-A*_+[_7M=>DLEHQ
M[1@D41O^"Z<@QGK5JZS,#)F*L8<%<CMQ/PAFME=(!V;XQKYKYMIZ*3FD8 ))
M117P(3HR.I$[*YWPKG7:]H.,)^V"GDZ5<O#Q)&ZCK .C6*EC!I-%B)R61C3&
MJ,"-*,7VX/8]I'C21NI?-YZT@1KV$T]:@\"G>-+&JMP\GK2%'O8"&"]LT#9J
M<-;464?H:FX; B*C12)+M(P_#J!L&T_J%">;B+_[>!(/Q4A9+?2YV:6(5R=4
M!B%MIO]ZF\12!LE#CB=M)/N[XTF;"*[G>-)%866X4E-)QO9M/]XA9K3%6UK&
MA79E<BGV4P+W,BH=C24?%45DJ13R5Y/#I+W/@RW>M^.TBE7EL9>VM7%2658T
M\.(B*!<D[5$Y ;E,WIA,%G9LO9/?3]7.4SI6O8&^/H^LX6L,4YS/S7Y;?I^>
MIRX\PS*>X%%*9Z=G\\%)+_#S!--P'GVC/STZ'4]FP_\^+V,PS'+GE8; ZOA&
M6\,4+EC@26478F:&MXX5]<!6_SMN8XS>F!AR8%#H(&*U)8MK,L<BB\2#A5A$
M 943?25RAER4R=Z16Z2:#[3IDJ$GA'>F_@Y<D6V9*S.<K,DA1^=B$#67<AY=
M(C:=Y@FT9PY-X-&[UG?CW7/UA/)N@=!!^ZA-3J-K=$?4AGO+:[";Z+;.0LA"
M0XDE")>CR[IU6N*VM#XZ6/:BM ZZ,:UW,%RCV#.;M4H9F*LUYBZRVN*Z@.&Y
MF*QS;'_=M3F5/Q+ 6BBJT[$H*T6S2-U$QIG@!O*\19,4M!@\TP0#;ZVB+T7S
M(.*ZM/5U[=4Q>#I1Q:%<>JUDZ=FWC_2(>1B63-<B<A(0772@1.UG*BU9KU;6
MQNW!I.SZLNTNR=K_95A+.*QKJ&VIECZ=BDK@(LR[#HD=78FM0=Y^+L6:JW9=
MZ.RHESU!B),A)WCB4#(&4,9&<%X(0&^RR99GF=-C@<X]UV2'@)Q-U-$!8KZ3
MM+C\T3$)F:K%+Q4Y ,7-SW4).689LPL93>M2QR42#LA6WE9-XW8R[B P.S?:
MC\<G^=7IY\GXR]S\F2Y(L\$&Z44&KP6"JJU):R->\,YQ:9(D/EO/ KR#G,<'
MA5:R[V GJ-VPSF8X648K-ZF2Q8#7>*LJODX:\AJ84B8(JV3AK1WL%:0\/CBT
MD'D7,;^S"4GV;(+S*.;7^M4%2)4.FCBJT<A"E'E7)X4C@@]!1%M4=+9U7X[5
MU#P^0#22? >AN3J F?SG5.7[:D1R^$2D7="FF1=H?($4(GEF"06$+ -X(7,L
MN0B.K;O]WT7/X\-%,^FOC*SUFK!S];YC,1:@?;[.'2_I(5UG71:7LG5R2LB-
M3$D65,+P*(/G/$?,(7K#TJILG3M>UWFRCLS,:ATR2%>K5)5)X'VIHZ\9BT6A
M=*PWC_)UJV2=JP(=>$8'+M,*8D9R E,B(TU:!E(6:5Q&QEQKL_CJ^P]H/]M.
MZ\O;V=;"[< =6CO\*',IDG$'OA;JD@U6NZM9!09Y=EI9:V+KJ.T#O!C8!1:=
MJ.)0+@;.*\(^S,)L_MS7]0\N\K)C2LQ[F\G -[0$LA-09[A"$%E8$YQ1L?5=
M^1WD'/Q%P$;J'W>CA@X\\!6D7828UR"NH]#_G83M)^C?3(WKP6,''?0.%"D#
M6?V9D1XUUHMV41.&'&B11)&*H92MFQKN 2#WA/;W@X]-1-])"&\Z>UL^A)/O
M08,<!7*M"@BA"Q&4',18"A1IE7<B9L5:IX/?(*)_Z[6ADF[XX;M(N /K]3U.
MD1Y8AP._P"]X,IX?DPL/<$$B4\I&SSPP;ZN![70MZ/&@?; \%B>PM,Z57H.L
MQP2+UEKHH@T GM"O/OT51S@)M?OE43XEB4]G$Q+"%US0>H%J@5D8F35DJP,H
M;2)$$@&@M2&$HGSVS7V=30A\3.#I3C,KKP:Z"?9=M%8-BPF?RX/@WN#LU_H^
M?$ULW1@3MT, L,V+6P8%.Q#%4J!0$-Y8L")G0[N(",[6\372"U,$4]X.VI"P
M<S[OJA=<C1@DKITT$"5:6CM.@D>3(80H4PC&2=\Z?+@.70URF5>]XZ^3VA<&
M=;1<UN9^/-=&P\;4+N@%M,0D5!9H<^MC^3Z:^M]6FR/DEDSE=FKHP("[@[Y5
MF=0R%*)*1) EE=IF/8$K7 '+68EBR:F1K1OT;$[ECP6E%JKJP.B[@^+:ZEQD
ME$*2Q^*XJ=!G$;Q/"GS2#%4H,N@>@;27]O3[!,VF*NBFNFL5=>^Q"I ,TZN
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MOC+JNT?#[M)^,)GT@1O+@G2 CNQ?A4'58)DESKQC]?_R>NU]'G F?3.=;YI
MOXGL]Y,+O0Z%3PGT6VAS\Z3H;52Q']!$:W7R,0*BX#6:&LC)DN1N9>G18F"9
MKV6Q'#!8=DV@[Q@KFVA@WPGT&,C?$L5#+"0/9=&#2[4=7I)6^U(G+*YU6?\C
M)-!OI-==$N@W44I78Y$O;F?.S@WQ\XY D1==4@!I @G D)'GD6$URPT1E@/1
MUMS@O9V6QV*M-)5Y)Y>H-^FZZ RV!F4=I2NOIFH_2<MMM+<&)'80?0=IJ7=0
M6$HN*3-RV;/(H*+6M)D9#9JV3B]#-B*USWSK%Q3W9"SWC8E-)-XZ$^?=<#:;
MQK/)I^/S^[]%.JP,5M:Z^A!RG2YE#1UCNM;M6"^C#E[:I5E^*Z*GMSY^'W&P
M-L(?-Y5<Z_YF2Q3].IQ,9Q^&7W\COH\O^J]9SXJL(\."342?4#737A:0+*N@
MO95*;*79VU[6GYY;*>0._>XLS8Y7[E&9X629OB)RX28Q8-F1M6NX Z>#!>T=
M;5;*Y6+NS1I?]V6/2ML[2[,#@V[#0AI-?G'"ZO)D0R:MMN!9T(#,8P@<)6L^
MZ?=!5#-VY09TIYT.VMC?7D"W!DU/18S;JW&M(L8M=-!7$:,R$F5("H*SN?;+
M\V3]TJ(+S/GY $DL3T6,W<!B$]'OK8A1)J><- IXL;1[AI2 B,L@=8E<>YV#
M:AUC>DA%C!OI<*LBQDT4T',1XZ]A./E;.#DC.RU,SR;G:^7[#\\;"81K?687
M'\SCT7M,9Y,)\?XL3(>[=.AM3T3+TLF.1;14=6F+L@R]85J3DU)R,-XE$Q@C
M9Y@0Z0;MR=EQC,#U5Q_=^NJWEZ^F#[P9CR;7*'G]/=4A&RZUD+D:>;7=M> 0
MO+? 8S "T3++6_?Z:,K SE.VP[0.^JW_>?FOL^&7<')-O2^&TYIL010--!J5
M5<Y "RF"4HJ!3\6 UL8DD[(A8366U-K$[:&M^MY0>&.*=R<:[.!.:BZIHT0T
M3N?*J6$X$@512U]-AWF>/U9WS8MFO#%SI#-1T/%8:DMFIB'4\8,V%IZREM&4
MULE9F]+X(P.O4WUV,7^F@>3.PP,I)LN$RH AUY:SN5IP.4'D 9G1P<G0?,!6
M*^)[&_AV,#C=C][WG;]X@_MGWZX8<+].\%]G9'=^F[NIRDKG97$U1$H'@W$)
M@J;5*:T4&!3WTG9F!*TF:U^!P3WA915J&^FMRPWU-@(OQLFL06)7,^/N)V]/
M<^):JW85=!KK94\0$J64(*,&+K.BO=\AA.0+.)F-="EDX5OW$]D;=.Z;_78
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MQ:@8"M;6OE6(*H"7=,!H[IE-N90B6M^=;4'F$WI[573KGNT;I U>\7;FWNU
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MGYJ.\@BN4[*?I('M-;-"Q3N(M7ME2\F5CZ8 @15!)5^GS=@$F7%'$-8JJ_0
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M0])^Z7^M\T(*[;9V)K*JI[1V<^L=E?I*_129/YH[RUF8T3@+,P543$* $)*
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M/VCLPW&I?=M'+/EO;ZM:XJ_6A9[S]"R8+T55\/"]_+WZ2SF# BE(501(1B%
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M06581:!UX9--ANWVJIM@=Q!; S?7W@2UC<&OS7\'*1XUQ&AX8FJOJHU*Y$.
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MG+<UII/PD5>1?8#97R?V>DI?+TLJ611-N>'Z_*0._9AQAJ2@:6(.,1A DBE
MH':V$(Q"R5$LDLRI^=9Q45,CK(VF;4A869_PY74TTX_YHOF-8__K$V#;>E(^
M(!S<@VK1VST?K17UZ2^= \.;GW14T,C^T3F#]_VBLW>XQUF\:M;>II'8#/-4
M(I@@H-==7%,#T22!S$\J(C'*> B5U1G \P=/C1):W:JF=/81$CM8G?[&+T%@
MX"_:SGBGV(9#EO:*8MAYT&CQ"H?4[T8F'/S[R+5&SO;P?/U-%CPOY<<BY_+3
M<CY7R\+<.(N@DHIQ!)(8F58S+ 04P@@H$3&6I91(,4YMDMXF3(T^6CV#2M&1
M:I'T?P'LO)%I#^O G#A>6^G==V>0_/[KC>2U"ZKT-^#[*,!R\0!Y*]ARN28C
MSY]F$W'U]':AO[9J+B^KT]HO=W31F/)^615ED,(H^Z:=.Q,4A1F5 $69TJMF
MO6"F(9(@)%0@F0H:8:?LW7'5G]J\>;@3FWNT\I5>AH'GT<&'>/IS: U!T,&@
M">!9:12V,^P&"/WCVAQ.;CH!EL&O!IR@06<*D^I%PWKM";6?\M_'9'K1P'B;
M2"_3HM\D^M(@:_:BJ[3GO/SMA5SPNWM:_-9$6Z<HC$B&)5 \S #*% .,$@@4
M">,X2U6<)$X%T<\)G-I$M:-O8!0.-AKW#'<_B[G=[.(3R8'G@\M ="9H6V0\
M4>I9<:.2H*WQSVG+^K[K['9INE,R7ZWU:VGB +X]Y+6FY=M%G<4\@VF,(5$0
M4!B&FJD8T0XZQX )*: 4*(ZT.NY]+@=7W.H[';]Q9J.W%#^]-!&K\_DE!V3#
MC_XX.UM^!O.[<<(W;G;'[CIP:FMYH-^)VO8)>-BNPW1MI]I:W^_#CW:%W_<>
ME+W@GFFC^4(SXKO\T53N7&FE\DU9H)_I?RZ+EW-:EN_U-]DX<CQ&+"90 <:A
M=IX5(0!C'@.5A4)@06(5ADZ)HV[RI^9+U^J#2O]@:\"FMUEE0U 9$1@K^J:3
M.HZ2W=0Q(/8#3P3^87=/,^T'GJ]$4T?IXZ::]H-F+]FTYV,FN_?^[!#AK_K1
MJU?:^=TDT,XDC1,1,@22)(3:X8<0,)QF("),,4&C&+)P]E#Q_N<5+5:3V9<_
M:YH+>3PW<#@>V1Q@TN8 \ZM1/!!:\T"9M/7'*FV=:J]2?LT7IHMMP.B\RJLT
M*P>QG,]I409:XWH5,=8BPN=+!Q%-4)1@0"#6J\PDC@!30@(88A8I&(L$1LU+
M]WHA_B>_<JUY4WCA9'5D]#_O;9O,.9/7]V?Z"U_WTZ>]Z(X*HL!@%&QK>DQ@
MB3S F%][%>W3I.]CH3W (%[A&,M>MWY>:N7^=BK(WW[+RQGA,D$4"Q AA<V!
ME@ X@0S$G,<)#G&L?W!9DQ\2,K6%=Z5CMY%"\*M1TW%=?1!.NQGJ4I &GC&<
M\7&FZU, >*+/@R)&I;-31CZGEY/7NGWN9;$RB:)BS5=FV^^S+!YS+LMF=X>E
MF9"93('DT'16)1&@3&0@9C%,84HE0U;?^TDI4_O@&T6KO?I&4\?-M-.@GO[J
MO4$U\&??"R7K3]\*A5/?OGY Y[O7_]I^\Z>?/<I';V5>^]7;7=RW-.SG.SF?
M&R^%+IYF-$H842P%D2G1B)(T!!@) 2C*.(:0JTQ9U8XX_/BI?>BUAD&E8M#H
MZ%KG=0>^TU_VY: ,_$D[X=&C:.LALR\HTKKSN)&+LAXR9;\(Z\&K^KGCKYJ<
MQ;<+OKR77^BWU]_,ND*^D NI\M4LHS 5IG=%*GD,$ LAH)1"$*:0R8Q%H1!.
MIV5GY$WM4V[5#?)*WV!%O[G6$#R'L)VS[A&W@;_V#62UJH'6-6B4#7YLU#V^
M[>?LQ%L"X\F?/R=M5-?>TO3G7K[M;3UK'-2[#N679=.4I]II:/R,_+$Y_IHI
M31P)PV:Q3QE *90 8ZEYA0C,HTQ2&89M8)@=L]@)[A'8-<H^ -VNNAS+'-CA
M;<<R'C$<:;70*&R:!S4J-YO"6Z6;,W6/M1"<4/)5%\%.Z+@U$IR V*N7X':W
MIUCZJJ;8+ ZQ%!!3(#G3',0(!D2&#'"81@G/I$BIO"B"OA(S-6_F0,AW76/M
MTF#Y&E0[CKD<JH$YI0=*ET?#[X P5 Q\+>2ZD>\[AIZ-=]^]VEO/[?8XI&E5
M6U=I^5"8_QJ!==;:![53-(@JB6.641#'40@0(110"6/ .>-A)!A.L=-*R(]:
M4Z.837/1CD-S$RPV:8"[Q9V61?535>8Q7P1ZX!<EY=5WUSNLW=-PVY'9^(,X
M,/D=[O"].7IO>JN_W0Q?:]9^JN>@[;XO 'FX]M]]E+IV._ +@+1H#W[)T_ON
M9SW*^?+!I./PN\5ROOSZ],D<:)=-S6Q$$AC+A($PY @@C!# /.8 48$5BE4:
M*J=BH6?D38V>-^H&JXV^KMM9IP&VW<[R!MO@VUDM8EM5@UK7\U7<>^QF6>'B
M;3?KM+21=[.L3-_?S;*[K7_IO8]M9*4)@YDQ21.1$ @REG+C!F* <8P R:(D
M2H@2PLX-/"IA<I31UJ.KM0RTFE4$G7M=OET@SQ]J70S/T-3@BDROHGT'K;^H
M>M_N$T<OXW?0H$/U_ Y?V*,)RTM9+);E*N?EMGD&$C)6E&4@440!E*55T^,$
MA F-<88Y)9A:MV$Y(&!JG_%6Q:J_QI\<.H\<@N_TU^L#E*%W>9[AT:<ERR%@
M')JR7 C02&U9K%\<M\XL)XP_V9OET'WC=6<YH?5.?Y93U_4@L(_%DDLI2E.F
M_&,A'_/ENGP>K#?C HHL2YEF-,@ "B4$+!(2,)D0AK.4((QGC[)@2RM.LY'I
M\KIV)4_N-,T>98(B$0F5 1SJ*0,1&0,F]"H2932D2<(89\IZWO"-\2@3"2WO
M@J)JGZ87155?!*WP:EZG<"Q5\S>SOO>-O<6DXQO1H<\O&W5K'%N%@[W89]](
M.LQ2OA$=:=JZ&%FWZ<P%I9/SF]6#QIOP7.S:F0&=;KSL8.?E\I[EB_K,J.YZ
M\]]2O!7Z'<M53C<IU\TIL[A=B'?ZU_E<ZR"-3OIU%._E:A9EH1(THR 5)G=9
MQ%0O[2$!"5."J 2+6&2SU7)%YVXG/)[T<YH(-EH.]X5IE?20;*T(:&5&/?D6
M)YI/C#*8;N<W5QBBL0YR.J;=!%OC@JYU38A,&T(CJNC[CH5!8^+IQG:]#W8\
MH^_YA,>7=E<YZO$,[;$S']]B+L@M+&<)@TD8,P9P%)F%D/;320I3D$4X)%'$
M0\$C%QYWCWH;@WZ_&!D-Y_;(&73*$IQ2R)_O:+Y!HO6N$8UW.MK.2S3=:UJ8
M"B+E1UE49[9M=X09E0I%BI)F5<PA S1+4D"YBAB&*1>1U:KXG*"I+89;/<T1
M0!WW8-,RP@U;N^_4!V(#?[G]P'+^H,\AX>D3/RIFU(_^G+'/:>#L]?V(X4M!
MA=2S>A7">\OY<KU8E9\V&T%U&\59RK,XPXP"P1G1+($30(0AC42H-$&IPG'D
MPA)64J=&&:V>P2?'?3(WK.U8PSN"0T_^^^ -VW[5"2!/S&(G<U2:<8+A.>>X
MW=R/@.IDIL\KNJKVH=^9@6W+87!36R1E$D!!3'DP) "!F01)'&&.3>M$YM1A
M[82LJ9%-DX.WT35HE>U5;.04R'9\XPFZ@5FF-VK.]&*!AR=2.25I5"JQ,/DY
M@=C<TN-4]<M=7HB/U+2RIT_+8B_YH#G1YY)FG*4"8)(Q@!"B@,F( "51$H4)
MPYE#I(B=S*G12*4UJ-0.*KV#_209AR,J2^ MCOO\PSDPM=@@V2<4Q1)2AW,_
M_]".=/+G!V*WXS\WL$X> %H^:KPC0#?;=@X!'6_MN>N[YU&^EZOW6M2Z*+2T
MF61IR+%"VOU#$4!1 @'E+ )8XE@D<0:96\'W,_*FQMWOEHNO0 NZ#VB[>-I&
M:-P$BQ,'.KW@MMQ6]@?B^$O.FX JC6AP.Y\O?Z^*VRK#,H44N?$5R[H*:6.*
MQYUJ.\Q\;6&?D3;NWK:=Z7N;WI:W]22>Q2H7^7QMDM4_2_W,ZC3K]3<^7PLI
M3."#J=&SKN>[#^KYUMN+I\,/J)93:9:FE*<)X"+5I(5#"2@DVO/DD9 DH4J[
MH$ZD-9RN4R.\KJ;!5M5^Y34''&)+HIS&P U-LOW&S)U"AT?3%_T.J.FXU#T\
MY'NT/X+(OK[J)OCMDYR;ZD(OE^4F=Q(C*04+,8"4&]+/4D"DP"!*XXQBR2(4
M.54E.2EM<K2]5184M;9!I:ZK>WH*85OGU!-N@[NF1R ;(#/5"A-OKN<I62,[
MGA9F[[N=-C<-U.6G/-./[?4W6?"\E)O^:\\JOK=__UCD7,XTZU"&LP2@$$F
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MF_/WC'WFMUQ\J'PMD_.\>GJ[*%=%50.W_*N^5[M>LXQ0&&H7!R0DUJMXCB)
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M'$L;_2N,F(B)Z@CA?0$27'#G4WJKR;ANIZ^=U1T=]4&!U5:W4LK6XG+.K[\
M%XE*211  11K9BEGID2><QZ0#PZ LWR?LC2-B?%)4D(EP# GH$CC#*@\DQDL
M,DF@L,\0\JC9Z(A&B-(F.G^50_E,7\ILHJH.S-($OGR?R1]50*&)BY$K4]:K
MC(^1*S[3-WB:S>5ZLUS8>CW^A[V;UVXZF$-3X?I\0F8[-E1_K;3.#&ECWRX"
MQ]AXJZ%T29JZT9 .E6$U^- Z9F4%@+\[A<NGP 'SO0+@=)@<%D+ %:U^OR_G
MXO[I>;6L9HUFZUN[\RR6, >2)S'  D% I<@!*E*1)"FG,'&,.#@K:VRS[4[5
M:-;2M4>GWS/0VOGUG@ +/*/ML6JK&>!8P0(.GTU_ST@:ON]OM\DG6_]>N,1/
M&>=6)>.ZD/$T1D2DB8A!IC)9-0@G11P#D5.>(94*CITV 2Z+'!MSM,L["Q_E
MG4^@K/(TX9P(D'-L.@C"&#!64(#2G&08Y4+ =/I#KMCR-CBW18=<$?USN]Z4
MRYS-4J]ZPN-NQ]I^L0Q,WL?EMG\Y4:#\?+[BU;6WSZ,3J [W"8$WK<E]'H!+
M];D[KNRYLWM4M."3W#1-R#,NA2@@ T@E4'N#+#8MWBG E,)80)GGU*D78)>P
M$9)Z53MCU:J=L9".#-,)K^5.KR?00F]RG*HU0I4>JL@4#?VCS-DR-0+?KJ28
M;:*/R_7^/-KCEK %6KXVAKM$#;L];&'TT2:QS377U@WOZ#U2E>*0J>1<I$1[
MBX9A8,X!Q3(V_T$(<::7G4Z- >Q%CXUO#IKI=78MO[9/\L5!L>.E,% '9BF/
M*%]12ML6,.^UL2\*OE&Q:UM SE>OMK[#E=67JO1QDW.^7)A5]MW/V7J*8BQX
M4G" ]%H78(PRP##%0!)89")CDF>P5S&F4]+&1EQUB8J]DM'O1LV^)9I. FS)
M2+Y@"TQ"SHCUK^/4A83OLDXG9=VFRE.7V6>+/G5>Y$8;Z]5&<Y-<T-5L^=MB
M_2SY3,WTDJV*\, )CV.:8) *S10XHR8U)Y% LD(EJ!!,9E:!^YU2QD83C:*.
MP3+=2';S@C=\@CLEMM!8$X&5Z5T$H&_0>OGU;_L7O_O>@[SP5N8U+[K=EZ_L
M15YWHJW.[9I>M/7)C\J2E*BT #GG^GTG$@-*. ,<%3A-$$N+S*ETBXW0L;W^
M[0[2.U5[MO?NPMK.4_"-8&"". E>B"0>!UA\]\#N$GF;GM86()SM46US[<!E
M)>OR5N]_FHBPM5D3O:IM57\B/Z]F7$X+2DB6J13 3)G: Q@!JN(<%$@@D<)<
MR<PIAV @O<?&>[7VD=RK/XG^:(KST;HX7_VIC)Z-#;<M(.GXG%@NS<8W^J&=
MNNN+/^[*.[YO/SQ'E1T;!*(2@A&4=.PW9K<NV.BH]9^C'&._H?!6;+&G^-YM
MAY]7\KM6;_9#WB],S-SGY7S&7ZK_[GM/I@IBR%,%X@0K@+E@@*D, SWA%227
MC"#FE#AO*WAL<].!WN6!G'.K8CO [>:($# &)OE#!"N=)U&E;_1[_6^0OIRN
M8/EKA6PG=N@.R4Y@G&B<[';]=:W%6F' GU?+#\O5$[U?*/./^=/^M4$R%2R!
M*2"8YP CFI@NR3'(DH0IJ!2,,Z=6E8[RQT97[;.[WQ9T*V;&"](61*7NYCR/
M+LIDEY8U9=V+3W)3OYS]>HS9#I@=SP4<AL!TM^LMUE)]4HY J?T![B&;$O=$
MT'-S,5OI-VDLY@C-N:9BKK?I7[_LPVS-Z?P?DJX^Z+^LIPBA+,X)!DP6$F#%
M.2 Y84#%*::"Q))AJ_V'#AEC([A=@:Y*S\@H&I6:NA<P>PUG-S5Y BDP_?3
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MG]AL46X.6%0D?_O=_'B_N'LRM>,>U)E+=@V(T#0E,J99R@%/<@APJAA@)*>
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M2U>OW:XN(N*OP]5Y44-WM;IH](E.5I>OZ<<EORZ7XH_9?#YE0L1%"@G E"0
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MME4#K6BY"ZV@.PO_'\=TXA!/@!UIWGI< [/LJR'=&=AJEUN'PIB/Q] E+>2
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MI5>N (YE# B4#*B$)QE/<H(A=B&K3FEC8ZA*V6BG;=2HV[,'1#?4=FSD#<#
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M1N*@W.( P6N*<;FT=Q6 ]6:UY>;6]PM][V_Z<5O7>6&89;)(I 0LH=P4O".
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M"^KG =QQ;MR*M195ULNJ:@.T5P\+4=;(:?UIGV165S;>[P8@15$"35>E."X
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ML/7KS+D!Y;&$F(70P4N(V0-QJH28P]5!HMCV;H/B5,92<,!SB@&.50**#*>
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MC"QI.M[JT;G$KP[B@>C18;>DU-^0YI<H:#:7$@=;[OP!$.9?9L>W)L1O*?T
MIJW.3>.-T/Y",2[@IVCL2NOHJ4Z5344H*,HAH3*"&.<Z<29+8<Y$%N$P8SB,
MG;DI#@XUN.G+T !<QD%Q&%.[R<(/4AW[]1*D'8Z$K9R>:1).8N&3(N'P0/W3
M(YQ4^" UPNDKVCF'RCL53XOJ".MAJ2MZ5S\?U).P&L]-#XX7_94)$H@0'!(H
M\RB!*F16;D-( 5G(8IX%$<=DDX]BYR[L!V^16-*Q WE0-_JJ_'NA$\->*KG-
M_INHA79S*0Z6L',QGM'MQ^740H/5HC["![7<(V D'QF4;\ZB[.R'W 'SY)<<
M!N[53[D#LN^W6MRAG1][%(50%WU5M[P6W\5L86Y:;1!5M:-!$(92Y]()Q 7$
M*(Y@'F0AI(@RE(>"Q*E3-QZ+,8<6]M0BFU>(;X5V<U4V8-OY*,\0=NR<=M!K
MR%MO1((OI<@>#U8< /+DC&Q&[-4+.4"P[WY<+FWG=ZZG!7U^7NJ00ZWL[N6C
M&F:^%A^G<W&[$M^*21PD4I( PX31#.)<TTOE#,.0)ZG,1*CYI5R<SKD!A^9Q
M=N75P5(E,?BB909&:,>"A+.@VSD?GU!V['DN1-'9[=A"X\GGG!VN5X=CJ_R^
MM[&^SGOCP?&WQ7(U_<.,6WFW._%C]?2[F'T7_US,5U^+29!QFHDDA &1@5J^
MA0S2C$50TB2.B,@8$4Y[/9>),S0WI1Y)Y*W=H(TY[%Q4?R!W[,!.-B4<F0"*
MF3W^AE8C\)N:O<']W./FOA] N^]8:"/,4)H8.@#GT-?0Y:YMF\04NCB,SD11
M+5JHB DA(H))QI6/C%D."1(QC*(4H2")N2!.[=I?C3 TMZ<%U-%$H44$[\0/
M-EL7RAKZ=[1A /-S75$QW;Z^U)C*\?CV->YVSO B-#OV;S601KH.UH%'=??6
M^&7__CVW>SFBWNLF+\>^>%EONVM1L.74',^IQ>)[6DR+>_F@GI"ZO$DW]C%]
M?2:8HTA0F<)((!U(10FD2&^+QQPG)$M8S%,7)^$NPM"\R/WRF<YK3U'NC6Q4
MT2]%K6&[5G@.IK'S(]T"WK&CV13#-3'6F!OY-=I-#<"73AI2M4?0<Z,\!P'>
MI%V>.T#'FN:UN%-K=JV*G'##35A2$][\6*D@3$_['Z>%IMD*\QB3& 99K/-X
MDQAF0BTJ$4M(0EB N%T#*\=QA^;[3G(Y;D4'-_/UMZH'B>-NEZU![)Q?!S!W
M[/&\(MR&L\L%+W_D75:C]LWBY0+% 3HOI\N/N:^F;3^J3W_]2_T;]1^=8?_7
MO_P_4$L#!!0    ( 'J("%5Z89A,RGL  &S0!0 5    8W-T;"TR,#(R,#8S
M,%]P<F4N>&ULY+U9=UM+CB[X7K_B=/9K(T_,0ZVJNLO'0Y;7=1[[VL[*6_W"
M%0/"9B5%^I*4CUV_OA&49,T2A]C<(7<.LB12W!B^0  (!/ O_^/;R>R7K[A<
M31?S?_T3_S/[TR\X3XL\G7_ZUS_][>,K<'_Z'__V3__T+_\7P/_^[?V;7UXL
MTND)SM>_/%]B6&/^Y8_I^O,O?\^X^L<O9;DX^>7OB^4_IE\#P+]M_NCYXLOW
MY?33Y_4O@@EQ\]7E/XMDK; ^@;<V@V(B0.11@,["8V;>,)G_GT__G(-+K$@'
M(@=);RN%WB8E^)(M3UQS9+CYT-ET_H]_KE]B6.$OQ-Q\M?GQ7__T>;W^\L^_
M_OK''W_\^5M<SOZ\6'[Z53 F?[UX]Y_.W_[MUOO_D)MW<^_]KYM7?[QU-;WK
MC?2Q_-?__=<W'])G/ DPG:_689[J U;3?UYM?OEFD<)Z(_-'Z?KEWG?4G^#B
M;5!_!5R Y'_^MLI_^K=_^N67,W$L%S-\C^67^N_?WK^^]L@45NL9QNEBE::D
M>%S].2U.?JWO_/7Y@G!!-&\^8_W]"_[KGU;3DR\SO/C=YR66?_U3H@^ JEQF
M)*M/_K_/_O#72P*^+'%%F-DP_(9^<?[W]2D'$(/?UCC/>,;IQ:-FBW3M3;,J
MY\6/OYR%B+/-;R<9IY/-ISZ+J_4RI/5$\JB,U 1#Y06H9 3XI!1D[F/V@6%V
MX3KOE?85$;]1RPK3GS\MOOY*'_QKE4?]9B.8C5!N/>Y,0/O1?;$*/])[)UE[
M](DIX$%:4*(PB"@#H$NB".5YDOX@LJ\^[3K55Q7[;)E^62PS+LF,7#PN+-,M
M)5^'\/D[?OT2EO1!D#Y/9_GBKZL]::&K]:*!Y,[40N3^Z1?BNN!RB?G-F5;N
M96[#V9J,*V[>V4+C_^LT+.D39]_?XY?%<CT166>M<P+',I(P+"<Y6 O2:BS1
MR!C989B]Y\%;X4#TCX-#Y-D))-[A<KK(+^?Y!6W(D\!BR1$CI!@5J,PB1!<=
M9),$B^BME*P)(*X]=BLXR/[AL+\L.P'#QV68KZ95\.> UF3%"-(9HE6.;)QF
M$*S4X)VQ9.>*%2JWV1UN/'DK2*C^(7&01$=&Q<OY>KK^_FHZP]]/3R(N)T)$
M[XTU8 JC'4^%",$S#:D8S%[QG"P_" TWG[@5"G2_*#A(@EUH_SU^FE8AS->_
MAQ.<Q.@8:O1 ;#!0AI'/PPH'],PDSW7D*C9 P/6G;H4"TSL*#I!D%TAX38']
MDDS81O ?2/[X?'$Z7R^_/U]DG#C,*FA'F/8Y@I+10#2)@^->R1"RB*$T ,:#
M1&R%$]L[3MK)N0O8? S?7F<2W[1,SW(6YY90><,,^<J 0GI0L9"01"%7F6$J
M@ADK0VH F'L>OQ547.]0:2';+D#R+&=2P>K\GS?3.?))\<BRX!E\%.0^T\9)
M3&A.?A-C*3BFI#,- '+'H[<"A^\='(?*M%-@B(D(/&<721C.$Q-1*PB<29 1
MN>8BEQ1;6(X['KU=^HH]/63L)M2>D/&<OGV[_+CX8SZ1PDHNBJ-XVU-DI<BC
M(FE$D%(43L@G/ZM%='+KP=NAHN.L9@N!]H2)C=/T=OENN?@ZG2=RM8D'%"8"
M/316J\? 98D@A-7:J6 L.RS%_=#3MT-'Q[G.9J+M"2+O%JMUF/V_TR\;I]I;
M[ES2$@HG!A2KQD\Y0S^B#8:)%$5#RW'MV=O!H^/<9R.QC@R.:O6>+3%LZ!8)
MT9420 =-='-!=D\H"]Q9'1&-2$D=!(>K3]L. !UG.O<6W<@JKV?HLW>?%_.+
MW%SR/ ?E&5 \707 /83,$5).P::$+EAQD-IO/G$[U7><WCQ(A".K_P.FTR5!
MEXOX<;J>X<0Y[:6BO2N60-!U,H#SM*GY2K?"R$,\+(-U\XG;J;_CO.9!(AQ9
M_1^7H58I??A^$A>SB4XFR< X<&T#N3&9"$^)XF+",OV;C1%XD.ZO/6X[Q7><
MJ-Q?>)TL^I??TN<P_X2;3+S,S&BA+<1<D-R4E"%RU&"+4"Y*I]V!IUIW/74[
M#'2<@3Q8E%V$ \]/EU5<9V>S%=*D@]/5)&66L],4ZG)/?!@1P".2C((V&)TH
M.1QF#QYZ^G;0Z#[_V$"T74#D]9P^C<0Q_8HOPCJ<LS4A5]:QFBLKGB(<I8FC
M&%4"VN5X<H[1IM@"(G<_?;OZJ>X3D0U$VP5$Z@'_\GE8XZ?%\OO$NB(1"=SD
M!'D23%$047GPRK%48Z#"6B#CVD.W T3W.<C]!=D%#CZ<A-GLM]/5=(ZKU<0)
M+DS)&9PP!&-K)7@F/>0<HDO(34+=  ?7'KH=#KK/-NXOR"YP\/($EY]HR_O+
M<O''^O/SQ<F7,/\^2=98KC% X-K5G0\A6 (V8T6A#V397(LT])T/WPX7W:<9
M#Q=L%_CX\!EGLPOJC2;X!E/K0OTFA4[4<X> PC-RHX7*O$5)U=5G;H>&CG..
M!XJQ"Q 0X2>UP&>1_O'A,\EM]?9T76_ZU,AZ(KS4BA<#R3 %RCL%OD0/KG!7
M;#0*38L3B8=HV XD'6<G&XNY#]"0Y)9A]GJ>\=O_Q.^3:$-)F5SE;%PA!K2'
M$)R#F+*+&E4D]ZD%3JX_=CMH=)RY/%R88Y]7G85*KZ:K%&;_B6%Y<>G I$3V
MSULPH=Z(Y"40^9Q^) )*<"D%<]@%CON>O!TF.DYJ-A%I)_<X+IEX1;]937*P
M7J QP%&2G9/TG3-2@#'>Z2B8$_(P,W'/@[<#1<=9SA8"[0H39U>4SIC0U67B
MDD%UD$%A9A1::P;HBI=.H/7,-D3%E4=OAXN.4YQMA#HR,IX1!WG#Q2Q\FB0L
MSM0 FP@T!.D@P$F%H)4UY$YGH]UAYY_7'K?=E;^.,YC["Z^9UO_EUUO">T._
M./SJ_MO?7[S\_</+%_3-A[=O7K]X]O'EB]^>O7GV^_.7'_[]Y<N/'ZZSLN6]
M_L<_M?&E_QW9.+ CP.D*/H7P9;(ID:O >%M>3>=AGJ9D(!9G=P!_H*XD"DLU
MLQ!4H/U#Z03>,0&"PHXBBR O]*$:YA)6<0..\X>>K3B<K5<7O[E<>KO0M:\U
MN7C&L]4*UZL?7.82?$P4CM-:8J"*XN0YD?MDK<Y2)<V8>:B$?Q\NKU,P3K^!
MP9!P87\:B'O$K><Z]>=N]P\F4K*)2RO.6[J8>G?%* /1DBR2-);IAUS5_3%S
M@Y!QH7.(9N\$R2%B[@ KS\/J\[-YKO^\_#^GTZ]A1LRLGJV?A^7R^W3^Z3_"
M[!0GB@)UDZ*EO3=H$E-R$#!$R,G%DHIRTK:VJEL1U@.6#@+ 8FAM[ TQ<N7B
MHI5!2JG>M%R]QX3$5)SA[[B^.)1VP>58(H(K]=X^>DT>/FJ(2IBH IEP]U":
M?B^[]  ]XW10&0Y2S63?@;%Z/?]*5"^6WXF%"4,E17824'(2BLX.HE$17,[&
M1H=1Q8>JBO?!S=7GC]-:93B<["W;#G#Q;HE?PC2__/8%YRLD _IV_9DBT:LR
MFE 0&F.Q"A*/-=G($@0C' C/$:TA;G-K,[,%6>-T8QD.1:TUT0&XKA//8Y$1
MA2)J;:*5D1+))6D(DFM>$AHM6WM"NP.F^=GA@-O3WM+='QJ+=9@-Y]?\OIBG
M"Z1C*#8XBCZ-M:""Y\2)3Z!M3DD)1<;TH3.C9J[-)4D]>#=M@J^&HN_ R+Q;
M+K[@<OW]W2S0PIKGZOU_J1F.NAM;AH[7!66D)EZD,[01LP).8_9%,<'D0\<)
M^VU=]]/3@^?3!$/-A-X!@-X2)Z%6@[_!L,+WM;7OV_(WVH*KN"8E2.U%]>=B
M(&9RHMA12 TFNB*-X RQ=>[G08)Z<'N:0*B=V#O T&O2P?S3E&SIF81H&;R>
MI]EIK>CYRV*1_YC.9A.CA4V.>'(^<U">ED2P7 /GJ4B/.H3PT!W>_<*NQ^GJ
MP2]J@JCF2N@ 6%>"@"M;-%E8GTHJD$A>H!*+Y#9&"T)X6A>*J>@>:H&YEU&Z
MBY!QNN -88P.%G,'6#FC?^)0:&^5(%O)">$IJ'KN:T#Z7'CBJ)EO[?.</7F<
M7G>#'4_L),@.0JHWTQ"GL^EZBBORR#;5I9\7,Q+ZJGIGZ^\_1&,E64!;$Y:\
M7HY%C1!TX9"YY5A;+CW<2V(?@&Q+V[A!UN"'HX.HJ /+<X6OFQD.U#*'Q&G5
MB-I=EM$75PM8'=E.X3-MP/:A&T<'@JVK ]1AM'\_Q Y110>@NLA3O O?:Y+B
M(M%%;\2@&,64RD10FBD(!2,(730WF?9L?.@:PB&9H>N4= .F@_1\3W+H *%W
M )V7)U]FB^^([W%61_K<EM6$:VEC=@@^8"'WP&2(&#SHE*-CG#9X?*BR<!\4
M/4K4N)O?0(!JJXH.L'4];W'!S_<?Y\):8C3>@+>,_,X<,L4,*=1^,XR)X'5^
M\$;EX?FBFQ2-FW,<"%4-E= #I#;19TK+TSL7"),^(3$$GA<-RJI "T238T"K
M X-4GC]X4V+_:/\^BL;-00X%J79*Z !2=W"0I?3.10DZL S*EWH_Q ?(*DHM
MC#1<#>^)CYML' @Z!PJ[@]S!15^#YXN32)%OU<?SQ;P:6&*&OEM-,R[/"]_/
M;>V5/%FL[$2+P.MAH?)"0O3<0^'.,Z4Y,Z%UQND@@KMQM(8+ X^GT Z,W3W>
MP!6&*MG%N@B9(A50BH>S?H"85&2TMK,1K<L)'B6J&\=L.!2V54P'2'MQ_M@Z
M$.4$/X9O5\2X.?HN)GAF)#"3*);A=:R!J[>O3&$9G<X\/32\<!^</4)2-[[:
M<"AKJ90.,+9Q1*^R<+E:I&96"D]V6616+W)&<*I$B"GXR S/5K3>:.^GIAM7
M;D#[U485'8#J"A,3;;Q72*$,)DZAC,MU]DKQ0#S$D*1+XO+Z>_M 8-PSXV/G
MX'<2=@>!0&U-,UV?;.[.S/,/ES%55I@,)1<=06M-7J%(!GQ@ 80) 94SW-C6
MYX8/D#/N:?-1<-1*&1W8GP<D%'B./#$/7M8!Q8RBY&"8 6U8I/U96!)38U@=
M> #=O#G(45'52!4=@.K=Q7,W+&UN^%WMI%4D\T9X"3+5MKZIU!)4GR"H+#F+
MG G5^J3P88K&OOK=1N^W[ZVT4D('D+K2FNT6*PR%%+1C@TCU\JA+"-'G #Y+
M&6.1%%VT-E0/D#-VJ<P@8&HE_@Z0]"SG3>%0F+T+4XI-GX<O4_+2)M9D:57T
M$#SMV2I(#I%9#\71 BE,>12M4P3WD#)N FH@!+40>P?H>8_K,)UC?AF6<P+_
MZEE*IR>GFR/T%UBF:;J>).-LTE9 ""J2#V \N)0=B!*%HA>=*[(QD!ZG:MQT
MTT"8:JR,#N!U6U 3;VE+3@HAIWIQ.<L(+I9:'>]-DK9(SUOGEFY3,6Y.:2#X
M'"CL#K("C\4E$ZT<BIPR6$&@5U8X<";7P8N6-F>K*"9M[6H_1M,X$Y/'RC,=
MKI9F,!NO!=R[C6H^XWJ:R+NYQE>K?G#7'W'LYG /,'C,3G$Z!I\+4B0G:I-"
MZW,]'M:0LZZWUH,4^!0[Q5V/9$G6;Y>;Q^9-*/(.EYMFW1-EG>326(IHLR+;
M+2PXI^IU:665CXJ%-&Q:X3[*QDXO-$;.PXF&)NKIP!.[SM59._AGI^O/B^7T
MOS%/5&8V(G?@A:P-(FK#(4$_9NYD(%9]S*VCQ8<I&COM<%20':2.3L'U>K4Z
M)4XR.C12UE.#3 &+]Q%B4>0I.!U3MEKPYH> ]U,S=B9B!%#MH89. 74M1Y?1
M)%\T8&$)% \.8FW](-&;X+TRMOE9SB,DC9V0& %:^RJD WQ=R?_>N\%[&ZT5
MQ8/0IO:U9K5D3!!+)AO-O6'6#7$,_0A98V<N!L99:\7TA;5;^WS4C#9XH8%(
M9Z"B(U88+Q X,E.L<Y:WOA[V #GCELP<$UL'*:)'3%UL\Z:48*0%S6LH4EN&
M1K8Y%$4>F0N*E];)U7M(&;=LYOA8VD,!/>+HZIYNM,RE. <F:22?L;88C;7"
M3&0?(U?1N,'!M*N'-5C)S/$1M:\JGN:,C0\?Z>M?7_[^\</;5V_?O7S_[.-K
M>O79[_2FO[Y[__+?Z0]>_\?+-V\_M!O L<,CCY" W5< C1*R9T7M/U#^ ]*>
MQVQ]'41L:'=4.BGPF0G(%$<&R[)VHGTSL3M).?RH^RO.3_$5+>U:XE@_\N_3
M]>?GIZLU/6[Y\MMY"Z_:E8?^ES^&;Q-AN)"><S";.YBA'K<R6^L@=39"8';-
MX\P]R!PW(=L".;=/PH?5U8A;;S5.EQ>6SMLPKR[Z,/]XX4RJESM+X3H93B)D
MA5ARY*22.^'!2FZ#C"JQFT48MXW@7D\>-P_;$EO#"[X+AVY%'LKY\J%(V4J9
M7:(EX20HEB4X54L*.$;4CC'#6G=4OT; .(;I"(J^Y;OM*_4.(/.>M$($U*DF
M+XB#V6+38/=<;!,54^#U$$*0$TN!L73@/<]@1%918R)OM_7^_R!!X]BCXT.J
MG58Z@-@'G,UJ<U2<DZ!FQ-*S?#*=3ZN8UM.O>,&544KZVDQ>%%GG$7H.7EL+
M.:882C'1-^_AMAUEXYP;'1]T ^BI _0].UDLU]/_WNCK;;G9O7<B>99&D(1R
M,M5O% Q"8B0ZK8T)(F65F_<Q?9"B<8Z2CH^VAGKI &7;=\)XMEP2IQN'=O7\
M<_WV]9QD<5IS2X\US^"37+(+K"@0HM:=)&$@1NG)$^:VE!+)RVC=^.M(K(US
MM'5\W/>(E%&'T-VM@M^1N+Q+"1/M=;WE;,"R&NF7("&(4NI(FGH]QTLA;RR!
M;8/A>Y\YSM'8\; YI HZ*"R_0?Z;Q6HU<9H7;4V"5*(A%C"!LUK2:@DR1&MI
MLVE=F70'&>.6) V1NSM4UAW I4[:6VTNQ)_Q0+X)DF;6$^E,C.@TQ%)OP\OH
MP4?R2;R702<M%#;'S'VTC%MP- 1PFDB] T_P@NZ+<,GY9 SW=50C24()'\!S
M)2$KAD&F6%AJ7>1Q@X1QBX:&P<K^,MX=(OX,(G/\5*N1/C9$RH6%?+9>+Z?Q
M=%V;87]<G-V_F&01O;,9P<5Z&2P60W%V+%!$LM&@%;KY%=Z'*1JW0&@8'#73
M0!?[UGEGLO-E\1O.L6QNC19R"HL#K6J74#09G*?58534#$51W+>^2',/*>.6
M!0V'H,-DWL&F1<$H/?HS<3#]BF<\;;S_>K**KHC > 2NLP=%<00XGB,8I@(B
M*RXVO[+[ #GCU@$- :%6LN\ 1F>ST"[<_NBBX8%S"*Y&B?0?B$G5>)$SYG@=
M<=-Z /@U L:]FSL$5/:7;P?;TT5?@XM*[M_":IHFWGN"LF>0"W>@G*[CKXH$
MG:*3G!<EFP^9NY.0[0ZKV5-"R^$"[\"DW&3BQ71V2E[X1%N11;9D#T6=YU%;
M^GJ#$IQ#:[SRPH363LT]I&R'G"=5@-5"Z!U@Y^]8Y[UB?O85E^$3_GYZ$G'Y
MMMPJL#U;&"AI&8A2^T-+ RJAAYAK(TVF6,G",F9:^SD[$;@=SIY$,=;P"NH7
M?>=KZ7:5-WI$S;4 $42LT:8@PUQKR .6*$22WK2V:#N2N!T"GU2Z>D@E/?U2
M_ \?WS[_G__^]LV+E^\_O/Q??WO]\3\'*;^_XS%'+KE_C-'V?4\>:-9CD@F.
MDTN?=:S>O$VTWY+#YAQ')E#3EMLZ8[P588>W SM_R,>:99MXJY-%249<U%LM
MN?86KHV)>#888S(EM*_WND9!-YU,&F'A=D>PO>7=P?;Y@_HSB=0LR6)>2R&>
M?9NN)C)CDJX:7BW)YIN X"QY!3H*69C.TIG6;0D?)*@3+.VAZ?M <[#8.\#0
M#1Y>+$["=#XIP7OF10;$6AGC3()HB@;NLN)8"L^V-7;N)*03S!RNZ)O1X\%2
M[P ZUUM>_!6K7SCA,21CE0&4BA:63!:"))]3EEI:$R6+LC5R[J)C7. T4.^#
M[47VD'4'>+ER@?>< 1:8ETEE8);7NM5Z&3Q:!BQGSTM"0\%#^W.3ZT2,>W^K
M/5(.DW(',+FG<?0Y,S'HZ!Q*,#YFBBXYV5\C"C"6/'I77,+6UVT>)&C<\K3V
M\&DG_0Z@=+-?] 47OJ#0C %:M.3\10&^T!Z>M8J&F:"$-8TQ=#<EXY:HM0=/
M WF/B)K5<CUY?M9/O-[E*073^ATNIXO\MCS+BR\;O53/SQA?+%$.(7,&REJL
MV;181VG4*CR3PG:-K^B!5[!#/UWB9EM:.ND"N7]0-8C0.P?1^4J37G'-Z] Z
MJ>L01!; "UT <V%HO/0Z;Y7=.1!&8T9:PVA_!VCMH8K.P?4L_]?I69'P#^OK
M-Z/(($=+>[9RJ?*6P,7 <Y*\A.W&4QQJK6[0U2_@]L'$+M;L$ 5UX%3],/IO
M:*M_3=^N)K7-<_("(9A<0-6^O%%:"]P3[0YM5,VG#MRFHI/>M0WSB_L)N .(
MO)ZG91TT_0+/_GT]OYV_?[^8S5XMEG^$99Y$C (=<2:5D/7VBP3/K 2!B$P'
MG65I[9#O2&(GB<@]$7&[(G<P]72 OMM'TMEHD9G/8$,)H!C96D\B@E#SM!3<
M1(ZM\TQ[5@8,6!@PG,IOVJ^#Y+\W@+YL]EE:*LMUHWWNUAB7R*U!80P84X=+
MB2J57!"D(-N>2&")M[YOLN<\G2%KG(X'I,,TT V2+CV^U<?%/0FVB_)3S#4A
M@_/51J,;";S=N(VK]T@B6$W7^ &77Z<)S_S*]Y@6G^:;3YQDC<4JXT E2<)A
MMM0;%05TW1,REIQUZW*!([$V^B7@HV&^1ZSTL*=7YLY:"+\X7=*><L;1V59S
ME?.7WW"9IB2:23+,1Q,34'RUZ3(F**(B/SPP&SU%5=*:UGU =J=R]$O*QS7F
MPVFP7XQN>O/?S6"V2FBN#,049.W(6< 7XE<CR3:C4UJTG]^U(Y&C7XT>&Z&-
M]-<O0,^6X'M<K9?3M#XO,7A6Q;FY9$>B+3A=G])[)L;3?R)Y[MXA ^5+ N\K
MUX8;8;3A5K>O*3N0Z-'O9(\-X('TVR^@-RMV*WZ#2M9YC:!+K%,MM*\#Q5A-
MO1;N= BF>:^P0VD>_8+XV' >1KO]HOEL^;X\^3);?,>SC>C=Z3)])NF_FX7Y
M:B)+5DQ'!YL[BRJ7.KJL-CS-T2C'F,JN=1/C/4D=_6;ZV-AMJLM^(;M9HO=R
M.0DF:EZ;%$56UR7J#%&D2#R+E,BE<M&WO]:P!Z&CWXX?&ZX-]=@Y6'_'/S:O
MK";>6.4<<T ,)% N2O+N$_GTM&$H98*1OG6!X5:$C7_[O@LT[J>H?M%W/F@M
MG>7K:G@Y25F+(@R#E'VFJ)(IB#E&L$X([T/DKGF_Y:V)&_\F_]@H/%!A_2)Q
ML[RN\84FLI)R!I>\(?_9U^FX4A%?QA=5O,KVF-'1[CC\>4[!6JNK QA>[]13
M@DG<)09%U?G+H9;.*&,A<*,=ECJM:/Q.2(->W#\:H/87_ &-(1N=R=\J+2C&
M:^%# 6]KJ5ZPEFRO(QYBYIG<@6*P=>G0GJ4=/\<ISD$*./!$_N4\#U79X7QT
MJI@"Z!BM@J*)"Z_)@-JDE.2!V\2&V.IVK^S@/\]9R_XJZ 1(SU*JLP9H&7RH
MRX&$LOK;EQS6^+(VPUC561UOIJOUA/9>7I11D$6LK 7:H[,0D!T*A1@Q\=:;
MVY:D=7)_Y$V3NL8AU/'T.]0\?_;AWU^]>?OW8>;"7G[ZD?O1W,-6^S8TS\/J
M\ZO9XH_5CXXCD@(^)FJ?D5+LV;%OD"Y"(,GQPJ1 V3[A?C\]#1SQ^IGOEHNO
M4Y+<;]__ML+\>OYC3,&SM)Y^I1@#+R7 6=(H98+(R>HK6R(%'?5+3+2"N&7)
MMR[XWYW*3FJV#T70'>[[D.KJ+C+,0H9L@@.>D,):15^B3 Z*Y2S7T5=!MBZ2
MV2,R' I&0VO[P=AP%]&/.B#ISNK)6NXX3],97F/JXV)7>09&7JUF%.%08$/R
M3+7#-"8(RHA@ THMFL^_&X"/<5V](^-X="!T8$9?(#TY33<JIN]GN-'U/%\=
M*SB1%*7GXE@=?U;/\(BQP)*$[(LK&H,4S2<@;T/7N$9W?/0L!E9E!_"\NXI]
M(C+&4E@"RWUMONTSA+29$.TDRW5R;VI^Z' G)>/:R^X@V$!='8#N6*,EHV+<
M"&^ :^]I01H2LK0:G W<BL!"XC_S$-+!SDFZ6Q8] JJ#=?;B_+'W#?^17&#T
M-H,H2.P8(\$G8D<JEXQ%([UN'=0]0M*X-W&ZPW5+!7: Q\V,UM])JB3",Y8N
M!N,EX:26 @&=UZ!"9!!"IB\J(1IKO8VM'>![B1GWKDUW&&RCM*ZF&=XX8/LA
MN?.;G9<)0AEU0B_JO.!4QXAL>"-SKSGY\;072-?Z/')[ZL9U 8Z<21A(:1W8
MQ-N<G1^@K6CQX_3KII%-2CQX[A!"EISLO"6IJ1(@8\"DC&,JM,[T;T-7;]TT
MVF#B4>@=J*">3>&[)7X)TWSA=YQ;^HM1[L]6*URO)BAM,+%DR*9&F[PVIXR.
M@2E*E)BBBKK]I.!]*.VM2<>1\-E<B3TCMH[CGM,?T4XS$3F1'QPC%$D+4%GM
M(6J?(>E8@F<X0,/\!PGJK6'&D?"WKTK&AUDMO7A(;F_JS^_K)*:WA1R>\Z64
MO43I9:S>=:AM,3,X2RY.8L;29SOA;G8ROEWBL=>3>^M;T11?P^MB?+P](,IJ
MJB^]Z3/F%,K$,]ELD>MEFQ@LN,!I61FOI92(D@^_\=Y%66_M*8YDZ Y64L\(
MO/!RWX7O&Q?7Q2BTS!)J P)0WC"(1="/CKDL2HEHA@??#:)ZZRIQY !D']5T
M&?)>-^H_$NZ3S%6Q$CWH8H@Q# Q\81J0/%04,LDKT^F'3\!<)ZZW%A#'LGD-
M5-4E!B]N6+_'636M%YQ5)]:R8- Y#M&CJFEV)-X,AUQ8(;^B)"QN<!C>3U]O
M#1V.A,1&"NL2C/4HLHKL[]/UY^>GJ_7B!)>7:PVMY<X4!D);)'N?+,241;W\
MD[-F$@MK/8M^1Q)[:]IP)$BV4UN7J#S+'Z6T/+V^W+20TO'$(;G-<E,%?"H!
M;&1<%V>U:SY!;&OBNNO8<,S8Y$!==0#"[<^9)D$P&X21((NAT%^'0LO+:A"8
M0LQ2%MZ\B')[ZL9-U1R_?GT(I>T/QP6MLR'A6#.>J_L$:9-T.6;R1;@!168>
MG'<2@J 0+:6@L/D$X-VI[.0&XI%NZ;125P?V\5WX?M&FNG:A6"+Q2LML_;WV
MAEH_F^=ZK_=+?<N$!R_0R0C<<0V**P?D'2-8K8O/468N6Q\B;T]=E_=[FN'D
MYAS9891V:#;Q\*,3XB,AYM4KDO"[)7Z=+DY7F[3HE18I$Q;0:TTLB<SJR.9(
M:UD[!CJ(8+PN290;.+SGN&2;IW5YWZ8UKH:1?1=WR6XME8U?2[SFTRJ[BV,?
MXYF4P6C@IK;,+866210%-*^=<S%8KUI7:FU'69=56D>S:X<K:U2;=B]?%_7F
MN-JTNZTR/G\E$W<!,=;:GXP4QNG:14'+ (6EQ.OM'V];MR[<A;XN Y&C ;*5
MXOHYN+MJ]C^$&;XM]SL3%IVV22<HH?:*4;* J[,5):H<H\ B1'-H;D_>N(?(
MQT;F0&KK("397I(38Q)+T7'0L=1!4N3BNA 8,!<\CRK%HEI?ZMZ>NG$/EX^,
MQX&4UF_*YM5T'N;I;D&*$#T6DB'*NA,@\>KKR)LDE8Q>H;"L];W!W:GL9-+J
MD5(VK=35@7V\<$K>EA]-18DU?+Y8D6_,2^;6U%''-B/%^]F#KT/VLN!69$DF
M7[;NROX0/5VF99IAX1YO\6#%=.H=WCD]2667,"51W5RLG2,C.$NK%FFQ<E;!
M$EI/TWR4J"Z3-H.AKJF*.K)OYW49'Q<?P[=Z(%X;39+X7BV6]W0Q""SQY+@$
M*:0C/H6%D'4!CLF9)#GFYN6M^]+:95IG:+LXJ$([MIEG0V&T]2:3_P)<6$]N
M+W$410Q [FX,QMB<=>NBF[LIZ3*#<S3KN+LR.C")9]+!3<GDN^64!/6E3I,]
M6U83KR5317DH?G-YL-2N$CX"EXZX<8RBM];AQH,$=9F(&0I@[533CP7;7H3D
M6UB%Q@DPG@E03M<QFB*#J?=614B2G(S10MTN,S!# 7$@I760@:ELU?_7C.;7
M,#MS)2XF!VY2\/-\_1=7WGDV9^-V?5N:G5;GX^6WM.GB\[XVF"X%20ED^QTM
M4@U6>G*7#:.]P=L FMQG+W@QA,C&D#XNA^,Z (-E?CJ&R5-?1!,K9;+$&3";
M:1_+6,!E:\&[K#P&+F7SP2X'$3RN"](GQ'=2XH&S&4@"RS;#8@YC6: 54DL-
MF&T]TE )?,@%F'<\<EZ$,*T/B(;'[6 >2Z>XW46)G<P4N1#?C[Y7%\=@\WR'
M0_9BNDJSQ>ITB3^D'0.Z4BNGM=(*5+09//H$C"'+,ANA8NN8[E":Q[W0."AV
MCZ;*#G(-Y]=*-EU?\MD,;G*#3BLEOYVN?U^L_Q/7[\(T3P*SE@O4$$W1M"P=
M"963%X1HHW1U8&)J?;EV6]K&/78Z+F)NP74 ]74 RRL#%/D$%5?&6PE,U<2P
M#QJ"MN38H'=H8@B\M(;>U>>/>[XT*KSV5L.($-J4-]_1XO=<@/>T[?W+]"O.
M)Y))QH/.D .C**]D3;Y'$:"ER"S9%#0^.G[I@.>/>TXT"M*.I:T.;-JFO/G#
M]--\6J8IS-?G+'Y<AOF*Q$=L;>;#;CI+WV"53TK(SII$X9MW9+]MG7\669W[
MF75)6A7Z36,;> B]XR:=1K691U-S]V/NWBX_A?GYI(LPSR]PE9;33;G"HEPL
M^>O,;#?@;JO/;3O:;G=6&@VUN_K@"IC%;)K#^221=U?X>EO.D1UF/V*CRX@H
M"5Y;BS+PQOAZA\*#0]K$C;$\<\&3%<VM1PO"6XV.N*(O>OQO835=U1+J2RH^
MDKI^H[_\QR1&1AZQ9U $[2>*S "%D=E"L,9D$WU6J76%T^Y4CAOQ'!^3]TUP
M&$BOW5O6#Z<G)V'Y?5&N[#.7DU3?D4)2/1#=P[9N^<EMK>L^[#2RK[<?\P.@
M/B>30_#D7DIR D2D73E*!&:4TCPP\@A:6X+[J3DXH'Y(LI>K)#GRF@UR8,ZX
M6JV?R/_PJO;[4**H)%3SP8W;43;R<+$V*+D57K=7RD]BNH8W8:.:LK%,FHNT
M!89B(&O"CV).@G<J ><AAFPP1-VZ?F<XDW:^W=]XP/>SKY>KQSA'T5K,D#(G
MGE%)<#(@""^+L3HY$ULWLMB.LFY-VBXHN>69M5=*!ZF;:U[N35ZB%2P&*\"Q
M0N:9>0DAZ0BL<$Z2LHG^:7TR\@ ](\] ' 96S130 9C^ML*WY>5J/3VAF&@U
M,8P'6W,\J0J#5D6 Z)!!E)99I@N3S:>U7*=@Y.F PP#F "%W )'S(HF;56LW
M<.^DSU+(#+R$7.M'*9H-*9)-=3QZ*85SK6__;478R&/Y!K) S572 \X6Y+W6
M)J15.>^GJW\\)QJFZ_K=!"FP45980)MK@\GDP-%N#5[&(HSC7K+FQ53WDS/R
MF+W!=K4FXN\ 2>_Q*\Y/L5Z\N:NM[<UUDE114E'4K$(M\O+"0+!R,RDU2Q6-
MXKYUC^S=*!RW-&\@O VHI X@^'$9\N7<JEM3U\ZXF^202N!5="5I4,ES"$(I
MH/>Y((7E)-S&R-N*L''KZ08"7'N5=("S2_I7C_#W;#9;_%'OB[U:+%\L3N.Z
MG,Y^3.,XXUV@$H$[!E*:.O5%4^SB36W9DW0HD2?R4)L;PG;TCSM,8# S.9*"
M.P#W7Q:+_,=T-B.>7Y,FYY^FE<U-)[Z+E\X92\HGS$9!8K6Q#UH-7AO:(KQ.
M6$2=)]W:D&Y-W+@#!0:"Y3"JZ;!2CQB\V8IT=4\:,3(LV642IR!&*?2"D"C<
M<BP*YJQ._F9=P_;U>EM3,?+,@,9H.ZY2.K!X5WM0G/>LV/3PN>4-.UU#,47H
MD;6 0'OPA<MZC5980RRKYN-"MR1M.P ^M9.$(?32"=R6^)DXFWZM-TXI\+I[
M&97$@\9"IMO7BOU4++BL$;+E3&E,$4/S[-Z6M&T'N*=WQC" 9GZ2\_C?P[)F
MJ;[B"UR'Z6S <_E;3QKC?/YA=H<_I]>J:,&U(TCI5*]:!(C2:'!)%RO(XHG2
MNO7N<.?T#P5)EZ'4Q IAL@H()216[3C%2%$Q*$QYP5.0IODQZG:4=7M.OPM*
M;AJ[ 932P>9Z/L'JM\7\=(6KY_4>W*8[<JW!/_MAHAW&$$H KFRI0I,0.<5&
MW$1+\F(H9'.8/4I5MV?V!T&LK3(Z@-=%F/WZY$N8+FLY\YO%:C4)G/P*91/H
MP$A(UB0(5F?@NF0?,,J06U=5W4U)MR?YA\"H@="[=\+.#V;V\:HN_K2MFW0G
M08W\GD=.H7Z AKD@I,($*3I;&Y3[VG+' 8^JI)Q1J^;%BEN2-O!AZ95( V.)
M.AH*9KD#)46"J#/]*)4LCH> UAQ7!)U4+PZ!H1U/2_?3TE,Q11\WQQ\'&*3S
M#QC$+-U%W+&-4Q(B1QY!)'*'5?",@"4-:)6,CK2=Q>:U5T<R3B^FJ_#IT[)V
MF=S<X;HJ\RLUERGJ$KP%IK6O.1 .GM=1[D&KF"W'V#Q:VXJP)V*6=D#/3;/4
M7C\=>-8?TF?,I[2H-]>B+XNBB+WIZA^_?:]?7Y'D%E?,;N9*:.,D&*$RJ"($
MQ,0UD#'.Q6MTHGF+Y3W('#>T.P8@A];=4]DR6^1([_NH0;;1HV0YMT4@Q8%>
MV< )#"&"XB)#B-;7>>9UV+B1AK5>S0-OJ)N3U+L^^$>]W5G?Z(^X/%E-1(IU
M3A*#1.$Q&>QZCY I!"4\HQ!7<F[%8^C9Z8E/8Z?<!1;7CK '$7P'.^6=A9NX
M+(OE24WGOHVSZ9EG\(&^KLJT=H6^&/!ZUO9VDD0Q.B<&FC&2*4,/P2<)L0I"
MY9AL^U9N!U/]-/;1?> ZDF:?RK9ZW=]=7/B[AV^RCWSP(%ON+LP<>0-V*1>9
MR 74&BE.4%@H8I *,,@8I95%I">V 6\3,4U25I)K82'7YL@J2(10I*P+.&3O
M6<RI]4V$A^AY&KOR+EC9)7[=21LC;L:KY7IR/JCZ[?(#+K].$S[[-EU-%+J8
M"@O M2,7PAM1BT0,.1,4CT>MLHU;I87H 5>01#]=HNB^9X^+G'9:7304<1\0
M63V;YW,.5B\6)V$ZGZ22@M")HEZGR>D41@*%O!1^UXIPU"0KN56'_>UP<IN
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M<U*HL+R>'2\"YSD3!5GXFH\I#J(UF71'R2(SF5>W5<YJ2XS<?_N( &DCTD=
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MM9Z6_&26;?.#^J76DO[?__/_ 5!+ P04    " !ZB A5VU-YI_ (   T/0
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MPI#?4JIAB9!3TN.)TI:HF'Q2.B*5<N$WHD+2I@8\7_)1*!,('@?<Y$DW#HH
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M0UPG@9V@A"=(>RB2QM8S$-"C2,!]VW#0AH,>Y:#@!_:(.F,J4^<V($9Y&/+
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MW#KW.U^P/"R5;Z^Q3-Q[<G9A";ES^#91_O1QTW^M,.9+QW'GD^06@?*\"AW
M3*5VN<HC)WBSJS]/[$XV'_T?4$L#!!0    ( 'J("%5:+CZ$X @  /(\   5
M    97AH:6)I=#,Q,BUQ,C(P,C(N:'1M[5MK4^,X%OV^OT*3KNV!JCSL/( $
MFJIT"-NI8H )Z>J93UN*+2<J;,LCR0G97S_W2D[BD "AFQWH[O AV-;K2O(Y
M.O?*.OGE[*HS^/.Z2\8Z"LGUYX\7O0XIE"J5+[5.I7(V.".?!K]=D'K9<<E
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M[?#S*!MIKHT"CF83"A\%-$N$@F#0;5&%B .94=;3Q:P+6FKI&%0BLK9*12J
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M;"TR,#(R,#8S,%]P<F4N>&UL4$L! A0#%     @ >H@(5=M3>:?P"   -#T
M !4              ( !\-($ &5X:&EB:70S,3$M<3(R,#(R+FAT;5!+ 0(4
M Q0    ( 'J("%5:+CZ$X @  /(\   5              "  1/<! !E>&AI
M8FET,S$R+7$R,C R,BYH=&U02P$"% ,4    " !ZB A5Y0>?_6H&  "<'@
M%0              @ $FY00 97AH:6)I=#,R,2UQ,C(P,C(N:'1M4$L%!@
0   )  D 4P(  ,/K!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
